

Mutations of the BRAF gene in human cancer

Nature

417, 949-954

DOI: [10.1038/nature00766](https://doi.org/10.1038/nature00766)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Detailed minutes concerning actions taken in the emendation of the International Code of Nomenclature of Bacteria and Viruses during the meetings of the Judicial Commission of the International Committee on Bacteriological Nomenclature at the VIII International Microbiological Congress in Montreal August, 1962. <i>International Journal of Systematic Bacteriology</i> , 1963, 13, 1-22.	2.8	0
3	Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo. <i>Oncology Reports</i> , 1994, 21, 237.	1.2	15
4	RAF expression in human astrocytic tumors. <i>International Journal of Molecular Medicine</i> , 1998, 23, 17.	1.8	10
5	Keratin Subunit Expression in Human Cultured Melanocytes and Mouse Neural Crest Cells Without Formation of Filamentous Structures. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 1999, 4, 110-115.	0.8	10
6	Skin tumors. , 2000, , 15-42.		0
7	Ras Family Signaling: Therapeutic Targeting. <i>Cancer Biology and Therapy</i> , 2002, 1, 599-606.	1.5	191
8	Developments in mitogen-induced extracellular kinase 1 inhibitors and their use in the treatment of disease. <i>Expert Opinion on Therapeutic Patents</i> , 2002, 12, 1795-1811.	2.4	9
9	High Throughput Sequencing and Cancer Genetics. <i>Cell Cycle</i> , 2002, 1, 321-322.	1.3	0
10	The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer. <i>Oncology Research and Treatment</i> , 2002, 25, 511-518.	0.8	183
11	The RASputin effect. <i>Genes and Development</i> , 2002, 16, 2033-2038.	2.7	25
12	Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 14398-14403.	3.3	140
13	Skin cancer and exposure to sunlight, polycyclic aromatic hydrocarbons, and arsenic. <i>Clinics in Occupational and Environmental Medicine</i> , 2002, 2, 803-828.	0.5	7
14	Targeting the Raf kinase cascade in cancer therapy – novel molecular targets and therapeutic strategies. <i>Expert Opinion on Therapeutic Targets</i> , 2002, 6, 659-678.	1.5	27
16	Rules for Making Human Tumor Cells. <i>New England Journal of Medicine</i> , 2002, 347, 1593-1603.	13.9	876
17	Antisense therapy for cancer – the time of truth. <i>Lancet Oncology</i> , The, 2002, 3, 672-683.	5.1	160
18	Subcutaneous seeding of pancreatic carcinoma along a VP shunt catheter. <i>Lancet Oncology</i> , The, 2002, 3, 683.	5.1	14
19	A genome-based strategy uncovers frequent BRAF mutations in melanoma. <i>Cancer Cell</i> , 2002, 2, 5-7.	7.7	139
20	Medulloblastoma: A problem of developmental biology. <i>Cancer Cell</i> , 2002, 2, 7-8.	7.7	56

#	ARTICLE	IF	CITATIONS
21	Focus on melanoma. <i>Cancer Cell</i> , 2002, 2, 275-278.	7.7	225
22	Of mice and men, and cancer research. <i>Drug Discovery Today</i> , 2002, 7, 981-982.	3.2	1
24	Progress in Cutaneous Cancer Research11We have attempted to adhere to standard nomenclature guidelines (http://www.nature.com/ng/web_specials/nomen/nomen_guidelines.html) through most of the text. Human genes and proteins are indicated in upper case, with only the gene name italicized (e.g.,) Tj ETQq00.0 rgBT /Overlock 1 <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2002, 7, 17-26.	0.0	0
25	Initial sequencing and comparative analysis of the mouse genome. <i>Nature</i> , 2002, 420, 520-562.	13.7	6,319
26	Lucky draw in the gene raffle. <i>Nature</i> , 2002, 417, 906-907.	13.7	34
27	Thin-film cliffhanger. <i>Nature</i> , 2002, 417, 907-909.	13.7	85
28	Fast heating scalable to laser fusion ignition. <i>Nature</i> , 2002, 418, 933-934.	13.7	445
29	RAF/RAS oncogenes and mismatch-repair status. <i>Nature</i> , 2002, 418, 934-934.	13.7	1,110
31	Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling. <i>EMBO Journal</i> , 2002, 21, 5611-5622.	3.5	73
32	The Role of Altered Cell-Cell Communication in Melanoma Progression. <i>Journal of Molecular Histology</i> , 2003, 35, 309-318.	1.0	135
33	Molecular pathology of tumor metastasis III. <i>Pathology and Oncology Research</i> , 2003, 9, 49-72.	0.9	10
34	The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 45-56.	1.1	53
35	Can different genetic changes characterize histogenetic subtypes and biologic behavior in sporadic malignant melanoma of the skin?. <i>Cellular and Molecular Life Sciences</i> , 2003, 60, 1923-1932.	2.4	21
36	Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. <i>Human Genetics</i> , 2003, 114, 118-120.	1.8	61
37	Mechanisms of regulating the Raf kinase family. <i>Cellular Signalling</i> , 2003, 15, 463-469.	1.7	356
38	Molecular pathogenesis of thyroid cancer. <i>Surgical Oncology</i> , 2003, 12, 69-90.	0.8	75
39	Cell cycle target validation: approaches and successes. <i>Targets</i> , 2003, 2, 154-161.	0.3	1
40	Oncogenomics: opportunities to integrate basic and clinical research. <i>Targets</i> , 2003, 2, 162-168.	0.3	0

#	ARTICLE	IF	CITATIONS
41	Altered receptor trafficking in Huntingtin Interacting Protein 1-transformed cells. <i>Cancer Cell</i> , 2003, 3, 471-482.	7.7	103
42	ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. <i>Cancer Cell</i> , 2003, 4, 67-79.	7.7	354
43	BRAF as a potential therapeutic target in melanoma and other malignancies. <i>Cancer Cell</i> , 2003, 4, 95-98.	7.7	154
44	Cell signaling and cancer. <i>Cancer Cell</i> , 2003, 4, 167-174.	7.7	246
45	Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. <i>Seminars in Oncology</i> , 2003, 30, 79-92.	0.8	29
46	Raf proteins and cancer: B-Raf is identified as a mutational target. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2003, 1653, 25-40.	3.3	236
47	Dissection of signal-regulated transcriptional modules by signaling pathway interference in oncogene-transformed cells. <i>Advances in Enzyme Regulation</i> , 2003, 43, 379-391.	2.9	8
48	Raf kinases in lung tumor development. <i>Advances in Enzyme Regulation</i> , 2003, 43, 183-195.	2.9	18
49	The prohibitin 3â€™ untranslated region polymorphism is not associated with risk of ovarian cancer. <i>Gynecologic Oncology</i> , 2003, 90, 145-149.	0.6	19
50	Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2003, 90, 378-381.	0.6	211
51	Vasoactive intestinal peptide stimulates proliferation in HT29 human colonic adenocarcinoma cells: concomitant activation of Ras/Rap1â€™B-Rafâ€™ERK signalling pathway. <i>Neuropeptides</i> , 2003, 37, 98-104.	0.9	21
52	Absence of exon 15BRAF germline mutations in familial melanoma. <i>Human Mutation</i> , 2003, 21, 327-330.	1.1	64
53	A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. <i>International Journal of Cancer</i> , 2003, 104, 527-532.	2.3	312
54	Exclusion of BRAFV599E as a melanoma susceptibility mutation. <i>International Journal of Cancer</i> , 2003, 106, 78-80.	2.3	36
55	Frequent allelic changes at chromosome 7q34 but lack of mutation of the BRAF in papillary renal cell tumors. <i>International Journal of Cancer</i> , 2003, 106, 980-981.	2.3	18
56	Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer. <i>International Journal of Cancer</i> , 2003, 107, 962-969.	2.3	31
57	Overcoming resistance of cancer cells to apoptosis. <i>Journal of Cellular Physiology</i> , 2003, 196, 9-18.	2.0	112
58	Mutational analysis of salvador gene in human carcinomas. <i>Apmis</i> , 2003, 111, 595-598.	0.9	7

#	ARTICLE	IF	CITATIONS
59	Animal Models of Melanoma: An HGF/SF Transgenic Mouse Model May Facilitate Experimental Access to UV Initiating Events. <i>Pigment Cell & Melanoma Research</i> , 2003, 16, 16-25.	4.0	76
60	Tyrosinase Gene Correction Using Fluorescent Oligonucleotides. <i>Pigment Cell & Melanoma Research</i> , 2003, 16, 133-138.	4.0	5
61	Î2-Catenin in the Melanocyte Lineage. <i>Pigment Cell & Melanoma Research</i> , 2003, 16, 312-317.	4.0	49
62	Cutaneous Photobiology. The Melanocyte vs. the Sun: Who Will Win the Final Round?. <i>Pigment Cell & Melanoma Research</i> , 2003, 16, 434-447.	4.0	149
63	Farnesyl Thiosalicylic Acid Chemosensitizes Human Melanoma In Vivo. <i>Journal of Investigative Dermatology</i> , 2003, 120, 1-7.	0.3	28
64	The Great Escape: Another Way for Melanoma to Leave Physiological Control?. <i>Journal of Investigative Dermatology</i> , 2003, 121, xi-xii.	0.3	0
65	Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions. <i>Journal of Investigative Dermatology</i> , 2003, 121, 1160-1162.	0.3	196
66	Activation of B-raf in Non-Malignant Nevi Predicts a Novel Tumor Suppressor Gene in Melanoma (MAP) Tj ETQq1 1 0,784314,rgBT /Over	0.3	12
67	Tyrosine phosphate in melanoma progression. <i>British Journal of Dermatology</i> , 2003, 149, 289-295.	1.4	11
68	Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript. <i>British Journal of Haematology</i> , 2003, 123, 637-645.	1.2	24
69	Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. <i>British Journal of Cancer</i> , 2003, 88, 1403-1405.	2.9	92
70	BRAF mutations in non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2003, 89, 1958-1960.	2.9	64
71	Mutation of BRAF is uncommon in AML FAB type M1 and M2. <i>Leukemia</i> , 2003, 17, 274-275.	3.3	23
72	Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. <i>Leukemia</i> , 2003, 17, 1263-1293.	3.3	632
73	Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. <i>Leukemia</i> , 2003, 17, 1765-1782.	3.3	55
74	Small-molecule inhibitors of signal transduction pathways in leukemia therapeutics: how to assess selectivity for malignant signals. <i>Leukemia</i> , 2003, 17, 1759-1761.	3.3	3
75	BRAF gene is not mutated in plasma cell leukemia and multiple myeloma. <i>Leukemia</i> , 2003, 17, 2238-2240.	3.3	15
76	Activation of ERK1/2 by Î”Raf-1â€‰:â€‰ER* represses Bim expression independently of the JNK or PI3K pathways. <i>Oncogene</i> , 2003, 22, 1281-1293.	2.6	161

#	ARTICLE	IF	CITATIONS
77	Human melanocyte senescence and melanoma susceptibility genes. <i>Oncogene</i> , 2003, 22, 3063-3069.	2.6	193
78	Gene-expression profiling in human cutaneous melanoma. <i>Oncogene</i> , 2003, 22, 3076-3080.	2.6	107
79	Oncogenes in melanoma. <i>Oncogene</i> , 2003, 22, 3087-3091.	2.6	107
80	Ultraviolet radiation and cutaneous malignant melanoma. <i>Oncogene</i> , 2003, 22, 3099-3112.	2.6	236
81	PTEN signaling pathways in melanoma. <i>Oncogene</i> , 2003, 22, 3113-3122.	2.6	408
82	Apoptosis and melanoma chemoresistance. <i>Oncogene</i> , 2003, 22, 3138-3151.	2.6	757
83	Death receptors and melanoma resistance to apoptosis. <i>Oncogene</i> , 2003, 22, 3152-3161.	2.6	201
84	The INK4a/ARF locus and melanoma. <i>Oncogene</i> , 2003, 22, 3092-3098.	2.6	229
85	ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. <i>Oncogene</i> , 2003, 22, 4092-4101.	2.6	129
86	Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. <i>Oncogene</i> , 2003, 22, 4757-4759.	2.6	121
87	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. <i>Oncogene</i> , 2003, 22, 4578-4580.	2.6	616
88	BRAF mutations in papillary carcinomas of the thyroid. <i>Oncogene</i> , 2003, 22, 6455-6457.	2.6	280
89	BRAF and KRAS mutations in stomach cancer. <i>Oncogene</i> , 2003, 22, 6942-6945.	2.6	131
90	Both products of the mouse <i>Ink4a/Arf</i> locus suppress melanoma formation in vivo. <i>Oncogene</i> , 2003, 22, 5055-5059.	2.6	94
91	Reciprocal regulation of MelCAM and AKT in human melanoma. <i>Oncogene</i> , 2003, 22, 6891-6899.	2.6	82
92	Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. <i>Oncogene</i> , 2003, 22, 9217-9224.	2.6	88
93	BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. <i>Oncogene</i> , 2003, 22, 9192-9196.	2.6	132
94	Opposite long-term regulation of c-Myc and p27Kip1 through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells. <i>Oncogene</i> , 2003, 22, 8813-8822.	2.6	32

#	ARTICLE	IF	CITATIONS
95	Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. <i>Oncogene</i> , 2003, 22, 8823-8834.	2.6	103
96	Absence of Mutations of the BRAF Gene and Constitutive Activation of Extracellular-Regulated Kinase in Malignant Melanomas of the Uvea. <i>Laboratory Investigation</i> , 2003, 83, 1771-1776.	1.7	99
97	High frequency of BRAF mutations in nevi. <i>Nature Genetics</i> , 2003, 33, 19-20.	9.4	1,547
98	The genetics and genomics of cancer. <i>Nature Genetics</i> , 2003, 33, 238-244.	9.4	495
99	Chromosome aberrations in solid tumors. <i>Nature Genetics</i> , 2003, 34, 369-376.	9.4	702
100	RAS oncogenes: the first 30 years. <i>Nature Reviews Cancer</i> , 2003, 3, 459-465.	12.8	1,597
101	The genetics of malignant melanoma: lessons from mouse and man. <i>Nature Reviews Cancer</i> , 2003, 3, 559-570.	12.8	243
102	Targeting RAS signalling pathways in cancer therapy. <i>Nature Reviews Cancer</i> , 2003, 3, 11-22.	12.8	2,800
103	Issues and progress with protein kinase inhibitors for cancer treatment. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 296-313.	21.5	471
104	Sequence-based cancer genomics: progress, lessons and opportunities. <i>Nature Reviews Genetics</i> , 2003, 4, 409-418.	7.7	69
105	Pharmacogenetic candidate genes for melanoma. <i>Pharmacogenomics</i> , 2003, 4, 753-765.	0.6	2
106	Review Article: The Role of Ras Superfamily Proteins in Bladder Cancer Progression. <i>Journal of Urology</i> , 2003, 170, 1987-1993.	0.2	78
107	Protein Kinase Inhibitors as a Therapeutic Modality. <i>Accounts of Chemical Research</i> , 2003, 36, 462-469.	7.6	173
108	Molecular responses to hypoxia in tumor cells. <i>Molecular Cancer</i> , 2003, 2, 23.	7.9	162
109	Unbiased Whole-Genome Amplification Directly From Clinical Samples. <i>Genome Research</i> , 2003, 13, 954-964.	2.4	369
110	Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. <i>Carcinogenesis</i> , 2003, 25, 527-533.	1.3	247
111	Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib. <i>Pharmacological Reviews</i> , 2003, 55, 401-423.	7.1	305
112	BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) Mutations in Distinct Subsets of Pancreatic Cancer. <i>American Journal of Pathology</i> , 2003, 163, 1255-1260.	1.9	225

#	ARTICLE	IF	CITATIONS
113	MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma. American Journal of Pathology, 2003, 163, 333-343.	1.9	266
114	KrÄppel Cripples Prostate Cancer. American Journal of Pathology, 2003, 162, 1047-1052.	1.9	41
115	BRAF Mutation in Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 2003, 95, 625-627.	3.0	849
116	Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4393-4397.	1.8	527
117	Biomarkers in melanoma: predisposition, screening and diagnosis. Expert Review of Molecular Diagnostics, 2003, 3, 163-184.	1.5	25
118	Dissecting the genetic alterations involved in lung carcinogenesis. Lung Cancer, 2003, 40, 111-121.	0.9	32
119	Insulin-like growth factor I-stimulated melanoma cell migration requires phosphoinositide 3-kinase but not extracellular-regulated kinase activation. Experimental Cell Research, 2003, 286, 128-137.	1.2	35
120	Ras-induced serine phosphorylation of the focal adhesion protein paxillin is mediated by the RafâMEKâERK pathway. Experimental Cell Research, 2003, 287, 325-338.	1.2	27
121	BRAF and K-ras gene mutations in human pancreatic cancers. Cancer Letters, 2003, 199, 169-173.	3.2	64
123	Novel raf kinase proteinâprotein interactions found by an exhaustive yeast two-hybrid analysis. Genomics, 2003, 81, 112-125.	1.3	39
124	Modeling geneâenvironment interactions in malignant melanoma. Trends in Molecular Medicine, 2003, 9, 102-108.	3.5	30
125	BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 5399-5404.	1.8	950
126	Health effects from stratospheric ozone depletion and interactions with climate change This article is published as part of the United Nations Environmental Programme: Environmental effects of ozone depletion and its interactions with climate change: 2002 assessment.. Photochemical and Photobiological Sciences, 2003, 2, 16.	1.6	93
127	Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opinion on Investigational Drugs, 2003, 12, 51-64.	1.9	119
128	Breast and Ovarian Cancer. New England Journal of Medicine, 2003, 348, 2339-2347.	13.9	535
130	Lack of BRAF Mutation in Primary Uveal Melanoma. , 2003, 44, 2876.		117
131	Mutation of B-Raf in Human Choroidal Melanoma Cells Mediates Cell Proliferation and Transformation through the MEK/ERK Pathway. Journal of Biological Chemistry, 2003, 278, 42409-42418.	1.6	105
132	Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. Journal of Cell Science, 2003, 116, 4957-4963.	1.2	107

#	ARTICLE	IF	CITATIONS
133	Opportunities and challenges in the development of kinase inhibitor therapy for cancer. <i>Genes and Development</i> , 2003, 17, 2998-3010.	2.7	149
134	Determinants of BRAF Mutations in Primary Melanomas. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1878-1890.	3.0	604
135	Oncogenomics: prospects for the future. <i>Expert Review of Anticancer Therapy</i> , 2003, 3, 891-901.	1.1	6
136	Role of MC1R variants in uveal melanoma. <i>British Journal of Cancer</i> , 2003, 89, 1961-1965.	2.9	14
137	Epithelial to Mesenchymal Transition in Madin-Darby Canine Kidney Cells Is Accompanied by Down-regulation of Smad3 Expression, Leading to Resistance to Transforming Growth Factor- β -induced Growth Arrest. <i>Journal of Biological Chemistry</i> , 2003, 278, 3251-3256.	1.6	65
138	Regulation of Raf through Phosphorylation and N Terminus-C Terminus Interaction. <i>Journal of Biological Chemistry</i> , 2003, 278, 36269-36276.	1.6	92
139	p16/Cyclin-Dependent Kinase Inhibitor 2A Deficiency in Human Melanocyte Senescence, Apoptosis, and Immortalization: Possible Implications for Melanoma Progression. <i>Journal of the National Cancer Institute</i> , 2003, 95, 723-732.	3.0	106
140	Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 484-486.	3.0	762
141	Adhesion-dependent Activation of the ERK1/2 Cascade Is Bypassed in Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 34548-34554.	1.6	46
142	Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 1221-1225.	3.3	116
143	β Raf-1:ER* Bypasses the Cyclic AMP Block of Extracellular Signal-Regulated Kinase 1 and 2 Activation but Not CDK2 Activation or Cell Cycle Reentry. <i>Molecular and Cellular Biology</i> , 2003, 23, 9303-9317.	1.1	18
144	Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations. <i>Journal of the National Cancer Institute</i> , 2003, 95, 790-798.	3.0	70
145	MAP Kinase-dependent Degradation of p27Kip1 by Calpains in Choroidal Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 12443-12451.	1.6	49
146	Chemoprevention of Melanoma: An Unexplored Strategy. <i>Journal of Clinical Oncology</i> , 2003, 21, 158-165.	0.8	64
147	Novel Anticancer Agents in Clinical Development. <i>Cancer Biology and Therapy</i> , 2003, 2, 4-14.	1.5	30
148	Recent Advances with Molecular Target Agents in Cancer: Opportunities for Imaging. <i>Cancer Biology and Therapy</i> , 2003, 2, 599-607.	1.5	14
149	In Search of an Early Warning System for Pancreatic Cancer. <i>Cancer Biology and Therapy</i> , 2003, 2, 85-87.	1.5	15
150	The role of functional and molecular imaging in cancer drug discovery and development. <i>British Journal of Radiology</i> , 2003, 76, S128-S138.	1.0	58

#	ARTICLE	IF	CITATIONS
151	Overview: Translating Hsp90 Biology into Hsp90 Drugs. <i>Current Cancer Drug Targets</i> , 2003, 3, 297-300.	0.8	137
152	The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future. <i>Current Cancer Drug Targets</i> , 2003, 3, 385-390.	0.8	83
153	Ocular Melanoma. <i>Archives of Dermatology</i> , 2003, 139, 1067.	1.7	85
154	Increased risk of breast cancer in relatives of malignant melanoma patients from families with strong cancer familial aggregation. <i>European Journal of Cancer Prevention</i> , 2003, 12, 241-245.	0.6	14
155	New prognostic factors and developing therapy of cutaneous melanoma. <i>Annals of Medicine</i> , 2003, 35, 66-78.	1.5	14
156	BRAF Mutation. <i>American Journal of Dermatopathology</i> , 2003, 25, 365-370.	0.3	136
157	Is there a role for genetic testing in patients with melanoma?. <i>Current Opinion in Oncology</i> , 2003, 15, 157-161.	1.1	42
158	Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. <i>Melanoma Research</i> , 2003, 13, 167-170.	0.6	35
159	Successful amplification of extremely GC-rich promoter regions using a novel ???slowdown PCR??? technique. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 759-766.	5.7	62
160	Population Frequencies of Single Nucleotide Polymorphisms (SNPs) in Immuno-Modulatory Genes. <i>Human Heredity</i> , 2003, 55, 171-178.	0.4	33
162	Molecular Mechanisms of Cancer. , 0, , 71-142.		3
163	Malignant Melanoma 2003. <i>Pathology Patterns Reviews</i> , 2003, 120, S101-S127.	0.4	13
165	Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. <i>Journal of Carcinogenesis</i> , 2004, 3, 6.	2.5	258
166	Proteomic Approaches for Biomarker Discovery in Colorectal Cancer. , 2004, , 111-131.		0
167	Genomic Approaches to Identifying Breast Cancer Susceptibility Factors. <i>Breast Disease</i> , 2004, 19, 3-9.	0.4	5
169	Cancer Genetics and Drug Target Selection. , 2004, , 41-53.		0
170	Gene Microarray Technologies for Cancer Drug Discovery and Development. , 2004, , 141-186.		0
171	The Genetic Basis of Kidney Cancer: Why is Tuberous Sclerosis Complex Often Overlooked?. <i>Current Molecular Medicine</i> , 2004, 4, 825-831.	0.6	40

#	ARTICLE	IF	CITATIONS
172	Kinase Inhibitors in Leukemia. <i>Advances in Pharmacology</i> , 2004, 51, 1-33.	1.2	0
173	High sensitivity EndoV mutation scanning through real-time ligase proofreading. <i>Nucleic Acids Research</i> , 2004, 32, e148-e148.	6.5	23
174	Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5175-5180.	1.8	252
175	Challenging Dogma in Thyroid Cancer Molecular Genetics—Role of RET/PTC and BRAF in Tumor Initiation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4264-4266.	1.8	83
176	Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?. <i>Current Pharmaceutical Design</i> , 2004, 10, 1885-1905.	0.9	54
177	Mechanisms Regulating the Constitutive Activation of the Extracellular Signal-Regulated Kinase (ERK) Signaling Pathway in Ovarian Cancer and the Effect of Ribonucleic Acid Interference for ERK1/2 on Cancer Cell Proliferation. <i>Molecular Endocrinology</i> , 2004, 18, 2570-2582.	3.7	128
178	A Rapid and Simple Detection Method for the BRAF T1796A Mutation in Fine-Needle Aspirated Thyroid Carcinoma Cells. <i>Thyroid</i> , 2004, 14, 910-915.	2.4	69
180	Exon 15 BRAF Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites: Fig. 1.. <i>Clinical Cancer Research</i> , 2004, 10, 3444-3447.	3.2	128
181	Reduction in Raf Kinase Inhibitor Protein Expression Is Associated with Increased Ras-Extracellular Signal-Regulated Kinase Signaling in Melanoma Cell Lines. <i>Cancer Research</i> , 2004, 64, 5186-5192.	0.4	181
182	Oncogenic Mutations of PIK3CA in Human Cancers. <i>Cell Cycle</i> , 2004, 3, 1221-1224.	1.3	435
183	BRAF Mutation Is Frequently Present in Sporadic Colorectal Cancer with Methylated hMLH1, But Not in Hereditary Nonpolyposis Colorectal Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 191-195.	3.2	378
184	Cooperative Regulation of the Cell Division Cycle by the Protein Kinases RAF and AKT. <i>Molecular and Cellular Biology</i> , 2004, 24, 10868-10881.	1.1	109
185	Mutational Analysis of BRAF in Fine Needle Aspiration Biopsies of the Thyroid: A Potential Application for the Preoperative Assessment of Thyroid Nodules. <i>Clinical Cancer Research</i> , 2004, 10, 2761-2765.	3.2	213
186	BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. <i>Endocrine-Related Cancer</i> , 2004, 11, 855-860.	1.6	39
187	Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia. <i>Cancer Research</i> , 2004, 64, 8816-8820.	0.4	472
188	Disruption of the Rb-Raf-1 Interaction Inhibits Tumor Growth and Angiogenesis. <i>Molecular and Cellular Biology</i> , 2004, 24, 9527-9541.	1.1	96
189	Ras/Mitogen-Activated Protein Kinase Signaling Activates Ets-1 and Ets-2 by CBP/p300 Recruitment. <i>Molecular and Cellular Biology</i> , 2004, 24, 10954-10964.	1.1	167
190	Different Effects of Point Mutations within the B-Raf Glycine-Rich Loop in Colorectal Tumors on Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase and Nuclear Factor κ B Pathway and Cellular Transformation. <i>Cancer Research</i> , 2004, 64, 3428-3435.	0.4	69

#	ARTICLE	IF	CITATIONS
191	Gleevec: Prototype or Outlier?. Science Signaling, 2004, 2004, pe12-pe12.	1.6	19
192	B-Raf Acts via the ROCKII/LIMK/Cofilin Pathway To Maintain Actin Stress Fibers in Fibroblasts. Molecular and Cellular Biology, 2004, 24, 5937-5952.	1.1	91
193	Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression. Genes and Development, 2004, 18, 1800-1805.	2.7	59
194	Absence of BRAF mutations in UV-protected mucosal melanomas. Journal of Medical Genetics, 2004, 41, 270-272.	1.5	157
195	How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. Journal of Endocrinology, 2004, 183, 249-256.	1.2	142
196	Inhibition of Melanoma Growth and Metastasis by ATF2-Derived Peptides. Cancer Research, 2004, 64, 8222-8230.	0.4	47
197	Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers. Science, 2004, 304, 1164-1166.	6.0	498
198	Up-regulation of Flotillin-2 Is Associated with Melanoma Progression and Modulates Expression of the Thrombin Receptor Protease Activated Receptor 1. Cancer Research, 2004, 64, 7361-7369.	0.4	92
199	Incidence of BRAF Oncogene Mutation and Clinical Relevance for Primary Cutaneous Melanomas. Clinical Cancer Research, 2004, 10, 1753-1757.	3.2	208
200	Early Occurrence of RASSF1A Hypermethylation and Its Mutual Exclusion with BRAF Mutation in Thyroid Tumorigenesis. Cancer Research, 2004, 64, 1664-1668.	0.4	142
201	Topical Treatment with Inhibitors of the Phosphatidylinositol 3-kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient Mice. Cancer Research, 2004, 64, 2552-2560.	0.4	74
202	B-Raf Is Dispensable for K-Ras-Mediated Oncogenesis in Human Cancer Cells 1. Cancer Research, 2004, 64, 1932-1937.	0.4	32
203	Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors. Cancer Research, 2004, 64, 6915-6918.	0.4	186
204	BRAF Mutations in Conjunctival Melanoma. , 2004, 45, 2484.		105
205	Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas.. Pigment Cell & Melanoma Research, 2004, 17, 430-430.	4.0	293
206	Subcellular Localization Determines the Protective Effects of Activated ERK2 against Distinct Apoptogenic Stimuli in Myeloid Leukemia Cells. Journal of Biological Chemistry, 2004, 279, 32813-32823.	1.6	51
207	Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma. Clinical Cancer Research, 2004, 10, 6388S-6392S.	3.2	232
208	Genome coverage and sequence fidelity of Φ 29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Research, 2004, 32, e71-e71.	6.5	266

#	ARTICLE	IF	CITATIONS
209	Crucial Role of Phospholipase C μ in Chemical Carcinogen-Induced Skin Tumor Development. <i>Cancer Research</i> , 2004, 64, 8808-8810.	0.4	195
210	Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. <i>Human Molecular Genetics</i> , 2004, 13, 2303-2311.	1.4	127
211	The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. <i>International Journal of Oncology</i> , 2004, 25, 1729.	1.4	23
212	Molecular Findings in Barrett's Epithelium. <i>Digestive Diseases</i> , 2004, 22, 126-133.	0.8	15
213	Role for Raf in the entry of viruses associated with AIDS (Review). <i>International Journal of Oncology</i> , 2004, 25, 469.	1.4	1
214	Role of Raf Isoforms in Signal Transduction Pathways Relevant to Leukemia Cell Proliferation. <i>Cell Cycle</i> , 2004, 3, 171-173.	1.3	1
215	Regulation of B-Raf Kinase Activity by Tuberin and Rheb Is Mammalian Target of Rapamycin (mTOR)-independent. <i>Journal of Biological Chemistry</i> , 2004, 279, 29930-29937.	1.6	91
216	Roles of Stem Cell Factor/c-Kit and Effects of Glivec®/STI571 in Human Uveal Melanoma Cell Tumorigenesis. <i>Journal of Biological Chemistry</i> , 2004, 279, 31769-31779.	1.6	75
217	Cation Diffusion Facilitator Proteins Modulate Raf-1 Activity. <i>Journal of Biological Chemistry</i> , 2004, 279, 27807-27815.	1.6	64
218	Immunogenicity of Constitutively Active V599EBRaf. <i>Cancer Research</i> , 2004, 64, 5456-5460.	0.4	71
219	Molecular Differences between Sporadic Serrated and Conventional Colorectal Adenomas. <i>Clinical Cancer Research</i> , 2004, 10, 3082-3090.	3.2	74
220	SPRY2 Is an Inhibitor of the Ras/Extracellular Signal-Regulated Kinase Pathway in Melanocytes and Melanoma Cells with Wild-Type BRAF but Not with the V599E Mutant. <i>Cancer Research</i> , 2004, 64, 5556-5559.	0.4	107
221	MEK1 and MEK2, Different Regulators of the G1/S Transition. <i>Journal of Biological Chemistry</i> , 2004, 279, 43861-43869.	1.6	96
222	BRAF Gene Is Somatic Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 286-292.	0.8	55
223	Telomere-based DNA damage responses: a new approach to melanoma. <i>FASEB Journal</i> , 2004, 18, 1373-1381.	0.2	76
224	Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4222-4227.	3.3	54
225	Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis. <i>Cancer Research</i> , 2004, 64, 4585-4592.	0.4	184
226	Induction of Melanoma Phenotypes in Human Skin by Growth Factors and Ultraviolet B. <i>Cancer Research</i> , 2004, 64, 807-811.	0.4	82

#	ARTICLE	IF	CITATIONS
227	Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 33168-33176.	1.6	137
228	Conferring specificity on the ubiquitous Raf/MEK signalling pathway. <i>British Journal of Cancer</i> , 2004, 90, 283-288.	2.9	148
229	BRAF Mutations Are Not an Alternative Explanation for the Molecular Etiology of ras -Mutation Negative Cold Thyroid Nodules. <i>Thyroid</i> , 2004, 14, 359-361.	2.4	14
230	Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. <i>Molecular and Cellular Biology</i> , 2004, 24, 25-35.	1.1	115
232	Targeting protein kinases in cancer therapy: a success?. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1113-1124.	1.1	44
234	BRAF T1796A Transversion Mutation in Various Thyroid Neoplasms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1365-1368.	1.8	125
235	Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens: A New Diagnostic Tool for Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2867-2872.	1.8	239
236	Recent Advances in Melanoma Biology. <i>Oncologist</i> , 2004, 9, 182-187.	1.9	59
237	Principles behind the multifarious control of signal transduction. <i>FEBS Journal</i> , 2004, 272, 244-258.	2.2	135
238	Association between melanoma and dermal mast cell prevalence in sun-unexposed skin. <i>British Journal of Dermatology</i> , 2004, 150, 895-903.	1.4	46
239	Autonomously functioning thyroid nodules are not associated with BRAF mutations. <i>Clinical Endocrinology</i> , 2004, 60, 394-396.	1.2	3
240	Tall stories: the devilish detail of genetic association studies. <i>Clinical Endocrinology</i> , 2004, 60, 394-394.	1.2	1
241	BRAF mutations in an Italian cohort of thyroid cancers. <i>Clinical Endocrinology</i> , 2004, 61, 239-243.	1.2	167
242	K-ras and B-raf gene mutations are not associated with gastrin- and CCK2-receptor mRNA expression in human colorectal tumour tissues. <i>European Journal of Clinical Investigation</i> , 2004, 34, 100-106.	1.7	6
243	Kinase inhibitors in cancer therapy. <i>Veterinary and Comparative Oncology</i> , 2004, 2, 177-193.	0.8	30
244	Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. <i>Apmis</i> , 2004, 112, 233-238.	0.9	32
245	The Transcription Network Regulating Melanocyte Development and Melanoma. <i>Pigment Cell & Melanoma Research</i> , 2004, 17, 318-325.	4.0	167
246	The T1796A mutation of the BRAF gene is absent in Spitz nevi. <i>Journal of Cutaneous Pathology</i> , 2004, 31, 266-270.	0.7	66

#	ARTICLE	IF	CITATIONS
247	Tandem BRAF Mutations in Primary Invasive Melanomas. <i>Journal of Investigative Dermatology</i> , 2004, 122, 1245-1250.	0.3	51
248	Lack of BRAF Mutations in Spitz nevi. <i>Journal of Investigative Dermatology</i> , 2004, 122, 1325-1326.	0.3	60
249	In This Issueâ€™Oncogenes, Tumor Suppressor Genes and Melanocytic Lesions. <i>Journal of Investigative Dermatology</i> , 2004, 122, vii-viii.	0.3	0
250	BRAF Point Mutations in Primary Melanoma Show Different Prevalences by Subtype. <i>Journal of Investigative Dermatology</i> , 2004, 123, 177-183.	0.3	79
251	Epidermal Growth Factor Gene (EGF) Polymorphism and Risk of Melanocytic Neoplasia. <i>Journal of Investigative Dermatology</i> , 2004, 123, 760-762.	0.3	44
252	BRAF Kinase Gene V599E Mutation in Growing Melanocytic Lesions. <i>Journal of Investigative Dermatology</i> , 2004, 123, 733-736.	0.3	45
253	Loitering with Intent: New Evidence for the Role of BRAF Mutations in the Proliferation of Melanocytic Lesions. <i>Journal of Investigative Dermatology</i> , 2004, 123, xvi-xvii.	0.3	12
254	Method of Mutation Analysis May Contribute to Discrepancies in Reports of V599EBRAF Mutation Frequencies in Melanocytic Neoplasms. <i>Journal of Investigative Dermatology</i> , 2004, 123, 990-992.	0.3	35
255	MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation. <i>Nature Cell Biology</i> , 2004, 6, 770-776.	4.6	149
256	Cancer genes and the pathways they control. <i>Nature Medicine</i> , 2004, 10, 789-799.	15.2	3,689
257	Switching on kinases: oncogenic activation of BRAF and the PDGFR family. <i>Nature Reviews Cancer</i> , 2004, 4, 718-727.	12.8	160
258	Targeting the mitogen-activated protein kinase cascade to treat cancer. <i>Nature Reviews Cancer</i> , 2004, 4, 937-947.	12.8	1,051
259	The RAF proteins take centre stage. <i>Nature Reviews Molecular Cell Biology</i> , 2004, 5, 875-885.	16.1	1,066
260	PI3K mediates protection against TRAIL-induced apoptosis in primary human melanocytes. <i>Cell Death and Differentiation</i> , 2004, 11, 1084-1091.	5.0	88
261	BRAF mutations in acute leukemias. <i>Leukemia</i> , 2004, 18, 170-172.	3.3	42
262	JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. <i>Leukemia</i> , 2004, 18, 189-218.	3.3	601
263	BRAF gene is not mutated in mismatch repair-proficient or -deficient plasma cell dyscrasias. <i>Leukemia</i> , 2004, 18, 658-659.	3.3	3
264	Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. <i>Oncogene</i> , 2004, 23, 554-558.	2.6	73

#	ARTICLE	IF	CITATIONS
265	Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. <i>Oncogene</i> , 2004, 23, 2264-2274.	2.6	71
266	Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. <i>Oncogene</i> , 2004, 23, 2347-2356.	2.6	99
267	Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. <i>Oncogene</i> , 2004, 23, 3426-3433.	2.6	85
268	Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. <i>Oncogene</i> , 2004, 23, 4037-4040.	2.6	111
269	Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. <i>Oncogene</i> , 2004, 23, 4014-4022.	2.6	231
270	Microarray expression profiling in melanoma reveals a BRAF mutation signature. <i>Oncogene</i> , 2004, 23, 4060-4067.	2.6	169
271	Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. <i>Oncogene</i> , 2004, 23, 4536-4555.	2.6	76
272	Raf promotes human herpesvirus-8 (HHV-8/KSHV) infection. <i>Oncogene</i> , 2004, 23, 5227-5241.	2.6	40
273	Melanoma cells secrete follistatin, an antagonist of activin-mediated growth inhibition. <i>Oncogene</i> , 2004, 23, 5330-5339.	2.6	38
274	BRAF alterations are associated with complex mutational profiles in malignant melanoma. <i>Oncogene</i> , 2004, 23, 5968-5977.	2.6	189
275	B-RAF is a therapeutic target in melanoma. <i>Oncogene</i> , 2004, 23, 6292-6298.	2.6	410
276	Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. <i>Oncogene</i> , 2004, 23, 6031-6039.	2.6	177
277	CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. <i>Oncogene</i> , 2004, 23, 8695-8699.	2.6	55
278	Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. <i>Oncogene</i> , 2004, 23, 7436-7440.	2.6	239
279	Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines. <i>Oncogene</i> , 2004, 23, 8796-8804.	2.6	91
280	Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma. <i>British Journal of Cancer</i> , 2004, 91, 1495-1499.	2.9	68
281	Molecular genetic analysis of ovarian serous cystadenomas. <i>Laboratory Investigation</i> , 2004, 84, 778-784.	1.7	53
282	BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. <i>Modern Pathology</i> , 2004, 17, 1359-1363.	2.9	161

#	ARTICLE	IF	CITATIONS
283	The V599E BRAF mutation is uncommon in biliary tract cancers. <i>Modern Pathology</i> , 2004, 17, 1386-1391.	2.9	40
284	Oncogenomics and the development of new cancer therapies. <i>Nature</i> , 2004, 429, 469-474.	13.7	92
285	G1 cell-cycle control and cancer. <i>Nature</i> , 2004, 432, 298-306.	13.7	1,082
286	Targeted cancer therapy. <i>Nature</i> , 2004, 432, 294-297.	13.7	988
287	Bittersweet evolution. <i>Nature</i> , 2004, 428, 813-813.	13.7	1
288	Molecular biology of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2004, 7, 6-20.	2.0	38
289	Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?. <i>Trends in Cell Biology</i> , 2004, 14, 639-647.	3.6	274
290	Oncogenic Ras and its role in tumor cell invasion and metastasis. <i>Seminars in Cancer Biology</i> , 2004, 14, 105-114.	4.3	246
291	Targets for molecular therapy of skin cancer. <i>Seminars in Cancer Biology</i> , 2004, 14, 63-69.	4.3	56
292	Oncogenic B-Raf mutations. <i>Cancer Cell</i> , 2004, 5, 303-304.	7.7	55
293	Molecular classification and molecular genetics of human lung cancers. <i>Seminars in Oncology</i> , 2004, 31, 4-19.	0.8	56
294	Bioinformatics and cancer target discovery. <i>Drug Discovery Today</i> , 2004, 9, 795-802.	3.2	42
295	Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors. <i>Gynecologic Oncology</i> , 2004, 95, 603-609.	0.6	19
296	Rapid detection of mutations in the BRAF gene using real-time polymerase chain reaction and melting curve analysis. <i>Cancer Genetics and Cytogenetics</i> , 2004, 149, 68-71.	1.0	15
297	Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure. <i>BMC Cancer</i> , 2004, 4, 24.	1.1	42
298	Genome wide in silico SNP-tumor association analysis. <i>BMC Cancer</i> , 2004, 4, 4.	1.1	19
299	B-Raf specific antibody responses in melanoma patients. <i>BMC Cancer</i> , 2004, 4, 62.	1.1	21
300	BAG-1 haplo-insufficiency impairs lung tumorigenesis. <i>BMC Cancer</i> , 2004, 4, 85.	1.1	27

#	ARTICLE	IF	CITATIONS
301	Bcl-2 proteins: master switches at the intersection of death signaling and the survival control by Raf kinases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2004, 1644, 149-158.	1.9	25
302	Tyrosine kinase inhibitors. <i>Cancer Cell</i> , 2004, 5, 525-531.	7.7	89
303	Guilty as charged. <i>Cancer Cell</i> , 2004, 6, 313-319.	7.7	736
304	Somatic alterations in the human cancer genome. <i>Cancer Cell</i> , 2004, 6, 433-438.	7.7	148
305	Ras inhibition leads to transcriptional activation of p53 and down-regulation of Mdm2: two mechanisms that cooperatively increase p53 function in colon cancer cells. <i>Cellular Signalling</i> , 2004, 16, 1319-1327.	1.7	45
306	RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 935-939.	0.7	32
308	Genetic Alterations Involved in the Transition from Well-Differentiated to Poorly Differentiated and Anaplastic Thyroid Carcinomas. <i>Endocrine Pathology</i> , 2004, 15, 319-328.	5.2	204
309	Molecular Analysis of Structural Abnormalities in Papillary Thyroid Carcinoma Genome. <i>Molecular Biology</i> , 2004, 38, 538-548.	0.4	3
310	Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. <i>New England Journal of Medicine</i> , 2004, 350, 2129-2139.	13.9	10,632
311	Brn-2 Expression Controls Melanoma Proliferation and Is Directly Regulated by β -Catenin. <i>Molecular and Cellular Biology</i> , 2004, 24, 2915-2922.	1.1	111
312	The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation. <i>Molecular and Cellular Biology</i> , 2004, 24, 2923-2931.	1.1	110
313	Circulating Nucleic Acids and Proteomics of Plasma/Serum: Clinical Utility. <i>Annals of the New York Academy of Sciences</i> , 2004, 1022, 1-8.	1.8	59
314	Mutant Form of BRAF Gene in Blood Plasma of Cancer Patients. <i>Annals of the New York Academy of Sciences</i> , 2004, 1022, 228-231.	1.8	16
315	A New Technology for Mutation Detection. <i>Annals of the New York Academy of Sciences</i> , 2004, 1022, 257-262.	1.8	22
316	Regulation of Tumor Cell Motility by ERK Mitogen-Activated Protein Kinases. <i>Annals of the New York Academy of Sciences</i> , 2004, 1030, 208-218.	1.8	86
317	Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 179-82.	1.4	59
318	Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. <i>Acta Neuropathologica</i> , 2004, 108, 467-470.	3.9	136
319	Raf kinases and cancer. <i>Onkologie</i> , 2004, 10, S64-S68.	0.7	0

#	ARTICLE	IF	CITATIONS
320	BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas. <i>Gastric Cancer</i> , 2004, 7, 246-253.	2.7	40
321	From gene function to improved health: genome research in the United Kingdom. <i>Journal of Molecular Medicine</i> , 2004, 82, 74-90.	1.7	5
322	Targeting multiple signal transduction pathways through inhibition of Hsp90. <i>Journal of Molecular Medicine</i> , 2004, 82, 488-99.	1.7	325
323	Involvement of metabotropic glutamate receptor γ 21, a G protein coupled receptor, in melanoma development. <i>Journal of Molecular Medicine</i> , 2004, 82, 735-749.	1.7	53
324	Chemoprevention of melanoma. <i>Current Oncology Reports</i> , 2004, 6, 406-413.	1.8	6
325	BRAF Mutations Are Common Somatic Events in Melanocytic Nevi 11 Tables 2 and 3 can be found at http://www.blackwellpublishing.com/products/journals/suppmat/jid/jid22225/jid22225sm.htm . <i>Journal of Investigative Dermatology</i> , 2004, 122, 342-348.	0.3	206
326	Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma. <i>Journal of Investigative Dermatology</i> , 2004, 122, 337-341.	0.3	411
327	BRAF mutations are associated with some histological types of papillary thyroid carcinoma. <i>Journal of Pathology</i> , 2004, 202, 247-251.	2.1	334
328	In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. <i>Journal of Pathology</i> , 2004, 202, 336-340.	2.1	229
329	The genetics of skin cancer. <i>American Journal of Medical Genetics Part A</i> , 2004, 131C, 82-92.	2.4	68
330	Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. <i>Genes Chromosomes and Cancer</i> , 2004, 39, 138-142.	1.5	87
331	Genetic similarities between Spitz nevus and Spitzoid melanoma in children. <i>Cancer</i> , 2004, 101, 2636-2640.	2.0	85
332	Mutations of BRAF are associated with extensive MLH1 promoter methylation in sporadic colorectal carcinomas. <i>International Journal of Cancer</i> , 2004, 108, 237-242.	2.3	128
333	Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. <i>International Journal of Cancer</i> , 2004, 108, 167-169.	2.3	45
334	Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. <i>International Journal of Cancer</i> , 2004, 109, 377-384.	2.3	133
335	Identification of five chromosomal regions involved in predisposition to melanoma by genome-wide scan in the MeLiM swine model. <i>International Journal of Cancer</i> , 2004, 110, 39-50.	2.3	31
336	High BRAF mutation frequency does not characterize all melanocytic tumor types. <i>International Journal of Cancer</i> , 2004, 111, 705-710.	2.3	144
337	Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. <i>International Journal of Cancer</i> , 2004, 112, 190-199.	2.3	41

#	ARTICLE	IF	CITATIONS
338	Increased Single-Nucleotide Discrimination of PCR by Primer Probes Bearing Hydrophobic 4-Å ² C Modifications. <i>ChemBioChem</i> , 2004, 5, 333-339.	1.3	15
339	3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 6415-6425.	1.4	24
340	Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma*1. <i>Hepatology Research</i> , 2004, 29, 113-121.	1.8	121
341	MALDI-TOF MS: a platform technology for genetic discovery. <i>International Journal of Mass Spectrometry</i> , 2004, 238, 173-188.	0.7	17
342	Mutational activation of the RAS-RAF-MAPK and the wnt pathway in small intestinal adenocarcinomas. <i>Scandinavian Journal of Gastroenterology</i> , 2004, 39, 748-753.	0.6	61
343	BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. <i>Journal of Medical Genetics</i> , 2004, 41, 664-668.	1.5	305
344	Colorectal Cancer With Mutation in BRAF, KRAS, and Wild-Type With Respect to Both Oncogenes Showing Different Patterns of DNA Methylation. <i>Journal of Clinical Oncology</i> , 2004, 22, 4584-4594.	0.8	202
345	The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. <i>British Journal of Cancer</i> , 2004, 91, 355-358.	2.9	1,118
346	BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. <i>Gut</i> , 2004, 53, 1137-1144.	6.1	628
347	BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis. <i>Cancer Research</i> , 2004, 64, 7099-7109.	0.4	3,718
348	Mining Disease Susceptibility Genes through SNP Analyses and Expression Profiling Using MALDI-TOF Mass Spectrometry. <i>Journal of Proteome Research</i> , 2004, 3, 218-227.	1.8	50
349	Quantitative methods for the analysis of protein phosphorylation in drug development. <i>Expert Review of Proteomics</i> , 2004, 1, 327-341.	1.3	76
350	BRAF mutations distinguish anorectal from cutaneous melanoma at the molecular level. <i>Gastroenterology</i> , 2004, 127, 1815-1820.	0.6	31
351	Network-targeted combination therapy: a new concept in cancer treatment. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 425-433.	0.5	14
352	SIGNALING PATHWAYS IN INTESTINAL DEVELOPMENT AND CANCER. <i>Annual Review of Cell and Developmental Biology</i> , 2004, 20, 695-723.	4.0	453
353	Melanocytes and the Microphthalmia Transcription Factor Network. <i>Annual Review of Genetics</i> , 2004, 38, 365-411.	3.2	682
354	Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1-19.	1.9	48
355	BRAFV599E Mutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2414-2420.	1.8	259

#	ARTICLE	IF	CITATIONS
356	Inhibitors of HSP90 and other chaperones for the treatment of cancer. Expert Opinion on Therapeutic Patents, 2004, 14, 837-847.	2.4	46
357	Development of Rationally Designed, Target-Based Agents for the Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, 107-123.	1.0	4
358	Clinical significance of BRAF mutations in metastatic melanoma. Journal of Translational Medicine, 2004, 2, 46.	1.8	58
359	Management of Cutaneous Melanoma. New England Journal of Medicine, 2004, 351, 998-1012.	13.9	735
360	<i>B-raf</i> Exon 15 Mutations Are Common in Primary Melanoma Resection Specimens but Not Associated with Clinical Outcome. Oncology, 2004, 66, 411-419.	0.9	19
361	Human RAS Superfamily Proteins and Related GTPases. Science Signaling, 2004, 2004, re13-re13.	1.6	614
362	BRAF Mutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4267-4271.	1.8	171
363	Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer. Cancer Letters, 2004, 211, 105-109.	3.2	24
364	A study of the role of cell cycle events mediating the action of coumarin derivatives in human malignant melanoma cells. Cancer Letters, 2004, 214, 43-54.	3.2	52
365	Genetic progression of metastatic melanoma. Cancer Letters, 2004, 214, 133-147.	3.2	62
366	Heme controls the expression of cell cycle regulators and cell growth in HeLa cells. Biochemical and Biophysical Research Communications, 2004, 315, 546-554.	1.0	41
367	Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. Biochemical and Biophysical Research Communications, 2004, 322, 609-613.	1.0	18
368	14-3-3 Proteins—a focus on cancer and human disease. Journal of Molecular and Cellular Cardiology, 2004, 37, 633-642.	0.9	229
369	Ovarian Tumorigenesis. American Journal of Pathology, 2004, 164, 1511-1518.	1.9	1,107
370	Mechanisms of Cell-Cycle Arrest in Spitz Nevi with Constitutive Activation of the MAP-Kinase Pathway. American Journal of Pathology, 2004, 164, 1783-1787.	1.9	99
371	MDA-7/IL-24 is a unique cytokine—a tumor suppressor in the IL-10 Family. International Immunopharmacology, 2004, 4, 649-667.	1.7	127
372	Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E. Molecular and Cellular Probes, 2004, 18, 349-352.	0.9	85
373	Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell, 2004, 116, 855-867.	13.5	2,479

#	ARTICLE	IF	CITATIONS
374	Oncogenic Mutations in B-Raf. <i>Cell</i> , 2004, 116, 764-766.	13.5	28
375	Enzymes play molecular tag. <i>Nature</i> , 2004, 428, 813-815.	13.7	6
376	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy. <i>Science</i> , 2004, 304, 1497-1500.	6.0	9,038
377	Automation and Robotics for Genetic Analysis. <i>Current Protocols in Human Genetics</i> , 2004, 40, 16.0.1.	3.5	0
378	The RAS-BRAF kinase pathway is not involved in uveal melanoma. <i>Melanoma Research</i> , 2004, 14, 203-205.	0.6	45
379	BRAF and KRAS Mutations in Hyperplastic Polyps and Serrated Adenomas of the Colorectum. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1452-1459.	2.1	277
380	Analysis of the ERK1,2 transcriptome in mammary epithelial cells. <i>Biochemical Journal</i> , 2004, 381, 635-644.	1.7	27
381	BRAF mutations are detectable in conjunctival but not uveal melanomas. <i>Melanoma Research</i> , 2004, 14, 449-452.	0.6	110
382	Orthotopic Transplantation Models of Pancreatic Adenocarcinoma Derived From Cell Lines and Primary Tumors and Displaying Varying Metastatic Activity. <i>Pancreas</i> , 2004, 29, 193-203.	0.5	140
383	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. <i>Blood</i> , 2004, 103, 2325-2331.	0.6	415
384	Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. <i>Biochemical Society Transactions</i> , 2004, 32, 393-396.	1.6	91
385	Oncogenes. , 2004, , 571-606.		0
387	Pancreatic Carcinoma: An Introduction. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, 3, 279-304.	0.0	0
388	Somatic Mutations in Human Cancer: Insights from Resequencing the Protein Kinase Gene Family. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 43-49.	2.0	27
389	CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2. <i>Journal of Immunotherapy</i> , 2005, 28, 120-128.	1.2	199
390	Identification of susceptibility genes and genetic modifiers of human diseases. , 2005, , .		2
391	Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. <i>Melanoma Research</i> , 2005, 15, 235-244.	0.6	50
392	Uveal Melanoma: Genetic Aspects. <i>Ophthalmology Clinics of North America</i> , 2005, 18, 85-97.	1.8	46

#	ARTICLE	IF	CITATIONS
393	Analysis of Mutations in B-RAF, N-RAS, and H-RAS Genes in the Differential Diagnosis of Spitz Nevus and Spitzoid Melanoma. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1145-1151.	2.1	167
394	Detection of Oncogenic Mutations in the EGFR Gene in Lung Adenocarcinoma with Differential Sensitivity to EGFR Tyrosine Kinase Inhibitors. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 73-81.	2.0	37
395	Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2005, 12, 55-61.	1.2	11
396	Meningeal Melanocytoma Associated with Ipsilateral Nevus of Ota Presenting as Intracerebral Hemorrhage: Case Report. <i>Neurosurgery</i> , 2005, 56, E1376-E1376.	0.6	33
397	Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 499-515.	2.0	31
398	"Lineage Addiction" in Human Cancer: Lessons from Integrated Genomics. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 25-34.	2.0	28
399	Screens Using RNAi and cDNA Expression as Surrogates for Genetics in Mammalian Tissue Culture Cells. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 449-459.	2.0	22
400	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1068-1081.	3.9	231
401	Human SK-Mel 28 melanoma cells resume neural crest cell migration after transplantation into the chick embryo. <i>Melanoma Research</i> , 2005, 15, 225-234.	0.6	24
402	Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi. <i>Melanoma Research</i> , 2005, 15, 401-407.	0.6	57
403	Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases. <i>Melanoma Research</i> , 2005, 15, 427-434.	0.6	17
404	Fluorescence in situ hybridization (FISH) evaluation of chromosomes 6, 7, 9 and 10 throughout human melanocytic tumorigenesis. <i>Melanoma Research</i> , 2005, 15, 155-160.	0.6	35
405	The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. <i>Anti-Cancer Drugs</i> , 2005, 16, 129-136.	0.7	42
406	Pathophysiology, pleiotropy and paradigm shifts: genetic lessons from Parkinson's disease. <i>Biochemical Society Transactions</i> , 2005, 33, 586-590.	1.6	39
407	B-Raf-dependent expression of vascular endothelial growth factor-A in Kaposi sarcoma-associated herpesvirus-infected human B cells. <i>Blood</i> , 2005, 105, 4516-4522.	0.6	44
408	Cutaneous melanoma: pathogenesis and rationale for chemoprevention. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 225-239.	2.0	25
409	Targeting Intracellular Signaling Pathways as a Novel Strategy in Melanoma Therapeutics. <i>Annals of the New York Academy of Sciences</i> , 2005, 1059, 16-25.	1.8	78
410	BRAF Copy Number Gains in Thyroid Tumors Detected by Fluorescence In Situ Hybridization. <i>Endocrine Pathology</i> , 2005, 16, 099-106.	5.2	48

#	ARTICLE	IF	CITATIONS
411	Alterations of the <I>BRAF</I> Gene in Thyroid Tumors. <i>Endocrine Pathology</i> , 2005, 16, 163-172.	5.2	101
412	Understanding the Genotype of Follicular Thyroid Tumors. <i>Endocrine Pathology</i> , 2005, 16, 311-322.	5.2	26
413	Cancer Targets in the Ras Pathway. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 461-467.	2.0	95
414	Oncogenic Ras in tumour progression and metastasis. <i>Biological Chemistry</i> , 2005, 386, 193-205.	1.2	240
415	Raf Kinase Inhibitors in Oncology. <i>Oncology Research and Treatment</i> , 2005, 28, 101-107.	0.8	31
416	Management of advanced renal cancer. <i>Kidney International</i> , 2005, 67, 2069-2082.	2.6	14
417	Somatic mutations in thePTCH,SMOH,SUFUHandTP53genes in sporadic basal cell carcinomas. <i>British Journal of Dermatology</i> , 2005, 152, 43-51.	1.4	367
418	T1796A BRAF mutation is absent in Merkel cell carcinoma. <i>British Journal of Dermatology</i> , 2005, 153, 229-232.	1.4	18
419	Evaluation of germline CDKN2A, ARF, CDK4, PTEN, and BRAF alterations in atypical mole syndrome. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 68-70.	0.6	23
420	The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. <i>Clinical Endocrinology</i> , 2005, 63, 263-266.	1.2	41
421	The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. <i>Clinical Endocrinology</i> , 2005, 63, 588-593.	1.2	209
422	Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. <i>British Journal of Cancer</i> , 2005, 92, 1855-1861.	2.9	321
423	Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. <i>British Journal of Cancer</i> , 2005, 92, 1997-2003.	2.9	31
424	Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. <i>British Journal of Cancer</i> , 2005, 92, 2032-2038.	2.9	222
425	Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. <i>Nature Genetics</i> , 2005, 37, 745-749.	9.4	192
426	Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 988-1004.	21.5	1,853
427	Short interfering RNAs as a tool for cancer gene therapy. <i>Cancer Gene Therapy</i> , 2005, 12, 217-227.	2.2	175
428	Raf and VEGF: emerging therapeutic targets in Kaposi's sarcoma-associated herpesvirus infection and angiogenesis in hematopoietic and nonhematopoietic tumors. <i>Leukemia</i> , 2005, 19, 18-26.	3.3	38

#	ARTICLE	IF	CITATIONS
429	Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. <i>Leukemia</i> , 2005, 19, 310-312.	3.3	45
430	Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 2232-2240.	3.3	108
431	Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. <i>Oncogene</i> , 2005, 24, 616-626.	2.6	60
432	Signaling properties and expression in normal and tumor tissues of two phospholipase C epsilon splice variants. <i>Oncogene</i> , 2005, 24, 90-100.	2.6	58
433	B-Raf and Ha-ras mutations in chemically induced mouse liver tumors. <i>Oncogene</i> , 2005, 24, 1290-1295.	2.6	43
434	Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. <i>Oncogene</i> , 2005, 24, 1122-1127.	2.6	100
435	HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. <i>Oncogene</i> , 2005, 24, 1423-1433.	2.6	71
436	RKIP downregulates B-Raf kinase activity in melanoma cancer cells. <i>Oncogene</i> , 2005, 24, 3535-3540.	2.6	109
437	Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. <i>Oncogene</i> , 2005, 24, 3459-3471.	2.6	133
438	BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. <i>Oncogene</i> , 2005, 24, 3995-3998.	2.6	155
439	A-Raf and Raf-1 work together to influence transient ERK phosphorylation and G1/S cell cycle progression. <i>Oncogene</i> , 2005, 24, 5207-5217.	2.6	41
440	Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V600E) B-RAF. <i>Oncogene</i> , 2005, 24, 6292-6302.	2.6	47
441	Control of MAPK signalling: from complexity to what really matters. <i>Oncogene</i> , 2005, 24, 5533-5542.	2.6	175
442	Wild-type blocking polymerase chain reaction for detection of single nucleotide minority mutations from clinical specimens. <i>Oncogene</i> , 2005, 24, 6830-6834.	2.6	86
443	The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. <i>Oncogene</i> , 2005, 24, 6861-6869.	2.6	254
444	Retroviral insertional mutagenesis: past, present and future. <i>Oncogene</i> , 2005, 24, 7656-7672.	2.6	250
445	RASSF1A and NRE1A methylation and BRAFV600E mutations in thyroid tumors. <i>Laboratory Investigation</i> , 2005, 85, 1065-1075.	1.7	104
446	Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors. <i>Modern Pathology</i> , 2005, 18, 1079-1087.	2.9	71

#	ARTICLE	IF	CITATIONS
447	Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. <i>Nature</i> , 2005, 433, 764-769.	13.7	361
448	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. <i>Nature</i> , 2005, 436, 117-122.	13.7	1,329
449	Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. <i>Nature</i> , 2005, 436, 272-276.	13.7	396
450	Interaction maps for kinase inhibitors. <i>Nature Biotechnology</i> , 2005, 23, 308-309.	9.4	14
451	Adding diversity to plant transformation. <i>Nature Biotechnology</i> , 2005, 23, 309-310.	9.4	17
452	The weakest link?. <i>Nature</i> , 2005, 436, 33-35.	13.7	5
453	Where slugs may safely graze. <i>Nature</i> , 2005, 436, 35-36.	13.7	0
454	Mutations in a signalling pathway. <i>Nature</i> , 2005, 436, 792-792.	13.7	510
456	Mutational analysis of the ARAF gene in human cancers. <i>Apmis</i> , 2005, 113, 54-7.	0.9	40
457	<i>ERBB2</i> kinase domain mutation in a gastric cancer metastasis. <i>Apmis</i> , 2005, 113, 683-687.	0.9	17
458	BRAF and NRAS Mutations Are Frequent in Nodular Melanoma but Are not Associated with Tumor Cell Proliferation or Patient Survival. <i>Journal of Investigative Dermatology</i> , 2005, 125, 312-317.	0.3	109
459	Constitutive Activation of the Mitogen-Activated Protein Kinase Signaling Pathway in Acral Melanomas. <i>Journal of Investigative Dermatology</i> , 2005, 125, 318-322.	0.3	56
460	Prevalence of Exon 15 BRAF Mutations in Primary Melanoma of the Superficial Spreading, Nodular, Acral, and Lentigo Maligna Subtypes. <i>Journal of Investigative Dermatology</i> , 2005, 125, 575-579.	0.3	65
461	A Missense Mutation in the Cadherin Interaction Site of The Desmoglein 4 Gene Underlies Localized Autosomal Recessive Hypotrichosis. <i>Journal of Investigative Dermatology</i> , 2005, 125, 1077-1079.	0.3	27
462	Neonatal Ultraviolet Radiation Exposure Is Critical for Malignant Melanoma Induction in Pigmented Tpras Transgenic Mice. <i>Journal of Investigative Dermatology</i> , 2005, 125, 1074-1077.	0.3	28
463	Recurrent Patterns of Dual RB and p53 Pathway Inactivation in Melanoma. <i>Journal of Investigative Dermatology</i> , 2005, 125, 1242-1251.	0.3	54
464	BRAF Polymorphisms and Risk of Melanocytic Neoplasia. <i>Journal of Investigative Dermatology</i> , 2005, 125, 1252-1258.	0.3	23
465	The SNPs of RAF. <i>Journal of Investigative Dermatology</i> , 2005, 125, xiv-xv.	0.3	1

#	ARTICLE	IF	CITATIONS
466	Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 334-339.	0.7	43
467	Notch and NOXA-Related Pathways in Melanoma Cells. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2005, 10, 95-104.	0.8	56
468	Normal Human Melanocyte Homeostasis as a Paradigm for Understanding Melanoma. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2005, 10, 153-163.	0.8	177
469	Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of) Tj ETQq1 1 0.784314 rgBT /Overl	1.0	82
470	RalGDS is required for tumor formation in a model of skin carcinogenesis. <i>Cancer Cell</i> , 2005, 7, 219-226.	7.7	162
471	Mutant PIK3CA promotes cell growth and invasion of human cancer cells. <i>Cancer Cell</i> , 2005, 7, 561-573.	7.7	818
472	A conditional feedback loop regulates Ras activity through EphA2. <i>Cancer Cell</i> , 2005, 8, 111-118.	7.7	219
473	The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. <i>Cancer Cell</i> , 2005, 8, 443-454.	7.7	164
474	A-Raf associates with and regulates platelet-derived growth factor receptor signalling. <i>Cellular Signalling</i> , 2005, 17, 857-868.	1.7	18
475	Activation of mitogen activated protein kinase pathways and melanogenesis by novel nitro-derivatives of 7-hydroxycoumarin in human malignant melanoma cells. <i>European Journal of Pharmaceutical Sciences</i> , 2005, 26, 16-25.	1.9	51
476	Detection of B-RAF and N-RAS mutations in human melanoma. <i>Journal of the American College of Surgeons</i> , 2005, 200, 362-370.	0.2	82
477	BRAF Mutations Are Sufficient to Promote Nevi Formation and Cooperate with p53 in the Genesis of Melanoma. <i>Current Biology</i> , 2005, 15, 249-254.	1.8	626
478	K-ras as a target for cancer therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2005, 1756, 127-144.	3.3	137
479	Aberrant DNA Methylation in Cutaneous Malignancies. <i>Seminars in Oncology</i> , 2005, 32, 479-487.	0.8	69
480	Spectroscopic analysis of Kaposi's sarcoma-associated herpesvirus infected cells by Raman tweezers. <i>Journal of Virological Methods</i> , 2005, 129, 145-151.	1.0	29
481	Role of Raf Proteins in Cardiac Hypertrophy and Cardiomyocyte Survival. <i>Trends in Cardiovascular Medicine</i> , 2005, 15, 225-229.	2.3	52
482	Selective evolutionary pressure from the tissue microenvironment drives tumor progression. <i>Seminars in Cancer Biology</i> , 2005, 15, 451-459.	4.3	53
483	The Role of Mitogen-Activated ERK-Kinase Inhibitors in Lung Cancer Therapy. <i>Clinical Lung Cancer</i> , 2005, 7, 221-223.	1.1	28

#	ARTICLE	IF	CITATIONS
484	Targeting Multiple Signal Transduction Pathways in Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 7, S39-S44.	1.1	18
485	Use of a recombinant <i>Salmonella enterica</i> serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice. <i>BMC Cancer</i> , 2005, 5, 15.	1.1	32
486	Mutations of PIK3CA in gastric adenocarcinoma. <i>BMC Cancer</i> , 2005, 5, 29.	1.1	159
487	Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases. <i>BMC Cancer</i> , 2005, 5, 58.	1.1	8
488	BRAF polymorphisms and the risk of ovarian cancer of low malignant potential. <i>Gynecologic Oncology</i> , 2005, 97, 807-812.	0.6	12
489	Histone modifications as a platform for cancer therapy. <i>Journal of Cellular Biochemistry</i> , 2005, 94, 1088-1102.	1.2	59
490	Molecular markers in malignant cutaneous melanoma: Gift horse or one-trick pony?. <i>Journal of Cellular Biochemistry</i> , 2005, 96, 473-483.	1.2	12
491	Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. <i>Journal of Cellular Physiology</i> , 2005, 204, 484-488.	2.0	79
492	BRAF mutation detection and identification by cycling temperature capillary electrophoresis. <i>Electrophoresis</i> , 2005, 26, 2553-2561.	1.3	25
493	B-RAF mutations in tumors from melanoma-breast cancer families. <i>International Journal of Cancer</i> , 2005, 113, 336-337.	2.3	2
494	Mutations of BRAF and RAS are rare events in germ cell tumours. <i>International Journal of Cancer</i> , 2005, 113, 329-335.	2.3	51
495	Activation of gef-h1, a guanine nucleotide exchange factor for RhoA, by DNA transfection. <i>International Journal of Cancer</i> , 2005, 113, 533-540.	2.3	17
496	Alterations of cancer-related genes in soft tissue sarcomas: Hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. <i>International Journal of Cancer</i> , 2005, 114, 442-447.	2.3	50
497	Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type p16 ^{INK4A} in melanoma cells. <i>International Journal of Cancer</i> , 2005, 115, 164-169.	2.3	27
498	Mutations of the BRAF gene in ulcerative colitis-related colorectal carcinoma. <i>International Journal of Cancer</i> , 2005, 115, 673-677.	2.3	36
499	BRAF mutation associated with dysregulation of apoptosis in human colorectal neoplasms. <i>International Journal of Cancer</i> , 2005, 115, 943-950.	2.3	48
500	Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms. <i>International Journal of Cancer</i> , 2005, 116, 894-902.	2.3	16
501	Absence of V599E BRAF mutations in desmoplastic melanomas. <i>Cancer</i> , 2005, 103, 788-792.	2.0	60

#	ARTICLE	IF	CITATIONS
502	Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. <i>Cancer</i> , 2005, 103, 2261-2268.	2.0	195
503	BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. <i>Cancer</i> , 2005, 104, 952-961.	2.0	67
504	Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. <i>Cancer</i> , 2005, 104, 1678-1686.	2.0	61
505	Enhanced Fidelity in Mismatch Extension by DNA Polymerase through Directed Combinatorial Enzyme Design. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 4712-4715.	7.2	59
507	The molecular biology of esophageal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2005, 92, 169-190.	0.8	117
508	Functional consequences of mutations in a putative Akt phosphorylation motif of B-raf in human cancers. <i>Molecular Carcinogenesis</i> , 2005, 43, 59-63.	1.3	15
509	Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 126-137.	1.1	147
510	Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas. <i>Mammalian Genome</i> , 2005, 16, 211-217.	1.0	40
513	Genetic analysis of the kinome and phosphatome in cancer. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 2092-2099.	2.4	52
514	Mutation analysis of B-RAF gene in human gliomas. <i>Acta Neuropathologica</i> , 2005, 109, 207-210.	3.9	85
515	Molecular pathology of well-differentiated thyroid carcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 447, 787-793.	1.4	67
516	Tracing origin of serrated adenomas with BRAF and KRAS mutations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 447, 597-602.	1.4	42
517	Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 589-595.	1.4	242
518	Early cancers of the skin: clinical, histopathological, and molecular characteristics. <i>International Journal of Clinical Oncology</i> , 2005, 10, 391-397.	1.0	31
519	Lrrk2 pathogenic substitutions in Parkinson's disease. <i>Neurogenetics</i> , 2005, 6, 171-177.	0.7	237
520	Promising systemic therapy for renal cell carcinoma. <i>Current Treatment Options in Oncology</i> , 2005, 6, 357-365.	1.3	8
521	Chemotherapies and immunotherapies for metastatic kidney cancer. <i>Current Urology Reports</i> , 2005, 6, 35-42.	1.0	6
522	Integrin signaling in malignant melanoma. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 195-222.	2.7	256

#	ARTICLE	IF	CITATIONS
523	Functional and therapeutic significance of Akt deregulation in malignant melanoma. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 273-285.	2.7	162
524	Protein kinase C in melanoma. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 287-300.	2.7	65
525	Role of nuclear factor- κ B in melanoma. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 301-313.	2.7	176
526	Immunological detection of altered signaling molecules involved in melanoma development. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 357-366.	2.7	10
527	The role of B-RAF in melanoma. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 165-183.	2.7	143
528	Frequency of BRAF T1796A mutation in papillary thyroid carcinoma relates to age of patient at diagnosis and not to radiation exposure. <i>Journal of Pathology</i> , 2005, 205, 558-564.	2.1	84
529	Targeted therapy: For kids, too. <i>Pediatric Blood and Cancer</i> , 2005, 45, 623-634.	0.8	2
530	Cutaneous Melanoma: Prognostic Factors. <i>Cancer Control</i> , 2005, 12, 223-229.	0.7	98
531	Skin Cancer Prevention. , 2005, , 161-201.		1
532	ROLES OF RAS AND BRAF MUTATIONS IN THYROID CARCINOGENESIS. <i>Fukushima Journal of Medical Sciences</i> , 2005, 51, 67-75.	0.1	24
533	Chemoprevention of Melanoma: Theoretical and Practical Considerations. <i>Cancer Control</i> , 2005, 12, 219-222.	0.7	9
534	T1799ABRAF Mutations in Conjunctival Melanocytic Lesions. , 2005, 46, 3027.		75
535	From Tumorigenesis to Tumor Progression: Signaling Pathways Driving Tumor Invasion and Metastasis. , 2005, , 299-339.		3
536	Ten Best Readings Relating to Melanoma. <i>Cancer Control</i> , 2005, 12, 261-262.	0.7	0
537	The herpes simplex virus type 2 protein icp10pk: a master of versatility. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2820.	3.0	20
538	Magnetic Resonance Spectroscopy Monitoring of Mitogen-Activated Protein Kinase Signaling Inhibition. <i>Cancer Research</i> , 2005, 65, 3356-3363.	0.4	80
539	Melanoma genetics and the development of rational therapeutics. <i>Journal of Clinical Investigation</i> , 2005, 115, 813-824.	3.9	152
540	The Relationship between the BRAF Mutations in Thyroid Papillary Carcinomas and the Prognostic Factors. <i>Journal of Korean Endocrine Society</i> , 2005, 20, 224.	0.1	6

#	ARTICLE	IF	CITATIONS
541	Molecular Characterization of PDGFR- α /PDGF-A and c-KIT/SCF in Gliosarcomas. Analytical Cellular Pathology, 2005, 27, 319-326.	0.7	14
543	AIDS Related Viruses, their Association with Leukemia, and Raf Signaling. Current HIV Research, 2005, 3, 319-327.	0.2	13
544	Expression genomics and drug development: Towards predictive pharmacology. Briefings in Functional Genomics & Proteomics, 2005, 3, 303-321.	3.8	9
545	Telomeres, Telomerase and Malignant Transformation. Current Molecular Medicine, 2005, 5, 219-226.	0.6	26
546	Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. Carcinogenesis, 2005, 26, 1224-1232.	1.3	127
547	Gene Expression Analysis Reveals Evidence for Increased Expression of Cell Cycle-Associated Genes and Gq-Protein-Protein Kinase C Signaling in Cold Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1163-1170.	1.8	37
548	Fibronectin-Induced Proliferation in Thyroid Cells Is Mediated by $\alpha_5\beta_1$ Integrin through Ras/Raf-1/MEK/ERK and Calcium/CaMKII Signals. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2865-2873.	1.8	72
549	BRAF Gene Mutations Are Rare Events in Gastroenteropancreatic Neuroendocrine Tumors. American Journal of Clinical Pathology, 2005, 123, 256-260.	0.4	45
550	Development of a Conditional In vivo Model to Evaluate the Efficacy of Small Molecule Inhibitors for the Treatment of Raf-Transformed Hematopoietic Cells. Cancer Research, 2005, 65, 9962-9970.	0.4	16
551	Hypoxia-inducible factor 1 α is a new target of microphthalmia-associated transcription factor (MITF) in melanoma cells. Journal of Cell Biology, 2005, 170, 49-59.	2.3	155
552	BRAF Mutation in Endometrial Carcinoma and Hyperplasia: Correlation with KRAS and p53 Mutations and Mismatch Repair Protein Expression. Clinical Cancer Research, 2005, 11, 6133-6138.	3.2	81
553	Building Upon the Standard of Care in Adjuvant Therapy of High-Risk Melanoma. Journal of Clinical Oncology, 2005, 23, 8559-8563.	0.8	7
554	Caenorhabditis elegans CNK-1 promotes Raf activation but is not essential for Ras/Raf signaling. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11757-11762.	3.3	23
555	Expression of Endogenous Oncogenic V600E-raf Induces Proliferation and Developmental Defects in Mice and Transformation of Primary Fibroblasts. Cancer Research, 2005, 65, 11493-11500.	0.4	147
556	BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Molecular Cancer Therapeutics, 2005, 4, 1303-1310.	1.9	66
557	The gene expression signatures of melanoma progression. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 6092-6097.	3.3	396
558	BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. Journal of Clinical Pathology, 2005, 58, 640-644.	1.0	123
559	Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins. Cancer Research, 2005, 65, 6401-6408.	0.4	242

#	ARTICLE	IF	CITATIONS
560	Pharmacologic Inhibition of RAF→MEK→ERK Signaling Elicits Pancreatic Cancer Cell Cycle Arrest Through Induced Expression of p27Kip1. <i>Cancer Research</i> , 2005, 65, 4870-4880.	0.4	126
561	Mutations of C-RAF Are Rare in Human Cancer because C-RAF Has a Low Basal Kinase Activity Compared with B-RAF. <i>Cancer Research</i> , 2005, 65, 9719-9726.	0.4	166
562	Role of Epidermal Growth Factor Receptor Signaling in RAS-Driven Melanoma. <i>Molecular and Cellular Biology</i> , 2005, 25, 4176-4188.	1.1	58
563	Conditional BRAFV600E Expression Induces DNA Synthesis, Apoptosis, Dedifferentiation, and Chromosomal Instability in Thyroid PCCL3 Cells. <i>Cancer Research</i> , 2005, 65, 2465-2473.	0.4	198
564	Molecular Responses to Stress Induced in Normal Human Caucasian Melanocytes in Culture by Exposure to Simulated Solar UV-A. <i>Photochemistry and Photobiology</i> , 2005, 81, 367.	1.3	29
565	No Evidence for BRAF as a Melanoma/Nevis Susceptibility Gene. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 913-918.	1.1	24
566	Proteasome Inhibitors Trigger NOXA-Mediated Apoptosis in Melanoma and Myeloma Cells. <i>Cancer Research</i> , 2005, 65, 6282-6293.	0.4	300
567	High Prevalence and Possible de Novo Formation of BRAF Mutation in Metastasized Papillary Thyroid Cancer in Lymph Nodes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5265-5269.	1.8	114
568	NO News is not Necessarily Good News in Cancer. <i>Current Cancer Drug Targets</i> , 2005, 5, 103-115.	0.8	69
569	Distinct Sets of Genetic Alterations in Melanoma. <i>New England Journal of Medicine</i> , 2005, 353, 2135-2147.	13.9	2,501
570	Cdc2-mediated Inhibition of Epidermal Growth Factor Activation of the Extracellular Signal-regulated Kinase Pathway during Mitosis. <i>Journal of Biological Chemistry</i> , 2005, 280, 24524-24531.	1.6	33
571	Cloning of Immunoglobulin Chromosomal Translocations by Long-Distance Inverse Polymerase Chain Reaction. , 2005, 115, 217-230.		4
572	Modern Approaches to Age-Old Questions About Thyroid Tumors. <i>Thyroid</i> , 2005, 15, 575-582.	2.4	7
573	Novel agents in development for the treatment of melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 885-892.	1.9	13
574	Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3395-3400.	3.3	303
575	BRAF Mutations are Uncommon in Papillary Thyroid Cancer of Young Patients. <i>Thyroid</i> , 2005, 15, 320-325.	2.4	107
576	Genetic Diversity in Melanoma. <i>New England Journal of Medicine</i> , 2005, 353, 2104-2107.	13.9	15
578	Biomarkers in melanoma: Stage III and IV disease. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 65-74.	1.5	17

#	ARTICLE	IF	CITATIONS
579	Elevated expression of MITF counteracts B-RAF ^{V600E} -stimulated melanocyte and melanoma cell proliferation. <i>Journal of Cell Biology</i> , 2005, 170, 703-708.	2.3	162
580	Mutant V599E-B-Raf Regulates Growth and Vascular Development of Malignant Melanoma Tumors. <i>Cancer Research</i> , 2005, 65, 2412-2421.	0.4	296
581	Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. <i>Annals of Oncology</i> , 2005, 16, 1688-1694.	0.6	270
582	Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (H ⁺ /rthle cell) tumours of the thyroid. <i>British Journal of Cancer</i> , 2005, 92, 1892-1898.	2.9	191
583	Targeting the stromal fibroblasts: a novel approach to melanoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 1069-1078.	1.1	20
584	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2005, 97, 339-346.	3.0	2,194
585	Inactivation of the Mitogen-Activated Protein Kinase Pathway as a Potential Target-Based Therapy in Ovarian Serous Tumors with KRAS or BRAF Mutations. <i>Cancer Research</i> , 2005, 65, 1994-2000.	0.4	114
586	B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms. <i>Journal of Biological Chemistry</i> , 2005, 280, 16244-16253.	1.6	125
587	CNK1 Is a Scaffold Protein That Regulates Src-mediated Raf-1 Activation. <i>Journal of Biological Chemistry</i> , 2005, 280, 24205-24211.	1.6	49
588	Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers. <i>Cancer Research</i> , 2005, 65, 6063-6069.	0.4	701
589	Phase I Study of Gefitinib Plus Celecoxib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2005, 23, 6976-6981.	0.8	106
590	Leucine-rich repeat kinase 2: A new player with a familiar theme for Parkinson's disease pathogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16535-16536.	3.3	15
591	Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation. <i>Journal of Biological Chemistry</i> , 2005, 280, 35217-35227.	1.6	266
592	The oncogenic properties of mutant p110 ^A and p110 ^B phosphatidylinositol 3-kinases in human mammary epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18443-18448.	3.3	313
593	Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. <i>Journal of Experimental Medicine</i> , 2005, 201, 249-257.	4.2	224
594	Molecularly-targeted therapies for non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2667-2679.	0.9	7
595	Genomic Profiling of Cancer: What Next?. <i>Journal of Clinical Oncology</i> , 2005, 23, 7253-7256.	0.8	13
596	Mapping Molecular Networks Using Proteomics: A Vision for Patient-Tailored Combination Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3614-3621.	0.8	170

#	ARTICLE	IF	CITATIONS
597	Detection of BRAF mutations in colorectal tumours and peritoneal washings using a mismatch ligation assay. <i>Journal of Clinical Pathology</i> , 2005, 58, 372-375.	1.0	6
598	UV Exposure, Genetic Targets in Melanocytic Tumors and Transgenic Mouse Models. <i>Photochemistry and Photobiology</i> , 2005, 81, 52.	1.3	10
599	Molecular Pathogenesis of Ovarian Borderline Tumors: New Insights and Old Challenges. <i>Clinical Cancer Research</i> , 2005, 11, 7273-7279.	3.2	131
600	Biallelic Deletions in INK4 in Cutaneous Melanoma Are Common and Associated with Decreased Survival. <i>Clinical Cancer Research</i> , 2005, 11, 2991-2997.	3.2	55
601	Tbx2 Is Overexpressed and Plays an Important Role in Maintaining Proliferation and Suppression of Senescence in Melanomas. <i>Cancer Research</i> , 2005, 65, 2260-2268.	0.4	202
602	Targeted Expression of BRAFV600E in Thyroid Cells of Transgenic Mice Results in Papillary Thyroid Cancers that Undergo Dedifferentiation. <i>Cancer Research</i> , 2005, 65, 4238-4245.	0.4	376
603	Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 5472-5480.	3.2	332
604	Activated B-RAF Is an Hsp90 Client Protein That Is Targeted by the Anticancer Drug 17-Allylamino-17-Demethoxygeldanamycin. <i>Cancer Research</i> , 2005, 65, 10686-10691.	0.4	235
605	EGFR Gene Mutations: A Call for Global x Global Views of Cancer. <i>Journal of the National Cancer Institute</i> , 2005, 97, 326-328.	3.0	27
606	Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. <i>Journal of Clinical Pathology</i> , 2005, 58, 1163-1169.	1.0	74
607	Crosstalk Between Pten and Ras Signaling Pathways in Tumor Development. <i>Cell Cycle</i> , 2005, 4, 1185-1188.	1.3	23
608	Genes Involved in Hepatocellular Carcinoma. <i>Handbook of Immunohistochemistry and in Situ Hybridization of Human Carcinomas</i> , 2005, , 171-176.	0.0	2
609	Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. <i>International Journal of Oncology</i> , 2005, 26, 1637.	1.4	8
610	Ras-MAPK Pathways. <i>Science Signaling</i> , 2005, 2005, tr5-tr5.	1.6	9
611	Hypersialylation of β 1 Integrins, Observed in Colon Adenocarcinoma, May Contribute to Cancer Progression by Up-regulating Cell Motility. <i>Cancer Research</i> , 2005, 65, 4645-4652.	0.4	288
612	Identification of Raf-1 S471 as a Novel Phosphorylation Site Critical for Raf-1 and B-Raf Kinase Activities and for MEK Binding. <i>Molecular Biology of the Cell</i> , 2005, 16, 4733-4744.	0.9	33
613	BRAF Kinase Activation via Chromosomal Rearrangement in Radiation-Induced and Sporadic Thyroid Cancer. <i>Cell Cycle</i> , 2005, 4, 547-548.	1.3	19
614	Cutaneous melanoma. <i>Lancet</i> , The, 2005, 365, 687-701.	6.3	511

#	ARTICLE	IF	CITATIONS
615	Analysis of BRAF Mutation in Primary and Metastatic Melanoma. <i>Cell Cycle</i> , 2005, 4, 1382-1384.	1.3	91
616	BRAF mutation in thyroid cancer. <i>Endocrine-Related Cancer</i> , 2005, 12, 245-262.	1.6	1,114
617	The MAPK signalling pathways and colorectal cancer. <i>Lancet Oncology</i> , The, 2005, 6, 322-327.	5.1	867
618	Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. <i>Experimental Cell Research</i> , 2005, 308, 222-235.	1.2	62
619	Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations. <i>American Journal of Human Genetics</i> , 2005, 76, 672-680.	2.6	524
620	Genomic Analysis of Melanocytic Neoplasia. <i>Advances in Dermatology</i> , 2005, 21, 81-99.	2.0	12
621	Oncogenic Potential of MEK1 in Rat Intestinal Epithelial Cells Is Mediated via Cyclooxygenase-2. <i>Gastroenterology</i> , 2005, 129, 577-590.	0.6	27
622	Melanoma Treatment Update. <i>Dermatologic Clinics</i> , 2005, 23, 323-333.	1.0	23
623	The Differentiation of Benign and Malignant Thyroid Nodules. <i>Advances in Surgery</i> , 2005, 39, 355-377.	0.6	8
624	Insights into familial colon cancer: The plot thickens. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 216-217.	2.4	4
625	Activating Mutations and/or Expression Levels of Tyrosine Kinase Receptors GRB7, RAS, and BRAF in Testicular Germ Cell Tumors. <i>Neoplasia</i> , 2005, 7, 1047-1052.	2.3	70
627	Raf: A Strategic Target for Therapeutic Development Against Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 6771-6790.	0.8	256
628	Genomics and the second golden era of cancer drug development. <i>Molecular BioSystems</i> , 2005, 1, 17.	2.9	48
629	Advances in Myeloma Genetics and Prospects for Pharmacogenomic Testing in Multiple Myeloma. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 35-43.	3.3	3
630	Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab. <i>Journal of the National Cancer Institute</i> , 2005, 97, 981-989.	3.0	313
631	Role of Tyrosine Kinase Inhibitors in Cancer Therapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 315, 971-979.	1.3	846
632	Wild-Type and Mutant B-RAF Activate C-RAF through Distinct Mechanisms Involving Heterodimerization. <i>Molecular Cell</i> , 2005, 20, 963-969.	4.5	367
633	Analysis of LRRK2 G2019S and I2020T mutations in Parkinson's disease. <i>Neuroscience Letters</i> , 2005, 390, 1-3.	1.0	36

#	ARTICLE	IF	CITATIONS
634	Molecular diagnostics in melanoma. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 743-775.	0.6	131
635	The promise of molecular targeted therapies: Protein kinase inhibitors in the treatment of cutaneous malignancies. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 291-302.	0.6	48
636	B-RAF and melanocytic neoplasia. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 108-114.	0.6	61
637	Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. <i>Human Pathology</i> , 2005, 36, 486-493.	1.1	215
638	A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. <i>Human Pathology</i> , 2005, 36, 694-697.	1.1	93
639	Mutational analysis of gene families in human cancer. <i>Current Opinion in Genetics and Development</i> , 2005, 15, 5-12.	1.5	47
640	Recent developments related to the EGFR as a target for cancer chemotherapy. <i>Current Opinion in Pharmacology</i> , 2005, 5, 343-349.	1.7	30
641	Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. <i>Current Opinion in Pharmacology</i> , 2005, 5, 350-356.	1.7	198
642	Tailoring Ras-pathway-inhibitor combinations for cancer therapy. <i>Drug Resistance Updates</i> , 2005, 8, 369-380.	6.5	53
643	Molecular profile of hyalinizing trabecular tumours of the thyroid: High prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations. <i>European Journal of Cancer</i> , 2005, 41, 816-821.	1.3	87
644	Retroviral expression screening of oncogenes in pancreatic ductal carcinoma. <i>European Journal of Cancer</i> , 2005, 41, 2170-2175.	1.3	12
645	Expression of JC virus regulatory proteins in human cancer: Potential mechanisms for tumourigenesis. <i>European Journal of Cancer</i> , 2005, 41, 2537-2548.	1.3	30
646	Stress kinase signaling in cancer: fact or fiction?. <i>Cancer Letters</i> , 2005, 217, 1-9.	3.2	40
647	Cutaneous melanoma susceptibility and progression genes. <i>Cancer Letters</i> , 2005, 230, 153-186.	3.2	102
648	Identification of cancer genes by mutational profiling of tumor genomes. <i>FEBS Letters</i> , 2005, 579, 1884-1890.	1.3	23
649	Activation of Mitogen-Activated Protein Kinase Is Required for Migration and Invasion of Placental Site Trophoblastic Tumor. <i>American Journal of Pathology</i> , 2005, 167, 879-885.	1.9	27
650	BRAF Mutations in Aberrant Crypt Foci and Hyperplastic Polyposis. <i>American Journal of Pathology</i> , 2005, 166, 1069-1075.	1.9	109
651	Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. <i>Vaccine</i> , 2005, 23, 884-889.	1.7	105

#	ARTICLE	IF	CITATIONS
652	Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. <i>Journal of Translational Medicine</i> , 2005, 3, 39.	1.8	105
653	Improving Outcomes in Advanced Malignant Melanoma. <i>Drugs</i> , 2005, 65, 733-743.	4.9	35
654	Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, 188-196.	1.0	107
655	Familial Nonmedullary Thyroid Cancer. <i>Thyroid</i> , 2005, 15, 588-593.	2.4	91
656	Oncogenic Potential of MEK1 in Rat Intestinal Epithelial Cells Is Mediated via Cyclooxygenase-2. <i>Gastroenterology</i> , 2005, 129, 577-590.	0.6	23
657	Mutated kinases as targets for cancer drugs. <i>Drug Discovery Today Disease Mechanisms</i> , 2005, 2, 139-144.	0.8	7
658	Melanocyte signaling pathways and the etiology of melanoma. <i>Drug Discovery Today Disease Mechanisms</i> , 2005, 2, 179-183.	0.8	4
659	Array-based approaches to cancer genome analysis. <i>Drug Discovery Today Disease Mechanisms</i> , 2005, 2, 171-177.	0.8	5
660	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. <i>Lung Cancer</i> , 2005, 50, 25-33.	0.9	74
661	BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6373-6379.	1.8	893
662	A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040. <i>Neoplasia</i> , 2005, 7, 336-347.	2.3	46
663	Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions. <i>Journal of Clinical Oncology</i> , 2005, 23, 2556-2568.	0.8	579
664	Taking Human Cancer Genes to the Fish: A Transgenic Model of Melanoma in Zebrafish. <i>Zebrafish</i> , 2005, 1, 363-368.	0.5	27
665	Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 5386-5403.	0.8	191
666	ret/PTC and BRAF Act as Distinct Molecular, Time-Dependant Triggers in a Sporadic Irish Cohort of Papillary Thyroid Carcinoma. <i>International Journal of Surgical Pathology</i> , 2005, 13, 1-8.	0.4	43
667	Detection of BRAF V600E Mutation in Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 540-543.	1.2	136
669	Oncogene-Induced Cell Senescence – Halting on the Road to Cancer. <i>New England Journal of Medicine</i> , 2006, 355, 1037-1046.	13.9	336
670	Low Frequency of BRAF Mutations in Adult Patients with Papillary Thyroid Cancers Following Childhood Radiation Exposure. <i>Thyroid</i> , 2006, 16, 61-66.	2.4	29

#	ARTICLE	IF	CITATIONS
673	Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression. <i>Molecular Cancer Research</i> , 2006, 4, 779-792.	1.5	134
674	Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2378-2387.	1.9	102
675	Principles of Targeted and Biological Therapies. , 2006, , 73-90.		0
676	Characteristics of the Metastatic Phenotype. , 2006, , 181-200.		0
677	Sorafenib (BAY 43â€9006, NexavarÂ®), a Dualâ€Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature. <i>Methods in Enzymology</i> , 2006, 407, 597-612.	0.4	387
678	Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. <i>Endocrine-Related Cancer</i> , 2006, 13, S125-S135.	1.6	252
679	Hsp90 Inhibitors in the Clinic. , 2006, , 331-358.		88
680	Genetic Variation and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway. <i>OMICS A Journal of Integrative Biology</i> , 2006, 10, 66-81.	1.0	4
681	Azine-carboxamides as anticancer agents. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1175-1178.	2.4	8
682	In Vitro Transformation Models: Modeling Human Cancer. <i>Cell Cycle</i> , 2006, 5, 631-635.	1.3	8
683	Inhibition of Tumor Endothelial ERK Activation, Angiogenesis, and Tumor Growth by Sorafenib (BAY43-9006). <i>American Journal of Pathology</i> , 2006, 169, 1875-1885.	1.9	139
684	Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation. <i>American Journal of Pathology</i> , 2006, 169, 665-672.	1.9	53
685	Uncommon V599E BRAF Mutations in Japanese Patients with Lung Cancer. <i>Journal of Surgical Research</i> , 2006, 133, 203-206.	0.8	64
686	Phenotypeâ€genotype correlation: Challenge of intestinal-type adenocarcinoma of the nasal cavity and paranasal sinuses. <i>Head and Neck</i> , 2006, 28, 909-915.	0.9	33
687	Mitotic Arrest, Apoptosis, and Sensitization to Chemotherapy of Melanomas by Methionine Deprivation Stress. <i>Molecular Cancer Research</i> , 2006, 4, 575-589.	1.5	37
688	The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 5268-5272.	3.2	776
689	Novel Inhibitors of B-RAF Based on a Disubstituted Pyrazine Scaffold. Generation of a Nanomolar Lead. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 407-416.	2.9	54
690	Host genetics influence tumour metastasis. <i>Nature Reviews Cancer</i> , 2006, 6, 141-146.	12.8	121

#	ARTICLE	IF	CITATIONS
691	The Effects of a Novel MEK Inhibitor PD184161 on MEK-ERK Signaling and Growth in Human Liver Cancer. <i>Neoplasia</i> , 2006, 8, 1-8.	2.3	64
692	BRAFV600E Promotes Invasiveness of Thyroid Cancer Cells through Nuclear Factor κ B Activation. <i>Endocrinology</i> , 2006, 147, 5699-5707.	1.4	111
693	Targeting Tyrosine Kinases in Cancer: The Second Wave. <i>Science</i> , 2006, 312, 1175-1178.	6.0	437
694	Rapid and Simple Detection of Hot Spot Point Mutations of Epidermal Growth Factor Receptor, BRAF, and NRAS in Cancers Using the Loop-Hybrid Mobility Shift Assay. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 504-512.	1.2	45
695	High Prevalence of Sessile Serrated Adenomas With BRAF Mutations: A Prospective Study of Patients Undergoing Colonoscopy. <i>Gastroenterology</i> , 2006, 131, 1400-1407.	0.6	512
697	BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. <i>Molecular Cancer</i> , 2006, 5, 2.	7.9	155
698	Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. <i>Molecular Cancer</i> , 2006, 5, 29.	7.9	744
699	Somatic deletion of the NF1 gene in a neurofibromatosis type 1-associated malignant melanoma demonstrated by digital PCR. <i>Molecular Cancer</i> , 2006, 5, 36.	7.9	17
700	Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. <i>Molecular Cancer</i> , 2006, 5, 63.	7.9	12
701	Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2606-2612.	1.9	374
702	Melanoma. <i>New England Journal of Medicine</i> , 2006, 355, 51-65.	13.9	1,276
703	Targeting the ERK signaling pathway in cancer therapy. <i>Annals of Medicine</i> , 2006, 38, 200-211.	1.5	357
704	HUMAN T CELL RESPONSES AGAINST MELANOMA. <i>Annual Review of Immunology</i> , 2006, 24, 175-208.	9.5	596
705	Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 441-444.	2.9	45
706	Genetic alterations in melanocytic tumors. <i>Journal of Dermatological Science</i> , 2006, 43, 1-10.	1.0	63
707	Profiling the kinome for drug discovery. <i>Drug Discovery Today: Technologies</i> , 2006, 3, 269-276.	4.0	4
708	Sleeping beauty: a novel cancer gene discovery tool. <i>Human Molecular Genetics</i> , 2006, 15, R75-R79.	1.4	43
709	Cytotoxic Hypothemycin Analogues from <i>Hypomyces subiculosus</i> . <i>Journal of Natural Products</i> , 2006, 69, 1456-1459.	1.5	39

#	ARTICLE	IF	CITATIONS
710	Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. <i>British Journal of Cancer</i> , 2006, 95, 1101-1107.	2.9	73
711	Genetics and biology of pancreatic ductal adenocarcinoma. <i>Genes and Development</i> , 2006, 20, 1218-1249.	2.7	1,118
712	The BRAF ^{v600E} MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. <i>Journal of Experimental Medicine</i> , 2006, 203, 1651-1656.	4.2	614
713	Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 4234-4239.	3.3	163
714	An Inducible Mouse Model of Melanoma Expressing a Defined Tumor Antigen. <i>Cancer Research</i> , 2006, 66, 3278-3286.	0.4	47
715	The Synthesis of a Novel Inhibitor of B-Raf Kinase. <i>Organic Process Research and Development</i> , 2006, 10, 70-77.	1.3	28
716	Spotlight on Richard Marais. <i>FEBS Letters</i> , 2006, 580, 3343-3343.	1.3	0
717	Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach. <i>Cell</i> , 2006, 125, 1253-1267.	13.5	989
718	Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene. <i>Cell</i> , 2006, 125, 1269-1281.	13.5	380
719	Cross-Species Oncogenomics in Cancer Gene Identification. <i>Cell</i> , 2006, 125, 1230-1233.	13.5	20
720	Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. <i>Biochemical and Biophysical Research Communications</i> , 2006, 339, 1171-1177.	1.0	44
721	Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. <i>Biochemical and Biophysical Research Communications</i> , 2006, 340, 469-475.	1.0	57
722	Transforming science: cancer gene identification. <i>Current Opinion in Genetics and Development</i> , 2006, 16, 23-29.	1.5	12
723	Methionine-stress: A pleiotropic approach in enhancing the efficacy of chemotherapy. <i>Cancer Letters</i> , 2006, 233, 195-207.	3.2	21
724	A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. <i>Cancer Letters</i> , 2006, 239, 227-233.	3.2	35
725	Sprouty and cancer: The first terms report. <i>Cancer Letters</i> , 2006, 242, 141-150.	3.2	81
726	Targeted therapies in melanoma. <i>Cancer Treatment Reviews</i> , 2006, 32, 524-531.	3.4	20
727	An Intrinsic Cell Cycle Checkpoint Pathway Mediated by MEK and ERK in <i>Drosophila</i> . <i>Developmental Cell</i> , 2006, 11, 575-582.	3.1	21

#	ARTICLE	IF	CITATIONS
728	Key cancer cell signal transduction pathways as therapeutic targets. <i>European Journal of Cancer</i> , 2006, 42, 290-294.	1.3	131
729	Mutational analysis of PDGFR/RAS/MAPK pathway activation in childhood medulloblastoma. <i>European Journal of Cancer</i> , 2006, 42, 646-649.	1.3	34
730	Targeting events in melanoma carcinogenesis for the prevention of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1559-1568.	1.1	59
731	MITF: master regulator of melanocyte development and melanoma oncogene. <i>Trends in Molecular Medicine</i> , 2006, 12, 406-414.	3.5	993
732	The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. <i>Human Pathology</i> , 2006, 37, 562-568.	1.1	26
733	BRAF and c-kit gene copy number in mutation-positive malignant melanoma. <i>Human Pathology</i> , 2006, 37, 520-527.	1.1	90
734	B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. <i>Human Pathology</i> , 2006, 37, 781-786.	1.1	72
735	High throughput DNA sequence variant detection by conformation sensitive capillary electrophoresis and automated peak comparison. <i>Genomics</i> , 2006, 87, 427-432.	1.3	38
736	Crystallization of MAP kinases. <i>Methods</i> , 2006, 40, 224-233.	1.9	16
738	The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology. <i>Neuron</i> , 2006, 52, 587-593.	3.8	520
739	Molecular genetics and targeted therapies for cutaneous melanoma. <i>Update on Cancer Therapeutics</i> , 2006, 1, 59-64.	0.9	0
740	Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. <i>Oncology Reports</i> , 2006, 16, 451.	1.2	17
741	Genetic Considerations in Thyroid Cancer. <i>Cancer Control</i> , 2006, 13, 111-118.	0.7	22
745	The WNT/Beta-catenin pathway in melanoma. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 733.	3.0	220
746	From existing therapies to novel targets: a current view on melanoma. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 2081.	3.0	14
747	Cutaneous photoprotection and melanoma susceptibility: reaching beyond melanin content to the frontiers of DNA repair. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 2157.	3.0	40
748	Advances in malignant melanoma: genetic insights from mouse and man. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 928.	3.0	11
749	Recent advances in melanoma research. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 3003.	3.0	5

#	ARTICLE	IF	CITATIONS
750	Wilms Tumor 1 Expression Present in Most Melanomas but Nearly Absent in Nevi. Archives of Dermatology, 2006, 142, 1031-4.	1.7	17
751	Protein Tyrosine Kinases as Targets for Cancer and Other Indications. , 2006, , 1-29.		4
752	Antisense therapy in malignant diseases: status quo and quo vadis?. Clinical Science, 2006, 110, 427-442.	1.8	37
753	When Fine-Needle Aspiration Biopsy Cannot Exclude Papillary Thyroid Cancer. Archives of Surgery, 2006, 141, 961.	2.3	25
754	Clinicopathologic and genetic characteristics of gastric cancer in young male and female patients. Oncology Reports, 2006, 16, 11.	1.2	7
755	The Akt/mTOR and Mitogen-Activated Protein Kinase Pathways in Lung Cancer Therapy. Journal of Thoracic Oncology, 2006, 1, 749-751.	0.5	9
757	The Akt/mTOR and Mitogen-Activated Protein Kinase Pathways in Lung Cancer Therapy. Journal of Thoracic Oncology, 2006, 1, 749-751.	0.5	32
758	BRAF Mutation Analysis in Fine Needle Aspiration (FNA) Cytology of the Thyroid. Diagnostic Molecular Pathology, 2006, 15, 136-143.	2.1	133
759	Development of Small-Molecule Inhibitors of Raf. Recent Patents on Anti-infective Drug Discovery, 2006, 1, 241-246.	0.5	2
760	Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets. Current Signal Transduction Therapy, 2006, 1, 13-23.	0.3	35
761	Sorafenib (BAY 43-9006): Review of Clinical Development. Current Clinical Pharmacology, 2006, 1, 223-228.	0.2	26
762	The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites. International Journal of Oncology, 2006, 29, 139.	1.4	3
763	The Ras/Raf/MAPK Pathway. Journal of Thoracic Oncology, 2006, 1, 7-9.	0.5	181
764	Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Current Opinion in Oncology, 2006, 18, 189-196.	1.1	39
765	What about chemoprevention for melanoma?. Current Opinion in Oncology, 2006, 18, 180-184.	1.1	9
766	Oncogenic PI3K and its role in cancer. Current Opinion in Oncology, 2006, 18, 77-82.	1.1	454
767	Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes. Melanoma Research, 2006, 16, 297-307.	0.6	17
768	Lymphatic Mapping Establishes the Role of BRAF Gene Mutation in Papillary Thyroid Carcinoma. Annals of Surgery, 2006, 244, 799-804.	2.1	69

#	ARTICLE	IF	CITATIONS
769	BRAF mutation in thyroid carcinogenesis and its clinical implications. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2006, 13, 455-459.	0.6	2
770	New molecular targeted therapies in thyroid cancer. <i>Anti-Cancer Drugs</i> , 2006, 17, 869-879.	0.7	21
771	Mutations of PIK3CA are rare in cutaneous melanoma. <i>Melanoma Research</i> , 2006, 16, 197-200.	0.6	90
772	BRAF somatic mutations in malignant melanoma and melanocytic naevi. <i>Melanoma Research</i> , 2006, 16, 97-103.	0.6	100
773	BRAF and NRAS mutations in melanoma and melanocytic nevi. <i>Melanoma Research</i> , 2006, 16, 267-273.	0.6	213
774	NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. <i>Melanoma Research</i> , 2006, 16, 471-478.	0.6	305
775	Assessing the Utility of a Mutational Assay for B-RAF as an Adjunct to Conventional Fine Needle Aspiration of the Thyroid Gland. <i>Advances in Anatomic Pathology</i> , 2006, 13, 228-237.	2.4	16
776	Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458. <i>International Journal of Oncology</i> , 2006, 28, 955.	1.4	7
777	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. <i>Topics in Medicinal Chemistry</i> , 2006, , 83-132.	0.4	1
778	ERK1 and ERK2 mitogen-activated protein kinases affect Ras-dependent cell signaling differentially. <i>Journal of Biology</i> , 2006, 5, 14.	2.7	185
779	Parkinsonism genes: culprits and clues. <i>Journal of Neurochemistry</i> , 2006, 99, 1062-1072.	2.1	106
780	BRAF V599E mutation occurs in Spitz and Reed naevi. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006, 20, 1164-1165.	1.3	20
781	Parkinson's disease: the genetics of a heterogeneous disorder. <i>European Journal of Neurology</i> , 2006, 13, 616-627.	1.7	41
782	Cutaneous melanoma: available therapy for metastatic disease. <i>Dermatologic Therapy</i> , 2006, 19, 19-25.	0.8	121
783	Immune resistance orchestrated by the tumor microenvironment. <i>Immunological Reviews</i> , 2006, 213, 131-145.	2.8	409
784	NF-kappaB activation in melanoma. <i>Pigment Cell & Melanoma Research</i> , 2006, 19, 112-124.	4.0	141
785	Pocket protein function in melanocyte homeostasis and neoplasia. <i>Pigment Cell & Melanoma Research</i> , 2006, 19, 260-283.	4.0	6
786	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. <i>Pigment Cell & Melanoma Research</i> , 2006, 19, 290-302.	4.0	483

#	ARTICLE	IF	CITATIONS
788	Ein Streifzug durch die (Signal-)Wege des malignen Melanoms. JDDG - Journal of the German Society of Dermatology, 2006, 4, ---.	0.4	0
789	Distinct phenotypic changes between the superficial and deep component of giant congenital melanocytic naevi: a rationale for curettage. British Journal of Dermatology, 2006, 154, 485-492.	1.4	47
791	Detection of BRAFV600Emutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAFV600Emutation-prevalent area. Clinical Endocrinology, 2006, 65, 660-666.	1.2	174
792	Fluorescence (Forster) resonance energy transfer imaging of oncogene activity in living cells. Cancer Science, 2006, 97, 8-15.	1.7	46
793	Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nature Cell Biology, 2006, 8, 1053-1063.	4.6	296
794	New approaches to molecular cancer therapeutics. Nature Chemical Biology, 2006, 2, 689-700.	3.9	361
795	Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nature Genetics, 2006, 38, 294-296.	9.4	517
796	Oxygen deprivation provokes melanoma. Nature Medicine, 2006, 12, 168-169.	15.2	6
797	Rich route for sugar. Nature Medicine, 2006, 12, 169-169.	15.2	0
798	Embryogenesis meets tumorigenesis. Nature Medicine, 2006, 12, 882-884.	15.2	15
799	Turning neurogenesis up a Notch. Nature Medicine, 2006, 12, 884-885.	15.2	17
800	Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nature Reviews Cancer, 2006, 6, 146-155.	12.8	297
801	Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews Cancer, 2006, 6, 292-306.	12.8	797
802	Modelling cancer in human skin tissue. Nature Reviews Cancer, 2006, 6, 270-280.	12.8	138
803	Lineage dependency and lineage-survival oncogenes in human cancer. Nature Reviews Cancer, 2006, 6, 593-602.	12.8	316
804	Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. British Journal of Cancer, 2006, 95, 581-586.	2.9	608
805	Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Modern Pathology, 2006, 19, 59-68.	2.9	218
806	The Spitzoid lesion: rethinking Spitz tumors, atypical variants, â€˜Spitzoid melanomaâ€™™ and risk assessment. Modern Pathology, 2006, 19, S21-S33.	2.9	222

#	ARTICLE	IF	CITATIONS
807	BRAF and NRAS mutations in spitzoid melanocytic lesions. <i>Modern Pathology</i> , 2006, 19, 1324-1332.	2.9	92
808	BRAF mutation predicts sensitivity to MEK inhibition. <i>Nature</i> , 2006, 439, 358-362.	13.7	1,264
809	Validating cancer drug targets. <i>Nature</i> , 2006, 441, 451-456.	13.7	150
810	Mechanisms of drug inhibition of signalling molecules. <i>Nature</i> , 2006, 441, 457-462.	13.7	281
811	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006, 14, 322-331.	1.4	152
812	Lack of Association between BRAF Mutation and MAPK ERK Activation in Melanocytic Nevi. <i>Journal of Investigative Dermatology</i> , 2006, 126, 161-166.	0.3	67
813	Examination of Mutations in BRAF, NRAS, and PTEN in Primary Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2006, 126, 154-160.	0.3	334
814	Absence of Classical MAP Kinase Pathway Signalling in Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1135-1142.	0.3	54
815	T1799A BRAF Mutation is Common in PUVA Lentiginos. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1915-1917.	0.3	16
816	High Frequency of BRAFV600E Mutation in Acquired Nevi and Small Congenital Nevi, but Low Frequency of Mutation in Medium-Sized Congenital Nevi. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2111-2118.	0.3	119
817	Could BRAF Mutations in Melanocytic Lesions Arise from DNA Damage Induced by Ultraviolet Radiation?. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1693-1696.	0.3	72
818	Histone deacetylase inhibitor FK228 suppresses the Ras/MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. <i>Oncogene</i> , 2006, 25, 512-524.	2.6	53
819	B-Raf and C-Raf are required for Ras-stimulated p42 MAP kinase activation in <i>Xenopus</i> egg extracts. <i>Oncogene</i> , 2006, 25, 3307-3315.	2.6	6
820	Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. <i>Oncogene</i> , 2006, 25, 3357-3364.	2.6	157
821	Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. <i>Oncogene</i> , 2006, 25, 3956-3962.	2.6	41
822	Biochemical and molecular characterization of the novel BRAFV599Ins mutation detected in a classic papillary thyroid carcinoma. <i>Oncogene</i> , 2006, 25, 4235-4240.	2.6	56
823	B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis. <i>Oncogene</i> , 2006, 25, 4848-4856.	2.6	61
824	Functional analysis of the regulatory requirements of B-Raf and the B-RafV600E oncoprotein. <i>Oncogene</i> , 2006, 25, 6262-6276.	2.6	70

#	ARTICLE	IF	CITATIONS
825	Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. <i>Oncogene</i> , 2006, 25, 6291-6303.	2.6	125
826	Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. <i>Oncogene</i> , 2006, 25, 6574-6581.	2.6	55
827	Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG. <i>Oncogene</i> , 2006, 25, 7373-7380.	2.6	36
828	Kinase inhibitors in the treatment of renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 216-226.	2.0	34
829	The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 378-381.	1.0	179
830	The Biology of Xeroderma Pigmentosum. , 2006, , 291-310.		1
831	Presence of the BRAF V600E Point Mutation in Morphologically Benign Appearing Thyroid Inclusions of Cervical Lymph Nodes. <i>Endocrine Pathology</i> , 2006, 17, 183-190.	5.2	14
832	Oncogenes Are to Lose Control on Signaling Following Mutation: Should We Aim Off Target?. <i>Molecular Biotechnology</i> , 2006, 34, 109-116.	1.3	7
833	Pathology and genetics of thyroid carcinoma. <i>Journal of Surgical Oncology</i> , 2006, 94, 662-669.	0.8	156
834	Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. <i>Advances in Enzyme Regulation</i> , 2006, 46, 249-279.	2.9	584
835	Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. <i>Investigational New Drugs</i> , 2006, 25, 107-114.	1.2	7
836	Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. <i>Cancer and Metastasis Reviews</i> , 2006, 25, 243-252.	2.7	26
837	Individualized therapy of disseminated cancer using malignant melanoma as a model. <i>Cancer and Metastasis Reviews</i> , 2006, 25, 253-256.	2.7	4
838	Targeting growth factors and angiogenesis; using small molecules in malignancy. <i>Cancer and Metastasis Reviews</i> , 2006, 25, 279-292.	2.7	25
839	Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. <i>Journal of Neuro-Oncology</i> , 2006, 81, 27-38.	1.4	33
840	Adenovirus-mediated TA-p73 ^{Δ2} gene transfer increases chemosensitivity of human malignant melanomas. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 235-243.	2.2	26
841	Current concepts in the molecular genetics of pediatric brain tumors: implications for emerging therapies. <i>Child's Nervous System</i> , 2006, 22, 1379-1394.	0.6	14
842	Anatomic site-specific patterns of gene copy number gains in skin, mucosal, and uveal melanomas detected by fluorescence in situ hybridization. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 449, 328-333.	1.4	40

#	ARTICLE	IF	CITATIONS
843	Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 788-796.	1.4	83
844	Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment. <i>International Journal of Clinical Oncology</i> , 2006, 11, 13-21.	1.0	27
845	Back to the roots: the remarkable RAF oncogene story. <i>Cellular and Molecular Life Sciences</i> , 2006, 63, 1314-1330.	2.4	94
847	Therapeutic targets in melanoma: MAPKinase pathway. <i>Current Oncology Reports</i> , 2006, 8, 400-405.	1.8	18
848	Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. <i>Gynecologic Oncology</i> , 2006, 100, 596-600.	0.6	63
849	KRAS and BRAF mutations in ovarian tumors: A comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. <i>Gynecologic Oncology</i> , 2006, 103, 883-887.	0.6	196
850	Mitogen-activated protein kinase (MAPK)-docking sites in MAPK kinases function as tethers that are crucial for MAPK regulation in vivo. <i>Cellular Signalling</i> , 2006, 18, 123-134.	1.7	40
851	Mitogen-Activated Protein Kinase Signaling is Activated in Prostate Tumors but not Mediated by B-RAF Mutations. <i>European Urology</i> , 2006, 50, 1102-1110.	0.9	20
852	Divergent Roles for RalA and RalB in Malignant Growth of Human Pancreatic Carcinoma Cells. <i>Current Biology</i> , 2006, 16, 2385-2394.	1.8	212
853	Emerging applications for phospho-proteomics in cancer molecular therapeutics. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1766, 230-241.	3.3	16
854	From Mendelian to molecular genetics: the Xiphophorus melanoma model. <i>Trends in Genetics</i> , 2006, 22, 654-661.	2.9	115
855	Mutations in PIK3CA are infrequent in neuroblastoma. <i>BMC Cancer</i> , 2006, 6, 177.	1.1	29
856	Are all melanomas the same?. <i>Cancer</i> , 2006, 106, 907-913.	2.0	47
857	Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma. <i>Cancer</i> , 2006, 106, 2005-2011.	2.0	286
858	Molecularly targeted therapy for melanoma. <i>Cancer</i> , 2006, 107, 2317-2327.	2.0	50
859	Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi. <i>International Journal of Cancer</i> , 2006, 118, 472-476.	2.3	58
860	Elevation of thyroid cancer risk among cutaneous melanoma survivors. <i>International Journal of Cancer</i> , 2006, 118, 185-188.	2.3	27
861	Somatic mutations of the ERBB4 kinase domain in human cancers. <i>International Journal of Cancer</i> , 2006, 118, 1426-1429.	2.3	99

#	ARTICLE	IF	CITATIONS
862	Relationship between genetic alterations and prognosis in sporadic colorectal cancer. <i>International Journal of Cancer</i> , 2006, 118, 1721-1727.	2.3	94
863	Molecular targets in melanoma: Strategies and challenges for diagnosis and therapy. <i>International Journal of Cancer</i> , 2006, 118, 523-526.	2.3	16
864	BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer. <i>International Journal of Cancer</i> , 2006, 118, 2765-2771.	2.3	127
865	RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. <i>International Journal of Cancer</i> , 2006, 119, 1316-1321.	2.3	35
866	BRAF and KRAS mutations in prostatic adenocarcinoma. <i>International Journal of Cancer</i> , 2006, 119, 1858-1862.	2.3	93
867	Raf kinases: Oncogenesis and drug discovery. <i>International Journal of Cancer</i> , 2006, 119, 2261-2271.	2.3	94
868	Association between ulcerative growth and hypoxia inducible factor-1 α polymorphisms in colorectal cancer patients. <i>Molecular Carcinogenesis</i> , 2006, 45, 833-840.	1.3	67
869	The Spitzoid Lesion: The Importance of Atypical Variants and Risk Assessment. <i>American Journal of Dermatopathology</i> , 2006, 28, 75-83.	0.3	76
870	Activating Ras Mutations Fail to Ensure Efficient Replication of Adenovirus Mutants Lacking VA-RNA. <i>Cell Cycle</i> , 2006, 5, 315-321.	1.3	8
871	Regulation of ERK3/MAPK6 expression by BRAF. <i>International Journal of Oncology</i> , 2006, 29, 839.	1.4	5
872	Multiple-criterion evaluation of reported mutations: A proposed scoring system for the intragenic somatic mutation literature. <i>Cancer Biology and Therapy</i> , 2006, 5, 360-370.	1.5	13
873	Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders. <i>Cell Cycle</i> , 2006, 5, 1607-1611.	1.3	49
874	Detection of BRAF gene mutation in primary choroidal melanoma tissue. <i>Cancer Biology and Therapy</i> , 2006, 5, 225-227.	1.5	34
875	“Oncogenic Shock”: Turning an Activated Kinase against the Tumor Cell. <i>Cell Cycle</i> , 2006, 5, 2878-2880.	1.3	35
876	Skin Hypoxia: A Promoting Environmental Factor in Melanomagenesis. <i>Cell Cycle</i> , 2006, 5, 1258-1261.	1.3	28
877	BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. <i>Pathology</i> , 2006, 38, 201-204.	0.3	51
878	Systemic Anthrax Lethal Toxin Therapy Produces Regressions of Subcutaneous Human Melanoma Tumors in Athymic Nude Mice. <i>Clinical Cancer Research</i> , 2006, 12, 7437-7443.	3.2	38
879	Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. <i>Cancer Biology and Therapy</i> , 2006, 5, 779-785.	1.5	165

#	ARTICLE	IF	CITATIONS
880	Point mutations of protein kinases and individualised cancer therapy. Expert Opinion on Pharmacotherapy, 2006, 7, 2243-2261.	0.9	27
881	The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells. Cancer Research, 2006, 66, 1611-1619.	0.4	161
882	Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biology and Therapy, 2006, 5, 928-932.	1.5	200
883	Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14477-14482.	3.3	120
884	Which drugs for which patients?. Future Oncology, 2006, 2, 317-319.	1.1	0
885	Genetic and Pharmacologic Dissection of Ras Effector Utilization in Oncogenesis. Methods in Enzymology, 2006, 407, 195-217.	0.4	21
886	Sequencing Analysis of BRAF Mutations in Human Cancers. Methods in Enzymology, 2006, 407, 218-224.	0.4	14
887	Human Leukocyte Antigen-A2â€“Restricted CTL Responses to Mutated BRAF Peptides in Melanoma Patients. Cancer Research, 2006, 66, 3287-3293.	0.4	64
888	Is BRAF the Achilles' Heel of Thyroid Cancer?. Clinical Cancer Research, 2006, 12, 1661-1664.	3.2	23
889	Targeting Mitogen-Activated Protein Kinase/Extracellular Signalâ€“Regulated Kinase Kinase in the Mutant (V600E) B-Raf Signaling Cascade Effectively Inhibits Melanoma Lung Metastases. Cancer Research, 2006, 66, 8200-8209.	0.4	108
890	Molecular Bases of Human Neurocristopathies. , 2006, 589, 213-234.		79
891	Correlation between B-RAFV600E mutation and clinicoâ€“pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocrine-Related Cancer, 2006, 13, 455-464.	1.6	207
892	Protein Kinases as Drug Targets in Cancer. Current Cancer Drug Targets, 2006, 6, 623-634.	0.8	76
893	Recent Advances in the Research and Development of RAF Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2006, 6, 1071-1089.	1.0	51
894	Detection of BRAF mutation in thyroid papillary carcinomas by mutant allele-specific PCR amplification (MASA). European Journal of Endocrinology, 2006, 154, 341-348.	1.9	100
895	High-throughput mutational analysis of the human cancer genome. Pharmacogenomics, 2006, 7, 597-612.	0.6	15
896	Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. PLoS Medicine, 2006, 3, e485.	3.9	298
897	Statistical Analysis of Pathogenicity of Somatic Mutations in Cancer. Genetics, 2006, 173, 2187-2198.	1.2	146

#	ARTICLE	IF	CITATIONS
898	Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors. <i>Current Pharmaceutical Design</i> , 2006, 12, 529-548.	0.9	44
899	Towards the Targeted Therapy of Melanoma. <i>Mini-Reviews in Medicinal Chemistry</i> , 2006, 6, 387-393.	1.1	23
900	Influence of the Microenvironment on Melanoma Cell Fate Determination and Phenotype: Figure 1.. <i>Cancer Research</i> , 2006, 66, 7833-7836.	0.4	104
901	Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma: Table 1.. <i>Clinical Cancer Research</i> , 2006, 12, 2366s-2370s.	3.2	137
902	Somatic BRAF-V600E Mutations in Familial Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 2270-2273.	1.1	38
903	Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant Melanoma: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 2371s-2375s.	3.2	100
904	Ras-Associated Protein-1 Regulates Extracellular Signal-Regulated Kinase Activation and Migration in Melanoma Cells: Two Processes Important to Melanoma Tumorigenesis and Metastasis. <i>Cancer Research</i> , 2006, 66, 7880-7888.	0.4	91
905	Genetic Alterations in Signaling Pathways in Melanoma. <i>Clinical Cancer Research</i> , 2006, 12, 2301s-2307s.	3.2	168
906	Regulation and Role of Raf-1/B-Raf Heterodimerization. <i>Molecular and Cellular Biology</i> , 2006, 26, 2262-2272.	1.1	363
907	Risk of Second Primary Malignancies in Women with Papillary Thyroid Cancer. <i>American Journal of Epidemiology</i> , 2006, 163, 521-527.	1.6	67
908	Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 2505-2512.	0.8	1,002
909	Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma. <i>Cancer Research</i> , 2006, 66, 11187-11193.	0.4	148
910	The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na ⁺ /I ⁻ targeting to the membrane. <i>Endocrine-Related Cancer</i> , 2006, 13, 257-269.	1.6	324
911	Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. <i>Journal of Clinical Pathology</i> , 2006, 59, 580-584.	1.0	41
912	Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K- ras mutations. <i>Carcinogenesis</i> , 2006, 27, 392-404.	1.3	29
913	Induction of Senescence in Diterpene Esterâ€Treated Melanoma Cells via Protein Kinase Câ€Dependent Hyperactivation of the Mitogen-Activated Protein Kinase Pathway. <i>Cancer Research</i> , 2006, 66, 10083-10091.	0.4	57
914	V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 57-62.	3.3	285
915	Extracellular Signal-regulated Kinase 1/2 Activity Is Not Required in Mammalian Cells during Late G2 for Timely Entry into or Exit from Mitosis. <i>Molecular Biology of the Cell</i> , 2006, 17, 5227-5240.	0.9	29

#	ARTICLE	IF	CITATIONS
916	APC inhibits ERK pathway activation and cellular proliferation induced by RAS. <i>Journal of Cell Science</i> , 2006, 119, 819-827.	1.2	66
917	Current Strategies in Overcoming Resistance of Cancer Cells to Apoptosis Melanoma as a Model. <i>International Review of Cytology</i> , 2006, 251, 131-158.	6.2	42
918	IGF1R signalling and its inhibition. <i>Endocrine-Related Cancer</i> , 2006, 13, S33-S43.	1.6	231
919	Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3071-3077.	1.9	56
920	Targeted Therapies in Combination with Chemotherapy in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4451s-4457s.	3.2	20
921	Identification of Inhibitors of the Kinase Activity of Oncogenic V600EBRAF in an Enzyme Cascade High-Throughput Screen. <i>Journal of Biomolecular Screening</i> , 2006, 11, 145-154.	2.6	19
922	Cancer risks in LKB1 germline mutation carriers. <i>Gut</i> , 2006, 55, 984-990.	6.1	101
923	Genetic Alterations in Cancer Knowledge System: Analysis of Gene Mutations in Mouse and Human Liver and Lung Tumors. <i>Toxicological Sciences</i> , 2006, 90, 400-418.	1.4	39
924	Identification of Novel In Vivo Raf-1 Phosphorylation Sites Mediating Positive Feedback Raf-1 Regulation by Extracellular Signal-regulated Kinase. <i>Molecular Biology of the Cell</i> , 2006, 17, 1141-1153.	0.9	78
925	Activated MEK Suppresses Activation of PKR and Enables Efficient Replication and In Vivo Oncolysis by $\hat{\gamma}$ 1 34.5 Mutants of Herpes Simplex Virus 1. <i>Journal of Virology</i> , 2006, 80, 1110-1120.	1.5	103
926	Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies. <i>Clinical Cancer Research</i> , 2006, 12, 4499-4505.	3.2	122
927	Mutational Analysis of <i>AKT1</i> , <i>AKT2</i> and <i>AKT3</i> Genes in Common Human Carcinomas. <i>Oncology</i> , 2006, 70, 285-289.	0.9	69
928	The Importance of LRRK2 Mutations in Parkinson Disease. <i>Archives of Neurology</i> , 2006, 63, 1225.	4.9	36
929	Absence of BRAF Gene Mutation in Non-Melanoma Skin Tumors. <i>Cell Cycle</i> , 2006, 5, 968-970.	1.3	27
930	Rapid Screening of 4000 Individuals for Germ-line Variations in the BRAF Gene. <i>Clinical Chemistry</i> , 2006, 52, 1675-1678.	1.5	13
931	Identification of RAS-Mitogen-Activated Protein Kinase Signaling Pathway Modulators in an ERF1 Redistribution [®] Screen. <i>Journal of Biomolecular Screening</i> , 2006, 11, 423-434.	2.6	15
932	Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models. <i>Cancer Research</i> , 2006, 66, 999-1006.	0.4	204
933	Notch1 Signaling Promotes Primary Melanoma Progression by Activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-Kinase-Akt Pathways and Up-regulating N-Cadherin Expression. <i>Cancer Research</i> , 2006, 66, 4182-4190.	0.4	251

#	ARTICLE	IF	CITATIONS
934	In Melanoma, RAS Mutations Are Accompanied by Switching Signaling from BRAF to CRAF and Disrupted Cyclic AMP Signaling. <i>Cancer Research</i> , 2006, 66, 9483-9491.	0.4	271
935	Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas. <i>Clinical Cancer Research</i> , 2006, 12, 57-61.	3.2	204
936	Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2006, 12, 2526-2537.	3.2	50
937	Genomic Approaches to Lung Cancer: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 4384s-4391s.	3.2	49
938	The Retinoblastoma Protein Is Required for Ras-Induced Oncogenic Transformation. <i>Molecular and Cellular Biology</i> , 2006, 26, 1170-1182.	1.1	53
939	Extracellular Signal-regulated Kinase-dependent Proliferation Is Mediated through the Protein Kinase A/B-Raf Pathway in Human Uveal Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2006, 281, 9238-9250.	1.6	52
940	Rheb Inhibits C-Raf Activity and B-Raf/C-Raf Heterodimerization. <i>Journal of Biological Chemistry</i> , 2006, 281, 25447-25456.	1.6	73
941	A KSR/CNK complex mediated by HYP, a novel SAM domain-containing protein, regulates RAS-dependent RAF activation in <i>Drosophila</i> . <i>Genes and Development</i> , 2006, 20, 807-819.	2.7	51
942	The ABCs of Targeting Raf: Novel Approaches to Cancer Therapy. <i>Current Cancer Therapy Reviews</i> , 2006, 2, 305-314.	0.2	4
943	Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity. <i>Cancer Research</i> , 2006, 66, 6503-6511.	0.4	81
944	Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. <i>Cancer Biology and Therapy</i> , 2006, 5, 419-426.	1.5	162
945	From Melanocytes to Melanoma. , 2006, , .		21
946	Raf-1 is the predominant Raf isoform that mediates growth factor-stimulated growth in ovarian cancer cells. <i>Carcinogenesis</i> , 2006, 27, 729-739.	1.3	39
947	Cellular senescence in naevi and immortalisation in melanoma: a role for p16?. <i>British Journal of Cancer</i> , 2006, 95, 496-505.	2.9	364
948	Genetics and Epigenetics in Cancer Biology. , 2006, , 25-56.		1
949	ERK and Beyond: Insights from B-Raf and Raf-1 Conditional Knockouts. <i>Cell Cycle</i> , 2006, 5, 1514-1518.	1.3	90
950	Absence of Germline Mutations in Genes within the MAP Kinase Pathway in Familial Nonmedullary Thyroid Cancer. <i>Cell Cycle</i> , 2006, 5, 2036-2039.	1.3	18
951	RAF modulators and methods of use. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 1031-1036.	2.4	1

#	ARTICLE	IF	CITATIONS
952	High- and low-penetrance cutaneous melanoma susceptibility genes. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 657-670.	1.1	45
953	Cyclin D3 Expression in Melanoma Cells Is Regulated by Adhesion-dependent Phosphatidylinositol 3-Kinase Signaling and Contributes to G1-S Progression. <i>Journal of Biological Chemistry</i> , 2006, 281, 25644-25651.	1.6	36
954	Ras Triggers Ataxia-telangiectasia-mutated and Rad-3-related Activation and Apoptosis through Sustained Mitogenic Signaling. <i>Journal of Biological Chemistry</i> , 2006, 281, 34759-34767.	1.6	29
955	Two Transforming C-RAF Germ-Line Mutations Identified in Patients with Therapy-Related Acute Myeloid Leukemia. <i>Cancer Research</i> , 2006, 66, 3401-3408.	0.4	84
956	Molecular spectrum of pigmented skin lesions: from nevus to melanoma. <i>Expert Review of Dermatology</i> , 2006, 1, 679-700.	0.3	2
957	Novel molecular markers in well-differentiated thyroid cancers. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 685-693.	1.2	1
958	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1136-1144.	1.9	410
959	BRAF mutations and phosphorylation status of mitogen-activated protein kinases in the development of flat and depressed-type colorectal neoplasias. <i>British Journal of Cancer</i> , 2006, 94, 311-317.	2.9	13
960	Malignant melanoma: genetics and therapeutics in the genomic era. <i>Genes and Development</i> , 2006, 20, 2149-2182.	2.7	436
961	UV Radiation Induces Delayed Hyperrecombination Associated with Hypermutation in Human Cells. <i>Molecular and Cellular Biology</i> , 2006, 26, 6047-6055.	1.1	23
962	Microarrays for the Functional Analysis of the Chemical-Kinase Interactome. <i>Journal of Biomolecular Screening</i> , 2006, 11, 48-56.	2.6	38
963	Enhanced Killing of Melanoma Cells by Simultaneously Targeting Mcl-1 and NOXA. <i>Cancer Research</i> , 2006, 66, 9636-9645.	0.4	88
964	Frequent Alterations in the Expression of Serine/Threonine Kinases in Human Cancers. <i>Cancer Research</i> , 2006, 66, 8147-8154.	0.4	168
965	Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. <i>Genes and Development</i> , 2006, 20, 3426-3439.	2.7	495
966	AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma. <i>Cancer Research</i> , 2006, 66, 8722-8730.	0.4	54
967	Melanoma prevention strategy based on using tetrapeptide α -MSH analogs that protect human melanocytes from UV-induced DNA damage and cytotoxicity. <i>FASEB Journal</i> , 2006, 20, 1561-1563.	0.2	67
968	Lymphokine-Activated Killer T-Cell-Originated Protein Kinase Phosphorylation of Histone H2AX Prevents Arsenite-Induced Apoptosis in RPMI7951 Melanoma Cells. <i>Clinical Cancer Research</i> , 2006, 12, 6884-6893.	3.2	73
969	Cutaneous melanoma: an update on therapies. <i>Expert Review of Dermatology</i> , 2006, 1, 43-49.	0.3	0

#	ARTICLE	IF	CITATIONS
970	Pathogenesis, diagnosis and management of thyroid nodules in children. <i>Endocrine-Related Cancer</i> , 2006, 13, 427-453.	1.6	270
971	Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors. <i>Oncologist</i> , 2007, 12, 426-437.	1.9	386
972	Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2007, 12, 191-200.	1.9	109
973	Molecular Classification of Patients With Malignant Melanoma for New Therapeutic Strategies. <i>Journal of Clinical Oncology</i> , 2007, 25, e20-e21.	0.8	13
974	Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 991-997.	1.1	180
975	Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor. <i>Clinical Cancer Research</i> , 2007, 13, 1576-1583.	3.2	530
976	A Selective Cellular Screening Assay for B-Raf and c-Raf Kinases. <i>Journal of Biomolecular Screening</i> , 2007, 12, 818-827.	2.6	3
977	An Activating Mutation in <i>sos-1</i> Identifies Its Dbl Domain as a Critical Inhibitor of the Epidermal Growth Factor Receptor Pathway during <i>Caenorhabditis elegans</i> Vulval Development. <i>Molecular and Cellular Biology</i> , 2007, 27, 3695-3707.	1.1	9
978	Plexin-B1 mutations in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19040-19045.	3.3	81
979	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 19936-19941.	3.3	334
980	Molecular Analysis of Colorectal Cancer Tumors from Patients with Mismatch Repair-Proficient Hereditary Nonpolyposis Colorectal Cancer Suggests Novel Carcinogenic Pathways. <i>Clinical Cancer Research</i> , 2007, 13, 5729-5735.	3.2	43
981	Targeting Protein Translation in Human Non-Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression. <i>Cancer Research</i> , 2007, 67, 11300-11308.	0.4	88
982	A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. <i>Genes and Development</i> , 2007, 21, 379-384.	2.7	427
983	Role of stem cells in melanoma progression: hopes for a better treatment. <i>Expert Review of Dermatology</i> , 2007, 2, 191-201.	0.3	0
984	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. <i>Expert Review of Dermatology</i> , 2007, 2, 179-190.	0.3	0
985	Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 771-782.	1.5	5
986	BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2264-2271.	1.8	110
987	Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic. <i>Expert Review of Endocrinology and Metabolism</i> , 2007, 2, 225-238.	1.2	1

#	ARTICLE	IF	CITATIONS
988	Further Evidence for a Somatic <i>KRAS</i> Mutation in a Pilocytic Astrocytoma. <i>Neuropediatrics</i> , 2007, 38, 61-63.	0.3	60
989	RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer. <i>Annals of Oncology</i> , 2007, 18, 491-497.	0.6	30
990	Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis. <i>Journal of Clinical Pathology</i> , 2007, 60, 1211-1215.	1.0	47
991	Sorafenib in kidney cancer. <i>Annals of Oncology</i> , 2007, 18, ix90-ix93.	0.6	7
992	Killer Beacons for Combined Cancer Imaging and Therapy. <i>Current Medicinal Chemistry</i> , 2007, 14, 2110-2125.	1.2	50
993	Targeting Protein Multiple Conformations: A Structure-Based Strategy for Kinase Drug Design. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1394-1407.	1.0	34
994	Recent Advances of MEK Inhibitors and Their Clinical Progress. <i>Current Topics in Medicinal Chemistry</i> , 2007, 7, 1364-1378.	1.0	68
995	Flat Colorectal Cancers Are Genetically Determined and Progress to Invasion without Going through a Polypoid Stage. <i>Cancer Research</i> , 2007, 67, 11594-11600.	0.4	27
996	Functional Characterization of the T1799-1801del and G1799-1816ins BRAF Mutations in Papillary Thyroid Cancer. <i>Cell Cycle</i> , 2007, 6, 377-379.	1.3	86
997	Loss of p27 Expression Through RAS->BRAF->MAP Kinase-Dependent Pathway in Human Thyroid Carcinomas. <i>Cell Cycle</i> , 2007, 6, 2817-2825.	1.3	25
998	One of the Old Anatomist's Merits, the Isthmus of a Hair Follicle. <i>American Journal of Dermatopathology</i> , 2007, 29, 490.	0.3	0
999	Digital Karyotyping Reveals Frequent Inactivation of the dystrophin/DMD Gene in Malignant Melanoma. <i>Cell Cycle</i> , 2007, 6, 189-198.	1.3	23
1000	A role for cyclic nucleotide phosphodiesterase 4 in regulation of the growth of human malignant melanoma cells. <i>Oncology Reports</i> , 2007, 17, 1133.	1.2	4
1001	A Translational View of the Molecular Pathogenesis of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 327-343.	0.5	274
1002	Rap1/B-Raf Signaling Is Activated in Neuroendocrine Tumors of the Digestive Tract and Raf Kinase Inhibition Constitutes a Putative Therapeutic Target. <i>Neuroendocrinology</i> , 2007, 85, 45-53.	1.2	35
1003	Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 5895-5900.	3.3	465
1004	Novel inhibitors in the treatment of metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 715-724.	1.1	26
1005	AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinases: mechanism of action <i>in vivo</i> , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2209-2219.	1.9	377

#	ARTICLE	IF	CITATIONS
1006	Inhibitory Effects of the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 on the Proliferation and Tumor Growth of Thyroid Cancer Cells with <i>BRAF</i> or <i>RAS</i> Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4686-4695.	1.8	65
1007	Update in Thyroidology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3755-3761.	1.8	7
1008	Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. <i>Future Oncology</i> , 2007, 3, 545-556.	1.1	9
1009	Targeting signal transduction in pancreatic cancer treatment. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 673-694.	1.5	45
1010	Toward a Molecular Classification of Melanoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1606-1620.	0.8	234
1011	The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation. <i>Molecular Pharmacology</i> , 2007, 72, 788-795.	1.0	61
1012	Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4712-4718.	1.8	95
1013	Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms. <i>Cancer Research</i> , 2007, 67, 465-473.	0.4	108
1014	BRAF T1799A Mutation Occurring in a Case of Malignant Struma Ovarii. <i>International Journal of Surgical Pathology</i> , 2007, 15, 116-120.	0.4	31
1015	A Novel Platform for Accelerated Pharmacodynamic Profiling for Lead Optimization of Anticancer Drug Candidates. <i>Journal of Biomolecular Screening</i> , 2007, 12, 159-166.	2.6	9
1016	Targeting BRAFV600E in thyroid carcinoma: therapeutic implications. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1070-1078.	1.9	57
1017	B- and C-RAF Display Essential Differences in Their Binding to Ras. <i>Journal of Biological Chemistry</i> , 2007, 282, 26503-26516.	1.6	71
1018	K-Ras Promotes Growth Transformation and Invasion of Immortalized Human Pancreatic Cells by Raf and Phosphatidylinositol 3-Kinase Signaling. <i>Cancer Research</i> , 2007, 67, 2098-2106.	0.4	197
1019	Utility of Circulating B-RAF DNA Mutation in Serum for Monitoring Melanoma Patients Receiving Biochemotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 2068-2074.	3.2	158
1020	Mutant V600E BRAF Increases Hypoxia Inducible Factor-1 α Expression in Melanoma. <i>Cancer Research</i> , 2007, 67, 3177-3184.	0.4	127
1021	Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2007, 13, 5256-5261.	3.2	210
1022	Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question. <i>Genes and Development</i> , 2007, 21, 361-366.	2.7	7
1023	Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1. <i>Clinical Cancer Research</i> , 2007, 13, 4934-4942.	3.2	168

#	ARTICLE	IF	CITATIONS
1024	Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. <i>Human Molecular Genetics</i> , 2007, 17, 419-430.	1.4	30
1025	Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3766-3773.	0.8	230
1026	New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. <i>Endocrine-Related Cancer</i> , 2007, 14, 957-977.	1.6	86
1027	Oncogene addiction: setting the stage for molecularly targeted cancer therapy. <i>Genes and Development</i> , 2007, 21, 3214-3231.	2.7	377
1028	Specific Clinical and Biological Features Characterize Inflammatory Bowel Disease-Associated Colorectal Cancers Showing Microsatellite Instability. <i>Journal of Clinical Oncology</i> , 2007, 25, 4231-4238.	0.8	68
1029	Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) Diagnostics. <i>Journal of the National Cancer Institute</i> , 2007, 99, 291-299.	3.0	201
1030	Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines. <i>Molecular Cancer Research</i> , 2007, 5, 195-201.	1.5	271
1031	³ Deoxy- ³ [¹⁸ F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition. <i>Cancer Research</i> , 2007, 67, 11463-11469.	0.4	66
1032	Endometrial carcinoma: pathology and genetics. <i>Pathology</i> , 2007, 39, 72-87.	0.3	172
1033	Common and Distinct Genomic Events in Sporadic Colorectal Cancer and Diverse Cancer Types. <i>Cancer Research</i> , 2007, 67, 10736-10743.	0.4	64
1034	RaLP, a New Member of the Src Homology and Collagen Family, Regulates Cell Migration and Tumor Growth of Metastatic Melanomas. <i>Cancer Research</i> , 2007, 67, 3064-3073.	0.4	69
1035	Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma. <i>Cancer Research</i> , 2007, 67, 1502-1512.	0.4	80
1036	DNA repair gene polymorphisms and genetic predisposition to cutaneous melanoma. <i>Carcinogenesis</i> , 2007, 28, 1087-1093.	1.3	77
1037	Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 10974-10979.	3.3	65
1038	Genome-epigenome interactions in cancer. <i>Human Molecular Genetics</i> , 2007, 16, R96-R105.	1.4	60
1039	Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2220-2229.	1.9	30
1040	Adenocarcinoma, a molecular perspective. <i>Annals of Oncology</i> , 2007, 18, ix147-ix149.	0.6	19
1041	The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress. <i>Molecular and Cellular Biology</i> , 2007, 27, 5499-5513.	1.1	209

#	ARTICLE	IF	CITATIONS
1042	Filamin A-mediated Down-regulation of the Exchange Factor Ras-GRF1 Correlates with Decreased Matrix Metalloproteinase-9 Expression in Human Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 14816-14826.	1.6	51
1043	Targeting Mutant (V600E) B-Raf in Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma Extravasation. <i>Cancer Research</i> , 2007, 67, 5814-5820.	0.4	82
1044	RKIP does not contribute to MAP kinase pathway silencing in the Merkel Cell Carcinoma cell line UIISO. <i>Journal of Carcinogenesis</i> , 2007, 6, 16.	2.5	9
1045	Differential Regulation of B-Raf Isoforms by Phosphorylation and Autoinhibitory Mechanisms. <i>Molecular and Cellular Biology</i> , 2007, 27, 31-43.	1.1	35
1046	Tumor Necrosis Factor- β Blocks Apoptosis in Melanoma Cells when BRAF Signaling Is Inhibited. <i>Cancer Research</i> , 2007, 67, 122-129.	0.4	117
1047	Metabotropic Glutamate Receptor 1 and Glutamate Signaling in Human Melanoma. <i>Cancer Research</i> , 2007, 67, 2298-2305.	0.4	166
1048	Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models. <i>Cancer Research</i> , 2007, 67, 4933-4939.	0.4	155
1049	Docetaxel-Induced Apoptosis of Human Melanoma Is Mediated by Activation of c-Jun NH2-Terminal Kinase and Inhibited by the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase 1/2 Pathway. <i>Clinical Cancer Research</i> , 2007, 13, 1308-1314.	3.2	62
1050	IQGAP1 modulates activation of B-Raf. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 10465-10469.	3.3	141
1051	Dissecting the Senescence-like Program in Tumor Cells Activated by Ras Signaling. <i>Journal of Biological Chemistry</i> , 2007, 282, 2666-2675.	1.6	21
1052	Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. <i>Molecular Systems Biology</i> , 2007, 3, 151.	3.2	128
1053	The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants. <i>Journal of Thoracic Oncology</i> , 2007, 2, 321-324.	0.5	5
1056	Differential Responses of Human Papillary Thyroid Cancer Cell Lines Carrying the RET/PTC1 Rearrangement or a BRAF Mutation to MEK1/2 Inhibitors. <i>JAMA Otolaryngology</i> , 2007, 133, 810.	1.5	22
1057	Mouse models for BRAF-induced cancers. <i>Biochemical Society Transactions</i> , 2007, 35, 1329-1333.	1.6	30
1058	Mutational analysis of the BRAF gene in colorectal mucinous carcinoma in association with histological configuration. <i>Oncology Reports</i> , 2007, , .	1.2	4
1059	Distribution of BRAF T1799A(V600E) Mutations Across Various Types of Benign Nevi: Implications for Melanocytic Tumorigenesis. <i>American Journal of Dermatopathology</i> , 2007, 29, 534-537.	0.3	61
1060	Current topics in melanoma. <i>Current Opinion in Oncology</i> , 2007, 19, 116-120.	1.1	20
1061	CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. <i>Melanoma Research</i> , 2007, 17, 91-103.	0.6	18

#	ARTICLE	IF	CITATIONS
1062	Basal Cell Carinoma of the Sole: Implications for Fibroepithelioma of Pinkus. American Journal of Dermatopathology, 2007, 29, 494.	0.3	7
1063	Models of Melanoma Metastasis: Using a Transient siRNA-Based Protein Inhibition Strategy in Mice to Validate the Functional Relevance of Pharmacological Agents. Current Protocols in Pharmacology, 2007, 38, Unit 14.6.	4.0	3
1064	No evidence of RALGDS mutations in cutaneous melanoma. Melanoma Research, 2007, 17, 410-412.	0.6	3
1065	Melanocytic Lesions, Spitz Tumors, and Don Ferrante's Logic. American Journal of Dermatopathology, 2007, 29, 491-494.	0.3	8
1066	Thyroid cancer: are molecular studies making any difference?. Journal of Laryngology and Otology, 2007, 121, 917-926.	0.4	2
1067	Inhibitors of Raf kinase and MEK signaling. Update on Cancer Therapeutics, 2007, 2, 111-118.	0.9	16
1068	Overcoming apoptosis deficiency of melanoma—Hope for new therapeutic approaches. Drug Resistance Updates, 2007, 10, 218-234.	6.5	99
1069	Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. European Journal of Cancer, 2007, 43, 137-143.	1.3	28
1070	Chk1 frameshift mutation in sporadic and hereditary non-polyposis colorectal cancers with microsatellite instability. European Journal of Surgical Oncology, 2007, 33, 580-585.	0.5	25
1071	Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene. Cell, 2007, 129, 1065-1079.	13.5	538
1072	Stopping Ras in Its Tracks. Cell, 2007, 129, 855-857.	13.5	18
1073	The Role of Small Molecule Inhibitors for Veterinary Patients. Veterinary Clinics of North America - Small Animal Practice, 2007, 37, 1121-1136.	0.5	1
1074	Deregulated Ras signaling in developmental disorders: new tricks for an old dog. Current Opinion in Genetics and Development, 2007, 17, 15-22.	1.5	109
1075	New insight into BRAF mutations in cancer. Current Opinion in Genetics and Development, 2007, 17, 31-39.	1.5	251
1076	Melanocytes: The new Black. International Journal of Biochemistry and Cell Biology, 2007, 39, 275-279.	1.2	78
1077	BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Letters, 2007, 249, 242-248.	3.2	108
1078	Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Letters, 2007, 249, 87-96.	3.2	51
1079	RNA interference: Implications for cancer treatment. Molecular Aspects of Medicine, 2007, 28, 143-166.	2.7	60

#	ARTICLE	IF	CITATIONS
1080	Primer on the human genome. Journal of the American Academy of Dermatology, 2007, 56, 719-735.	0.6	10
1081	Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Human Pathology, 2007, 38, 607-613.	1.1	112
1082	Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Human Pathology, 2007, 38, 1810-1818.	1.1	40
1083	How to make a melanoma: what do we know of the primary clonal events?. Pigment Cell and Melanoma Research, 2008, 21, 27-38.	1.5	170
1084	BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications. Endocrine Reviews, 2007, 28, 742-762.	8.9	857
1087	Apoptosis, Senescence, and Cancer. , 2007, , .		8
1088	Cancer Biology. , 2007, , 1-31.		4
1089	The continuing search for cancer-causing somatic mutations. Breast Cancer Research, 2007, 9, 101.	2.2	3
1090	Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas. Breast Cancer Research, 2007, 9, R5.	2.2	28
1091	Selective Raf inhibition in cancer therapy. Expert Opinion on Therapeutic Targets, 2007, 11, 1587-1609.	1.5	63
1093	Cell Division and Survival. , 2007, , 45-191.		1
1094	Epithelial Tumors. , 2007, , 441-524.		0
1095	Roles of Aurora Kinases in Mitosis and Tumorigenesis. Molecular Cancer Research, 2007, 5, 1-10.	1.5	529
1096	Molecular mechanisms of cellular senescence and immortalization of human cells. Expert Opinion on Therapeutic Targets, 2007, 11, 1623-1637.	1.5	14
1097	Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features. Journal of Molecular Diagnostics, 2007, 9, 320-326.	1.2	188
1098	In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors. Cancer Research, 2007, 67, 2206-2216.	0.4	111
1099	Fine-Needle Aspiration Molecular Analysis for the Diagnosis of Papillary Thyroid Carcinoma Through BRAFV600E Mutation and RET/PTC Rearrangement. Thyroid, 2007, 17, 1109-1115.	2.4	94
1100	Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance. Expert Review of Anticancer Therapy, 2007, 7, 79-88.	1.1	30

#	ARTICLE	IF	CITATIONS
1101	An Update on Malignant Melanoma Vaccine Research. <i>American Journal of Clinical Dermatology</i> , 2007, 8, 123-141.	3.3	20
1102	Tyrosine Kinase Inhibitors in Pediatric Malignancies. <i>Cancer Investigation</i> , 2007, 25, 606-612.	0.6	11
1103	RET/PTC Rearrangements and BRAF Mutations in Thyroid Tumorigenesis. <i>Endocrinology</i> , 2007, 148, 936-941.	1.4	213
1104	Mitofusin 2 Triggers Vascular Smooth Muscle Cell Apoptosis via Mitochondrial Death Pathway. <i>Circulation Research</i> , 2007, 101, 1113-1122.	2.0	167
1105	Use of Docking Peptides to Design Modular Substrates with High Efficiency for Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase. <i>ACS Chemical Biology</i> , 2007, 2, 665-673.	1.6	26
1106	B-RAF mutations are a rare event in pituitary adenomas. <i>Journal of Endocrinological Investigation</i> , 2007, 30, RC1-RC3.	1.8	12
1107	Small Molecule Signal Transduction Inhibitors for the Treatment of Solid Tumors. <i>Cancer Investigation</i> , 2007, 25, 347-365.	0.6	16
1108	Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 178-183.	1.2	40
1109	Development and Applications of a BRAF Oligonucleotide Microarray. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 55-63.	1.2	8
1110	Cancer genomics: integrating form and function. <i>Carcinogenesis</i> , 2007, 28, 1387-1392.	1.3	16
1112	Growth Factors and Oncogenes as Targets in Melanoma: Lost in Translation?. <i>Advances in Dermatology</i> , 2007, 23, 99-129.	2.0	16
1113	Genetic Mutations Involved in Melanoma: A Summary of Our Current Understanding. <i>Advances in Dermatology</i> , 2007, 23, 61-79.	2.0	29
1114	Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment. <i>Mayo Clinic Proceedings</i> , 2007, 82, 490-513.	1.4	119
1115	Hyperplastic and Serrated Polyps of the Colorectum. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 947-968.	1.0	155
1116	Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 464-471.	1.2	95
1117	Sorafenib: delivering a targeted drug to the right targets. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 617-626.	1.1	58
1118	Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma. <i>Journal of Translational Medicine</i> , 2007, 5, 38.	1.8	35
1119	Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features. <i>British Journal of Cancer</i> , 2007, 97, 1425-1431.	2.9	32

#	ARTICLE	IF	CITATIONS
1120	Bidirectional Signals Transduced by TOPK-ERK Interaction Increase Tumorigenesis of HCT116 Colorectal Cancer Cells. <i>Gastroenterology</i> , 2007, 133, 219-231.	0.6	128
1121	Cancer genome analysis: a landscape seen from many angles. <i>Drug Discovery Today Disease Mechanisms</i> , 2007, 4, 269-276.	0.8	0
1122	<i>Bioinformatics and Cancer Genetics.</i> , 0, , 413-445.		0
1123	Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4085-4090.	1.8	370
1124	B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis. <i>PLoS ONE</i> , 2007, 2, e236.	1.1	133
1125	Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4. <i>PLoS ONE</i> , 2007, 2, e426.	1.1	77
1126	Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy. <i>PLoS ONE</i> , 2007, 2, e1279.	1.1	77
1127	Using molecular beacons for cancer imaging and treatment. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 4709.	3.0	56
1128	Molecular genetics of papillary thyroid carcinoma: great expectations.... <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 643-653.	1.3	28
1129	Highly Conserved Sequence of Exon 15 BRAF Gene and KRAS Codon 12 Mutation among Greek Patients with Colorectal Cancer. <i>International Journal of Biological Markers</i> , 2007, 22, 12-18.	0.7	15
1130	Pathogenetic Mechanisms and Therapeutic Implications of BRAFV600E in Papillary Thyroid Cancer. <i>Journal of Korean Endocrine Society</i> , 2007, 22, 245.	0.1	0
1131	The T1799A<i>BRAF</i> Mutation Is Present in Iris Melanoma. , 2007, 48, 4897.		46
1132	Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia. <i>Haematologica</i> , 2007, 92, 1574-1575.	1.7	13
1133	State of the Science. <i>Oncology Issues</i> , 2007, 22, 18-21.	0.0	0
1136	Directed DNA Polymerase Evolution: Effects of Mutations in Motif C on the Mismatch-Extension Selectivity of <i>Thermus aquaticus</i> DNA Polymerase. <i>ChemBioChem</i> , 2007, 8, 395-401.	1.3	28
1137	Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. <i>Human Mutation</i> , 2007, 28, 578-588.	1.1	222
1138	Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. <i>International Journal of Cancer</i> , 2007, 120, 7-12.	2.3	42
1139	Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients. <i>International Journal of Cancer</i> , 2007, 120, 2439-2444.	2.3	76

#	ARTICLE	IF	CITATIONS
1140	Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. <i>International Journal of Cancer</i> , 2007, 121, 301-307.	2.3	50
1141	Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. <i>International Journal of Cancer</i> , 2007, 121, 767-775.	2.3	53
1142	The cannabinoid Δ^9 -tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. <i>International Journal of Cancer</i> , 2007, 121, 2172-2180.	2.3	142
1143	Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. <i>Journal of Cellular Physiology</i> , 2007, 210, 740-749.	2.0	36
1144	Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: Role of the Eph receptors. <i>Developmental Dynamics</i> , 2007, 236, 3283-3296.	0.8	79
1145	Pathologic expression of MHC class II is driven by mitogen-activated protein kinases. <i>European Journal of Immunology</i> , 2007, 37, 788-797.	1.6	26
1146	Toward a global characterization of the phosphoproteome in prostate cancer cells: Identification of phosphoproteins in the LNCaP cell line. <i>Electrophoresis</i> , 2007, 28, 2027-2034.	1.3	22
1147	Differential gene expression in melanocytic nevi with the V600E BRAF mutation. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1019-1027.	1.5	17
1148	Clinicopathologic features and BRAF V600E mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas. <i>Cancer</i> , 2007, 109, 1965-1971.	2.0	17
1149	Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid. <i>Cancer</i> , 2007, 110, 38-46.	2.0	280
1150	<i>BRAF</i> ^{V600E} mutation and <i>p27</i> ^{kip1} expression in papillary carcinomas of the thyroid ≤ 1 cm and their paired lymph node metastases. <i>Cancer</i> , 2007, 110, 1218-1226.	2.0	81
1151	The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. <i>Molecular Carcinogenesis</i> , 2007, 46, 242-248.	1.3	39
1152	Melanoma susceptibility and cell cycle genes in <i>Xiphophorus</i> hybrids. <i>Molecular Carcinogenesis</i> , 2007, 46, 685-691.	1.3	9
1153	Models and mechanisms in malignant melanoma. <i>Molecular Carcinogenesis</i> , 2007, 46, 671-678.	1.3	22
1154	Synthesis and biological activity of vicinal diaryl-substituted 1H-imidazoles. <i>Tetrahedron</i> , 2007, 63, 4571-4624.	1.0	233
1155	Role of water molecules for binding inhibitors in the SH2 domain of Grb2: A molecular dynamics study. <i>Computational and Theoretical Chemistry</i> , 2007, 806, 51-66.	1.5	12
1156	Novel treatment strategies for malignant melanoma: A new beginning?. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 62, 16-22.	2.0	30
1157	SAR of a novel α -Anthraniamide Like™ series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4378-4381.	1.0	12

#	ARTICLE	IF	CITATIONS
1158	GAPDH is not regulated in human glioblastoma under hypoxic conditions. <i>BMC Molecular Biology</i> , 2007, 8, 55.	3.0	43
1159	pHUSH: a single vector system for conditional gene expression. <i>BMC Biotechnology</i> , 2007, 7, 61.	1.7	39
1160	Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. <i>Journal of Pathology</i> , 2007, 212, 124-133.	2.1	85
1161	A catalogue of proteins released by colorectal cancer cells in vitro as an alternative source for biomarker discovery. <i>Proteomics - Clinical Applications</i> , 2007, 1, 47-61.	0.8	28
1162	KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. <i>Oncogene</i> , 2007, 26, 158-163.	2.6	164
1163	Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells. <i>Oncogene</i> , 2007, 26, 1056-1066.	2.6	67
1164	Absence of tyrosine kinase mutations in Japanese colorectal cancer patients. <i>Oncogene</i> , 2007, 26, 2133-2135.	2.6	12
1165	Differential oncogenic potential of activated RAS isoforms in melanocytes. <i>Oncogene</i> , 2007, 26, 4563-4570.	2.6	60
1166	KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. <i>Oncogene</i> , 2007, 26, 3143-3158.	2.6	122
1167	Role of mitogen-activated protein kinase kinase kinases in signal integration. <i>Oncogene</i> , 2007, 26, 3159-3171.	2.6	247
1168	MAP kinase signalling pathways in cancer. <i>Oncogene</i> , 2007, 26, 3279-3290.	2.6	2,473
1169	Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. <i>Oncogene</i> , 2007, 26, 3291-3310.	2.6	2,421
1170	Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2. <i>Oncogene</i> , 2007, 26, 6071-6081.	2.6	73
1171	Drivers and passengers. <i>Nature</i> , 2007, 446, 145-146.	13.7	186
1172	Silicon life forms. <i>Nature</i> , 2007, 446, 146-147.	13.7	7
1173	The devil is in the DNA. <i>Nature Genetics</i> , 2007, 39, 283-284.	9.4	16
1174	Enhancing genome annotation with chromatin. <i>Nature Genetics</i> , 2007, 39, 284-285.	9.4	9
1175	Hyperactive Ras in developmental disorders and cancer. <i>Nature Reviews Cancer</i> , 2007, 7, 295-308.	12.8	1,422

#	ARTICLE	IF	CITATIONS
1176	Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53. <i>Cell Death and Differentiation</i> , 2007, 14, 818-829.	5.0	40
1177	A genome-wide scan for naevus count: linkage to CDKN2A and to other chromosome regions. <i>European Journal of Human Genetics</i> , 2007, 15, 94-102.	1.4	73
1178	Selective role for RGS12 as a Ras/Raf/MEK scaffold in nerve growth factor-mediated differentiation. <i>EMBO Journal</i> , 2007, 26, 2029-2040.	3.5	78
1179	Congenital Melanocytic Nevi Frequently Harbor NRAS Mutations but no BRAF Mutations. <i>Journal of Investigative Dermatology</i> , 2007, 127, 179-182.	0.3	302
1180	Tumor-Derived Fibronectin Is Involved in Melanoma Cell Invasion and Regulated by V600E B-Raf Signaling Pathway. <i>Journal of Investigative Dermatology</i> , 2007, 127, 400-410.	0.3	51
1181	BRAF Mutations in Multiple Sebaceous Hyperplasias of Patients Belonging to MYH-Associated Polyposis Pedigrees. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1387-1391.	0.3	17
1182	Chromosomal Translocations as a Mechanism of BRAF Activation in Two Cases of Large Congenital Melanocytic Nevi. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1468-1470.	0.3	64
1183	Activation of the MAP Kinase Pathway Induces Apoptosis in the Merkel Cell Carcinoma Cell Line UISO. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2116-2122.	0.3	27
1184	ERK1/2 Is Highly Phosphorylated in Melanoma Metastases and Protects Melanoma Cells from Cisplatin-Mediated Apoptosis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2207-2215.	0.3	70
1185	The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene. <i>Leukemia</i> , 2007, 21, 2216-2218.	3.3	8
1186	N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative study group. <i>Leukemia</i> , 2007, 21, 2218-2219.	3.3	19
1187	Targeting BRAF in thyroid cancer. <i>British Journal of Cancer</i> , 2007, 96, 16-20.	2.9	88
1188	Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. <i>Modern Pathology</i> , 2007, 20, 779-787.	2.9	91
1189	H-Ras mutation modulates the expression of major cell cycle regulatory proteins and disease prognosis in oral carcinoma. <i>Modern Pathology</i> , 2007, 20, 1141-1148.	2.9	37
1190	Patterns of somatic mutation in human cancer genomes. <i>Nature</i> , 2007, 446, 153-158.	13.7	2,802
1191	Melanoma biology and new targeted therapy. <i>Nature</i> , 2007, 445, 851-857.	13.7	1,161
1192	RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. <i>Nature</i> , 2007, 447, 865-869.	13.7	1,104
1193	Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. <i>Nature</i> , 2007, 447, 966-971.	13.7	355

#	ARTICLE	IF	CITATIONS
1194	Molecular Responses to Stress Induced in Normal Human Caucasian Melanocytes in Culture by Exposure to Simulated Solar UV ^{<sup>A</sup>. <i>Photochemistry and Photobiology</i>, 2005, 81, 367-375.}	1.3	6
1195	UV Exposure, Genetic Targets in Melanocytic Tumors and Transgenic Mouse Models ^{<sup>A</sup>. <i>Photochemistry and Photobiology</i>, 2005, 81, 52-64.}	1.3	0
1196	TACE: a new target in epidermal growth factor receptor dependent tumors. <i>Differentiation</i> , 2007, 75, 800-808.	1.0	57
1197	Signal-transduction inhibitors in renal cell carcinoma. <i>BJU International</i> , 2007, 99, 1289-1295.	1.3	12
1198	Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. <i>British Journal of Dermatology</i> , 2007, 156, 1204-1213.	1.4	111
1199	Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion. <i>British Journal of Dermatology</i> , 2007, 156, 1287-1294.	1.4	80
1200	Understanding spitzoid tumours: new insights from molecular pathology. <i>British Journal of Dermatology</i> , 2007, 158, 071004160508025-???	1.4	44
1201	Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation. <i>British Journal of Dermatology</i> , 2007, 157, 1297-1299.	1.4	33
1202	Constitutive activation of the phosphatidyl inositol 3 kinase signalling pathway in acral lentiginous melanoma. <i>British Journal of Dermatology</i> , 2007, 158, 071115063928004-???	1.4	17
1203	Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. <i>British Journal of Dermatology</i> , 2007, 158, 071119222739015-???	1.4	37
1204	Genetics of melanoma tumorigenesis. <i>British Journal of Dermatology</i> , 2008, 158, 15-21.	1.4	46
1205	A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. <i>Clinical Endocrinology</i> , 2007, 66, 348-352.	1.2	63
1206	Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. <i>Clinical Endocrinology</i> , 2007, 66, 678-683.	1.2	147
1207	Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis. <i>Cancer Science</i> , 2007, 98, 652-658.	1.7	58
1208	Identification of JTP-70902, a p15INK4b-inductive compound, as a novel MEK1/2 inhibitor. <i>Cancer Science</i> , 2007, 98, 1809-1816.	1.7	50
1209	Germ line and somatic mutations of BRAF V599E in ovarian carcinoma. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 794-797.	1.2	14
1210	Molecular markers of circulating melanoma cells. <i>Pigment Cell & Melanoma Research</i> , 2007, 20, 80-91.	4.0	37
1211	Confirmation of a BRAF mutation-associated gene expression signature in melanoma. <i>Pigment Cell & Melanoma Research</i> , 2007, 20, 216-221.	4.0	76

#	ARTICLE	IF	CITATIONS
1212	Melanoma invasion ? current knowledge and future directions. Pigment Cell & Melanoma Research, 2007, 20, 161-172.	4.0	99
1213	Potent p53-independent tumor suppressor activity of ARF in melanoma-genesis. Pigment Cell & Melanoma Research, 2007, 20, 070811024453003-???.	4.0	3
1214	Melanoma senescence: HDAC1 in focus. Pigment Cell & Melanoma Research, 2007, 20, 070811024453002-???.	4.0	2
1215	Cutaneous melanoma in genetically modified animals. Pigment Cell & Melanoma Research, 2007, 20, 485-497.	4.0	69
1216	DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell & Melanoma Research, 2007, 20, 466-484.	4.0	74
1217	Deletion mutation of BRAF in a serrated adenoma from a patient with familial adenomatous polyposis. Apmis, 2007, 115, 982-986.	0.9	9
1218	The genome and epigenome of malignant melanoma. Apmis, 2007, 115, 1161-1176.	0.9	151
1219	Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions. Journal of Cutaneous Pathology, 2007, 34, 448-455.	0.7	37
1220	Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma. Pathology International, 2007, 57, 12-20.	0.6	31
1221	Epidermal growth factor receptor mutations in lung cancers. Pathology International, 2007, 57, 233-244.	0.6	72
1222	Key Signaling Pathways and Targets in Lung Cancer Therapy. Clinical Lung Cancer, 2007, 8, S52-S60.	1.1	12
1223	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1263-1284.	1.9	1,858
1224	The integration of signaling by multiprotein complexes containing Raf kinases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1238-1247.	1.9	37
1225	MAP kinase pathways: The first twenty years. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1150-1160.	1.9	236
1226	Clinical experience of MEK inhibitors in cancer therapy. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1248-1255.	1.9	153
1227	ERK implication in cell cycle regulation. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1299-1310.	1.9	633
1228	Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1161-1176.	1.9	368
1229	Raf kinases: Function, regulation and role in human cancer. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1196-1212.	1.9	249

#	ARTICLE	IF	CITATIONS
1230	Expression and genomic profiling of colorectal cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2007, 1775, 103-137.	3.3	77
1231	Rewired ERK-JNK Signaling Pathways in Melanoma. <i>Cancer Cell</i> , 2007, 11, 447-460.	7.7	260
1232	Frequency and application of the hot spot BRAF gene mutation (p.V600E) in the diagnostic strategy for Hereditary Nonpolyposis Colorectal Cancer. <i>Cancer Detection and Prevention</i> , 2007, 31, 254-256.	2.1	12
1233	Novel mechanism of cyclic AMP mediated extracellular signal regulated kinase activation in an intestinal cell line. <i>Cellular Signalling</i> , 2007, 19, 1221-1228.	1.7	6
1234	Involvement of phosphatases in the anchorage-dependent regulation of ERK2 activation. <i>Experimental Cell Research</i> , 2007, 313, 1830-1838.	1.2	8
1235	Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. <i>Gynecologic Oncology</i> , 2007, 105, 662-666.	0.6	60
1236	Issues affecting molecular staging in the management of patients with melanoma. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1052-1068.	1.6	27
1237	Melanoma, long wavelength ultraviolet and sunscreens: Controversies and potential resolutions. , 2007, 114, 198-207.		39
1238	Identifying Molecular Markers for the Early Detection of Pancreatic Neoplasia. <i>Seminars in Oncology</i> , 2007, 34, 303-310.	0.8	89
1239	The RTK/RAS/BRAF/PI3K Pathways in Melanoma: Biology, Small Molecule Inhibitors, and Potential Applications. <i>Seminars in Oncology</i> , 2007, 34, 546-554.	0.8	56
1241	Critical Roles of the Raf/MEK/ERK Pathway in Apoptosis and Drug Resistance. , 2006, , 101-134.		2
1242	MAPK Signaling in Human Diseases. , 2006, , 135-149.		1
1243	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , 2007, 47, 64-103.	2.9	77
1244	Establishment of a novel melanoma cell line SMYM-PRGP showing cytogenetic and biological characteristics of the radial growth phase of acral melanomas. <i>Cancer Science</i> , 2007, 98, 958-963.	1.7	13
1246	An unexpected new role of mutant Ras: perturbation of human embryonic development. <i>Journal of Molecular Medicine</i> , 2007, 85, 227-235.	1.7	54
1247	WP760, a melanoma selective drug. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 625-633.	1.1	5
1250	Recent discoveries in the genetics of melanoma and their therapeutic implications. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2007, 55, 363-372.	1.0	19
1251	Notch and cancer: a double-edged sword. <i>Cellular and Molecular Life Sciences</i> , 2007, 64, 2746-2762.	2.4	308

#	ARTICLE	IF	CITATIONS
1252	LRRK2 Low-penetrance Mutations (Gly2019Ser) and Risk Alleles (Gly2385Arg) Linking Familial and Sporadic Parkinson's Disease. <i>Neurochemical Research</i> , 2007, 32, 1700-1708.	1.6	69
1253	Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway. <i>Investigational New Drugs</i> , 2007, 25, 391-395.	1.2	15
1254	Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. <i>Familial Cancer</i> , 2007, 6, 301-310.	0.9	153
1256	A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 619-626.	1.4	14
1257	Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 271-278.	1.2	48
1258	Role of MTHFR polymorphisms and folate levels in different phenotypes of sporadic colorectal cancers. <i>International Journal of Colorectal Disease</i> , 2007, 22, 483-489.	1.0	36
1259	Relationship of BRAF mutation, morphology, and apoptosis in early colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2007, 23, 7-13.	1.0	4
1260	RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations. <i>Acta Neuropathologica</i> , 2007, 114, 121-133.	3.9	105
1261	Hereditary nonpolyposis colon cancer: Revised Bethesda criteria, immunohistochemistry, microsatellite instability, germline analysis, and emerging issues in genetic testing. <i>Current Colorectal Cancer Reports</i> , 2007, 3, 10-15.	1.0	0
1262	RET Signaling in Endocrine Tumors: Delving Deeper into Molecular Mechanisms. <i>Endocrine Pathology</i> , 2007, 18, 57-67.	5.2	32
1263	Immunotherapeutic strategies employing RNA interference technology for the control of cancers. <i>Journal of Biomedical Science</i> , 2007, 14, 15-29.	2.6	20
1264	The clinical application of autologous bioengineered skin based on a hyaluronic acid scaffold. <i>Biomaterials</i> , 2008, 29, 1620-1629.	5.7	57
1265	Cell cycle control and adhesion signaling pathways in the development of metastatic melanoma. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 707-714.	2.7	6
1266	Follicular Histotypes of Oncocytic Thyroid Carcinomas Do Not Carry Mutations of the <i>BRAF</i> Hotspot. <i>World Journal of Surgery</i> , 2008, 32, 722-728.	0.8	26
1269	CpG Island methylator phenotype in colorectal cancer: A current perspective. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 77-83.	1.0	3
1270	The biology and management of uveal melanoma. <i>Current Oncology Reports</i> , 2008, 10, 431-438.	1.8	38
1271	K-ras Mutation, HPV Infection and Smoking or Alcohol Abuse Positively Correlate with Esophageal Squamous Carcinoma. <i>Pathology and Oncology Research</i> , 2008, 14, 267-273.	0.9	31
1272	A Mathematical Approach Predicting the Number of Events in Different Tumors. <i>Pathology and Oncology Research</i> , 2008, 14, 199-204.	0.9	2

#	ARTICLE	IF	CITATIONS
1273	Uveal vs. cutaneous melanoma. Origins and causes of the differences. <i>Clinical and Translational Oncology</i> , 2008, 10, 137-142.	1.2	20
1274	Mutational analysis of <i>SOS1</i> gene in acute myeloid leukemia. <i>International Journal of Hematology</i> , 2008, 88, 460-462.	0.7	7
1275	Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. <i>Journal of Gastroenterology</i> , 2008, 43, 905-911.	2.3	42
1276	<i>PIK3CA</i> , <i>KRAS</i> , and <i>BRAF</i> mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. <i>Langenbeck's Archives of Surgery</i> , 2008, 393, 289-296.	0.8	67
1277	Inter-cellular adhesion disruption and the <i>RAS/RAF</i> and beta-catenin signalling in lung cancer progression. <i>Cancer Cell International</i> , 2008, 8, 7.	1.8	13
1278	Coexisting somatic promoter hypermethylation and pathogenic <i>MLH1</i> germline mutation in Lynch syndrome. <i>Journal of Pathology</i> , 2008, 214, 10-16.	2.1	69
1279	<i>BRAF</i> provides proliferation and survival signals in MSI colorectal carcinoma cells displaying <i>BRAF</i> ^{V600E} but not <i>KRAS</i> mutations. <i>Journal of Pathology</i> , 2008, 214, 320-327.	2.1	53
1280	The <i>RAS/MAPK</i> syndromes: novel roles of the <i>RAS</i> pathway in human genetic disorders. <i>Human Mutation</i> , 2008, 29, 992-1006.	1.1	322
1281	Sunlight ultraviolet irradiation and <i>BRAF</i> ^{V600} mutagenesis in human melanoma. <i>Human Mutation</i> , 2008, 29, 983-991.	1.1	50
1282	Mutations in the <i>RAS</i> - <i>MAPK</i> , <i>PI(3)K</i> (phosphatidylinositol 3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. <i>International Journal of Cancer</i> , 2008, 122, 2255-2259.	2.3	273
1283	Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 1124-1149.	1.2	186
1284	Novel <i>V600E</i> <i>BRAF</i> mutations in imatinib-naïve and imatinib-resistant gastrointestinal stromal tumors. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 853-859.	1.5	329
1285	Biochemotherapy in patients with advanced head and neck mucosal melanoma. <i>Head and Neck</i> , 2008, 30, 1592-1598.	0.9	83
1286	4-Anilino-7-alkenylquinoline-3-carbonitriles as potent <i>MEK1</i> kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 9202-9211.	1.4	16
1287	Dual binding site inhibitors of <i>B-RAF</i> kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2825-2829.	1.0	17
1288	The identification of potent, selective and CNS penetrant furan-based inhibitors of <i>B-Raf</i> kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4373-4376.	1.0	25
1289	Potent and selective pyrazole-based inhibitors of <i>B-Raf</i> kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4692-4695.	1.0	65
1290	Pharmacophore identification of <i>Raf-1</i> kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 2346-2350.	1.0	8

#	ARTICLE	IF	CITATIONS
1291	Regional Therapeutic Strategies in Melanoma: Not Just Local Disease Control, but an Opportunity to Develop Novel Therapeutic Strategies with Potential Implications for Systemic Therapy. <i>Annals of Surgical Oncology</i> , 2008, 15, 2987-2990.	0.7	8
1292	Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development. <i>Clinical Cancer Research</i> , 2008, 14, 3571-3581.	3.2	120
1293	Compartmentalised MAPK Pathways. <i>Handbook of Experimental Pharmacology</i> , 2008, , 205-235.	0.9	42
1294	Systemic therapy for metastatic malignant melanoma " from deeply disappointing to bright future?. <i>Experimental Dermatology</i> , 2008, 17, 383-394.	1.4	46
1295	Mutational analysis of the BRAF gene in human tumor cells. <i>Human Cell</i> , 2008, 21, 13-17.	1.2	19
1296	Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2696-2704.	0.3	34
1297	From UVs to Metastases: Modeling Melanoma Initiation and Progression in the Mouse. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2381-2391.	0.3	61
1298	Melanoma Genetics and Therapeutic Approaches in the 21st Century: Moving from the Benchside to the Bedside. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2575-2595.	0.3	157
1299	Phospho-ERK Staining Is a Poor Indicator of the Mutational Status of BRAF and NRAS in Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2003-2012.	0.3	72
1300	Combined Inhibition of MAPK and mTOR Signaling Inhibits Growth, Induces Cell Death, and Abrogates Invasive Growth of Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2013-2023.	0.3	129
1301	MC1R Variants Increase Risk of Melanomas Harboring BRAF Mutations. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2485-2490.	0.3	78
1302	BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias. <i>Leukemia</i> , 2008, 22, 1619-1621.	3.3	23
1303	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. <i>Leukemia</i> , 2008, 22, 686-707.	3.3	337
1304	Translating insights from the cancer genome into clinical practice. <i>Nature</i> , 2008, 452, 553-563.	13.7	267
1305	Somatic mutations affect key pathways in lung adenocarcinoma. <i>Nature</i> , 2008, 455, 1069-1075.	13.7	2,694
1306	BRAF ^{V600E} in benign and malignant human tumours. <i>Oncogene</i> , 2008, 27, 877-895.	2.6	251
1307	High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. <i>Oncogene</i> , 2008, 27, 1834-1843.	2.6	40
1308	B-Raf ^{V600E} signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells. <i>Oncogene</i> , 2008, 27, 3122-3133.	2.6	44

#	ARTICLE	IF	CITATIONS
1309	Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes. <i>Oncogene</i> , 2008, 27, 3345-3359.	2.6	60
1310	Mutant B-RAF mediates resistance to anoikis via Bad and Bim. <i>Oncogene</i> , 2008, 27, 3301-3312.	2.6	91
1311	Deciphering the melanoma interactome. <i>Journal of Cutaneous Pathology</i> , 2008, 35, 11-15.	0.7	2
1312	Oncogene activation in melanocytes links reactive oxygen to multinucleated phenotype and senescence. <i>Oncogene</i> , 2008, 27, 7070-7082.	2.6	81
1313	Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. <i>Oncogene</i> , 2008, 27, 7162-7170.	2.6	65
1314	Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM. <i>Oncogene</i> , 2008, 27, 7150-7161.	2.6	64
1315	Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. <i>British Journal of Cancer</i> , 2008, 99, 83-89.	2.9	167
1316	Phase II trial of imatinib mesylate in patients with metastatic melanoma. <i>British Journal of Cancer</i> , 2008, 99, 734-740.	2.9	205
1317	A novel AKT3 mutation in melanoma tumours and cell lines. <i>British Journal of Cancer</i> , 2008, 99, 1265-1268.	2.9	237
1318	The T1799A point mutation is present in posterior uveal melanoma. <i>British Journal of Cancer</i> , 2008, 99, 1673-1677.	2.9	26
1319	KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. <i>British Journal of Cancer</i> , 2008, 99, 2020-2028.	2.9	89
1320	A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse. <i>Nature Genetics</i> , 2008, 40, 1004-1009.	9.4	271
1321	PCR-amplification of GC-rich regions: 'slowdown PCR'. <i>Nature Protocols</i> , 2008, 3, 1312-1317.	5.5	118
1322	High-throughput kinase profiling as a platform for drug discovery. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 391-397.	21.5	198
1323	Selective Amplification of Rare Mutations Using Locked Nucleic Acid Oligonucleotides that Competitively Inhibit Primer Binding to Wild-Type DNA. <i>Journal of Investigative Dermatology</i> , 2008, 128, 398-402.	0.3	31
1324	mTOR Is Activated in the Majority of Malignant Melanomas. <i>Journal of Investigative Dermatology</i> , 2008, 128, 980-987.	0.3	151
1325	Understanding Signaling Cascades in Melanoma. <i>Photochemistry and Photobiology</i> , 2008, 84, 289-306.	1.3	79
1326	Role of UV in Cutaneous Melanoma. <i>Photochemistry and Photobiology</i> , 2008, 84, 528-536.	1.3	90

#	ARTICLE	IF	CITATIONS
1327	The Melanocortin 1 Receptor and the UV Response of Human Melanocytes—A Shift in Paradigm. <i>Photochemistry and Photobiology</i> , 2008, 84, 501-508.	1.3	101
1328	Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency. <i>Colorectal Disease</i> , 2008, 10, 490-497.	0.7	39
1329	Genetic and epigenetic changes in aberrant crypt foci and serrated polyps. <i>Cancer Science</i> , 2008, 99, 1071-1076.	1.7	37
1330	Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors. <i>Cancer Science</i> , 2008, 99, 1348-1354.	1.7	22
1331	<i>BRAF</i> mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. <i>Clinical Endocrinology</i> , 2008, 68, 618-634.	1.2	116
1332	Genetic and epigenetic changes in colon cancer. <i>Experimental and Molecular Pathology</i> , 2008, 85, 64-67.	0.9	32
1333	Tyrosine kinase activating mutations in human malignancies: Implications for diagnostic pathology. <i>Experimental and Molecular Pathology</i> , 2008, 85, 68-75.	0.9	10
1334	Characterization of three new serous epithelial ovarian cancer cell lines. <i>BMC Cancer</i> , 2008, 8, 152.	1.1	48
1335	Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors. <i>BMC Cancer</i> , 2008, 8, 337.	1.1	56
1336	Role of cAMP in the promotion of colorectal cancer cell growth by Prostaglandin E2. <i>BMC Cancer</i> , 2008, 8, 380.	1.1	54
1337	Prevalence of mutations in APC, CTNNB1, and BRAF in Tunisian patients with sporadic colorectal cancer. <i>Cancer Genetics and Cytogenetics</i> , 2008, 187, 12-18.	1.0	18
1338	Cellular senescence in vivo: a barrier to tumorigenesis. <i>Current Opinion in Cell Biology</i> , 2008, 20, 150-155.	2.6	231
1339	Deregulation of Signaling Pathways in Acute Myeloid Leukemia. <i>Seminars in Oncology</i> , 2008, 35, 336-345.	0.8	136
1340	Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2008, 638, 66-74.	0.4	28
1341	Overcoming Resistance to Apoptosis in Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2008, 615, 105-126.	0.8	13
1342	Current Clinical and Research Approaches to Optimizing Regional Chemotherapy: Novel Strategies Generated Through a Better Understanding of Drug Pharmacokinetics, Drug Resistance, and the Development of Clinically Relevant Animal Models. <i>Surgical Oncology Clinics of North America</i> , 2008, 17, 731-758.	0.6	7
1343	Human cutaneous melanoma; a review of <i>NRAS</i> and <i>BRAF</i> mutation frequencies in relation to histogenetic subclass and body site. <i>Molecular Oncology</i> , 2008, 1, 395-405.	2.1	228
1344	Gene expression signature associated with <i>BRAF</i> mutations in human primary cutaneous melanomas. <i>Molecular Oncology</i> , 2008, 1, 425-430.	2.1	47

#	ARTICLE	IF	CITATIONS
1345	Design and Synthesis of Orally Bioavailable Benzimidazoles as Raf Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7049-7052.	2.9	73
1346	Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. <i>Molecular Cancer</i> , 2008, 7, 68.	7.9	70
1347	Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. <i>Molecular Cancer</i> , 2008, 7, 92.	7.9	32
1348	RAS: Target for Cancer Therapy. <i>Cancer Investigation</i> , 2008, 26, 948-955.	0.6	65
1349	Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4331-4341.	1.8	520
1350	KrÄppel-Like Factor 5 Mediates Cellular Transformation During Oncogenic KRAS-Induced Intestinal Tumorigenesis. <i>Gastroenterology</i> , 2008, 134, 120-130.	0.6	118
1351	Mutations in Both KRAS and BRAF May Contribute to the Methylator Phenotype in Colon Cancer. <i>Gastroenterology</i> , 2008, 134, 1950-1960.e1.	0.6	114
1352	B-RafV600E Cooperates With Alternative Spliced Rac1b to Sustain Colorectal Cancer Cell Survival. <i>Gastroenterology</i> , 2008, 135, 899-906.	0.6	65
1353	Molecular targets and biological modifiers in gastric cancer. <i>Seminars in Diagnostic Pathology</i> , 2008, 25, 274-287.	1.0	30
1354	Targeted therapeutic strategies in malignant melanoma. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e63-e68.	0.8	6
1355	Sunlight, Vitamin D and Skin Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, , .	0.8	10
1356	Chapter 1 Genetic Models of Cancer in Zebrafish. <i>International Review of Cell and Molecular Biology</i> , 2008, 271, 1-34.	1.6	99
1357	Signalling by the EGF receptor in human cancers: accentuate the positive, eliminate the negative. , 2008, , 224-244.		1
1358	Inhibition of casein kinase 1-epsilon induces cancer-cell-selective, PERIOD2-dependent growth arrest. <i>Genome Biology</i> , 2008, 9, R92.	13.9	77
1359	EGFR Signaling Networks in Cancer Therapy. , 2008, , .		11
1360	Novel Inhibitors of the v-raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) Based on a 2,6-Disubstituted Pyrazine Scaffold. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3261-3274.	2.9	31
1361	Epithelial Morphogenesis and Intestinal Cancer: New Insights in Signaling Mechanisms. <i>Advances in Cancer Research</i> , 2008, 100, 85-111.	1.9	15
1362	Melanoma Biology and the Promise of Zebrafish. <i>Zebrafish</i> , 2008, 5, 247-255.	0.5	58

#	ARTICLE	IF	CITATIONS
1363	Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape. Mayo Clinic Proceedings, 2008, 83, 825-846.	1.4	120
1364	RAS Signaling in Colorectal Carcinomas through Alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia, 2008, 10, 680-IN3.	2.3	52
1365	Immunohistochemistry versus Microsatellite Instability Testing for Screening Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. Journal of Molecular Diagnostics, 2008, 10, 301-307.	1.2	177
1366	Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB Journal, 2008, 22, 954-965.	0.2	714
1367	Targeted Cancer Therapy. , 2008, , .		11
1368	Genetic alterations in colorectal cancers with demethylation of insulin-like growth factor II. Human Pathology, 2008, 39, 1301-1308.	1.1	17
1369	CRAF Autophosphorylation of Serine 621 Is Required to Prevent Its Proteasome-Mediated Degradation. Molecular Cell, 2008, 31, 862-872.	4.5	80
1370	Small RNAs in development and disease. Journal of the American Academy of Dermatology, 2008, 59, 725-737.	0.6	63
1371	Somatic genetics and targeted therapies for cutaneous melanoma. Update on Cancer Therapeutics, 2008, 3, 81-87.	0.9	0
1372	Melanocytes in Development, Regeneration, and Cancer. Cell Stem Cell, 2008, 3, 242-252.	5.2	133
1373	Clinical implications of BRAF mutation in thyroid carcinoma. Trends in Endocrinology and Metabolism, 2008, 19, 138-145.	3.1	81
1374	Oncogenes and Cancer. New England Journal of Medicine, 2008, 358, 502-511.	13.9	898
1375	Oncogenic potential of BRAF versus RAS. Cancer Letters, 2008, 261, 137-146.	3.2	1
1376	RKIP and BRAF aberrations in human nasal polyps and the adjacent turbinate mucosae. Cancer Letters, 2008, 264, 288-298.	3.2	21
1377	Hypermethylation of CpG island loci of multiple tumor suppressor genes in retinoblastoma. Experimental Eye Research, 2008, 86, 201-206.	1.2	41
1378	Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochemical and Biophysical Research Communications, 2008, 370, 509-513.	1.0	32
1379	Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells. Biochemical and Biophysical Research Communications, 2008, 372, 845-849.	1.0	17
1380	High-content analysis of cancer genome DNA alterations. Current Opinion in Genetics and Development, 2008, 18, 68-72.	1.5	14

#	ARTICLE	IF	CITATIONS
1381	Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7. <i>Cell</i> , 2008, 132, 363-374.	13.5	787
1382	Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network. <i>Cell</i> , 2008, 133, 1019-1031.	13.5	1,685
1383	Therapeutic strategies for inhibiting oncogenic BRAF signaling. <i>Current Opinion in Pharmacology</i> , 2008, 8, 419-426.	1.7	72
1384	Metastatic melanoma: an AJCC review. <i>Community Oncology</i> , 2008, 5, 441-445.	0.2	4
1385	Involvement of FKHRL1 in melanoma cell survival and death. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 139-146.	1.5	24
1386	Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 368-378.	1.5	73
1387	G-protein-coupled receptors and melanoma. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 415-428.	1.5	47
1388	Effectively targeting BRAF in melanoma: a formidable challenge. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 410-411.	1.5	11
1389	Oncogenic BRAF ^{V600E} inhibits BIM expression to promote melanoma cell survival. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 534-544.	1.5	109
1390	POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumorigenesis. <i>Pigment Cell and Melanoma Research</i> , 2008, 21, 611-626.	1.5	62
1391	A Prospective, Multicenter, Population-Based Study of BRAF Mutational Analysis for Lynch Syndrome Screening. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 206-214.	2.4	85
1392	Constitutive Activation of Raf-1 Induces Glioma Formation in Mice. <i>Neoplasia</i> , 2008, 10, 501-510.	2.3	72
1393	p16INK4a Expression and Absence of Activated B-RAF Are Independent Predictors of Chemosensitivity in Melanoma Tumors. <i>Neoplasia</i> , 2008, 10, 1231-1239.	2.3	39
1394	Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical Implications. <i>Otolaryngologic Clinics of North America</i> , 2008, 41, 1135-1146.	0.5	70
1395	<i>PIK3CA</i> , <i>HRAS</i> and <i>KRAS</i> Gene Mutations in Human Penile Cancer. <i>Journal of Urology</i> , 2008, 179, 2030-2034.	0.2	51
1396	Pancreatic Carcinogenesis. <i>Pancreatology</i> , 2008, 8, 110-125.	0.5	155
1397	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3041-3046.	3.3	1,206
1398	Target Validation to Biomarker Development. <i>Molecular Diagnosis and Therapy</i> , 2008, 12, 63-70.	1.6	11

#	ARTICLE	IF	CITATIONS
1399	Tandem Duplication Producing a Novel Oncogenic <i>BRAF</i> Fusion Gene Defines the Majority of Pilocytic Astrocytomas. <i>Cancer Research</i> , 2008, 68, 8673-8677.	0.4	786
1400	Wild-Type <i>KRAS</i> Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 1626-1634.	0.8	3,032
1401	Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer. <i>Cancer Investigation</i> , 2008, 26, 671-679.	0.6	14
1402	BRAF Silencing by Short Hairpin RNA or Chemical Blockade by PLX4032 Leads to Different Responses in Melanoma and Thyroid Carcinoma Cells. <i>Molecular Cancer Research</i> , 2008, 6, 751-759.	1.5	178
1403	Modern cancer drug discovery: integrating targets, technologies and treatments. , 2008, , 3-38.		4
1404	Phase II Trial of Sorafenib in Advanced Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4714-4719.	0.8	615
1405	Prognostic Significance of Defective Mismatch Repair and BRAF V600E in Patients with Colon Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3408-3415.	3.2	218
1406	Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2008, 68, 9375-9383.	0.4	235
1407	Inducible BRAF Suppression Models for Melanoma Tumorigenesis. <i>Methods in Enzymology</i> , 2008, 439, 25-38.	0.4	8
1408	Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors. <i>Oncologist</i> , 2008, 13, 845-858.	1.9	99
1409	A Pivotal Role for Heat Shock Protein 90 in Ewing Sarcoma Resistance to Anti-Insulin-like Growth Factor 1 Receptor Treatment: <i>In vitro</i> and <i>In vivo</i> Study. <i>Cancer Research</i> , 2008, 68, 6260-6270.	0.4	72
1410	Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells. <i>FASEB Journal</i> , 2008, 22, 2379-2392.	0.2	67
1411	BRAF kinase in melanoma development and progression. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e6.	1.6	28
1412	Skp2 Regulates G2/M Progression in a p53-dependent Manner. <i>Molecular Biology of the Cell</i> , 2008, 19, 4602-4610.	0.9	42
1413	A Small Molecule Disruptor of Rb/Raf-1 Interaction Inhibits Cell Proliferation, Angiogenesis, and Growth of Human Tumor Xenografts in Nude Mice. <i>Cancer Research</i> , 2008, 68, 3810-3818.	0.4	46
1414	RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells. <i>Carcinogenesis</i> , 2008, 29, 1157-1163.	1.3	58
1415	Evidence that Natural Immunity to Breast Cancer and Prostate Cancer Exists in the Majority of Their Risk Populations Is Predicted by a Novel, Inherently Saturated, Ordered Mutation Model. <i>Computational and Mathematical Methods in Medicine</i> , 2008, 9, 1-26.	0.7	1
1416	B-RAF Regulation of Rnd3 Participates in Actin Cytoskeletal and Focal Adhesion Organization. <i>Molecular Biology of the Cell</i> , 2008, 19, 498-508.	0.9	66

#	ARTICLE	IF	CITATIONS
1417	Plitidepsin Has a Dual Effect Inhibiting Cell Cycle and Inducing Apoptosis via Rac1/c-Jun NH ₂ -Terminal Kinase Activation in Human Melanoma Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 324, 1093-1101.	1.3	45
1418	Treatment of Melanoma and Nonmelanoma Skin Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2008, 624, 296-318.	0.8	12
1419	Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1218-1226.	1.9	18
1420	Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma. <i>Cancer Research</i> , 2008, 68, 4853-4861.	0.4	474
1421	Skin Cancer Prevention. , 2008, , 239-289.		0
1422	Histopathological Features of Patients with Chronic Pancreatitis due to Mutations in the PRSS1 Gene: Evaluation of <i>BRAF</i> and <i>KRAS2</i> Mutations. <i>Digestion</i> , 2008, 78, 60-65.	1.2	10
1423	From oncogene to network addiction: the new frontier of cancer genomics and therapeutics. <i>Future Oncology</i> , 2008, 4, 569-577.	1.1	27
1424	Survival for Patients With Invasive Cutaneous Melanoma Among Ethnic Groups: The Effects of Socioeconomic Status and Treatment. <i>Journal of Clinical Oncology</i> , 2008, 26, 66-75.	0.8	150
1425	Oxidative Stress Plays a Critical Role in Inactivating Mutant BRAF by Geldanamycin Derivatives. <i>Cancer Research</i> , 2008, 68, 6324-6330.	0.4	35
1426	<i>RET/PTC</i> Rearrangements Preferentially Occurred in Papillary Thyroid Cancer among Atomic Bomb Survivors Exposed to High Radiation Dose. <i>Cancer Research</i> , 2008, 68, 7176-7182.	0.4	147
1427	Tbx3 Represses E-Cadherin Expression and Enhances Melanoma Invasiveness. <i>Cancer Research</i> , 2008, 68, 7872-7881.	0.4	130
1428	Brn-2 Represses Microphthalmia-Associated Transcription Factor Expression and Marks a Distinct Subpopulation of Microphthalmia-Associated Transcription Factor-Negative Melanoma Cells. <i>Cancer Research</i> , 2008, 68, 7788-7794.	0.4	173
1429	The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel. <i>Clinical Cancer Research</i> , 2008, 14, 230-239.	3.2	214
1430	Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 2178-2185.	0.8	238
1431	Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 890-896.	1.9	70
1432	Interfering with protein-protein interactions: Potential for cancer therapy. <i>Cell Cycle</i> , 2008, 7, 1569-1574.	1.3	28
1433	ROCO Kinase Activity Is Controlled by Internal GTPase Function. <i>Science Signaling</i> , 2008, 1, pe27.	1.6	14
1434	Cutaneous head and neck melanoma: the old and the new. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 403-412.	1.1	12

#	ARTICLE	IF	CITATIONS
1435	Phacoemulsification in Pseudoexfoliation Syndrome. <i>Ophthalmologica</i> , 2008, 222, 112-116.	1.0	25
1437	Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists. <i>Postgraduate Medical Journal</i> , 2008, 84, 78-82.	0.9	56
1438	Molecular profiling in the age of cancer genomics. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 263-276.	1.5	8
1439	Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 737-740.	4.3	111
1440	Regulation of Gene Expression in the Tumor Environment. , 2008, , .		0
1441	Clinical and molecular aspects of RAS related disorders. <i>Journal of Medical Genetics</i> , 2008, 45, 695-703.	1.5	77
1442	BRAF V600E Disrupts AZD6244-Induced Abrogation of Negative Feedback Pathways between Extracellular Signal-Regulated Kinase and Raf Proteins. <i>Cancer Research</i> , 2008, 68, 6145-6153.	0.4	140
1443	Oncogenic B-RafV600E Inhibits Apoptosis and Promotes ERK-dependent Inactivation of Bad and Bim. <i>Journal of Biological Chemistry</i> , 2008, 283, 22128-22135.	1.6	64
1444	Increasing Melanoma Cell Death Using Inhibitors of Protein Disulfide Isomerases to Abrogate Survival Responses to Endoplasmic Reticulum Stress. <i>Cancer Research</i> , 2008, 68, 5363-5369.	0.4	165
1445	Differential Regulation of Chemokines by IL-17 in Colonic Epithelial Cells. <i>Journal of Immunology</i> , 2008, 181, 6536-6545.	0.4	108
1446	Positive Regulation of A-RAF by Phosphorylation of Isoform-specific Hinge Segment and Identification of Novel Phosphorylation Sites. <i>Journal of Biological Chemistry</i> , 2008, 283, 27239-27254.	1.6	35
1447	Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors. <i>Molecular Cancer Research</i> , 2008, 6, 1678-1690.	1.5	108
1448	GSK-3 β Inhibition Enhances Sorafenib-induced Apoptosis in Melanoma Cell Lines. <i>Journal of Biological Chemistry</i> , 2008, 283, 726-732.	1.6	53
1449	Characterization of Ser338 Phosphorylation for Raf-1 Activation. <i>Journal of Biological Chemistry</i> , 2008, 283, 31429-31437.	1.6	58
1450	DLC1: a significant GAP in the cancer genome. <i>Genes and Development</i> , 2008, 22, 1724-1730.	2.7	78
1451	Noonan, Costello and cardiofaciocutaneous syndromes: dysregulation of the Ras-MAPK pathway. <i>Expert Reviews in Molecular Medicine</i> , 2008, 10, e37.	1.6	94
1452	PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab. <i>Cancer Research</i> , 2008, 68, 1953-1961.	0.4	435
1453	Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 270-280.	3.2	83

#	ARTICLE	IF	CITATIONS
1454	Clinicopathologic Factors Identify Sporadic Mismatch Repair-Defective Colon Cancers. <i>American Journal of Clinical Pathology</i> , 2008, 129, 238-244.	0.4	44
1455	Matrix Metalloproteinase-activated Anthrax Lethal Toxin Demonstrates High Potency in Targeting Tumor Vasculature. <i>Journal of Biological Chemistry</i> , 2008, 283, 529-540.	1.6	72
1456	Conservation of Genetic Alterations in Recurrent Melanoma Supports the Melanoma Stem Cell Hypothesis. <i>Cancer Research</i> , 2008, 68, 122-131.	0.4	42
1457	Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3509-3518.	1.9	44
1458	Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2008, 68, 6803-6809.	0.4	129
1459	Akt3 and Mutant V600E-Raf Cooperate to Promote Early Melanoma Development. <i>Cancer Research</i> , 2008, 68, 3429-3439.	0.4	174
1460	BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC. <i>Journal of Carcinogenesis</i> , 2008, 7, 1.	2.5	17
1461	Prioritization of candidate cancer genes—an aid to oncogenomic studies. <i>Nucleic Acids Research</i> , 2008, 36, e115-e115.	6.5	31
1462	BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2194-2201.	1.8	112
1463	Identification of BRAF as a new interactor of PLC μ 1, the protein mutated in nephrotic syndrome type 3. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 294, F93-F99.	1.3	34
1464	Oncogenes and Signal Transduction. , 2008, , 17-30.		0
1465	Raf Activation Is Regulated by Tyrosine 510 Phosphorylation in Drosophila. <i>PLoS Biology</i> , 2008, 6, e128.	2.6	18
1466	Expression and Function of Bcl-2 Proteins in Melanoma. <i>Current Genomics</i> , 2008, 9, 409-419.	0.7	52
1467	Defining the blueprint of the cancer genome. <i>Carcinogenesis</i> , 2008, 29, 1087-1091.	1.3	57
1469	Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement. <i>Clinical Cancer Research</i> , 2008, 14, 4908-4914.	3.2	44
1470	Activation of the RAF/Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase/Extracellular Signal-Regulated Kinase Pathway Mediates Apoptosis Induced by Chelerythrine in Osteosarcoma. <i>Clinical Cancer Research</i> , 2008, 14, 6396-6404.	3.2	59
1471	A novel B-RAF inhibitor blocks interleukin-8 (IL-8) synthesis in human melanoma xenografts, revealing IL-8 as a potential pharmacodynamic biomarker. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 492-499.	1.9	27
1472	Focal Adhesion Kinase Controls Aggressive Phenotype of Androgen-Independent Prostate Cancer. <i>Molecular Cancer Research</i> , 2008, 6, 1639-1648.	1.5	40

#	ARTICLE	IF	CITATIONS
1473	Detection of Copy Number Alterations in Metastatic Melanoma by a DNA Fluorescence <i>In situ</i> Hybridization Probe Panel and Array Comparative Genomic Hybridization: A Southwest Oncology Group Study (S9431). <i>Clinical Cancer Research</i> , 2008, 14, 2927-2935.	3.2	46
1474	Future directions in regional treatment strategies for melanoma and sarcoma. <i>International Journal of Hyperthermia</i> , 2008, 24, 301-309.	1.1	19
1475	The Genomics of Colorectal Cancer: State of the Art. <i>Current Genomics</i> , 2008, 9, 1-10.	0.7	14
1476	Cutaneous Melanoma: Fishing with Chips. <i>Current Molecular Medicine</i> , 2008, 8, 235-243.	0.6	19
1477	Epigenetic-Genetic Interactions in the <i>APC/WNT</i> , <i>RAS/RAF</i> , and <i>P53</i> Pathways in Colorectal Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 2560-2569.	3.2	94
1478	Inhibition of MAPK Kinase Signaling Pathways Suppressed Renal Cell Carcinoma Growth and Angiogenesis <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 81-88.	0.4	194
1479	Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 20864-20869.	3.3	95
1480	Detection of BRAF V600E mutation by pyrosequencing. <i>Pathology</i> , 2008, 40, 295-298.	0.3	88
1482	Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma. <i>Cancer Research</i> , 2008, 68, 664-673.	0.4	275
1483	Advances in the Development of Cancer Therapeutics Directed against the RAS-Mitogen-Activated Protein Kinase Pathway. <i>Clinical Cancer Research</i> , 2008, 14, 3651-3656.	3.2	151
1484	Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung. <i>Cell Cycle</i> , 2008, 7, 665-669.	1.3	174
1485	Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development. <i>Journal of Cell Biology</i> , 2008, 180, 947-955.	2.3	72
1486	Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2008, 15, 183-190.	1.6	41
1487	Identification of a Novel Recepteur d'Origine Nantais/c-Met Small-Molecule Kinase Inhibitor with Antitumor Activity <i>In vivo</i> . <i>Cancer Research</i> , 2008, 68, 6680-6687.	0.4	53
1488	<i>BRAF</i> and <i>NRAS</i> mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 737-739.	1.9	65
1489	Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of <i>C-Raf</i> and <i>B-Raf</i> isoforms by FGFR and MC1R. <i>FASEB Journal</i> , 2008, 22, 1393-1403.	0.2	18
1490	NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. <i>Cancer Research</i> , 2008, 68, 2850-2860.	0.4	433
1491	Is B-Raf a Good Therapeutic Target for Melanoma and Other Malignancies?. <i>Cancer Research</i> , 2008, 68, 5-8.	0.4	79

#	ARTICLE	IF	CITATIONS
1492	Notch1 is an effector of Akt and hypoxia in melanoma development. <i>Journal of Clinical Investigation</i> , 2008, 118, 3660-3670.	3.9	187
1493	HSP90 as a marker of progression in melanoma. <i>Annals of Oncology</i> , 2008, 19, 590-594.	0.6	112
1494	A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4836-4842.	3.2	136
1495	<i>In vitro</i> differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1337-1346.	1.9	14
1496	Characterization of a novel complex BRAF mutation in a follicular variant papillary thyroid carcinoma. <i>European Journal of Endocrinology</i> , 2008, 159, 77-80.	1.9	21
1497	Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3112-3121.	1.9	43
1498	Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2008, 14, 8302-8307.	3.2	193
1499	PBISe, a novel selenium-containing drug for the treatment of malignant melanoma. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1297-1308.	1.9	73
1500	Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma. , 2008, 49, 5230.		329
1501	Emerging insights into the molecular pathogenesis of uveal melanoma. <i>Future Oncology</i> , 2008, 4, 629-636.	1.1	100
1503	Somatic pharmacogenomics in cancer. <i>Pharmacogenomics Journal</i> , 2008, 8, 305-314.	0.9	22
1504	Transcriptional control of the melanoma malignant phenotype. <i>Cancer Biology and Therapy</i> , 2008, 7, 997-1003.	1.5	52
1505	Targeting V600E-B-Raf and Akt3 Using Nanoliposomal-Small Interfering RNA Inhibits Cutaneous Melanocytic Lesion Development. <i>Cancer Research</i> , 2008, 68, 7638-7649.	0.4	150
1506	New small-molecule inhibitors of mitogen-activated protein kinase kinase. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 801-817.	2.5	1
1507	Emerging therapies for melanoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 553-560.	1.1	24
1508	Knockdown of B-Raf impairs spindle formation and the mitotic checkpoint in human somatic cells. <i>Cell Cycle</i> , 2008, 7, 2894-2901.	1.3	28
1509	Global gene expression analyses reveal changes in biological processes after hyperthermia in a rat glioma model. <i>International Journal of Hyperthermia</i> , 2008, 24, 425-441.	1.1	17
1510	Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244. <i>Yearbook of Endocrinology</i> , 2008, 2008, 133-136.	0.0	0

#	ARTICLE	IF	CITATIONS
1511	Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients. <i>Oncology Reports</i> , 0, , .	1.2	2
1512	How Do Chemokine/Chemokine Receptor Activations Affect Tumorigenesis?. <i>Novartis Foundation Symposium</i> , 2008, , 74-91.	1.2	34
1513	Geographic variations of human papilloma virus infection and their possible impact on the effectiveness of the vaccination programme. <i>Oncology Reports</i> , 2008, , .	1.2	5
1514	Combining chemo-, hormonal and targeted therapies to treat breast cancer (Review). <i>Molecular Medicine Reports</i> , 0, , .	1.1	3
1515	Heterologous carcinosarcoma of Douglasâ€™ pouch with adenocarcinomas of the fallopian tube and the peritoneal cavity. <i>Pathology</i> , 2008, 40, 641-645.	0.3	4
1517	The MAPK pathway in melanoma. <i>Current Opinion in Oncology</i> , 2008, 20, 183-189.	1.1	215
1518	Targeted Therapies in Breast Cancer: Established Drugs and Recent Developments. <i>Current Clinical Pharmacology</i> , 2008, 3, 85-98.	0.2	23
1519	Inhibitory Effects of the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 on the Proliferation and Tumor Growth of Thyroid Cancer Cells with BRAF or RAS Mutations. <i>Yearbook of Endocrinology</i> , 2008, 2008, 131-133.	0.0	0
1520	Computational Approaches for Predicting Causal Missense Mutations in Cancer Genome Projects. <i>Current Bioinformatics</i> , 2008, 3, 46-55.	0.7	6
1521	Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. <i>Anti-Cancer Drugs</i> , 2008, 19, 189-200.	0.7	29
1522	Molecular Mechanisms of Uterine Leiomyosarcomas: Involvement of Defect in LMP2 Expression. <i>Gene Regulation and Systems Biology</i> , 2008, 2, GRSB.S470.	2.3	1
1523	Pyrosequencing Analysis for Detection of a BRAFV600E Mutation in an FNAB Specimen of Thyroid Nodules. <i>Diagnostic Molecular Pathology</i> , 2008, 17, 118-125.	2.1	139
1524	Systematic analyses of the cancer genome: lessons learned from sequencing most of the annotated human protein-coding genes. <i>Current Opinion in Oncology</i> , 2008, 20, 66-71.	1.1	21
1525	Integrative oncogenomic approaches for accelerated cancer-gene discovery. <i>Current Opinion in Oncology</i> , 2008, 20, 72-76.	1.1	13
1526	Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. <i>Melanoma Research</i> , 2008, 18, 147-151.	0.6	44
1527	Mutation analysis of the EGFRâ€™NRASâ€™BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. <i>Melanoma Research</i> , 2008, 18, 29-35.	0.6	75
1528	Pleuro-pulmonary Solitary Fibrous Tumors. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1627-1642.	2.1	113
1529	Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. <i>Melanoma Research</i> , 2008, 18, 241-245.	0.6	6

#	ARTICLE	IF	CITATIONS
1530	Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas. <i>Melanoma Research</i> , 2008, 18, 336-345.	0.6	24
1531	Mutational Analyses of Multiple Oncogenic Pathways in Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Pancreas</i> , 2008, 36, 168-172.	0.5	38
1532	The Histopathology of BRAF-V600E-mutated Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1317-1321.	2.1	90
1533	Towards a Treatment for RAS-MAPK Pathway Disorders. <i>Monographs in Human Genetics</i> , 2008, , 151-164.	0.5	0
1534	Pyrophosphorolysis Detects B-RAF Mutations in Primary Uveal Melanoma. , 2008, 49, 23.		41
1535	Molecular Biology of Melanoma. , 2008, , 463-470.		2
1536	Signal Transduction by Growth Factor Receptors. , 2008, , 155-168.		0
1537	Sorafenib for the treatment of unresectable hepatocellular carcinoma. <i>Biologics: Targets and Therapy</i> , 2008, 2, 779.	3.0	34
1538	The biology and oncology of RAF-ERK signaling. , 2008, , 382-402.		0
1539	Targeting inactive kinases: structure as a foundation for cancer drug discovery. , 2008, , 229-252.		7
1540	Neurofibromatosis Type 1 and Other Syndromes of the Ras Pathway. , 2008, , 32-45.		5
1541	Epigenetic Regulation Identifies RASEF as a Tumor-Suppressor Gene in Uveal Melanoma. , 2008, 49, 1291.		43
1542	The Critical Role of PPAR γ^3 in Human Malignant Melanoma. <i>PPAR Research</i> , 2008, 2008, 1-5.	1.1	7
1543	Malignant Melanoma in Organ Transplant Recipients. , 0, , 182-189.		0
1544	Protein Complex, Gene, and Regulatory Modules in Cancer Heterogeneity. <i>Molecular Medicine</i> , 2008, 14, 543-545.	1.9	1
1545	The genetics of malignant melanoma. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 5071.	3.0	26
1547	Mutational Analysis of the BRAF Gene in Transitional Cell Carcinoma of the Bladder. <i>International Journal of Biological Markers</i> , 2009, 24, 17-21.	0.7	22
1549	Epithelial Neoplasms of the Large Intestine. , 2009, , 597-637.		7

#	ARTICLE	IF	CITATIONS
1550	Evolving role of cetuximab in the treatment of colorectal cancer. <i>Cancer Management and Research</i> , 2009, Volume 1, 79-88.	0.9	6
1551	Genetics, cellular biology and tumor microenvironment of melanoma. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 918.	3.0	13
1552	Molecular pathways supporting the proliferation staging of malignant melanoma (Review). <i>International Journal of Molecular Medicine</i> , 2009, 24, 295-301.	1.8	17
1553	The future of genetics in everyday medicine. <i>Journal of the Royal College of Physicians of Edinburgh</i> , The, 2009, 39, 348-351.	0.2	0
1554	Promoter Methylation in the Genesis of Gastrointestinal Cancer. <i>Yonsei Medical Journal</i> , 2009, 50, 309.	0.9	23
1556	Inhibition of the Growth of Papillary Thyroid Carcinoma Cells by CI-1040. <i>JAMA Otolaryngology</i> , 2009, 135, 347.	1.5	15
1557	Identification of Differentially Expressed Genes in Papillary Thyroid Cancers. <i>Yonsei Medical Journal</i> , 2009, 50, 60.	0.9	19
1558	Activation of the FGF2/FGFR1 Autocrine Loop for Cell Proliferation and Survival in Uveal Melanoma Cells. , 2009, 50, 1047.		45
1559	The Activated NF- κ B-Snail-RKIP Circuitry in Cancer Regulates Both the Metastatic Cascade and Resistance to Apoptosis by Cytotoxic Drugs. <i>Critical Reviews in Immunology</i> , 2009, 29, 241-254.	1.0	116
1561	Biophysical mechanisms of modification of skin optical properties in the UV wavelength range with nanoparticles. <i>Journal of Applied Physics</i> , 2009, 105, .	1.1	12
1562	Modeling oncology gene pathways network with multiple genotypes and phenotypes via a copula method. , 2009, , .		2
1563	The future of targeted therapy approaches in melanoma. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 445-456.	2.5	1
1564	Detection of defective DNA in carbon nanotubes by combined molecular dynamics/tight-binding technique. <i>Applied Physics Letters</i> , 2009, 95, 113116.	1.5	6
1565	Advances in preclinical small molecules for the treatment of NSCLC. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 731-751.	2.4	12
1566	<i>PIK3CA</i> Mutations Predict Local Recurrences in Rectal Cancer Patients. <i>Clinical Cancer Research</i> , 2009, 15, 6956-6962.	3.2	94
1567	High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. <i>European Respiratory Journal</i> , 2009, 34, 489-506.	3.1	44
1568	Rnd3 Regulation of the Actin Cytoskeleton Promotes Melanoma Migration and Invasive Outgrowth in Three Dimensions. <i>Cancer Research</i> , 2009, 69, 2224-2233.	0.4	79
1569	mRNA Expression and BRAF Mutation in Circulating Melanoma Cells Isolated from Peripheral Blood with High Molecular Weight Melanoma-Associated Antigen-Specific Monoclonal Antibody Beads. <i>Clinical Chemistry</i> , 2009, 55, 757-764.	1.5	71

#	ARTICLE	IF	CITATIONS
1570	^{V600E} BRAF is associated with disabled feedback inhibition of RAFâ€™MEK signaling and elevated transcriptional output of the pathway. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4519-4524.	3.3	535
1571	Genetics and genomics of melanoma. Expert Review of Dermatology, 2009, 4, 131-143.	0.3	49
1572	Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. Gut, 2009, 58, 1234-1241.	6.1	56
1573	Diacylglycerol Kinase Î· Augments C-Raf Activity and B-Raf/C-Raf Heterodimerization. Journal of Biological Chemistry, 2009, 284, 29559-29570.	1.6	55
1574	Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12073-12078.	3.3	98
1575	PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Annals of Oncology, 2009, 20, 84-90.	0.6	366
1576	Total ERK1/2 activity regulates cell proliferation. Cell Cycle, 2009, 8, 705-711.	1.3	90
1577	Combining the Endoplasmic Reticulum Stressâ€™Inducing Agents Bortezomib and Fenretinide as a Novel Therapeutic Strategy for Metastatic Melanoma. Clinical Cancer Research, 2009, 15, 1192-1198.	3.2	59
1578	New therapeutic advances in the management of progressive thyroid cancer. Endocrine-Related Cancer, 2009, 16, 715-731.	1.6	42
1579	PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers. Cancer Research, 2009, 69, 4286-4293.	0.4	393
1580	Mutations and Response to Epidermal Growth Factor Receptor Inhibitors: Fig. 1.. Clinical Cancer Research, 2009, 15, 1133-1139.	3.2	120
1581	Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7957-7961.	3.3	116
1582	Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Human Molecular Genetics, 2009, 18, 2543-2554.	1.4	89
1583	Pathologic intracellular signaling in childhood pilocytic astrocytomas. Neurology, 2009, 73, 1522-1523.	1.5	2
1584	Regulation of RAF Activity by 14-3-3 Proteins. Journal of Biological Chemistry, 2009, 284, 3183-3194.	1.6	79
1585	Targeting Akt3 Signaling in Malignant Melanoma Using Isoselenocyanates. Clinical Cancer Research, 2009, 15, 1674-1685.	3.2	92
1586	High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid Carcinoma. Clinical Cancer Research, 2009, 15, 485-491.	3.2	118
1587	<i>EGFR/KRAS/BRAF</i> Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases. Clinical Cancer Research, 2009, 15, 4554-4560.	3.2	258

#	ARTICLE	IF	CITATIONS
1588	V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFR α wild-type gastrointestinal stromal tumours. <i>Journal of Clinical Pathology</i> , 2009, 62, 613-616.	1.0	183
1589	Distinct Genetic Alterations in the Mitogen-Activated Protein Kinase Pathway Dictate Sensitivity of Thyroid Cancer Cells to Mitogen-Activated Protein Kinase Kinase 1/2 Inhibition. <i>Thyroid</i> , 2009, 19, 825-835.	2.4	29
1590	Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2009, 4, 28-35.	0.8	132
1591	Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2009, 4, 125-136.	0.8	41
1592	Joint surveillance of the replication foci by PCNA and CtIP. <i>Cell Cycle</i> , 2009, 8, 1305-1307.	1.3	0
1593	BRAF and RASIP aberrations in actinic keratosis and non-melanoma skin cancers. <i>Cell Cycle</i> , 2009, 8, 1305-1307.	1.3	1
1594	Oxygen availability sHIFs the cell cycle. <i>Cell Cycle</i> , 2009, 8, 1305-1307.	1.3	0
1595	BRAF and RASIP are significantly decreased in cutaneous squamous cell carcinoma. <i>Cell Cycle</i> , 2009, 8, 1402-1408.	1.3	46
1596	Tetraploidy triggers mitochondria. <i>Cell Cycle</i> , 2009, 8, 1305-1307.	1.3	0
1598	Yin Yang 1 as a prognostic factor. <i>Cell Cycle</i> , 2009, 8, 1305-1307.	1.3	7
1599	Current systemic therapy for metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 587-595.	1.1	151
1600	Development of Extracellular Signal-Regulated Kinase Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 678-689.	1.0	30
1601	Theme: Oncology - Molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates. <i>Biomarkers in Medicine</i> , 2009, 3, 139-151.	0.6	4
1602	Modeling Thyroid Cancer in the Mouse. <i>Hormone and Metabolic Research</i> , 2009, 41, 488-499.	0.7	11
1603	MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. <i>Cell Cycle</i> , 2009, 8, 2122-2124.	1.3	73
1604	Emerging Raf inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 633-648.	1.0	33
1605	Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. <i>Future Oncology</i> , 2009, 5, 775-778.	1.1	18
1606	Is EGR1 a potential target for prostate cancer therapy?. <i>Future Oncology</i> , 2009, 5, 993-1003.	1.1	102

#	ARTICLE	IF	CITATIONS
1607	Simultaneous Detection of Colorectal Cancer Mutations in Stool Samples with Biochip Arrays. <i>Journal of Medical Biochemistry</i> , 2009, 28, 285-292.	0.7	1
1608	Oncogenic Ras, but not V600E-BRAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells. <i>Carcinogenesis</i> , 2009, 30, 1670-1677.	1.3	20
1609	Microsatellite Instability, Mismatch Repair Deficiency, and BRAF Mutation in Treatment-Resistant Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2009, 27, 2129-2136.	0.8	167
1610	Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. <i>Clinical Cancer Research</i> , 2009, 15, 7711-7718.	3.2	104
1611	Review: Systemic therapy for advanced renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 15-27.	1.4	8
1612	A t-butylloxycarbonyl-modified Wnt5a-derived hexapeptide functions as a potent antagonist of Wnt5a-dependent melanoma cell invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19473-19478.	3.3	123
1613	PAX3 across the spectrum: from melanoblast to melanoma. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2009, 44, 85-97.	2.3	35
1614	No Incidence of BRAF Mutations in Salivary Gland Carcinomas—Implications for Anti-EGFR Therapies. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-3.	3.0	10
1615	The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway. <i>Oncology</i> , 2009, 77, 57-68.	0.9	49
1616	The BRAFV600E Oncogene Induces Transforming Growth Factor β 2 Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer. <i>Cancer Research</i> , 2009, 69, 8317-8325.	0.4	236
1617	The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of CH4987655 in Healthy Volunteers: Target Suppression Using a Biomarker. <i>Clinical Cancer Research</i> , 2009, 15, 7368-7374.	3.2	40
1618	Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species. <i>Xenobiotica</i> , 2009, 39, 700-709.	0.5	8
1619	Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2079-2085.	1.9	178
1620	The Variant rs1867277 in FOXE1 Gene Confers Thyroid Cancer Susceptibility through the Recruitment of USF1/USF2 Transcription Factors. <i>PLoS Genetics</i> , 2009, 5, e1000637.	1.5	140
1621	Heat Shock Protein 90 as a Drug Target: Some Like It Hot. <i>Clinical Cancer Research</i> , 2009, 15, 9-14.	3.2	241
1622	Oncogenic KRAS and BRAF Differentially Regulate Hypoxia-Inducible Factor-1 α and -2 α in Colon Cancer. <i>Cancer Research</i> , 2009, 69, 8499-8506.	0.4	93
1623	Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib. <i>Clinical Cancer Research</i> , 2009, 15, 1076-1085.	3.2	38
1624	Pharmacodynamics of 2-[4-[(1E)-1-(Hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a Potent and Selective B-Raf Kinase Inhibitor: Understanding Relationships between Systemic Concentrations, Phosphorylated Mitogen-Activated Protein Kinase Kinase 1 Inhibition, and Efficacy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 360-367.	1.3	50

#	ARTICLE	IF	CITATIONS
1625	Polyclonality of BRAF Mutations in Acquired Melanocytic Nevi. Journal of the National Cancer Institute, 2009, 101, 1423-1427.	3.0	60
1626	Targeting oncogenic signaling pathways by exploiting nanotechnology. Cell Cycle, 2009, 8, 3480-3487.	1.3	17
1627	Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy. Cancer Research, 2009, 69, 1924-1932.	0.4	32
1628	Bipolar cellular morphology of malignant melanoma in unstained human melanoma skin tissue. Journal of Biomedical Optics, 2009, 14, 024042.	1.4	3
1629	Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Molecular Cancer Therapeutics, 2009, 8, 3009-3014.	1.9	42
1630	Mitogen-Activated Protein Kinase Inhibition Induces Translocation of Bmf to Promote Apoptosis in Melanoma. Cancer Research, 2009, 69, 1985-1994.	0.4	70
1631	Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression. Cancer Research, 2009, 69, 3042-3051.	0.4	164
1632	Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology. Journal of Clinical Oncology, 2009, 27, 5650-5659.	0.8	115
1633	Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis. Molecular Cancer Research, 2009, 7, 549-556.	1.5	112
1634	Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition. Cancer Research, 2009, 69, 7538-7547.	0.4	83
1635	MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Molecular Cancer Therapeutics, 2009, 8, 433-440.	1.9	41
1636	Down-regulation of α -Epidermal Growth Factor Receptor by Selective Expansion of a 5' End Regulatory Dinucleotide Repeat in Colon Cancer with Microsatellite Instability. Clinical Cancer Research, 2009, 15, 4531-4537.	3.2	16
1637	GAB2 Amplifications Refine Molecular Classification of Melanoma. Clinical Cancer Research, 2009, 15, 4288-4291.	3.2	54
1638	Implementation of Novel Pyrosequencing Assays to Screen for Common Mutations of BRAF and KRAS in a Cohort of Sporadic Colorectal Cancers. Diagnostic Molecular Pathology, 2009, 18, 62-71.	2.1	48
1639	Oncogenic Activating Mutations Are Associated with Local Copy Gain. Molecular Cancer Research, 2009, 7, 1244-1252.	1.5	59
1640	A Germline Mutation (A339V) in Thyroid Transcription Factor-1 (TTF-1/NKX2.1) in Patients With Multinodular Goiter and Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 2009, 101, 162-175.	3.0	105
1641	Sample Type Bias in the Analysis of Cancer Genomes. Cancer Research, 2009, 69, 5630-5633.	0.4	29
1642	Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clinical Cancer Research, 2009, 15, 7538-7546.	3.2	221

#	ARTICLE	IF	CITATIONS
1643	Melanoma: Molecular pathogenesis and emerging target therapies (Review). <i>International Journal of Oncology</i> , 2009, 34, 1481-9.	1.4	64
1644	Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 3315-3324.	3.2	44
1645	Deciphering the genetic landscape of cancer “ from genes to pathways. <i>Trends in Genetics</i> , 2009, 25, 455-462.	2.9	35
1646	A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth. <i>BMC Cancer</i> , 2009, 9, 198.	1.1	49
1647	Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. <i>BMC Cancer</i> , 2009, 9, 352.	1.1	42
1648	Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. <i>BMC Cancer</i> , 2009, 9, 387.	1.1	24
1649	Computational modelling of cancerous mutations in the EGFR/ERK signalling pathway. <i>BMC Systems Biology</i> , 2009, 3, 100.	3.0	54
1650	Version control of pathway models using XML patches. <i>BMC Systems Biology</i> , 2009, 3, 34.	3.0	7
1651	Absence of GAPDH regulation in tumor-cells of different origin under hypoxic conditions in “ vitro. <i>BMC Research Notes</i> , 2009, 2, 8.	0.6	32
1652	Novel Agents on the Horizon for Cancer Therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2009, 59, 111-137.	157.7	275
1653	Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. <i>Gynecologic Oncology</i> , 2009, 114, 128-134.	0.6	97
1654	Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 1634-1645.	1.9	26
1655	Role of B-RafV600E in differentiated thyroid cancer and preclinical validation of compounds against B-RafV600E. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1795, 152-161.	3.3	39
1656	Cancer gene discovery in mouse and man. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1796, 140-161.	3.3	13
1657	IQGAPs in cancer: A family of scaffold proteins underlying tumorigenesis. <i>FEBS Letters</i> , 2009, 583, 1817-1824.	1.3	263
1658	A Therapeutic Opportunity in Melanoma: ErbB4 Makes a Mark on Skin. <i>Cancer Cell</i> , 2009, 16, 278-279.	7.7	16
1659	Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. <i>Current Opinion in Cell Biology</i> , 2009, 21, 296-303.	2.6	107
1660	Tyrosine phosphorylation: thirty years and counting. <i>Current Opinion in Cell Biology</i> , 2009, 21, 140-146.	2.6	576

#	ARTICLE	IF	CITATIONS
1661	Linking somatic genetic alterations in cancer to therapeutics. <i>Current Opinion in Cell Biology</i> , 2009, 21, 304-310.	2.6	61
1662	Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. <i>European Journal of Pharmacology</i> , 2009, 606, 38-44.	1.7	40
1663	Cell Culture Modeling of Genotype-Directed Sensitivity to Selective Kinase Inhibitors: Targeting the Anaplastic Lymphoma Kinase (ALK). <i>Seminars in Oncology</i> , 2009, 36, S36-S41.	0.8	16
1664	Off-Target Decoding of a Multitarget Kinase Inhibitor by Chemical Proteomics. <i>ChemBioChem</i> , 2009, 10, 1163-1174.	1.3	14
1665	Detectable <i>BRAF</i> mutation in serum DNA samples from patients with papillary thyroid carcinomas. <i>Head and Neck</i> , 2010, 32, 229-234.	0.9	43
1666	Dual priming oligonucleotide-based multiplex PCR analysis for detection of <i>BRAF</i> ^{V600E} mutation in FNAB samples of thyroid nodules in <i>BRAF</i> ^{V600E} mutation-prevalent area. <i>Head and Neck</i> , 2010, 32, 490-498.	0.9	53
1667	Germline <i>BRAF</i> mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: Molecular diversity and associated phenotypic spectrum. <i>Human Mutation</i> , 2009, 30, 695-702.	1.1	251
1668	Oncogenic <i>NRAS</i> has multiple effects on the malignant phenotype of human melanoma cells cultured <i>in vitro</i> . <i>International Journal of Cancer</i> , 2009, 124, 16-26.	2.3	54
1669	<i>MET</i> gene amplification or <i>EGFR</i> mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , 2009, 124, 1778-1784.	2.3	131
1670	Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. <i>International Journal of Cancer</i> , 2009, 124, 2744-2749.	2.3	48
1671	Selective inhibition of proliferation in colorectal carcinoma cell lines expressing mutant APC or activated <i>Raf</i> . <i>International Journal of Cancer</i> , 2009, 125, 297-307.	2.3	36
1672	Constitutively active MEK1 is sufficient to induce epithelial-mesenchymal transition in intestinal epithelial cells and to promote tumor invasion and metastasis. <i>International Journal of Cancer</i> , 2009, 125, 1575-1586.	2.3	74
1673	Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-42886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. <i>International Journal of Cancer</i> , 2009, 125, 2332-2341.	2.3	125
1674	TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors. <i>International Journal of Cancer</i> , 2009, 125, 2127-2135.	2.3	25
1675	Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma. <i>International Journal of Cancer</i> , 2009, 125, 2349-2359.	2.3	47
1676	RNAi-mediated MEK1 knockdown prevents ERK1/2 activation and abolishes human hepatocarcinoma growth <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2010, 126, 1367-1377.	2.3	31
1677	Microsatellite instability, <i>MLH1</i> promoter methylation, and <i>BRAF</i> mutation analysis in sporadic colorectal cancers of different ethnic groups in Israel. <i>Cancer</i> , 2009, 115, 760-769.	2.0	40
1678	Assessment of <i>ras</i> mutation. <i>Cancer</i> , 2009, 115, 3609-3617.	2.0	69

#	ARTICLE	IF	CITATIONS
1679	MAPK pathway activation and the origins of pediatric low-grade astrocytomas. <i>Journal of Cellular Physiology</i> , 2010, 222, 509-514.	2.0	87
1680	Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 10-21.	1.5	71
1681	Distinct patterns of DNA copy number alterations associate with <i>BRAF</i> mutations in melanomas and melanoma-derived cell lines. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 419-428.	1.5	21
1682	The functional $\sim 443T/C$ osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. <i>Molecular Carcinogenesis</i> , 2009, 48, 14-23.	1.3	48
1683	Recent developments in testicular germ cell tumor research. <i>Birth Defects Research Part C: Embryo Today Reviews</i> , 2009, 87, 96-113.	3.6	51
1684	Over-expression of cathepsin E and trefoil factor 1 in sessile serrated adenomas of the colorectum identified by gene expression analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 291-302.	1.4	31
1685	Esophageal melanomas harbor frequent <i>NRAS</i> mutations unlike melanomas of other mucosal sites. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 513-517.	1.4	36
1686	Mutational spectra of human cancer. <i>Human Genetics</i> , 2009, 125, 493-506.	1.8	160
1687	Genetic risk factors for melanoma. <i>Human Genetics</i> , 2009, 126, 499-510.	1.8	118
1689	Molecular biology, models, and histopathology of chronic pancreatitis and pancreatic cancer. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2009, 41, 250-267.	0.3	3
1690	Hallmarks for senescence in carcinogenesis: novel signaling players. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2009, 14, 392-408.	2.2	37
1691	Protein and lipid kinase inhibitors as targeted anticancer agents of the <i>Ras/Raf/MEK</i> and <i>PI3K/PKB</i> pathways. <i>Purinergic Signalling</i> , 2009, 5, 117-125.	1.1	25
1692	A Novel Complex <i>BRAF</i> Mutation Detected in a Solid Variant of Papillary Thyroid Carcinoma. <i>Endocrine Pathology</i> , 2009, 20, 122-126.	5.2	74
1693	<i>PIK3CA</i> mutation occurs in nasopharyngeal carcinoma but does not significantly influence the disease-specific survival. <i>Medical Oncology</i> , 2009, 26, 322-326.	1.2	30
1694	Lung cancer biology: a genetic and genomic perspective. <i>Clinical and Translational Oncology</i> , 2009, 11, 263-269.	1.2	14
1695	Inside life of melanoma cell signaling, molecular insights, and therapeutic targets. <i>Current Oncology Reports</i> , 2009, 11, 405-411.	1.8	9
1696	Molecular Analysis of <i>PIK3CA</i> , <i>BRAF</i> , and <i>RAS</i> Oncogenes in Periampullary and Ampullary Adenomas and Carcinomas. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 1510-1516.	0.9	52
1698	Merkel cell carcinoma. <i>Cellular and Molecular Life Sciences</i> , 2009, 66, 1-8.	2.4	68

#	ARTICLE	IF	CITATIONS
1699	Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1085-1094.	2.0	44
1700	Cancer-associated mutations are preferentially distributed in protein kinase functional sites. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009, 77, 892-903.	1.5	26
1701	Germline and somatic <i>NF1</i> mutations in sporadic and <i>NF1</i> -associated malignant peripheral nerve sheath tumours. <i>Journal of Pathology</i> , 2009, 217, 693-701.	2.1	107
1702	Aberrant <i>BRAF</i> splicing as an alternative mechanism for oncogenic <i>B-Raf</i> activation in thyroid carcinoma. <i>Journal of Pathology</i> , 2009, 217, 707-715.	2.1	34
1703	Human testicular (non)seminomatous germ cell tumours: the clinical implications of recent pathobiological insights. <i>Journal of Pathology</i> , 2009, 218, 146-162.	2.1	84
1704	Recent progress in understanding the pathology of malignant melanoma. <i>Journal of Pathology</i> , 2009, 219, 400-409.	2.1	68
1705	Fusion genes and chromosome translocations in the common epithelial cancers. <i>Journal of Pathology</i> , 2010, 220, 244-254.	2.1	105
1706	An in silico study of the molecular basis of B-RAF activation and conformational stability. <i>BMC Structural Biology</i> , 2009, 9, 47.	2.3	15
1707	DMBT1 expression distinguishes anorectal from cutaneous melanoma. <i>Histopathology</i> , 2009, 54, 233-240.	1.6	14
1708	Primary dermal melanoma: A case report and molecular characterization. <i>Journal of Dermatology</i> , 2009, 36, 346-352.	0.6	16
1709	RAF may induce cell proliferation through hypermethylation of tumor suppressor gene promoter in gastric epithelial cells. <i>Cancer Science</i> , 2009, 100, 117-125.	1.7	11
1710	RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. <i>British Journal of Dermatology</i> , 2009, 160, 368-375.	1.4	39
1711	Cytoplasmic β -catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis?. <i>British Journal of Dermatology</i> , 2009, 160, 600-608.	1.4	5
1712	A cell-based screening to detect inhibitors of BRAF signaling pathway. <i>Journal of Antibiotics</i> , 2009, 62, 105-107.	1.0	4
1713	Characterization of Coordinated Immediate Responses by p16INK4A and p53 Pathways in UVB-Irradiated Human Skin Cells. <i>Journal of Investigative Dermatology</i> , 2009, 129, 175-183.	0.3	25
1714	Proliferation Arrest in B-Raf Mutant Melanoma Cell Lines upon MAPK Pathway Activation. <i>Journal of Investigative Dermatology</i> , 2009, 129, 406-414.	0.3	18
1715	Active N-Ras and B-Raf Inhibit Anoikis by Downregulating Bim Expression in Melanocytic Cells. <i>Journal of Investigative Dermatology</i> , 2009, 129, 432-437.	0.3	24
1716	Frequencies of NRAS and BRAF Mutations Increase from the Radial to the Vertical Growth Phase in Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1483-1488.	0.3	49

#	ARTICLE	IF	CITATIONS
1717	Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1759-1768.	0.3	54
1718	Progression of NRAS and BRAF Mutations in Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1318.	0.3	6
1719	Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors. <i>Journal of Investigative Dermatology</i> , 2009, 129, 1983-1991.	0.3	68
1720	Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma. <i>Modern Pathology</i> , 2009, 22, 1367-1378.	2.9	40
1721	Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. <i>Nature</i> , 2009, 457, 599-602.	13.7	1,433
1722	The cancer genome. <i>Nature</i> , 2009, 458, 719-724.	13.7	2,904
1723	A dimerization-dependent mechanism drives RAF catalytic activation. <i>Nature</i> , 2009, 461, 542-545.	13.7	420
1724	Tumour cell survival signalling by the ERK1/2 pathway. <i>Cell Death and Differentiation</i> , 2009, 16, 368-377.	5.0	410
1725	BrafV600E cooperates with Pten loss to induce metastatic melanoma. <i>Nature Genetics</i> , 2009, 41, 544-552.	9.4	1,022
1726	Targeting cancer with small molecule kinase inhibitors. <i>Nature Reviews Cancer</i> , 2009, 9, 28-39.	12.8	2,278
1727	Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. <i>Nature Reviews Drug Discovery</i> , 2009, 8, 709-723.	21.5	285
1728	A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal. <i>Nature Structural and Molecular Biology</i> , 2009, 16, 294-303.	3.6	154
1729	CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. <i>Oncogene</i> , 2009, 28, 85-94.	2.6	195
1730	Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. <i>Oncogene</i> , 2009, 28, 2697-2709.	2.6	51
1731	Functional RET G691S polymorphism in cutaneous malignant melanoma. <i>Oncogene</i> , 2009, 28, 3058-3068.	2.6	62
1732	Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. <i>Oncogene</i> , 2009, 28, 2119-2123.	2.6	288
1733	Integrating BRAF/MEK inhibitors into combination therapy for melanoma. <i>British Journal of Cancer</i> , 2009, 100, 431-435.	2.9	82
1734	Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009, 101, 465-472.	2.9	283

#	ARTICLE	IF	CITATIONS
1735	Episodic Src activation in uveal melanoma revealed by kinase activity profiling. <i>British Journal of Cancer</i> , 2009, 101, 312-319.	2.9	22
1736	Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. <i>British Journal of Cancer</i> , 2009, 101, 813-815.	2.9	139
1737	Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. <i>British Journal of Cancer</i> , 2009, 101, 1724-1730.	2.9	95
1738	Two cutaneous malignant melanomas at the same anatomic site: a case report with molecular evaluation. <i>Journal of Cutaneous Pathology</i> , 2009, 36, 74-79.	0.7	6
1739	Molecular pathogenesis of Merkel cell carcinoma. <i>Experimental Dermatology</i> , 2009, 18, 193-198.	1.4	87
1740	Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics. <i>FEBS Journal</i> , 2009, 276, 6050-6062.	2.2	90
1741	SUPERFICIALLY ELEVATED TYPE SERRATED HYPERPLASTIC LESION OF THE STOMACH WITH MINUTE ADENOCARCINOMA. <i>Digestive Endoscopy</i> , 2009, 21, 101-105.	1.3	12
1742	Duplication of 7q34 in Pediatric Low-Grade Astrocytomas Detected by High-Density Single-Nucleotide Polymorphism-Based Genotype Arrays Results in a Novel <i>BRAF</i> Fusion Gene. <i>Brain Pathology</i> , 2009, 19, 449-458.	2.1	227
1743	Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 2735-2738.	1.0	39
1744	Identification and functional validation of therapeutic targets for malignant melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 194-214.	2.0	10
1745	Ultra-sensitive detection of mutated papillary thyroid carcinoma DNA using square wave stripping voltammetry method and amplified gold nanoparticle biomarkers. <i>Biosensors and Bioelectronics</i> , 2009, 24, 1899-1904.	5.3	26
1746	Label-free biosensing of a gene mutation using a silicon nanowire field-effect transistor. <i>Biosensors and Bioelectronics</i> , 2009, 25, 820-825.	5.3	72
1747	Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1026-1029.	1.0	9
1748	Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: Development of potential substrate-specific ERK1/2 inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6042-6046.	1.0	39
1749	Discovery of highly potent and selective type I B-Raf kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6571-6574.	1.0	23
1750	Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6519-6523.	1.0	31
1751	Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6890-6892.	1.0	14
1752	A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans. <i>Cancer Epidemiology</i> , 2009, 33, 123-129.	0.8	11

#	ARTICLE	IF	CITATIONS
1753	Knockdown of IGF-binding protein 7 inhibits transformation of the endometrial gland in an in vitro model. <i>Molecular Reproduction and Development</i> , 2010, 77, 265-272.	1.0	10
1754	Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 1493-1509.	2.9	152
1755	Protein kinase inhibitors: contributions from structure to clinical compounds. <i>Quarterly Reviews of Biophysics</i> , 2009, 42, 1-40.	2.4	228
1756	A Review of Kinases Implicated in Pancreatic Cancer. <i>Pancreatology</i> , 2009, 9, 738-754.	0.5	35
1757	Investigation of BRAF and CTNNB1 activating mutations in adrenocortical tumors. <i>Journal of Endocrinological Investigation</i> , 2009, 32, 597-600.	1.8	24
1758	The Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF Kinase. <i>Biochemistry</i> , 2009, 48, 5187-5198.	1.2	72
1759	Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment. <i>Cancer Research</i> , 2009, 69, 3077-3085.	0.4	911
1760	The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. <i>Carcinogenesis</i> , 2009, 30, 377-386.	1.3	1,058
1761	A Morpho-Molecular Diagnosis of Papillary Thyroid Carcinoma: BRAF V600E Detection as an Important Tool in Preoperative Evaluation of Fine-Needle Aspirates. <i>Thyroid</i> , 2009, 19, 837-842.	2.4	81
1762	Evaluation of High-Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors. <i>Journal of Molecular Diagnostics</i> , 2009, 11, 140-147.	1.2	82
1763	Cancer driver mutations in protein kinase genes. <i>Cancer Letters</i> , 2009, 281, 117-127.	3.2	84
1764	Targeting the RAF-MEK-ERK pathway in cancer therapy. <i>Cancer Letters</i> , 2009, 283, 125-134.	3.2	411
1765	New techniques in dermatopathology that help to diagnose and prognosticate melanoma. <i>Clinics in Dermatology</i> , 2009, 27, 75-102.	0.8	41
1766	Unusual variants of malignant melanoma. <i>Clinics in Dermatology</i> , 2009, 27, 564-587.	0.8	61
1767	Chemotherapy and biologic therapies for melanoma: do they work?. <i>Clinics in Dermatology</i> , 2009, 27, 614-625.	0.8	83
1768	Integrative genomic approaches to understanding cancer. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2009, 1790, 478-484.	1.1	7
1769	Modelling oncogenic Ras/Raf signalling in the mouse. <i>Current Opinion in Genetics and Development</i> , 2009, 19, 4-11.	1.5	55
1770	Malignant Melanoma—a Genetic Overview. <i>Actas Dermo-sifiliográficas</i> , 2009, 100, 38-51.	0.2	16

#	ARTICLE	IF	CITATIONS
1771	Bypassing melanocyte senescence by \hat{I}^2 -catenin: A novel way to promote melanoma. <i>Pathologie Et Biologie</i> , 2009, 57, 543-547.	2.2	25
1772	Sebaceous lesions and their associated syndromes: Part II. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 563-578.	0.6	90
1773	Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation. <i>Molecular Cell</i> , 2009, 33, 237-247.	4.5	318
1774	Functional Proteomics Identifies Targets of Phosphorylation by B-Raf Signaling in Melanoma. <i>Molecular Cell</i> , 2009, 34, 115-131.	4.5	127
1775	Protein Phosphorylation Goes Negative. <i>Molecular Cell</i> , 2009, 34, 139-140.	4.5	1
1776	C-Raf Inhibits MAPK Activation and Transformation by B-RafV600E. <i>Molecular Cell</i> , 2009, 36, 477-486.	4.5	61
1777	Molecular Basis of Colorectal Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 2449-2460.	13.9	1,581
1778	How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer?. <i>Cell Cycle</i> , 2009, 8, 1168-1175.	1.3	804
1779	Clinicopathologic and molecular disease prognostication for papillary thyroid cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1261-1275.	1.1	7
1780	RNA interference as an anticancer therapy: a patent perspective. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 475-491.	2.4	24
1781	Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 6189-6192.	2.9	92
1782	Computational Modeling of Structurally Conserved Cancer Mutations in the RET and MET Kinases: The Impact on Protein Structure, Dynamics, and Stability. <i>Biophysical Journal</i> , 2009, 96, 858-874.	0.2	40
1783	HSP90 Inhibition as an Anticancer Strategy: Novel Approaches and Future Directions. , 2009, , 111-138.		1
1784	NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. <i>British Journal of Cancer</i> , 2009, 101, 1448-1455.	2.9	66
1785	Cellular and Molecular Pathology of Adrenocortical Carcinoma. , 2009, , 127-150.		0
1787	Loss of the Ras Regulator RASAL1: Another Route to Ras Activation in Colorectal Cancer. <i>Gastroenterology</i> , 2009, 136, 46-48.	0.6	10
1788	Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1583-1598.	1.1	26
1789	KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents. <i>Clinical Colorectal Cancer</i> , 2009, 8, 135-140.	1.0	4

#	ARTICLE	IF	CITATIONS
1790	The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis. <i>Molecular Cancer</i> , 2009, 8, 124.	7.9	33
1791	PIK3CA alterations in Middle Eastern ovarian cancers. <i>Molecular Cancer</i> , 2009, 8, 51.	7.9	36
1792	14-3-3 β gene silencing during melanoma progression and its role in cell cycle control and cellular senescence. <i>Molecular Cancer</i> , 2009, 8, 53.	7.9	42
1793	Main roads to melanoma. <i>Journal of Translational Medicine</i> , 2009, 7, 86.	1.8	157
1794	Cutaneous short-interfering RNA therapy. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 1333-1349.	2.4	61
1795	Serrated Polyps and Colorectal Cancer: New Pathway to Malignancy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 343-364.	9.6	234
1796	Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 551-579.	9.6	110
1797	Mutational analysis of CASP10 gene in acute leukaemias and multiple myelomas. <i>Pathology</i> , 2009, 41, 484-487.	0.3	11
1798	Molecular Basis of Inactive B-RAFWT and B-RAFV600E Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study. <i>Molecular Pharmaceutics</i> , 2009, 6, 144-157.	2.3	15
1800	A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors. <i>Breast Cancer Research</i> , 2009, 11, R78.	2.2	52
1801	The Classification of Cutaneous Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 501-513.	0.9	56
1802	A Decade of Cancer Gene Profiling: From Molecular Portraits to Molecular Function. <i>Methods in Molecular Biology</i> , 2009, 576, 61-87.	0.4	13
1803	Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3881-3891.	2.9	46
1804	Chapter 1 Ras Signaling and Therapies. <i>Advances in Cancer Research</i> , 2009, 102, 1-17.	1.9	182
1805	Signalling Pathways Operated by Receptor Protein Tyrosine Kinases. , 2009, , 315-374.		0
1806	RNA interference screening for the discovery of oncology targets. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 1027-1035.	1.5	20
1807	Glucose Deprivation Contributes to the Development of <i>KRAS</i> Pathway Mutations in Tumor Cells. <i>Science</i> , 2009, 325, 1555-1559.	6.0	797
1808	Novel therapeutics for melanoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 839-849.	1.1	19

#	ARTICLE	IF	CITATIONS
1809	Melanoma Biomarkers. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 283-296.	1.6	36
1810	Optimizing regional infusion treatment strategies for melanoma of the extremities. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1599-1609.	1.1	14
1811	Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. <i>Endocrine-Related Cancer</i> , 2009, 16, 565-572.	1.6	41
1812	Clinical implications of molecular markers in follicular cell-derived thyroid cancer. <i>Expert Review of Molecular Diagnostics</i> , 2009, 9, 679-694.	1.5	4
1813	Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1611-1630.	1.1	47
1814	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. <i>Molecular Cancer</i> , 2009, 8, 118.	7.9	159
1815	Germline variation of the melanocortin-4 receptor does not explain shared risk for melanoma and thyroid cancer. <i>Experimental Dermatology</i> , 2009, 18, 548-552.	1.4	4
1816	The Role of BRAF Mutation and p53 Inactivation during Transformation of a Subpopulation of Primary Human Melanocytes. <i>American Journal of Pathology</i> , 2009, 174, 2367-2377.	1.9	73
1817	Novel therapeutic agents for osteosarcoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 511-523.	1.1	75
1818	Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF). <i>Journal of Medicinal Chemistry</i> , 2009, 52, 2255-2264.	2.9	37
1819	MEK1 mutations confer resistance to MEK and B-RAF inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20411-20416.	3.3	574
1820	Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 66-76.	1.5	62
1821	Mouse pigmentation mutants help identify a uveal melanoma oncogene. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 2-3.	1.5	0
1823	<i>Met</i> amplification and tumor progression in <i>Cdkn2a</i> -deficient melanocytes. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 454-460.	1.5	8
1824	Frequent mutations in the MITF pathway in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 435-444.	1.5	132
1825	Use of liposomes as drug delivery vehicles for treatment of melanoma. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 388-399.	1.5	92
1826	Identification of direct transcriptional targets of ^{V600E} BRAF/MEK signalling in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 785-798.	1.5	58
1827	Inhibition of Siah2 ubiquitin ligase by vitamin K3 (menadione) attenuates hypoxia and MAPK signaling and blocks melanoma tumorigenesis. <i>Pigment Cell and Melanoma Research</i> , 2009, 22, 799-808.	1.5	66

#	ARTICLE	IF	CITATIONS
1828	How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer: Table 1. <i>Journal of Clinical Pathology</i> , 2009, 62, 414-421.	1.0	25
1829	Analysis of <i>PTEN</i> , <i>BRAF</i> , and <i>EGFR</i> Status in Determining Benefit From Cetuximab Therapy in Wild-Type <i>KRAS</i> Metastatic Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5924-5930.	0.8	645
1830	Surgical Management of Well-Differentiated Thyroid Cancer: State of the Art. <i>Surgical Clinics of North America</i> , 2009, 89, 1171-1191.	0.5	22
1831	Drug Targeting of Oncogenic Pathways in Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 599-618.	0.9	6
1832	<i>BRAF</i> V600E Efficient Transformation and Induction of Microsatellite Instability Versus <i>KRAS</i> G12V Induction of Senescence Markers in Human Colon Cancer Cells. <i>Neoplasia</i> , 2009, 11, 1116-IN2.	2.3	36
1833	6563 Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. <i>European Journal of Cancer, Supplement</i> , 2009, 7, 379.	2.2	0
1834	<i>BRAF</i> Signaling and Targeted Therapies in Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 529-545.	0.9	159
1835	Oncogenic Activation of MAP Kinase by <i>BRAF</i> Pseudogene in Thyroid Tumors. <i>Neoplasia</i> , 2009, 11, 57-65.	2.3	43
1836	Applications of Genomics in Melanoma Oncogene Discovery. <i>Hematology/Oncology Clinics of North America</i> , 2009, 23, 397-414.	0.9	26
1837	Molecular Aspects of Melanoma. <i>Surgical Pathology Clinics</i> , 2009, 2, 565-574.	0.7	0
1838	Polymorphisms in the syntaxin 17 gene are not associated with human cutaneous malignant melanoma. <i>Melanoma Research</i> , 2009, 19, 80-86.	0.6	8
1839	CpG island methylation profiling in human melanoma cell lines. <i>Melanoma Research</i> , 2009, 19, 146-155.	0.6	91
1840	Melanoma Hyperpigmentation Is Strongly Associated With <i>KIT</i> Alterations. <i>American Journal of Dermatopathology</i> , 2009, 31, 619-625.	0.3	12
1841	The Role of <i>BRAF</i> V600E Mutation in the Management of Thyroid Papillary Carcinoma. , 2009, 14, 231-235.		3
1842	<i>ErbB</i> receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839). <i>Melanoma Research</i> , 2009, 19, 156-166.	0.6	44
1843	Allelotyping, Microsatellite Instability, and <i>BRAF</i> Mutation Analyses in Common and Atypical Melanocytic Nevi and Primary Cutaneous Melanomas. <i>American Journal of Dermatopathology</i> , 2009, 31, 354-363.	0.3	19
1844	Benign Nodal Nevi Frequently Harbor the Activating V600E <i>BRAF</i> Mutation. <i>American Journal of Surgical Pathology</i> , 2009, 33, 568-571.	2.1	40
1845	Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 636-647.	1.9	14

#	ARTICLE	IF	CITATIONS
1846	Coexpression of major histocompatibility complex class II with chemokines and nuclear NF κ B p50 in melanoma: a rationale for their association with poor prognosis. <i>Melanoma Research</i> , 2009, 19, 226-237.	0.6	21
1847	Diagnostically Challenging Melanocytic Lesions in Children. , 2009, 14, 85-92.		2
1848	BRAF Mutation in Papillary Thyroid Carcinoma in a Japanese Population: Its Lack of Correlation with High-Risk Clinicopathological Features and Disease-Free Survival of Patients. <i>Endocrine Journal</i> , 2009, 56, 89-97.	0.7	227
1849	Possible Involvement of BRAFV600E in Altered Gene Expression in Papillary Thyroid Cancer. <i>Endocrine Journal</i> , 2009, 56, 407-414.	0.7	27
1850	Targeting of the BRAF gene in papillary thyroid carcinoma (Review). <i>Oncology Reports</i> , 2009, 22, 671-81.	1.2	27
1851	Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. <i>Blood</i> , 2009, 113, 6182-6192.	0.6	349
1852	Colorectal Cancer Due to Deficiency in DNA Mismatch Repair Function. <i>Advances in Anatomic Pathology</i> , 2009, 16, 405-417.	2.4	132
1853	v-Raf Murine Sarcoma Viral Oncogene Mutation Status in Serous Borderline Ovarian Tumors and the Effect on Clinical Behavior. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1560-1563.	1.2	7
1854	Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations. <i>Pathology</i> , 2009, 41, 327-334.	0.3	23
1855	BRAF ^{V600E} mutation in papillary thyroid carcinoma: a potential target for therapy?. <i>Expert Review of Endocrinology and Metabolism</i> , 2009, 4, 467-480.	1.2	0
1856	Phase II Trial of Sorafenib in Advanced Thyroid Cancer. <i>Yearbook of Medicine</i> , 2009, 2009, 571-574.	0.1	0
1857	Phase II Trial of Sorafenib in Advanced Thyroid Cancer. <i>Yearbook of Endocrinology</i> , 2009, 2009, 129-132.	0.0	0
1858	Highly Selective MEK Inhibitors. <i>Current Enzyme Inhibition</i> , 2010, 6, 146-157.	0.3	9
1859	Antiangiogenesis agents in colorectal cancer. <i>Current Opinion in Oncology</i> , 2010, 22, 374-380.	1.1	28
1860	Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis. <i>Current Pharmaceutical Design</i> , 2010, 16, 1396-1409.	0.9	11
1861	Cellular Senescence in the Development and Treatment of Cancer. <i>Current Pharmaceutical Design</i> , 2010, 16, 79-100.	0.9	77
1862	Effects of Ultraviolet B Radiation on the Cornea of Adult Male Albino Rats and the Possible Role of Lornoxicam. <i>Egyptian Journal of Histology</i> , 2010, 33, 156-167.	0.0	1
1863	Paving the way to the cure of melanoma. <i>Melanoma Research</i> , 2010, 20, 441-442.	0.6	2

#	ARTICLE	IF	CITATIONS
1864	Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. <i>Melanoma Research</i> , 2010, 20, 107-117.	0.6	67
1865	Mutation-driven drug development in melanoma. <i>Current Opinion in Oncology</i> , 2010, 22, 178-183.	1.1	94
1866	Novel Agents in the Treatment of Metastatic Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2010, 16, 273-282.	1.0	6
1867	Cutaneous melanoma in the elderly: epidemiology and management. <i>Aging Health</i> , 2010, 6, 383-392.	0.3	0
1868	Genetic and Epigenetic Analysis of erbB Signaling Pathway Genes in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1887-1893.	0.5	31
1869	Oncogene-induced Cellular Senescence. <i>Advances in Anatomic Pathology</i> , 2010, 17, 42-48.	2.4	95
1871	Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma. <i>Annals of Internal Medicine</i> , 2010, 153, 587.	2.0	34
1872	GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma. <i>European Journal of Medical Research</i> , 2010, 15, 422.	0.9	15
1874	Recurrent BRAF mutations in Langerhans cell histiocytosis. <i>Blood</i> , 2010, 116, 1919-1923.	0.6	996
1875	BRAF, a piece of the LCH puzzle. <i>Blood</i> , 2010, 116, 1825-1827.	0.6	18
1876	Genetic markers of melanoma. <i>Russian Journal of Genetics</i> , 2010, 46, 146-156.	0.2	1
1877	Role of RAS in the Regulation of PI 3-Kinase. <i>Current Topics in Microbiology and Immunology</i> , 2010, 346, 143-169.	0.7	99
1878	Molecular pathogenesis of follicular cell derived thyroid cancers. <i>International Journal of Surgery</i> , 2010, 8, 186-193.	1.1	50
1879	Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. <i>Advances in Enzyme Regulation</i> , 2010, 50, 285-307.	2.9	41
1880	Can BAD pores be good? New insights from examining BAD as a target of RAF kinases. <i>Advances in Enzyme Regulation</i> , 2010, 50, 147-159.	2.9	3
1881	Personalized Medicine in Non-Small-Cell Lung Cancer: Is KRAS a Useful Marker in Selecting Patients for Epidermal Growth Factor Receptor-Targeted Therapy?. <i>Journal of Clinical Oncology</i> , 2010, 28, 4769-4777.	0.8	243
1882	Profiling the Cancer Genome. <i>Annual Review of Genomics and Human Genetics</i> , 2010, 11, 133-159.	2.5	43
1883	Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies. <i>Science Translational Medicine</i> , 2010, 2, 35ra41.	5.8	142

#	ARTICLE	IF	CITATIONS
1884	Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 183-193.	2.0	15
1885	Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 3163-3171.	1.9	29
1886	Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 6934-6952.	1.4	27
1887	The phosphorylation specificity of B-RAF ^{WT} , B-RAF ^{D594V} , B-RAF ^{V600E} and B-RAF ^{K601E} kinases: An in silico study. <i>Journal of Molecular Graphics and Modelling</i> , 2010, 28, 598-603.	1.3	22
1888	Genetic alterations in malignant melanoma. <i>Diagnostic Histopathology</i> , 2010, 16, 317-320.	0.2	3
1889	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. <i>Angiogenesis</i> , 2010, 13, 1-14.	3.7	408
1891	Management Strategies for Patients with KRAS Mutations. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 199-205.	1.0	0
1892	The Biology of K-Ras and B-Raf Mutations in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 206-211.	1.0	0
1893	B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma. <i>Current Oncology Reports</i> , 2010, 12, 146-152.	1.8	49
1894	How Sunlight Causes Melanoma. <i>Current Oncology Reports</i> , 2010, 12, 319-326.	1.8	104
1895	QM/MM based 3D QSAR models for potent B-Raf inhibitors. <i>Journal of Computer-Aided Molecular Design</i> , 2010, 24, 385-397.	1.3	14
1896	Journal Impact Factors for evaluating scientific performance: use of h-like indicators. <i>Scientometrics</i> , 2010, 82, 613-626.	1.6	10
1897	Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. <i>Familial Cancer</i> , 2010, 9, 167-172.	0.9	47
1898	Detection of genetic alterations in hereditary colorectal cancer screening. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2010, 693, 19-31.	0.4	29
1899	Statistical method on nonrandom clustering with application to somatic mutations in cancer. <i>BMC Bioinformatics</i> , 2010, 11, 11.	1.2	76
1900	Molecular alterations in key-regulator genes among patients with T4 breast carcinoma. <i>BMC Cancer</i> , 2010, 10, 458.	1.1	11
1901	Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families. <i>BMC Cancer</i> , 2010, 10, 544.	1.1	8
1902	Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. <i>BMC Cancer</i> , 2010, 10, 587.	1.1	28

#	ARTICLE	IF	CITATIONS
1903	Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study. <i>BMC Cancer</i> , 2010, 10, 99.	1.1	52
1904	From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. <i>Journal of Hematology and Oncology</i> , 2010, 3, 8.	6.9	206
1905	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. <i>Drug Discovery Today</i> , 2010, 15, 88-97.	3.2	69
1906	BRAF as therapeutic target in melanoma. <i>Biochemical Pharmacology</i> , 2010, 80, 561-567.	2.0	151
1907	Using genetics and genomics strategies to personalize therapy for cancer: Focus on melanoma. <i>Biochemical Pharmacology</i> , 2010, 80, 755-761.	2.0	33
1908	Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. <i>Biochemical Pharmacology</i> , 2010, 80, 624-637.	2.0	174
1909	The Raf Inhibitor Paradox: Unexpected Consequences of Targeted Drugs. <i>Cancer Cell</i> , 2010, 17, 221-223.	7.7	37
1910	BRAF Inhibitor Unveils Its Potential against Advanced Melanoma. <i>Cancer Cell</i> , 2010, 18, 301-302.	7.7	15
1911	Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. <i>Cancer Cell</i> , 2010, 18, 683-695.	7.7	1,139
1912	Oncogene-induced senescence: the bright and dark side of the response. <i>Current Opinion in Cell Biology</i> , 2010, 22, 816-827.	2.6	213
1913	HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. <i>Clinical Immunology</i> , 2010, 134, 237-250.	1.4	131
1914	Circulating free tumor DNA and colorectal cancer. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 662-681.	0.9	51
1915	Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: A new potential therapy for the treatment of melanoma. <i>Experimental Cell Research</i> , 2010, 316, 1994-2007.	1.2	43
1916	PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. <i>Experimental and Molecular Pathology</i> , 2010, 88, 150-155.	0.9	41
1917	Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 504-527.	1.6	57
1918	^{V600E} Braf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of <i>p16</i> ^{<i>} <i>INK4a</i> ^{</i>} . <i>EMBO Molecular Medicine</i> , 2010, 2, 458-471.	3.3	128
1919	p21 loss blocks senescence following Apc loss and provokes tumourigenesis in the renal but not the intestinal epithelium. <i>EMBO Molecular Medicine</i> , 2010, 2, 472-486.	3.3	35
1920	Somatic alterations in the melanoma genome: A high-resolution array-based comparative genomic hybridization study. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 733-745.	1.5	85

#	ARTICLE	IF	CITATIONS
1921	No evidence for V600E BRAF mutation in the seminoma cell line TCam-2. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 963-966.	1.5	6
1922	BRAF, a target in melanoma. <i>Cancer</i> , 2010, 116, 4902-4913.	2.0	106
1923	Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. <i>International Journal of Cancer</i> , 2010, 126, 350-361.	2.3	20
1924	The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, <i>in vivo</i> tumor growth and increases survival of sorafenib-treated melanoma cells. <i>International Journal of Cancer</i> , 2010, 126, 1549-1561.	2.3	39
1925	Macroscopic morphologic subtypes of laterally spreading colorectal tumors showing distinct molecular alterations. <i>International Journal of Cancer</i> , 2010, 127, 1562-1569.	2.3	21
1926	RAF Kinase Inhibitors in Cancer Treatment: Like a Bull in a China Shop?. <i>ChemBioChem</i> , 2010, 11, 1645-1648.	1.3	1
1927	Models for Prediction of ^{V600E} BRAF and Melanoma Cells Growth Inhibitory Activities of Pyridoimidazolones. <i>Archiv Der Pharmazie</i> , 2010, 343, 664-679.	2.1	0
1928	Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. <i>Leukemia Research</i> , 2010, 34, 379-386.	0.4	26
1929	1,4-Dihydropyrazolo[4,3-d]imidazole phenyl derivatives: A novel type II Raf kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3805-3808.	1.0	30
1930	Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 292-304.	1.4	47
1931	Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1573-1577.	1.0	30
1932	B-Raf kinase inhibitors: Hit enrichment through scaffold hopping. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2431-2434.	1.0	17
1933	Discovery and optimization of N-acyl and N-arylpyrazolines as B-Raf kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4795-4799.	1.0	38
1934	Discovery and optimization of pyrazoline compounds as B-Raf inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 4800-4804.	1.0	15
1935	Genetic and functional characterization of putative Ras/Raf interaction inhibitors in <i>C. elegans</i> and mammalian cells. <i>Journal of Molecular Signaling</i> , 2010, 5, 2.	0.5	34
1936	The (non)malignancy of cancerous amino acidic substitutions. <i>Proteins: Structure, Function and Bioinformatics</i> , 2010, 78, 518-529.	1.5	15
1937	Our changing view of the genomic landscape of cancer. <i>Journal of Pathology</i> , 2010, 220, 231-243.	2.1	82
1938	Initial testing (stage 1) of AZD6244 (ARRY-42886) by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2010, 55, 668-677.	0.8	94

#	ARTICLE	IF	CITATIONS
1939	Activating <i>BRAF</i> mutations in eruptive melanocytic naevi. <i>British Journal of Dermatology</i> , 2010, 163, 1095-1098.	1.4	25
1940	Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti- <i>myeloma</i> activity <i>in vitro</i> and <i>in vivo</i> . <i>British Journal of Haematology</i> , 2010, 149, 537-549.	1.2	119
1941	Activated <i>BRAF</i> induces gliomas in mice when combined with <i>Ink4a/Arf</i> loss or <i>Akt</i> activation. <i>Oncogene</i> , 2010, 29, 335-344.	2.6	86
1942	Dissection of <i>RAS</i> downstream pathways in melanomagenesis: a role for <i>Ral</i> in transformation. <i>Oncogene</i> , 2010, 29, 2449-2456.	2.6	61
1943	Somatic <i>p16INK4a</i> loss accelerates melanomagenesis. <i>Oncogene</i> , 2010, 29, 5809-5817.	2.6	63
1944	Analysis of the genome to personalize therapy for melanoma. <i>Oncogene</i> , 2010, 29, 5545-5555.	2.6	125
1945	Cooperative interactions of <i>PTEN</i> deficiency and <i>RAS</i> activation in melanoma metastasis. <i>Oncogene</i> , 2010, 29, 6222-6232.	2.6	97
1946	Oncogenic mutations as predictive factors in colorectal cancer. <i>Oncogene</i> , 2010, 29, 3033-3043.	2.6	98
1947	The proapoptotic <i>BH3</i> -only protein <i>Bim</i> is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic <i>COX-2/PGE2</i> signalling in colorectal adenoma cells. <i>Oncogene</i> , 2010, 29, 3398-3410.	2.6	42
1948	Whole-genome cancer analysis as an approach to deeper understanding of tumour biology. <i>British Journal of Cancer</i> , 2010, 102, 243-248.	2.9	8
1949	<i>BRAF</i> mutations, microsatellite instability status and cyclin <i>D1</i> expression predict metastatic colorectal patients' outcome. <i>British Journal of Cancer</i> , 2010, 102, 1762-1768.	2.9	94
1950	Recovery of phospho- <i>ERK</i> activity allows melanoma cells to escape from <i>BRAF</i> inhibitor therapy. <i>British Journal of Cancer</i> , 2010, 102, 1724-1730.	2.9	283
1951	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	13.7	2,114
1952	<i>HIF-1</i> antagonizes <i>p53</i> -mediated apoptosis through a secreted neuronal tyrosinase. <i>Nature</i> , 2010, 465, 577-583.	13.7	179
1953	Clinical efficacy of a <i>RAF</i> inhibitor needs broad target blockade in <i>BRAF</i> -mutant melanoma. <i>Nature</i> , 2010, 467, 596-599.	13.7	1,610
1954	The histone variant <i>macroH2A</i> suppresses melanoma progression through regulation of <i>CDK8</i> . <i>Nature</i> , 2010, 468, 1105-1109.	13.7	345
1955	Melanomas acquire resistance to <i>B-RAF(V600E)</i> inhibition by <i>RTK</i> or <i>N-RAS</i> upregulation. <i>Nature</i> , 2010, 468, 973-977.	13.7	1,944
1956	<i>COT</i> drives resistance to <i>RAF</i> inhibition through <i>MAP</i> kinase pathway reactivation. <i>Nature</i> , 2010, 468, 968-972.	13.7	1,325

#	ARTICLE	IF	CITATIONS
1957	Oncogenic <i>BRAF</i> and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevocellular proliferations. <i>Journal of Cutaneous Pathology</i> , 2010, 37, 344-349.	0.7	17
1958	Rare victory in fight against melanoma. <i>Nature</i> , 2010, 467, 140-141.	13.7	4
1959	How melanomas bypass new therapy. <i>Nature</i> , 2010, 468, 902-903.	13.7	52
1960	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. <i>Nature Medicine</i> , 2010, 16, 793-798.	15.2	436
1961	RAF translocations expand cancer targets. <i>Nature Medicine</i> , 2010, 16, 749-750.	15.2	5
1962	Targeting the cancer kinome through polypharmacology. <i>Nature Reviews Cancer</i> , 2010, 10, 130-137.	12.8	618
1963	Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. <i>Nature Reviews Cancer</i> , 2010, 10, 241-253.	12.8	506
1964	Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. <i>Nature Reviews Cancer</i> , 2010, 10, 605-617.	12.8	181
1965	Harnessing transposons for cancer gene discovery. <i>Nature Reviews Cancer</i> , 2010, 10, 696-706.	12.8	147
1966	Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 760-774.	12.8	943
1967	Genomics drugs in clinical trials. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 988-988.	21.5	12
1968	Advances in understanding cancer genomes through second-generation sequencing. <i>Nature Reviews Genetics</i> , 2010, 11, 685-696.	7.7	1,014
1969	Review of the genetics of thyroid tumours: diagnostic and prognostic implications. <i>ANZ Journal of Surgery</i> , 2010, 80, 33-40.	0.3	16
1970	Inactivation of the Retinoblastoma Protein by Mutant B-Raf in Malignant Melanoma. <i>Nature Precedings</i> , 2010, , .	0.1	0
1971	6.8 Signaltransduktionsinhibition. , 2010, , .		0
1972	7.10 Zielgerichtete Therapie. , 2010, , .		0
1974	7.1 Melanozytäre NÄvi als PrÄkursoren und Risikomarker f¼r das maligne Melanom. , 2010, , .		0
1975	Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. <i>Melanoma Research</i> , 2010, 20, 392-400.	0.6	44

#	ARTICLE	IF	CITATIONS
1976	Current Research and Development of Chemotherapeutic Agents for Melanoma. <i>Cancers</i> , 2010, 2, 397-419.	1.7	22
1977	Relationship between BRAF Mutations in Papillary Thyroid Carcinomas and Clinicopathologic Factors. <i>The Korean Journal of Endocrine Surgery</i> , 2010, 10, 147.	0.1	0
1978	Multistage Carcinogenesis: Cell and Animal Models. , 2010, , 11-33.		0
1979	The PI3K/Akt and mTOR/P70S6K Signaling Pathways in Human Uveal Melanoma Cells: Interaction with B-Raf/ERK. , 2010, 51, 421.		95
1980	CREB Inhibits AP-2 β Expression to Regulate the Malignant Phenotype of Melanoma. <i>PLoS ONE</i> , 2010, 5, e12452.	1.1	52
1981	Mutational Profiling of Kinases in Human Tumours of Pancreatic Origin Identifies Candidate Cancer Genes in Ductal and Ampulla of Vater Carcinomas. <i>PLoS ONE</i> , 2010, 5, e12653.	1.1	16
1982	A Network of Cancer Genes with Co-Occurring and Anti-Co-Occurring Mutations. <i>PLoS ONE</i> , 2010, 5, e13180.	1.1	31
1983	Genomic Aberrations in Lung Adenocarcinoma in Never Smokers. <i>PLoS ONE</i> , 2010, 5, e15145.	1.1	62
1984	B-raf Alternative Splicing Is Dispensable for Development but Required for Learning and Memory Associated with the Hippocampus in the Adult Mouse. <i>PLoS ONE</i> , 2010, 5, e15272.	1.1	9
1985	A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates. <i>PLoS ONE</i> , 2010, 5, e15588.	1.1	90
1986	Isolated familial somatotropinoma: 11q13-loh and gene/protein expression analysis suggests a possible involvement of aip also in non-pituitary tumorigenesis. <i>Clinics</i> , 2010, 65, 407-415.	0.6	33
1988	Mutation Analysis of Braf Exon 15 and Kras Codons 12 and 13 in Moroccan Patients with Colorectal Cancer. <i>International Journal of Biological Markers</i> , 2010, 25, 179-184.	0.7	12
1989	Analyse des gènes du MisMatch Repair dans le syndrome de Lynch. <i>Cancéro Digest</i> , 2010, , .	0.0	0
1990	Lack of Oncogenic GNAQ Mutations in Melanocytic Lesions of the Conjunctiva as Compared to Uveal Melanoma. , 2010, 51, 6180.		40
1991	Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines. <i>Cancer Research</i> , 2010, 70, 9846-9854.	0.4	109
1992	BRAF Drives Synovial Fibroblast Transformation in Rheumatoid Arthritis. <i>Journal of Biological Chemistry</i> , 2010, 285, 34299-34303.	1.6	14
1993	Targets of Raf in tumorigenesis. <i>Carcinogenesis</i> , 2010, 31, 1165-1174.	1.3	120
1994	IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. <i>Carcinogenesis</i> , 2010, 31, 342-349.	1.3	90

#	ARTICLE	IF	CITATIONS
1995	MEK Inhibitor PD0325901 Significantly Reduces the Growth of Papillary Thyroid Carcinoma Cells <i>in vitro</i> and <i>In vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1968-1976.	1.9	70
1996	BRAF Inactivation Drives Aneuploidy by Deregulating CRAF. <i>Cancer Research</i> , 2010, 70, 8475-8486.	0.4	40
1997	New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways. <i>Clinical Cancer Research</i> , 2010, 16, 3811-3818.	3.2	41
1998	Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin. <i>Clinical Cancer Research</i> , 2010, 16, 3795-3804.	3.2	57
1999	Inhibition of Tumor Angiogenesis by the Matrix Metalloproteinase-Activated Anthrax Lethal Toxin in an Orthotopic Model of Anaplastic Thyroid Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 190-201.	1.9	28
2000	The Evolving Field of Tyrosine Kinase Inhibitors in the Treatment of Endocrine Tumors. <i>Endocrine Reviews</i> , 2010, 31, 578-599.	8.9	56
2001	Correlation between the BRAF V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4197-4205.	1.8	162
2002	Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor-Activating Mutations. <i>Cancer Research</i> , 2010, 70, 3843-3850.	0.4	55
2003	Beyond BRAF in Melanoma. <i>Current Topics in Microbiology and Immunology</i> , 2010, 355, 99-117.	0.7	14
2004	Zebrafish Models of p53 Functions. <i>Cold Spring Harbor Perspectives in Biology</i> , 2010, 2, a001123-a001123.	2.3	48
2005	BRAF Mutation Status in Gastrointestinal Stromal Tumors. <i>American Journal of Clinical Pathology</i> , 2010, 133, 141-148.	0.4	199
2006	Clinical Implications of the Cancer Genome. <i>Journal of Clinical Oncology</i> , 2010, 28, 5219-5228.	0.8	185
2007	A Novel, Selective, and Efficacious Nanomolar Pyridopyrazinone Inhibitor of V600EBRAF. <i>Cancer Research</i> , 2010, 70, 8036-8044.	0.4	25
2008	FOXO3 Is a Mutant B-RAF-Regulated Inhibitor of G1-S Progression in Melanoma Cells. <i>Cancer Research</i> , 2010, 70, 2891-2900.	0.4	82
2009	Basal and Treatment-Induced Activation of AKT Mediates Resistance to Cell Death by AZD6244 (ARRY-142886) in BRAF-Mutant Human Cutaneous Melanoma Cells. <i>Cancer Research</i> , 2010, 70, 8736-8747.	0.4	222
2010	A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2450-2457.	3.2	215
2011	Viral Oncolysis That Targets Raf-1 Signaling Control of Nuclear Transport. <i>Journal of Virology</i> , 2010, 84, 2090-2099.	1.5	32
2012	Rapid Multiplex Real-time PCR by Molecular Beacons for Different BRAF Allele Detection in Papillary Thyroid Carcinoma. <i>Diagnostic Molecular Pathology</i> , 2010, 19, 1-8.	2.1	14

#	ARTICLE	IF	CITATIONS
2013	Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Reviews in Molecular Medicine, 2010, 12, e10.	1.6	39
2014	An Oncogenic Role for <i>ETV1</i> in Melanoma. Cancer Research, 2010, 70, 2075-2084.	0.4	107
2015	Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response. Clinical Cancer Research, 2010, 16, 3329-3334.	3.2	160
2016	Survivin Enhances Motility of Melanoma Cells by Supporting Akt Activation and $\alpha 5$ Integrin Upregulation. Cancer Research, 2010, 70, 7927-7937.	0.4	66
2017	PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling. Cancer Research, 2010, 70, 6804-6814.	0.4	146
2018	On or Off Target: Mutations, Models, and Predictions. Science Translational Medicine, 2010, 2, 35ps28.	5.8	3
2019	Importance of Hormones and Proteins Determination in the Material Obtained by Fine-Needle Aspiration. Journal of Medical Biochemistry, 2010, 29, 237-244.	0.7	2
2020	Toxin-Based Therapeutic Approaches. Toxins, 2010, 2, 2519-2583.	1.5	118
2021	Role of the G Protein-Coupled Receptor, mGlu1, in Melanoma Development. Pharmaceuticals, 2010, 3, 2821-2837.	1.7	4
2022	KLF6 Gene and Early Melanoma Development in a Collagen I-Rich Extracellular Environment. Journal of the National Cancer Institute, 2010, 102, 1131-1147.	3.0	12
2023	Mucosal Melanomas: A Case-Based Review of the Literature. Oncologist, 2010, 15, 772-781.	1.9	101
2024	Widespread Immunity to Breast and Prostate Cancers is Predicted by a Novel Model that also Determines Sporadic and Hereditary Susceptible Population Sizes. Mathematical Modelling of Natural Phenomena, 2010, 5, 134-164.	0.9	0
2025	Insulin Signal Transduction in Normal Cells and its Role in Carcinogenesis. Experimental and Clinical Endocrinology and Diabetes, 2010, 118, 356-359.	0.6	11
2026	Preclinical <i>In vivo</i> Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models. Molecular Cancer Therapeutics, 2010, 9, 134-144.	1.9	31
2027	Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth. Molecular Cancer Therapeutics, 2010, 9, 2399-2410.	1.9	74
2028	A Plate-Based Assay to Measure Cellular ERK Substrate Phosphorylation: Utility for Drug Discovery of the MAPK-Signaling Cascade. Assay and Drug Development Technologies, 2010, 8, 497-503.	0.6	0
2029	Endocrine Neoplasia. Cancer Treatment and Research, 2010, , .	0.2	2
2030	The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression. Journal of Clinical Pharmacology, 2010, 50, 1397-1405.	1.0	8

#	ARTICLE	IF	CITATIONS
2031	Noonan Syndrome: Clinical Aspects and Molecular Pathogenesis. <i>Molecular Syndromology</i> , 2010, 1, 2-26.	0.3	197
2032	Activating K-Ras mutations outwith "hotspot" codons in sporadic colorectal tumours " implications for personalised cancer medicine. <i>British Journal of Cancer</i> , 2010, 102, 693-703.	2.9	156
2033	Setting up a Kinase Discovery and Development Project. <i>Current Topics in Microbiology and Immunology</i> , 2010, 355, 3-18.	0.7	6
2034	PLX4032: does it keep its promise for metastatic melanoma treatment?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1439-1449.	1.9	24
2035	Allelic variant at ~79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. <i>Endocrine-Related Cancer</i> , 2010, 17, 317-328.	1.6	35
2036	Redefining disease. <i>Clinical Medicine</i> , 2010, 10, 584-594.	0.8	13
2037	Oncogenic B-RafV600E Induces Spindle Abnormalities, Supernumerary Centrosomes, and Aneuploidy in Human Melanocytic Cells. <i>Cancer Research</i> , 2010, 70, 675-684.	0.4	41
2038	Activation of Forkhead Box O Transcription Factors by Oncogenic BRAF Promotes p21cip1-Dependent Senescence. <i>Cancer Research</i> , 2010, 70, 8526-8536.	0.4	81
2039	Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers. <i>Gut</i> , 2010, 59, 1516-1526.	6.1	51
2040	Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. <i>Human Molecular Genetics</i> , 2010, 19, 697-706.	1.4	26
2041	Vitamin D, Ultraviolet Exposure, and Skin Cancer in the Elderly. <i>Gerontology</i> , 2010, 56, 410-413.	1.4	22
2042	MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2062-2070.	0.3	204
2043	Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways. <i>Expert Review of Molecular Diagnostics</i> , 2010, 10, 75-87.	1.5	18
2044	Oncogenic Mutations of PIK3CA in Human Cancers. <i>Current Topics in Microbiology and Immunology</i> , 2010, 347, 21-41.	0.7	202
2045	Melanoma " An Unlikely Poster Child for Personalized Cancer Therapy. <i>New England Journal of Medicine</i> , 2010, 363, 876-878.	13.9	70
2046	Pharmacotherapy of regional melanoma therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 79-93.	0.9	7
2047	The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14903-14908.	3.3	417
2048	Pleiotropic Effects of p300-mediated Acetylation on p68 and p72 RNA Helicase. <i>Journal of Biological Chemistry</i> , 2010, 285, 30443-30452.	1.6	55

#	ARTICLE	IF	CITATIONS
2049	c-Jun Regulates Phosphoinositide-dependent Kinase 1 Transcription. <i>Journal of Biological Chemistry</i> , 2010, 285, 903-913.	1.6	36
2050	Oncogenic BRAFV600E Induces Expression of Neuronal Differentiation Marker MAP2 in Melanoma Cells by Promoter Demethylation and Down-regulation of Transcription Repressor HES1. <i>Journal of Biological Chemistry</i> , 2010, 285, 242-254.	1.6	35
2051	Targeting Oncogenic BRAF in Human Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2010, 355, 83-98.	0.7	42
2052	Identification of a Novel Raf-1 Pathway Activator that Inhibits Gastrointestinal Carcinoid Cell Growth. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 429-437.	1.9	31
2053	Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. <i>Journal of Carcinogenesis</i> , 2010, 9, 3.	2.5	40
2054	Progress and applications of mouse models for human lung cancer. <i>European Respiratory Journal</i> , 2010, 35, 426-443.	3.1	39
2055	Molecular Genetics of Thyroid Cancer. , 2010, , 117-138.		3
2056	Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203. <i>Journal of Clinical Oncology</i> , 2010, 28, 2947-2951.	0.8	199
2057	Akt3-Mediated Resistance to Apoptosis in B-RAF Targeted Melanoma Cells. <i>Cancer Research</i> , 2010, 70, 6670-6681.	0.4	166
2058	The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF- κ B/Snail/RKIP/PTEN Circuit. <i>Genes and Cancer</i> , 2010, 1, 409-420.	0.6	127
2060	Simultaneous Inhibition of MEK and CDK4 Leads to Potent Apoptosis in Human Melanoma Cells. <i>Cancer Investigation</i> , 2010, 28, 350-356.	0.6	21
2061	Targeting angiogenesis in melanoma: prospects for the future. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 367-380.	1.4	20
2062	Detection of BRAF Mutations in Thyroid Nodules by Allele-Specific PCR Using a Dual Priming Oligonucleotide System. <i>American Journal of Clinical Pathology</i> , 2010, 133, 802-808.	0.4	45
2063	Identification of Y-Box Binding Protein 1 As a Core Regulator of MEK/ERK Pathway-Dependent Gene Signatures in Colorectal Cancer Cells. <i>PLoS Genetics</i> , 2010, 6, e1001231.	1.5	80
2064	Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, F944-F951.	1.3	65
2065	Lack of Correlation between IGFBP7 Expression and BRAF Mutational Status in Melanoma. <i>Journal of Investigative Dermatology</i> , 2010, 130, 897-898.	0.3	7
2066	Targeting X-Linked Inhibitor of Apoptosis Protein to Increase the Efficacy of Endoplasmic Reticulum Stress-Induced Apoptosis for Melanoma Therapy. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2250-2258.	0.3	33
2067	The Wrath of RAFs: Rogue Behavior of B-RAF Kinase Inhibitors. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2669-2671.	0.3	10

#	ARTICLE	IF	CITATIONS
2068	Induction of Autophagy and Inhibition of Melanoma Growth In Vitro and In Vivo by Hyperactivation of Oncogenic BRAF. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1657-1667.	0.3	67
2069	Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1310-1321.	3.0	182
2070	Genetics of Uveal Melanoma and Cutaneous Melanoma: Two of a Kind?. <i>Dermatology Research and Practice</i> , 2010, 2010, 1-13.	0.3	60
2071	SWItching on the transcriptional circuitry in melanoma. <i>Epigenetics</i> , 2010, 5, 469-475.	1.3	10
2072	A growing family: Adding mutated Erbb4 as a novel cancer target. <i>Cell Cycle</i> , 2010, 9, 1487-1503.	1.3	34
2073	Smoking, Gender, and Ethnicity Predict Somatic <i>BRAF</i> Mutations in Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 838-843.	1.1	64
2074	Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1734-1740.	0.5	90
2075	Tumor suppression by ARF: Gatekeeper and caretaker. <i>Cell Cycle</i> , 2010, 9, 86-89.	1.3	42
2076	Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. <i>Neuro-Oncology</i> , 2010, 12, 621-630.	0.6	268
2077	Recent Advances in the Research and Development of B-Raf Inhibitors. <i>Current Medicinal Chemistry</i> , 2010, 17, 1618-1634.	1.2	26
2078	Measurement of Constitutive MAPK and PI3K/AKT Signaling Activity in Human Cancer Cell Lines. <i>Methods in Enzymology</i> , 2010, 484, 549-567.	0.4	14
2079	Increased Cancer Predisposition in Family Members of Colorectal Cancer Patients Harboring the p.V600E <i>BRAF</i> Mutation: a Population-Based Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1831-1839.	1.1	21
2080	Understanding Melanoma Signaling Networks as the Basis for Molecular Targeted Therapy. <i>Journal of Investigative Dermatology</i> , 2010, 130, 28-37.	0.3	116
2081	Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations. <i>Journal of Investigative Dermatology</i> , 2010, 130, 618-620.	0.3	37
2082	RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models. <i>Cancer Research</i> , 2010, 70, 5518-5527.	0.4	375
2083	Clinical Impact of the Detection of BRAF Mutations in Thyroid Pathology: Potential Usefulness as Diagnostic, Prognostic and Theragnostic Applications. <i>Current Medicinal Chemistry</i> , 2010, 17, 1839-1850.	1.2	39
2084	Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas. <i>Current Cancer Drug Targets</i> , 2010, 10, 840-848.	0.8	82
2085	The Thyroid Gland: A Crossroad in Inflammation-Induced Carcinoma? An Ongoing Debate with New Therapeutic Potential.. <i>Current Medicinal Chemistry</i> , 2010, 17, 3449-3461.	1.2	49

#	ARTICLE	IF	CITATIONS
2086	Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. <i>Cell Death and Disease</i> , 2010, 1, e69-e69.	2.7	85
2087	Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. <i>Small GTPases</i> , 2010, 1, 161-164.	0.7	6
2088	From Systems Biology to Systems Pathology: A New Subspecialty in Diagnostic and Personalized Medicine. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2010, 8, 108-116.	0.2	0
2089	Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies. <i>Current Cancer Drug Targets</i> , 2010, 10, 799-812.	0.8	28
2090	Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens. <i>Acta Cytologica</i> , 2010, 54, 291-295.	0.7	12
2091	The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer. <i>Oncologist</i> , 2010, 15, 1285-1293.	1.9	58
2092	Expression analysis of Akt and MAPK signaling pathways in lung tissue of patients with idiopathic pulmonary fibrosis (IPF). <i>Journal of Receptor and Signal Transduction Research</i> , 2010, 30, 262-269.	1.3	36
2093	Cooperativity of <i>Cdk4R24C</i> and <i>Ras</i> in melanoma development. <i>Cell Cycle</i> , 2010, 9, 3325-3334.	1.3	18
2094	Emerging MEK inhibitors. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 203-223.	1.0	54
2095	Prognostic and Predictive Biomarkers in Resected Colon Cancer: Current Status and Future Perspectives for Integrating Genomics into Biomarker Discovery. <i>Oncologist</i> , 2010, 15, 390-404.	1.9	155
2096	Future Advances in Melanoma Research. <i>Clinics in Plastic Surgery</i> , 2010, 37, 169-176.	0.7	5
2098	Mutations in the c-Kit Gene Disrupt Mitogen-Activated Protein Kinase Signaling during Tumor Development in Adenoid Cystic Carcinoma of the Salivary Glands. <i>Neoplasia</i> , 2010, 12, 708-717.	2.3	39
2099	Indazolylpyrazolopyrimidine as Highly Potent B-Raf Inhibitors with in Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 7874-7878.	2.9	16
2100	Cancer Epigenome. <i>Advances in Genetics</i> , 2010, 70, 247-276.	0.8	37
2101	Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1205-1216.	1.9	14
2102	Identification of Driver and Passenger DNA Methylation in Cancer by Epigenomic Analysis. <i>Advances in Genetics</i> , 2010, 70, 277-308.	0.8	128
2103	Familial clustering of giant congenital melanocytic nevi. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2010, 63, 906-913.	0.5	29
2104	New era in metastatic melanoma. <i>Molecular Oncology</i> , 2010, 4, 91-97.	2.1	3

#	ARTICLE	IF	CITATIONS
2105	Progress in understanding melanoma propagation. <i>Molecular Oncology</i> , 2010, 4, 451-457.	2.1	31
2106	Molecularly Targeted Therapy for Osteosarcoma: Where Do We Go from Here?. , 2010, , 459-498.		1
2107	Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancer. <i>Molecular Cancer</i> , 2010, 9, 266.	7.9	27
2108	TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status. <i>Journal of Translational Medicine</i> , 2010, 8, 15.	1.8	7
2109	Melanoma: A model for testing new agents in combination therapies. <i>Journal of Translational Medicine</i> , 2010, 8, 38.	1.8	53
2110	Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032. <i>Journal of Translational Medicine</i> , 2010, 8, 39.	1.8	203
2111	Clinical overview of sorafenib in breast cancer. <i>Future Oncology</i> , 2010, 6, 655-663.	1.1	26
2112	Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 809-819.	13.9	3,288
2113	ATP-binding Cassette Transporter ABCB5 Gene is Expressed with Variability in Malignant Melanoma. <i>Actas Dermo-sifiliogrÁficas</i> , 2010, 101, 341-348.	0.2	0
2114	Role of the Serrated Pathway in Colorectal Cancer Pathogenesis. <i>Gastroenterology</i> , 2010, 138, 2088-2100.	0.6	844
2115	Biomolecular motor proteins as targets for cancer treatment- a computational study.. , 2010, , .		1
2116	Detection of Low-Level KRAS Mutations Using PNA-Mediated Asymmetric PCR Clamping and Melting Curve Analysis with Unlabeled Probes. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 418-424.	1.2	60
2117	Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function. <i>Cancer Research</i> , 2010, 70, 5213-5219.	0.4	659
2118	Mutations in <i>GNA11</i> in Uveal Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 2191-2199.	13.9	1,312
2119	The essence of senescence: Figure 1.. <i>Genes and Development</i> , 2010, 24, 2463-2479.	2.7	1,698
2120	TD-GC-MS Analysis of Volatile Metabolites of Human Lung Cancer and Normal Cells <i>In vitro</i> . <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 182-195.	1.1	205
2121	mTOR signaling in glioblastoma: lessons learned from bench to bedside. <i>Neuro-Oncology</i> , 2010, 12, 882-889.	0.6	159
2122	Prognostic Role of <i>KRAS</i> and <i>BRAF</i> in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 466-474.	0.8	1,048

#	ARTICLE	IF	CITATIONS
2123	Phosphorylation of the Transcription Factor Ets-1 by ERK2: Rapid Dissociation of ADP and Phospho-Ets-1. <i>Biochemistry</i> , 2010, 49, 3619-3630.	1.2	26
2124	Enrichment and Detection of Rare Alleles by Means of Snapback Primers and Rapid-Cycle PCR. <i>Clinical Chemistry</i> , 2010, 56, 814-822.	1.5	22
2125	Notch Signaling in Solid Tumors. <i>Current Topics in Developmental Biology</i> , 2010, 92, 411-455.	1.0	98
2126	Ras history. <i>Small GTPases</i> , 2010, 1, 2-27.	0.7	586
2127	AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. <i>Future Oncology</i> , 2010, 6, 457-470.	1.1	338
2128	The Role of the Epigenome in Human Cancers. , 2010, , 471-486.		0
2129	Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7"challenging the concept of dysplastic nevi as precursor lesions?. <i>Human Pathology</i> , 2010, 41, 886-894.	1.1	27
2130	Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. <i>Human Pathology</i> , 2010, 41, 1299-1309.	1.1	53
2131	Risk of second primary malignancies following cutaneous melanoma diagnosis: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 757-767.	0.6	65
2132	Prognostic utility of BRAF mutation in papillary thyroid cancer. <i>Molecular and Cellular Endocrinology</i> , 2010, 321, 86-93.	1.6	188
2133	Signal transduction in the human thyrocyte and its perversion in thyroid tumors. <i>Molecular and Cellular Endocrinology</i> , 2010, 321, 3-19.	1.6	32
2134	Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. <i>Molecular and Cellular Endocrinology</i> , 2010, 322, 8-28.	1.6	114
2135	Scaffold-based design of kinase inhibitors for cancer therapy. <i>Current Opinion in Genetics and Development</i> , 2010, 20, 79-86.	1.5	16
2136	Catalogue, cause, complexity and cure; the many uses of cancer genome sequence. <i>Current Opinion in Genetics and Development</i> , 2010, 20, 336-341.	1.5	7
2137	Geldanamycin and its anti-cancer activities. <i>Cancer Letters</i> , 2010, 290, 24-35.	3.2	135
2138	Combating melanoma: The use of photodynamic therapy as a novel, adjuvant therapeutic tool. <i>Cancer Treatment Reviews</i> , 2010, 37, 465-75.	3.4	86
2139	RAF protein-serine/threonine kinases: Structure and regulation. <i>Biochemical and Biophysical Research Communications</i> , 2010, 399, 313-317.	1.0	296
2140	Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients. <i>Clinica Chimica Acta</i> , 2010, 411, 1319-1324.	0.5	60

#	ARTICLE	IF	CITATIONS
2141	Lineage-Specific Transcriptional Regulation of DICER by MITF in Melanocytes. <i>Cell</i> , 2010, 141, 994-1005.	13.5	113
2142	Environmental and Genetic Activation of a Brain-Adipocyte BDNF/Leptin Axis Causes Cancer Remission and Inhibition. <i>Cell</i> , 2010, 142, 52-64.	13.5	287
2143	Key Roles for Transforming Growth Factor β^2 in Melanocyte Stem Cell Maintenance. <i>Cell Stem Cell</i> , 2010, 6, 130-140.	5.2	197
2144	Mutational analyses of the BRAF, KRAS, and PIK3CA genes in oral squamous cell carcinoma. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2010, 110, 632-637.	1.6	31
2145	The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. <i>Research in Veterinary Science</i> , 2010, 88, 94-100.	0.9	20
2146	Targeted Molecular Therapy in Melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 196-201.	1.6	45
2147	Pathways to Melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 210-217.	1.6	25
2148	ATP-binding Cassette Transporter ABCB5 Gene is Expressed with Variability in Malignant Melanoma. <i>Actas Dermo-sifiliogr</i> , 2010, 101, 341-348.	0.2	22
2149	Surgical implications of B-RafV600E mutation in fine-needle aspiration of thyroid nodules. <i>American Journal of Surgery</i> , 2010, 200, 136-143.	0.9	23
2150	Novel Hinge Binder Improves Activity and Pharmacokinetic Properties of BRAF Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5639-5655.	2.9	37
2151	Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma. <i>Clinical Cancer Research</i> , 2010, 16, 6029-6039.	3.2	77
2152	<i>BRAF</i> Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation. <i>Science Signaling</i> , 2010, 3, ra84.	1.6	314
2153	Microsatellite instability in colorectal cancer—the stable evidence. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 153-162.	12.5	736
2154	Dormancy of metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 41-56.	1.5	109
2155	β -crystallin is mutant B-RAF regulated and contributes to cyclin D1 turnover in melanocytic cells. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 201-209.	1.5	16
2156	Stepping up melanocytes to the challenge of UV exposure. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 171-186.	1.5	108
2157	Growth and progression of melanoma and non-melanoma skin cancers regulated by ubiquitination. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 338-351.	1.5	22
2158	Genetic and environmental melanoma models in fish. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 314-337.	1.5	61

#	ARTICLE	IF	CITATIONS
2159	Reactive oxygen species and melanoma: an explanation for gender differences in survival?. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 352-364.	1.5	53
2160	Targeted delivery of <i>NRAS</i> ^{Q61R} and <i>Cre</i> recombinase to postnatal melanocytes induces melanoma in <i>Ink4a/Arf</i> ^{lox/lox} mice. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 531-541.	1.5	27
2161	Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 542-553.	1.5	20
2162	Targeting GRP78 to enhance melanoma cell death. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 675-682.	1.5	44
2163	Cancer stem cells versus phenotype switching in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 746-759.	1.5	408
2164	PLX4032, a potent inhibitor of the <i>B-Raf</i> V600E oncogene, selectively inhibits V600E positive melanomas. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 820-827.	1.5	142
2165	Mouse melanoma models and cell lines. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 853-859.	1.5	24
2166	Oncogenic RAF: a brief history of time. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 760-762.	1.5	9
2167	BRAF Inhibitors Based on an Imidazo[4,5]pyridin-2-one Scaffold and a Meta Substituted Middle Ring. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 1964-1978.	2.9	19
2168	Colorectal cancer screening Methodology. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2010, 8, 164-171.	0.8	27
2169	Morphological and molecular basis of ovarian serous carcinoma. <i>Journal of Biomedical Research</i> , 2010, 24, 257-263.	0.7	15
2170	KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2010, 94, 76-81.	0.3	90
2171	Adjuvant colon cancer chemotherapy: where we are and where we'll go. <i>Cancer Treatment Reviews</i> , 2010, 36, S34-S41.	3.4	70
2172	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. <i>Cancer Research</i> , 2010, 70, 5901-5911.	0.4	245
2174	Methods of Cancer Diagnosis, Therapy, and Prognosis. , 2010, , .		2
2175	Serrated Adenoma: A Distinct Form of Non-Polypoid Colorectal Neoplasia?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2010, 20, 543-563.	0.6	16
2176	Induction of Heparanase-1 Expression by Mutant B-Raf Kinase: Role of GA Binding Protein in Heparanase-1 Promoter Activation. <i>Neoplasia</i> , 2010, 12, 946-956.	2.3	23
2178	Chromosomal Aberrations in Solid Tumors. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 95, 55-94.	0.9	26

#	ARTICLE	IF	CITATIONS
2179	Ultraviolet Radiation as a Carcinogen*. , 2010, , 161-179.		2
2180	Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment. Biomarkers in Medicine, 2010, 4, 535-541.	0.6	16
2181	Proteomic Study of Thyroid Tumors Reveals Frequent Up-Regulation of the Ca ²⁺ -Binding Protein S100A6 in Papillary Thyroid Carcinoma. Thyroid, 2010, 20, 1067-1076.	2.4	32
2183	5-Carboxyfluorescein tagged N-phenylanthranilamide as a tracer reagent for fluorescence polarization: a robust method to screen MAPK pathway allosteric inhibitors. Chemical Communications, 2010, 46, 2043.	2.2	1
2184	Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase Inhibitors. ACS Chemical Biology, 2010, 5, 121-138.	1.6	55
2187	Sorafenib: Rays of Hope in Thyroid Cancer. Thyroid, 2010, 20, 1351-1358.	2.4	19
2188	Simultaneous Inhibition of MEK and CDK4 Leads to Potent Apoptosis in Human Melanoma Cells. Cancer Investigation, 2010, 28, 350-356.	0.6	24
2189	BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. Journal of Endocrinological Investigation, 2010, 33, 318-324.	1.8	37
2190	B-Raf ^{V600E} and thrombospondin-1 promote thyroid cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10649-10654.	3.3	164
2191	Targeted treatments in colorectal cancer: state of the art and future perspectives. Gut, 2010, 59, 838-858.	6.1	45
2192	EGFR and KRAS in Colorectal Cancer. Advances in Clinical Chemistry, 2010, 51, 71-119.	1.8	103
2193	Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome. Journal of Medical Genetics, 2010, 47, 445-452.	1.5	74
2194	Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process. Xenobiotica, 2011, 41, 1076-1087.	0.5	6
2195	PLX4032 and melanoma: resistance, expectations and uncertainty. Expert Review of Anticancer Therapy, 2011, 11, 325-328.	1.1	12
2196	A ¹²⁵ I-Camera Integrated with a Microfluidic Chip for Radioassays Based on Real-Time Imaging of Glycolysis in Small Cell Populations. Journal of Nuclear Medicine, 2011, 52, 815-821.	2.8	35
2197	HIF-1 α in Epidermis: Oxygen Sensing, Cutaneous Angiogenesis, Cancer, and Non-Cancer Disorders. Journal of Investigative Dermatology, 2011, 131, 1793-1805.	0.3	114
2198	<i>BRAF</i> Mutations in Hairy-Cell Leukemia. New England Journal of Medicine, 2011, 364, 2305-2315.	13.9	949
2199	Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations. Journal of Clinical Oncology, 2011, 29, 2046-2051.	0.8	616

#	ARTICLE	IF	CITATIONS
2200	Regional Treatment Strategies for In-Transit Melanoma Metastasis. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 79-103.	0.6	30
2201	Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 669-677.	1.2	81
2202	Mutationally Activated BRAFV600E Elicits Papillary Thyroid Cancer in the Adult Mouse. <i>Cancer Research</i> , 2011, 71, 3863-3871.	0.4	87
2203	Association studies in thyroid cancer susceptibility: are we on the right track?. <i>Journal of Molecular Endocrinology</i> , 2011, 47, R43-R58.	1.1	48
2204	Targeted Therapy for Melanoma: A Primer. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 165-180.	0.6	25
2205	Surgical Approach to Primary Cutaneous Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 39-56.	0.6	12
2206	BRAF1799A mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma. <i>Endocrinología Y Nutrición (English Edition)</i> , 2011, 58, 175-184.	0.5	11
2208	Rasopathies: Developmental Disorders That Predispose to Cancer and Skin Manifestations. <i>Actas Dermo-sifiligráficas</i> , 2011, 102, 402-416.	0.2	19
2209	Novel Cytochrome P450 Bioactivation of a Terminal Phenyl Acetylene Group: Formation of a One-Carbon Loss Benzaldehyde and Other Oxidative Products in the Presence of N-Acetyl Cysteine or Glutathione. <i>Chemical Research in Toxicology</i> , 2011, 24, 677-686.	1.7	7
2210	Molecular Biology of Lung Cancer: Clinical Implications. <i>Clinics in Chest Medicine</i> , 2011, 32, 703-740.	0.8	194
2211	Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 61-74.	1.9	9
2212	Genomics and the Continuum of Cancer Care. <i>New England Journal of Medicine</i> , 2011, 364, 340-350.	13.9	282
2213	Generating and Analyzing Fish Models of Melanoma. <i>Methods in Cell Biology</i> , 2011, 105, 339-366.	0.5	30
2215	Molecular Dynamics Simulation, Free Energy Calculation and Structure-Based 3D-QSAR Studies of B-RAF Kinase Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 680-692.	2.5	76
2216	Preclinical Models for Anticancer Drug Development. , 2011, , 89-114.		1
2217	Carcinoma colorrectal en el síndrome de poliposis hiperplásica: caracterización clinicopatológica y molecular. <i>Revista Española De Patología</i> , 2011, 44, 75-82.	0.6	1
2218	Biological challenges of BRAF inhibitor therapy. <i>Molecular Oncology</i> , 2011, 5, 116-123.	2.1	30
2219	Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. <i>Molecular Oncology</i> , 2011, 5, 124-136.	2.1	135

#	ARTICLE	IF	CITATIONS
2220	Epidermal Melanocytes: Regulation of Their Survival, Proliferation, and Function in Human Skin. , 2011, , 7-33.		4
2221	Chapter 5. Kinase Mutations and Resistance in Cancer. RSC Drug Discovery Series, 2011, , 126-160.	0.2	1
2222	Zebrafish Models for Cancer. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 71-93.	9.6	135
2223	Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma. Drugs, 2011, 71, 1233-1250.	4.9	20
2224	Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs, 2011, 71, 2231-2246.	4.9	23
2225	Vemurafenib for Melanoma Metastases to the Brain. New England Journal of Medicine, 2011, 365, 2439-2441.	13.9	80
2226	Zebrafish as a Model for the Study of Human Cancer. Methods in Cell Biology, 2011, 105, 309-337.	0.5	51
2227	Genetic Determinants of Uveal Melanoma. Developments in Ophthalmology, 2012, 49, 150-165.	0.1	9
2228	Nanomedicine Approaches for Cancer Stem Cell Targeting and Personalized Cancer Treatment. Else-KrÄ¶ner-Fresenius-Symposia, 2011, , 135-144.	0.1	0
2229	The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors. Molecular Cancer, 2011, 10, 54.	7.9	53
2230	Phosphoinositide 3-kinase in Health and Disease. Current Topics in Microbiology and Immunology, 2011, , ,	0.7	1
2231	The molecular pathology of cutaneous melanoma. Cancer Biomarkers, 2011, 9, 267-286.	0.8	27
2232	Aberrant methylation of hMLH1 and p16INK4a in Tunisian patients with sporadic colorectal adenocarcinoma. Bioscience Reports, 2011, 31, 257-264.	1.1	17
2233	The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. Blood, 2011, 118, 1052-1061.	0.6	41
2234	Principles of Anticancer Drug Development. , 2011, , ,		0
2235	Spatial density of primary malignant melanoma in sun-shielded body sites: A potential guide to melanoma genesis. Acta OncolÄ³gica, 2011, 50, 323-328.	0.8	16
2236	Ras and Rap Signaling in Synaptic Plasticity and Mental Disorders. Neuroscientist, 2011, 17, 54-78.	2.6	131
2237	BRAF targeted therapy changes the treatment paradigm in melanoma. Nature Reviews Clinical Oncology, 2011, 8, 426-433.	12.5	229

#	ARTICLE	IF	CITATIONS
2238	<i>BRAF</i> mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma. Expert Opinion on Medical Diagnostics, 2011, 5, 277-290.	1.6	24
2239	The landscape of <i>EGFR</i> pathways and personalized management of non-small-cell lung cancer. Future Oncology, 2011, 7, 519-541.	1.1	47
2240	Vemurafenib. Nature Reviews Drug Discovery, 2011, 10, 811-812.	21.5	135
2241	Molecular Aspects of Melanoma. Clinics in Laboratory Medicine, 2011, 31, 331-343.	0.7	4
2242	Optimized Allele-Specific Real-Time PCR Assays for the Detection of Common Mutations in KRAS and BRAF. Journal of Molecular Diagnostics, 2011, 13, 23-28.	1.2	91
2244	Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation. American Journal of Pathology, 2011, 178, 1395-1402.	1.9	122
2245	Pirin Inhibits Cellular Senescence in Melanocytic Cells. American Journal of Pathology, 2011, 178, 2397-2406.	1.9	31
2246	BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clinica Chimica Acta, 2011, 412, 901-905.	0.5	49
2247	The Evolving War on Cancer. Cell, 2011, 145, 19-24.	13.5	197
2248	In Vivo Identification of Tumor-Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma. Cell, 2011, 147, 382-395.	13.5	602
2249	Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 279-289.	1.0	24
2250	Development of Novel Targeted Agents in the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 266-278.	1.0	6
2251	Iatrogenic effects of photoprotection recommendations on skin cancer development, vitamin D levels, and general health. Clinics in Dermatology, 2011, 29, 644-651.	0.8	11
2252	Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts. Clinics in Dermatology, 2011, 29, 587-601.	0.8	19
2253	Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?. Cancer Treatment Reviews, 2011, 37, 533-542.	3.4	31
2254	Molecular Alternations in Uveal Melanoma. Current Problems in Cancer, 2011, 35, 211-224.	1.0	9
2255	Melanoma and Nevi: Detection and Diagnosis. Current Problems in Cancer, 2011, 35, 138-161.	1.0	6
2256	Vascular endothelial growth factor inhibition: Conflicting roles in tumor growth. Cytokine, 2011, 53, 115-129.	1.4	17

#	ARTICLE	IF	CITATIONS
2257	Protein kinase signaling networks in cancer. <i>Current Opinion in Genetics and Development</i> , 2011, 21, 4-11.	1.5	202
2258	Mutant onco-proteins as drug targets: successes, failures, and future prospects. <i>Current Opinion in Genetics and Development</i> , 2011, 21, 29-33.	1.5	10
2259	B-RAF: A contributor to the melanoma phenotype. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 29-32.	1.2	8
2260	KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients. <i>Biomedicine and Pharmacotherapy</i> , 2011, 65, 22-26.	2.5	52
2261	Centrosomal dysregulation in human metastatic melanoma cell lines. <i>Cancer Genetics</i> , 2011, 204, 477-485.	0.2	14
2263	A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. <i>Cancer Letters</i> , 2011, 312, 158-167.	3.2	42
2264	Oncogenic mutations in gastric cancer with microsatellite instability. <i>European Journal of Cancer</i> , 2011, 47, 443-451.	1.3	92
2265	Enhanced detection of BRAF-mutants by pre-PCR cleavage of wild-type sequences revealed circulating melanoma cells heterogeneity. <i>European Journal of Cancer</i> , 2011, 47, 1971-1976.	1.3	12
2266	Cyclic AMP-mediated cyst expansion. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1291-1300.	1.8	123
2267	The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. <i>Biochemical and Biophysical Research Communications</i> , 2011, 414, 563-568.	1.0	19
2269	Exploring the Genomes of Cancer Cells: Progress and Promise. <i>Science</i> , 2011, 331, 1553-1558.	6.0	606
2270	Next-generation sequencing applied to molecular diagnostics. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 425-444.	1.5	33
2271	Synthesis and biological evaluation of 2,3-bis(het)aryl-4-azaindole derivatives as protein kinase inhibitors. <i>MedChemComm</i> , 2011, 2, 899.	3.5	28
2272	Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 1836-1846.	2.9	32
2273	Pediatric "STUMP" lesions: Evaluation and management of difficult atypical Spitzoid lesions in children. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 559-572.	0.6	58
2274	Spitz nevi and other Spitzoid lesions. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 1073-1084.	0.6	76
2275	Activation of the PIK3CA/AKT Pathway Suppresses Senescence Induced by an Activated RAS Oncogene to Promote Tumorigenesis. <i>Molecular Cell</i> , 2011, 42, 36-49.	4.5	179
2276	Somatic mutations in GNAQ in amelanotic/hypomelanotic blue nevi. <i>Human Pathology</i> , 2011, 42, 136-140.	1.1	29

#	ARTICLE	IF	CITATIONS
2277	Dissecting the effect of targeting the epidermal growth factor receptor on TGF- β ² -induced-apoptosis in human hepatocellular carcinoma cells. <i>Journal of Hepatology</i> , 2011, 55, 351-358.	1.8	48
2278	Mutation and copy number detection in human cancers using a custom genotyping assay. <i>Genomics</i> , 2011, 98, 296-301.	1.3	1
2279	New driver mutations in non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2011, 12, 175-180.	5.1	1,038
2280	Treatment implications of the emerging molecular classification system for melanoma. <i>Lancet Oncology</i> , The, 2011, 12, 913-922.	5.1	82
2281	P-Rex1 is required for efficient melanoblast migration and melanoma metastasis. <i>Nature Communications</i> , 2011, 2, 555.	5.8	152
2282	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
2283	Therapy for metastatic melanoma: an overview and update. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 725-737.	1.1	55
2284	Different types of DNA damage play different roles in the etiology of sunlight-induced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 119-124.	1.5	25
2285	Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 107-109.	1.5	5
2286	A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 326-333.	1.5	60
2287	Parsing out the complexity of RAF inhibitor resistance. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 361-365.	1.5	6
2288	<i>BRAF</i> mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 345-351.	1.5	180
2289	Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 551-563.	1.5	48
2290	The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 879-897.	1.5	225
2291	The role of mitogen- and stress-activated protein kinase pathways in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 902-921.	1.5	59
2292	Oncogene-induced senescence and melanoma: where do we stand?. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 1107-1111.	1.5	20
2293	Multikinase inhibitors: a new option for the treatment of thyroid cancer. <i>Nature Reviews Endocrinology</i> , 2011, 7, 617-624.	4.3	130
2294	Research Highlights. <i>Pharmacogenomics</i> , 2011, 12, 1379-1382.	0.6	2

#	ARTICLE	IF	CITATIONS
2295	Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 142-150.	12.5	277
2296	Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. <i>Radiotherapy and Oncology</i> , 2011, 98, 394-399.	0.3	130
2297	Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. <i>Biochemical Pharmacology</i> , 2011, 82, 201-209.	2.0	162
2298	Identification of Phosphoproteins and their Impact as Biomarkers in Cancer Therapeutics. <i>Current Signal Transduction Therapy</i> , 2011, 6, 113-140.	0.3	5
2299	New Perspectives of omics Applications in Melanoma Research. <i>The Open Biochemistry Journal</i> , 2011, 5, 60-66.	0.3	5
2300	Genotype-Dependent Sensitivity of Uveal Melanoma Cell Lines to Inhibition of B-Raf, MEK, and Akt Kinases: Rationale for Personalized Therapy. , 2011, 52, 7248.		41
2301	Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. <i>Research and Reports in Urology</i> , 2011, Volume 3, 69-82.	0.6	0
2302	BRAF V600E Mutated Gene Variant as a Circulating Molecular Marker in Metastatic Melanoma Patients. , 2011, , .		1
2303	Insulin-Like-Growth Factor-Binding-Protein 7: An Antagonist to Breast Cancer. , 0, , .		1
2304	New Molecular Targets for the Systemic Therapy of Melanoma. , 0, , .		2
2305	Cutaneous Melanoma: Therapeutic Approaches for Metastatic Disease. , 0, , 313-324.		0
2306	Molecular Biology of Thyroid Cancer. , 2011, , .		0
2307	Clinical application of high throughput molecular screening techniques for pharmacogenomics. <i>Pharmacogenomics and Personalized Medicine</i> , 2011, 4, 109.	0.4	10
2308			

#	ARTICLE	IF	CITATIONS
2313	Impact of KRAS Mutations on Management of Colorectal Carcinoma. Pathology Research International, 2011, 2011, 1-11.	1.4	18
2314	Molecular Bases of Cutaneous and Uveal Melanomas. Pathology Research International, 2011, 2011, 1-8.	1.4	14
2315	Skin Pigmentation and Melanoma Risk. , 2011, , .		4
2316	Resistance to Cancer Treatment: The Role of Somatic Genetic Events and the Challenges for Targeted Therapies. Frontiers in Pharmacology, 2011, 2, 59.	1.6	19
2317	EGFR Signaling in Colorectal Carcinoma. Pathology Research International, 2011, 2011, 1-6.	1.4	118
2318	A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm. Frontiers in Bioscience - Landmark, 2011, 16, 422.	3.0	68
2319	Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment. Frontiers in Oncology, 2011, 1, .	1.3	42
2320	The Jak-STAT Signal Transduction Pathway in Melanoma. , 0, , .		9
2321	Novel Oncology Drug Development Strategies in the Era of Personalised Medicine. , 0, , .		0
2322	BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS ONE, 2011, 6, e17948.	1.1	268
2323	High Throughput Interrogation of Somatic Mutations in High Grade Serous Cancer of the Ovary. PLoS ONE, 2011, 6, e24433.	1.1	44
2324	Cross-Regulation between Oncogenic BRAFV600E Kinase and the MST1 Pathway in Papillary Thyroid Carcinoma. PLoS ONE, 2011, 6, e16180.	1.1	36
2325	MEK2 Is Sufficient but Not Necessary for Proliferation and Anchorage-Independent Growth of SK-MEL-28 Melanoma Cells. PLoS ONE, 2011, 6, e17165.	1.1	16
2326	Cytoplasmic Skp2 Expression Is Increased in Human Melanoma and Correlated with Patient Survival. PLoS ONE, 2011, 6, e17578.	1.1	28
2327	Spotlight on Differentially Expressed Genes in Urinary Bladder Cancer. PLoS ONE, 2011, 6, e18255.	1.1	40
2328	A Melanoma Molecular Disease Model. PLoS ONE, 2011, 6, e18257.	1.1	77
2329	Network-Guided Analysis of Genes with Altered Somatic Copy Number and Gene Expression Reveals Pathways Commonly Perturbed in Metastatic Melanoma. PLoS ONE, 2011, 6, e18369.	1.1	51
2330	Live-Cell Microscopy Reveals Small Molecule Inhibitor Effects on MAPK Pathway Dynamics. PLoS ONE, 2011, 6, e22607.	1.1	13

#	ARTICLE	IF	CITATIONS
2331	PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers. PLoS ONE, 2011, 6, e22769.	1.1	174
2332	BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes. PLoS ONE, 2011, 6, e25806.	1.1	83
2333	Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway. PLoS ONE, 2011, 6, e28973.	1.1	196
2334	Autoantibodies against the Catalytic Domain of BRAF Are Not Specific Serum Markers for Rheumatoid Arthritis. PLoS ONE, 2011, 6, e28975.	1.1	5
2335	Expression of B-RAF V600E in Type II Pneumocytes Causes Abnormalities in Alveolar Formation, Airspace Enlargement and Tumor Formation in Mice. PLoS ONE, 2011, 6, e29093.	1.1	3
2337	Overexpression of GLUT1 in Colorectal Cancer is Independently Associated with Poor Prognosis. International Journal of Biological Markers, 2011, 26, 166-172.	0.7	41
2338	Proliferative Nodules Arising Within Congenital Melanocytic Nevi. American Journal of Surgical Pathology, 2011, 35, 656-669.	2.1	107
2339	Central Compartment Dissection in Thyroid Papillary Carcinoma. Annals of Surgery, 2011, 253, 123-130.	2.1	44
2340	Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells. Anti-Cancer Drugs, 2011, 22, 507-518.	0.7	44
2341	Company Profile: N-of-One: realizing personalized medicine. Personalized Medicine, 2011, 8, 311-315.	0.8	0
2342	A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Research, 2011, 21, 357-363.	0.6	33
2343	Loss of p16INK4A Expression in Low-grade Ovarian Serous Carcinomas. International Journal of Gynecological Pathology, 2011, 30, 22-29.	0.9	16
2344	Lack of BRAFV600E Mutations in Giant Congenital Melanocytic Nevi in a Chinese Population. American Journal of Dermatopathology, 2011, 33, 341-344.	0.3	31
2345	Malignant Neurocristic Hamartoma. American Journal of Surgical Pathology, 2011, 35, 1570-1577.	2.1	26
2346	PATHWAY REGULATORY ANALYSIS IN THE CONTEXT OF BAYESIAN NETWORKS USING THE COEFFICIENT OF DETERMINATION. Journal of Biological Systems, 2011, 19, 651-682.	0.5	5
2347	New Targeted Therapies for Thyroid Cancer. Current Genomics, 2011, 12, 626-631.	0.7	52
2348	Sessile Serrated Adenoma With Early Neoplastic Progression. American Journal of Surgical Pathology, 2011, 35, 295-304.	2.1	95
2349	Heat Shock Proteins: A Potential Anticancer Target. Current Drug Targets, 2011, 12, 2001-2008.	1.0	32

#	ARTICLE	IF	CITATIONS
2350	Small Molecules in Cancer Therapy: Cytotoxics and Molecularly Targeted Agents. <i>Current Signal Transduction Therapy</i> , 2011, 6, 2-19.	0.3	5
2351	Clinically important molecular features of Peruvian colorectal tumours: high prevalence of DNA mismatch repair deficiency and low incidence of KRAS mutations. <i>Pathology</i> , 2011, 43, 228-233.	0.3	15
2352	Genetic alterations in uveal melanoma. <i>Expert Review of Ophthalmology</i> , 2011, 6, 129-132.	0.3	0
2353	BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety. <i>Clinical Investigation</i> , 2011, 1, 1127-1139.	0.0	6
2354	Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies. <i>Oncology Letters</i> , 2011, 2, 1131-1137.	0.8	51
2355	NRAS and BRAF mutation frequency in primary oral mucosal melanoma. <i>Oncology Reports</i> , 2011, 26, 783-7.	1.2	35
2356	Effect of classification based on combination of mutation and methylation in colorectal cancer prognosis. <i>Oncology Reports</i> , 2011, 25, 789-94.	1.2	44
2357	An approach to personalized medicine: the BATTLE trial. <i>Clinical Investigation</i> , 2011, 1, 699-705.	0.0	0
2359	Targeting Inflammatory Kinase as an Adjuvant Treatment for Osteosarcomas. <i>Journal of Bone and Joint Surgery - Series A</i> , 2011, 93, 723-732.	1.4	28
2360	Rare allele enrichment and detection by allele-specific PCR, competitive probe blocking, and melting analysis. <i>BioTechniques</i> , 2011, 50, 311-318.	0.8	19
2361	Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. <i>Expert Review of Dermatology</i> , 2011, 6, 355-357.	0.3	2
2362	Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 695-700.	0.8	25
2363	A Correction to the Research Article Titled: "Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook. <i>Science Signaling</i> , 2011, 4, er2.	1.6	10
2365	Mechanism of EGFR-related cancer drug resistance. <i>Anti-Cancer Drugs</i> , 2011, 22, 963-970.	0.7	9
2366	Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome. <i>Clinical Genetics</i> , 2011, 79, 468-474.	1.0	21
2367	Analysis of <i>KRAS</i> , <i>BRAF</i> , and <i>PIK3CA</i> mutations in laterally spreading tumors of the colorectum. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 599-607.	1.4	13
2368	Immunohistochemical expression of cyclooxygenase-2 in melanocytic skin lesions. <i>International Journal of Dermatology</i> , 2011, 50, 24-29.	0.5	17
2369	Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. <i>British Journal of Dermatology</i> , 2011, 164, 776-784.	1.4	368

#	ARTICLE	IF	CITATIONS
2370	Tumour heterogeneity of mucosal melanomas during treatment with imatinib. <i>British Journal of Dermatology</i> , 2011, 165, 419-424.	1.4	7
2371	Mutational analysis of VACM-1/cul5 exons in cancer cell lines. <i>Apmis</i> , 2011, 119, 421-430.	0.9	8
2372	EGFR in melanoma: clinical significance and potential therapeutic target. <i>Journal of Cutaneous Pathology</i> , 2011, 38, 492-502.	0.7	77
2373	Identification of new genes associated with melanoma. <i>Experimental Dermatology</i> , 2011, 20, 502-507.	1.4	37
2374	Therapeutic cancer vaccines: are we there yet?. <i>Immunological Reviews</i> , 2011, 239, 27-44.	2.8	249
2375	Apoptotic gene expression by human periodontal ligament cells following cyclic stretch. <i>Journal of Periodontal Research</i> , 2011, 46, 742-748.	1.4	24
2376	Oncogenetics of melanoma: basis for molecular diagnostics and therapy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 510-516.	0.4	3
2377	Onkogenetik des Melanoms: Grundlage für molekulare Diagnostik und Therapie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011, 9, 510-517.	0.4	5
2378	Exome sequencing identifies GRIN2A as frequently mutated in melanoma. <i>Nature Genetics</i> , 2011, 43, 442-446.	9.4	449
2379	Taming the dragon: genomic biomarkers to individualize the treatment of cancer. <i>Nature Medicine</i> , 2011, 17, 304-312.	15.2	94
2380	Cancer genomics: from discovery science to personalized medicine. <i>Nature Medicine</i> , 2011, 17, 297-303.	15.2	534
2381	Unravelling the complexity of metastasis – molecular understanding and targeted therapies. <i>Nature Reviews Cancer</i> , 2011, 11, 735-748.	12.8	318
2382	ERK and PDE4 cooperate to induce RAF isoform switching in melanoma. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 584-591.	3.6	81
2383	Hyperactivation of MEK/ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. <i>Oncogene</i> , 2011, 30, 366-371.	2.6	109
2384	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. <i>Oncogene</i> , 2011, 30, 2547-2557.	2.6	471
2385	Raf kinases in cancer – roles and therapeutic opportunities. <i>Oncogene</i> , 2011, 30, 3477-3488.	2.6	247
2386	Targeting BRAF for patients with melanoma. <i>British Journal of Cancer</i> , 2011, 104, 392-398.	2.9	129
2387	Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. <i>British Journal of Cancer</i> , 2011, 104, 464-468.	2.9	116

#	ARTICLE	IF	CITATIONS
2388	Initial impact of the sequencing of the human genome. <i>Nature</i> , 2011, 470, 187-197.	13.7	919
2389	The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. <i>Nature</i> , 2011, 471, 513-517.	13.7	506
2390	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011, 471, 467-472.	13.7	1,288
2391	DHODH modulates transcriptional elongation in the neural crest and melanoma. <i>Nature</i> , 2011, 471, 518-522.	13.7	411
2392	Ciglitazone negatively regulates CXCL1 signaling through MITF to suppress melanoma growth. <i>Cell Death and Differentiation</i> , 2011, 18, 109-121.	5.0	31
2393	Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. <i>Histopathology</i> , 2011, 58, 679-692.	1.6	78
2394	Clinical features and molecular alterations of traditional serrated adenoma in sporadic colorectal carcinogenesis. <i>Journal of Digestive Diseases</i> , 2011, 12, 193-198.	0.7	10
2395	Molecular Profiling of Melanoma and the Evolution of Patient-Specific Therapy. <i>Seminars in Oncology</i> , 2011, 38, 236-242.	0.8	28
2396	A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells. <i>BMC Cancer</i> , 2011, 11, 412.	1.1	49
2397	The NADPH oxidase inhibitor VAS2870 impairs cell growth and enhances TGF- β 2-induced apoptosis of liver tumor cells. <i>Biochemical Pharmacology</i> , 2011, 81, 917-924.	2.0	44
2398	Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6760-6767.	1.4	14
2399	Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure-activity relationships. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5533-5537.	1.0	50
2400	Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A. <i>Cancer Cell</i> , 2011, 19, 45-57.	7.7	190
2401	Mutant BRAF Melanomas Dependence and Resistance. <i>Cancer Cell</i> , 2011, 19, 11-15.	7.7	226
2402	Defective Regulation of Autophagy upon Leucine Deprivation Reveals a Targetable Liability of Human Melanoma Cells In Vitro and In Vivo. <i>Cancer Cell</i> , 2011, 19, 613-628.	7.7	203
2403	mTOR signaling in disease. <i>Current Opinion in Cell Biology</i> , 2011, 23, 744-755.	2.6	409
2404	B Type RAF Kinase (BRAF) Mutational Status in Metastatic Differentiated Thyroid Cancer. <i>Laryngoscope</i> , 2011, 121, S105-S105.	1.1	0
2405	Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling. <i>Journal of Clinical Oncology</i> , 2011, 29, 3085-3096.	0.8	890

#	ARTICLE	IF	CITATIONS
2406	Clinical Implementation of Comprehensive Strategies to Characterize Cancer Genomes: Opportunities and Challenges. <i>Cancer Discovery</i> , 2011, 1, 297-311.	7.7	47
2407	Novel therapies in melanoma. <i>Immunotherapy</i> , 2011, 3, 1461-1469.	1.0	18
2408	Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the <i>B-Raf</i> V600E Mutation. <i>Cancer Research</i> , 2011, 71, 5535-5545.	0.4	73
2409	Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1399-1405.	0.9	44
2410	Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. <i>Endocrine-Related Cancer</i> , 2011, 18, 687-697.	1.6	70
2411	Pyrazolopyridine Inhibitors of B-Raf ^{V600E} . Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 342-347.	1.3	60
2412	Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate). <i>ACS Medicinal Chemistry Letters</i> , 2011, 2, 320-324.	1.3	131
2413	Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. <i>Investigational New Drugs</i> , 2011, 29, 481-488.	1.2	46
2414	Familial colorectal cancer type X syndrome: two distinct molecular entities?. <i>Familial Cancer</i> , 2011, 10, 623-631.	0.9	27
2415	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 101, 57-66.	1.4	118
2416	Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome. <i>Journal of Neuro-Oncology</i> , 2011, 102, 509-514.	1.4	16
2417	Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 749-759.	1.4	15
2418	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 397-405.	3.9	914
2419	A preliminary study on K-ras, EGFR, and B-raf mutations of esophageal squamous cell carcinoma. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 497-501.	0.1	0
2420	The expression and clinical significance of BRAF in prostate cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2011, 10, 523-525.	0.1	1
2422	Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 349-360.	1.1	42
2423	Statins are logical candidates for overcoming limitations of targeting therapies on malignancy: their potential application to gastrointestinal cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 729-739.	1.1	26
2424	Prognostic significance of autoimmunity during treatment of melanoma with interferon. <i>Seminars in Immunopathology</i> , 2011, 33, 385-391.	2.8	143

#	ARTICLE	IF	CITATIONS
2425	Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development. Immunologic Research, 2011, 49, 248-268.	1.3	82
2426	Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Medical Oncology, 2011, 28, 1048-1053.	1.2	16
2427	A new era in the treatment of melanoma: from biology to clinical practice. Clinical and Translational Oncology, 2011, 13, 787-792.	1.2	9
2428	Biphasic Low-Grade Nasopharyngeal Papillary Adenocarcinoma with a Prominent Spindle Cell Component: Report of a Case Localized to the Posterior Nasal Septum. Head and Neck Pathology, 2011, 5, 306-313.	1.3	26
2429	Targeting angiogenesis for the treatment of advanced melanoma. Oncology Reviews, 2011, 5, 167-176.	0.8	2
2430	Implication of RAF and RKIP Genes in Urinary Bladder Cancer. Pathology and Oncology Research, 2011, 17, 181-190.	0.9	31
2431	Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors. Pathology and Oncology Research, 2011, 17, 551-559.	0.9	49
2432	B-Raf Mutations, Microsatellite Instability and p53 Protein Expression in Sporadic Basal Cell Carcinomas. Pathology and Oncology Research, 2011, 17, 633-637.	0.9	5
2433	High Frequency of Genesâ€™ Promoter Methylation, but Lack of BRAF V600E Mutation among Iranian Colorectal Cancer Patients. Pathology and Oncology Research, 2011, 17, 819-825.	0.9	36
2434	Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Targeted Oncology, 2011, 6, 103-117.	1.7	37
2435	An Update on the Biology of RAS/RAF Mutations in Colorectal Cancer. Current Colorectal Cancer Reports, 2011, 7, 113-120.	1.0	33
2436	Future Solutions for Patients with Metastatic Colorectal Cancer Positive for K-RAS Mutations. Current Colorectal Cancer Reports, 2011, 7, 275-280.	1.0	0
2437	Predictive and Prognostic Markers in Colorectal Cancer. Current Oncology Reports, 2011, 13, 206-215.	1.8	48
2438	The â€™SWOTâ€™ of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?. Current Oncology Reports, 2011, 13, 479-487.	1.8	33
2439	Malignant melanoma arising from a perianal fistula and harbouring a BRAF gene mutation: a case report. BMC Cancer, 2011, 11, 343.	1.1	9
2440	A switch in RND3-RHOA signaling is critical for melanoma cell invasion following mutant-BRAF inhibition. Molecular Cancer, 2011, 10, 114.	7.9	24
2441	BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Molecular Cancer, 2011, 10, 118.	7.9	116
2442	Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. Journal of Translational Medicine, 2011, 9, 76.	1.8	82

#	ARTICLE	IF	CITATIONS
2443	Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations. <i>Molecular Cytogenetics</i> , 2011, 4, 26.	0.4	18
2444	Regulation of tissue- and stimulus-specific cell fate decisions by p53 in vivo. <i>Journal of Pathology</i> , 2011, 223, 127-137.	2.1	49
2445	Genetically informed lung cancer medicine. <i>Journal of Pathology</i> , 2011, 223, 231-241.	2.1	59
2446	KRAS and BRAF: drug targets and predictive biomarkers. <i>Journal of Pathology</i> , 2011, 223, 220-230.	2.1	133
2447	A new era: melanoma genetics and therapeutics. <i>Journal of Pathology</i> , 2011, 223, 242-251.	2.1	107
2448	Cancer biology and genomics: translating discoveries, transforming pathology. <i>Journal of Pathology</i> , 2011, 223, 99-101.	2.1	6
2449	Cutaneous melanoma: A model to study cancer metastasis. <i>Journal of Surgical Oncology</i> , 2011, 103, 538-549.	0.8	38
2450	Neoadjuvant therapy for high-risk bulky regional melanoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 386-390.	0.8	22
2451	Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 420-424.	0.8	47
2452	Epigallocatechin gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex. <i>Journal of Surgical Oncology</i> , 2011, 104, 776-780.	0.8	59
2453	Systemic treatment of metastatic melanoma: New approaches. <i>Journal of Surgical Oncology</i> , 2011, 104, 425-429.	0.8	11
2454	Small-Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics. <i>ChemMedChem</i> , 2011, 6, 38-48.	1.6	67
2455	A valuable adjunct to FNA diagnosis of papillary thyroid carcinoma: In-house PCR assay for BRAF T1799A (V600E). <i>Diagnostic Cytopathology</i> , 2011, 39, 424-427.	0.5	6
2456	Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF ^{V600E} mutation. <i>International Journal of Cancer</i> , 2011, 128, 2075-2084.	2.3	200
2457	Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. <i>International Journal of Cancer</i> , 2011, 129, 2297-2303.	2.3	75
2458	Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgf ^{R24C} C57BL/6 mice. <i>International Journal of Cancer</i> , 2011, 129, 285-294.	2.3	32
2459	Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 745-749.	1.2	32
2460	Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1915-1923.	1.4	26

#	ARTICLE	IF	CITATIONS
2461	Non-oxime pyrazole based inhibitors of B-Raf kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3488-3492.	1.0	36
2462	The Discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1248-1252.	1.0	21
2463	Non-oxime inhibitors of B-RafV600E kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1243-1247.	1.0	28
2464	Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1795-1801.	1.0	70
2465	Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1315-1319.	1.0	108
2466	Design and synthesis of 5,6-fused heterocyclic amides as Raf kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3286-3289.	1.0	19
2467	Molecular pathology of thyroid cancer. <i>Diagnostic Histopathology</i> , 2011, 17, 124-139.	0.2	11
2468	Protein signatures for survival and recurrence in metastatic melanoma. <i>Journal of Proteomics</i> , 2011, 74, 1002-1014.	1.2	104
2469	Alteration of skin light-scattering and absorption properties by application of sunscreen nanoparticles: A Monte Carlo study. <i>Journal of Quantitative Spectroscopy and Radiative Transfer</i> , 2011, 112, 1891-1897.	1.1	11
2470	Targeting BRAFV600E with PLX4720 Displays Potent Antimigratory and Anti-invasive Activity in Preclinical Models of Human Thyroid Cancer. <i>Oncologist</i> , 2011, 16, 296-309.	1.9	86
2471	The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment. <i>Pathobiology</i> , 2011, 78, 99-114.	1.9	101
2472	Complexity in KSR function revealed by Raf inhibitor and KSR structure studies. <i>Small GTPases</i> , 2011, 2, 276-281.	0.7	23
2473	Combinatorial Treatments That Overcome PDGFR ² -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition. <i>Cancer Research</i> , 2011, 71, 5067-5074.	0.4	206
2474	PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression. <i>Cancer Research</i> , 2011, 71, 2750-2760.	0.4	488
2475	Mechanisms of Resistance to RAF Inhibitors in Melanoma. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1817-1820.	0.3	70
2476	Therapeutic options in cutaneous melanoma: latest developments. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 245-251.	1.4	8
2477	Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations. <i>Current Medicinal Chemistry</i> , 2011, 18, 1613-1628.	1.2	32
2478	Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma. <i>Current Molecular Medicine</i> , 2011, 11, 553-563.	0.6	37

#	ARTICLE	IF	CITATIONS
2479	Improved outcomes for patients with metastatic melanoma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 513-515.	12.5	20
2480	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. <i>Cancer Biology and Therapy</i> , 2011, 11, 777-792.	1.5	209
2481	Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma. <i>Modern Pathology</i> , 2011, 24, 739-749.	2.9	103
2482	Epidermal Growth Factor Receptor Pathway Mutations and Colorectal Cancer Therapy. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 1278-1282.	1.2	22
2483	Mitochondrial Localization and Regulation of BRAFV600E in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAFV600E. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E19-E30.	1.8	51
2484	Signaling from the Human Melanocortin 1 Receptor to ERK1 and ERK2 Mitogen-Activated Protein Kinases Involves Transactivation of cKIT. <i>Molecular Endocrinology</i> , 2011, 25, 138-156.	3.7	91
2485	Upregulation of Endocrine Gland-Derived Vascular Endothelial Growth Factor in Papillary Thyroid Cancers Displaying Infiltrative Patterns, Lymph Node Metastases, and BRAF Mutation. <i>Thyroid</i> , 2011, 21, 391-399.	2.4	34
2486	Receptor for Activated Protein C Kinase 1 (RACK1) Is Overexpressed in Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2011, 21, 1217-1225.	2.4	14
2487	Reflex BRAF Testing in Thyroid Fine-Needle Aspiration Biopsy with Equivocal and Positive Interpretation: A Prospective Study. <i>Thyroid</i> , 2011, 21, 717-723.	2.4	62
2488	Novel mitogen-activated protein kinase kinase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 209-220.	1.9	34
2489	Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1565-1574.	1.9	32
2490	Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1239-1246.	0.8	942
2491	RAS Interaction with PI3K: More Than Just Another Effector Pathway. <i>Genes and Cancer</i> , 2011, 2, 261-274.	0.6	580
2492	Raf Inhibition Causes Extensive Multiple Tissue Hyperplasia and Urinary Bladder Neoplasia in the Rat. <i>Toxicologic Pathology</i> , 2011, 39, 809-822.	0.9	22
2493	Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 229-235.	3.2	237
2494	The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. <i>Journal of Endocrinology</i> , 2011, 211, 79-85.	1.2	24
2495	BRAF Inhibitors and Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 505-511.	1.0	28
2496	Optic Pathway Gliomas. <i>Journal of Neuro-Ophthalmology</i> , 2011, 31, 269-278.	0.4	137

#	ARTICLE	IF	CITATIONS
2497	Targeted Therapies for Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 512-527.	1.0	91
2498	Oncogenic B-RAF Signaling in Melanoma Impairs the Therapeutic Advantage of Autophagy Inhibition. <i>Clinical Cancer Research</i> , 2011, 17, 2216-2226.	3.2	61
2499	Is It Good or Bad to Find a <i>BRAF</i> Mutation?. <i>Journal of Clinical Oncology</i> , 2011, 29, 1229-1230.	0.8	10
2500	Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Harboring <i>BRAF</i> Mutations. <i>Journal of Clinical Oncology</i> , 2011, 29, 3574-3579.	0.8	500
2501	Role of BRAF in Thyroid Oncogenesis. <i>Clinical Cancer Research</i> , 2011, 17, 7511-7517.	3.2	101
2502	Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 337, 644-654.	1.3	71
2503	Regulators of G-Protein Signaling and Their Substrates: Promises and Challenges in Their Use as Drug Discovery Targets. <i>Pharmacological Reviews</i> , 2011, 63, 728-749.	7.1	205
2504	Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling. <i>Cancer Research</i> , 2011, 71, 4280-4291.	0.4	23
2505	KIT as a Therapeutic Target in Metastatic Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2327.	3.8	755
2506	Induction of Monocyte Chemoattractant Protein-1 and Interleukin-10 by TGF- β 1 in Melanoma Enhances Tumor Infiltration and Immunosuppression. <i>Cancer Research</i> , 2011, 71, 812-821.	0.4	65
2507	Targeted Therapy for <i>BRAFV600E</i> Malignant Astrocytoma. <i>Clinical Cancer Research</i> , 2011, 17, 7595-7604.	3.2	143
2508	Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease. <i>Clinical Cancer Research</i> , 2011, 17, 1658-1663.	3.2	65
2509	FOXD3 Regulates Migration Properties and Rnd3 Expression in Melanoma Cells. <i>Molecular Cancer Research</i> , 2011, 9, 545-552.	1.5	37
2510	Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies. <i>Clinical Cancer Research</i> , 2011, 17, 7080-7092.	3.2	58
2511	Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. <i>Genes and Development</i> , 2011, 25, 2147-2157.	2.7	138
2512	A new frontier in personalized cancer therapy: mapping molecular changes. <i>Future Oncology</i> , 2011, 7, 873-894.	1.1	12
2513	Making sense of cancer genomic data. <i>Genes and Development</i> , 2011, 25, 534-555.	2.7	313
2514	Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. <i>European Journal of Endocrinology</i> , 2011, 165, 315-322.	1.9	184

#	ARTICLE	IF	CITATIONS
2515	Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management. <i>Biomarkers in Medicine</i> , 2011, 5, 333-360.	0.6	6
2517	Towards new therapeutic approaches for malignant melanoma. <i>Expert Reviews in Molecular Medicine</i> , 2011, 13, e33.	1.6	38
2518	Positive Feedback Loop Between PI3K-Akt-mTORC1 Signaling and the Lipogenic Pathway Boosts Akt Signaling: Induction of the Lipogenic Pathway by a Melanoma Antigen. <i>Cancer Research</i> , 2011, 71, 4989-4997.	0.4	85
2519	Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 1615-1620.	3.3	183
2520	Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options. <i>Cancer Research</i> , 2011, 71, 7137-7140.	0.4	148
2521	<i>BRAF</i> analysis by fine needle aspiration biopsy of thyroid nodules improves preoperative identification of papillary thyroid carcinoma and represents a prognostic factor. A mono-institutional experience. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 325-329.	1.4	48
2522	BRAFV600E: Implications for Carcinogenesis and Molecular Therapy. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 385-394.	1.9	373
2523	Review of Histopathological and Molecular Prognostic Features in Colorectal Cancer. <i>Cancers</i> , 2011, 3, 2767-2810.	1.7	84
2524	Molecular Nevogenesis. <i>Dermatology Research and Practice</i> , 2011, 2011, 1-9.	0.3	73
2525	Thyroid Function and Growth Regulation under Normal and Abnormal Conditions. <i>Journal of Thyroid Research</i> , 2011, 2011, 1-2.	0.5	2
2526	Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma. <i>Open Access Journal of Urology</i> , 2011, 3, 69.	0.3	4
2527	BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-8.	0.5	46
2528	Prognostic Parameters for the Primary Care of Melanoma Patients: What Is Really Risky in Melanoma?. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-13.	0.5	6
2529	The Role of Epigenetic Alterations in Papillary Thyroid Carcinogenesis. <i>Journal of Thyroid Research</i> , 2011, 2011, 1-7.	0.5	15
2530	Bioinformatic Prediction of Ultraviolet Light Mutagenesis Sensitivity of Human Genes and a Method for Genetically Engineering UVB Resistance. <i>Cancer Informatics</i> , 2011, 10, CIN.S6670.	0.9	0
2531	Targeted Treatment of Differentiated and Medullary Thyroid Cancer. <i>Journal of Thyroid Research</i> , 2011, 2011, 1-11.	0.5	6
2532	Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers. <i>Journal of Clinical Oncology</i> , 2011, 29, 2357-2363.	0.8	272
2533	Pazopanib Reveals a Role for Tumor Cell B-Raf in the Prevention of HER2+ Breast Cancer Brain Metastasis. <i>Clinical Cancer Research</i> , 2011, 17, 142-153.	3.2	76

#	ARTICLE	IF	CITATIONS
2534	MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720. <i>Clinical Cancer Research</i> , 2011, 17, 721-730.	3.2	103
2535	Enhancement of 5-Fluorouracil-induced <i>In Vitro</i> and <i>In Vivo</i> Radiosensitization with MEK Inhibition. <i>Clinical Cancer Research</i> , 2011, 17, 5038-5047.	3.2	40
2536	B-Raf Associates with and Activates the NHE1 Isoform of the Na ⁺ /H ⁺ Exchanger. <i>Journal of Biological Chemistry</i> , 2011, 286, 13096-13105.	1.6	33
2537	Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Oncology</i> , 2011, 39, 23-31.	1.4	127
2538	BRAFV600E and Microenvironment in Thyroid Cancer: A Functional Link to Drive Cancer Progression. <i>Cancer Research</i> , 2011, 71, 2417-2422.	0.4	81
2539	Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 2087-2100.	3.2	103
2540	Amplification of the Driving Oncogene, <i>KRAS</i> or <i>BRAF</i> , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells. <i>Science Signaling</i> , 2011, 4, ra17.	1.6	186
2541	BRAFV600E mutation, TIMP-1 upregulation, and NF- κ B activation: closing the loop on the papillary thyroid cancer trilogy. <i>Endocrine-Related Cancer</i> , 2011, 18, 669-685.	1.6	60
2542	Opportunities and Challenges in the Development of Experimental Drug Combinations for Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1222-1226.	3.0	100
2543	Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials. <i>Oncology</i> , 2011, 81, 135-140.	0.9	6
2544	Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma. <i>Oncology</i> , 2011, 81, 403-409.	0.9	3
2545	Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. <i>Cell Cycle</i> , 2011, 10, 977-988.	1.3	60
2546	An <i>in vitro</i> chemoresponse assay defines a subset of colorectal and lung carcinomas responsive to cetuximab. <i>Cancer Biology and Therapy</i> , 2011, 11, 196-203.	1.5	4
2547	Gene expression inhibition of N-Myc downregulated gene 1 (NDRG1) monitoring and facilitation via transfectional transfer of NDRG1-siRNA constructs into <i>in vitro</i> -cultured human glioblastoma cells. , 2011, , .		0
2548	Activation and Involvement of Ral GTPases in Colorectal Cancer. <i>Cancer Research</i> , 2011, 71, 206-215.	0.4	74
2549	Raf Family Kinases: Old Dogs Have Learned New Tricks. <i>Genes and Cancer</i> , 2011, 2, 232-260.	0.6	322
2550	The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery. <i>Genes and Cancer</i> , 2011, 2, 275-287.	0.6	98
2551	Germline Fitness-Based Scoring of Cancer Mutations. <i>Genetics</i> , 2011, 188, 383-393.	1.2	15

#	ARTICLE	IF	CITATIONS
2552	Hyperspectral imaging: A non-invasive method of imaging melanoma lesions in a patient with stage IV melanoma, being treated with a RAF inhibitor. <i>Cancer Biology and Therapy</i> , 2011, 12, 326-334.	1.5	5
2553	Targeting the DFG-in kinase conformation: a new trend emerging from a patent analysis. <i>Future Medicinal Chemistry</i> , 2011, 3, 309-337.	1.1	17
2554	Single Substitution within the RKTR Motif Impairs Kinase Activity but Promotes Dimerization of RAF Kinase. <i>Journal of Biological Chemistry</i> , 2011, 286, 16491-16503.	1.6	30
2555	Genomics and Drug Response. <i>New England Journal of Medicine</i> , 2011, 364, 1144-1153.	13.9	552
2556	Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5015-5020.	3.3	61
2557	BAD Contributes to RAF-mediated Proliferation and Cooperates with B-RAF-V600E in Cancer Signaling. <i>Journal of Biological Chemistry</i> , 2011, 286, 17934-17944.	1.6	23
2558	Multiplex Ligation-Dependent Probe Amplification of Conjunctival Melanoma Reveals Common <i>BRAF</i> V600E Gene Mutation and Gene Copy Number Changes. , 2011, 52, 5598.		85
2559	New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances. <i>Clinical Cancer Research</i> , 2011, 17, 4922-4928.	3.2	34
2560	Aberrant Promoter Methylation in Overexpression of <i>CITED1</i> in Papillary Thyroid Cancer. <i>Thyroid</i> , 2011, 21, 511-517.	2.4	21
2561	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. <i>British Journal of Cancer</i> , 2011, 105, 353-359.	2.9	48
2562	Sequence analysis of 515 kinase genes in chronic lymphocytic leukemia. <i>Leukemia</i> , 2011, 25, 1908-1910.	3.3	28
2563	Fibroblast Growth Factor Receptors as Therapeutic Targets in Human Melanoma: Synergism with BRAF Inhibition. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2087-2095.	0.3	70
2564	Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. <i>British Journal of Cancer</i> , 2011, 105, 246-254.	2.9	23
2565	Identification of <i>BRAF</i> mutations in eruptive melanocytic nevi: new insights into melanomagenesis?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 711-714.	1.1	17
2566	GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition. <i>Clinical Cancer Research</i> , 2011, 17, 989-1000.	3.2	528
2567	Therapeutic Strategies for Targeting Ras Proteins. <i>Genes and Cancer</i> , 2011, 2, 359-372.	0.6	282
2568	EZH2-Dependent Suppression of a Cellular Senescence Phenotype in Melanoma Cells by Inhibition of <i>p21</i> / <i>CDKN1A</i> Expression. <i>Molecular Cancer Research</i> , 2011, 9, 418-429.	1.5	162
2569	<i>BRAF</i> Exon 15 T1799A Mutation Is Common in Melanocytic Nevi, but Less Prevalent in Cutaneous Malignant Melanoma, in Chinese Han. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1129-1138.	0.3	42

#	ARTICLE	IF	CITATIONS
2570	Melanoma Prevention Using Topical PBISe. <i>Cancer Prevention Research</i> , 2011, 4, 935-948.	0.7	27
2571	Occupational hazards: allosteric regulation of protein kinases through the nucleotide-binding pocket. <i>Biochemical Society Transactions</i> , 2011, 39, 472-476.	1.6	5
2572	Management of Melanoma Brain Metastases in the Era of Targeted Therapy. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-6.	0.5	12
2573	Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. <i>American Journal of Physiology - Cell Physiology</i> , 2011, 301, C609-C618.	2.1	62
2574	Forty Years of Translational Cancer Research. <i>Cancer Discovery</i> , 2011, 1, 383-390.	7.7	17
2575	Impact of KRAS and BRAF Gene Mutations on Targeted Therapies in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2728-2729.	0.8	7
2576	Recent Advances in Molecular Diagnosis of Thyroid Cancer. <i>Journal of Thyroid Research</i> , 2011, 2011, 1-8.	0.5	13
2577	<i>KRAS</i> and <i>BRAF</i> Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective. <i>Clinical Cancer Research</i> , 2011, 17, 6338-6346.	3.2	74
2578	Decoding Melanoma Metastasis. <i>Cancers</i> , 2011, 3, 126-163.	1.7	142
2579	The Farnesyl Transferase Inhibitor Lonafarnib Inhibits mTOR Signaling and Enforces Sorafenib-Induced Apoptosis in Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2011, 131, 468-479.	0.3	69
2580	Global Analysis of BRAFV600E Target Genes in Human Melanocytes Identifies Matrix Metalloproteinase-1 as a Critical Mediator of Melanoma Growth. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1579-1583.	0.3	13
2581	Upregulation of Fanconi Anemia DNA Repair Genes in Melanoma Compared with Non-Melanoma Skin Cancer. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2139-2142.	0.3	18
2582	What hope for the future? GNAQ and uveal melanoma. <i>British Journal of Ophthalmology</i> , 2011, 95, 620-623.	2.1	14
2583	Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. <i>Cancer Biomarkers</i> , 2011, 7, 153-161.	0.8	77
2584	Ras in Cancer and Developmental Diseases. <i>Genes and Cancer</i> , 2011, 2, 344-358.	0.6	714
2585	Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer. <i>European Journal of Endocrinology</i> , 2012, 167, 93-101.	1.9	28
2586	Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials. <i>Current Oncology</i> , 2012, 19, 73-85.	0.9	9
2587	Rapid Detection and Quantitation of <i>BRAF</i> Mutations in Hairy Cell Leukemia Using a Sensitive Pyrosequencing Assay. <i>American Journal of Clinical Pathology</i> , 2012, 138, 153-156.	0.4	37

#	ARTICLE	IF	CITATIONS
2588	Targeted Therapies and Predictive Markers in Epithelial Malignancies of the Gastrointestinal Tract. Archives of Pathology and Laboratory Medicine, 2012, 136, 496-503.	1.2	8
2589	A Micro-RNA Connection in $\langle \text{mml:math} \text{xmlns:mml="http://www.w3.org/1998/Math/MathML"} \rangle \langle \text{mml:msup} \rangle \langle \text{mml:mi} \rangle \text{BRaf} \langle \text{mml:mi} \rangle \langle \text{mml:mrow} \rangle \langle \text{mml:mi} \rangle \text{V600E} \langle \text{mml:mi} \rangle$ Premature Senescence of Human Melanocytes. International Journal of Cell Biology, 2012, 2012, 1-9.		
2590	Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition. Cancer Research, 2012, 72, 210-219.	0.4	228
2591	Molecular Dermatopathology in Malignant Melanoma. Dermatology Research and Practice, 2012, 2012, 1-6.	0.3	6
2592	BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance. Clinical Cancer Research, 2012, 18, 33-39.	3.2	120
2593	Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901. Molecular Cancer Therapeutics, 2012, 11, 2274-2283.	1.9	9
2594	Oncogenic MAP2K1 mutations in human epithelial tumors. Carcinogenesis, 2012, 33, 956-961.	1.3	38
2595	Clinicopathological and molecular study of penile melanoma. Journal of Clinical Pathology, 2012, 65, 228-231.	1.0	16
2597	The Role of Molecular Pathology in Non-Small-Cell Lung Carcinoma—Now and in the Future. Current Oncology, 2012, 19, 24-32.	0.9	25
2598	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO Journal, 2012, 31, 2629-2647.	3.5	110
2599	HRAS-mutated Spitz Nevus on the Cheek in a Middle-aged Man. Acta Dermato-Venereologica, 2012, 92, 326-327.	0.6	0
2600	Role and Regulation of STAT3 Phosphorylation at Ser727 in Melanocytes and Melanoma Cells. Journal of Investigative Dermatology, 2012, 132, 1877-1885.	0.3	88
2601	$\langle \text{i} \rangle \text{BRAF} \langle \text{i} \rangle \langle \text{sup} \rangle \text{V600E} \langle \text{sup} \rangle$ Mutation and Papillary Thyroid Cancer: Chicken or Egg?. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2295-2298.	1.8	24
2602	Molecular Pathways: Targeting Hsp90—Who Benefits and Who Does Not. Clinical Cancer Research, 2012, 18, 4508-4513.	3.2	56
2603	CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer. Chemotherapy Research and Practice, 2012, 2012, 1-10.	1.6	20
2604	Rethinking the Role of Oncogenes in Papillary Thyroid Cancer Initiation. Frontiers in Endocrinology, 2012, 3, 83.	1.5	8
2605	Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma. Journal of Biological Chemistry, 2012, 287, 28087-28098.	1.6	171
2606	BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment. Medicine (United States), 2012, 91, 274-286.	0.4	264

#	ARTICLE	IF	CITATIONS
2607	Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1758-E1765.	1.8	83
2608	Promises from Trametinib in RAF Active Tumors. <i>New England Journal of Medicine</i> , 2012, 367, 171-172.	13.9	7
2609	p53 Rescue through HDM2 Antagonism Suppresses Melanoma Growth and Potentiates MEK Inhibition. <i>Journal of Investigative Dermatology</i> , 2012, 132, 356-364.	0.3	66
2610	BRAF ^{V600E} remodels the melanocyte transcriptome and induces <i>BANCR</i> to regulate melanoma cell migration. <i>Genome Research</i> , 2012, 22, 1006-1014.	2.4	254
2611	A Phosphatidylinositol 3-Kinase/Pax3 Axis Regulates Brn-2 Expression in Melanoma. <i>Molecular and Cellular Biology</i> , 2012, 32, 4674-4683.	1.1	39
2612	The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 149-154.	3.3	136
2613	Targeted Therapy for Brain Metastases. <i>Advances in Pharmacology</i> , 2012, 65, 109-142.	1.2	11
2614	NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i> . <i>Cancer Research</i> , 2012, 72, 4587-4596.	0.4	26
2615	Investigation of the <i>BRAF</i> V600E Mutation by Pyrosequencing in Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2012, 138, 877-883.	0.4	29
2616	B-Raf Activation Cooperates with PTEN Loss to Drive c-Myc Expression in Advanced Prostate Cancer. <i>Cancer Research</i> , 2012, 72, 4765-4776.	0.4	87
2617	Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007 – present). <i>Expert Opinion on Therapeutic Patents</i> , 2012, 22, 1263-1287.	2.4	15
2618	Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution. <i>Clinical Cancer Research</i> , 2012, 18, 350-359.	3.2	58
2619	Superficial spreading and nodular melanoma are distinct biological entities. <i>Melanoma Research</i> , 2012, 22, 1-8.	0.6	73
2620	A brief history of melanoma. <i>Melanoma Research</i> , 2012, 22, 114-122.	0.6	111
2621	Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma. <i>Diagnostic Molecular Pathology</i> , 2012, 21, 1-8.	2.1	145
2622	Targeting Mutant BRAF in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 124-131.	1.0	70
2623	Targeting NRAS in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 132-136.	1.0	61
2624	Molecular Testing in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 117-123.	1.0	22

#	ARTICLE	IF	CITATIONS
2625	Multiplex Ligation-dependent Probe Amplification (MLPA) in Tumor Diagnostics and Prognostics. <i>Diagnostic Molecular Pathology</i> , 2012, 21, 189-206.	2.1	124
2626	Update in Molecular Diagnostics in Melanocytic Neoplasms. <i>Advances in Anatomic Pathology</i> , 2012, 19, 410-416.	2.4	17
2627	Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. <i>Annals of Oncology</i> , 2012, 23, 524-530.	0.6	109
2628	Therapeutic Implications of KIT in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 137-141.	1.0	51
2629	<i>BRAF</i> Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1792-1798.	1.1	113
2630	Intra- and Inter-Tumor Heterogeneity of BRAFV600E Mutations in Primary and Metastatic Melanoma. <i>PLoS ONE</i> , 2012, 7, e29336.	1.1	250
2631	Selenium-containing histone deacetylase inhibitors for melanoma management. <i>Cancer Biology and Therapy</i> , 2012, 13, 756-765.	1.5	51
2632	New therapies in the treatment of melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1643-1659.	1.9	9
2633	Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid Cancer. <i>Endocrinology</i> , 2012, 153, 985-994.	1.4	57
2634	CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and <i>In Vivo</i> Antitumor Activity. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 930-941.	1.9	42
2635	Functional Effects of GRM1 Suppression in Human Melanoma Cells. <i>Molecular Cancer Research</i> , 2012, 10, 1440-1450.	1.5	36
2636	Specific delivery of kinase inhibitors in nonmalignant and malignant diseases. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 59-70.	2.4	5
2637	BAG3 Down-Modulation Reduces Anaplastic Thyroid Tumor Growth by Enhancing Proteasome-Mediated Degradation of BRAF Protein. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E115-E120.	1.8	28
2638	Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?. <i>Genes and Cancer</i> , 2012, 3, 467-480.	0.6	116
2639	The genesis of Zelboraf: Targeting mutant B-Raf in melanoma. <i>Journal of Cell Biology</i> , 2012, 199, 15-19.	2.3	7
2640	Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4794-4805.	3.2	65
2641	Therapeutic Kinase Inhibitors. <i>Current Topics in Microbiology and Immunology</i> , 2012, , .	0.7	1
2642	The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 61-73.	1.4	26

#	ARTICLE	IF	CITATIONS
2643	Signal Transduction Pathways of the Epidermal Growth Factor Receptor in Colorectal Cancer and their Inhibition by Small Molecules. <i>Current Medicinal Chemistry</i> , 2012, 19, 5735-5744.	1.2	49
2644	Signal control through Raf: in sickness and in health. <i>Cell Research</i> , 2012, 22, 14-22.	5.7	45
2645	Synthesis of Biologically Active Bridged Diazabicycloheptanes. <i>Current Medicinal Chemistry</i> , 2012, 19, 5342-5363.	1.2	12
2646	Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 531-539.	1.9	22
2647	<i>BRAF</i> Mutation Analysis and Sonography as Adjuncts to Fine-Needle Aspiration Cytology of Papillary Thyroid Carcinoma: Their Relationships and Roles. <i>American Journal of Roentgenology</i> , 2012, 198, 668-674.	1.0	24
2648	Personalized medicine in colorectal cancer: the evidence so far. <i>Clinical Investigation</i> , 2012, 2, 1013-1021.	0.0	0
2649	<i>K-Ras</i> gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy. <i>Cancer Biology and Therapy</i> , 2012, 13, 1235-1243.	1.5	10
2650	Resistance to Selective BRAF Inhibition Can Be Mediated by Modest Upstream Pathway Activation. <i>Cancer Research</i> , 2012, 72, 969-978.	0.4	159
2651	Relationship between 18F-Fluorodeoxyglucose Accumulation and <i>KRAS</i> / <i>BRAF</i> Mutations in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1696-1703.	3.2	91
2652	Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?. <i>CNS Oncology</i> , 2012, 1, 137-148.	1.2	6
2653	Panitumumab: a summary of clinical development in colorectal cancer and future directions. <i>Future Oncology</i> , 2012, 8, 373-389.	1.1	16
2654	Intratumoral Heterogeneity as a Therapy Resistance Mechanism. <i>Advances in Pharmacology</i> , 2012, 65, 335-359.	1.2	76
2655	Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis. <i>Cancer Biology and Therapy</i> , 2012, 13, 92-100.	1.5	41
2656	Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1850-1859.	0.3	76
2658	Targeted treatment for melanoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1113-1115.	1.1	1
2659	Novel roles of PAK1 in the heart. <i>Cellular Logistics</i> , 2012, 2, 89-94.	0.9	17
2660	NHE-1: A Promising Target for Novel Anti-cancer Therapeutics. <i>Current Pharmaceutical Design</i> , 2012, 18, 1372-1382.	0.9	68
2661	The BRAF V600E Mutation in Papillary Thyroid Carcinoma Is Associated with Glucose Transporter 1 Overexpression. <i>Thyroid</i> , 2012, 22, 377-382.	2.4	21

#	ARTICLE	IF	CITATIONS
2662	First-in-Human, Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of RO5126766, a First-in-Class Dual MEK/RAF Inhibitor in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 4806-4819.	3.2	136
2663	Gene of the month: BRAF. <i>Journal of Clinical Pathology</i> , 2012, 65, 986-988.	1.0	12
2664	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative. <i>Clinical Cancer Research</i> , 2012, 18, 6373-6383.	3.2	458
2665	The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 2316-2325.	3.2	382
2666	Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. <i>Oncolmmunology</i> , 2012, 1, 609-617.	2.1	67
2668	Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. <i>British Journal of Cancer</i> , 2012, 106, 939-946.	2.9	91
2669	The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. <i>British Journal of Cancer</i> , 2012, 106, 1386-1394.	2.9	67
2670	The PKC δ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. <i>Oncogene</i> , 2012, 31, 4889-4897.	2.6	60
2671	PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. <i>Oncogene</i> , 2012, 31, 3397-3408.	2.6	133
2672	NF- κ B inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β -catenin pathway. <i>Oncogene</i> , 2012, 31, 2580-2592.	2.6	40
2673	Desmoplastic Malignant Melanoma: A Study of Ten Cases and Status of BRAF Mutation. <i>Dermatology</i> , 2012, 225, 168-171.	0.9	12
2674	BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. <i>Cell Death and Disease</i> , 2012, 3, e259-e259.	2.7	74
2675	Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 29887-29898.	1.6	70
2676	Ring Finger Protein 149 Is an E3 Ubiquitin Ligase Active on Wild-type v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF). <i>Journal of Biological Chemistry</i> , 2012, 287, 24017-24025.	1.6	37
2677	Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2012, 18, 2443-2451.	3.2	274
2678	EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. <i>Cancer Discovery</i> , 2012, 2, 227-235.	7.7	852
2679	BRAF Inhibition in Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 2038-2040.	13.9	240
2680	Investigative pathology: leading the post-genomic revolution. <i>Laboratory Investigation</i> , 2012, 92, 4-8.	1.7	23

#	ARTICLE	IF	CITATIONS
2681	Matrix Metalloprotease-1a Promotes Tumorigenesis and Metastasis. <i>Journal of Biological Chemistry</i> , 2012, 287, 24330-24338.	1.6	48
2682	Bridging the Gap between Preclinical and Clinical Studies Using Pharmacokineticâ€“Pharmacodynamic Modeling: An Analysis of GDC-0973, a MEK Inhibitor. <i>Clinical Cancer Research</i> , 2012, 18, 3090-3099.	3.2	74
2683	<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2522-2529.	0.8	419
2684	Distinguishing Clinicopathologic Features of Patients with V600E and V600K <i>BRAF</i> -Mutant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 3242-3249.	3.2	405
2685	BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 34-41.	0.8	172
2686	Fragment Based Drug Design: From Experimental to Computational Approaches. <i>Current Medicinal Chemistry</i> , 2012, 19, 5128-5147.	1.2	130
2687	Pre-Invasive Ovarian Mucinous Tumors Are Characterized by <i>CDKN2A</i> and <i>RAS</i> Pathway Aberrations. <i>Clinical Cancer Research</i> , 2012, 18, 5267-5277.	3.2	57
2688	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E353-9.	3.3	51
2689	Molecular targets in melanoma: time for â€œethnic personalizationâ€™. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 601-608.	1.1	8
2690	<i>BRAF</i> (V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency. <i>Clinical Cancer Research</i> , 2012, 18, 2326-2335.	3.2	109
2691	Lynch or Not Lynch? Is that Always a Question?. <i>Advances in Cancer Research</i> , 2012, 113, 121-166.	1.9	31
2692	Marked, Homogeneous, and Early [¹⁸ F]Fluorodeoxyglucoseâ€“Positron Emission Tomography Responses to Vemurafenib in <i>BRAF</i> -Mutant Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1628-1634.	0.8	172
2693	Regulated temporal-spatial astrocyte precursor cell proliferation involves BRAF signalling in mammalian spinal cord. <i>Development (Cambridge)</i> , 2012, 139, 2477-2487.	1.2	112
2694	<i>KRAS</i> G12D- and <i>BRAF</i> V600E-Induced Transformation of Murine Pancreatic Epithelial Cells Requires MEK/ERK-Stimulated IGF1R Signaling. <i>Molecular Cancer Research</i> , 2012, 10, 1228-1239.	1.5	21
2695	The Prognostic Value of BRAF Mutation in Colorectal Cancer and Melanoma: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e47054.	1.1	184
2696	Cutaneous Toxic Effects Associated With Vemurafenib and Inhibition of the BRAF Pathway. <i>Archives of Dermatology</i> , 2012, 148, 628-33.	1.7	89
2697	Photodynamic Therapy for Multiple Eruptive Keratoacanthomas Associated With Vemurafenib Treatment for Metastatic Melanoma. <i>Archives of Dermatology</i> , 2012, 148, 363.	1.7	48
2698	MEK genomics in development and disease. <i>Briefings in Functional Genomics</i> , 2012, 11, 300-310.	1.3	62

#	ARTICLE	IF	CITATIONS
2699	Wnt/ β -Catenin and MAPK Signaling: Allies and Enemies in Different Battlefields. <i>Science Signaling</i> , 2012, 5, pe15.	1.6	58
2700	Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors. <i>Journal of Clinical Oncology</i> , 2012, 30, 765-766.	0.8	35
2701	Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S5855.	0.6	47
2702	Cell Proliferation in Cutaneous Malignant Melanoma: Relationship with Neoplastic Progression. <i>ISRN Dermatology</i> , 2012, 2012, 1-12.	1.9	20
2703	Lessons from Cancer Immunoediting in Cutaneous Melanoma. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-14.	3.3	18
2704	Dorsal Midbrain Syndrome from a Ring-Enhancing Lesion. <i>Seminars in Ophthalmology</i> , 2012, 27, 65-68.	0.8	2
2705	The MAPK MEK1/2-ERK1/2 Pathway and Its Implication in Hepatocyte Cell Cycle Control. <i>International Journal of Hepatology</i> , 2012, 2012, 1-13.	0.4	43
2706	RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-5.	0.3	113
2707	Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer. <i>Lung Cancer International</i> , 2012, 2012, 1-12.	1.2	17
2708	The Role of Semaphorins and Their Receptors in Gliomas. <i>Journal of Signal Transduction</i> , 2012, 2012, 1-14.	2.0	20
2709	Genetic and Biochemical Alterations in Non-Small Cell Lung Cancer. <i>Biochemistry Research International</i> , 2012, 2012, 1-18.	1.5	42
2710	Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438). <i>Clinical Cancer Research</i> , 2012, 18, 1129-1137.	3.2	86
2711	<i>BRAF</i> L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 791-797.	7.7	194
2712	Abrogation of BRAF ^{V600E} -induced senescence by PI3K pathway activation contributes to melanomagenesis. <i>Genes and Development</i> , 2012, 26, 1055-1069.	2.7	229
2713	Pharmacogenomics-based RNA interference nanodelivery: focus on solid malignant tumors. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 755-766.	2.4	2
2714	BREAKing a path for progress—dabrafenib confirms class effect. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 496-497.	12.5	7
2715	Wnt/ β -Catenin Signaling and AXIN1 Regulate Apoptosis Triggered by Inhibition of the Mutant Kinase BRAF ^{V600E} in Human Melanoma. <i>Science Signaling</i> , 2012, 5, ra3.	1.6	150
2716	The intermediate-activity ^{L597V} BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. <i>Genes and Development</i> , 2012, 26, 1945-1958.	2.7	54

#	ARTICLE	IF	CITATIONS
2717	An analysis of substitution, deletion and insertion mutations in cancer genes. <i>Nucleic Acids Research</i> , 2012, 40, 6401-6413.	6.5	47
2718	Molecular targeted therapy in acute myeloid leukemia. <i>Hematology</i> , 2012, 17, s59-s62.	0.7	26
2719	Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. <i>Case Reports in Oncology</i> , 2012, 5, 280-289.	0.3	8
2720	Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by <i>NRAS</i> or <i>MEK</i> Mutations. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 909-920.	1.9	312
2721	Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 342, 33-40.	1.3	151
2722	Gene expression-based diagnostics for molecular cancer classification of difficult to diagnose tumors. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 407-419.	1.6	6
2723	Novel mutations of the HRAS gene and absence of hotspot mutations of the BRAF genes in oral squamous cell carcinoma in a Greek population. <i>Oncology Reports</i> , 2012, 27, 1555-60.	1.2	13
2724	Frequencies and Prognostic Role of KRAS and BRAF Mutations in Patients With Localized Pancreatic and Ampullary Adenocarcinomas. <i>Pancreas</i> , 2012, 41, 759-766.	0.5	60
2725	Board of Education Trainee Poster Prize. <i>Pathology</i> , 2012, 44, S58-S63.	0.3	0
2726	Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. <i>International Journal of Oncology</i> , 2012, 40, 1900-6.	1.4	1
2727	Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. <i>Pathology</i> , 2012, 44, 357-359.	0.3	50
2728	Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases. <i>Pathology</i> , 2012, 44, 661-664.	0.3	3
2729	Systemic Therapy for Metastatic Melanoma in 2012: Dawn of a New Era. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 403-412.	2.3	22
2730	Squamoproliferative Lesions Arising in the Setting of BRAF Inhibition. <i>American Journal of Dermatopathology</i> , 2012, 34, 822-826.	0.3	44
2731	Recent Developments in Targeted Therapies of the RAF-MEK and PI3KAKT Pathways in Cancer Treatment. <i>Current Cancer Therapy Reviews</i> , 2012, 8, 205-217.	0.2	0
2732	Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution. <i>Current Molecular Medicine</i> , 2012, 12, 1108-1124.	0.6	62
2733	Sarcomatoid transformation of a pleomorphic xanthoastrocytoma. <i>Pathology</i> , 2012, 44, S59.	0.3	0
2734	The prognostic significance of the V600E B-Raf mutation in papillary thyroid carcinoma: data from an Australian population. <i>Pathology</i> , 2012, 44, S58-S59.	0.3	0

#	ARTICLE	IF	CITATIONS
2735	Cellular blue naevus involving the urinary bladder. <i>Pathology</i> , 2012, 44, 664-668.	0.3	5
2736	Reduction of False-Negative Papillary Thyroid Carcinomas by the Routine Analysis of BRAFT1799A Mutation on Fine-Needle Aspiration Biopsy Specimens. <i>Annals of Surgery</i> , 2012, 255, 986-992.	2.1	39
2737	Development of Pediatric Glioma Models for BRAF-targeted Therapy. <i>Neurosurgery</i> , 2012, 71, E575.	0.6	4
2738	Challenges in the codevelopment of companion diagnostics. <i>Personalized Medicine</i> , 2012, 9, 485-496.	0.8	13
2739	Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 844-850.	2.1	177
2740	A Molecular Signature for Oncogenic BRAF in Human Colon Cancer Cells is Revealed by Microarray Analysis. <i>Current Cancer Drug Targets</i> , 2012, 12, 873-898.	0.8	19
2741	Considerations on the Performance of Immunohistochemistry for Mismatch Repair Gene Proteins in Cases of Sebaceous Neoplasms and Keratoacanthomas With Reference to Muir-Torre Syndrome. <i>American Journal of Dermatopathology</i> , 2012, 34, 416-422.	0.3	18
2742	Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17. <i>Anti-Cancer Drugs</i> , 2012, 23, 119-130.	0.7	3
2743	BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis. <i>Diseases of the Colon and Rectum</i> , 2012, 55, 128-133.	0.7	124
2744	A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). <i>Anti-Cancer Drugs</i> , 2012, 23, 761-764.	0.7	9
2745	Targeted Therapies in Melanoma: Knowledge, Resistance and Perspectives. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2012, S4, .	0.3	0
2747	Panniculitis With Arthralgia in Patients With Melanoma Treated With Selective BRAF Inhibitors and Its Management. <i>Archives of Dermatology</i> , 2012, 148, 357.	1.7	96
2748	Long-term Survival in Metastatic Malignant Melanoma: Ipilimumab Followed by Vemurafenib in a Patient with Brain Metastasis. <i>Internal Medicine</i> , 2012, 51, 2819-2823.	0.3	13
2749	The Involvement of Mitogen-Activated Protein Kinases in the 1^{α} ,25-Dihydroxy-Cholecalciferol-Induced Inhibition of Adipocyte Differentiation In Vitro. <i>Journal of Nutritional Science and Vitaminology</i> , 2012, 58, 1-8.	0.2	17
2750	Lichenoid drug reaction to vemurafenib. <i>Pathology</i> , 2012, 44, S59.	0.3	1
2751	Angioleiomyoma of soft tissue: clinicopathology, immunohistochemistry, and MRI findings. <i>Pathology</i> , 2012, 44, S59-S60.	0.3	0
2752	BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (Review). <i>Molecular Medicine Reports</i> , 2012, 6, 687-694.	1.1	25
2753	A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma. <i>Clinical Investigation</i> , 2012, 2, 883-893.	0.0	1

#	ARTICLE	IF	CITATIONS
2754	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. <i>Blood</i> , 2012, 119, 188-191.	0.6	150
2755	Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia. <i>Blood</i> , 2012, 119, 3151-3154.	0.6	54
2756	BRAF mutation: supporting diversity in HCL. <i>Blood</i> , 2012, 119, 3193-3194.	0.6	5
2757	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. <i>Blood</i> , 2012, 120, 2700-2703.	0.6	589
2758	Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116 colon cancer cells. <i>International Journal of Oncology</i> , 2012, 41, 1855-1862.	1.4	10
2759	Translational biomarker in oncology early clinical development: decision case study for MEK inhibitors in healthy volunteer studies. <i>Clinical Investigation</i> , 2012, 2, 215-223.	0.0	1
2761	- LRRK2-Associated Parkinson's Disease. , 2012, , 174-191.		0
2762	The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1767-1774.	0.5	96
2763	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2012, 379, 1893-1901.	6.3	856
2764	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 358-365.	6.3	2,691
2765	Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 6089-6096.	1.4	28
2766	Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. <i>Clinical Cancer Research</i> , 2012, 18, 2056-2065.	3.2	141
2767	Role of translocator protein in melanoma growth and progression. <i>Archives of Dermatological Research</i> , 2012, 304, 839-845.	1.1	18
2768	Stimulation of the Na ⁺ -coupled glucose transporter SGLT1 by B-RAF. <i>Biochemical and Biophysical Research Communications</i> , 2012, 427, 689-693.	1.0	8
2769	Metastatic melanoma: the new era of targeted therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S61-S70.	1.5	21
2770	Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. <i>Veterinary and Comparative Oncology</i> , 2012, 10, 163-173.	0.8	25
2771	Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 819-831.	1.5	43
2772	ERK1/2 MAP kinases: Structure, function, and regulation. <i>Pharmacological Research</i> , 2012, 66, 105-143.	3.1	1,246

#	ARTICLE	IF	CITATIONS
2773	The paradigm of personalized therapy in oncology. Expert Opinion on Therapeutic Targets, 2012, 16, S7-S16.	1.5	17
2774	BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines. PLoS ONE, 2012, 7, e42598.	1.1	51
2775	Cancer genomics and pathology: <i>All Together Now</i>. Pathology International, 2012, 62, 647-659.	0.6	6
2776	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology, 2012, 52, 549-573.	4.2	96
2777	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Expert Review of Anticancer Therapy, 2012, 12, 1437-1448.	1.1	24
2778	Quinazoline derivatives as potential anticancer agents: a patent review (2007 â€“ 2010). Expert Opinion on Therapeutic Patents, 2012, 22, 223-252.	2.4	104
2779	Oral Availability and Brain Penetration of the B-RAF^{V600E} Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar. Molecular Pharmaceutics, 2012, 9, 3236-3245.	2.3	113
2780	p120RasGAP-Mediated Activation of c-Src Is Critical for Oncogenic Ras to Induce Tumor Invasion. Cancer Research, 2012, 72, 2405-2415.	0.4	23
2781	Molecular Pathogenesis of Melanoma: Established and Novel Pathways. , 2012, , 19-37.		0
2782	Molecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma. Seminars in Cutaneous Medicine and Surgery, 2012, 31, 267-273.	1.6	48
2783	Survival in BRAF V600â€“Mutant Advanced Melanoma Treated with Vemurafenib. New England Journal of Medicine, 2012, 366, 707-714.	13.9	1,955
2784	Development of a novel class of B-RafV600E-selective inhibitors through virtual screening and hierarchical hit optimization. Organic and Biomolecular Chemistry, 2012, 10, 7402.	1.5	20
2785	Oncogenes in Cell Survival and Cell Death. Cold Spring Harbor Perspectives in Biology, 2012, 4, a009829-a009829.	2.3	99
2786	Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. Modern Pathology, 2012, 25, 1203-1211.	2.9	21
2787	Reviewing the somatic genetics of melanoma: from current to future analytical approaches. Pigment Cell and Melanoma Research, 2012, 25, 144-154.	1.5	46
2788	Delving into somatic variation in sporadic melanoma. Pigment Cell and Melanoma Research, 2012, 25, 155-170.	1.5	35
2789	The genetics of uveal melanoma: an emerging framework for targeted therapy. Pigment Cell and Melanoma Research, 2012, 25, 171-181.	1.5	150
2790	Systematic classification of melanoma cells by phenotypeâ€“specific gene expression mapping. Pigment Cell and Melanoma Research, 2012, 25, 343-353.	1.5	155

#	ARTICLE	IF	CITATIONS
2791	The photobiology of melanocytes modulates the impact of UVA on sunlight-induced melanoma. <i>Photochemical and Photobiological Sciences</i> , 2012, 11, 69-73.	1.6	18
2792	Both variant and IGHV4-34 ⁺ expressing hairy cell leukemia lack the BRAF V600E mutation. <i>Blood</i> , 2012, 119, 3330-3332.	0.6	202
2793	Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern?. <i>Journal of Clinical Oncology</i> , 2012, 30, 329-330.	0.8	62
2794	Whole Genome and Exome Sequencing of Melanoma. <i>Advances in Pharmacology</i> , 2012, 65, 399-435.	1.2	10
2795	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. <i>New England Journal of Medicine</i> , 2012, 367, 2316-2321.	13.9	222
2796	Stabilization of HIF-2 α Induces sVEGFR-1 Production from Tumor-Associated Macrophages and Decreases Tumor Growth in a Murine Melanoma Model. <i>Journal of Immunology</i> , 2012, 189, 3168-3177.	0.4	57
2797	Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. <i>Current Oncology Reports</i> , 2012, 14, 449-457.	1.8	56
2799	Molecular markers of glioma: an update on recent progress and perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1971-1981.	1.2	51
2800	AERIO News in brief. <i>Oncologie</i> , 2012, 14, 491-494.	0.2	0
2801	Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. <i>Cancer Cell</i> , 2012, 22, 668-682.	7.7	469
2802	Ethical issues in cutaneous melanoma. <i>Clinics in Dermatology</i> , 2012, 30, 501-510.	0.8	4
2803	BRAF Mutations in Metanephric Adenoma of the Kidney. <i>European Urology</i> , 2012, 62, 917-922.	0.9	95
2804	BRAF, GNAQ, and GNA11 mutations and copy number in pediatric low α grade glioma. <i>FEBS Open Bio</i> , 2012, 2, 129-134.	1.0	19
2805	Validation and application of a liquid chromatography α tandem mass spectrometric method for the determination of GDC-0879 and its metabolite in dog plasma using solid phase extraction. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012, 70, 354-361.	1.4	3
2806	Identifying mutated proteins secreted by colon cancer cell lines using mass spectrometry. <i>Journal of Proteomics</i> , 2012, 76, 141-149.	1.2	54
2807	Differences in the Susceptibility to Iodine ¹³¹ -induced Thyroid Tumours amongst Inbred Mouse Strains. <i>Journal of Radiation Research</i> , 2012, 53, 343-352.	0.8	2
2808	The BRAF-V600E mutation in hematological malignancies: a new player in hairy cell leukemia and Langerhans cell histiocytosis. <i>Leukemia and Lymphoma</i> , 2012, 53, 2339-2340.	0.6	13
2809	Moving Toward Personalized Medicine in Castration-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 483-490.	0.8	6

#	ARTICLE	IF	CITATIONS
2810	Analysis of the BRAFV600E Mutation in Central Nervous System Tumors. <i>Translational Oncology</i> , 2012, 5, 430-436.	1.7	51
2811	Molecular Pathology of Gastrointestinal Cancer. <i>Surgical Pathology Clinics</i> , 2012, 5, 821-842.	0.7	1
2812	Identification of novel 3,5-diarylpyrazoline derivatives containing salicylamide moiety as potential anti-melanoma agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6596-6601.	1.0	14
2813	Detection of the BRAFV600E Mutation in Fine Needle Aspiration Cytology of Thyroid Papillary Microcarcinoma Cells Selected by Manual Macrodissection: An Easy Tool to Improve the Preoperative Diagnosis. <i>Thyroid</i> , 2012, 22, 292-298.	2.4	37
2814	Head and Neck Mucosal Malignant Melanoma. <i>International Journal of Surgical Pathology</i> , 2012, 20, 37-46.	0.4	27
2815	Predicting cancer drivers: are we there yet?. <i>Genome Medicine</i> , 2012, 4, 88.	3.6	5
2816	Absence of BRAF V600E mutation in a cohort of 402 patients with various chronic and acute myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2012, 53, 2496-2497.	0.6	13
2817	Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: novel targeted therapies and advances in the treatment of colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2012, 5, 319-337.	1.4	24
2818	Two new compounds with cytotoxic activity on the human melanoma A375-S2 cells from <i>Daphne giraldii</i> callus cells. <i>Journal of Asian Natural Products Research</i> , 2012, 14, 1020-1026.	0.7	8
2819	Transactional Database Transformation and Its Application in Prioritizing Human Disease Genes. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2012, 9, 294-304.	1.9	13
2820	Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2498-2499.	0.6	10
2821	Melanoma: New Insights and New Therapies. <i>Journal of Investigative Dermatology</i> , 2012, 132, 854-863.	0.3	136
2822	<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors. <i>New England Journal of Medicine</i> , 2012, 366, 207-215.	13.9	978
2823	Sorafenib in melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 557-568.	1.9	48
2824	Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 841-846.	1.7	14
2825	The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells. <i>Cell Cycle</i> , 2012, 11, 286-295.	1.3	84
2826	Identification of a Novel Family of BRAF ^{V600E} Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 5220-5230.	2.9	66
2827	Sorafenib in non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1417-1426.	1.9	25

#	ARTICLE	IF	CITATIONS
2828	MDM4 is a key therapeutic target in cutaneous melanoma. <i>Nature Medicine</i> , 2012, 18, 1239-1247.	15.2	266
2829	Impact of Genomics on Personalized Cancer Medicine. <i>Clinical Cancer Research</i> , 2012, 18, 612-618.	3.2	52
2830	Eruptive Squamous Cell Carcinomas Associated with BRAF-Inhibitor Therapy in a Patient with Metastatic Melanoma. <i>Dermatologic Surgery</i> , 2012, 38, 1086-1090.	0.4	2
2831	How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. <i>Annals of Oncology</i> , 2012, 23, viii15-viii21.	0.6	49
2832	What are we learning from the cancer genome?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 621-630.	12.5	50
2833	Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications. <i>Clinical Cancer Research</i> , 2012, 18, 1506-1512.	3.2	217
2834	Navigating cancer network attractors for tumor-specific therapy. <i>Nature Biotechnology</i> , 2012, 30, 842-848.	9.4	132
2835	Rationally Designed Aberrant Kinase-Targeted Endogenous Protein Nanomedicine against Oncogene Mutated/Amplified Refractory Chronic Myeloid Leukemia. <i>Molecular Pharmaceutics</i> , 2012, 9, 3062-3078.	2.3	20
2836	Mutant BRAF Induces DNA Strand Breaks, Activates DNA Damage Response Pathway, and Up-Regulates Glucose Transporter-1 in Nontransformed Epithelial Cells. <i>American Journal of Pathology</i> , 2012, 180, 1179-1188.	1.9	29
2837	Is the BRAFV600E mutation useful as a predictor of preoperative risk in papillary thyroid cancer?. <i>American Journal of Surgery</i> , 2012, 203, 436-441.	0.9	76
2838	Pediatric melanomas and the atypical spitzoid melanocytic neoplasms. <i>American Journal of Surgery</i> , 2012, 203, 761-767.	0.9	30
2839	Targeting the RAS pathway in melanoma. <i>Trends in Molecular Medicine</i> , 2012, 18, 27-35.	3.5	70
2840	Prediction in the face of uncertainty: A Monte Carlo-based approach for systems biology of cancer treatment. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2012, 746, 163-170.	0.9	29
2841	c-kit gene mutation and CD117 expression in human anorectal melanomas. <i>Human Pathology</i> , 2012, 43, 801-807.	1.1	43
2842	The dysplastic nevus: From historical perspective to management in the modern era. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 19.e1-19.e12.	0.6	100
2843	Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 889-890, 144-147.	1.2	14
2844	Novel zebrafish model reveals a critical role for MAPK in lymphangiogenesis. <i>Journal of Pediatric Surgery</i> , 2012, 47, 177-182.	0.8	8
2845	The role of autophagy in cytotoxicity induced by new oncogenic B-Raf inhibitor UI-152 in v-Ha-ras transformed fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 857-863.	1.0	9

#	ARTICLE	IF	CITATIONS
2846	Synthesis, biological evaluation and 3D-QSAR studies of novel 4,5-dihydro-1H-pyrazole niacinamide derivatives as BRAF inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 3746-3755.	1.4	22
2847	Combining pharmacophore, docking and substructure search approaches to identify and optimize novel B-RafV600E inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 5428-5437.	1.0	8
2848	Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. <i>Cancer Letters</i> , 2012, 314, 244-255.	3.2	60
2849	P-21 activated kinase 1 knockdown inhibits β -catenin signalling and blocks colorectal cancer growth. <i>Cancer Letters</i> , 2012, 317, 65-71.	3.2	46
2850	Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations. <i>Cancer Letters</i> , 2012, 322, 213-222.	3.2	15
2851	Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations. <i>European Journal of Cancer</i> , 2012, 48, 1842-1852.	1.3	74
2852	Lung cancer in never smokers – A review. <i>European Journal of Cancer</i> , 2012, 48, 1299-1311.	1.3	694
2853	Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. <i>Current Opinion in Genetics and Development</i> , 2012, 22, 45-49.	1.5	43
2854	Screens, maps & networks: from genome sequences to personalized medicine. <i>Current Opinion in Genetics and Development</i> , 2012, 22, 36-44.	1.5	15
2855	The Response of Cancers to BRAF Inhibition Underscores the Importance of Cancer Systems Biology. <i>Science Signaling</i> , 2012, 5, pe46.	1.6	20
2856	Identification of 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea Hydrochloride (CEP-32496), a Highly Potent and Orally Efficacious Inhibitor of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) V600E. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1082-1105.	2.9	51
2857	Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines. <i>BMC Cancer</i> , 2012, 12, 141.	1.1	20
2858	Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. <i>Molecular Cancer</i> , 2012, 11, 22.	7.9	65
2859	Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status. <i>Molecular Cancer</i> , 2012, 11, 75.	7.9	36
2860	Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib. <i>World Journal of Surgical Oncology</i> , 2012, 10, 155.	0.8	8
2861	Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. <i>Journal of Translational Medicine</i> , 2012, 10, 178.	1.8	31
2862	The role of BRAF V600 mutation in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 85.	1.8	563
2863	Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5. <i>Journal of Molecular Signaling</i> , 2012, 7, 9.	0.5	32

#	ARTICLE	IF	CITATIONS
2864	BRAF mutations in thyroid tumors from an ethnically diverse group. <i>Hereditary Cancer in Clinical Practice</i> , 2012, 10, 10.	0.6	37
2865	Overcoming implementation challenges of personalized cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 542-548.	12.5	115
2866	Resistance to Chemotherapy. <i>Advances in Pharmacology</i> , 2012, 65, 315-334.	1.2	17
2867	Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. <i>British Journal of Dermatology</i> , 2012, 167, 987-994.	1.4	102
2868	Cancer treatment according to BRCA1 and BRCA2 mutations. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 520-528.	12.5	69
2869	New therapeutical strategies in the treatment of metastatic disease. <i>Dermatologic Therapy</i> , 2012, 25, 452-457.	0.8	11
2870	Frequent BRAF Gain in Low-Grade Diffuse Gliomas with 1p/19q Loss. <i>Brain Pathology</i> , 2012, 22, 834-840.	2.1	34
2871	Rac1 in the driver's seat for melanoma. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 762-764.	1.5	14
2872	Vemurafenib. <i>Drugs</i> , 2012, 72, 2207-2222.	4.9	89
2873	Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 9-14.	3.2	59
2874	Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. <i>Bioscience Reports</i> , 2012, 32, 25-33.	1.1	17
2875	Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. <i>Nature Genetics</i> , 2012, 44, 165-169.	9.4	170
2876	Genomic biomarkers for patient selection and stratification: the cancer paradigm. <i>Bioanalysis</i> , 2012, 4, 2499-2511.	0.6	8
2877	Predictors of EGF receptor monoclonal antibody activity in metastatic colorectal cancer: current status. <i>Colorectal Cancer</i> , 2012, 1, 423-432.	0.8	0
2878	Targeted Therapies for Metastatic Melanoma. <i>Dermatologic Clinics</i> , 2012, 30, 517-524.	1.0	5
2879	Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. <i>Pharmacogenomics Journal</i> , 2012, 12, 277-286.	0.9	32
2880	A new era for the management of metastatic melanoma. <i>Expert Review of Dermatology</i> , 2012, 7, 27-35.	0.3	1
2881	MEK and RAF inhibitors for BRAF-mutated cancers. <i>Expert Reviews in Molecular Medicine</i> , 2012, 14, e17.	1.6	26

#	ARTICLE	IF	CITATIONS
2882	Process Research and Kilogram Synthesis of an Investigational, Potent MEK Inhibitor. <i>Organic Process Research and Development</i> , 2012, 16, 1652-1659.	1.3	10
2883	BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF^{V600E} mutation. <i>Future Oncology</i> , 2012, 8, 499-507.	1.1	69
2884	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 782-789.	5.1	479
2885	Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma. <i>Human Pathology</i> , 2012, 43, 1463-1470.	1.1	55
2886	Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. <i>Human Pathology</i> , 2012, 43, 2197-2206.	1.1	59
2887	Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 1375-1379.	0.6	49
2888	Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells. <i>American Journal of Surgery</i> , 2012, 204, 868-873.	0.9	44
2889	Design, modification and 3D QSAR studies of novel 2,3-dihydrobenzo[b][1,4]dioxin-containing 4,5-dihydro-1H-pyrazole derivatives as inhibitors of B-Raf kinase. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 6048-6058.	1.4	21
2890	Molecular alterations in colitis-associated colorectal neoplasia: Study from a low prevalence area using magnifying chromo colonoscopy. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 647-654.	0.6	11
2891	Simplified identification of Lynch syndrome: A prospective, multicenter study. <i>Digestive and Liver Disease</i> , 2012, 44, 515-522.	0.4	19
2892	In silico analysis of Single Nucleotide Polymorphisms (SNPs) in human BRAF gene. <i>Gene</i> , 2012, 508, 188-196.	1.0	55
2893	BRAF status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. <i>Surgery</i> , 2012, 152, 984-990.	1.0	59
2894	BRAF and GNAQ mutations in melanocytic tumors of the oral cavity. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 114, 778-784.	0.2	14
2895	KRAS and BRAF mutations in sinonasal cancer. <i>Oral Oncology</i> , 2012, 48, 692-697.	0.8	52
2896	Cutting Edge in Medical Management of Cutaneous Oncology. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, 140-149.	1.6	7
2897	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. <i>Lung Cancer</i> , 2012, 76, 1-18.	0.9	206
2898	Melanoma Brain Metastases and Vemurafenib: Need for Further Investigation. <i>Mayo Clinic Proceedings</i> , 2012, 87, 976-981.	1.4	41
2899	Structural and genic characterization of stable genomic regions in breast cancer: Relevance to chemotherapy. <i>Molecular Oncology</i> , 2012, 6, 347-359.	2.1	15

#	ARTICLE	IF	CITATIONS
2900	Discovery of small molecule cancer drugs: Successes, challenges and opportunities. <i>Molecular Oncology</i> , 2012, 6, 155-176.	2.1	447
2901	Co-development of a companion diagnostic for targeted cancer therapy. <i>New Biotechnology</i> , 2012, 29, 682-688.	2.4	40
2902	Vemurafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2533-2543.	0.9	28
2903	Medical management of langerhans cell histiocytosis from diagnosis to treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1309-1322.	0.9	86
2905	Driving transcriptional regulators in melanoma metastasis. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 621-632.	2.7	38
2906	Targeted therapies: how personal should we go?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 87-97.	12.5	94
2907	Epidemiology and Management of Uveal Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1169-1184.	0.9	61
2908	Trp2 Peptide Vaccine Adjuvanted with (R)-DOTAP Inhibits Tumor Growth in an Advanced Melanoma Model. <i>Molecular Pharmaceutics</i> , 2012, 9, 261-268.	2.3	44
2909	ZCCHC12, a potential molecular marker of papillary thyroid carcinoma: a preliminary study. <i>Medical Oncology</i> , 2012, 29, 1409-1417.	1.2	11
2910	Targeted drug development in melanoma and nonsmall cell lung cancer: BRAF, MEK, and ALK inhibitors. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 302-308.	0.3	0
2911	Pyrazolopyridine inhibitors of B-RafV600E. Part 4: Rational design and kinase selectivity profile of cell potent type II inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 6237-6241.	1.0	26
2912	Targeting BRAF in an Inducible Murine Model of Melanoma. <i>American Journal of Pathology</i> , 2012, 181, 785-794.	1.9	58
2913	Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. <i>Nature Genetics</i> , 2012, 44, 133-139.	9.4	369
2915	Cytogenetic and Mutational Analyses of Melanocytic Tumors. <i>Dermatologic Clinics</i> , 2012, 30, 555-566.	1.0	15
2916	Mixed versus pure variants of desmoplastic melanoma: a genetic and immunohistochemical appraisal. <i>Modern Pathology</i> , 2012, 25, 505-515.	2.9	47
2917	From genes to drugs: targeted strategies for melanoma. <i>Nature Reviews Cancer</i> , 2012, 12, 349-361.	12.8	323
2918	Tumors of the Central Nervous System, Volume 5. , 2012, , .		0
2919	RAF Fusion Genes and MAPK Activation in Pilocytic Astrocytomas. , 2012, , 99-105.		0

#	ARTICLE	IF	CITATIONS
2920	The specificity of UVA-induced DNA damage in human melanocytes. <i>Photochemical and Photobiological Sciences</i> , 2012, 11, 155-162.	1.6	72
2921	Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. <i>Oncogene</i> , 2012, 31, 446-457.	2.6	179
2922	Vemurafenib: the first drug approved for BRAF-mutant cancer. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 873-886.	21.5	667
2923	Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. <i>Oncogene</i> , 2012, 31, 2471-2479.	2.6	52
2924	BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. <i>Cell Death and Differentiation</i> , 2012, 19, 2029-2039.	5.0	61
2925	Dabrafenib and its potential for the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2012, 6, 391.	2.0	102
2926	TGF- β 2 Signaling, Activated Stromal Fibroblasts, and Cysteine Cathepsins B and L Drive the Invasive Growth of Human Melanoma Cells. <i>American Journal of Pathology</i> , 2012, 181, 2202-2216.	1.9	65
2927	Allele Specific Locked Nucleic Acid Quantitative PCR (ASLNAqPCR): An Accurate and Cost-Effective Assay to Diagnose and Quantify KRAS and BRAF Mutation. <i>PLoS ONE</i> , 2012, 7, e36084.	1.1	55
2928	High-Throughput Genotyping in Metastatic Esophageal Squamous Cell Carcinoma Identifies Phosphoinositide-3-Kinase and BRAF Mutations. <i>PLoS ONE</i> , 2012, 7, e41655.	1.1	35
2929	Merlin Is a Negative Regulator of Human Melanoma Growth. <i>PLoS ONE</i> , 2012, 7, e43295.	1.1	29
2930	Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma. <i>PLoS ONE</i> , 2012, 7, e43369.	1.1	87
2931	CD3 expression in plasma cell neoplasm (multiple myeloma): A diagnostic pitfall. <i>Pathology</i> , 2012, 44, 668-670.	0.3	9
2932	Metastatic Melanoma: A Regional Review and Future Directions. <i>Tumori</i> , 2012, 98, 575-580.	0.6	14
2933	Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-9.	0.3	12
2934	Molecular Therapeutic Advances in Personalized Therapy of Melanoma and Non-Small Cell Lung Cancer. <i>Journal of Personalized Medicine</i> , 2012, 2, 35-49.	1.1	6
2935	Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer. <i>Frontiers in Oncology</i> , 2012, 2, 15.	1.3	49
2936	The Role of Tyrosine Kinases in the Pathogenesis and Treatment of Lung Disease. , 2012, , .		2
2937	Braf and erbb2 mutations correlate with smoking status in lung cancer patients. <i>Experimental and Therapeutic Medicine</i> , 2012, 3, 771-775.	0.8	20

#	ARTICLE	IF	CITATIONS
2938	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. Oncotarget, 2012, 3, 954-987.	0.8	244
2939	BRAF V600E Mutation Detection Using High Resolution Probe Melting Analysis. , 0, , .		0
2940	Frequency of BRAF Mutation and Clinical Relevance for Primary Melanomas. Korean Journal of Pathology, 2012, 46, 246.	1.2	12
2941	Activating Mutations and Targeted Therapy in Cancer. , 0, , .		3
2942	Thyroid Neoplasm. , 2012, , .		0
2943	Aberrant B-Raf Signaling in Human Cancer ~ 10 Years from Bench to Bedside. Critical Reviews in Oncogenesis, 2012, 17, 97-121.	0.2	56
2945	Identification of a Rare 3 bp BRAF Gene Deletion in a Thyroid Nodule by Mutant Enrichment with 3'-Modified Oligonucleotides Polymerase Chain Reaction. Annals of Laboratory Medicine, 2012, 32, 238-241.	1.2	13
2946	Inoperable bulky melanoma responds to neoadjuvant therapy with vemurafenib. BMJ Case Reports, 2012, 2012, bcr2012007034-bcr2012007034.	0.2	14
2947	AZT on telomerase activity and cell proliferation in HS 839.T melanoma cells. Acta Cirurgica Brasileira, 2012, 27, 855-860.	0.3	1
2948	Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients. Neoplasma, 2012, 59, 376-383.	0.7	20
2949	Polymerase Chain Reaction: Types, Utilities and Limitations. , 2012, , .		2
2950	What is new in the treatment of advanced melanoma? State of the art. Wspolczesna Onkologia, 2012, 5, 363-370.	0.7	8
2951	Targeted agents for the treatment of metastatic melanoma. OncoTargets and Therapy, 2012, 5, 31.	1.0	13
2952	Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. Cancer Management and Research, 2012, 4, 243.	0.9	50
2953	Primary Anorectal Melanoma: An Update. Journal of Cancer, 2012, 3, 449-453.	1.2	35
2954	Current management and novel agents for malignant melanoma. Journal of Hematology and Oncology, 2012, 5, 3.	6.9	39
2955	KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2012, 18, 1769-1776.	3.2	154
2956	Sensitization of (colon) cancer cells to death receptor related therapies. Cancer Biology and Therapy, 2012, 13, 458-466.	1.5	4

#	ARTICLE	IF	CITATIONS
2957	PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2012, 30, 777-782.	0.8	414
2958	MAPK pathway activation in pilocytic astrocytoma. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1799-1811.	2.4	177
2959	Targeting the MAPK/RAS/RAF signaling pathway in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 103-119.	1.5	740
2960	Molecular pathology of lung cancer: key to personalized medicine. <i>Modern Pathology</i> , 2012, 25, 347-369.	2.9	215
2961	BRAF mutation testing in clinical practice. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 127-138.	1.5	39
2962	Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , 2012, 72, 779-789.	0.4	199
2963	The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S17-S27.	1.5	580
2964	Melanoma whole-exome sequencing identifies V600E-BRAF amplification-mediated acquired B-RAF inhibitor resistance. <i>Nature Communications</i> , 2012, 3, 724.	5.8	567
2965	Clinically useful biomarkers in neurooncology. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 201-204.	0.3	1
2966	A simple, high sensitivity mutation screening using Ampligase mediated T7 endonuclease I and Surveyor nuclease with microfluidic capillary electrophoresis. <i>Electrophoresis</i> , 2012, 33, 788-796.	1.3	40
2967	Predicting malignancy in thyroid nodules: Molecular advances. <i>Head and Neck</i> , 2012, 34, 1355-1361.	0.9	5
2968	Real-time PCR based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia. <i>Hematological Oncology</i> , 2012, 30, 190-193.	0.8	15
2969	Effects of cold ischemia and inflammatory tumor microenvironment on detection of PI3K/AKT and MAPK pathway activation patterns in clinical cancer samples. <i>International Journal of Cancer</i> , 2012, 131, 1621-1632.	2.3	20
2970	Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas. <i>International Journal of Cancer</i> , 2012, 131, 1790-1799.	2.3	44
2971	Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. <i>Nature</i> , 2012, 483, 100-103.	13.7	1,769
2972	A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 888-897.	1.9	45
2973	Melanoma: from mutations to medicine. <i>Genes and Development</i> , 2012, 26, 1131-1155.	2.7	415
2974	Clinical and molecular detection of inherited colorectal cancers in northeast Italy. <i>Tumor Biology</i> , 2012, 33, 857-864.	0.8	3

#	ARTICLE	IF	CITATIONS
2975	Conformation-Specific Effects of Raf Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 7332-7341.	2.9	46
2976	A Decade of the Human Genome Sequence—How Does the Medicinal Chemist Benefit?. <i>ChemMedChem</i> , 2012, 7, 194-203.	1.6	19
2977	The association of the <i>BRAF</i> ^{V600E} mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer. <i>Cancer</i> , 2012, 118, 1764-1773.	2.0	368
2978	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	13.9	1,976
2979	Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management. <i>Current Oncology Reports</i> , 2012, 14, 441-448.	1.8	138
2980	Molecular testing in malignant melanoma. <i>Diagnostic Cytopathology</i> , 2012, 40, 503-510.	0.5	27
2981	Defining MAP3 kinases required for MDA-MB-231 cell tumor growth and metastasis. <i>Oncogene</i> , 2012, 31, 3889-3900.	2.6	80
2982	Cooperative interactions of BRAF ^{V600E} kinase and <i>CDKN2A</i> locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 8710-8715.	3.3	77
2983	Oncogenomics Methods and Resources. <i>Cold Spring Harbor Protocols</i> , 2012, 2012, pdb.top069229.	0.2	8
2984	Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 3452-3478.	2.9	58
2985	Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. <i>Future Oncology</i> , 2012, 8, 509-523.	1.1	22
2986	Chemotherapy for Melanoma. , 2012, , 247-263.		0
2987	Integrating New Therapies in the Treatment of Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2012, 13, 327-339.	1.3	8
2988	Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways. <i>Clinical Cancer Research</i> , 2012, 18, 748-757.	3.2	203
2989	Targeting Metastatic Melanoma. <i>Annual Review of Medicine</i> , 2012, 63, 171-183.	5.0	57
2990	Insights into melanoma: targeting the mTOR pathway for therapeutics. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 689-705.	1.5	34
2991	Characterization of a new human melanoma cell line with CD133 expression. <i>Human Cell</i> , 2012, 25, 61-67.	1.2	10
2992	Driver mutations as predictive biomarkers in lung cancer. <i>Current Respiratory Care Reports</i> , 2012, 1, 21-29.	0.6	0

#	ARTICLE	IF	CITATIONS
2993	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. <i>Journal of Molecular Medicine</i> , 2012, 90, 667-679.	1.7	54
2994	Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 561-567.	1.1	61
2995	Cooperate concept of metastasis: site-specific requirement of activated differentiation and dynamic deterioration. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 269-276.	2.7	4
2996	Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway. <i>Molecular Biology Reports</i> , 2012, 39, 7743-7753.	1.0	39
2997	BRAF V600E Mutation in Papillary Thyroid Carcinoma: Significant Association with Node Metastases and Extra Thyroidal Invasion. <i>Endocrine Pathology</i> , 2012, 23, 83-93.	5.2	82
2998	Lynch syndrome diagnostics: decision-making process for germ-line testing. <i>Clinical and Translational Oncology</i> , 2012, 14, 254-262.	1.2	2
2999	Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 733-737.	2.0	84
3000	Upcoming strategies for the treatment of metastatic melanoma. <i>Archives of Dermatological Research</i> , 2012, 304, 177-184.	1.1	44
3001	MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 573-584.	1.2	117
3002	Review of biomarkers in colorectal cancer. <i>Colorectal Disease</i> , 2012, 14, 3-17.	0.7	100
3003	Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. <i>Histopathology</i> , 2012, 60, 1052-1059.	1.6	61
3004	MAPK and PI3K/AKT mediated YBâ€1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop. <i>Experimental Dermatology</i> , 2012, 21, 265-270.	1.4	59
3005	How to Fool a Wonder Drug: Truncate and Dimerize. <i>Cancer Cell</i> , 2012, 21, 7-9.	7.7	5
3006	Cell surface adhesion molecules and adhesion-initiated signaling: Understanding of anoikis resistance mechanisms and therapeutic opportunities. <i>Cellular Signalling</i> , 2012, 24, 393-401.	1.7	135
3007	Vemurafenib in Patients With BRAF V600E Mutationâ€Positive Advanced Melanoma. <i>Clinical Therapeutics</i> , 2012, 34, 1474-1486.	1.1	80
3008	Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review. <i>Clinical Oncology</i> , 2012, 24, 410-412.	0.6	3
3009	Design, synthesis and biological evaluation of novel (E)-1±-benzylsulfonyl chalcone derivatives as potential BRAF inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2012, 50, 288-295.	2.6	34
3010	HSP90 as a platform for the assembly of more effective cancer chemotherapy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 756-766.	1.9	74

#	ARTICLE	IF	CITATIONS
3011	Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 89-102.	3.3	46
3012	Small molecule inhibitors of BRAF in clinical trials. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 789-792.	1.0	58
3013	Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-RafV600E kinase with favorable physicochemical and pharmacokinetic properties. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1165-1168.	1.0	21
3014	Design and synthesis of 6,6-fused heterocyclic amides as raf kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 1678-1681.	1.0	17
3015	The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3387-3391.	1.0	17
3016	Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy. <i>Seminars in Oncology</i> , 2012, 39, 215-226.	0.8	34
3017	The Current State of Targeted Therapy in Melanoma: This Time It's Personal. <i>Seminars in Oncology</i> , 2012, 39, 204-214.	0.8	27
3018	<i>RET/PTC</i> rearrangement is prevalent in follicular H _{1/4} thle cell carcinomas. <i>Histopathology</i> , 2012, 61, 833-843.	1.6	42
3019	Mutational analysis of <i>PIK3CA</i> , <i>JAK2</i> , <i>BRAF</i> , <i>FOXL2</i> , <i>DNM1</i> and <i>EZH2</i> oncogenes in sarcomas. <i>Apmis</i> , 2012, 120, 635-639.	0.7	48
3020	<i>BRAF</i> , <i>NRAS</i> and <i>KIT</i> sequencing analysis of spindle cell melanoma. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 821-825.	0.7	22
3021	Rapid, microwave-assisted organic synthesis of selective V600EBRAF inhibitors for preclinical cancer research. <i>Tetrahedron Letters</i> , 2012, 53, 4161-4165.	0.7	18
3022	Novel approach to abuse the hyperactive K-Ras pathway for adenoviral gene therapy of colorectal cancer. <i>Experimental Cell Research</i> , 2012, 318, 160-168.	1.2	7
3023	Ovarian low-grade serous carcinoma: A comprehensive update. <i>Gynecologic Oncology</i> , 2012, 126, 279-285.	0.6	92
3024	Low-grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosis-1. <i>Neuropathology and Applied Neurobiology</i> , 2012, 38, 241-253.	1.8	4
3025	Primary pure squamous cell carcinoma of the thyroid: Report and histogenic consideration of a case involving a BRAF mutation. <i>Pathology International</i> , 2012, 62, 43-48.	0.6	19
3026	Role of endobronchial ultrasound in diagnosis and molecular assessment of metastatic melanoma. <i>Respirology</i> , 2012, 17, 991-996.	1.3	13
3027	Associations between environmental factors and incidence of cutaneous melanoma. Review. <i>Environmental Health</i> , 2012, 11, S12.	1.7	66
3028	ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics. <i>World Journal of Surgical Oncology</i> , 2012, 10, 47.	0.8	31

#	ARTICLE	IF	CITATIONS
3029	Specifically targeting ERK1 or ERK2 kills Melanoma cells. <i>Journal of Translational Medicine</i> , 2012, 10, 15.	1.8	36
3030	Therapy for metastatic melanoma: the past, present, and future. <i>BMC Medicine</i> , 2012, 10, 23.	2.3	179
3031	Docking based 3D-QSAR studies applied at the BRAF inhibitors to understand the binding mechanism. <i>Journal of Cheminformatics</i> , 2012, 4, .	2.8	0
3032	Monocillin II Inhibits Human Breast Cancer Growth Partially by Inhibiting MAPK Pathways and CDK2 Thr160 Phosphorylation. <i>ChemBioChem</i> , 2012, 13, 465-475.	1.3	12
3033	Role of <i>BRAF</i> V600E mutation analysis and second cytologic review of fine-needle aspiration for evaluating thyroid nodule. <i>Cancer Cytopathology</i> , 2012, 120, 44-51.	1.4	33
3034	Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway. <i>International Journal of Cancer</i> , 2012, 130, 967-978.	2.3	35
3036	Barcoded Nucleotides. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 254-257.	7.2	67
3037	Multivariate Analysis of Several Molecular Markers and Clinicopathological Features in Postoperative Prognosis of Hepatocellular Carcinoma. <i>Anatomical Record</i> , 2012, 295, 423-431.	0.8	28
3039	<i>BRAF</i> ^{V600E} Mutation is Associated with Tumor Aggressiveness in Papillary Thyroid Cancer. <i>World Journal of Surgery</i> , 2012, 36, 310-317.	0.8	137
3040	Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 229-237.	1.1	12
3041	A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. <i>Investigational New Drugs</i> , 2012, 30, 341-349.	1.2	122
3042	Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. <i>Investigational New Drugs</i> , 2012, 30, 306-315.	1.2	51
3043	Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. <i>Journal of Gastroenterology</i> , 2012, 47, 203-213.	2.3	73
3044	Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases. <i>Head and Neck</i> , 2013, 35, 1066-1077.	0.9	114
3045	RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth. <i>Oncogene</i> , 2013, 32, 2917-2926.	2.6	56
3046	Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 11-18.	1.3	78
3047	MicroRNAs in the pathogenesis of malignant melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 142-150.	1.3	28
3048	Clinical implication of the BRAFV600E mutation in papillary thyroid carcinoma. <i>World Journal of Surgical Oncology</i> , 2013, 11, 99.	0.8	23

#	ARTICLE	IF	CITATIONS
3049	Historical review of melanoma treatment and outcomes. <i>Clinics in Dermatology</i> , 2013, 31, 141-147.	0.8	62
3050	Lack of SF3B1 R625 mutations in cutaneous melanoma. <i>Diagnostic Pathology</i> , 2013, 8, 87.	0.9	27
3051	B-Raf and the inhibitors: from bench to bedside. <i>Journal of Hematology and Oncology</i> , 2013, 6, 30.	6.9	80
3052	Colorectal cancer: a researcher's perspective of the molecular angel's gone eccentric in the Vale of Kashmir. <i>Tumor Biology</i> , 2013, 34, 1301-1315.	0.8	15
3053	Tailored management of advanced squamous non-small cell lung cancer (NSCLC). <i>Current Respiratory Care Reports</i> , 2013, 2, 10-16.	0.6	0
3054	The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma. <i>Current Dermatology Reports</i> , 2013, 2, 84-100.	1.1	6
3055	hsc70 modulates melanoma invasion by altering actin cytoskeletal dynamics. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 218-225.	1.5	25
3056	Vemurafenib and radiation therapy in melanoma brain metastases. <i>Journal of Neuro-Oncology</i> , 2013, 113, 411-416.	1.4	105
3057	In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF V600E mutation status and together with hypoxia-related proteins predicts aggressive behavior. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 437-444.	1.4	20
3058	Why is autophagy important for melanoma? Molecular mechanisms and therapeutic implications. <i>Seminars in Cancer Biology</i> , 2013, 23, 337-343.	4.3	46
3059	Integrating Chemotherapy to Surgery: Novel Approaches in Regionally Aggressive Cancer Metastasis. , 2013, , 319-350.		0
3061	Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , .	0.1	8
3062	The Impact of Genomic Changes on Treatment of Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 770-775.	2.5	91
3063	The Genetics of Melanoma: Recent Advances. <i>Annual Review of Genomics and Human Genetics</i> , 2013, 14, 257-279.	2.5	66
3064	Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma. <i>IUBMB Life</i> , 2013, 65, 748-758.	1.5	53
3065	Investigation of BRAF V600E Mutation in Papillary Thyroid Carcinoma and Tumor-Surrounding Nontumoral Tissues. <i>DNA and Cell Biology</i> , 2013, 32, 13-18.	0.9	18
3066	Structure-Based Design of Covalent Siah Inhibitors. <i>Chemistry and Biology</i> , 2013, 20, 973-982.	6.2	47
3067	TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. <i>British Journal of Cancer</i> , 2013, 109, 497-501.	2.9	103

#	ARTICLE	IF	CITATIONS
3068	Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 67-76.	0.5	0
3069	MicroRNA Cancer Regulation. <i>Advances in Experimental Medicine and Biology</i> , 2013, , .	0.8	17
3070	Case 21-2013. <i>New England Journal of Medicine</i> , 2013, 369, 173-183.	13.9	30
3071	Clinicopathologic Implications of the <i>BRAF</i> ^{V600E} Mutation in Papillary Thyroid Cancer: A Subgroup Analysis of 3130 Cases in a Single Center. <i>Thyroid</i> , 2013, 23, 1423-1430.	2.4	97
3072	Resistance to Immunotherapeutic Antibodies in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , .	0.1	2
3073	Expression of β -catenin and cyclin D1 in Merkel cell carcinomas of the head and neck. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 501-507.	1.0	7
3074	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1493.	3.8	775
3075	Utilizing protein structure to identify non-random somatic mutations. <i>BMC Bioinformatics</i> , 2013, 14, 190.	1.2	52
3076	High resolution melting analysis of KRAS, BRAF and PIK3CA in KRASexon 2 wild-type metastatic colorectal cancer. <i>BMC Cancer</i> , 2013, 13, 169.	1.1	44
3077	Correlation of MLH1 and MGMT expression and promoter methylation with genomic instability in patients with thyroid carcinoma. <i>BMC Cancer</i> , 2013, 13, 79.	1.1	24
3078	Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations. <i>BMC Cancer</i> , 2013, 13, 17.	1.1	38
3079	Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 893-899.	1.5	64
3080	Systemic therapies for inflammatory eye disease: Past, Present and Future. <i>BMC Ophthalmology</i> , 2013, 13, 18.	0.6	25
3081	PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1395-1409.	1.1	190
3082	Impact of Genetic Targets on Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, v-vi.	0.8	1
3083	Circulating <i>BRAF</i> ^{V600E} in the Diagnosis and Follow-Up of Differentiated Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3359-3365.	1.8	65
3084	Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?. <i>Cancer Treatment Reviews</i> , 2013, 39, 305-312.	3.4	13
3085	Computational approaches to identify functional genetic variants in cancer genomes. <i>Nature Methods</i> , 2013, 10, 723-729.	9.0	161

#	ARTICLE	IF	CITATIONS
3086	New Targets in Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2013, 15, 411-423.	1.8	12
3087	Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem. <i>Current Oncology Reports</i> , 2013, 15, 249-259.	1.8	53
3088	Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. <i>Acta Neuropathologica Communications</i> , 2013, 1, 20.	2.4	52
3089	Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor. <i>Clinical and Translational Oncology</i> , 2013, 15, 425-433.	1.2	11
3090	Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 211-217.	1.4	5
3092	Poor prognosis of <i>KRAS</i> or <i>BRAF</i> mutant colorectal liver metastasis without microsatellite instability. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2013, 20, 223-233.	1.4	50
3093	Clinical characteristics and outcomes with specific <i>BRAF</i> and <i>NRAS</i> mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013, 119, 3821-3829.	2.0	87
3094	Hairy Cell Leukemia—New Genes, New Targets. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 184-195.	1.2	20
3095	Cutaneous side effects of vemurafenib: a case report and discussion. <i>Wiener Medizinische Wochenschrift</i> , 2013, 163, 376-379.	0.5	2
3096	Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAFV600E inhibitors. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 6328.	1.5	25
3097	Docking Studies on a Series of Novel Potent BRAF Inhibitors. <i>Advanced Materials Research</i> , 2013, 634-638, 930-933.	0.3	0
3098	Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 5896-5899.	1.0	23
3099	Trametinib (GSK1120212) in the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 619-627.	0.9	39
3100	Aberrant Overexpression of Pyruvate Kinase M2 Is Associated With Aggressive Tumor Features and the <i>BRAF</i> Mutation in Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1524-E1533.	1.8	50
3101	Melanoma genotypes and phenotypes get personal. <i>Laboratory Investigation</i> , 2013, 93, 858-867.	1.7	23
3102	Targets, Structures, and Recent Approaches in Malignant Melanoma Chemotherapy. <i>ChemMedChem</i> , 2013, 8, 1751-1765.	1.6	8
3103	Next Generation Sequencing in Cancer Research. , 2013, , .		5
3104	Bioremediation of the tobacco waste-contaminated soil by <i>Pseudomonas</i> sp. HF-1: nicotine degradation and microbial community analysis. <i>Applied Microbiology and Biotechnology</i> , 2013, 97, 6077-6088.	1.7	14

#	ARTICLE	IF	CITATIONS
3105	Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. <i>Annals of Hematology</i> , 2013, 92, 1149-1149.	0.8	9
3106	Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 577-584.	1.1	26
3107	Anti-vascular endothelial growth factor therapy in the era of personalized medicine. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 1-12.	1.1	17
3108	Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. <i>Nature</i> , 2013, 501, 232-236.	13.7	270
3109	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. <i>Acta Neuropathologica</i> , 2013, 125, 891-900.	3.9	177
3110	Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1582-1590.	0.3	122
3111	Multiplex detection of KRAS and BRAF mutations using cationic conjugated polymers. <i>Science Bulletin</i> , 2013, 58, 873-878.	1.7	2
3112	Trametinib: First Global Approval. <i>Drugs</i> , 2013, 73, 1245-1254.	4.9	151
3114	MITF, the Janus transcription factor of melanoma. <i>Future Oncology</i> , 2013, 9, 235-244.	1.1	36
3115	A Quantitative Allele-Specific PCR Test for the BRAF V600E Mutation Using a Single Heterozygous Control Plasmid for Quantitation. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 248-254.	1.2	21
3116	Clinicopathologic features of hyperplastic/serrated polyposis syndrome in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1693-1698.	1.4	16
3117	Phosphorylation of Mps1 by BRAFV600E prevents Mps1 degradation and contributes to chromosome instability in melanoma. <i>Oncogene</i> , 2013, 32, 713-723.	2.6	34
3119	Emerging phytochemicals for prevention of melanoma invasion. <i>Cancer Letters</i> , 2013, 335, 251-258.	3.2	22
3120	Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. <i>Journal of Pathology</i> , 2013, 230, 261-269.	2.1	180
3121	Current Applications of Molecular Genetic Technologies to the Diagnosis and Treatment of Cutaneous Melanocytic Neoplasms. <i>Clinics in Laboratory Medicine</i> , 2013, 33, 881-890.	0.7	1
3122	V600EBRAF promotes invasiveness of thyroid cancer cells by decreasing E-cadherin expression through a Snail-dependent mechanism. <i>Cancer Letters</i> , 2013, 335, 232-241.	3.2	49
3123	Contributions of molecular analysis to the diagnosis and treatment of gastrointestinal neoplasms. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 329-361.	1.0	13
3124	Identification of Aurora Kinase B and Wee1-Like Protein Kinase as Downstream Targets of V600EB-RAF in Melanoma. <i>American Journal of Pathology</i> , 2013, 182, 1151-1162.	1.9	33

#	ARTICLE	IF	CITATIONS
3125	Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. <i>Lung Cancer</i> , 2013, 80, 120-130.	0.9	43
3126	Loss of ARF Sensitizes Transgenic BRAFV600E Mice to UV-Induced Melanoma via Suppression of XPC. <i>Cancer Research</i> , 2013, 73, 4337-4348.	0.4	26
3127	The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 5320-5328.	3.2	226
3128	Direct Targeting of MEK1/2 and RSK2 by Silybin Induces Cell-Cycle Arrest and Inhibits Melanoma Cell Growth. <i>Cancer Prevention Research</i> , 2013, 6, 455-465.	0.7	51
3129	Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. <i>British Journal of Haematology</i> , 2013, 160, 725-733.	1.2	11
3130	Targeted therapy for NSCLC with driver mutations. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1401-1412.	1.4	42
3131	Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. <i>Pathologie Et Biologie</i> , 2013, 61, 273-276.	2.2	20
3132	Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. <i>Human Pathology</i> , 2013, 44, 2563-2570.	1.1	103
3133	Tall Cell Variant of Papillary Thyroid Microcarcinoma: Clinicopathologic Features with <i>BRAF</i> ^{V600E} Mutational Analysis. <i>Thyroid</i> , 2013, 23, 1525-1531.	2.4	44
3134	Detection of BRAF V600 Mutations in Metastatic Melanoma. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 790-795.	1.2	46
3135	Nanotechnology in Dermatology. , 2013, , .		8
3136	Immunotherapy for advanced melanoma: Fulfilling the promise. <i>Cancer Treatment Reviews</i> , 2013, 39, 879-885.	3.4	44
3137	Clinical Utility of KRAS and BRAF Mutations in a Cohort of Patients With Colorectal Neoplasms Submitted for Microsatellite Instability Testing. <i>Clinical Colorectal Cancer</i> , 2013, 12, 168-178.	1.0	35
3138	Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. <i>Expert Opinion on Drug Discovery</i> , 2013, 8, 1381-1397.	2.5	6
3139	Genetic alterations defining NSCLC subtypes and their therapeutic implications. <i>Lung Cancer</i> , 2013, 82, 179-189.	0.9	262
3140	Peroxiredoxin-2 Represses Melanoma Metastasis by Increasing E-Cadherin/ β -Catenin Complexes in Adherens Junctions. <i>Cancer Research</i> , 2013, 73, 4744-4757.	0.4	58
3141	Misregulation of Pre-mRNA Alternative Splicing in Cancer. <i>Cancer Discovery</i> , 2013, 3, 1228-1237.	7.7	265
3142	BRAF Mutations and KIT Aberrations and Their Clinicopathological Correlation in 202 Korean Melanomas. <i>Journal of Investigative Dermatology</i> , 2013, 133, 579-582.	0.3	64

#	ARTICLE	IF	CITATIONS
3143	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013, 126, 907-915.	3.9	254
3144	Local cAMP signaling in disease at a glance. <i>Journal of Cell Science</i> , 2013, 126, 4537-4543.	1.2	69
3145	Combination of a modified block PCR and endonuclease IV-based signal amplification system for ultra-sensitive detection of low-abundance point mutations. <i>Methods</i> , 2013, 64, 255-259.	1.9	10
3146	Advancing Precision Medicine for Prostate Cancer Through Genomics. <i>Journal of Clinical Oncology</i> , 2013, 31, 1866-1873.	0.8	84
3147	Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers. <i>Cell</i> , 2013, 154, 1036-1046.	13.5	236
3148	Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13481-13486.	3.3	147
3149	Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 3664-3672.	0.8	233
3150	Tumor adaptation and resistance to RAF inhibitors. <i>Nature Medicine</i> , 2013, 19, 1401-1409.	15.2	512
3151	B-Raf mutation: A key player in molecular biology of cancer. <i>Experimental and Molecular Pathology</i> , 2013, 95, 336-342.	0.9	53
3152	Molecular Mechanism of SLC5A8 Inactivation in Breast Cancer. <i>Molecular and Cellular Biology</i> , 2013, 33, 3920-3935.	1.1	27
3153	Reconstructing skin cancers using animal models. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 123-128.	2.7	12
3154	Pilocytic Astrocytoma. <i>Journal of Child Neurology</i> , 2013, 28, 625-632.	0.7	51
3155	Molecular Diagnostics in Colorectal Carcinoma. <i>Clinics in Laboratory Medicine</i> , 2013, 33, 835-859.	0.7	19
3156	Down-Regulation of Autophagy-Related Protein 5 (ATG5) Contributes to the Pathogenesis of Early-Stage Cutaneous Melanoma. <i>Science Translational Medicine</i> , 2013, 5, 202ra123.	5.8	147
3158	Targeted Sequencing Strategies in Cancer Research. , 2013, , 137-163.		2
3159	Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. <i>Cancer Treatment Reviews</i> , 2013, 39, 664-672.	3.4	84
3160	The Cancer Genome Atlas Pan-Cancer analysis project. <i>Nature Genetics</i> , 2013, 45, 1113-1120.	9.4	6,265
3161	Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 318-337.	2.0	28

#	ARTICLE	IF	CITATIONS
3162	Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay. <i>Science</i> , 2013, 341, 84-87.	6.0	1,444
3163	PIK3CA mutations are frequently observed in BRCA1 but not BRCA2-associated male breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R69.	2.2	22
3164	Hierarchical scaffolding of an ERK1/2 activation pathway. <i>Cell Communication and Signaling</i> , 2013, 11, 65.	2.7	29
3165	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 202.	1.8	31
3166	Influence of Pharmacogenomic Profiling Prior to Pharmaceutical Treatment in Metastatic Colorectal Cancer on Cost Effectiveness. <i>Pharmacoeconomics</i> , 2013, 31, 215-228.	1.7	29
3167	Rapid detection of K-, N-, H-RAS, and BRAF hotspot mutations in thyroid cancer using the multiplex primer extension. <i>Clinical Biochemistry</i> , 2013, 46, 1572-1577.	0.8	6
3168	Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment. <i>SpringerPlus</i> , 2013, 2, 679.	1.2	8
3169	Safety and efficacy of vemurafenib in end stage renal failure. <i>BMC Cancer</i> , 2013, 13, 581.	1.1	12
3170	Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate. <i>Cancer Microenvironment</i> , 2013, 6, 247-261.	3.1	14
3171	Targeting MAPK pathway in melanoma therapy. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 567-584.	2.7	72
3172	Metastatic melanoma in an esophagus demonstrating Barrett esophagus with high grade dysplasia. <i>BMC Research Notes</i> , 2013, 6, 457.	0.6	2
3173	Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 867-876.	1.7	16
3174	Neoadjuvant treatment of melanoma: case reports and review. <i>Experimental Hematology and Oncology</i> , 2013, 2, 30.	2.0	7
3175	Cutaneous Adverse Events to Type I BRAF Inhibitors: An Analysis of Effects Associated with Each Inhibitor and Therapeutic Time Interval to Onset. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 461-471.	3.3	13
3176	Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 623-631.	1.4	26
3177	Emerging patterns of somatic mutations in cancer. <i>Nature Reviews Genetics</i> , 2013, 14, 703-718.	7.7	442
3178	Innate and adaptive immune cells in the tumor microenvironment. <i>Nature Immunology</i> , 2013, 14, 1014-1022.	7.0	3,109
3179	Current management of melanoma. <i>Current Problems in Surgery</i> , 2013, 50, 351-382.	0.6	36

#	ARTICLE	IF	CITATIONS
3180	Mechanisms of Targeted Therapy Resistance Take a De-TOR. <i>Cancer Cell</i> , 2013, 24, 284-286.	7.7	5
3181	A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention. <i>Cancer Cell</i> , 2013, 24, 15-29.	7.7	183
3182	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. <i>European Journal of Cancer</i> , 2013, 49, 3229-3241.	1.3	40
3183	Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI. <i>British Journal of Cancer</i> , 2013, 109, 1562-1569.	2.9	22
3184	Pathological Consequence of Misguided Dendritic Cell Differentiation in Histiocytic Diseases. <i>Advances in Immunology</i> , 2013, 120, 127-161.	1.1	61
3185	Case History. <i>Annual Reports in Medicinal Chemistry</i> , 2013, 48, 435-449.	0.5	3
3186	Regorafenib for Gastrointestinal Malignancies. <i>BioDrugs</i> , 2013, 27, 213-224.	2.2	37
3187	Drug safety evaluation of vemurafenib in the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 767-775.	1.0	4
3188	Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2041-2049.	0.3	95
3189	Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients. <i>British Journal of Dermatology</i> , 2013, 168, 708-716.	1.4	20
3190	Reply to Amiodarone and the risk of cancer: A nationwide population-based study. <i>Cancer</i> , 2013, 119, 3578-3579.	2.0	0
3191	Melanocytomas of the central nervous system: a clinicopathological and molecular study. <i>European Journal of Clinical Investigation</i> , 2013, 43, 809-815.	1.7	26
3192	Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. <i>Histopathology</i> , 2013, 62, 543-550.	1.6	39
3193	It takes two to tango – signalling by dimeric Raf kinases. <i>Molecular BioSystems</i> , 2013, 9, 551-558.	2.9	39
3194	Isolation of a Novel Thioflavin S-Derived Compound That Inhibits BAG-1-Mediated Protein Interactions and Targets BRAF Inhibitor-Resistant Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 2400-2414.	1.9	23
3195	Synthetic lethality between CCNE1 amplification and loss of BRCA1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 19489-19494.	3.3	201
3196	Analysis of oncology research from 2001 to 2010: A scientometric perspective. <i>Oncology Reports</i> , 2013, 29, 1441-1452.	1.2	18
3197	Gene amplification: mechanisms and involvement in cancer. <i>Biomolecular Concepts</i> , 2013, 4, 567-582.	1.0	77

#	ARTICLE	IF	CITATIONS
3198	Latest Developments in the Biology and Management of Uveal Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 509-516.	1.8	25
3199	TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system. <i>Cellular Signalling</i> , 2013, 25, 490-500.	1.7	24
3200	Isolation and characterization of potent bioactive fraction with antioxidant and UV absorbing activity from <i>Aloe barbadensis</i> Miller gel. <i>Journal of Plant Biochemistry and Biotechnology</i> , 2013, 22, 483-487.	0.9	28
3201	Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma. <i>Oncogene</i> , 2013, 32, 4836-4844.	2.6	20
3202	Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 220-226.	1.2	195
3203	Therapeutic targeting of c-KIT in cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 103-115.	1.9	126
3204	Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma. <i>Cancer Discovery</i> , 2013, 3, 158-167.	7.7	300
3205	Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 241-255.	1.4	50
3207	Nano-Based Gene Therapy for Dermatologic Diseases. , 2013, , 109-117.		2
3208	Targeting Oncogenic Drivers and the Immune System in Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 499-506.	0.8	98
3209	BRAF mutations in melanoma and colorectal cancer: A single oncogenic mutation with different tumour phenotypes and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 55-68.	2.0	56
3210	Toward personalized cancer nanomedicine – past, present, and future. <i>Integrative Biology (United Tj ETQq1 1 0.784314 rgBT /Ove</i>	0.6	41
3211	Diagnostic value of immunohistochemistry for the detection of the BRAF mutation in primary lung adenocarcinoma Caucasian patients. <i>Annals of Oncology</i> , 2013, 24, 742-748.	0.6	103
3212	A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic Signals Initiated by G Protein-Coupled Receptors. <i>Molecular Cell</i> , 2013, 49, 94-108.	4.5	131
3213	Wnt Signaling in Skin Development, Homeostasis, and Disease. <i>Cold Spring Harbor Perspectives in Biology</i> , 2013, 5, a008029-a008029.	2.3	205
3214	The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1052-1062.	0.3	49
3215	RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance. <i>Oncogene</i> , 2013, 32, 4480-4489.	2.6	32
3216	Pathological and Molecular Advances in Pediatric Low-Grade Astrocytoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2013, 8, 361-379.	9.6	68

#	ARTICLE	IF	CITATIONS
3217	Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 358-362.	1.3	186
3218	Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 2301-2309.	3.2	77
3219	New Targetable Oncogenes in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1097-1104.	0.8	280
3220	TERT Promoter Mutations in Familial and Sporadic Melanoma. <i>Science</i> , 2013, 339, 959-961.	6.0	1,574
3221	Use of Zebrafish Embryos for Small Molecule Screening Related to Cancer. <i>Developmental Dynamics</i> , 2013, 242, 97-107.	0.8	27
3222	A Multifactorial Likelihood Model for MMR Gene Variant Classification Incorporating Probabilities Based on Sequence Bioinformatics and Tumor Characteristics: A Report from the Colon Cancer Family Registry. <i>Human Mutation</i> , 2013, 34, 200-209.	1.1	81
3223	Modeling Tumor Progression by the Sequential Introduction of Genetic Alterations into the Genome of Human Normal Cells. <i>Human Mutation</i> , 2013, 34, 330-337.	1.1	6
3224	Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma. <i>Journal of Pathology</i> , 2013, 229, 132-140.	2.1	34
3225	Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. <i>Biochemical Pharmacology</i> , 2013, 85, 325-334.	2.0	70
3226	Loss of PI(4,5)P2 5-Phosphatase A Contributes to Resistance of Human Melanoma Cells to RAF/MEK Inhibitors. <i>Translational Oncology</i> , 2013, 6, 470-IN15.	1.7	7
3227	Melanoma. Shall we move away from the sun and focus more on embryogenesis, body weight and longevity?. <i>Medical Hypotheses</i> , 2013, 81, 846-850.	0.8	8
3228	Inhibition of autophagy with chloroquine is effective in melanoma. <i>Journal of Surgical Research</i> , 2013, 184, 274-281.	0.8	53
3229	Ibuprofen Inhibits Colitis-Induced Overexpression of Tumor-Related Rac1b. <i>Neoplasia</i> , 2013, 15, 102-111.	2.3	31
3230	Targeting BRAF in melanoma: Biological and clinical challenges. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 239-255.	2.0	41
3231	Radiation-induced dermatitis with vemurafenib therapy. <i>Practical Radiation Oncology</i> , 2013, 3, e195-e198.	1.1	6
3232	Targeting melanoma by small molecules: challenges ahead. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 464-469.	1.5	10
3233	ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers. <i>Oncogene</i> , 2013, 32, 3207-3212.	2.6	66
3235	Therapy Response Assessment in Metastatic Melanoma Patients Treated with a BRAF Inhibitor. <i>Academic Radiology</i> , 2013, 20, 423-429.	1.3	6

#	ARTICLE	IF	CITATIONS
3236	Prolapse-related changes are a confounding factor in misdiagnosis of sessile serrated adenomas in the rectum. <i>Human Pathology</i> , 2013, 44, 480-486.	1.1	22
3237	Molecular pathology of melanocytic tumors. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 362-374.	1.0	38
3239	Melanoma epidemiology, biology and prognosis. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 81-91.	2.2	178
3240	Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses. <i>Virology</i> , 2013, 446, 37-48.	1.1	11
3241	Proliferative Activity, Chromosomal Aberrations, and Tumor-Specific Mutations in the Differential Diagnosis between Blue Nevi and Melanoma. <i>American Journal of Pathology</i> , 2013, 182, 640-645.	1.9	33
3242	Translational Research in Endocrine Surgery. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 857-884.	0.6	11
3243	The role of radiotherapy in the overall treatment of melanoma. <i>Clinics in Dermatology</i> , 2013, 31, 282-289.	0.8	10
3244	Targeted therapy in melanoma. <i>Clinics in Dermatology</i> , 2013, 31, 200-208.	0.8	23
3245	Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. <i>Lung Cancer</i> , 2013, 82, 365-367.	0.9	32
3246	BRCA1 Gene Mutation in Thymic Malignant Melanoma. <i>Annals of Thoracic Surgery</i> , 2013, 96, 677-680.	0.7	1
3247	Translational Research in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 785-804.	0.6	0
3249	Melanocytes, melanocyte stem cells, and melanoma stem cells. <i>Clinics in Dermatology</i> , 2013, 31, 166-178.	0.8	60
3250	Amelanotic acral melanomas: Clinicopathological, BRAF mutation, and KIT aberration analyses. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 700-707.	0.6	32
3251	Expression analysis of B-Raf oncogene in V600E-negative benign and malignant tumors of the thyroid gland: correlation with late disease onset. <i>Medical Oncology</i> , 2013, 30, 336.	1.2	9
3252	Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of <i>EGFR</i> , <i>KRAS</i> , and <i>BRAF</i> Mutations on Formalin-Fixed, Paraffin-Embedded Tumor Material of Non-Small Cell Lung Carcinoma—Superiority of NGS. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 503-511.	1.5	142
3253	Inside Out: Targeting NHE1 as an Intracellular and Extracellular Regulator of Cancer Progression. <i>Chemical Biology and Drug Design</i> , 2013, 81, 85-101.	1.5	33
3254	<i>BRAF</i> V600E and <i>KRAS</i> G12S mutations in peripheral nerve sheath tumours. <i>Histopathology</i> , 2013, 62, 499-504.	1.6	32
3255	BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report. <i>British Journal of Dermatology</i> , 2013, 168, 428-430.	1.4	13

#	ARTICLE	IF	CITATIONS
3256	Kinase dysfunction and kinase inhibitors. <i>Veterinary Dermatology</i> , 2013, 24, 181.	0.4	17
3257	Advances in the management of skin cancer. <i>Veterinary Dermatology</i> , 2013, 24, 173.	0.4	1
3258	Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR. <i>Biomarker Research</i> , 2013, 1, 3.	2.8	64
3259	Oncogenic BRAF Regulates Oxidative Metabolism via PGC1 α and MITF. <i>Cancer Cell</i> , 2013, 23, 302-315.	7.7	689
3260	Other signalization targets. <i>Targeted Oncology</i> , 2013, 8, 69-77.	1.7	6
3261	Discovery and Optimization of a Novel Series of Potent Mutant B-RafV600E Selective Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1996-2015.	2.9	29
3262	Molecular/Targeted Therapy of Cancer. , 2013, , 215-244.		0
3263	Inhibition of melanoma development in the <i>Nras</i> ^{Q61K} mouse model by the small molecule <i>B16A11</i> . <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 136-142.	1.5	18
3264	Emerging molecular targets in melanoma invasion and metastasis. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 39-57.	1.5	94
3265	Vemurafenib Induces Senescence Features in Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1601-1609.	0.3	95
3266	Commentary: BRAF inhibitors for metastatic melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 471-473.	1.4	0
3267	In Vivo SILAC-Based Proteomics Reveals Phosphoproteome Changes during Mouse Skin Carcinogenesis. <i>Cell Reports</i> , 2013, 3, 552-566.	2.9	90
3268	The Assay that Defines Desmosome Hyper-Adhesion. <i>Journal of Investigative Dermatology</i> , 2013, 133, 577-578.	0.3	9
3269	Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. <i>Nature</i> , 2013, 494, 251-255.	13.7	665
3270	Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes. <i>Gastroenterology</i> , 2013, 144, 829-840.	0.6	438
3271	Resistance to BRAF-targeted therapy in melanoma. <i>European Journal of Cancer</i> , 2013, 49, 1297-1304.	1.3	311
3272	Radionuclide Therapy in Melanoma. , 2013, , 101-111.		0
3273	KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. <i>British Journal of Cancer</i> , 2013, 108, 1757-1764.	2.9	191

#	ARTICLE	IF	CITATIONS
3274	Lessons from the Cancer Genome. <i>Cell</i> , 2013, 153, 17-37.	13.5	1,133
3275	Human cancer regression antigens. <i>Current Opinion in Immunology</i> , 2013, 25, 284-290.	2.4	38
3276	<i>BRAF</i> mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. <i>British Journal of Dermatology</i> , 2013, 168, 700-707.	1.4	36
3277	Activation of nuclear factor- κ B contributes to growth and aggressiveness of papillary thyroid carcinoma. <i>Pathology Research and Practice</i> , 2013, 209, 228-232.	1.0	40
3278	Journeys into the genome of cancer cells. <i>EMBO Molecular Medicine</i> , 2013, 5, 169-172.	3.3	27
3279	Obesity and melanoma: Exploring molecular links. <i>Journal of Cellular Biochemistry</i> , 2013, 114, 1955-1961.	1.2	18
3280	Regulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins. <i>Developmental Cell</i> , 2013, 24, 459-471.	3.1	242
3281	MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands. <i>International Journal of Oncology</i> , 2013, 42, 2028-2036.	1.4	16
3282	Existing and Emerging Technologies for Tumor Genomic Profiling. <i>Journal of Clinical Oncology</i> , 2013, 31, 1815-1824.	0.8	129
3283	The role of high-throughput technologies in clinical cancer genomics. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 167-181.	1.5	26
3284	Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 1284-1304.	1.4	34
3285	Clinical Responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring BRAF ^{V600E} Mutation. <i>Thyroid</i> , 2013, 23, 1277-1283.	2.4	184
3286	Implementing personalized cancer genomics in clinical trials. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 358-369.	21.5	267
3287	Oncoapoptotic signaling and deregulated target genes in cancers: Special reference to oral cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1836, 123-145.	3.3	43
3288	MEK and the inhibitors: from bench to bedside. <i>Journal of Hematology and Oncology</i> , 2013, 6, 27.	6.9	219
3289	Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing. <i>Journal of Surgical Research</i> , 2013, 182, 85-93.	0.8	28
3290	Identification of driver mutations in lung cancer: first step in personalized cancer. <i>Targeted Oncology</i> , 2013, 8, 3-14.	1.7	26
3291	¹⁸ F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. <i>European Journal of Cancer</i> , 2013, 49, 395-402.	1.3	42

#	ARTICLE	IF	CITATIONS
3292	Targeting the RAS oncogene. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 507-531.	1.5	105
3293	Genetic mutations, molecular markers and future directions in research. <i>Oral Oncology</i> , 2013, 49, 711-721.	0.8	6
3294	Chloroquine Promotes Apoptosis in Melanoma Cells by Inhibiting BH3 Domain-Mediated PUMA Degradation. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2247-2254.	0.3	57
3295	Developing melanoma therapeutics: overview and update. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2013, 5, 257-271.	6.6	13
3296	Phase I/II RAF kinase inhibitors in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 739-749.	1.9	11
3297	Basic Science of the Merkel Cell. , 2013, , 3-19.		0
3298	Pharmacotherapy of metastatic melanoma: Emerging trends and opportunities for a cure. , 2013, 139, 405-411.		12
3299	Targeting apoptosis pathways in pancreatic cancer. <i>Cancer Letters</i> , 2013, 332, 346-358.	3.2	116
3300	The Hematopoietic Stem Cell Regulatory Gene Latexin Has Tumor-Suppressive Properties in Malignant Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1827-1833.	0.3	26
3301	Translating next generation sequencing to practice: Opportunities and necessary steps. <i>Molecular Oncology</i> , 2013, 7, 743-755.	2.1	34
3302	Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. <i>Journal of Human Genetics</i> , 2013, 58, 346-352.	1.1	52
3303	A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. <i>Nature</i> , 2013, 498, 109-112.	13.7	517
3304	Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. <i>European Journal of Endocrinology</i> , 2013, 168, 675-681.	1.9	42
3305	Erdheim-Chester Disease. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 299-311.	0.8	91
3306	Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options. <i>Annals of Pharmacotherapy</i> , 2013, 47, 519-526.	0.9	16
3307	Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 390-399.	12.5	171
3308	Vemurafenib in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 513-522.	1.1	9
3309	Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 394-401.	1.0	27

#	ARTICLE	IF	CITATIONS
3310	Oncogenic KRAS and BRAF activation of the MEK/ERK signaling pathway promotes expression of dual-specificity phosphatase 4 (DUSP4/MKP2) resulting in nuclear ERK1/2 inhibition. <i>Oncogene</i> , 2013, 32, 564-576.	2.6	72
3311	Melanoma Genetics: From Susceptibility to Progression. , 2013, , .		1
3312	Directed Phenotype Switching as an Effective Antimelanoma Strategy. <i>Cancer Cell</i> , 2013, 24, 105-119.	7.7	109
3313	The role of reactivity in DNA templated native chemical PNA ligation during PCR. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 3458-3464.	1.4	26
3314	MicroRNAs in Melanoma Biology. <i>Advances in Experimental Medicine and Biology</i> , 2013, 774, 103-120.	0.8	60
3315	BRAF as a therapeutic target: a patent review (2006 – 2012). <i>Expert Opinion on Therapeutic Patents</i> , 2013, 23, 155-164.	2.4	12
3316	RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation. <i>Cancer Cell</i> , 2013, 23, 594-602.	7.7	112
3317	Which drug, and when, for patients with BRAF-mutant melanoma?. <i>Lancet Oncology</i> , The, 2013, 14, e60-e69.	5.1	164
3318	Oncogenic B-RafV600E abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells. <i>Cancer Letters</i> , 2013, 337, 125-132.	3.2	15
3319	Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. <i>Human Pathology</i> , 2013, 44, 329-335.	1.1	77
3320	Involvement of mixed lineage kinase 3 in cancer. <i>Canadian Journal of Physiology and Pharmacology</i> , 2013, 91, 268-274.	0.7	16
3321	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. <i>Current Opinion in Pharmacology</i> , 2013, 13, 486-496.	1.7	55
3322	Mouse models for lung cancer. <i>Molecular Oncology</i> , 2013, 7, 165-177.	2.1	121
3323	The TRAIL of oncogenes to apoptosis. <i>BioFactors</i> , 2013, 39, 343-354.	2.6	33
3324	The Tumor Immunoenvironment. , 2013, , .		4
3325	Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview. <i>Genetic Testing and Molecular Biomarkers</i> , 2013, 17, 515-523.	0.3	14
3326	Synergistic Effect of Pasireotide and Teriflunomide in Carcinoids in vitro. <i>Neuroendocrinology</i> , 2013, 97, 183-192.	1.2	10
3327	Direct detection of a BRAF mutation in total RNA from melanoma cells using cantilever arrays. <i>Nature Nanotechnology</i> , 2013, 8, 125-129.	15.6	137

#	ARTICLE	IF	CITATIONS
3328	Current and Future Trials of Targeted Therapies in Cutaneous Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 223-255.	0.8	27
3329	Inhibition of Pancreatitis and Carcinogenesis by Capsaicin. , 2013, , 89-106.		0
3330	Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 3706.	1.5	29
3331	Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date. <i>Drugs</i> , 2013, 73, 767-777.	4.9	11
3332	Low RKIP expression associates with poor prognosis in bladder cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 445-453.	1.4	16
3333	Roles of Ion Transport in Control of Cell Motility. , 2013, 3, 59-119.		32
3334	The evolution of S100B inhibitors for the treatment of malignant melanoma. <i>Future Medicinal Chemistry</i> , 2013, 5, 97-109.	1.1	46
3335	Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 13.e1-13.e13.	0.6	11
3336	Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. <i>British Journal of Dermatology</i> , 2013, 169, 320-328.	1.4	24
3337	KRAS and BRAF Mutations in 203 Esophageal Squamous Cell Carcinomas: Pyrosequencing Technology and Literature Review. <i>Annals of Surgical Oncology</i> , 2013, 20, 485-491.	0.7	32
3338	Molecularly targeted therapies for melanoma. <i>International Journal of Dermatology</i> , 2013, 52, 523-530.	0.5	13
3341	BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 748-752.	1.5	54
3342	Crystal Structure of a Promoter Sequence in the <i>B-raf</i> Gene Reveals an Intertwined Dimer Quadruplex. <i>Journal of the American Chemical Society</i> , 2013, 135, 19319-19329.	6.6	45
3343	Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. <i>Oncogene</i> , 2013, 32, 1959-1970.	2.6	47
3344	Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. <i>Haematologica</i> , 2013, 98, 1058-1066.	1.7	67
3345	Detection of BRAF p.V600E Mutations in Melanomas. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 94-100.	1.2	144
3346	Mutual Exclusivity Analysis of Genetic and Epigenetic Drivers in Melanoma Identifies a Link Between p14ARF and RAR1 ² Signaling. <i>Molecular Cancer Research</i> , 2013, 11, 1166-1178.	1.5	23
3347	Assessing colorectal cancer heterogeneity: one step closer to tailored medicine. <i>Journal of Applied Biomedicine</i> , 2013, 11, 115-129.	0.6	2

#	ARTICLE	IF	CITATIONS
3348	Low Incidence of Minor BRAF V600 Mutation-Positive Subclones in Primary and Metastatic Melanoma Determined by Sensitive and Quantitative Real-Time PCR. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 355-361.	1.2	8
3349	The dioxin receptor has tumor suppressor activity in melanoma growth and metastasis. <i>Carcinogenesis</i> , 2013, 34, 2683-2693.	1.3	63
3350	Inhibition of Angiogenesis for the Treatment of Metastatic Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 492-499.	1.8	5
3351	MEK Inhibition in the Treatment of Advanced Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 473-482.	1.8	21
3352	Has discovery-based cancer research been a bust?. <i>Clinical and Translational Oncology</i> , 2013, 15, 865-870.	1.2	3
3353	Autophagy Sustains Mitochondrial Glutamine Metabolism and Growth of <i>Braf</i> ^{V600E} -Driven Lung Tumors. <i>Cancer Discovery</i> , 2013, 3, 1272-1285.	7.7	382
3354	The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be. <i>Clinical Cancer Research</i> , 2013, 19, 5283-5291.	3.2	54
3355	Protein kinase inhibitors in melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 2195-2201.	0.9	9
3356	Emerging BRAF inhibitors for melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 431-443.	1.0	5
3357	Senescent Fibroblasts in Melanoma Initiation and Progression: An Integrated Theoretical, Experimental, and Clinical Approach. <i>Cancer Research</i> , 2013, 73, 6874-6885.	0.4	51
3358	miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma. <i>Physiological Genomics</i> , 2013, 45, 1049-1059.	1.0	49
3359	RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver. <i>Journal of Surgical Oncology</i> , 2013, 107, 393-401.	0.8	14
3360	Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. <i>Oncogene</i> , 2013, 32, 1207-1215.	2.6	95
3361	GAB2 induces tumor angiogenesis in NRAS-driven melanoma. <i>Oncogene</i> , 2013, 32, 3627-3637.	2.6	25
3362	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. <i>Oncogene</i> , 2013, 32, 3009-3018.	2.6	127
3363	Clinical responses to selumetinib (AZD6244; ARRY142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013, 119, 799-805.	2.0	63
3364	Targeting tyrosine kinases in cancer. <i>Cancer Cytopathology</i> , 2013, 121, 61-71.	1.4	12
3365	<i>BRAF</i> mutation detection in indeterminate thyroid cytology specimens. <i>Cancer Cytopathology</i> , 2013, 121, 197-205.	1.4	71

#	ARTICLE	IF	CITATIONS
3366	Identification of the V600D mutation in Exon 15 of the <i>BRAF</i> oncogene in congenital, benign langerhans cell histiocytosis. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 99-106.	1.5	53
3367	Pharmacophore model generation and 3D-QSAR analysis of N-acyl and N-aroilpyrazolines for enzymatic and cellular B-Raf kinase inhibition. <i>Medicinal Chemistry Research</i> , 2013, 22, 2174-2187.	1.1	6
3368	Cutaneous effects of BRAF inhibitor therapy: a case series. <i>Annals of Oncology</i> , 2013, 24, 530-537.	0.6	73
3369	Bioorthogonal reactions challenged: DNA templated native chemical ligation during PCR. <i>Chemical Science</i> , 2013, 4, 432-436.	3.7	50
3370	MAP kinase signaling and inhibition in melanoma. <i>Oncogene</i> , 2013, 32, 2373-2379.	2.6	127
3373	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. <i>Expert Review of Dermatology</i> , 2013, 8, 479-487.	0.3	4
3374	Relief of Feedback Inhibition of <i>HER3</i> Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in <i>BRAF</i> -Mutant Thyroid Carcinomas. <i>Cancer Discovery</i> , 2013, 3, 520-533.	7.7	328
3375	Targeting BRAF in Multiple Myeloma. <i>Cancer Discovery</i> , 2013, 3, 840-842.	7.7	15
3376	Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2215-2224.	1.7	41
3377	The diagnostic role and clinical relevance of determination of <i>BRAF</i> status in brain tumors. <i>Personalized Medicine</i> , 2013, 10, 405-412.	0.8	7
3378	Harnessing massively parallel DNA sequencing for the personalization of cancer management. <i>Personalized Medicine</i> , 2013, 10, 183-190.	0.8	2
3379	BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. <i>Clinical Cancer Research</i> , 2013, 19, 393-403.	3.2	336
3380	DÅ©jÅ Vu: EGF Receptors Drive Resistance to BRAF Inhibitors. <i>Cancer Discovery</i> , 2013, 3, 487-490.	7.7	25
3383	Analysis of clinical and dermoscopic features in melanocytic lesions with special emphasis on problematic lesions in children. <i>Expert Review of Dermatology</i> , 2013, 8, 155-170.	0.3	3
3384	Single-molecule force measurement via optical tweezers reveals different kinetic features of two BRaf mutants responsible for cardio-facial-cutaneous (CFC) syndrome. <i>Biomedical Optics Express</i> , 2013, 4, 2835.	1.5	3
3385	A Two-Hybrid Approach to Identify Inhibitors of the RASâ€“RAF Interaction. <i>The Enzymes</i> , 2013, 33 Pt A, 213-248.	0.7	7
3386	Usefulness of Immunocytochemistry for the Detection of the BRAFV600E Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1378-1381.	0.3	39
3387	Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4532-4540.	3.2	307

#	ARTICLE	IF	CITATIONS
3388	Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of <i>BRAF</i> V600E Colorectal Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2688-2698.	3.2	76
3389	Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with <i>BRAF</i> V600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression. <i>Clinical Cancer Research</i> , 2013, 19, 5749-5757.	3.2	113
3390	Personalizing Therapy in Advanced Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2013, 34, 822-836.	0.8	20
3391	In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis. <i>Frontiers in Oncology</i> , 2013, 3, 127.	1.3	9
3392	Peptide nucleic acid clamp polymerase chain reaction reveals a deletion mutation of the <i>BRAF</i> gene in papillary thyroid carcinoma: A case report. <i>Experimental and Therapeutic Medicine</i> , 2013, 6, 1550-1552.	0.8	7
3393	The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. <i>Biochemical Journal</i> , 2013, 450, 285-294.	1.7	53
3394	Pseudokinase drug intervention: a potentially poisoned chalice. <i>Biochemical Society Transactions</i> , 2013, 41, 1083-1088.	1.6	12
3395	Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. <i>Carcinogenesis</i> , 2013, 34, 885-892.	1.3	10
3397	Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy. <i>Frontiers in Oncology</i> , 2013, 3, 136.	1.3	22
3398	Downregulation of <i>DLC-1</i> Gene by Promoter Methylation during Primary Colorectal Cancer Progression. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	15
3399	Combinatorial Resistance: The Best Defense is a Good Offense. <i>Frontiers in Oncology</i> , 2013, 3, 280.	1.3	0
3400	ERK Phosphorylation Is Not Increased in Papillary Thyroid Carcinomas with <i>BRAF</i> ^{V600E} Mutation Compared to That of Corresponding Normal Thyroid Tissues. <i>Endocrine Research</i> , 2013, 38, 89-97.	0.6	6
3402	Vemurafenib and ipilimumab: New agents for metastatic melanoma. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1205-1210.	0.5	16
3403	Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. <i>Expert Review of Molecular Diagnostics</i> , 2013, 13, 613-623.	1.5	32
3405	Topical 5-Fluorouracil Elicits Regressions of <i>BRAF</i> Inhibitor-Induced Cutaneous Squamous Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 274-276.	0.3	14
3406	The Scientific Drunk and the Lamppost: Massive Sequencing Efforts in Cancer Discovery and Treatment. <i>Science Signaling</i> , 2013, 6, pe13.	1.6	64
3407	Erythema Nodosum-Like Panniculitis in Patients With Melanoma Treated With Vemurafenib. <i>Journal of Clinical Oncology</i> , 2013, 31, e320-e321.	0.8	29
3408	³ â€²-Deoxy- ³ â€²- ¹⁸ F-Fluorothymidine PET Predicts Response to ^{V600E} <i>BRAF</i> -Targeted Therapy in Preclinical Models of Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 424-430.	2.8	25

#	ARTICLE	IF	CITATIONS
3409	Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Tumors. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2013, 29, 57-62.	0.4	61
3410	Pathology and genetics of uveal melanoma. <i>Pathology</i> , 2013, 45, 18-27.	0.3	31
3411	Cumulative dermatologic toxicity with ipilimumab and vemurafenib responsive to corticosteroids. <i>Melanoma Research</i> , 2013, 23, 496-497.	0.6	5
3412	C-kit-mutated melanomas. <i>Current Opinion in Oncology</i> , 2013, 25, 160-165.	1.1	15
3413	BRAF Mutation-Positive Folliculotropic Metastatic Melanoma. <i>American Journal of Dermatopathology</i> , 2013, 35, 609-612.	0.3	3
3414	Biological insights into BRAF ^{V600} mutations in melanoma patient. <i>Oncolmmunology</i> , 2013, 2, e25594.	2.1	6
3415	Hematopoietic Expression of Oncogenic <i>BRAF</i> Promotes Aberrant Growth of Monocyte-Lineage Cells Resistant to PLX4720. <i>Molecular Cancer Research</i> , 2013, 11, 1530-1541.	1.5	7
3416	Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma. <i>Melanoma Research</i> , 2013, 23, 373-380.	0.6	12
3417	BRAF V600E Mutations in Endometrial Adenocarcinoma. <i>Diagnostic Molecular Pathology</i> , 2013, 22, 35-40.	2.1	10
3418	Ras, Raf, and MAP Kinase in Melanoma. <i>Advances in Anatomic Pathology</i> , 2013, 20, 217-226.	2.4	60
3419	Predictors of BRAF Mutation in Melanocytic Nevi. <i>American Journal of Dermatopathology</i> , 2013, 35, 412-418.	0.3	28
3420	Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2013, 31, 482-489.	0.8	439
3421	Low-copy <i>piggyBac</i> transposon mutagenesis in mice identifies genes driving melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E3640-9.	3.3	28
3422	BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1592-1602.	2.1	125
3423	Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1767-1774.	0.8	335
3424	Lessons from in-vivo models of castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 214-219.	0.9	8
3425	Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 263-271.	1.0	4
3426	BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2013, 2, e26615.	2.1	97

#	ARTICLE	IF	CITATIONS
3427	Detection of <i>BRAF</i> V600E Mutation With Thyroid Tissue Using Pyrosequencing. <i>American Journal of Clinical Pathology</i> , 2013, 139, 759-764.	0.4	31
3428	Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1232-1243.	3.2	60
3429	DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. <i>Endocrine-Related Cancer</i> , 2013, 20, 23-37.	1.6	41
3430	Brainstem Ganglioglioma Successfully Treated With Vemurafenib. <i>Journal of Clinical Oncology</i> , 2013, 31, e159-e160.	0.8	120
3431	P21-Activated Kinase 1 (PAK1) as a Therapeutic Target in BRAF Wild-Type Melanoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 606-607.	3.0	73
3432	MITF: A Critical Transcription Factor in Melanoma Transcriptional Regulatory Network. , 2013, , .		0
3433	Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma. <i>Cancer Research</i> , 2013, 73, 7043-7055.	0.4	102
3434	The FBXO4 Tumor Suppressor Functions as a Barrier to <i>Braf</i> ^{V600E} -Dependent Metastatic Melanoma. <i>Molecular and Cellular Biology</i> , 2013, 33, 4422-4433.	1.1	32
3435	Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy. <i>Clinical Cancer Research</i> , 2013, 19, 3796-3807.	3.2	77
3436	Microscopic coherent Raman imaging using low-cost continuous wave lasers. <i>Laser Physics Letters</i> , 2013, 10, 065701.	0.6	27
3437	Biomarkers in precision therapy in colorectal cancer. <i>Gastroenterology Report</i> , 2013, 1, 166-183.	0.6	86
3438	Melanoma: Treatments and Resistance. , 0, , .		0
3439	Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells. <i>Science Signaling</i> , 2013, 6, ra7.	1.6	114
3440	Application of <i>BRAF</i> , <i>NRAS</i> , <i>KRAS</i> mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1673-1680.	1.4	30
3441	Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 105-118.	1.4	45
3442	<i>RAS</i> , <i>BRAF</i> , and <i>TP53</i> Gene Mutations in Taiwanese Colorectal Cancer Patients. <i>Oncology Research and Treatment</i> , 2013, 36, 719-724.	0.8	17
3443	<i>BRAF</i> in Melanoma: Current Strategies and Future Directions. <i>Clinical Cancer Research</i> , 2013, 19, 4326-4334.	3.2	76
3444	<i>BRAF</i> V600E mutation in adult acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 1105-1106.	0.6	4

#	ARTICLE	IF	CITATIONS
3445	Imatinib for Melanomas Harboring Mutationally Activated or Amplified <i>KIT</i> Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. <i>Journal of Clinical Oncology</i> , 2013, 31, 3182-3190.	0.8	530
3446	C-RAF Mutations Confer Resistance to RAF Inhibitors. <i>Cancer Research</i> , 2013, 73, 4840-4851.	0.4	30
3447	Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment. <i>Clinical Cancer Research</i> , 2013, 19, 480-490.	3.2	105
3448	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 2257-2264.	3.2	136
3449	An Unholy Alliance: Cooperation between BRAF and NF1 in Melanoma Development and BRAF Inhibitor Resistance. <i>Cancer Discovery</i> , 2013, 3, 260-263.	7.7	37
3450	Immunohistochemical and molecular pathology of ocular uveal melanocytoma: evidence for somatic <i>GNAQ</i> mutations. <i>British Journal of Ophthalmology</i> , 2013, 97, 924-928.	2.1	16
3451	Lack of BRAF V600E Protein Expression in Primary Central Nervous System Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 351-353.	0.6	7
3452	Clinicopathological relevance of BRAF mutations in human cancer. <i>Pathology</i> , 2013, 45, 346-356.	0.3	131
3453	Colorectal Cancer: Molecular Mutations and Polymorphisms. <i>Frontiers in Oncology</i> , 2013, 3, 114.	1.3	121
3454	Dabrafenib for treatment of BRAF-mutant melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 21.	0.4	14
3455	Altered mRNA Expression Related to the Apoptotic Effect of Three Xanthenes on Human Melanoma SK-MEL-28 Cell Line. <i>BioMed Research International</i> , 2013, 2013, 1-10.	0.9	13
3456	The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe. <i>Frontiers in Oncology</i> , 2013, 3, 304.	1.3	23
3457	Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S9565.	0.6	8
3458	Mechanisms Limiting Distribution of the Threonine-Protein Kinase B-RaF ^{V600E} Inhibitor Dabrafenib to the Brain: Implications for the Treatment of Melanoma Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 655-664.	1.3	158
3459	TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in <i>BRAF</i> Mutant Melanoma. <i>Science Translational Medicine</i> , 2013, 5, 196ra98.	5.8	124
3460	Eruptive Squamous Cell Carcinomas after Vemurafenib Therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2013, 17, 419-422.	0.6	14
3461	Melanoma: From Melanocyte to Genetic Alterations and Clinical Options. <i>Scientifica</i> , 2013, 2013, 1-22.	0.6	80
3462	Latest Approved Therapies for Metastatic Melanoma: What Comes Next?. <i>Journal of Skin Cancer</i> , 2013, 2013, 1-10.	0.5	26

#	ARTICLE	IF	CITATIONS
3463	A New Role of Vemurafenib as a Neoadjuvant Treatment of Axillary and Brain Melanoma Metastases. Case Reports in Oncological Medicine, 2013, 2013, 1-3.	0.2	7
3464	Gene Therapy for Advanced Melanoma: Selective Targeting and Therapeutic Nucleic Acids. Journal of Drug Delivery, 2013, 2013, 1-15.	2.5	18
3465	crcTRP: A Translational Research Platform for Colorectal Cancer. Computational and Mathematical Methods in Medicine, 2013, 2013, 1-9.	0.7	5
3466	Honokiol thwarts gastric tumor growth and peritoneal dissemination by inhibiting Tpl2 in an orthotopic model. Carcinogenesis, 2013, 34, 2568-2579.	1.3	45
3467	Formation of Gelsolin Amyloid Fibrils in the Rough Endoplasmic Reticulum of Skeletal Muscle in the Gelsolin Mouse Model of Inclusion Body Myositis: Comparative Analysis to Human Sporadic Inclusion Body Myositis. Ultrastructural Pathology, 2013, 37, 304-311.	0.4	3
3468	There is a world beyond protein mutations: the role of non-coding <i>scnRNA</i> s in melanomagenesis. Experimental Dermatology, 2013, 22, 303-306.	1.4	4
3469	Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies. Clinical Pharmacology and Therapeutics, 2013, 95, 24-31.	2.3	75
3470	Genotyping by Induced Förster Resonance Energy Transfer (iFRET) Mechanism and Simultaneous Mutation Scanning. Human Mutation, 2013, 34, n/a-n/a.	1.1	2
3471	The clinical significance of <i>BRAF</i> and <i>NRAS</i> mutations in a clinic-based metastatic melanoma cohort. British Journal of Dermatology, 2013, 169, 1049-1055.	1.4	97
3472	Recurrent <i>BRAF</i> kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell and Melanoma Research, 2013, 26, 845-851.	1.5	114
3473	RAC1b overexpression in papillary thyroid carcinoma: a role to unravel. European Journal of Endocrinology, 2013, 168, 795-804.	1.9	29
3474	The path of least resistance: enhancing the effectiveness of <i>BRAF</i> inhibitors. Pigment Cell and Melanoma Research, 2013, 26, 296-297.	1.5	2
3475	<i>BCL2</i> and <i>BCL2L1</i> are key determinants of resistance to antitubulin chemotherapeutics in melanoma cells. Experimental Dermatology, 2013, 22, 518-523.	1.4	21
3476	Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer, 2013, 20, 603-610.	1.6	500
3477	The current and future role of sequence-based analysis in prostate cancer treatment. Personalized Medicine, 2013, 10, 257-273.	0.8	0
3478	Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment. Australasian Journal of Dermatology, 2013, 54, 163-172.	0.4	13
3479	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. Pharmacological Reviews, 2013, 65, 1351-1395.	7.1	33
3480	Group sequential enrichment design incorporating subgroup selection. Statistics in Medicine, 2013, 32, 2695-2714.	0.8	61

#	ARTICLE	IF	CITATIONS
3481	<sc>DNA</sc> repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. Pigment Cell and Melanoma Research, 2013, 26, 805-816.	1.5	22
3482	CD133+ cell content correlates with tumour growth in melanomas from skin with chronic sun-induced damage. British Journal of Dermatology, 2013, 169, 830-837.	1.4	11
3483	Surgical Management of the Patient with Metastatic Melanoma to the Heart. Journal of Cardiac Surgery, 2013, 28, 124-128.	0.3	7
3484	Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54). Clinical and Experimental Dermatology, 2013, 38, 222-223.	0.6	55
3485	That which does not kill me makes me stronger; combining <sc>ERK</sc> 1/2 pathway inhibitors and <sc>BH</sc>3 mimetics to kill tumour cells and prevent acquired resistance. British Journal of Pharmacology, 2013, 169, 1708-1722.	2.7	19
3486	Impact of <sc>MET</sc> expression on outcome in <sc>BRAF</sc> V600E/K advanced melanoma. Histopathology, 2013, 63, 351-361.	1.6	14
3487	Genetic alteration and immunohistochemical staining patterns of ovarian high-grade serous adenocarcinoma with special emphasis on p53 immunostaining pattern. Pathology International, 2013, 63, 252-259.	0.6	11
3488	Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. British Journal of Dermatology, 2013, 169, 1310-1313.	1.4	41
3489	Alternative splicing of <i>BRAF</i> transcripts and characterization of C-terminally truncated B-Raf isoforms in colorectal cancer. International Journal of Cancer, 2013, 133, 590-596.	2.3	14
3490	Targeting hyperactivation of the <sc>AKT</sc> survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Medicine, 2013, 2, 76-85.	1.3	126
3491	<i>EGFR</i>, <i>KRAS</i>, <i>BRAF</i>, and <i>HER2</i> molecular status in brain metastases from 77 <sc>NSCLC</sc> patients. Cancer Medicine, 2013, 2, 296-304.	1.3	32
3492	<i>BRAF</i> mutations in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 1177-1182.	0.6	45
3493	Vemurafenib: an unusual <sc>UVA</sc>-induced photosensitivity. Experimental Dermatology, 2013, 22, 297-298.	1.4	76
3494	Inhibition of CXCR4-induced CXCL12 chemotaxis in melanoma by AMD11070. British Journal of Cancer, 2013, 108, 1634-1640.	2.9	55
3495	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an <i>In Vivo</i> Model of Childhood Astrocytoma. Clinical Cancer Research, 2013, 19, 6716-6729.	3.2	50
3496	Mixed Lineage Kinase MLK4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis. Cancer Research, 2013, 73, 1912-1921.	0.4	15
3497	Acute Mitochondrial Inhibition by Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK) 1/2 Inhibitors Regulates Proliferation. Journal of Biological Chemistry, 2013, 288, 2933-2940.	1.6	19
3498	PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 2013, 4, 1508.	5.8	67

#	ARTICLE	IF	CITATIONS
3499	Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance. <i>Oncologist</i> , 2013, 18, 850-864.	1.9	82
3500	Targeting the BRAF V600E Mutation in Multiple Myeloma. <i>Cancer Discovery</i> , 2013, 3, 862-869.	7.7	202
3501	Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation. <i>Journal of Clinical Oncology</i> , 2013, 31, e351-e352.	0.8	60
3502	SC-535, a Novel Oral Multikinase Inhibitor, Showed Potent Antitumor Activity in Human Melanoma Models. <i>Cellular Physiology and Biochemistry</i> , 2013, 32, 138-153.	1.1	6
3503	Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. <i>Physical Biology</i> , 2013, 10, 026004.	0.8	3
3504	Diverse Roles for MAPK Signaling in Circadian Clocks. <i>Advances in Genetics</i> , 2013, 84, 1-39.	0.8	76
3505	Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 33-46.	3.0	85
3506	AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. <i>Cell Death and Disease</i> , 2013, 4, e914-e914.	2.7	55
3507	MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. <i>Blood Cancer Journal</i> , 2013, 3, e105-e105.	2.8	55
3508	Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 5957-5962.	3.3	233
3509	RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. <i>Oncogenesis</i> , 2013, 2, e55-e55.	2.1	26
3510	KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases. <i>British Journal of Cancer</i> , 2013, 109, 559-564.	2.9	118
3511	U1 Adaptor Oligonucleotides Targeting BCL2 and GRM1 Suppress Growth of Human Melanoma Xenografts In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2013, 2, e92.	2.3	5
3512	Rare mutations in non-small-cell lung cancer. <i>Future Oncology</i> , 2013, 9, 699-711.	1.1	23
3513	Conformation-Specific Inhibitors of Raf Kinases. <i>The Enzymes</i> , 2013, 34 Pt. B, 41-66.	0.7	3
3514	Ipilimumab for Patients With Advanced Mucosal Melanoma. <i>Oncologist</i> , 2013, 18, 726-732.	1.9	140
3515	Phosphodiesterase-8A binds to and regulates Raf-1 kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E1533-42.	3.3	49
3516	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 373-379.	0.8	199

#	ARTICLE	IF	CITATIONS
3517	Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma. <i>Oncologist</i> , 2013, 18, 314-322.	1.9	192
3518	Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 361-372.	1.9	20
3519	Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer. <i>Cancer Biology and Therapy</i> , 2013, 14, 703-710.	1.5	30
3520	The importance of Raf dimerization in cell signaling. <i>Small GTPases</i> , 2013, 4, 180-185.	0.7	76
3521	Skin toxicity of targeted cancer agents: mechanisms and intervention. <i>Future Oncology</i> , 2013, 9, 1161-1170.	1.1	24
3522	Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. <i>Annals of Oncology</i> , 2013, 24, 1691-1697.	0.6	172
3523	Mosaic RASopathies. <i>Cell Cycle</i> , 2013, 12, 43-50.	1.3	87
3524	Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. <i>Scientific Reports</i> , 2013, 3, 3494.	1.6	44
3525	A moving target: challenges in treating BRAF-mutant colorectal cancer. <i>Colorectal Cancer</i> , 2013, 2, 197-204.	0.8	0
3526	Melanoma treatment: where are we now and what are the trends on the horizon?. <i>Clinical Practice (London, England)</i> , 2013, 13, 101-106.	0.1	0
3527	BRAF Test and Cytological Diagnosis with a Single Fine Needle Cytology Sample. <i>Acta Cytologica</i> , 2013, 57, 337-340.	0.7	11
3528	Human hepatocyte carcinogenesis. <i>International Journal of Oncology</i> , 2013, 42, 1133-1138.	1.4	105
3529	Malignes Melanom S3-Leitlinie – Diagnostik, Therapie und Nachsorge des Melanoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1-126.	0.4	9
3530	Malignant Melanoma S3-Guideline – Diagnosis, Therapy and Follow-up of Melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1-116.	0.4	122
3531	Dermatopathology, then and now – have we travelled?. <i>Expert Review of Dermatology</i> , 2013, 8, 585-587.	0.3	0
3532	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 183-232.		0
3533	Gefitinib: re-emerging from the shadows. <i>Lung Cancer Management</i> , 2013, 2, 423-437.	1.5	0
3534	Melanoma Mutagenesis and Aberrant Cell Signaling. <i>Cancer Control</i> , 2013, 20, 261-281.	0.7	29

#	ARTICLE	IF	CITATIONS
3535	New Targeted Therapies in Melanoma. <i>Cancer Control</i> , 2013, 20, 282-288.	0.7	11
3536	The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models. <i>Genome Biology</i> , 2013, 14, R113.	13.9	40
3537	A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. <i>Scientific Reports</i> , 2013, 3, 1659.	1.6	36
3538	Identifying BRAF and KIT mutations in melanoma. <i>Expert Review of Dermatology</i> , 2013, 8, 171-176.	0.3	1
3540	Mutation analysis in malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 2-10.	0.4	2
3541	Changes in Tumor Morphology and Cyclin-Dependent Kinase Inhibitor Expression in Metastatic Melanoma Treated With Selective Second-Generation BRAF Inhibitor. <i>American Journal of Dermatopathology</i> , 2013, 35, 125-128.	0.3	5
3542	Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways. <i>Current Pharmaceutical Design</i> , 2013, 19, 841-863.	0.9	12
3543	Stimulated Raman microscopy without ultrafast lasers. <i>Proceedings of SPIE</i> , 2013, , .	0.8	0
3544	The Role of BRAF-Targeted Therapy in Astrocytomas. <i>Neurosurgery</i> , 2013, 60, 110-112.	0.6	5
3546	Current Advances in Therapy for Metastatic Melanoma. <i>Current Cancer Therapy Reviews</i> , 2013, 9, 8-23.	0.2	0
3547	Autres biomarqueurs potentiels des anti-EGFR. , 2013, , 177-191.		0
3548	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65.	2.1	289
3549	Peptide Vaccine Therapy for Childhood Gliomas. <i>Neurosurgery</i> , 2013, 60, 113-119.	0.6	8
3550	S3â€œGuideline â€œDiagnosis, therapy and followâ€œup of melanomaâ€œ short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 563-602.	0.4	63
3551	Mutationsanalysen im malignen Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 2-11.	0.4	11
3552	Impact of chromosomal translocation and genomic instability on personalized medicine. <i>Personalized Medicine</i> , 2013, 10, 111-114.	0.8	0
3553	Clonally Related Follicular Lymphomas and Langerhans Cell Neoplasms. <i>American Journal of Surgical Pathology</i> , 2013, 37, 978-986.	2.1	69
3554	The brain microenvironment negatively regulates miRNA-768-3p to promote K-ras expression and lung cancer metastasis. <i>Scientific Reports</i> , 2013, 3, 2392.	1.6	31

#	ARTICLE	IF	CITATIONS
3555	A new model to evaluate Raf signaling in hematopoietic cells. <i>International Journal of Oncology</i> , 2013, 43, 903-910.	1.4	0
3557	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. <i>Haematologica</i> , 2013, 98, 635-639.	1.7	75
3558	Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles. <i>International Journal of Oncology</i> , 2013, 43, 919-926.	1.4	6
3560	A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients. <i>Journal of Nucleic Acids Investigation</i> , 2013, 4, 1.	0.5	24
3561	Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases. <i>Cancer Imaging</i> , 2013, 13, 306-313.	1.2	35
3562	Critical appraisal of the use of regorafenib in the management of colorectal cancer. <i>Cancer Management and Research</i> , 2013, 5, 49.	0.9	5
3563	Personalized treatment for advanced colorectal cancer: KRAS and beyond. <i>Cancer Management and Research</i> , 2013, 5, 387.	0.9	17
3564	KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13748-13762.	1.8	24
3565	The genetics and biology of KRAS in lung cancer. <i>Chinese Journal of Cancer</i> , 2013, 32, 63-70.	4.9	76
3566	Molecular targeted therapies in metastatic melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 49.	0.4	24
3567	Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography. <i>Genetics and Molecular Research</i> , 2013, 12, 4990-4997.	0.3	1
3568	Melanoma "Epidemiology, Genetics and Risk Factors. , 2013, , .		2
3569	Osteopontin expression in papillary thyroid carcinoma and its relationship with the BRAF mutation and tumor characteristics. [Chapchi] <i>Journal Taehan Oekwa Hakhoe</i> , 2013, 84, 9.	1.1	9
3570	Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment. <i>Chinese Journal of Cancer</i> , 2013, 32, 594-603.	4.9	84
3571	Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression. <i>PLoS ONE</i> , 2013, 8, e54302.	1.1	119
3572	Ablation of BRaf Impairs Neuronal Differentiation in the Postnatal Hippocampus and Cerebellum. <i>PLoS ONE</i> , 2013, 8, e58259.	1.1	21
3573	Epidermal Growth Factor Receptor (EGFR)-RAS Signaling Pathway in Penile Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2013, 8, e62175.	1.1	41
3574	Decreased Tumor Progression and Invasion by a Novel Anti-Cell Motility Target for Human Colorectal Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e66439.	1.1	7

#	ARTICLE	IF	CITATIONS
3575	Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas. PLoS ONE, 2013, 8, e66933.	1.1	11
3576	NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi. PLoS ONE, 2013, 8, e69639.	1.1	63
3577	Voting-Based Cancer Module Identification by Combining Topological and Data-Driven Properties. PLoS ONE, 2013, 8, e70498.	1.1	9
3578	Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing. PLoS ONE, 2013, 8, e70826.	1.1	97
3579	Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens. PLoS ONE, 2013, 8, e77065.	1.1	62
3580	The Homeobox Gene MEIS1 Is Methylated in BRAFp.V600E Mutated Colon Tumors. PLoS ONE, 2013, 8, e79898.	1.1	11
3581	Common Oncogenic Mutations Are Infrequent in Oral Squamous Cell Carcinoma of Asian Origin. PLoS ONE, 2013, 8, e80229.	1.1	38
3582	BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients' Outcome. PLoS ONE, 2013, 8, e84604.	1.1	48
3583	Genetics of melanoma. Frontiers in Genetics, 2012, 3, 330.	1.1	27
3584	Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors. Frontiers in Genetics, 2013, 4, 66.	1.1	40
3585	Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring. Frontiers in Oncology, 2013, 3, 54.	1.3	27
3586	In situ Protein Detection for Companion Diagnostics. Frontiers in Oncology, 2013, 3, 271.	1.3	9
3587	Insights into the Transforming Growth Factor- β Signaling Pathway in Cutaneous Melanoma. Annals of Dermatology, 2013, 25, 135.	0.3	72
3588	Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics. International Journal of Nanomedicine, 2013, 8, 2677.	3.3	83
3589	Signal Transduction in Human Cutaneous Melanoma and Target Drugs. Current Cancer Drug Targets, 2013, 13, 843-866.	0.8	56
3590	Targeted Agents for the Treatment of Melanoma: An Overview. , 0, , .		0
3591	The Menace of Melanoma: A Photodynamic Approach to Adjunctive Cancer Therapy. , 0, , .		6
3592	Overcoming Resistance to BRAF and MEK Inhibitors by Simultaneous Suppression of CDK4. , 0, , .		0

#	ARTICLE	IF	CITATIONS
3593	Acquired Resistance to Targeted MAPK Inhibition in Melanoma. , 2013, , .		0
3594	Colon and rectal cancer. , 0, , 547-556.		0
3595	Tyrosine kinome profiling: oncogenic mutations and therapeutic targeting in cancer. , 0, , 58-75.		0
3596	BRAF mutations in human cancer: biologic and therapeutic implications. , 0, , 272-277.		0
3597	BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget, 2013, 4, 310-315.	0.8	140
3599	Adenocarcinoma of the lung. , 2013, , 1043-1092.		1
3600	Diagnosis, Histopathologic and Genetic Classification of Uveal Melanoma. , 2013, , .		1
3601	Current Therapies and New Pharmacologic Targets for Metastatic Melanoma. , 2013, , .		1
3602	Pilocytic Astrocytoma: Anatomic, Pathological and Molecular Aspects. , 2013, , .		1
3603	Glutamate Signaling in Human Cancers. , 0, , .		0
3604	Targeted Therapies in Melanoma: Successes and Pitfalls. , 0, , .		1
3605	Genetically Engineered Mouse Models for Human Lung Cancer. , 2013, , .		3
3606	Frontline Approach to Metastatic <i>BRAF</i> -Mutant Melanoma Diagnosis, Molecular Evaluation, and Treatment Choice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e412-e421.	1.8	4
3607	Conjunctival Melanoma and BRAF Inhibitor Therapy. Journal of Clinical & Experimental Ophthalmology, 2014, 05, .	0.1	26
3608	Benign Melanocytic Lesions and Melanoma. , 2014, , 1182-1192.		0
3609	Up-Regulation of hERG K ⁺ Channels by B-RAF. PLoS ONE, 2014, 9, e87457.	1.1	8
3610	Survival According to BRAF-V600 Tumor Mutations â€œ An Analysis of 437 Patients with Primary Melanoma. PLoS ONE, 2014, 9, e86194.	1.1	42
3611	BRAF-V600 Mutations Have No Prognostic Impact in Stage IV Melanoma Patients Treated with Monochemotherapy. PLoS ONE, 2014, 9, e89218.	1.1	18

#	ARTICLE	IF	CITATIONS
3612	FGFR2 Is Amplified in the NCI-H716 Colorectal Cancer Cell Line and Is Required for Growth and Survival. PLoS ONE, 2014, 9, e98515.	1.1	39
3613	BRAF Mutations in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e101354.	1.1	85
3614	ZNF367 Inhibits Cancer Progression and Is Targeted by miR-195. PLoS ONE, 2014, 9, e101423.	1.1	36
3615	A Novel miR-451a isomiR, Associated with Amelanotypic Phenotype, Acts as a Tumor Suppressor in Melanoma by Retarding Cell Migration and Invasion. PLoS ONE, 2014, 9, e107502.	1.1	43
3616	Oncogenic GNAQ and GNA11 Mutations in Uveal Melanoma in Chinese. PLoS ONE, 2014, 9, e109699.	1.1	22
3617	Cutaneous Epithelial Tumors Induced by Vemurafenib Involve the MAPK and PI3KCA Pathways but Not HPV nor HPyV Viral Infection. PLoS ONE, 2014, 9, e110478.	1.1	16
3618	The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells. PLoS ONE, 2014, 9, e113217.	1.1	38
3619	Advances in Proteomic Technologies and Its Contribution to the Field of Cancer. Advances in Medicine, 2014, 2014, 1-25.	0.3	31
3620	New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy. Drug, Healthcare and Patient Safety, 2014, 6, 77.	1.0	32
3621	Pathways and therapeutic targets in melanoma. Oncotarget, 2014, 5, 1701-1752.	0.8	202
3622	Dermatology: Where are We Coming from and Where are We Going to?. Frontiers in Medicine, 2014, 1, 40.	1.2	0
3623	miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. ELife, 2014, 3, e01460.	2.8	101
3624	Oral malignant melanoma: A report of two cases with BRAF molecular analysis. Oncology Letters, 2014, 8, 1283-1286.	0.8	6
3625	BRAF mutation in hairy cell leukemia. Oncology Reviews, 2014, 8, 253.	0.8	12
3626	Mucosal melanomas in the elderly: challenging cases and review of the literature. Clinical Interventions in Aging, 2014, 9, 929.	1.3	22
3627	PI3K-AKT-mTOR-Signaling and beyond: the Complex Network in Gastroenteropancreatic Neuroendocrine Neoplasms. Theranostics, 2014, 4, 336-365.	4.6	78
3628	<i>hMLH1</i> promoter methylation and <i>BRAF</i> mutations in high-frequency microsatellite instability colorectal cancers not fulfilling the revised Bethesda guidelines. Annals of Surgical Treatment and Research, 2014, 87, 123.	0.4	9
3629	Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer. World Journal of Gastroenterology, 2014, 20, 9862.	1.4	18

#	ARTICLE	IF	CITATIONS
3630	Cyclooxygenase-2 immunohistochemical expression in serrated polyps of the colon. <i>Wspolczesna Onkologia</i> , 2014, 6, 409-413.	0.7	1
3631	BRAF Mutation in Melanoma and Dietary Polyphenols as Adjunctive Treatment Strategy. , 2014, , 1353-1365.		3
3632	Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2014, 8, 775.	2.0	32
3633	Analysis of the BRAF V600E mutation in primary cutaneous melanoma. <i>Genetics and Molecular Research</i> , 2014, 13, 2840-2848.	0.3	21
3634	Role of Mc1r in UV-Induced Melanoma in Animal Models. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2014, 05, .	0.3	0
3635	<i>BRAF</i> mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer. <i>Annals of Surgical Treatment and Research</i> , 2014, 87, 174.	0.4	5
3636	Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study. <i>Annals of Dermatology</i> , 2014, 26, 195.	0.3	26
3637	Insulin induces drug resistance in melanoma through activation of the PI3K/Akt pathway. <i>Drug Design, Development and Therapy</i> , 2014, 8, 255.	2.0	26
3638	Profile of selumetinib and its potential in the treatment of melanoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1631.	1.0	15
3639	The Frequency and Clinical Implications of the BRAF ^{V600E} Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades. <i>Endocrinology and Metabolism</i> , 2014, 29, 505.	1.3	47
3640	Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients. <i>Oncology Reports</i> , 2014, 32, 808-814.	1.2	6
3641	RAF Inhibitor Therapy Promotes Melanocytic Antigen Expression and Enhanced Anti-Tumor Immunity in Melanoma. <i>Journal of Pigmentary Disorders</i> , 2014, 01, .	0.2	0
3642	Molecular Pathogenesis and Targeted Therapies in Well-Differentiated Thyroid Carcinoma. <i>Endocrinology and Metabolism</i> , 2014, 29, 211.	1.3	11
3643	MicroRNA-17 inhibits tumor growth by stimulating T-cell mediated host immune response. <i>Oncoscience</i> , 2014, 1, 531-539.	0.9	32
3646	Precision Cancer Medicine: The Future Is Now, Only Better. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 61-69.	1.8	38
3647	Mechanisms of resistance to EGFR inhibitors in colorectal cancers. <i>Colorectal Cancer</i> , 2014, 3, 511-520.	0.8	0
3648	Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E748-57.	3.3	90
3649	Cucurbitacins: potential candidates targeting mitogen-activated protein kinase pathway for treatment of melanoma. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2014, 29, 162-167.	2.5	26

#	ARTICLE	IF	CITATIONS
3650	Trametinib. Recent Results in Cancer Research, 2014, 201, 241-248.	1.8	23
3651	Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nature Communications, 2014, 5, 3901.	5.8	68
3652	Biomarkers in melanoma: where are we now?. Melanoma Management, 2014, 1, 139-150.	0.1	1
3653	Past, current and future approaches to querying MAPK pathway activation: status and clinical implications. Personalized Medicine, 2014, 11, 745-760.	0.8	0
3654	The preclinical development of regorafenib for the treatment of colorectal cancer. Expert Opinion on Drug Discovery, 2014, 9, 1087-1101.	2.5	27
3655	Non-BRAF targeted therapies for melanoma: protein kinase inhibitors in Phase II clinical trials. Expert Opinion on Investigational Drugs, 2014, 23, 489-500.	1.9	3
3656	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opinion on Biological Therapy, 2014, 14, 663-686.	1.4	17
3657	Cancer <i>In Silico</i> Drug Discovery: A Systems Biology Tool for Identifying Candidate Drugs to Target Specific Molecular Tumor Subtypes. Molecular Cancer Therapeutics, 2014, 13, 3230-3240.	1.9	21
3658	Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma. Future Oncology, 2014, 10, 1559-1570.	1.1	17
3659	TSH Signaling Overcomes B-RafV600E-Induced Senescence in Papillary Thyroid Carcinogenesis through Regulation of DUSP6. Neoplasia, 2014, 16, 1107-1120.	2.3	30
3660	The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Endocrine Research, 2014, 39, 189-193.	0.6	22
3662	B-Raf Regulation of Integrin $\alpha 4 \beta 1$ -mediated Resistance to Shear Stress through Changes in Cell Spreading and Cytoskeletal Association in T Cells. Journal of Biological Chemistry, 2014, 289, 23141-23153.	1.6	11
3663	The Minority Report: Targeting the Rare Oncogenes in NSCLC. Current Treatment Options in Oncology, 2014, 15, 644-657.	1.3	12
3664	Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations. Memo - Magazine of European Medical Oncology, 2014, 7, 181-186.	0.3	1
3665	Information transfer by leaky, heterogeneous, protein kinase signaling systems. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E326-33.	3.3	94
3666	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics, 2014, 15, 1701-1715.	0.6	4
3667	Prospects for MEK inhibitors for treating cancer. Expert Opinion on Drug Safety, 2014, 13, 483-495.	1.0	17
3668	Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1. BMC Cancer, 2014, 14, 884.	1.1	14

#	ARTICLE	IF	CITATIONS
3669	Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma. <i>Molecular Cancer</i> , 2014, 13, 204.	7.9	92
3670	When unity makes strength. <i>Oncolmmunology</i> , 2014, 3, e28048.	2.1	3
3671	The clinical response to vemurafenib in a patient with a rare BRAF V600DK601del mutation-positive melanoma. <i>BMC Cancer</i> , 2014, 14, 727.	1.1	19
3672	Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent. <i>Journal of Translational Medicine</i> , 2014, 12, 356.	1.8	79
3674	Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker. <i>Journal of Clinical Pathology</i> , 2014, 67, 520-528.	1.0	30
3675	Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1249-1258.	1.0	15
3676	High-Sensitivity BRAF Mutation Analysis: BRAF V600E Is Acquired Early During Tumor Development but Is Heterogeneously Distributed in a Subset of Papillary Thyroid Carcinomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1530-E1538.	1.8	64
3677	Is a Single BRAF Wild-Type Test Sufficient to Exclude Melanoma Patients from Vemurafenib Therapy?. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1468-1470.	0.3	37
3678	Molecular pathology of cutaneous melanoma. <i>Melanoma Management</i> , 2014, 1, 151-164.	0.1	4
3679	Targeting Oncogenic Drivers. <i>Progress in Tumor Research</i> , 2014, 41, 1-14.	0.1	7
3680	RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells. <i>Epigenetics</i> , 2014, 9, 1496-1503.	1.3	45
3681	Automation of diagnostic genetic testing: Mutation detection by cyclic minisequencing. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2014, 74, 44-52.	0.6	2
3682	BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. <i>Modern Pathology</i> , 2014, 27, 1028-1034.	2.9	96
3683	Human skin neural crest progenitor cells are susceptible to BRAFV600E-induced transformation. <i>Oncogene</i> , 2014, 33, 832-841.	2.6	13
3684	Oncogenic suppression of PHLPP1 in human melanoma. <i>Oncogene</i> , 2014, 33, 4756-4766.	2.6	29
3685	Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 262-266.	1.4	36
3686	Metabolism addiction in pancreatic cancer. <i>Cell Death and Disease</i> , 2014, 5, e1065-e1065.	2.7	124
3687	ERBB3 is required for metastasis formation of melanoma cells. <i>Oncogenesis</i> , 2014, 3, e110-e110.	2.1	37

#	ARTICLE	IF	CITATIONS
3688	Targeting molecular addictions in cancer. <i>British Journal of Cancer</i> , 2014, 111, 2033-2038.	2.9	35
3689	Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. <i>Cell Death and Disease</i> , 2014, 5, e1104-e1104.	2.7	41
3690	The role of systemic and targeted therapies in brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 93-103.	1.1	6
3691	Proteomic analysis of phosphorylation in cancer. <i>Expert Review of Proteomics</i> , 2014, 11, 259-267.	1.3	44
3692	Immunohistochemical detection of the <sc>BRAF V600E</sc> mutation in melanoma patients with monoclonal antibody <sc>VE1</sc>. <i>Pathology International</i> , 2014, 64, 601-606.	0.6	8
3694	In Vitro Treatment of Melanoma Brain Metastasis by Simultaneously Targeting the MAPK and PI3K Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2014, 15, 8773-8794.	1.8	25
3695	Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study. <i>Annals of Oncology</i> , 2014, 25, 700-706.	0.6	47
3696	Localized insulin-dependent amyloidosis with scar-tissue formation. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e160-e162.	0.6	6
3697	PTEN functions as a melanoma tumor suppressor by promoting host immune response. <i>Oncogene</i> , 2014, 33, 4632-4642.	2.6	86
3698	Vemurafenib. <i>Recent Results in Cancer Research</i> , 2014, 201, 215-225.	1.8	30
3699	BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. <i>Oncology Letters</i> , 2014, 8, 1947-1952.	0.8	104
3700	Mouse Models of Thyroid Neoplasia: Insights into Thyroid Pathophysiology. , 2014, , 1206-1222.		0
3701	Drug Design of Cyclin-Dependent Kinase 2 Inhibitor for Melanoma from Traditional Chinese Medicine. <i>BioMed Research International</i> , 2014, 2014, 1-17.	0.9	11
3702	Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15R α and NKG2D Triggering. <i>Cancer Research</i> , 2014, 74, 68-80.	0.4	43
3703	Presence of Human Polyomavirus 6 in Mutation-Specific BRAF Inhibitor-Induced Epithelial Proliferations. <i>JAMA Dermatology</i> , 2014, 150, 1180.	2.0	51
3704	Neurocristopathies. , 2014, , 361-394.		16
3705	Correlation among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, 268-272.	0.6	4
3706	NFAT5-mediated expression of S100A4 contributes to proliferation and migration of renal carcinoma cells. <i>Frontiers in Physiology</i> , 2014, 5, 293.	1.3	56

#	ARTICLE	IF	CITATIONS
3707	BRAF Pyrosequencing Analysis Aided by a Lookup Table. American Journal of Clinical Pathology, 2014, 141, 639-647.	0.4	5
3708	Data-Derived Modeling Characterizes Plasticity of MAPK Signaling in Melanoma. PLoS Computational Biology, 2014, 10, e1003795.	1.5	20
3709	BRAF and beyond: Tailoring strategies for the individual melanoma patient. Journal of Carcinogenesis, 2014, 13, 1.	2.5	19
3710	Cutaneous Adverse Events during Vemurafenib Therapy. Journal of Cutaneous Medicine and Surgery, 2014, 18, 223-228.	0.6	10
3711	Prediction and Prioritization of Rare Oncogenic Mutations in the Cancer Kinome Using Novel Features and Multiple Classifiers. PLoS Computational Biology, 2014, 10, e1003545.	1.5	23
3712	Detection of BRAF V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. Archives of Pathology and Laboratory Medicine, 2014, 138, 71-75.	1.2	57
3713	The MEK inhibitor trametinib for the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2014, 2, 1341-1349.	0.5	0
3714	Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition. Cell Reports, 2014, 9, 1375-1386.	2.9	34
3715	Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. Laboratory Investigation, 2014, 94, 13-30.	1.7	63
3716	New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome. Human Molecular Genetics, 2014, 23, 6553-6566.	1.4	49
3717	Congenital Nevi and Variants. , 2014, , 111-141.		0
3718	Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanomas. Disease Markers, 2014, 2014, 1-3.	0.6	9
3719	Construction and analysis of regulatory genetic networks in cervical cancer based on involved microRNAs, target genes, transcription factors and host genes. Oncology Letters, 2014, 7, 1279-1283.	0.8	13
3720	Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma. Oncology Letters, 2014, 7, 439-443.	0.8	20
3721	The CIMP Phenotype in BRAF Mutant Serrated Polyps from a Prospective Colonoscopy Patient Cohort. Gastroenterology Research and Practice, 2014, 2014, 1-10.	0.7	41
3722	A comparison of consistency of detecting BRAF gene mutations in peripheral blood and tumor tissue of non-small-cell lung cancer patients. Journal of Cancer Research and Therapeutics, 2014, 10, 150.	0.3	3
3723	Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines. BioMed Research International, 2014, 2014, 1-13.	0.9	18
3724	New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response. European Respiratory Review, 2014, 23, 367-378.	3.0	78

#	ARTICLE	IF	CITATIONS
3725	BRAFV600E immunopositive Melanomas Show Low Frequency of Heterogeneity and Association With Epithelioid Tumor Cells. <i>Medicine (United States)</i> , 2014, 93, e285.	0.4	13
3726	The molecular background of mucinous carcinoma beyond MUC2. <i>The Clinical Journal of Pathology</i> , 2014, , n/a-n/a.	0.0	1
3727	Ocular albinism type 1-induced melanoma cell migration is mediated through the RAS/RAF/MEK/ERK signaling pathway. <i>Molecular Medicine Reports</i> , 2014, 10, 491-495.	1.1	23
3728	BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. <i>Oncology Letters</i> , 2014, 8, 869-875.	0.8	103
3729	RET and other genes: therapeutic targets in lung adenocarcinoma. <i>Lung Cancer Management</i> , 2014, 3, 219-226.	1.5	0
3730	Genomics in Multiple Myeloma. , 2014, , 301-319.		2
3732	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2014, , .	1.5	12
3734	Molecular Pathology of Skin Neoplasms of the Head and Neck. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 759-787.	1.2	50
3735	Ultraviolet radiation therapy and UVR dose models. <i>Medical Physics</i> , 2015, 42, 440-455.	1.6	29
3736	Application of Genomic Principles to Pharmacotherapy of Cancer. <i>American Journal of Pharmaceutical Education</i> , 2014, 78, 55.	0.7	10
3737	Breakthrough therapies in melanoma. <i>Future Oncology</i> , 2014, 10, 781-784.	1.1	0
3738	Lupus erythematosus-like skin eruption after vemurafenib therapy. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e159-e160.	0.6	7
3739	Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. <i>Future Oncology</i> , 2014, 10, 2045-2059.	1.1	10
3740	Factors Influencing the CNS Distribution of a Novel MEK-1/2 Inhibitor: Implications for Combination Therapy for Melanoma Brain Metastases. <i>Drug Metabolism and Disposition</i> , 2014, 42, 1292-1300.	1.7	89
3741	The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 368-374.	1.0	41
3742	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. <i>Nature Communications</i> , 2014, 5, 5712.	5.8	503
3743	The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. <i>Cancer Research</i> , 2014, 74, 4845-4852.	0.4	148
3744	High frequency of <sc>PTEN</sc> mutations in nevi and melanomas from xeroderma pigmentosum patients. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 454-464.	1.5	40

#	ARTICLE	IF	CITATIONS
3745	Targeting RASâ€“ERK signalling in cancer: promises and challenges. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 928-942.	21.5	887
3746	Xanthoceraside Induces Apoptosis in Melanoma Cells Through the Activation of Caspases and the Suppression of the IGF-1R/Raf/MEK/ERK Signaling Pathway. <i>Journal of Medicinal Food</i> , 2014, 17, 1070-1078.	0.8	15
3747	Molecular diagnostic testing of cytology specimens: current applications and future considerations. <i>Journal of the American Society of Cytopathology</i> , 2014, 3, 280-294.	0.2	9
3748	Dynamic interplay between autophagic flux and <i>Akt</i> during melanoma progression <i>in vitro</i> . <i>Experimental Dermatology</i> , 2014, 23, 101-106.	1.4	21
3749	The <i>BRAF</i> ^{V600E} mutation in papillary thyroid microcarcinoma: does the mutation have an impact on clinical outcome?. <i>Clinical Endocrinology</i> , 2014, 80, 899-904.	1.2	52
3750	Expression of insulinâ€“like growth factorâ€“1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 297-308.	1.5	42
3751	Activating BRAF and PIK3CA Mutations Cooperate to Promote Anaplastic Thyroid Carcinogenesis. <i>Molecular Cancer Research</i> , 2014, 12, 979-986.	1.5	92
3752	Medical management of metastatic medullary thyroid cancer. <i>Cancer</i> , 2014, 120, 3287-3301.	2.0	38
3753	Personalized oncology: genomic screening in phase 1. <i>Apmis</i> , 2014, 122, 723-733.	0.9	18
3754	The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2253-2263.	1.9	126
3755	Implication of ultraviolet light in the etiology of uveal melanoma: A review. <i>Photochemistry and Photobiology</i> , 2014, 90, 15-21.	1.3	28
3756	Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for <i>Annals of Oncology</i> . <i>Annals of Oncology</i> , 2014, 25, 917-918.	0.6	5
3757	Pediatric Brainstem Gangliogliomas Show <i>BRAF</i> ^{V600E} Mutation in a High Percentage of Cases. <i>Brain Pathology</i> , 2014, 24, 173-183.	2.1	52
3758	Exploiting the curative potential of adoptive Tâ€“cell therapy for cancer. <i>Immunological Reviews</i> , 2014, 257, 56-71.	2.8	422
3759	Src inhibitors in suppression of papillary thyroid carcinoma growth. <i>Head and Neck</i> , 2014, 36, 375-384.	0.9	18
3760	The Biology and Clinical Development of MEK Inhibitors for Cancer. <i>Drugs</i> , 2014, 74, 2111-2128.	4.9	35
3761	Pulmonary squamous cell carcinoma and sorafenib. <i>Clinical Case Reports (discontinued)</i> , 2014, 2, 206-208.	0.2	0
3762	Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival. <i>Annals of Oncology</i> , 2014, 25, 1253-1255.	0.6	31

#	ARTICLE	IF	CITATIONS
3763	<i>BRAF</i> kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type <i>RAS</i> . <i>American Journal of Hematology</i> , 2014, 89, 499-504.	2.0	30
3764	Diagnostic value of <i>RAF</i> ^{V600E} in difficult-to-diagnose thyroid nodules using fine-needle aspiration: Systematic review and meta-analysis. <i>Diagnostic Cytopathology</i> , 2014, 42, 94-101.	0.5	28
3765	A novel method for somatic transgenesis of the mouse prostate using the Sleeping Beauty transposon system. <i>Prostate</i> , 2014, 74, 781-791.	1.2	1
3766	Molecular alterations in non-small cell lung carcinomas of the young. <i>Human Pathology</i> , 2014, 45, 2379-2387.	1.1	33
3767	<i>BRAF</i> mutation in "sarcomas": a possible method to detect dedifferentiated melanomas. <i>Histopathology</i> , 2014, 64, 639-646.	1.6	33
3768	Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. <i>Cancer Discovery</i> , 2014, 4, 1377-1386.	7.7	76
3769	Resistance to vemurafenib resulting from a novel mutation in the <i>BRAF</i> ^{V600E} kinase domain. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 124-133.	1.5	51
3770	Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. <i>British Journal of Cancer</i> , 2014, 111, 477-485.	2.9	97
3771	Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung. <i>Cancer Medicine</i> , 2014, 3, 337-348.	1.3	31
3772	The role of ERK2 in colorectal carcinogenesis is partly regulated by TRAPPC4. <i>Molecular Carcinogenesis</i> , 2014, 53, E72-84.	1.3	14
3773	Mouse Matrix Metalloprotease-1a (Mmp1a) Gives New Insight Into MMP Function. <i>Journal of Cellular Physiology</i> , 2014, 229, 1875-1880.	2.0	27
3774	Molecular detection of <i>BRAF</i> ^{V600E} is superior to flow cytometry for disease evaluation in hairy cell leukaemia. <i>Hematological Oncology</i> , 2014, 32, 158-161.	0.8	5
3775	Targeting glutamine transport to suppress melanoma cell growth. <i>International Journal of Cancer</i> , 2014, 135, 1060-1071.	2.3	179
3776	Progress in skin cancer: the U.K. experience. <i>British Journal of Dermatology</i> , 2014, 171, 443-445.	1.4	17
3777	<i>BRAF</i> mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 615-625.	1.3	12
3778	Opening the melanoma black box. <i>British Journal of Dermatology</i> , 2014, 170, 9-10.	1.4	0
3779	Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 761-769.	1.7	16
3780	FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju107.	3.0	87

#	ARTICLE	IF	CITATIONS
3781	Validation of the <sc>VE1</sc> immunostain for the <i><sc>BRAF</sc></i> <sc>V600E</sc> mutation in melanoma. Journal of Cutaneous Pathology, 2014, 41, 724-732.	0.7	49
3782	The use of vemurafenib in <sc>A</sc>ustralian patients with unresectable or metastatic melanoma containing the <sc>V</sc>600 <sc><i>BRAF</i></sc> gene mutation. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 1-15.	0.7	4
3783	Major therapeutic developments and current challenges in advanced melanoma. British Journal of Dermatology, 2014, 170, 36-44.	1.4	20
3784	<sc>MicroRNA</sc>â€³0b functions as a tumour suppressor in human colorectal cancer by targeting <i><sc>KRAS</sc></i>, <i><sc>PIK3CD</sc></i> and <sc><i>BCL2</i></sc>. Journal of Pathology, 2014, 232, 415-427.	2.1	129
3785	Molecular mechanisms of asymmetric RAF dimer activation. Biochemical Society Transactions, 2014, 42, 784-790.	1.6	28
3786	Dermoscopic criteria associated with <i><sc>BRAF</sc></i> and <i><sc>NRAS</sc></i> mutation status in primary cutaneous melanoma. British Journal of Dermatology, 2014, 171, 754-759.	1.4	26
3787	Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites. Cancer Cytopathology, 2014, 122, 504-511.	1.4	19
3788	Decatenation checkpointâ€defective melanomas are dependent on <sc>PI</sc>3K for survival. Pigment Cell and Melanoma Research, 2014, 27, 813-821.	1.5	10
3789	p53-Independent Effects of Mdm2. Sub-Cellular Biochemistry, 2014, 85, 235-246.	1.0	70
3790	Sildenafil Use and Increased Risk of Incident Melanoma in US Men. JAMA Internal Medicine, 2014, 174, 964.	2.6	108
3791	Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?. Expert Opinion on Pharmacotherapy, 2014, 15, 589-592.	0.9	23
3792	Cutaneous Granulomatous Eruption and Successful Response to Potent Topical Steroids in Patients Undergoing Targeted BRAF Inhibitor Treatment for Metastatic Melanoma. JAMA Dermatology, 2014, 150, 307.	2.0	44
3793	Dabrafenib for the treatment of melanoma. Expert Opinion on Pharmacotherapy, 2014, 15, 1043-1050.	0.9	4
3794	BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency. Journal of Endocrinological Investigation, 2014, 37, 1009-1014.	1.8	21
3795	MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. Archives of Dermatological Research, 2014, 306, 873-884.	1.1	11
3796	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITC expert meeting ECCO 2013. Expert Review of Anticancer Therapy, 2014, 14, 1477-1493.	1.1	12
3797	TRAP1 Is Involved in BRAF Regulation and Downstream Attenuation of ERK Phosphorylation and Cell-Cycle Progression: A Novel Target for BRAF-Mutated Colorectal Tumors. Cancer Research, 2014, 74, 6693-6704.	0.4	43
3798	A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations. BMC Bioinformatics, 2014, 15, 86.	1.2	26

#	ARTICLE	IF	CITATIONS
3799	Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses. <i>BMC Cancer</i> , 2014, 14, 857.	1.1	21
3800	Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma. <i>BMC Cancer</i> , 2014, 14, 967.	1.1	6
3801	A global assessment of cancer genomic alterations in epigenetic mechanisms. <i>Epigenetics and Chromatin</i> , 2014, 7, 29.	1.8	64
3802	KRAS and BRAF mutational status in colon cancer from Albanian patients. <i>Diagnostic Pathology</i> , 2014, 9, 187.	0.9	11
3803	Selective inhibitors of nuclear export (SINE)â€“ a novel class of anti-cancer agents. <i>Journal of Hematology and Oncology</i> , 2014, 7, 78.	6.9	111
3804	MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis. <i>Genome Biology</i> , 2014, 15, 489.	3.8	54
3805	<i>BRAF</i> ^{V600E} Mutation Status of Involuting and Stable Nevi in Dabrafenib Therapy With or Without Trametinib. <i>JAMA Dermatology</i> , 2014, 150, 1079.	2.0	26
3806	Downregulation of reversion-inducing cysteine-rich protein with Kazal motifs in malignant melanoma. <i>Melanoma Research</i> , 2014, 24, 32-39.	0.6	9
3807	Histological Features Associated With Vemurafenib-Induced Skin Toxicities. <i>American Journal of Dermatopathology</i> , 2014, 36, 557-561.	0.3	17
3808	The role of MEK inhibitors in the treatment of metastatic melanoma. <i>Current Opinion in Oncology</i> , 2014, 26, 196-203.	1.1	39
3809	GNAQ and GNA11 mutations in uveal melanoma. <i>Melanoma Research</i> , 2014, 24, 525-534.	0.6	99
3810	Clinicopathologic Findings and BRAF Mutation in Cutaneous Melanoma in Young Adults. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 57-64.	0.6	12
3811	Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma. <i>Pathology</i> , 2014, 46, 509-517.	0.3	69
3812	BRAF Analysis on a Spectrum of Melanocytic Neoplasms. <i>American Journal of Dermatopathology</i> , 2014, 36, 68-73.	0.3	12
3813	Where to start with systemic melanoma therapy?. <i>Melanoma Management</i> , 2014, 1, 15-18.	0.1	0
3814	Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors. <i>Cancer Research</i> , 2014, 74, 2238-2245.	0.4	28
3815	Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1669-1674.	0.5	106
3816	Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma. <i>Melanoma Research</i> , 2014, 24, 322-331.	0.6	5

#	ARTICLE	IF	CITATIONS
3817	Desmoplastic Melanoma With Sarcomatoid Dedifferentiation. <i>American Journal of Surgical Pathology</i> , 2014, 38, 864-870.	2.1	36
3818	BRAF Mutations in Metastatic Malignant Melanoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2014, 22, 648-651.	0.6	20
3819	Development of potent autophagy inhibitors that sensitize oncogenic BRAF V600E mutant melanoma tumor cells to vemurafenib. <i>Autophagy</i> , 2014, 10, 1120-1136.	4.3	90
3820	Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. <i>Cancer Research</i> , 2014, 74, 4122-4132.	0.4	45
3821	MEK Inhibitor for Gastric Cancer with <i>MEK1</i> Gene Mutations. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3098-3106.	1.9	16
3822	Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 353-363.	1.9	83
3823	Akt and PI3K-dependent but CREB-independent upregulation of MCAM by endothelin-3 in human melanocytes. <i>Melanoma Research</i> , 2014, 24, 404-407.	0.6	8
3824	No Increase in IgG4-positive Plasma Cells in Limbal Rosai's "Dorfman Disease. <i>Cornea</i> , 2014, 33, 844-847.	0.9	6
3825	BRAF alterations in brain tumours. <i>Current Opinion in Neurology</i> , 2014, 27, 689-696.	1.8	34
3826	Detection of the BRAF V600E Mutation in Colon Carcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1235-1241.	2.1	55
3827	Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. <i>Pathology</i> , 2014, 46, 193-198.	0.3	19
3828	Mitogen-activated Protein Kinase (MAPK) Hyperactivation and Enhanced NRAS Expression Drive Acquired Vemurafenib Resistance in V600E BRAF Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 27714-27726.	1.6	44
3829	Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. <i>Annals of Oncology</i> , 2014, 25, 138-142.	0.6	121
3830	Management of conjunctival malignant melanoma: a review and update. <i>Expert Review of Ophthalmology</i> , 2014, 9, 185-204.	0.3	116
3831	New RAF kinase inhibitors in cancer therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1235-1245.	0.9	13
3832	Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma. <i>Current Oncology</i> , 2014, 21, 151.	0.9	36
3833	ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors. <i>Cancer Research</i> , 2014, 74, 7079-7089.	0.4	90
3834	Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-expressing Melanoma. <i>Molecular Cancer Research</i> , 2014, 12, 795-802.	1.5	20

#	ARTICLE	IF	CITATIONS
3835	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. <i>Cancer Research</i> , 2014, 74, 2340-2350.	0.4	266
3836	Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas. <i>Annals of Oncology</i> , 2014, 25, 246-250.	0.6	47
3837	Combined microsatellite instability and <i>BRAF</i> gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 982-988.	0.8	28
3838	Biomarkers for Predicting the Efficacy of Anti-Epidermal Growth Factor Receptor Antibody in the Treatment of Colorectal Cancer. <i>Digestion</i> , 2014, 89, 18-23.	1.2	16
3839	Long Non-Coding RNA BANC1 Promotes Proliferation in Malignant Melanoma by Regulating MAPK Pathway Activation. <i>PLoS ONE</i> , 2014, 9, e100893.	1.1	137
3840	Drug development: A chance of survival. <i>Nature</i> , 2014, 515, S118-S120.	13.7	8
3841	A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. <i>Cancer Discovery</i> , 2014, 4, 69-79.	7.7	141
3842	Evaluating biomarkers in melanoma. <i>Frontiers in Oncology</i> , 2014, 4, 383.	1.3	38
3843	Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. <i>Clinical Epidemiology</i> , 2014, 6, 423.	1.5	139
3844	67-kDa Laminin Receptor-dependent Protein Phosphatase 2A (PP2A) Activation Elicits Melanoma-specific Antitumor Activity Overcoming Drug Resistance. <i>Journal of Biological Chemistry</i> , 2014, 289, 32671-32681.	1.6	60
3845	Modeling Melanoma In Vitro and In Vivo. <i>Healthcare (Switzerland)</i> , 2014, 2, 27-46.	1.0	90
3846	Increased Melanoma Risk in Individuals With Papillary Thyroid Carcinoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 423.	1.2	24
3847	Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence. <i>Biochemistry Research International</i> , 2014, 2014, 1-9.	1.5	18
3848	Structure-Functional Prediction and Analysis of Cancer Mutation Effects in Protein Kinases. <i>Computational and Mathematical Methods in Medicine</i> , 2014, 2014, 1-24.	0.7	30
3849	Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. <i>Frontiers in Oncology</i> , 2014, 4, 160.	1.3	112
3850	BRAF V600E MUTATIONS IN METASTATIC MELANOMA - CASE REPORT. <i>Acta Medica Medianae</i> , 2014, , 39-41.	0.0	0
3851	<i>ROCK</i> 1 is a potential combinatorial drug target for <i>BRAF</i> mutant melanoma. <i>Molecular Systems Biology</i> , 2014, 10, 772.	3.2	48
3852	Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy?. <i>Cancer & Metabolism</i> , 2014, 2, 16.	2.4	55

#	ARTICLE	IF	CITATIONS
3853	Elimination of B-RAF in Oncogenic C-RAF-expressing Alveolar Epithelial Type II Cells Reduces MAPK Signal Intensity and Lung Tumor Growth. <i>Journal of Biological Chemistry</i> , 2014, 289, 26804-26816.	1.6	9
3854	BRAF Mutations in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1594-1595.	0.5	8
3855	Basal Cell Carcinosarcoma With PTCH1 Mutations in Both Epithelial and Sarcomatoid Primary Tumor Components and in the Sarcomatoid Metastasis. <i>American Journal of Surgical Pathology</i> , 2014, 38, 138-142.	2.1	18
3856	BRAF V600E Expression in Langerhans Cell Histiocytosis. <i>American Journal of Surgical Pathology</i> , 2014, 38, 548-551.	2.1	131
3857	BRAF V600E Immunohistochemistry Is Reliable in Primary and Metastatic Colorectal Carcinoma Regardless of Treatment Status and Shows High Intratumoral Homogeneity. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1418-1428.	2.1	38
3858	BRAF mutation status in primary and metastatic melanomas in two regions with differing potential ultraviolet radiation exposure. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 932-943.	0.6	4
3859	Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma. <i>International Journal of Dermatology</i> , 2014, 53, 1428-1433.	0.5	3
3860	Dermoscopic features of cutaneous melanoma are associated with clinical characteristics of patients and tumours and with MC1R genotype. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1768-1775.	1.3	16
3861	Adaptive resistance to RAF inhibitors in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 1032-1038.	1.5	50
3862	Melanoma: Clinical Features and Genomic Insights. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a015388-a015388.	2.9	42
3863	Cutaneous melanoma. <i>Lancet</i> , The, 2014, 383, 816-827.	6.3	465
3864	A personalized view on cancer immunotherapy. <i>Cancer Letters</i> , 2014, 352, 113-125.	3.2	63
3865	Zebrafish models of cancer: progress and future challenges. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 38-45.	1.5	49
3866	Combined mutational analysis of RAS, BRAF, PIK3CA, and TP53 genes in Taiwanese patients with oral squamous cell carcinoma. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014, 118, 110-116.e1.	0.2	16
3867	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 297-304.	5.1	55
3868	Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of WTBRF/WTNRAS melanoma cells to vemurafenib. <i>European Journal of Cancer</i> , 2014, 50, 1310-1320.	1.3	19
3870	Osteopontin Promotes the Invasive Growth of Melanoma Cells by Activating Integrin $\alpha 5 \beta 1$ and Down-Regulating Tetraspanin CD9. <i>American Journal of Pathology</i> , 2014, 184, 842-858.	1.9	25
3871	Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-RafV600E kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 1923-1927.	1.0	18

#	ARTICLE	IF	CITATIONS
3872	AP-1/c-Jun transcription factors: Regulation and function in malignant melanoma. <i>European Journal of Cell Biology</i> , 2014, 93, 76-81.	1.6	135
3873	Resistance to Raf inhibition in cancer. <i>Drug Discovery Today: Technologies</i> , 2014, 11, 27-32.	4.0	31
3874	Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor. <i>Seminars in Oncology</i> , 2014, 41, 110-125.	0.8	60
3875	Targeted Therapies for Cutaneous Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 491-505.	0.9	11
3876	The role of a Schiff base scaffold, N-(2-hydroxy acetophenone) glycinate-in overcoming multidrug resistance in cancer. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 51, 96-109.	1.9	49
3877	Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. <i>Journal of Dermatological Treatment</i> , 2014, 25, 401-408.	1.1	59
3878	Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. <i>Journal of Investigative Dermatology</i> , 2014, 134, 488-497.	0.3	66
3879	Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review. <i>Familial Cancer</i> , 2014, 13, 1-12.	0.9	38
3880	Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. <i>Journal of Investigative Dermatology</i> , 2014, 134, 452-460.	0.3	20
3881	Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 229-232.	1.0	34
3882	Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. <i>BMC Cancer</i> , 2014, 14, 13.	1.1	220
3883	Prognostic and predictive biomarkers in lung cancer. A review. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 347-358.	1.4	77
3884	BRAF and MEK Gene Rearrangements in Melanoma: Implications for Targeted Therapy. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 285-91.	1.6	8
3885	Prognostic and Predictive Biomarkers: Tools in Personalized Oncology. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 273-284.	1.6	132
3886	BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?. <i>Endocrine</i> , 2014, 45, 341-343.	1.1	26
3887	Multifocal Fibrosing Thyroiditis and Its Association with Papillary Thyroid Carcinoma Using BRAF Pyrosequencing. <i>Endocrine Pathology</i> , 2014, 25, 236-240.	5.2	9
3888	Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line. <i>Tumor Biology</i> , 2014, 35, 2983-2988.	0.8	16
3889	Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt435-djt435.	3.0	64

#	ARTICLE	IF	CITATIONS
3890	Emerging insights into resistance to BRAF inhibitors in melanoma. <i>Biochemical Pharmacology</i> , 2014, 87, 381-389.	2.0	70
3891	Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. <i>Nature</i> , 2014, 508, 118-122.	13.7	702
3892	Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 409-418.	1.6	34
3893	Copper is required for oncogenic BRAF signalling and tumorigenesis. <i>Nature</i> , 2014, 509, 492-496.	13.7	425
3894	Recent progress in the identification of BRAF inhibitors as anti-cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 72, 170-205.	2.6	55
3895	BRAF – A new player in hematological neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 53, 77-83.	0.6	26
3896	MEK in cancer and cancer therapy. , 2014, 141, 160-171.		200
3897	Erdheim–Chester Disease. <i>Current Rheumatology Reports</i> , 2014, 16, 412.	2.1	110
3898	Visible light-curable polymers for biomedical applications. <i>Science China Chemistry</i> , 2014, 57, 510-521.	4.2	32
3899	Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients. <i>Tumor Biology</i> , 2014, 35, 5727-5733.	0.8	24
3900	Morphology predicts BRAF V600E mutation in papillary thyroid carcinoma: an interobserver reproducibility study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 435-442.	1.4	34
3901	Analysis of KIAA1549–BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. <i>Journal of Neuro-Oncology</i> , 2014, 117, 235-242.	1.4	31
3902	The GIST of Targeted Therapy for Malignant Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2059-2067.	0.7	17
3903	High-sensitivity PCR method for detecting BRAF V600E mutations in metastatic colorectal cancer using LNA/DNA chimeras to block wild-type alleles. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 2477-2487.	1.9	17
3904	Tissue prognostic biomarkers in primary cutaneous melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 265-281.	1.4	43
3905	Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targeting PPP2R2A. <i>Tumor Biology</i> , 2014, 35, 631-640.	0.8	69
3906	Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. <i>Clinical and Translational Oncology</i> , 2014, 16, 425-435.	1.2	17
3907	Predictive Values for Molecular Diagnostics: Converting Unknown Unknowns to Known Unknowns. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 1-4.	1.6	2

#	ARTICLE	IF	CITATIONS
3908	BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation. <i>Molecular Cancer Research</i> , 2014, 12, 447-463.	1.5	46
3909	Targeting tumour-supportive cellular machineries in anticancer drug development. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 179-196.	21.5	202
3910	Human relevance of NRAS/BRAF mouse melanoma models. <i>European Journal of Cell Biology</i> , 2014, 93, 82-86.	1.6	19
3912	RAGE overexpression confers a metastatic phenotype to the WM115 human primary melanoma cell line. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1017-1027.	1.8	27
3913	Locus-Specific Databases in Cancer: What Future in a Post-Genomic Era? The TP53 LSDB paradigm. <i>Human Mutation</i> , 2014, 35, 643-653.	1.1	15
3914	Double-stranded DNA in exosomes: a novel biomarker in cancer detection. <i>Cell Research</i> , 2014, 24, 766-769.	5.7	1,282
3915	The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2014, 9, 239-271.	9.6	392
3916	Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2516-2522.	3.2	108
3917	Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies. <i>Clinical Cancer Research</i> , 2014, 20, 2264-2275.	3.2	60
3918	Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 343-349.	1.2	44
3919	Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness. <i>Biomaterials</i> , 2014, 35, 4310-4318.	5.7	57
3920	Quasi-digital PCR: Enrichment and quantification of rare DNA variants. <i>Biomedical Microdevices</i> , 2014, 16, 639-644.	1.4	6
3921	The BRAF ^{V600E} Mutation Influences the Short- and Medium-Term Outcomes of Classic Papillary Thyroid Cancer, But Is Not an Independent Predictor of Unfavorable Outcome. <i>Thyroid</i> , 2014, 24, 1267-1274.	2.4	30
3922	Anthrax lethal and edema toxins in anthrax pathogenesis. <i>Trends in Microbiology</i> , 2014, 22, 317-325.	3.5	178
3923	Molecular Testing in Cancer. , 2014, , .		2
3924	Pharmacogenomics and Personalized Medicines in Cancer Treatment. , 2014, , 55-90.		0
3925	Targeting B-RAF. , 2014, , 529-563.		1
3927	Update on the Biology and Treatment Options for Hairy Cell Leukemia. <i>Current Treatment Options in Oncology</i> , 2014, 15, 187-209.	1.3	27

#	ARTICLE	IF	CITATIONS
3928	Small Molecules in Oncology. Recent Results in Cancer Research, 2014, , .	1.8	4
3929	Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors. Cancer Cell, 2014, 25, 697-710.	7.7	238
3930	Identification and Optimization of New Dual Inhibitors of B-Raf and Epidermal Growth Factor Receptor Kinases for Overcoming Resistance against Vemurafenib. Journal of Medicinal Chemistry, 2014, 57, 2692-2703.	2.9	33
3931	Identification of Type II Inhibitors Targeting BRAF Using Privileged Pharmacophores. Chemical Biology and Drug Design, 2014, 83, 27-36.	1.5	9
3932	Leelamine Mediates Cancer Cell Death through Inhibition of Intracellular Cholesterol Transport. Molecular Cancer Therapeutics, 2014, 13, 1690-1703.	1.9	63
3933	Hypoxia-regulated gene network in drug resistance and cancer progression. Experimental Biology and Medicine, 2014, 239, 779-792.	1.1	45
3934	The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?. Journal of Pathology, 2014, 232, 274-282.	2.1	48
3935	Insight into the Structural Features of Pyrazolopyrimidine- and Pyrazolopyridine-based BRAF ^{V600E} Kinase Inhibitors by Computational Explorations. Chemical Biology and Drug Design, 2014, 83, 643-655.	1.5	4
3936	A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients. Journal of Pharmaceutical and Biomedical Analysis, 2014, 97, 29-32.	1.4	19
3937	Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatric Blood and Cancer, 2014, 61, 2099-2100.	0.8	50
3938	Genomics and Molecular Profiling of Lung Cancer. , 2014, , 193-211.		0
3939	The paradox of FGFR3 signaling in skeletal dysplasia: Why chondrocytes growth arrest while other cells over proliferate. Mutation Research - Reviews in Mutation Research, 2014, 759, 40-48.	2.4	41
3940	Molecular markers in melanoma. British Journal of Dermatology, 2014, 170, 31-35.	1.4	23
3941	Near-genomewide RNAi screening for regulators of BRAF ^{V600E} -induced senescence identifies RASEF ¹ , a gene epigenetically silenced in melanoma. Pigment Cell and Melanoma Research, 2014, 27, 640-652.	1.5	15
3942	DNA Sequencing of Cancer: What Have We Learned?. Annual Review of Medicine, 2014, 65, 63-79.	5.0	41
3943	BRAF inhibitors in cancer therapy. , 2014, 142, 176-182.		87
3944	Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science, 2014, 343, 84-87.	6.0	4,210
3945	Detecting Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma. Methods in Molecular Biology, 2014, 1102, 163-174.	0.4	14

#	ARTICLE	IF	CITATIONS
3946	Thyroid nodules. Best Practice and Research in Clinical Endocrinology and Metabolism, 2014, 28, 245-277.	2.2	47
3947	Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 2014, 50, 406-410.	1.3	26
3948	Impact of molecular alterations of BRAF in the pathogenesis of thyroid cancer. Mutagenesis, 2014, 29, 131-137.	1.0	25
3949	mTOR Inhibition Specifically Sensitizes Colorectal Cancers with <i>KRAS</i> or <i>BRAF</i> Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1. Cancer Discovery, 2014, 4, 42-52.	7.7	116
3950	Molecularly targeted cancer therapy: some lessons from the past decade. Trends in Pharmacological Sciences, 2014, 35, 41-50.	4.0	255
3951	Relevance of MIA and S100 serum tumor markers to monitor BRAF inhibitor therapy in metastatic melanoma patients. Clinica Chimica Acta, 2014, 429, 168-174.	0.5	20
3952	BRAF mutation status in papillary thyroid carcinoma: significance for surgical strategy. Langenbeck's Archives of Surgery, 2014, 399, 225-228.	0.8	13
3953	Sustained IRE1 and ATF6 signaling is important for survival of melanoma cells undergoing ER stress. Cellular Signalling, 2014, 26, 287-294.	1.7	80
3954	Deregulation of microRNA expression in thyroid neoplasias. Nature Reviews Endocrinology, 2014, 10, 88-101.	4.3	103
3955	Validation of a Next-Generation Sequencing Assay for Clinical Molecular Oncology. Journal of Molecular Diagnostics, 2014, 16, 89-105.	1.2	168
3956	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery, 2014, 4, 80-93.	7.7	836
3957	A Practical Guide to Human Cancer Genetics. , 2014, , .		8
3958	Assaying for BRAF V600E in Tissue and Blood in Melanoma. Methods in Molecular Biology, 2014, 1102, 117-136.	0.4	5
3959	BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro-Oncology, 2014, 16, 466-467.	0.6	35
3960	Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. British Journal of Cancer, 2014, 110, 2655-2661.	2.9	52
3961	Modulation of BRAHMA expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation. Archives of Biochemistry and Biophysics, 2014, 563, 125-135.	1.4	4
3962	Sex disparities in melanoma outcomes: The role of biology. Archives of Biochemistry and Biophysics, 2014, 563, 42-50.	1.4	53
3963	Section IV: Non-small cell lung cancer and malignant melanoma. Current Problems in Cancer, 2014, 38, 180-198.	1.0	2

#	ARTICLE	IF	CITATIONS
3964	Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib. <i>Molecular Pharmaceutics</i> , 2014, 11, 4199-4207.	2.3	43
3965	AMPK "Sensing Energy while Talking to Other Signaling Pathways. <i>Cell Metabolism</i> , 2014, 20, 939-952.	7.2	462
3966	Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment. <i>Journal of Immunology</i> , 2014, 192, 2505-2513.	0.4	69
3967	The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. <i>Science</i> , 2014, 346, 945-949.	6.0	328
3968	MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2014, 20, 6034-6044.	3.2	122
3969	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> ^{V600} -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	0.8	173
3970	<i>BRAF</i> V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK. <i>Journal of Clinical Pathology</i> , 2014, 67, 684-689.	1.0	18
3971	Recent developments in the medical and surgical treatment of melanoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 171-185.	157.7	56
3972	Value of immunohistochemistry in the detection of <i>BRAF</i> ^{V600E} mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. <i>Cancer Cytopathology</i> , 2014, 122, 48-58.	1.4	69
3973	Thérapies ciblées : comment déterminer la cible ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2014, 6, 453-458.	0.0	0
3974	Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 621-629.	1.5	14
3975	Current management of advanced melanoma: a transformed landscape. <i>ANZ Journal of Surgery</i> , 2014, 84, 612-617.	0.3	13
3976	BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. <i>Laryngoscope</i> , 2014, 124, E389-E393.	1.1	53
3977	Catalytic Mechanisms and Regulation of Protein Kinases. <i>Methods in Enzymology</i> , 2014, 548, 1-21.	0.4	107
3978	Concise Review: Cancer Cells Escape from Oncogene Addiction: Understanding the Mechanisms Behind Treatment Failure for More Effective Targeting. <i>Stem Cells</i> , 2014, 32, 1373-1379.	1.4	27
3979	Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective <i>BRAF</i> kinase inhibitor, used in the treatment of melanoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 568-575.	0.7	13
3980	Isolated limb infusion as a model to test new agents to treat metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 357-365.	0.8	9
3981	Is Mcl-1L the new anti-apoptotic effector of B-RAFV600E in melanoma?. <i>Experimental Dermatology</i> , 2014, 23, 94-94.	1.4	1

#	ARTICLE	IF	CITATIONS
3982	Clinical implications of distinct metastasizing preferences of different melanoma subtypes. <i>European Journal of Dermatology</i> , 2014, 24, 236-241.	0.3	15
3983	Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1867-1876.	13.9	1,824
3984	Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of <i>BRAF</i> V600E. <i>Modern Pathology</i> , 2014, 27, 135-144.	2.9	49
3985	Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with <i>BRAF</i> V600 Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 5527-5536.	3.2	145
3986	Application of genotype-guided cancer therapy in solid tumors. <i>Pharmacogenomics</i> , 2014, 15, 79-93.	0.6	21
3987	MicroRNAs 206 and 21 Cooperate To Promote <i>RAS</i> Extracellular Signal-Regulated Kinase Signaling by Suppressing the Translation of <i>RASA1</i> and <i>SPRED1</i> . <i>Molecular and Cellular Biology</i> , 2014, 34, 4143-4164.	1.1	51
3988	Melanoma Patients under Vemurafenib: Prospective Follow-Up of Melanocytic Lesions by Digital Dermoscopy. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1351-1358.	0.3	56
3989	Natural Killer Cells Are Essential for the Ability of <i>BRAF</i> Inhibitors to Control <i>BRAF</i> V600E-Mutant Metastatic Melanoma. <i>Cancer Research</i> , 2014, 74, 7298-7308.	0.4	96
3990	Phosphoproteome Dynamics in Onset and Maintenance of Oncogene-induced Senescence. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2089-2100.	2.5	11
3991	No evidence of oncogenic <i>KRAS</i> mutations in squamous cell carcinomas of the anogenital tract and head and neck region independent of human papillomavirus and p16INK4a status. <i>Human Pathology</i> , 2014, 45, 2347-2354.	1.1	17
3992	Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential <i>BRAF</i> V600E inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6201-6208.	1.4	27
3993	Expression of <i>AID</i> in malignant melanoma with <i>BRAF</i> ^{V600E} mutation. <i>Experimental Dermatology</i> , 2014, 23, 347-348.	1.4	12
3994	Is <i>BRAF</i> a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection. <i>British Journal of Dermatology</i> , 2014, 171, 108-114.	1.4	26
3995	Atypical teratoid/rhabdoid tumor arising in pleomorphic xanthoastrocytoma: A case report. <i>Neuropathology</i> , 2014, 34, 398-405.	0.7	11
3996	The dream and reality of histology agnostic cancer clinical trials. <i>Molecular Oncology</i> , 2014, 8, 1057-1063.	2.1	28
3997	Phenotypic Profiling of Raf Inhibitors and Mitochondrial Toxicity in 3D Tissue Using Biodynamic Imaging. <i>Journal of Biomolecular Screening</i> , 2014, 19, 526-537.	2.6	28
3998	Design, synthesis and biological evaluation of (1,3-diphenyl-1H-pyrazol-4-yl) methyl benzoate derivatives as potential <i>BRAF</i> ^{V600E} inhibitors. <i>RSC Advances</i> , 2014, 4, 52702-52711.	1.7	10
3999	Controversies in the Management of Advanced Melanoma. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1456-1468.	0.9	10

#	ARTICLE	IF	CITATIONS
4000	Dabrafenib Therapy for Advanced Melanoma. <i>Annals of Pharmacotherapy</i> , 2014, 48, 519-529.	0.9	31
4001	Prevalence, Tumorigenic Role, and Biochemical Implications of Rare <i>BRAF</i> Alterations. <i>Thyroid</i> , 2014, 24, 809-819.	2.4	51
4002	Tumour <i>MLH1</i> promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC). <i>Journal of Medical Genetics</i> , 2014, 51, 789-796.	1.5	69
4003	Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2793-2804.	1.9	80
4004	Molecular Diagnostics for Dermatology. , 2014, , .		2
4005	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. <i>Genome Medicine</i> , 2014, 6, 5.	3.6	186
4006	Optimizing the treatment of BRAF mutant melanoma. <i>Genome Medicine</i> , 2014, 6, 30.	3.6	0
4007	Advancing clinical oncology through genome biology and technology. <i>Genome Biology</i> , 2014, 15, 427.	3.8	9
4009	microRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma. <i>Archives of Biochemistry and Biophysics</i> , 2014, 563, 118-124.	1.4	52
4010	MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells. <i>Cancer Immunology Research</i> , 2014, 2, 351-360.	1.6	122
4011	Complex Formation between S100B Protein and the p90 Ribosomal S6 Kinase (RSK) in Malignant Melanoma Is Calcium-dependent and Inhibits Extracellular Signal-regulated Kinase (ERK)-mediated Phosphorylation of RSK. <i>Journal of Biological Chemistry</i> , 2014, 289, 12886-12895.	1.6	25
4012	T-box transcription factors in cancer biology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 380-391.	3.3	50
4013	B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. <i>Haematologica</i> , 2014, 99, 222-231.	1.7	52
4014	Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: Implications on optimized targeted therapy. <i>Experimental and Molecular Pathology</i> , 2014, 97, 315-320.	0.9	23
4015	MAPK pathway inhibition in melanoma: resistance three ways. <i>Biochemical Society Transactions</i> , 2014, 42, 727-732.	1.6	21
4016	Prevalence and Implications of <i>TERT</i> Promoter Mutation in Uveal and Conjunctival Melanoma and in Benign and Premalignant Conjunctival Melanocytic Lesions. , 2014, 55, 6024.		74
4017	Response of <i>BRAF</i> -Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. <i>Cancer Discovery</i> , 2014, 4, 423-433.	7.7	242
4018	Therapeutic potential of siRNA and DNAzymes in cancer. <i>Tumor Biology</i> , 2014, 35, 9505-9521.	0.8	29

#	ARTICLE	IF	CITATIONS
4019	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. <i>Oncologist</i> , 2014, 19, 616-622.	1.9	94
4020	Small Molecule Inhibitors in Veterinary Oncology Practice. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2014, 44, 893-908.	0.5	20
4021	Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 989-992.	1.3	10
4022	Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter-Mediated Drug Resistance. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2978-2990.	1.9	57
4023	Detection of somatic mutations in tumors using unaligned clonal sequencing data. <i>Laboratory Investigation</i> , 2014, 94, 1173-1183.	1.7	2
4024	Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. <i>Nature Reviews Cancer</i> , 2014, 14, 455-467.	12.8	683
4025	Risk of second primary malignancies following a diagnosis of cutaneous malignant melanoma or nonmelanoma skin cancer in Alberta, Canada from 1979 to 2009. <i>British Journal of Dermatology</i> , 2014, 170, 136-143.	1.4	23
4026	Ocular Toxicity in BRAF Mutant Cutaneous Melanoma Patients Treated With Vemurafenib. <i>American Journal of Ophthalmology</i> , 2014, 158, 831-837.e2.	1.7	81
4027	Formation of wide band-gap CuInAlS ₂ thin film and its application to UV Detectors. <i>Thin Solid Films</i> , 2014, 572, 28-32.	0.8	5
4028	Optimal Management of Skin Cancer in Immunosuppressed Patients. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 339-356.	3.3	38
4029	No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. <i>Molecular Oncology</i> , 2014, 8, 1140-1158.	2.1	47
4030	Heparanase expression in Langerhans cell histiocytosis. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1883-1885.	0.8	2
4031	Translating Genomics for Precision Cancer Medicine. <i>Annual Review of Genomics and Human Genetics</i> , 2014, 15, 395-415.	2.5	63
4032	Somatic alterations as the basis for resistance to targeted therapies. <i>Journal of Pathology</i> , 2014, 232, 244-254.	2.1	31
4033	Non-small-cell lung cancers: a heterogeneous set of diseases. <i>Nature Reviews Cancer</i> , 2014, 14, 535-546.	12.8	1,375
4034	Sensitivity and specificity of the empirical lymphocyte genome sensitivity (LGS) assay: implications for improving cancer diagnostics. <i>FASEB Journal</i> , 2014, 28, 4563-4570.	0.2	21
4035	Comparison of molecular abnormalities in vulvar and vaginal melanomas. <i>Modern Pathology</i> , 2014, 27, 1386-1393.	2.9	70
4036	Primary Melanoma Tumors from CDKN2A Mutation Carriers Do Not Belong to a Distinct Molecular Subclass. <i>Journal of Investigative Dermatology</i> , 2014, 134, 3000-3003.	0.3	8

#	ARTICLE	IF	CITATIONS
4037	Science and Mechanism of Action of Targeted Therapies in Cancer Treatment. <i>Seminars in Oncology Nursing</i> , 2014, 30, 139-146.	0.7	8
4038	RAF signaling in neuroendocrine neoplasms: From bench to bedside. <i>Cancer Treatment Reviews</i> , 2014, 40, 974-979.	3.4	21
4039	Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling. <i>Cancer Cell</i> , 2014, 26, 402-413.	7.7	173
4040	The Molecular Landscape of Pediatric Brain Tumors in the Next-Generation Sequencing Era. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 474.	2.0	11
4041	New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs. <i>Clinical Cancer Research</i> , 2014, 20, 4425-4435.	3.2	33
4042	Ultrasensitive detection and identification of BRAF V600 mutations in fresh frozen, FFPE, and plasma samples of melanoma patients by E-ice-COLD-PCR. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 5513-5520.	1.9	29
4043	The Prognostic Implications from Molecular Testing of Thyroid Cancer. <i>Otolaryngologic Clinics of North America</i> , 2014, 47, 595-607.	0.5	13
4044	Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. <i>Nature Reviews Cancer</i> , 2014, 14, 632-641.	12.8	312
4045	Structural Optimization and Biological Screening of a Steroidal Scaffold Possessing Cucurbitacin-Like Functionalities as BRAF Inhibitors. <i>ChemMedChem</i> , 2014, 9, 1361-1367.	1.6	22
4046	Melanocytic Lesions. , 2014, , .		2
4047	Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial. <i>Clinical Cancer Research</i> , 2014, 20, 490-498.	3.2	99
4048	Mutant p53 and MDM2 in Cancer. <i>Sub-Cellular Biochemistry</i> , 2014, , .	1.0	6
4049	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. <i>Science</i> , 2014, 346, 256-259.	6.0	834
4050	Hairy cell leukemia: a "hair-raising" update. <i>Expert Review of Hematology</i> , 2014, 7, 659-669.	1.0	3
4051	Analysis of V600E BRAF and D816V KIT mutations in systemic mastocytosis. <i>Medical Oncology</i> , 2014, 31, 123.	1.2	7
4052	A spatial simulation approach to account for protein structure when identifying non-random somatic mutations. <i>BMC Bioinformatics</i> , 2014, 15, 231.	1.2	21
4053	DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability. <i>BMC Cancer</i> , 2014, 14, 466.	1.1	25
4054	GNAQ mutation in a patient with metastatic mucosal melanoma. <i>BMC Cancer</i> , 2014, 14, 516.	1.1	18

#	ARTICLE	IF	CITATIONS
4055	Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. <i>BMC Cancer</i> , 2014, 14, 630.	1.1	56
4056	Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. <i>Molecular Cancer</i> , 2014, 13, 154.	7.9	2
4057	A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma. <i>Molecular Cancer</i> , 2014, 13, 168.	7.9	31
4058	A novel cost effective and high-throughput isolation and identification method for marine microalgae. <i>Plant Methods</i> , 2014, 10, 26.	1.9	11
4059	New insights into the diagnosis of nodular goiter. <i>Thyroid Research</i> , 2014, 7, 6.	0.7	11
4060	AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. <i>Journal of Translational Medicine</i> , 2014, 12, 216.	1.8	43
4061	Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAFV600E inhibition. <i>Journal of Translational Medicine</i> , 2014, 12, 247.	1.8	38
4062	Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. , 2014, 2, 27.		7
4063	Incidence of New Primary Melanomas After Diagnosis of Stage III and IV Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 816-823.	0.8	20
4064	Indications and Options for Systemic Therapy in Melanoma. <i>Surgical Clinics of North America</i> , 2014, 94, 1049-1058.	0.5	12
4065	Surgical Treatment Options for Stage IV Melanoma. <i>Surgical Clinics of North America</i> , 2014, 94, 1075-1089.	0.5	10
4066	BRAF ^{V600E} in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration. <i>Thyroid</i> , 2014, 24, 1385-1393.	2.4	103
4067	Molecular Pathways: Targeting RAC ^{p21} -Activated Serine ^{Threonine} Kinase Signaling in RAS-Driven Cancers. <i>Clinical Cancer Research</i> , 2014, 20, 4740-4746.	3.2	43
4068	Drug therapies in dermatology. <i>Clinical Medicine</i> , 2014, 14, 47-53.	0.8	7
4069	Identification of recurrent SMO and BRAF mutations in ameloblastomas. <i>Nature Genetics</i> , 2014, 46, 722-725.	9.4	273
4070	Recent advances in personalized lung cancer medicine. <i>Personalized Medicine</i> , 2014, 11, 309-321.	0.8	22
4071	Association between BRAF V600E and NRAS Q61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma. <i>Cancer Causes and Control</i> , 2014, 25, 1379-1386.	0.8	22
4073	Metabolic Dysregulation in Melanoma: Cause or Consequence?. <i>Cancer Discovery</i> , 2014, 4, 390-391.	7.7	9

#	ARTICLE	IF	CITATIONS
4074	Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. <i>Science</i> , 2014, 346, 251-256.	6.0	962
4075	Oncogenic drivers, targeted therapies, and acquired resistance in non-small-cell lung cancer. <i>Journal of Molecular Medicine</i> , 2014, 92, 697-707.	1.7	58
4076	Growth factor transduction pathways: paradigm of anti-neoplastic targeted therapy. <i>Journal of Molecular Medicine</i> , 2014, 92, 723-733.	1.7	4
4077	Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitors. <i>Archives of Toxicology</i> , 2014, 88, 1189-1203.	1.9	47
4078	Upregulation of the Na ⁺ -Coupled Phosphate Cotransporters NaPi-IIa and NaPi-IIb by B-RAF. <i>Journal of Membrane Biology</i> , 2014, 247, 137-145.	1.0	11
4079	VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 637-643.	1.4	23
4080	The BRAF mutation is associated with the prognosis in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1863-1871.	1.2	21
4081	Establishing a Biological Profile for Interval Colorectal Cancers. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2390-2402.	1.1	16
4082	Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. <i>Investigational New Drugs</i> , 2014, 32, 312-322.	1.2	6
4083	Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. <i>Investigational New Drugs</i> , 2014, 32, 729-738.	1.2	27
4084	The siRNA-mediated downregulation of N-Ras sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors. <i>Molecular and Cellular Biochemistry</i> , 2014, 392, 239-247.	1.4	7
4085	Autogrid-based clustering of kinases: selection of representative conformations for docking purposes. <i>Molecular Diversity</i> , 2014, 18, 611-619.	2.1	3
4086	Pediatric posterior fossa ganglioglioma: unique MRI features and correlation with BRAF V600E mutation status. <i>Journal of Neuro-Oncology</i> , 2014, 118, 395-404.	1.4	26
4087	Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2014, 111, 292-299.	2.9	93
4088	Molecular Characterization and Patient Outcome of Melanoma Nodal Metastases and an Unknown Primary Site. <i>Annals of Surgical Oncology</i> , 2014, 21, 4317-4323.	0.7	23
4089	A new generation of companion diagnostics: cobasBRAF, KRASandEGFRmutation detection tests. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 517-524.	1.5	22
4090	Recent advances in personalized colorectal cancer research. <i>Cancer Letters</i> , 2014, 347, 15-21.	3.2	50
4091	EZH2: Not EZHY (Easy) to Deal. <i>Molecular Cancer Research</i> , 2014, 12, 639-653.	1.5	92

#	ARTICLE	IF	CITATIONS
4092	An update on molecular biology of thyroid cancers. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 233-252.	2.0	83
4093	MEK1/2 inhibitors in the treatment of gynecologic malignancies. <i>Gynecologic Oncology</i> , 2014, 133, 128-137.	0.6	88
4094	Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. <i>Human Molecular Genetics</i> , 2014, 23, 1527-1537.	1.4	19
4095	Updates on histiocytic disorders. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1329-1335.	0.8	80
4096	Mitochondrial function in melanoma. <i>Archives of Biochemistry and Biophysics</i> , 2014, 563, 56-59.	1.4	25
4097	Caveolin-1 Expression in Papillary Thyroid Carcinoma: Correlation with Clinicopathological Parameters and BRAF Mutation Status. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 150, 201-209.	1.1	14
4098	Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO). <i>Annals of Oncology</i> , 2014, 25, 1673-1678.	0.6	101
4099	A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors. <i>Cancer Discovery</i> , 2014, 4, 816-827.	7.7	448
4100	Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. <i>Medical Oncology</i> , 2014, 31, 16.	1.2	18
4101	Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2014, 16, 362-373.	1.2	7
4102	Treatment of Refractory Hairy Cell Leukemia with a BRAF-inhibitor: Lessons to be Learnt. <i>Pathology and Oncology Research</i> , 2014, 20, 973-980.	0.9	8
4103	DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach. <i>BMC Gastroenterology</i> , 2014, 14, 55.	0.8	34
4104	Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. <i>Molecular Cancer</i> , 2014, 13, 122.	7.9	18
4105	Discrepant alterations in main candidate genes among multiple primary melanomas. <i>Journal of Translational Medicine</i> , 2014, 12, 117.	1.8	24
4106	In silico modeling predicts drug sensitivity of patient-derived cancer cells. <i>Journal of Translational Medicine</i> , 2014, 12, 128.	1.8	26
4107	Disruption of mutated BRAF signaling modulates thyroid cancer phenotype. <i>BMC Research Notes</i> , 2014, 7, 187.	0.6	9
4108	A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. <i>Oncogene</i> , 2014, 33, 2531-2539.	2.6	29
4109	The RhoGEF GEF-H1 Is Required for Oncogenic RAS Signaling via KSR-1. <i>Cancer Cell</i> , 2014, 25, 181-195.	7.7	76

#	ARTICLE	IF	CITATIONS
4110	Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine. <i>Annals of Oncology</i> , 2014, 25, 1428-1436.	0.6	45
4111	Dabrafenib and Trametinib, Alone and in Combination for <i>BRAF</i> -Mutant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 2035-2043.	3.2	135
4112	Modern Cancer Drug Discovery. , 2014, , 3-53.		8
4113	Tumor Heterogeneity Revealed by <i>KRAS</i> , <i>BRAF</i> , and <i>PIK3CA</i> Pyrosequencing: <i>KRAS</i> and <i>PIK3CA</i> Intratumor Mutation Profile Differences and Their Therapeutic Implications. <i>Human Mutation</i> , 2014, 35, 329-340.	1.1	63
4114	Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAFV600E Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 1074-1080.	3.2	47
4115	Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. <i>Clinical Cancer Research</i> , 2014, 20, 3328-3337.	3.2	33
4116	TERT Promoter Mutation Status as an Independent Prognostic Factor in Cutaneous Melanoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	204
4117	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 164-171.	1.0	108
4118	Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection. <i>Molecular Cancer Research</i> , 2014, 12, 571-582.	1.5	94
4119	Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer Patients. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 660-672.	1.2	70
4120	Chordoma: the entity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 655-669.	3.3	47
4121	Incidence and Predictive Factors of Inadequate Fine-Needle Aspirates for BRAFV600E Mutation Analysis in Thyroid Nodules. <i>American Journal of Roentgenology</i> , 2014, 202, 391-396.	1.0	2
4122	Current concepts on the molecular pathology of non-small cell lung carcinoma. <i>Seminars in Diagnostic Pathology</i> , 2014, 31, 306-313.	1.0	43
4123	Routine use of the Ion Torrent AmpliSeq [®] Cancer Hotspot Panel for identification of clinically actionable somatic mutations. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 707-14.	1.4	123
4124	Chemical Biology Tools for Regulating RAS Signaling Complexity in Space and Time. <i>Chemistry and Biology</i> , 2014, 21, 1185-1195.	6.2	25
4125	Annexin A1 in primary tumors promotes melanoma dissemination. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 749-760.	1.7	45
4126	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1192-1198.	3.4	51
4127	Cyclin-dependent kinases as therapeutic targets in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 351-365.	1.5	21

#	ARTICLE	IF	CITATIONS
4128	Change or die: Targeting adaptive signaling to kinase inhibition in cancer cells. <i>Biochemical Pharmacology</i> , 2014, 91, 417-425.	2.0	8
4129	Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors. <i>Cell Reports</i> , 2014, 8, 1037-1048.	2.9	69
4130	Autophagy Inhibition Improves Chemosensitivity in BRAFV600E Brain Tumors. <i>Cancer Discovery</i> , 2014, 4, 773-780.	7.7	203
4131	Commentary: Molecular testing in melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 863-870.	0.6	4
4132	The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 232-247.	3.3	29
4133	BRAF-mutations in non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 84, 36-38.	0.9	70
4134	Mismatch repair protein immunohistochemistry: a useful population screening strategy for Lynch syndrome. <i>Human Pathology</i> , 2014, 45, 1388-1396.	1.1	19
4135	BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip1. <i>Life Sciences</i> , 2014, 102, 41-48.	2.0	16
4136	Clinical significance of the BRAFV600E mutation in multifocal papillary thyroid carcinoma in Korea. <i>Surgery</i> , 2014, 155, 689-695.	1.0	22
4137	Design, synthesis and biological evaluation of indole derivatives as novel inhibitors targeting B-Raf kinase. <i>Chinese Chemical Letters</i> , 2014, 25, 351-354.	4.8	5
4138	Melanoma as a model for precision medicine in oncology. <i>Lancet Oncology</i> , The, 2014, 15, 251-253.	5.1	6
4139	Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib). <i>Bone</i> , 2014, 59, 151-161.	1.4	22
4140	Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. <i>Molecular Oncology</i> , 2014, 8, 544-554.	2.1	98
4141	Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells. <i>Life Sciences</i> , 2014, 104, 38-46.	2.0	17
4142	Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. <i>Cancer Genetics</i> , 2014, 207, 111-123.	0.2	40
4143	Sorafenib tosylate as a radiosensitizer in malignant astrocytoma. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 131-136.	0.8	8
4144	A germline oncogenic MITF mutation and tumor susceptibility. <i>European Journal of Cell Biology</i> , 2014, 93, 71-75.	1.6	28
4145	Sensitization of melanoma cells for TRAIL-induced apoptosis by activation of mitochondrial pathways via Bax. <i>European Journal of Cell Biology</i> , 2014, 93, 42-48.	1.6	27

#	ARTICLE	IF	CITATIONS
4146	Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 3446-3457.	3.2	294
4147	Targeting the PD-1 pathway: a promising future for the treatment of melanoma. <i>Archives of Dermatological Research</i> , 2014, 306, 511-519.	1.1	63
4148	Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation. <i>Clinical Cancer Research</i> , 2014, 20, 2257-2263.	3.2	79
4149	New approach to cancer therapy based on a molecularly defined cancer classification. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 70-74.	157.7	22
4150	Cancer treatment and survivorship statistics, 2014. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 252-271.	157.7	2,474
4151	Chromatin barcodes as biomarkers for melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 788-800.	1.5	22
4152	Large-Scale Label-Free Comparative Proteomics Analysis of Polo-Like Kinase 1 Inhibition via the Small-Molecule Inhibitor BI 6727 (Volasertib) in BRAF ^{V600E} Mutant Melanoma Cells. <i>Journal of Proteome Research</i> , 2014, 13, 5041-5050.	1.8	31
4153	New technology in thyroid fine-needle aspiration. <i>Journal of Clinical Pathology</i> , 2014, 67, 457-457.	1.0	1
4154	Targeting Mitochondrial Metabolism by Inhibiting Autophagy in <i>BRAF</i> -Driven Cancers. <i>Cancer Discovery</i> , 2014, 4, 766-772.	7.7	75
4155	Review of therapeutic drug monitoring of anticancer drugs part two “ Targeted therapies. <i>European Journal of Cancer</i> , 2014, 50, 2020-2036.	1.3	248
4157	Novel pyrazoline derivatives as bi-inhibitor of COX-2 and B-Raf in treating cervical carcinoma. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4109-4118.	1.4	29
4158	Molecular Diagnostics for Thyroid Nodules. <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 345-365.	1.2	11
4159	RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells. <i>Journal of Investigative Dermatology</i> , 2014, 134, 430-440.	0.3	33
4160	The <i>MAPK</i> pathway across different malignancies: A new perspective. <i>Cancer</i> , 2014, 120, 3446-3456.	2.0	752
4161	Targeted Therapy Resistance Mechanisms and Therapeutic Implications in Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 523-536.	0.9	23
4162	Understanding the Biology of Melanoma and Therapeutic Implications. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 437-453.	0.9	33
4163	[¹¹ C-carbonyl]CEP-32496: Radiosynthesis, biodistribution and PET study of brain uptake in P-gp/BCRP knockout mice. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3574-3577.	1.0	11
4164	State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 415-435.	0.9	32

#	ARTICLE	IF	CITATIONS
4165	BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. <i>Lung Cancer</i> , 2014, 85, 326-330.	0.9	82
4166	Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma. <i>Mayo Clinic Proceedings</i> , 2014, 89, 504-519.	1.4	77
4167	Oncogenes in melanoma: An update. <i>European Journal of Cell Biology</i> , 2014, 93, 1-10.	1.6	51
4168	Targeted therapy for melanoma: rational combinatorial approaches. <i>Oncogene</i> , 2014, 33, 1-9.	2.6	85
4169	Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. <i>Oncogene</i> , 2014, 33, 2577-2588.	2.6	24
4172	Novel BRAF1599Ins Mutation Identified in a Follicular Variant of Papillary Thyroid Carcinoma: A Molecular Modeling Approach. <i>Endocrine Practice</i> , 2014, 20, e75-e79.	1.1	4
4173	The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). <i>Journal of Personalized Medicine</i> , 2014, 4, 52-64.	1.1	12
4174	Brain metastasis and treatment. <i>F1000prime Reports</i> , 2014, 6, 114.	5.9	44
4175	Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review). <i>International Journal of Oncology</i> , 2014, 45, 929-949.	1.4	34
4176	Identification of 2R-ohnologue gene families displaying the same mutation-load skew in multiple cancers. <i>Open Biology</i> , 2014, 4, 140029.	1.5	17
4177	Molecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome. <i>Oncology Letters</i> , 2014, 8, 47-54.	0.8	34
4178	Systemic and Targeted Therapies for Early-Stage Lung Cancer. <i>Cancer Control</i> , 2014, 21, 21-31.	0.7	22
4179	Colon Cancer, Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1028-1059.	2.3	192
4180	Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers. <i>Expert Review of Endocrinology and Metabolism</i> , 2014, 9, 571-577.	1.2	0
4181	Serrated polyposis syndrome. <i>Colorectal Cancer</i> , 2014, 3, 375-386.	0.8	0
4183	Hotspot mutations in common oncogenes are infrequent in nasopharyngeal carcinoma. <i>Oncology Reports</i> , 2014, 32, 1661-1669.	1.2	17
4184	Biomarkers in Myelodysplastic Syndrome. , 2014, , 807-836.		0
4185	Diagnostic and Prognostic Biomarkers in Cutaneous Melanoma. , 2014, , 911-928.		0

#	ARTICLE	IF	CITATIONS
4187	Advances in targeted therapy for melanoma: a focus on MEK inhibition. <i>Clinical Investigation</i> , 2014, 4, 903-913.	0.0	0
4188	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. <i>Blood</i> , 2014, 124, 3007-3015.	0.6	352
4191	BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies. <i>Cancer Control</i> , 2014, 21, 221-230.	0.7	80
4192	Langerhans Cell Histiocytosis. <i>Cancer Control</i> , 2014, 21, 328-334.	0.7	72
4193	NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1629-1649.	2.3	18
4194	Emerging targeted therapies for melanoma treatment (Review). <i>International Journal of Oncology</i> , 2014, 45, 516-524.	1.4	39
4195	<i>BRAF</i> refines clinical interpretation of mismatch repair deficiency in colorectal cancer. <i>Colorectal Cancer</i> , 2014, 3, 1-4.	0.8	2
4196	Advances in molecular profiling of malignant melanoma: ready for clinical practice?. <i>Melanoma Management</i> , 2014, 1, 3-6.	0.1	0
4197	Ligase-assisted, upconversion luminescence resonance energy transfer-based method for specific and sensitive detection of V600E mutation in the BRAF gene. <i>RSC Advances</i> , 2014, 4, 56235-56240.	1.7	10
4198	Relation between Different Stages of Oral Cancer and Aberrant Methylation in Taiwan: Preliminary Report. <i>Otolaryngology - Head and Neck Surgery</i> , 2014, 151, P153-P153.	1.1	0
4199	Combination therapies in advanced melanoma. <i>Melanoma Management</i> , 2014, 1, 47-56.	0.1	2
4200	Role of molecular diagnostic markers in the management of indeterminate and suspicious thyroid nodules. <i>International Journal of Endocrine Oncology</i> , 2014, 1, 49-57.	0.4	4
4201	Long non-coding RNAs drive metastatic progression in melanoma (Review). <i>International Journal of Oncology</i> , 2014, 45, 2181-2186.	1.4	9
4202	Relation Between F-18 FDG Uptake of PET/CT and BRAFV600E Mutation in Papillary Thyroid Cancer. <i>Medicine (United States)</i> , 2015, 94, e2063.	0.4	17
4203	Zielgerichtetes Vorgehen gegen onkogene Faktoren. <i>Karger Kompass Onkologie</i> , 2015, 2, 61-70.	0.0	0
4204	BRAF mutation detection in hairy cell leukaemia from archival haematolymphoid specimens. <i>Pathology</i> , 2015, 47, 349-354.	0.3	7
4205	BRAF-Targeted Therapy to Treat Superior Vena Cava Syndrome in a Patient With Metastatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, e101-e103.	0.8	12
4206	Adult mice expressing aBrafQ241R mutation on an ICR/CD-1 background exhibit a cardio-facio-cutaneous syndrome phenotype. <i>Human Molecular Genetics</i> , 2015, 24, 7349-7360.	1.4	17

#	ARTICLE	IF	CITATIONS
4207	Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1451-1457.	0.5	141
4208	Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 382-388.	0.6	7
4209	The spectrum of oncogene mutations differs among melanoma subtypes. <i>Molecular Biology</i> , 2015, 49, 917-923.	0.4	4
4210	MEK and PI3K inhibition in solid tumors: rationale and evidence to date. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 170-180.	1.4	105
4211	Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 559-564.	0.9	48
4212	Rafâ€interactome in tuning the complexity and diversity of Raf function. <i>FEBS Journal</i> , 2015, 282, 32-53.	2.2	17
4213	The Forecast Is Bright: Recent Advances in Melanoma Treatment / Perspectives prometteuses: RÃ©centes percÃ©es dans le traitement des mÃ©lanomes. <i>Journal of Cutaneous Medicine and Surgery</i> , 2015, 19, 435-439.	0.6	0
4214	Fibroblasts keep melanoma safe from harm. <i>Intravital</i> , 2015, 4, e1074788.	2.0	1
4215	Multi-center evaluation of the novel fully-automated PCR-based Idyllaâ„¢ BRAF Mutation Test on formalin-fixed paraffin-embedded tissue of malignant melanoma. <i>Experimental and Molecular Pathology</i> , 2015, 99, 485-491.	0.9	44
4216	Costâ€effectiveness analysis of staging strategies in patients with regionally metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2015, 111, 423-430.	0.8	13
4217	Genetics of melanocytic nevi. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 661-672.	1.5	135
4218	<i>BRAF</i> ^{V600E} mutations are found in Richter syndrome and may allow targeted therapy in a subset of patients. <i>British Journal of Haematology</i> , 2015, 170, 282-285.	1.2	7
4219	Biology of advanced uveal melanoma and next steps for clinical therapeutics. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 135-147.	1.5	81
4220	Cetuximab-induced insulin-like growth factor receptor I activation mediates cetuximab resistance in gastric cancer cells. <i>Molecular Medicine Reports</i> , 2015, 11, 4547-4554.	1.1	9
4221	Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer. <i>Molecular Medicine Reports</i> , 2015, 12, 1219-1224.	1.1	14
4222	Intra-tumor heterogeneity of BRAF V600E mutation in lung adenocarcinomas. <i>Experimental and Therapeutic Medicine</i> , 2015, 9, 1719-1722.	0.8	7
4223	Genome-wide mutational spectra analysis reveals significant cancer-specific heterogeneity. <i>Scientific Reports</i> , 2015, 5, 12566.	1.6	86
4224	EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis. <i>Scientific Reports</i> , 2015, 5, 13959.	1.6	34

#	ARTICLE	IF	CITATIONS
4225	Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. <i>Scientific Reports</i> , 2015, 5, 18592.	1.6	27
4226	Colorectal Cancers with the Uncommon Findings of KRAS Mutation and Microsatellite Instability. <i>Cytogenetic and Genome Research</i> , 2015, 146, 261-267.	0.6	2
4227	Structure and function of Gab2 and its role in cancer (Review). <i>Molecular Medicine Reports</i> , 2015, 12, 4007-4014.	1.1	56
4230	BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. <i>Blood</i> , 2015, 125, 1207-1216.	0.6	82
4231	Overshoot during phenotypic switching of cancer cell populations. <i>Scientific Reports</i> , 2015, 5, 15464.	1.6	31
4232	Hairy Cell Leukemia with Systemic Lymphadenopathy: Detection of BRAF Mutations in Both Lymph Node and Peripheral Blood Specimens. <i>Internal Medicine</i> , 2015, 54, 1397-1402.	0.3	4
4234	Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. <i>Scientific Reports</i> , 2015, 5, 9211.	1.6	32
4235	The cholesterol-binding protein NPC2 restrains recruitment of stromal macrophage lineage cells to early-stage lung tumours. <i>EMBO Molecular Medicine</i> , 2015, 7, 1119-1137.	3.3	31
4236	Synthetic lethality and chemoresistance in cancer. , 0, , 65-82.		0
4237	From Bench to Bedside and Back. <i>Current Topics in Developmental Biology</i> , 2015, 115, 459-492.	1.0	9
4238	Increased CD271 expression by the NF- κ B pathway promotes melanoma cell survival and drives acquired resistance to BRAF inhibitor vemurafenib. <i>Cell Discovery</i> , 2015, 1, 15030.	3.1	56
4239	Spatial intra-tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for clinical cancer studies. <i>EMBO Molecular Medicine</i> , 2015, 7, 1087-1089.	3.3	8
4240	Current State of Animal (Mouse) Modeling in Melanoma Research. <i>Cancer Growth and Metastasis</i> , 2015, 8s1, CGM.S21214.	3.5	74
4241	Key drivers of biomedical innovation in cancer drug discovery. <i>EMBO Molecular Medicine</i> , 2015, 7, 12-16.	3.3	4
4242	<i>BRAF</i> Mutation in Colorectal Cancer: An Update. <i>Biomarkers in Cancer</i> , 2015, 7s1, BIC.S25248.	3.6	106
4243	Carcinogenesis. , 2015, , 1135-1172.		0
4244	Novel melanoma therapy. <i>Experimental Hematology and Oncology</i> , 2015, 5, 23.	2.0	8
4245	Employing Digital Droplet PCR to Detect BRAF V600E Mutations in Formalin-fixed Paraffin-embedded Reference Standard Cell Lines. <i>Journal of Visualized Experiments</i> , 2015, , .	0.2	2

#	ARTICLE	IF	CITATIONS
4246	BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. <i>Melanoma Research</i> , 2015, 25, 486-495.	0.6	73
4247	Intracranial Interdigitating Dendritic Cell Sarcoma. <i>Neurosurgery</i> , 2015, 77, E979-E983.	0.6	13
4248	Targeting the Adnexal Epithelium. <i>American Journal of Dermatopathology</i> , 2015, 37, e57-e60.	0.3	3
4249	A novel somatic mutation in ACD induces telomere lengthening and apoptosis resistance in leukemia cells. <i>BMC Cancer</i> , 2015, 15, 621.	1.1	13
4250	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. <i>Acta Neuropathologica Communications</i> , 2015, 3, 88.	2.4	42
4251	ERK1 and ERK2 present functional redundancy in tetrapods despite higher evolution rate of ERK1. <i>BMC Evolutionary Biology</i> , 2015, 15, 179.	3.2	46
4252	Primary pulmonary melanoma: a report of two cases. <i>World Journal of Surgical Oncology</i> , 2015, 13, 274.	0.8	9
4253	<i>BRAF</i> testing and thyroid FNA. <i>Cancer Cytopathology</i> , 2015, 123, 689-695.	1.4	23
4254	Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in <i>BRAF</i> and <i>NRAS</i> mutant melanoma. <i>Proteomics</i> , 2015, 15, 327-339.	1.3	13

4255

#	ARTICLE	IF	CITATIONS
4264	Epigenetics could explain some Moroccan population colorectal cancers peculiarities: microsatellite instability pathway exploration. <i>Diagnostic Pathology</i> , 2015, 10, 77.	0.9	4
4265	CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. <i>Genome Biology</i> , 2015, 16, 160.	3.8	182
4266	Vemurafenib-resistant BRAF selects alternative branch points different from its wild-type BRAF in intron 8 for RNA splicing. <i>Cell and Bioscience</i> , 2015, 5, 70.	2.1	4
4267	Targeted therapy: resistance and re-sensitization. <i>Chinese Journal of Cancer</i> , 2015, 34, 496-501.	4.9	21
4268	<i>BRAF</i> V600E and loss of heterozygosity assessment in benign oralneural tumours. <i>Journal of Oral Pathology and Medicine</i> , 2015, 44, 634-637.	1.4	4
4269	<i>PTEN</i> regulates <i>IGF</i> -mediated therapy resistance in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 572-589.	1.5	22
4270	Recent advances in diagnosis and treatment of hairy cell leukemia. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 191-200.	0.7	0
4271	Converting biology into clinical benefit: lessons learned from BRAF inhibitors. <i>Melanoma Management</i> , 2015, 2, 241-254.	0.1	10
4272	Vemurafenib plus cobimetinib in the treatment of mutated metastatic melanoma: the CoBRIM trial. <i>Melanoma Management</i> , 2015, 2, 209-215.	0.1	7
4273	Primary Cutaneous Small/Medium CD4+ T-Cell Lymphoma Occurring During Treatment With Vemurafenib for Advanced Melanoma. <i>American Journal of Dermatopathology</i> , 2015, 37, 440-443.	0.3	8
4274	Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 438-443.	0.6	17
4275	Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer—Evidence for a Relevant Model System and Urine-Based Diagnostic Test. <i>Molecular Cancer Research</i> , 2015, 13, 993-1002.	1.5	117
4276	Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. <i>Veterinary and Comparative Oncology</i> , 2015, 13, 288-304.	0.8	58
4277	<i>BRAF</i> , <i>KIT</i> and <i>NRAS</i> mutations and expression of <i>KIT</i> , phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients. <i>Journal of Dermatology</i> , 2015, 42, 477-484.	0.6	13
4278	Mutational status of naevus-associated melanomas. <i>British Journal of Dermatology</i> , 2015, 173, 671-680.	1.4	42
4279	Residential and occupational exposure to pesticides may increase risk for cutaneous melanoma: a case-control study conducted in the south of Brazil. <i>International Journal of Dermatology</i> , 2015, 54, e527-38.	0.5	22
4280	Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2015, 31, e112-e115.	0.4	15
4281	BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma. <i>Melanoma Research</i> , 2015, 25, 559-563.	0.6	33

#	ARTICLE	IF	CITATIONS
4282	Overview of Genetically Engineered Mouse Models of Papillary and Anaplastic Thyroid Cancers: Enabling Translational Biology for Patient Care Improvement. <i>Current Protocols in Pharmacology</i> , 2015, 69, 14.33.1-14.33.14.	4.0	3
4283	Chromosome Band 7q34 Deletions Resulting in KIAA1549 and BRAF and FAM131B and BRAF Fusions in Pediatric Low-Grade Gliomas. <i>Brain Pathology</i> , 2015, 25, 182-192.	2.1	44
4284	BRAF V600E mutational status in bile duct adenomas and hamartomas. <i>Histopathology</i> , 2015, 67, 562-567.	1.6	21
4285	Langerhans cell histiocytosis in children with congenital anomalies: A population-based record linkage study. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2015, 103, 157-160.	1.6	1
4286	Impact of genome sequencing on cancer research and treatment. <i>Cancer Nursing Practice</i> , 2015, 14, 22-26.	0.2	3
4287	Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing. <i>Cancer Cytopathology</i> , 2015, 123, 471-479.	1.4	26
4288	MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer. <i>Drug Development Research</i> , 2015, 76, 328-342.	1.4	9
4289	Cytotoxic T-cell Cytokines Put Cancer Under Arrest. <i>Cancer Immunology Research</i> , 2015, 3, 23-25.	1.6	1
4290	Personalized medicine for gastroenteropancreatic neuroendocrine tumors: a distant dream?. <i>International Journal of Endocrine Oncology</i> , 2015, 2, 201-215.	0.4	1
4291	Comparative healthcare costs in patients with metastatic melanoma in the USA. <i>Melanoma Research</i> , 2015, 25, 312-320.	0.6	22
4292	Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma. <i>Melanoma Research</i> , 2015, 25, 399-405.	0.6	52
4293	Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of ¹⁸ F-FDG-PET and ¹⁸ F-FLT-PET. <i>Contrast Media and Molecular Imaging</i> , 2015, 10, 203-210.	0.4	7
4294	NFκB is activated by multiple mechanisms in hairy cell leukemia. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 418-432.	1.5	15
4295	Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. <i>British Journal of Dermatology</i> , 2015, 173, 1024-1031.	1.4	36
4296	Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. <i>Journal of Cutaneous Pathology</i> , 2015, 42, 308-317.	0.7	11
4297	The role of thioredoxin reductase 1 in melanoma metabolism and metastasis. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 685-695.	1.5	21
4298	Prognostic Factors Influencing the Outcome of 64 Consecutive Patients Undergoing Surgery for Metastatic Melanoma of the Spine. <i>Neurosurgery</i> , 2015, 77, 386-393.	0.6	18
4299	Confocal microscopy characterization of BRAFV600E mutated melanomas. <i>Melanoma Research</i> , 2015, 25, 367-371.	0.6	11

#	ARTICLE	IF	CITATIONS
4300	TERT promoter mutations in sinonasal malignant melanoma. <i>Melanoma Research</i> , 2015, 25, 185-188.	0.6	26
4301	BRAF mutation screening in melanoma. <i>Melanoma Research</i> , 2015, 25, 328-334.	0.6	9
4302	Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma. <i>Melanoma Research</i> , 2015, 25, 528-536.	0.6	8
4303	Tyrosine Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of Granulosa Cell Tumors of the Ovary. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1224-1231.	1.2	11
4304	Interstitial lung disease related to smoking. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 407-416.	1.2	14
4306	The Evolution of Therapies in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2015, 7, 1815-1846.	1.7	107
4307	Downstream Signaling of the Sos Gene is Not Required during the Pathogenesis of Cancer Cells Bearing KRAS and BRAF Mutations. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2015, 06, .	0.3	0
4308	The c-Jun/RHOB/AKT pathway confers resistance of <i>BRAF</i> -mutant melanoma cells to MAPK inhibitors. <i>Oncotarget</i> , 2015, 6, 15250-15264.	0.8	29
4309	Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2015, 8, 423.	0.8	18
4310	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 42008-42018.	0.8	278
4311	PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. <i>Journal of Cancer</i> , 2015, 6, 1320-1330.	1.2	6
4312	Adoptive Cell Therapy of Melanoma with Cytokine-induced Killer Cells. <i>Immune Network</i> , 2015, 15, 58.	1.6	11
4313	Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer. <i>Journal of Solid Tumors</i> , 2015, 5, .	0.1	1
4315	Comparative Aspects of BRAF Mutations in Canine Cancers. <i>Veterinary Sciences</i> , 2015, 2, 231-245.	0.6	25
4316	Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. <i>Oncotarget</i> , 2015, 6, 20785-20800.	0.8	112
4317	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. <i>OncoTargets and Therapy</i> , 2015, 8, 3561.	1.0	9
4318	BRAF G596R mutation in a slow-progressing melanoma. <i>Pathology and Laboratory Medicine International</i> , 2015, , 63.	0.2	0
4319	Insight into molecular dynamics simulation of <i>BRAF</i> (V600E) and potent novel inhibitors for malignant melanoma. <i>International Journal of Nanomedicine</i> , 2015, 10, 3131.	3.3	14

#	ARTICLE	IF	CITATIONS
4320	Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells. <i>OncoTargets and Therapy</i> , 2015, 8, 1043.	1.0	10
4321	Mitogen-activated protein kinase signaling pathway and invasion and metastasis of gastric cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 11673.	1.4	121
4322	Targeted Therapy for MAPK Alterations in Pediatric Gliomas. <i>Brain Disorders & Therapy</i> , 2015, s2, .	0.1	6
4323	OECI-EACR precision medicine for cancer: Conference report 1â€“4 March 2015, Luxembourg. <i>Ecancermedicalscience</i> , 2015, 9, 519.	0.6	0
4324	New developments in the management of advanced melanoma – role of pembrolizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 2535.	1.0	16
4325	BRAF overexpression is associated with BRAF V600E mutation in papillary thyroid carcinomas. <i>Genetics and Molecular Research</i> , 2015, 14, 5065-5075.	0.3	16
4326	Study of PIK3CA, BRAF, and KRAS mutations in breast carcinomas among Chinese women in Qinghai. <i>Genetics and Molecular Research</i> , 2015, 14, 14840-14846.	0.3	7
4327	Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma. <i>Clinical Cancer Drugs</i> , 2015, 2, 29-37.	0.3	0
4328	Melanoma â€” Epidemiology, Risk Factors, and the Role of Adaptive Pigmentation. , 2015, , .		1
4329	Vitamins and Melanoma. <i>Cancers</i> , 2015, 7, 1371-1387.	1.7	22
4330	Neoadjuvant Therapy for Melanoma: A Promising Therapeutic Approach and an Ideal Platform in Drug Development. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e535-e542.	1.8	8
4331	Comparison of Molecular Testing Methods for Detecting BRAF V600 Mutations in Melanoma Specimens with Challenging Attributes. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2015, 06, .	0.4	0
4332	Modern Brain Tumor Imaging. <i>Brain Tumor Research and Treatment</i> , 2015, 3, 8.	0.4	157
4333	Mass Spectrometry-Based N-Glycomics of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2015, 16, 29278-29304.	1.8	23
4334	Mitochondrial Dysfunction and Disturbed Coherence: Gate to Cancer. <i>Pharmaceuticals</i> , 2015, 8, 675-695.	1.7	21
4335	Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <i>Frontiers in Oncology</i> , 2015, 5, 183.	1.3	80
4336	Hedgehog-Gli signaling in basal cell carcinoma and other skin cancers: prospects for therapy. <i>Research and Reports in Biology</i> , 0, , 55.	0.2	3
4337	BRAF mutational analysis in ovarian tumors: recent perspectives. <i>Pathology and Laboratory Medicine International</i> , 2015, , 75.	0.2	3

#	ARTICLE	IF	CITATIONS
4338	Trametinib: a MEK inhibitor for management of metastatic melanoma. <i>OncoTargets and Therapy</i> , 2015, 8, 2251.	1.0	91
4339	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. <i>ImmunoTargets and Therapy</i> , 2015, 4, 79.	2.7	21
4340	Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells. <i>PLoS ONE</i> , 2015, 10, e0117021.	1.1	19
4341	Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0118210.	1.1	50
4342	Enzyme-Free Detection of Mutations in Cancer DNA Using Synthetic Oligonucleotide Probes and Fluorescence Microscopy. <i>PLoS ONE</i> , 2015, 10, e0136720.	1.1	15
4343	Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. <i>PLoS ONE</i> , 2015, 10, e0128202.	1.1	8
4344	Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation. <i>PLoS ONE</i> , 2015, 10, e0129859.	1.1	8
4345	Biophysical Characterization of Essential Phosphorylation at the Flexible C-Terminal Region of C-Raf with 14-3-3 σ Protein. <i>PLoS ONE</i> , 2015, 10, e0135976.	1.1	9
4346	Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism. <i>PLoS ONE</i> , 2015, 10, e0138002.	1.1	39
4347	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. <i>PLoS ONE</i> , 2015, 10, e0139438.	1.1	27
4349	MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. <i>Drug Design, Development and Therapy</i> , 2016, 10, 43.	2.0	22
4350	The role of BRAF in the pathogenesis of thyroid carcinoma. <i>Frontiers in Bioscience - Landmark</i> , 2015, 20, 1068-1078.	3.0	22
4351	Antiproliferative Effect of Rottlerin on Sk-Mel-28 Melanoma Cells. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-9.	0.5	19
4352	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. <i>BioMed Research International</i> , 2015, 2015, 1-16.	0.9	111
4353	Low Mutational Burden of Eight Genes Involved in the MAPK/ERK, PI3K/AKT, and GNAQ/11 Pathways in Female Genital Tract Primary Melanomas. <i>BioMed Research International</i> , 2015, 2015, 1-10.	0.9	16
4354	Hairy Cell Leukemia Presenting with Isolated Skeletal Involvement Successfully Treated by Radiation Therapy and Cladribine: A Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2015, 2015, 1-8.	0.3	5
4355	Colorectal Cancer Biomarkers: Where Are We Now?. <i>BioMed Research International</i> , 2015, 2015, 1-14.	0.9	136
4356	The Key Role of Mitochondrial Apoptotic Pathway in the Cytotoxic Effect of Mushroom Extracts on Cancer Cells. <i>Critical Reviews in Eukaryotic Gene Expression</i> , 2015, 25, 253-258.	0.4	4

#	ARTICLE	IF	CITATIONS
4357	What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment. <i>Oncotarget</i> , 2015, 6, 35589-35601.	0.8	57
4359	Recent Clinical Advances in the Treatment of Cutaneous Melanoma. <i>Clinical Cancer Drugs</i> , 2015, 2, 16-28.	0.3	0
4360	Achievements and Challenges of Molecular Targeted Therapy in Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 177-186.	1.8	37
4361	Ultraviolet Radiation-Induced Cytogenetic Damage in White, Hispanic and Black Skin Melanocytes: A Risk for Cutaneous Melanoma. <i>Cancers</i> , 2015, 7, 1586-1604.	1.7	4
4363	The Prognostic Value of Microsatellite Instability, KRAS, BRAF and PIK3CA Mutations in Stage II Colon Cancer Patients. <i>Molecular Medicine</i> , 2015, 21, 1038-1046.	1.9	17
4364	Targeting RTK Signaling Pathways in Cancer. <i>Cancers</i> , 2015, 7, 1758-1784.	1.7	290
4365	Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era. <i>Current Molecular Pharmacology</i> , 2015, 7, 33-43.	0.7	3
4366	Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. <i>Oncotarget</i> , 2015, 6, 28296-28311.	0.8	75
4367	Computational drug ZINPIP-Analog an ultimate solution to cure conserved domains of mutant EGFR, ALK and BRAF Proteins in NSCLC. <i>International Current Pharmaceutical Journal</i> , 2015, 4, 396-401.	0.2	1
4368	Signaling Pathways Altered During the Metastatic Progression of Melanoma. , 2015, , .		1
4369	An information theoretic method to identify combinations of genomic alterations that promote glioblastoma. <i>Journal of Molecular Cell Biology</i> , 2015, 7, 203-213.	1.5	14
4370	Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases. <i>Melanoma Research</i> , 2015, 25, 75-79.	0.6	27
4371	Cancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma. <i>Scientific Reports</i> , 2015, 5, 7857.	1.6	89
4372	BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E536-45.	3.3	121
4373	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1820-1828.	0.3	46
4374	BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress. <i>Molecular Therapy</i> , 2015, 23, 931-942.	3.7	44
4375	Activating MET kinase rearrangements in melanoma and Spitz tumours. <i>Nature Communications</i> , 2015, 6, 7174.	5.8	139
4376	Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. <i>European Journal of Cancer</i> , 2015, 51, 1435-1443.	1.3	61

#	ARTICLE	IF	CITATIONS
4377	Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. <i>Future Oncology</i> , 2015, 11, 997-1009.	1.1	2
4378	Primary pineal malignant melanoma with B-Raf V600E mutation: a case report and brief review of the literature. <i>Acta Neurochirurgica</i> , 2015, 157, 1267-1270.	0.9	12
4379	BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1285-1297.	0.9	24
4380	Long Noncoding RNAs in Lung Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2015, 394, 57-110.	0.7	39
4381	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 107-121.	1.4	8
4382	AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation. <i>Chemico-Biological Interactions</i> , 2015, 236, 9-18.	1.7	12
4383	Regulation of viability, differentiation and death of human melanoma cells carrying neural stem cell biomarkers: a possibility for neural trans-differentiation. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2015, 20, 996-1015.	2.2	5
4384	Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor. <i>Molecular and Cellular Biochemistry</i> , 2015, 406, 53-62.	1.4	3
4385	Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression. <i>European Journal of Cancer</i> , 2015, 51, 642-652.	1.3	30
4386	Dysplastic nevus: Fact and fiction. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 507-512.	0.6	47
4387	Dendritic Cell-Based Vaccination in Cancer: Therapeutic Implications Emerging from Murine Models. <i>Frontiers in Immunology</i> , 2015, 6, 243.	2.2	44
4388	Histogram analysis of iodine maps from dual energy computed tomography for monitoring targeted therapy of melanoma patients. <i>Future Oncology</i> , 2015, 11, 591-606.	1.1	16
4389	Prediagnostic Physical Activity and Colorectal Cancer Survival: Overall and Stratified by Tumor Characteristics. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1130-1137.	1.1	30
4390	Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle. <i>Clinical Cancer Research</i> , 2015, 21, 4410-4419.	3.2	55
4391	BRAF mutations in pediatric metanephric tumors. <i>Human Pathology</i> , 2015, 46, 1153-1161.	1.1	36
4392	Association Between <i>NRAS</i> and <i>BRAF</i> Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. <i>JAMA Oncology</i> , 2015, 1, 359.	3.4	164
4393	The relationship between hand hygiene and health care-associated infection: it's complicated. <i>Infection and Drug Resistance</i> , 2015, 8, 7.	1.1	39
4394	BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1680-1692.	1.9	32

#	ARTICLE	IF	CITATIONS
4395	Selumetinib for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 111-123.	1.9	31
4396	Raf/MEK/ERK Signaling. , 2015, , 275-305.		0
4397	The Utility of BRAF V600E Mutation-Specific Antibody VE1 for the Diagnosis of Hairy Cell Leukemia. <i>American Journal of Clinical Pathology</i> , 2015, 143, 120-125.	0.4	23
4398	New Strategies in Melanoma: Entering the Era of Combinatorial Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 2424-2435.	3.2	29
4399	Emerging clinical applications of selected biomarkers in melanoma. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2015, 8, 35.	0.8	18
4400	EGFR signaling in colorectal cancer: a clinical perspective. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 0, , 21.	5.5	10
4401	The management of thyroid nodules and cancer in the molecular era. <i>International Journal of Endocrine Oncology</i> , 2015, 2, 301-315.	0.4	1
4402	BRAF Mutations in Non-Metastatic Colorectal Cancer: Current Relevance and Future Implications. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 303-310.	1.0	0
4403	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 694-720.	1.8	83
4404	The molecular background of mucinous carcinoma beyond MUC2. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 3-17.	1.3	69
4405	Complete Cytologic Remission of V600E <i>BRAF</i> -Mutant Melanomaâ€‘Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib. <i>Journal of Clinical Oncology</i> , 2015, 33, e109-e111.	0.8	31
4406	Next-generation sequencing reveals rare genomic alterations in aggressive digital papillary adenocarcinoma. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 381-384.	0.6	24
4407	The role of autophagy in mechanisms of tumor cell death. <i>Biology Bulletin Reviews</i> , 2015, 5, 579-588.	0.3	4
4408	BRAF in metastatic colorectal cancer: the future starts now. <i>Pharmacogenomics</i> , 2015, 16, 2069-2081.	0.6	14
4409	BRAF inhibitor therapy in HCL. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 246-252.	0.7	13
4410	Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST. <i>Molecular and Cellular Biology</i> , 2015, 35, 2991-3004.	1.1	11
4411	Treating cancer when pRb and p53 cannot be reactivated. <i>Molecular and Cellular Oncology</i> , 2015, 2, e1004954.	0.3	0
4412	A combination of high dose rate (10X FFF/2400â€‘MU/min/10â€‘MV X-rays) and total low dose (0.5â€‘Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes. <i>Melanoma Research</i> , 2015, 25, 376-389.	0.6	13

#	ARTICLE	IF	CITATIONS
4413	The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 353-366.	0.1	1
4414	Clinical features and diagnosis of hairy cell leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 180-192.	0.7	18
4415	BRAFV600E induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. <i>Leukemia Research</i> , 2015, 39, 1270-1277.	0.4	11
4416	Is there a role for targeted medical therapies in patients with craniopharyngiomas?. <i>Future Oncology</i> , 2015, 11, 3221-3223.	1.1	4
4417	Langerhans cell histiocytosis: a comprehensive review. <i>Pathology</i> , 2015, 47, 294-301.	0.3	67
4418	First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2015, 3, 232470961560372.	0.3	4
4419	Intercellular Communication in Cancer. , 2015, , .		4
4420	BRAF Alterations as Therapeutic Targets in Non-“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1396-1403.	0.5	76
4421	Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor. <i>European Journal of Dermatology</i> , 2015, 25, 177-180.	0.3	18
4422	Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. <i>Genome Biology</i> , 2015, 16, 281.	3.8	330
4423	Quantitative fluorescence nanoscopy for cancer biomedicine. , 2015, , .		2
4424	CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-“Kinase Inhibition Redux. <i>Clinical Cancer Research</i> , 2015, 21, 5412-5414.	3.2	1
4425	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	1.3	269
4426	Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. <i>Cell Reports</i> , 2015, 11, 1458-1473.	2.9	55
4427	High-Resolution Melting Is a Sensitive, Cost-Effective, Time-Saving Technique for BRAF V600E Detection in Thyroid FNAB Washing Liquid: A Prospective Cohort Study. <i>European Thyroid Journal</i> , 2015, 4, 73-81.	1.2	11
4428	Modulation of the cancer cell transcriptome by culture media formulations and cell density. <i>International Journal of Oncology</i> , 2015, 46, 2067-2075.	1.4	24
4429	EGFR and HER2 signals play a salvage role in MEK1-mutated gastric cancer after MEK inhibition. <i>International Journal of Oncology</i> , 2015, 47, 499-505.	1.4	14
4430	U0126 Protects Cells against Oxidative Stress Independent of Its Function as a MEK Inhibitor. <i>ACS Chemical Neuroscience</i> , 2015, 6, 130-137.	1.7	41

#	ARTICLE	IF	CITATIONS
4431	Tenascin-C Signaling in melanoma. <i>Cell Adhesion and Migration</i> , 2015, 9, 125-130.	1.1	27
4432	BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity. <i>Hormones and Cancer</i> , 2015, 6, 21-36.	4.9	54
4433	Immunohistochemistry is highly sensitive and specific for the detection of NRASQ61R mutation in melanoma. <i>Modern Pathology</i> , 2015, 28, 487-497.	2.9	59
4434	<scp>KRAS</scp> and <scp>BRAF</scp> mutations in anal carcinoma. <i>Apmis</i> , 2015, 123, 53-59.	0.9	20
4435	Ran signaling in melanoma: Implications for the development of alternative therapeutic strategies. <i>Cancer Letters</i> , 2015, 357, 286-296.	3.2	11
4436	Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. <i>Pathology Research and Practice</i> , 2015, 211, 162-170.	1.0	26
4437	Trametinib: A novel signal transduction inhibitor for the treatment of metastatic cutaneous melanoma. <i>American Journal of Health-System Pharmacy</i> , 2015, 72, 101-110.	0.5	14
4438	Circulating Biomarkers in Malignant Melanoma. <i>Advances in Clinical Chemistry</i> , 2015, 69, 47-89.	1.8	34
4439	Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. <i>Biochemical Pharmacology</i> , 2015, 93, 290-304.	2.0	49
4440	Dabrafenib in combination with trametinib for the treatment of metastatic melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 25-33.	1.3	8
4441	Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?. <i>British Journal of Haematology</i> , 2015, 169, 3-13.	1.2	141
4442	Mitochondrial Division Is Requisite to RAS-Induced Transformation and Targeted by Oncogenic MAPK Pathway Inhibitors. <i>Molecular Cell</i> , 2015, 57, 521-536.	4.5	310
4443	Antitumor Activity of miR-1280 in Melanoma by Regulation of Src. <i>Molecular Therapy</i> , 2015, 23, 71-78.	3.7	19
4444	Prognostic and predictive values of oncogenic <i>BRAF</i> , <i>NRAS</i> , <i>KIT</i> and <i>MITF</i> in cutaneous and mucous melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1530-1538.	1.3	34
4445	The immune-related role of BRAF in melanoma. <i>Molecular Oncology</i> , 2015, 9, 93-104.	2.1	28
4446	A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 387-390.	1.3	5
4447	Recent Advances in Cancer Therapeutics. <i>Progress in Medicinal Chemistry</i> , 2015, 54, 1-63.	4.1	32
4448	Oncogenic Mutations and Chromosomal Aberrations in Primary Extranodal Diffuse Large B-Cell Lymphomas of the Thyroid—A Study of 21 Cases. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 754-762.	1.8	11

#	ARTICLE	IF	CITATIONS
4449	Structural Investigation of B-Raf Paradox Breaker and Inducer Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 1818-1831.	2.9	35
4450	A Modified Lynch Syndrome Screening Algorithm in Colon Cancer. <i>American Journal of Clinical Pathology</i> , 2015, 143, 336-343.	0.4	27
4452	<scp>CTLA</scp> blockade with ipilimumab: biology, safety, efficacy, and future considerations. <i>Cancer Medicine</i> , 2015, 4, 661-672.	1.3	100
4453	Discovery and Pharmacophore Studies of Novel Pyrazole-Based Anti-Melanoma Agents. <i>Chemistry and Biodiversity</i> , 2015, 12, 116-132.	1.0	7
4454	Targeting drivers of melanoma with synthetic small molecules and phytochemicals. <i>Cancer Letters</i> , 2015, 359, 20-35.	3.2	67
4455	The route to personalized medicine in bladder cancer: where do we stand?. <i>Targeted Oncology</i> , 2015, 10, 325-336.	1.7	14
4456	Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. , 2015, 149, 139-149.		27
4457	BRAF and MEK inhibition in melanoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 559-570.	1.0	67
4458	EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma. <i>Cancer Discovery</i> , 2015, 5, 274-287.	7.7	107
4459	KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance. <i>Gastric Cancer</i> , 2015, 18, 796-802.	2.7	17
4460	Therapeutic potential of benzothiazoles: a patent review (2010 – 2014). <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 335-349.	2.4	89
4461	Individualized Medicine. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , .	0.6	8
4462	Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors. <i>ACS Chemical Biology</i> , 2015, 10, 234-245.	1.6	52
4463	Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). <i>Targeted Oncology</i> , 2015, 10, 365-373.	1.7	24
4464	Application of Immunohistochemistry in Gastrointestinal and Liver Neoplasms: New Markers and Evolving Practice. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 14-23.	1.2	28
4465	Cutaneous adverse effects of targeted therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 221-236.	0.6	150
4466	Spontaneously hyperactive MEK-Erk pathway mediates paradoxical facilitation of cell proliferation in mild hypoxia. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2015, 1850, 640-646.	1.1	9
4467	Molecular Basis for Treating Cutaneous Melanoma. , 2015, , 591-600.e3.		0

#	ARTICLE	IF	CITATIONS
4468	Molecular drivers of cellular metabolic reprogramming in melanoma. Trends in Molecular Medicine, 2015, 21, 164-171.	3.5	103
4469	RSK1 Activation Promotes Invasion in Nodular Melanoma. American Journal of Pathology, 2015, 185, 704-716.	1.9	26
4470	Anaplastic Thyroid Cancer: Outcome and the Mutation/Expression Profiles of Potential Targets. Pathology and Oncology Research, 2015, 21, 695-701.	0.9	32
4471	The Genomic Landscape of Childhood and Adolescent Melanoma. Journal of Investigative Dermatology, 2015, 135, 816-823.	0.3	148
4472	ImmTACs for targeted cancer therapy: Why, what, how, and which. Molecular Immunology, 2015, 67, 67-74.	1.0	75
4473	BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. Endocrine-Related Cancer, 2015, 22, 159-168.	1.6	102
4474	Autophagy in malignant transformation and cancer progression. EMBO Journal, 2015, 34, 856-880.	3.5	1,012
4475	Epigenetics of Melanoma. , 2015, , 339-361.		1
4476	Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. Tumor Biology, 2015, 36, 5649-5653.	0.8	92
4479	Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens. Tumor Biology, 2015, 36, 1003-1013.	0.8	37
4480	Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemotherapy and Pharmacology, 2015, 75, 183-189.	1.1	136
4481	BRAF V600E mutation-specific antibody: A review. Seminars in Diagnostic Pathology, 2015, 32, 400-408.	1.0	116
4482	BRAF Mutation and Thyroid Cancer Recurrence. Journal of Clinical Oncology, 2015, 33, 7-8.	0.8	46
4483	Overview of Predictive Biomarkers and Integration of IHC into Molecular Pathology. , 2015, , 91-104.		1
4484	The Cancer Genomics Resource List 2014. Archives of Pathology and Laboratory Medicine, 2015, 139, 989-1008.	1.2	18
4485	Tumor-specific mutations in low-frequency genes affect their functional properties. Journal of Neuro-Oncology, 2015, 122, 461-470.	1.4	13
4486	Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas. Journal of Translational Medicine, 2015, 13, 37.	1.8	15
4487	Mutations in G Protein Encoding Genes and Chromosomal Alterations in Primary Leptomeningeal Melanocytic Neoplasms. Pathology and Oncology Research, 2015, 21, 439-447.	0.9	34

#	ARTICLE	IF	CITATIONS
4488	Pharmacogenomics and targeted therapy of cancer: Focusing on non-small cell lung cancer. <i>European Journal of Pharmacology</i> , 2015, 754, 82-91.	1.7	31
4489	Clinical Acquired Resistance to RAF Inhibitor Combinations in <i>BRAF</i> -Mutant Colorectal Cancer through MAPK Pathway Alterations. <i>Cancer Discovery</i> , 2015, 5, 358-367.	7.7	265
4490	The rare <i>BRAF</i> V600E mutation as a possible indicator of poor prognosis in rectal carcinoma – a report of a case. <i>BMC Medical Genetics</i> , 2015, 16, 1.	2.1	24
4491	The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1033-1042.	1.3	38
4492	Molecular biomarkers in colorectal carcinoma. <i>Pharmacogenomics</i> , 2015, 16, 1189-1222.	0.6	14
4493	Melanoma: Advances in Targeted Therapy and Molecular Markers. <i>Annals of Surgical Oncology</i> , 2015, 22, 3451-3458.	0.7	15
4494	Establishment of a novel Chinese metastatic melanoma cell line showing the new cytogenetic and biological properties. <i>Cell Biology International</i> , 2015, 39, 508-514.	1.4	4
4495	Targeted Therapies in Melanoma: Translational Research at Its Finest. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1929-1933.	0.3	12
4496	SMK-17, a MEK1/2-specific inhibitor, selectively induces apoptosis in β -catenin-mutated tumors. <i>Scientific Reports</i> , 2015, 5, 8155.	1.6	5
4497	Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 961-965.	1.3	37
4498	Somatic V600E <i>BRAF</i> Mutation in Linear and Sporadic Syringocystadenoma Papilliferum. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2536-2538.	0.3	31
4499	Adjusting for the Confounding Effects of Treatment Switching – The BREAK-3 Trial: Dabrafenib Versus Dacarbazine. <i>Oncologist</i> , 2015, 20, 798-805.	1.9	28
4500	Therapeutic Advances and Treatment Options in Metastatic Melanoma. <i>JAMA Oncology</i> , 2015, 1, 380.	3.4	66
4501	A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1599-1615.	2.5	94
4502	Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 616-622.	1.2	2
4503	c-Myc modulation: a key role in melanoma drug response. <i>Cancer Biology and Therapy</i> , 2015, 16, 1375-1386.	1.5	7
4504	<i>BRAF</i> -mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. <i>OncoTargets and Therapy</i> , 2015, 8, 157.	1.0	134
4505	Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <i>BRAF</i> mutations in the Lung Cancer Mutation Consortium. <i>Cancer</i> , 2015, 121, 448-456.	2.0	102

#	ARTICLE	IF	CITATIONS
4506	Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK. <i>Cancers</i> , 2015, 7, 930-949.	1.7	83
4507	Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. <i>Scientific Reports</i> , 2015, 5, 11198.	1.6	150
4508	The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 979-987.	1.5	14
4509	Impacts of Activation of the Mitogen-Activated Protein Kinase Pathway in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 23.	1.3	47
4510	Phenotype Switching in Melanoma: Implications for Progression and Therapy. <i>Frontiers in Oncology</i> , 2015, 5, 31.	1.3	138
4511	Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. <i>Frontiers in Oncology</i> , 2015, 5, 54.	1.3	87
4512	Malignant melanoma and papillary thyroid carcinoma that were diagnosed concurrently and treated simultaneously: A case report. <i>Oncology Letters</i> , 2015, 9, 468-470.	0.8	7
4513	Targeted Therapies for Melanoma. , 2015, , 1529-1541.		0
4514	Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. <i>Melanoma Management</i> , 2015, 2, 133-147.	0.1	3
4515	MEK inhibitors: a new class of chemotherapeutic agents with ocular toxicity. <i>Eye</i> , 2015, 29, 1003-1012.	1.1	66
4516	The Role of eIF4E in Response and Acquired Resistance to Vemurafenib in Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1368-1376.	0.3	24
4517	Cancer modelling in the NGS era – Part I: Emerging technology and initial modelling. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 274-307.	2.0	9
4518	Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 177-184.	1.4	59
4519	A historical overview of protein kinases and their targeted small molecule inhibitors. <i>Pharmacological Research</i> , 2015, 100, 1-23.	3.1	391
4520	Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model. <i>Free Radical Biology and Medicine</i> , 2015, 87, 193-203.	1.3	25
4521	Trametinib in metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 749-760.	1.1	8
4522	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. , 2015, , 709-738.e8.		0
4523	Cell-free DNA as a novel marker in cancer therapy. <i>Biomarkers in Medicine</i> , 2015, 9, 703-712.	0.6	13

#	ARTICLE	IF	CITATIONS
4524	The Biology and Management of the Zebrafish. , 2015, , 1015-1062.		5
4525	Nivolumab in the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2015, 3, 945-956.	0.5	0
4526	Metastatic Melanoma – A Review of Current and Future Treatment Options. Acta Dermato-Venereologica, 2015, 95, 516-524.	0.6	186
4527	Combined HSP90 and kinase inhibitor therapy: Insights from The Cancer Genome Atlas. Cell Stress and Chaperones, 2015, 20, 729-741.	1.2	19
4528	BRAF inhibitors: the current and the future. Current Opinion in Pharmacology, 2015, 23, 68-73.	1.7	37
4529	Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer. Cancer Treatment Reviews, 2015, 41, 653-659.	3.4	49
4530	Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Research, 2015, 75, 2737-2748.	0.4	57
4531	KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer. Journal of Molecular Endocrinology, 2015, 54, 115-124.	1.1	9
4532	Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment. Frontiers in Immunology, 2015, 6, 46.	2.2	69
4533	Targeting cancer with kinase inhibitors. Journal of Clinical Investigation, 2015, 125, 1780-1789.	3.9	364
4534	Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. Methods, 2015, 83, 118-127.	1.9	33
4535	VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 155-168.	1.4	20
4536	Dabrafenib in the treatment of metastatic or unresectable melanoma. Expert Review of Anticancer Therapy, 2015, 15, 265-276.	1.1	7
4537	Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells. Cancer Letters, 2015, 361, 86-96.	3.2	45
4538	Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma. Biomaterials, 2015, 56, 129-139.	5.7	27
4540	Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology, 2015, 35, S78-S103.	4.3	535
4541	Metaanalysis of BRAF mutations and clinicopathologic characteristics in primary melanoma. Journal of the American Academy of Dermatology, 2015, 72, 1036-1046.e2.	0.6	83
4542	Classification of <i>KIT/PDGFRA</i> wild-type gastrointestinal stromal tumors: implications for therapy. Expert Review of Anticancer Therapy, 2015, 15, 623-628.	1.1	26

#	ARTICLE	IF	CITATIONS
4543	How I treat Langerhans cell histiocytosis. <i>Blood</i> , 2015, 126, 26-35.	0.6	160
4544	Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapy. <i>Seminars in Cancer Biology</i> , 2015, 33, 3-15.	4.3	90
4545	Toxicidad cutánea de los inhibidores del BRAF y del MEK. <i>Piel</i> , 2015, 30, 309-315.	0.0	1
4546	Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 5366-5371.	3.3	52
4547	The future of immune checkpoint therapy. <i>Science</i> , 2015, 348, 56-61.	6.0	3,735
4548	The Effect of a Widespread Cancer-Causing Mutation on the Inactive to Active Dynamics of the B-Raf Kinase. <i>Journal of the American Chemical Society</i> , 2015, 137, 5280-5283.	6.6	37
4550	Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 641-651.	1.2	8
4551	LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. <i>Journal of Neuro-Oncology</i> , 2015, 122, 121-126.	1.4	62
4552	The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy. <i>Medical Oncology</i> , 2015, 32, 440.	1.2	6
4553	Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. <i>Modern Pathology</i> , 2015, 28, 884-894.	2.9	37
4554	Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. <i>Journal of Neurosurgery</i> , 2015, 123, 395-401.	0.9	64
4555	Melanoma Treatments: Advances and Mechanisms. <i>Journal of Cellular Physiology</i> , 2015, 230, 2626-2633.	2.0	40
4556	Regulation of RAF protein kinases in ERK signalling. <i>Nature Reviews Molecular Cell Biology</i> , 2015, 16, 281-298.	16.1	506
4557	Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. <i>BMC Cancer</i> , 2015, 15, 61.	1.1	25
4558	The leukemia inhibitory factor (LIF) and p21 mediate the TGF β 2 tumor suppressive effects in human cutaneous melanoma. <i>BMC Cancer</i> , 2015, 15, 200.	1.1	24
4559	Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines. <i>Molecular Cancer</i> , 2015, 14, 54.	7.9	17
4560	In-depth genomic data analyses revealed complex transcriptional and epigenetic dysregulations of BRAF V600E in melanoma. <i>Molecular Cancer</i> , 2015, 14, 60.	7.9	30
4561	Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. <i>Journal of Translational Medicine</i> , 2015, 13, 57.	1.8	49

#	ARTICLE	IF	CITATIONS
4562	Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing. <i>Human Genomics</i> , 2015, 9, 2.	1.4	36
4563	Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 401-411.	3.4	40
4564	Anti-cancer chalcones: Structural and molecular target perspectives. <i>European Journal of Medicinal Chemistry</i> , 2015, 98, 69-114.	2.6	382
4565	MicroRNA-378-5p suppresses cell proliferation and induces apoptosis in colorectal cancer cells by targeting BRAF. <i>Cancer Cell International</i> , 2015, 15, 40.	1.8	54
4566	Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma. <i>Molecular Cancer Research</i> , 2015, 13, 670-680.	1.5	22
4567	Serrated neoplasia's role in colorectal carcinogenesis and clinical implications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 401-409.	8.2	149
4568	Status and Prospects of Aptamers as Drug Components. <i>BioDrugs</i> , 2015, 29, 151-165.	2.2	9
4570	DNA polymerase-catalyzed incorporation of nucleotides modified with a G-quadruplex-derived DNAzyme. <i>Chemical Communications</i> , 2015, 51, 7379-7381.	2.2	31
4571	A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib. <i>Biochemical Pharmacology</i> , 2015, 95, 16-27.	2.0	29
4572	Primary Melanocytic Tumors of the Central Nervous System: a Review with Focus on Molecular Aspects. <i>Brain Pathology</i> , 2015, 25, 209-226.	2.1	88
4573	<i>Atg7</i> Overcomes Senescence and Promotes Growth of <i>Braf</i> ^{V600E} -Driven Melanoma. <i>Cancer Discovery</i> , 2015, 5, 410-423.	7.7	181
4574	Metastasectomy for Stage IV Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 279-298.	0.6	23
4575	Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 349-356.	1.2	27
4576	Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 366-373.	1.2	34
4577	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
4578	The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1354-1364.	1.9	33
4579	Quinazoline derivatives as anticancer drugs: a patent review (2011 – present). <i>Expert Opinion on Therapeutic Patents</i> , 2015, 25, 789-804.	2.4	93
4580	Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 519-526.	3.4	63

#	ARTICLE	IF	CITATIONS
4581	Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations. <i>Pathology and Oncology Research</i> , 2015, 21, 957-968.	0.9	10
4582	HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in <i>BRAF</i> -Mutant Colorectal Cancer by Downregulation of c-FLIPL. <i>Clinical Cancer Research</i> , 2015, 21, 3230-3240.	3.2	53
4583	Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations. <i>Seminars in Diagnostic Pathology</i> , 2015, 32, 381-391.	1.0	4
4584	<i>BRAF</i> and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, 172-177.	0.6	42
4585	Molecular and Immunohistochemical Characterization Reveals Novel BRAF Mutations in Metanephric Adenoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 549-557.	2.1	43
4586	Should Endometrial Clear Cell Carcinoma be Classified as Type II Endometrial Carcinoma?. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 74-84.	0.9	35
4587	<i>BRAF</i> V600 mutations and pathological features in Japanese melanoma patients. <i>Melanoma Research</i> , 2015, 25, 9-14.	0.6	43
4588	<i>NUAK2</i> Amplification Coupled with <i>PTEN</i> Deficiency Promotes Melanoma Development via CDK Activation. <i>Cancer Research</i> , 2015, 75, 2708-2715.	0.4	19
4589	Comparison of Next-generation Sequencing Mutation Profiling With <i>BRAF</i> and <i>IDH1</i> Mutation-specific Immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2015, 39, 454-461.	2.1	25
4590	Aberrant Expression of COT Is Related to Recurrence of Papillary Thyroid Cancer. <i>Medicine (United Tj ETQq1 1 0.784314 rgBj /Overl</i>	0.4	14
4591	Synthesis, characterization, DNA/BSA interactions and anticancer activity of achiral and chiral copper complexes. <i>Dalton Transactions</i> , 2015, 44, 9516-9527.	1.6	47
4592	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. <i>Cell</i> , 2015, 161, 205-214.	13.5	1,872
4593	Preliminary Results from a Prospective Trial of Preoperative Combined <i>BRAF</i> and MEK-Targeted Therapy in Advanced <i>BRAF</i> Mutation-Positive Melanoma. <i>Journal of the American College of Surgeons</i> , 2015, 220, 581-593e1.	0.2	26
4594	Targeted approaches to childhood cancer: progress in drug discovery and development. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 483-495.	2.5	3
4596	Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous <i>BRAF</i> Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2015, 16, 1389-1398.	5.1	206
4597	<i>MEK1</i> and <i>MEK2</i> inhibitors and cancer therapy: the long and winding road. <i>Nature Reviews Cancer</i> , 2015, 15, 577-592.	12.8	461
4598	Activation Status of the Pregnane X Receptor Influences Vemurafenib Availability in Humanized Mouse Models. <i>Cancer Research</i> , 2015, 75, 4573-4581.	0.4	23
4599	Precision medicine in colorectal cancer: the molecular profile alters treatment strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 252-262.	1.4	63

#	ARTICLE	IF	CITATIONS
4600	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600E Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4031.	0.8	430
4601	Non-p.V600E BRAF Mutations Are Common Using a More Sensitive and Broad Detection Tool. <i>American Journal of Clinical Pathology</i> , 2015, 144, 620-628.	0.4	43
4602	HSP90 Inhibitor-Based Strategies for Cancer Therapy: Advancing Toward Clinical Impact. <i>Heat Shock Proteins</i> , 2015, , 289-322.	0.2	2
4603	Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 385-398.	2.0	51
4604	MAP kinases and the inflammatory signaling cascade as targets for the treatment of endometriosis?. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1465-1483.	1.5	48
4605	The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. <i>Dermatology and Therapy</i> , 2015, 5, 151-169.	1.4	19
4606	MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. <i>Seminars in Oncology</i> , 2015, 42, 849-862.	0.8	96
4607	Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2173-2179.	0.6	74
4608	Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects. <i>Cell Reports</i> , 2015, 12, 1939-1949.	2.9	37
4609	Overcoming Resistance to Targeted Therapies in Cancer. <i>Seminars in Oncology</i> , 2015, 42, 896-908.	0.8	36
4610	A phase I/IIb study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1058-1067.	1.2	13
4611	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. <i>Clinical Epigenetics</i> , 2015, 7, 59.	1.8	49
4612	Markers in Colorectal Cancer and Clinical Trials Based Upon Them. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 317-325.	1.0	0
4613	Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature. <i>Cancer Biology and Therapy</i> , 2015, 16, 1128-1135.	1.5	26
4614	Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. <i>BMC Cancer</i> , 2015, 15, 415.	1.1	116
4616	STAP-2 Protein Expression in B16F10 Melanoma Cells Positively Regulates Protein Levels of Tyrosinase, Which Determines Organs to Infiltrate in the Body. <i>Journal of Biological Chemistry</i> , 2015, 290, 17462-17473.	1.6	10
4617	UVB Dependence of Quantum Dot Reactive Oxygen Species Generation in Common Skin Cell Models. <i>Journal of Biomedical Nanotechnology</i> , 2015, 11, 1644-1652.	0.5	8
4618	ER stress-induced autophagy in melanoma. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 811-816.	0.9	21

#	ARTICLE	IF	CITATIONS
4619	Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 287-289.	1.5	7
4620	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). <i>Clinical Cancer Research</i> , 2015, 21, 5294-5304.	3.2	70
4621	Heat Shock Protein-Based Therapies. <i>Heat Shock Proteins</i> , 2015, , .	0.2	5
4622	BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in <i>BRAF</i> -Mutated Colorectal Cancers. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2187-2197.	1.9	57
4623	Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients. <i>Dermatology</i> , 2015, 231, 127-133.	0.9	10
4624	Systematic analysis of <i>BRAF</i> ^V melanomas reveals a role for <i>JNK</i> / <i>c-Jun</i> pathway in adaptive resistance to drug-induced apoptosis. <i>Molecular Systems Biology</i> , 2015, 11, 797.	3.2	84
4625	BRAF V600E mutation-specific immunohistochemistry is a rare finding in dendritic cell- and histiocyte-derived tumors. <i>Leukemia and Lymphoma</i> , 2015, 56, 1132-1133.	0.6	7
4626	The Ras/ <i>MAPK</i> pathway and hepatocarcinoma: pathogenesis and therapeutic implications. <i>European Journal of Clinical Investigation</i> , 2015, 45, 609-623.	1.7	193
4627	Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 121-123.	0.7	17
4628	Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain. <i>Nature Communications</i> , 2015, 6, 7396.	5.8	64
4629	Hitting the Target in <i>BRAF</i> -Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3990-3992.	0.8	12
4630	Prevalence and Clinicopathological Characteristics of BRAF Mutations in Chinese Patients with Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 1284-1291.	0.7	7
4631	Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents. <i>Future Journal of Pharmaceutical Sciences</i> , 2015, 1, 33-41.	1.1	44
4632	RAF inhibitors that evade paradoxical MAPK pathway activation. <i>Nature</i> , 2015, 526, 583-586.	13.7	322
4633	The functional relevance of somatic synonymous mutations in melanoma and other cancers. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 673-684.	1.5	47
4634	Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. <i>BMC Cancer</i> , 2015, 15, 400.	1.1	38
4635	Variations of BRAF mutant allele percentage in melanomas. <i>BMC Cancer</i> , 2015, 15, 497.	1.1	36
4636	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. <i>Drugs and Aging</i> , 2015, 32, 821-834.	1.3	12

#	ARTICLE	IF	CITATIONS
4637	Assessment of <i>BRAF</i> V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2887-2895.	1.9	38
4638	YY1 regulates melanoma tumorigenesis through a miR-9~RYBP axis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 66.	3.5	54
4639	MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. <i>Nature Communications</i> , 2015, 6, 8583.	5.8	42
4640	Phase II Pilot Study of Vemurafenib in Patients With Metastatic <i>BRAF</i> -Mutated Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4032-4038.	0.8	583
4641	Clinical characteristics associated with <i>BRAF</i> , <i>NRAS</i> and <i>KIT</i> mutations in Japanese melanoma patients. <i>Journal of Dermatological Science</i> , 2015, 80, 33-37.	1.0	87
4643	How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). <i>Current Colorectal Cancer Reports</i> , 2015, 11, 151-159.	1.0	2
4644	Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules. <i>Journal of Proteome Research</i> , 2015, 14, 4179-4193.	1.8	7
4645	The dynamic control of signal transduction networks in cancer cells. <i>Nature Reviews Cancer</i> , 2015, 15, 515-527.	12.8	282
4646	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	13.9	1,483
4647	<i>BRAF</i> gene: From human cancers to developmental syndromes. <i>Saudi Journal of Biological Sciences</i> , 2015, 22, 359-373.	1.8	61
4648	Gastrointestinal and Pancreatobiliary Tumors. , 2015, , 375-406.		0
4649	Molecular Oncologic Testing of Skin and Adnexa Tumors. , 2015, , 567-618.		0
4650	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1185-1198.	1.9	4
4651	The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy. <i>Future Medicinal Chemistry</i> , 2015, 7, 269-289.	1.1	60
4652	Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and <i>FLT3</i> Amplification. <i>Case Reports in Oncology</i> , 2015, 8, 83-87.	0.3	24
4653	Cell(s) of Origin of Langerhans Cell Histiocytosis. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 825-838.	0.9	73
4654	Mitogen-activated protein kinases and Hedgehog-Gli signaling in cancer: A crosstalk providing therapeutic opportunities?. <i>Seminars in Cancer Biology</i> , 2015, 35, 154-167.	4.3	68
4655	Precision Molecular Pathology of Dermatologic Diseases. <i>Molecular Pathology Library</i> , 2015, , .	0.1	2

#	ARTICLE	IF	CITATIONS
4656	Recent progress on MAP kinase pathway inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 4047-4056.	1.0	55
4657	Potential breakthroughs with investigational drugs for hairy cell leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1419-1431.	1.9	10
4658	Hyaluronan synthase 3 (HAS3) overexpression downregulates MV3 melanoma cell proliferation, migration and adhesion. <i>Experimental Cell Research</i> , 2015, 337, 1-15.	1.2	25
4659	BRAFV600E Protein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases. <i>JAMA Dermatology</i> , 2015, 151, 410.	2.0	27
4660	<i>BRAF</i> Wild-Type Melanoma in Situ Arising In a <i>BRAF</i> V600E Mutant Dysplastic Nevus. <i>JAMA Dermatology</i> , 2015, 151, 417.	2.0	13
4661	Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 1733-1747.	13.9	281
4662	Expression of tumor-related Rac1b antagonizes B-Raf-induced senescence in colorectal cells. <i>Cancer Letters</i> , 2015, 369, 368-375.	3.2	19
4663	Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion. <i>Cellular Signalling</i> , 2015, 27, 2191-2200.	1.7	3
4664	Molecular phenotypes of colorectal cancer and potential clinical applications. <i>Gastroenterology Report</i> , 2015, 3, gov046.	0.6	105
4665	Thyroid and Parathyroid Tumors. , 2015, , 341-374.		0
4666	Central Nervous System Tumors. , 2015, , 537-565.		0
4667	Genetic Testing in the Multidisciplinary Management of Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 779-793.	0.6	3
4668	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10995-11000.	3.3	146
4669	BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. <i>Cancer Cell</i> , 2015, 28, 370-383.	7.7	392
4670	Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. <i>Cancer Cell</i> , 2015, 28, 384-398.	7.7	243
4671	Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1553-1566.	1.4	22
4672	Chemical biology of compounds obtained from screening using disease models. <i>Archives of Pharmacal Research</i> , 2015, 38, 1651-1660.	2.7	4
4673	The current management of brain metastasis in melanoma: a focus on riluzole. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 779-792.	1.4	12

#	ARTICLE	IF	CITATIONS
4674	Role of circulating-tumor DNA analysis in non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 90, 128-134.	0.9	80
4675	Kinome-wide Decoding of Network-Attacking Mutations Rewiring Cancer Signaling. <i>Cell</i> , 2015, 163, 202-217.	13.5	168
4677	Management of melanoma brain metastases. <i>Melanoma Management</i> , 2015, 2, 225-239.	0.1	2
4678	Atypical signaling of metabotropic glutamate receptor 1 in human melanoma cells. <i>Biochemical Pharmacology</i> , 2015, 98, 182-189.	2.0	10
4679	In silico investigation of new binding pocket for mitogen activated kinase kinase (MEK): Development of new promising inhibitors. <i>Computational Biology and Chemistry</i> , 2015, 59, 185-198.	1.1	8
4680	Genomic Alterations in Langerhans Cell Histiocytosis. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 839-851.	0.9	58
4681	Steroid hormone influence on melanomagenesis. <i>Molecular and Cellular Endocrinology</i> , 2015, 417, 94-102.	1.6	38
4682	Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. <i>Human Pathology</i> , 2015, 46, 1101-1110.	1.1	43
4683	Detection of BRAF mutations from solid tumors using Tumorplexâ„¢ technology. <i>MethodsX</i> , 2015, 2, 316-322.	0.7	0
4684	MicroRNA-3151 inactivates TP53 in <i>BRAF</i> -mutated human malignancies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E6744-51.	3.3	17
4685	Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. <i>Cancer Microenvironment</i> , 2015, 8, 111-118.	3.1	17
4686	A-Raf: A new star of the family of raf kinases. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2015, 50, 520-531.	2.3	31
4687	Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 192-197.	1.0	20
4688	BRAF Targets in Melanoma. <i>Cancer Drug Discovery and Development</i> , 2015, , .	0.2	2
4689	BRAF Inhibitor Dabrafenib in Patients with Metastatic <i>BRAF</i> -Mutant Thyroid Cancer. <i>Thyroid</i> , 2015, 25, 71-77.	2.4	189
4690	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. <i>Gastroenterology</i> , 2015, 148, 88-99.	0.6	273
4691	Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada. <i>Pharmacoeconomics</i> , 2015, 33, 367-380.	1.7	19
4692	Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. <i>Lung Cancer</i> , 2015, 87, 85-87.	0.9	28

#	ARTICLE	IF	CITATIONS
4693	Snowball: resampling combined with distance-based regression to discover transcriptional consequences of a driver mutation. <i>Bioinformatics</i> , 2015, 31, 84-93.	1.8	5
4694	Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas. <i>Journal of Investigative Dermatology</i> , 2015, 135, 532-541.	0.3	79
4695	Role of phosphoproteomics in the development of personalized cancer therapies. <i>Proteomics - Clinical Applications</i> , 2015, 9, 383-395.	0.8	40
4696	Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival. <i>Gastroenterology</i> , 2015, 148, 77-87.e2.	0.6	342
4697	A Novel Role for Microphthalmia-Associated Transcription Factor-Regulated Pigment Epithelium-Derived Factor during Melanoma Progression. <i>American Journal of Pathology</i> , 2015, 185, 252-265.	1.9	17
4698	PI3K-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in BRAF-Mutated Melanoma. <i>Cancer Discovery</i> , 2015, 5, 143-153.	7.7	51
4699	Lymph node metastases of melanoma: challenges for BRAF mutation detection. <i>Human Pathology</i> , 2015, 46, 113-119.	1.1	16
4700	The Src homology 3 binding domain is required for lysophosphatidic acid 3 receptor-mediated cellular viability in melanoma cells. <i>Cancer Letters</i> , 2015, 356, 589-596.	3.2	12
4701	Optimization of Diarylthiazole BRAF Inhibitors: Identification of a Compound Endowed with High Oral Antitumor Activity, Mitigated hERG Inhibition, and Low Paradoxical Effect. <i>ChemMedChem</i> , 2015, 10, 276-295.	1.6	8
4702	Photoprotection in changing times - UV filter efficacy and safety, sensitization processes and regulatory aspects. <i>International Journal of Cosmetic Science</i> , 2015, 37, 2-30.	1.2	71
4703	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. <i>Cancer Immunology Research</i> , 2015, 3, 37-47.	1.6	24
4704	Synthesis, biological evaluation and 3D-QSAR study of novel 4,5-dihydro-1H-pyrazole thiazole derivatives as BRAFV600E inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 46-54.	1.4	53
4705	Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance. <i>Oncogene</i> , 2015, 34, 857-867.	2.6	52
4706	Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway. <i>Targeted Oncology</i> , 2015, 10, 77-84.	1.7	32
4707	Ultraviolet exposure and risk of melanoma and basal cell carcinoma in Ulm and Dresden, Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 134-142.	1.3	30
4708	Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 1001-1011.	2.3	44
4709	Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015, 136, 83-90.	2.3	126
4710	Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 47-52.	1.3	14

#	ARTICLE	IF	CITATIONS
4711	Deciphering oncogenic drivers: from single genes to integrated pathways. Briefings in Bioinformatics, 2015, 16, 413-428.	3.2	24
4712	Beyond BRAF: where next for melanoma therapy?. British Journal of Cancer, 2015, 112, 217-226.	2.9	99
4714	Tumors of the neural crest: Common themes in development and cancer. Developmental Dynamics, 2015, 244, 311-322.	0.8	91
4715	Stress Response Pathways in Cancer. , 2015, , .		3
4716	Involvement of vacuolar H ⁺ -ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720. Pigment Cell and Melanoma Research, 2015, 28, 171-183.	1.5	19
4717	Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors. Clinical Chemistry, 2015, 61, 297-304.	1.5	221
4718	Molecular markers for colon diagnosis, prognosis and targeted therapy. Journal of Surgical Oncology, 2015, 111, 96-102.	0.8	50
4720	Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants. Molecular Cancer Therapeutics, 2015, 14, 317-325.	1.9	43
4721	Comparative analysis of BRAF, NRAS and KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma. Experimental Dermatology, 2015, 24, 70-73.	1.4	5
4722	Kinase Regulation by Hydrophobic Spine Assembly in Cancer. Molecular and Cellular Biology, 2015, 35, 264-276.	1.1	98
4723	Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene, 2015, 34, 3215-3225.	2.6	130
4724	Implementation of a companion diagnostic in the clinical laboratory: The BRAF example in melanoma. Clinica Chimica Acta, 2015, 439, 128-136.	0.5	5
4725	Targeting BRAF mutant metastatic colorectal cancer: clinical implications and emerging therapeutic strategies. Targeted Oncology, 2015, 10, 179-188.	1.7	35
4726	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. Journal of Investigative Dermatology, 2015, 135, 508-515.	0.3	138
4728	A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer. Targeted Oncology, 2015, 10, 99-109.	1.7	45
4729	Oncogenes and Signal Transduction. , 2015, , 19-34.e3.		2
4730	Metastatic Rhabdoid Meningioma with BRAF V600E Mutation and Good Response to Personalized Therapy: Case Report and Review of the Literature. Pediatric Hematology and Oncology, 2015, 32, 207-211.	0.3	30
4731	Genomic Applications in Pathology. , 2015, , .		1

#	ARTICLE	IF	CITATIONS
4732	miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways. <i>Oncotarget</i> , 2016, 7, 53558-53570.	0.8	86
4733	Skin melanoma heterogeneity and its molecular aspects. <i>Medicina</i> , 2016, 52, 370-376.	0.0	0
4734	Peptides and biocomplexes in anticancer therapy. <i>ChemistrySelect</i> , 2016, 1, .	0.7	0
4735	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. <i>Journal of Clinical Investigation</i> , 2016, 126, 1834-1856.	3.9	219
4736	Proteomics: An Indispensable Tool for Novel Biomarker Identification in Melanoma. <i>Journal of Data Mining in Genomics & Proteomics</i> , 2016, 7, .	0.5	2
4737	Can detection of Braf p.V600E mutation be improved? Comparison of allele specific multiplex sequencing to present tests. <i>Journal of Solid Tumors</i> , 2016, 7, 14.	0.1	0
4738	Kirsten Ras* oncogene: Significance of its discovery in human cancer research. <i>Oncotarget</i> , 2016, 7, 46717-46733.	0.8	57
4739	Disrupted cooperation between transcription factors across diverse cancer types. <i>BMC Genomics</i> , 2016, 17, 560.	1.2	4
4740	Limbic encephalitis following immunotherapy against metastatic malignant melanoma. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016215012.	0.2	56
4741	Malignant melanoma: diagnosis, treatment and cancer stem cells. <i>Neoplasma</i> , 2016, 63, 510-517.	0.7	57
4742	RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics. <i>Oncotarget</i> , 2016, 7, 79869-79884.	0.8	25
4743	Important molecular genetic markers of colorectal cancer. <i>Oncotarget</i> , 2016, 7, 53959-53983.	0.8	91
4744	Kras, Braf, PIK3CA and EGFR Gene Mutations are Associated with Lymph Node Metastasis and Right Sided Colon Carcinoma. <i>Journal of Cancer Science & Therapy</i> , 2016, 08, .	1.7	0
4745	Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors. <i>Molecular Medicine Reports</i> , 2016, 14, 3791-3797.	1.1	1
4746	Targeted therapies and immunotherapy in non-small-cell lung cancer. <i>Ecancermedalscience</i> , 2016, 10, 648.	0.6	29
4747	Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy. <i>Przegląd Dermatologiczny</i> , 2016, 2, 127-138.	0.0	0
4748	The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. <i>Journal of Immunology Research</i> , 2016, 2016, 1-11.	0.9	20
4749	New trends in molecular and cellular biomarker discovery for colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 5678.	1.4	69

#	ARTICLE	IF	CITATIONS
4750	Expression of Phosphatase and Tensin Homologue, phospho-Akt, and p53 in Acral Benign and Malignant Melanocytic Neoplasms (Benign Nevi, Dysplastic Nevi, and Acral Melanomas). <i>Annals of Dermatology</i> , 2016, 28, 548.	0.3	4
4751	A personalized Approach for Targeting the Melanoma: Inhibition of Oncogenic Signaling in Combination with Small Molecules. <i>General Medicine (Los Angeles, Calif)</i> , 2016, 04, .	0.2	1
4752	Optimal Selection of Targeted Therapies for Melanoma Patients. , 2016, , 169-183.		0
4753	Interrogating the Cancer Genome to Deliver More Precise Cancer Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e577-e583.	1.8	2
4754	Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. <i>World Journal of Clinical Oncology</i> , 2016, 7, 340.	0.9	7
4755	Tumor Heterogeneity and Therapeutic Resistance. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e585-e593.	1.8	30
4756	BRAF Mutation in Colorectal Cancer. , 0, , .		1
4757	Clinicopathological Implications of the BRAF V600E Mutation in PTC with Concurrent Hashimoto Thyroiditis. <i>International Journal of Thyroidology</i> , 2016, 9, 29.	0.1	0
4758	Liquid biopsy in early stage lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 517-524.	1.3	28
4759	Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 2369-2371.	0.6	3
4760	NUEVAS TERAPIAS SISTÃMICAS PARA EL TRATAMIENTO DEL MELANOMA. <i>Revista Chilena De Cirugia</i> , 2016, 68, 81-86.	0.1	1
4761	Dabrafenib in metastatic melanoma: a monocentric "real life" experience. <i>Ecancermedicalscience</i> , 2016, 10, 624.	0.6	4
4762	Cellular Blue Nevus Diagnosed following Excision of Melanoma: A Challenge in Diagnosis. <i>Case Reports in Pathology</i> , 2016, 2016, 1-5.	0.2	3
4763	Quercetin-Induced Cell Death in Human Papillary Thyroid Cancer (B-CPAP) Cells. <i>Journal of Thyroid Research</i> , 2016, 2016, 1-10.	0.5	35
4764	A Genomic Study of DNA Alteration Events Caused by Ionizing Radiation in Human Embryonic Stem Cells via Next-Generation Sequencing. <i>Stem Cells International</i> , 2016, 2016, 1-7.	1.2	3
4765	Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-4.	0.2	4
4766	A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.2	9
4767	Diagnostic potential of tumor DNA from ovarian cyst fluid. <i>ELife</i> , 2016, 5, .	2.8	30

#	ARTICLE	IF	CITATIONS
4768	Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth. <i>ELife</i> , 2016, 5, .	2.8	22
4769	Nanodelivery of Anticancer Agents in Melanoma. , 2016, , 189-201.		2
4770	Melanoma and the Unfolded Protein Response. <i>Cancers</i> , 2016, 8, 30.	1.7	32
4771	The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib. <i>OncoTargets and Therapy</i> , 2016, 9, 3739.	1.0	9
4773	Mechanisms of Oncogene Activation. , 0, , .		7
4774	Clinical utility of nivolumab in the treatment of advanced melanoma. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 313.	0.9	16
4775	The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF. <i>ELife</i> , 2016, 5, e12814.	2.8	34
4776	The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 33.	1.8	84
4777	ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 53.	1.8	209
4778	Non-small cell lung cancer: current treatment and future advances. <i>Translational Lung Cancer Research</i> , 2016, 5, 288-300.	1.3	1,256
4779	Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy. <i>Frontiers in Nutrition</i> , 2016, 3, 48.	1.6	41
4780	BRAF Mutation Is Associated with Improved Local Control of Melanoma Brain Metastases Treated with Gamma Knife Radiosurgery. <i>Frontiers in Oncology</i> , 2016, 6, 107.	1.3	15
4781	Prognostic Impact of Autophagy Biomarkers for Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2016, 6, 236.	1.3	55
4782	Updates in Therapy for Advanced Melanoma. <i>Cancers</i> , 2016, 8, 17.	1.7	37
4783	Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma. <i>Cancers</i> , 2016, 8, 110.	1.7	43
4784	Ectopic Expression of Testis Germ Cell Proteins in Cancer and Its Potential Role in Genomic Instability. <i>International Journal of Molecular Sciences</i> , 2016, 17, 890.	1.8	37
4785	Oncogenes: The Passport for Viral Oncolysis through PKR Inhibition. <i>Biomarkers in Cancer</i> , 2016, 8, BIC.S33378.	3.6	22
4786	A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. <i>BMC Cancer</i> , 2016, 16, 634.	1.1	32

#	ARTICLE	IF	CITATIONS
4787	The principle of safety evaluation in medicinal drug - how can toxicology contribute to drug discovery and development as a multidisciplinary science? -. Journal of Toxicological Sciences, 2016, 41, SP49-SP67.	0.7	7
4788	Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis. PLoS ONE, 2016, 11, e0146803.	1.1	22
4789	Multiplex Real-Time PCR Assays that Measure the Abundance of Extremely Rare Mutations Associated with Cancer. PLoS ONE, 2016, 11, e0156546.	1.1	29
4790	Precise Detection of IDH1/2 and BRAF Hotspot Mutations in Clinical Glioma Tissues by a Differential Calculus Analysis of High-Resolution Melting Data. PLoS ONE, 2016, 11, e0160489.	1.1	39
4791	The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia. Frontiers in Pharmacology, 2016, 7, 363.	1.6	26
4792	Cellular and Molecular Responses to Mechanical Expansion of Tissue. Frontiers in Physiology, 2016, 7, 540.	1.3	25
4793	Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Molecular and Clinical Oncology, 2016, 5, 458-462.	0.4	23
4794	Biomarker Development in Targeting Cancer Epigenetic. , 2016, , 123-142.		0
4795	Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags. Theranostics, 2016, 6, 1506-1513.	4.6	106
4796	Resistant mechanisms to BRAF inhibitors in melanoma. Annals of Translational Medicine, 2016, 4, 237-237.	0.7	186
4798	Molecular Alterations and Expression Dynamics in the Etiopathogenesis of Thyroid Cancer. , 2016, , .		1
4799	BRAFp.V600E, p.V600K, and p.V600R Mutations in Malignant Melanoma. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 30-34.	0.6	5
4800	Squamous cell carcinoma and keratoacanthomas are biologically distinct and can be diagnosed by light microscopy: a review. Histopathology, 2016, 69, 535-541.	1.6	9
4801	Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci. Pediatric Blood and Cancer, 2016, 63, 1704-1712.	0.8	46
4802	Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation. Melanoma Research, 2016, 26, 304-307.	0.6	12
4803	Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. Journal of Pediatric Hematology/Oncology, 2016, 38, 249-260.	0.3	26
4804	A Micro/Nano Composite for Combination Treatment of Melanoma Lung Metastasis. Advanced Healthcare Materials, 2016, 5, 936-946.	3.9	44
4805	Differential diagnosis of Spitzoid melanocytic neoplasms. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1269-1277.	1.3	13

#	ARTICLE	IF	CITATIONS
4806	Implications of mitogen-activated protein kinase signaling in glioma. <i>Journal of Neuroscience Research</i> , 2016, 94, 114-127.	1.3	56
4807	Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1207-1213.	0.8	20
4808	New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 419-426.	1.1	30
4809	BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. <i>Cell Reports</i> , 2016, 16, 263-277.	2.9	61
4810	BRAFV600E mutation correlates with suppressive tumor immune microenvironment and reduced disease-free survival in Langerhans cell histiocytosis. <i>Oncolmmunology</i> , 2016, 5, e1185582.	2.1	46
4811	Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation. <i>Apmsis</i> , 2016, 124, 271-277.	0.9	14
4812	Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status. <i>British Journal of Dermatology</i> , 2016, 174, 823-830.	1.4	26
4813	Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline. <i>Experimental Dermatology</i> , 2016, 25, 783-788.	1.4	34
4814	High expression of Mcl-1L via the MEK-ERK-phospho-STAT3 (Ser727) pathway protects melanocytes and melanoma from UVB-induced apoptosis. <i>Genes To Cells</i> , 2016, 21, 185-199.	0.5	13
4815	Progress in Silicon Nanowire-Based Field-Effect Transistor Biosensors for Label-Free Detection of DNA. <i>Chinese Journal of Chemistry</i> , 2016, 34, 308-316.	2.6	14
4816	Update on immune therapy in melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 799-808.	0.5	0
4817	Albumin expression distinguishes bile duct adenomas from metastatic adenocarcinoma. <i>Histopathology</i> , 2016, 69, 423-430.	1.6	12
4818	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1484-1499.	1.0	75
4819	A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 115, 223-227.	2.9	17
4820	Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas. <i>Melanoma Research</i> , 2016, 26, 93-99.	0.6	49
4821	Clear Cell Atypical Fibroxanthoma: Clinicopathological Study of 6 Cases and Review of the Literature With Special Emphasis on the Differential Diagnosis. <i>American Journal of Dermatopathology</i> , 2016, 38, 586-592.	0.3	16
4822	Immunohistochemical detection of the BRAF V600E mutant protein in colorectal cancers in Taiwan is highly concordant with the molecular test. <i>Histopathology</i> , 2016, 69, 54-62.	1.6	15
4823	Determination of a novel B-Raf V600E and EGFR dual inhibitor in rat plasma by HPLC-MS/MS and its application in a pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 129, 142-147.	1.4	0

#	ARTICLE	IF	CITATIONS
4824	MEK inhibitor treatment is effective in a patient with metastatic carcinoma of the ampulla of Vater with BRAF and NRAS mutations shown by next-generation sequencing. <i>Anti-Cancer Drugs</i> , 2016, 27, 569-572.	0.7	2
4825	Melanoma therapy: Check the checkpoints. <i>Journal of Dermatology</i> , 2016, 43, 121-124.	0.6	13
4826	Dual c-Jun^N-terminal kinase-cyclin D1 and extracellular signal-related kinase-c-Jun disjunction in human melanoma. <i>British Journal of Dermatology</i> , 2016, 175, 1221-1231.	1.4	15
4827	Profile of vemurafenib-induced severe skin toxicities. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 250-257.	1.3	27
4828	Clinicopathological characteristics associated with ^{K601E} and ^{L597} mutations in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 222-228.	1.5	16
4829	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	2.3	76
4830	The development of potential targets in the treatment of non-small cell lung cancer. <i>Open Life Sciences</i> , 2016, 11, 225-231.	0.6	0
4831	BRAF Inhibition in ^{V600E}-Positive Anaplastic Thyroid Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 249-254.	2.3	38
4832	An overview on the role of dietary phenolics for the treatment of cancers. <i>Nutrition Journal</i> , 2016, 15, 99.	1.5	323
4833	Resistance to Targeted Therapies Against Adult Brain Cancers. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , .	0.1	4
4834	Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma. <i>Translational Oncology</i> , 2016, 9, 557-564.	1.7	16
4835	AKT1 as the PageRank hub gene is associated with melanoma and its functional annotation is highly related to the estrogen signaling pathway that may regulate the growth of melanoma. <i>Oncology Reports</i> , 2016, 36, 2087-2093.	1.2	9
4836	CRAF R391W is a melanoma driver oncogene. <i>Scientific Reports</i> , 2016, 6, 27454.	1.6	13
4837	Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor. <i>International Journal of Oncology</i> , 2016, 49, 1164-1174.	1.4	52
4838	Current treatments for advanced melanoma and introduction of a promising novel gene therapy for melanoma (Review). <i>Oncology Reports</i> , 2016, 36, 1779-1786.	1.2	14
4839	Understanding of "Networks"™ In Vitro and/or In Vivo. , 2016, , 141-152.		0
4840	Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. <i>Radiology and Oncology</i> , 2016, 50, 274-279.	0.6	24
4841	Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes. <i>Cytogenetic and Genome Research</i> , 2016, 150, 194-207.	0.6	49

#	ARTICLE	IF	CITATIONS
4842	Molecular Biology and Genetic Mechanisms in the Progression of the Malignant Skin Melanoma. Prilozi - Makedonska Akademija Na Naukite I Umetnostite Oddelenie Za Medicinski Nauki, 2016, 37, 89-97.	0.2	7
4843	CD147-targeted siRNA in A375 malignant melanoma cells induces the phosphorylation of EGFR and downregulates cdc25C and MEK phosphorylation. Oncology Letters, 2016, 11, 2424-2428.	0.8	16
4844	Prognostic impact of mutation profiling in patients with stage II and III colon cancer. Scientific Reports, 2016, 6, 24310.	1.6	30
4845	Copy number variation in archival melanoma biopsies versus benign melanocytic lesions. Cancer Biomarkers, 2016, 16, 575-597.	0.8	4
4846	BRAFV600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. Scientific Reports, 2016, 6, 18949.	1.6	33
4847	JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discovery, 2016, 2, 16028.	3.1	57
4848	Single molecule targeted sequencing for cancer gene mutation detection. Scientific Reports, 2016, 6, 26110.	1.6	7
4849	The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncology Letters, 2016, 12, 3045-3050.	0.8	190
4850	Challenges in the Delivery of Therapies to Melanoma Brain Metastases. Current Pharmacology Reports, 2016, 2, 309-325.	1.5	18
4852	Differential Radiographic Appearance of BRAFV600E Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1536-1543.	2.3	17
4853	MicroRNA-106a suppresses proliferation, migration, and invasion of bladder cancer cells by modulating MAPK signaling cell cycle regulators, and Ets-1-mediated MMP-2 expression. Oncology Reports, 2016, 36, 2421-2429.	1.2	27
4854	Sequenzspezifischer Einbau von Enzymnukleotid-Chimären durch DNA-Polymerasen. Angewandte Chemie, 2016, 128, 10286-10290.	1.6	8
4855	Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. Oncology Letters, 2016, 12, 4427-4434.	0.8	5
4856	BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer. Medical Oncology, 2016, 33, 39.	1.2	22
4857	Targeting mutant NRAS signaling pathways in melanoma. Pharmacological Research, 2016, 107, 111-116.	3.1	37
4858	The proto-oncogene PBF binds p53 and is associated with prognostic features in colorectal cancer. Molecular Carcinogenesis, 2016, 55, 15-26.	1.3	27
4859	Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. Expert Opinion on Pharmacotherapy, 2016, 17, 1031-1038.	0.9	28
4860	Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2016, 18, 370-377.	1.2	25

#	ARTICLE	IF	CITATIONS
4861	Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. <i>Melanoma Management</i> , 2016, 3, 137-147.	0.1	1
4863	Design, biological evaluation and 3D QSAR studies of novel dioxin-containing triaryl pyrazoline derivatives as potential B-Raf inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 3052-3061.	1.4	24
4864	Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf V600E inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 2760-2763.	1.0	7
4865	Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells. <i>Cell Biology and Toxicology</i> , 2016, 32, 103-119.	2.4	13
4866	BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. <i>Clinical Cancer Research</i> , 2016, 22, 5312-5321.	3.2	39
4867	What Is New in Melanoma Genetics and Treatment?. <i>Dermatology</i> , 2016, 232, 259-264.	0.9	25
4868	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. <i>Current Oncology Reports</i> , 2016, 18, 42.	1.8	54
4869	Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections. <i>Human Pathology</i> , 2016, 53, 168-177.	1.1	11
4871	Improving patient outcomes to targeted therapies in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 633-641.	1.1	6
4872	Clinical Management of Head and Neck Cancer Cases: Role of Pharmacogenetics of CYP2 and GSTs. <i>Oncology Research and Treatment</i> , 2016, 39, 221-226.	0.8	7
4873	Frequent PIK3CA-activating mutations in hidradenoma papilliferums. <i>Human Pathology</i> , 2016, 55, 57-62.	1.1	17
4874	The path from big data to precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 129-143.	0.4	37
4875	LINE-1 hypomethylation and mutational status in cutaneous melanomas. <i>Journal of Investigative Medicine</i> , 2016, 64, 899-904.	0.7	10
4876	Teaching Real Data Interpretation with Models (TRIM): Analysis of Student Dialogue in a Large-Enrollment Cell and Developmental Biology Course. <i>CBE Life Sciences Education</i> , 2016, 15, ar17.	1.1	27
4877	Oncogenic BRAF-Mediated Melanoma Cell Invasion. <i>Cell Reports</i> , 2016, 15, 2012-2024.	2.9	46
4878	The molecular profile of metastatic melanoma in Australia. <i>Pathology</i> , 2016, 48, 188-193.	0.3	26
4879	Quinolone-1-(2H)-ones as hedgehog signalling pathway inhibitors. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 6304-6315.	1.5	8
4880	Carcinogen-specific mutations in preferred Ras-Raf pathway oncogenes directed by strand bias. <i>Carcinogenesis</i> , 2016, 37, 810-816.	1.3	7

#	ARTICLE	IF	CITATIONS
4881	The Role of PGC1 β in Cancer Metabolism and its Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 774-782.	1.9	149
4882	Concomitant Inhibition of PI3K β and BRAF or MEK in PTEN-Deficient/ <i>BRAF</i> -Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1460-1471.	1.9	18
4883	Genomically Driven Tumors and Actionability across Histologies: <i>BRAF</i> -Mutant Cancers as a Paradigm. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 533-547.	1.9	63
4884	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. <i>Trends in Immunology</i> , 2016, 37, 462-476.	2.9	232
4885	CIS is a potent checkpoint in NK cell-mediated tumor immunity. <i>Nature Immunology</i> , 2016, 17, 816-824.	7.0	289
4886	KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review. <i>Medical Oncology</i> , 2016, 33, 32.	1.2	25
4887	Infiltrating spinal cord astrocytomas: Epidemiology, diagnosis, treatments and future directions. <i>Journal of Clinical Neuroscience</i> , 2016, 29, 15-20.	0.8	28
4888	Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma. <i>Pharmacological Research</i> , 2016, 107, 42-47.	3.1	26
4889	Novel mutations in SKIV2L and TTC37 genes in Malaysian children with trichohepatoenteric syndrome. <i>Gene</i> , 2016, 586, 1-6.	1.0	24
4890	The Conundrum of Genetic "Drivers" in Benign Conditions. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw036.	3.0	113
4891	Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives. <i>Future Oncology</i> , 2016, 12, 1331-1344.	1.1	24
4892	Pustular psoriasis eruption with dabrafenib, a BRAF inhibitor. <i>Journal of Dermatological Treatment</i> , 2016, 27, 418-421.	1.1	7
4893	Purinyldiethylamino-based DFG-in/C-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 2215-2234.	1.4	13
4894	EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer. <i>Oncology Letters</i> , 2016, 11, 2371-2378.	0.8	14
4895	Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 642-650.	5.1	352
4896	Mitochondrial biogenesis meets chemoresistance in BRAF-mutant melanoma. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1179381.	0.3	4
4897	Emerging targeted therapies for melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 195-207.	1.0	22
4898	BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 32-39.	2.0	15

#	ARTICLE	IF	CITATIONS
4899	Metadherin Expression is Associated with Extrathyroidal Extension in Papillary Thyroid Cancer Patients. <i>Annals of Surgical Oncology</i> , 2016, 23, 2883-2888.	0.7	4
4900	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. <i>Leukemia and Lymphoma</i> , 2016, 57, 1991-2013.	0.6	26
4901	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	3.4	41
4902	Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. <i>Journal of Neuro-Oncology</i> , 2016, 128, 293-302.	1.4	51
4903	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2219-2231.	1.4	49
4904	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. <i>Physiological Reviews</i> , 2016, 96, 805-829.	13.1	49
4905	Noninferior response in BRAFV600E mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1034-1039.	3.3	18
4906	Time and tumor type (primary or metastatic) do not influence the detection of BRAF/NRAS mutations in formalin fixed paraffin embedded samples from melanomas. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 1733-1738.	1.4	2
4908	BRAF ^{V600E} Mutation is Associated with Decreased Disease-Free Survival in Papillary Thyroid Cancer. <i>World Journal of Surgery</i> , 2016, 40, 1618-1624.	0.8	33
4909	EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E-Mutant NSCLC Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1627-1636.	1.9	8
4910	Identifying Novel Cancer Therapies Using Chemical Genetics and Zebrafish. <i>Advances in Experimental Medicine and Biology</i> , 2016, 916, 103-124.	0.8	35
4911	Genetics of Melanoma. , 2016, , .		3
4912	Design, synthesis, broad-spectrum antiproliferative activity, and kinase inhibitory effect of triarylpyrazole derivatives possessing arylamides or arylureas moieties. <i>European Journal of Medicinal Chemistry</i> , 2016, 119, 122-131.	2.6	20
4913	Biology and treatment of BRAF mutant metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 33-45.	0.1	28
4914	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. <i>Blood</i> , 2016, 127, 2672-2681.	0.6	1,040
4915	Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2016, 18, 67.	1.8	10
4916	Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis. <i>Biomedicine and Pharmacotherapy</i> , 2016, 83, 1321-1326.	2.5	5
4917	Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAF ^{V600E} Conformation. <i>ACS Chemical Biology</i> , 2016, 11, 2876-2888.	1.6	26

#	ARTICLE	IF	CITATIONS
4918	Copper suppression as cancer therapy: the rationale for copper chelating agents in <i>BRAF</i> ^{V600} mutated melanoma. <i>Melanoma Management</i> , 2016, 3, 207-216.	0.1	21
4919	The emerging role of long non-coding <i>RNA</i> s in cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 619-626.	1.5	54
4920	Critical parameters in targeted drug development: the pharmacological audit trail. <i>Seminars in Oncology</i> , 2016, 43, 436-445.	0.8	64
4922	Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. <i>Cancer Medicine</i> , 2016, 5, 1883-1889.	1.3	45
4923	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. <i>Child's Nervous System</i> , 2016, 32, 1789-1797.	0.6	26
4924	Diagnostic and Prognostic Molecular Markers in Thyroid Cancer. , 2016, , 281-292.		1
4925	What's New in Dermatopathology?. , 2016, , 67-73.		0
4926	Immunotherapy of Melanoma. <i>Oncology Research and Treatment</i> , 2016, 39, 369-376.	0.8	14
4927	The Management of Thyroid and Parathyroid Cancer. , 2016, , 673-692.		0
4928	Hepatocyte growth factor renders <i>BRAF</i> mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. <i>Cell Death and Differentiation</i> , 2016, 23, 2054-2062.	5.0	24
4929	Dabrafenib in an elderly patient with metastatic melanoma and <i>BRAF</i> V600R mutation: a case report. <i>Journal of Medical Case Reports</i> , 2016, 10, 158.	0.4	9
4930	Frequency of <i>BRAF</i> V600E mutations in 969 central nervous system neoplasms. <i>Diagnostic Pathology</i> , 2016, 11, 55.	0.9	95
4931	Nephrotoxicity of anticancer treatment. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw338.	0.4	80
4933	Clinicopathological, Radiological, and Genetic Analyses of Cerebellar Gangliogliomas with Long-Term Survival. <i>World Neurosurgery</i> , 2016, 94, 521-528.	0.7	3
4934	Cobimetinib combined with vemurafenib in advanced <i>BRAF</i> V600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1248-1260.	5.1	832
4935	The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancers. <i>Seminars in Cell and Developmental Biology</i> , 2016, 58, 108-117.	2.3	10
4936	The dark side of the light: mechanisms of photocarcinogenesis. <i>Clinics in Dermatology</i> , 2016, 34, 563-570.	0.8	39
4937	A comparison of immunohistochemical and molecular methods used for analyzing the <i>BRAF</i> V600E gene mutation in malignant melanoma in Taiwan. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 403-408.	0.7	11

#	ARTICLE	IF	CITATIONS
4938	Cancer treatment and survivorship statistics, 2016. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 271-289.	157.7	4,123
4939	Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4652-4659.	1.4	23
4940	Violacein induces death of RAS-mutated metastatic melanoma by impairing autophagy process. <i>Tumor Biology</i> , 2016, 37, 14049-14058.	0.8	19
4941	Genomic and Transcriptomic Approaches to Study Cancer in Small Aquarium Fish Models. <i>Advances in Genetics</i> , 2016, 95, 31-63.	0.8	1
4942	<sc>NTRK3</sc> kinase fusions in Spitz tumours. <i>Journal of Pathology</i> , 2016, 240, 282-290.	2.1	128
4943	An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. <i>Cancer Cell</i> , 2016, 30, 485-498.	7.7	130
4944	Molecular Pathology. <i>Surgical Pathology Clinics</i> , 2016, 9, 489-521.	0.7	3
4945	The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 48.	1.3	36
4946	Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2442-2454.	1.9	47
4947	The distribution of <i><sc>BRAF</sc></i> gene fusions in solid tumors and response to targeted therapy. <i>International Journal of Cancer</i> , 2016, 138, 881-890.	2.3	248
4948	Impact of <sc><i>KRAS</i></sc>, <sc><i>BRAF</i></sc>, <sc><i>PIK3CA</i></sc>, <sc><i>TP53</i></sc> status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. <i>International Journal of Cancer</i> , 2016, 139, 647-656.	2.3	79
4949	Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy. <i>International Journal of Cancer</i> , 2016, 139, 1195-1201.	2.3	41
4950	Cross-species models of human melanoma. <i>Journal of Pathology</i> , 2016, 238, 152-165.	2.1	65
4951	Melanoma Regression and Recurrence in Zebrafish. <i>Methods in Molecular Biology</i> , 2016, 1451, 143-153.	0.4	6
4952	The genomic landscape of cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 266-283.	1.5	144
4953	Translating cancer genomes and transcriptomes for precision oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 75-88.	157.7	133
4954	FMNL2/FMNL3 formins are linked with oncogenic pathways and predict melanoma outcome. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 41-52.	1.3	28
4955	HLA class I downregulation is associated with enhanced NK cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. <i>European Journal of Immunology</i> , 2016, 46, 409-419.	1.6	31

#	ARTICLE	IF	CITATIONS
4956	Biomarkers in melanoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S104-S112.	0.6	8
4957	The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms. <i>Clinics in Colon and Rectal Surgery</i> , 2016, 29, 232-238.	0.5	17
4958	Estradiol differently affects melanin synthesis of malignant and normal melanocytes: a relationship with clock and clock-controlled genes. <i>Molecular and Cellular Biochemistry</i> , 2016, 421, 29-39.	1.4	20
4959	B-Raf mutation and papillary thyroid carcinoma patients. <i>Oncology Letters</i> , 2016, 11, 2699-2705.	0.8	9
4960	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. <i>EBioMedicine</i> , 2016, 10, 85-100.	2.7	56
4961	Energy parasites trigger oncogene mutation. <i>International Journal of Radiation Biology</i> , 2016, 92, 577-582.	1.0	5
4962	New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2710-2718.	1.9	27
4963	BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1397-1405.	1.5	17
4964	Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. <i>Journal of Cell Communication and Signaling</i> , 2016, 10, 191-196.	1.8	49
4965	Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry. <i>Analytica Chimica Acta</i> , 2016, 933, 144-155.	2.6	7
4966	Hot spot mutations in Finnish non-small cell lung cancers. <i>Lung Cancer</i> , 2016, 99, 102-110.	0.9	21
4967	Serrated polyposis associated with a family history of colorectal cancer and/or polyps: The preferential location of polyps in the colon and rectum defines two molecular entities. <i>International Journal of Molecular Medicine</i> , 2016, 38, 687-702.	1.8	3
4968	Applied Immunohistochemistry in the Evaluation of Skin Neoplasms. , 2016, , .		1
4969	MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. <i>Current Opinion in Structural Biology</i> , 2016, 41, 151-158.	2.6	72
4970	Diagnosis and Molecular Classification of Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 25-46.	0.2	172
4971	Quantitative Super-Resolution Microscopy for Cancer Biology and Medicine. <i>Series in Cellular and Clinical Imaging</i> , 2016, , 321-350.	0.2	0
4972	Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends. <i>World Journal of Surgical Oncology</i> , 2016, 14, 149.	0.8	46
4973	Inhibitory Effects of Oligostilbenoids from the Bark of <i>Shorea roxburghii</i> on Malignant Melanoma Cell Growth: Implications for Novel Topical Anticancer Candidates. <i>Biological and Pharmaceutical Bulletin</i> , 2016, 39, 1675-1682.	0.6	27

#	ARTICLE	IF	CITATIONS
4974	Activation of mutant <i>TERT</i> promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14402-14407.	3.3	81
4975	The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate→Lactate Exchange in BRAF-Mutant Human Melanoma Cells. Molecular Cancer Therapeutics, 2016, 15, 2987-2999.	1.9	43
4976	Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4413-4420.	1.8	45
4977	Intralesional and systemic immunotherapy for metastatic melanoma. Expert Opinion on Biological Therapy, 2016, 16, 1491-1499.	1.4	15
4978	Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy, 2016, 8, 1205-1218.	1.0	10
4979	Selective Covalent Targeting of Anti-Apoptotic BCL-1 by Cysteine-Reactive Stapled Peptide Inhibitors. Cell Chemical Biology, 2016, 23, 1123-1134.	2.5	59
4980	Zebrafish. Methods in Molecular Biology, 2016, , .	0.4	9
4981	Oncogene-Directed Alterations in Cancer Cell Metabolism. Trends in Cancer, 2016, 2, 365-377.	3.8	136
4982	Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma. Orthopaedic Surgery, 2016, 8, 129-138.	0.7	2
4983	Colorectal Cancer with <i>BRAF</i> V600E Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis. Oncology, 2016, 91, 162-170.	0.9	7
4985	Sequence-Specific Incorporation of Enzyme-Nucleotide Chimera by DNA Polymerases. Angewandte Chemie - International Edition, 2016, 55, 10131-10135.	7.2	37
4986	A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. Investigational New Drugs, 2016, 34, 604-613.	1.2	65
4987	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with <i>BRAF</i> V600E Mutation. Cancer Discovery, 2016, 6, 1352-1365.	7.7	192
4988	Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces. Scientific Reports, 2016, 6, 19709.	1.6	8
4989	Clinical implications of the extent of BRAFV600E alleles in patients with papillary thyroid carcinoma. Oral Oncology, 2016, 62, 72-77.	0.8	9
4990	A somatic reference standard for cancer genome sequencing. Scientific Reports, 2016, 6, 24607.	1.6	64
4991	Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncology, The, 2016, 17, 1743-1754.	5.1	266
4992	p15 Expression Differentiates Nevus from Melanoma. American Journal of Pathology, 2016, 186, 3094-3099.	1.9	14

#	ARTICLE	IF	CITATIONS
4993	BRAF V600E mutation in hairy cell leukemia: from bench to bedside. <i>Blood</i> , 2016, 128, 1918-1927.	0.6	84
4994	Anticancer effects of <i>Ilex dentata</i> (Thunb. ex Thunb.) nakai extract on human melanoma cells A375P and A375SM. <i>Journal of Ethnopharmacology</i> , 2016, 194, 1022-1031.	2.0	6
4995	Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase <i>BRAF</i> -mutant lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13456-13461.	3.3	65
4996	Methylation status of homeobox genes in common human cancers. <i>Genomics</i> , 2016, 108, 185-193.	1.3	39
4997	<i>Cancer Drug Discovery</i> . , 2016, , .		6
4998	Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 81, 121-132.	1.2	38
4999	Mutant <i>BRAF</i> Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 3015-3027.	1.9	36
5000	Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study. <i>Journal of Translational Medicine</i> , 2016, 14, 292.	1.8	43
5001	<i>Big Data Analytics in Genomics</i> . , 2016, , .		7
5003	<i>Molekulare Diagnostik und Techniken</i> . , 2016, , 51-60.		0
5004	The combination of vemurafenib and cobimetinib in advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1105-1111.	0.5	3
5005	Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2016, 14, 241.	0.8	97
5006	Brain Metastases From Melanoma: Therapy at the Crossroads. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 713-716.	0.4	4
5007	KinView: a visual comparative sequence analysis tool for integrated kinome research. <i>Molecular BioSystems</i> , 2016, 12, 3651-3665.	2.9	47
5008	Drug Combinations as the New Standard for Melanoma Treatment. <i>Current Treatment Options in Oncology</i> , 2016, 17, 61.	1.3	16
5009	The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes. <i>Nature Communications</i> , 2016, 7, 11479.	5.8	1,221
5010	Mining Massive Genomic Data for Therapeutic Biomarker Discovery in Cancer: Resources, Tools, and Algorithms. , 2016, , 337-355.		0
5011	Genetic epidemiology of melanoma. <i>European Journal of Dermatology</i> , 2016, 26, 335-339.	0.3	49

#	ARTICLE	IF	CITATIONS
5012	A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. <i>Genome Medicine</i> , 2016, 8, 116.	3.6	15
5013	Racial and Ethnic Differences in the Epidemiology and Genomics of Lung Cancer. <i>Cancer Control</i> , 2016, 23, 338-346.	0.7	78
5014	Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 993-1002.	1.1	33
5015	Langerhans Cell Histiocytosis and Langerhans Cell Sarcoma: Current Understanding and Differential Diagnosis. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2016, 56, 109-118.	0.3	39
5016	BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma. <i>Case Reports in Oncology</i> , 2016, 9, 241-245.	0.3	6
5018	Recent developments in melanoma management. <i>Trends in Urology & Men's Health</i> , 2016, 7, 8-12.	0.2	0
5020	Post ASCO update 2016â€™lung cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 215-218.	0.3	0
5021	BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study. <i>Melanoma Research</i> , 2016, 26, 442-447.	0.6	5
5022	BRAF-Directed Therapy in Metastatic Colorectal Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 175-178.	1.0	31
5023	Mitogen-Activated Protein Kinase/Extracellular Signalâ€™Regulated Kinase Kinase Inhibition During Sepsis Dampens the Early Systemic Inflammatory Response*. <i>Critical Care Medicine</i> , 2016, 44, 1628-1629.	0.4	1
5024	Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases. <i>Melanoma Research</i> , 2016, 26, 361-366.	0.6	9
5025	Eosinophilic Infiltrates in Vemurafenib-Associated Verrucous Keratoses. <i>American Journal of Dermatopathology</i> , 2016, 38, 766-768.	0.3	1
5026	Newly Identified BRAF Mutation in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1377-1383.	2.9	4
5027	Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. <i>Melanoma Research</i> , 2016, 26, 382-386.	0.6	31
5028	Design, synthesis, and <i>in vitro</i> antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2016, 31, 111-122.	2.5	9
5030	<i>BRAF</i> Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	1.9	78
5031	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. <i>Journal of Translational Medicine</i> , 2016, 14, 88.	1.8	10
5032	Impact of genomic sequencing on precision medicine for clinical oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 255-265.	0.4	0

#	ARTICLE	IF	CITATIONS
5033	Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 984-993.	5.1	689
5034	The dark side of the light: Phototherapy adverse effects. <i>Clinics in Dermatology</i> , 2016, 34, 556-562.	0.8	32
5035	BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features. <i>Cancer Biology and Therapy</i> , 2016, 17, 840-848.	1.5	17
5036	A federated ecosystem for sharing genomic, clinical data. <i>Science</i> , 2016, 352, 1278-1280.	6.0	175
5037	The Combination of Vemurafenib and Procaspace-3 Activation Is Synergistic in Mutant BRAF Melanomas. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1859-1869.	1.9	16
5038	Suppression of microphthalmia-associated transcription factor, but not NF-kappa B sensitizes melanoma specific cell death. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2016, 21, 928-940.	2.2	6
5039	Generation and analysis of zebrafish melanoma models. <i>Methods in Cell Biology</i> , 2016, 134, 531-549.	0.5	13
5040	GNA11 Mutation in a Patient With Cutaneous Origin Melanoma. <i>Medicine (United States)</i> , 2016, 95, e2336.	0.4	9
5041	The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 907-916.	2.5	111
5042	Common Diagnostic Pitfalls in Thyroid Cytopathology. , 2016, , .		5
5043	Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. <i>British Journal of Cancer</i> , 2016, 115, 145-155.	2.9	50
5044	Immunotherapy in glioblastoma: emerging options in precision medicine. <i>CNS Oncology</i> , 2016, 5, 175-186.	1.2	11
5046	Inhibition of BRAF kinase suppresses cellular proliferation, but not enough for complete growth arrest in BRAF V600E mutated papillary and undifferentiated thyroid carcinomas. <i>Endocrine</i> , 2016, 54, 129-138.	1.1	7
5047	Benign Odontogenic Tumors: Origins, Immunophenotypic Features, and Genetic Alterations. <i>Current Oral Health Reports</i> , 2016, 3, 93-101.	0.5	7
5048	Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin. <i>Dermatologica Sinica</i> , 2016, 34, 88-91.	0.2	5
5049	A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib. <i>EBioMedicine</i> , 2016, 8, 132-149.	2.7	44
5050	Current targeted therapies in the treatment of advanced colorectal cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 276-293.	1.4	72
5051	Genetic studies yield clues to the pathogenesis of Langerhans cell histiocytosis. <i>European Respiratory Journal</i> , 2016, 47, 1629-1631.	3.1	0

#	ARTICLE	IF	CITATIONS
5052	Emerging Role of mTOR in the Response to Cancer Therapeutics. <i>Trends in Cancer</i> , 2016, 2, 241-251.	3.8	95
5053	Mutational status of IDH1 in uveal melanoma. <i>Experimental and Molecular Pathology</i> , 2016, 100, 476-481.	0.9	6
5054	18 F-FDG PET/CT imaging of squamous cell carcinoma induced by Vemurafenib. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 64-66.	0.1	0
5055	Intra- and interspecies gene expression models for predicting drug response in canine osteosarcoma. <i>BMC Bioinformatics</i> , 2016, 17, 93.	1.2	31
5056	Mitogen-activated protein kinase signaling causes malignant melanoma cells to differentially alter extracellular matrix biosynthesis to promote cell survival. <i>BMC Cancer</i> , 2016, 16, 186.	1.1	13
5057	SOX5 is involved in balanced MITF regulation in human melanoma cells. <i>BMC Medical Genomics</i> , 2016, 9, 10.	0.7	34
5058	Obesity and colorectal cancer: molecular features of adipose tissue. <i>Journal of Translational Medicine</i> , 2016, 14, 21.	1.8	133
5059	BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay. <i>Diagnostic Pathology</i> , 2016, 11, 39.	0.9	12
5060	Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. <i>Cancer Research</i> , 2016, 76, 4504-4515.	0.4	91
5061	ERK mediated upregulation of death receptor 5 overcomes the lack of p53 functionality in the diaminothiazole DAT1 induced apoptosis in colon cancer models: efficiency of DAT1 in Ras-Raf mutated cells. <i>Molecular Cancer</i> , 2016, 15, 22.	7.9	7
5062	Postzygotic BRAF p.Lys601Asn Mutation in Phacomatosis Pigmentokeratotica with Woolly Hair Nevus and Focal Cortical Dysplasia. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1060-1062.	0.3	15
5063	Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. <i>Journal of Surgical Research</i> , 2016, 203, 407-415.	0.8	40
5064	The deubiquitinase Usp27x stabilizes the BH3-only protein Bim and enhances apoptosis. <i>EMBO Reports</i> , 2016, 17, 724-738.	2.0	40
5065	Transcriptional and post-translational modifications of Raf in quinolone-induced tuberous sclerosis renal cell carcinoma. <i>Molecular Carcinogenesis</i> , 2016, 55, 1243-1250.	1.3	0
5066	Lentiginous melanoma. A clinically malignant entity that histopathologically seems benign. Case study harbouring BRAF ^{V600R} mutation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1197-1198.	1.3	1
5067	Mutation scanning of BRAF, NRAS, KIT and GNAQ in oral mucosal melanoma: a study of 57 cases. <i>Journal of Oral Pathology and Medicine</i> , 2016, 45, 295-301.	1.4	58
5068	Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma. <i>Veterinary Ophthalmology</i> , 2016, 19, 44-55.	0.6	30
5069	Rare Genitourinary Tumors. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
5070	Negative feedback regulation of the ERK1/2 MAPK pathway. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 4397-4413.	2.4	400
5071	The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells. <i>Seminars in Cell and Developmental Biology</i> , 2016, 58, 96-107.	2.3	51
5072	Targeting the serrated pathway of colorectal cancer with mutation in BRAF. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 51-63.	3.3	8
5073	The role of phenotypic plasticity in the escape of cancer cells from targeted therapy. <i>Biochemical Pharmacology</i> , 2016, 122, 1-9.	2.0	34
5074	Solid tumor therapy by selectively targeting stromal endothelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E4079-87.	3.3	39
5075	A case series of anal melanoma including the results of treatment with imatinib in selected patients. <i>Colorectal Disease</i> , 2016, 18, 877-882.	0.7	13
5076	Histopathologic and mutational analysis of a case of blue nevus-like melanoma. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 776-780.	0.7	17
5077	Infrared A radiation promotes survival of human melanocytes carrying ultraviolet radiation-induced DNA damage. <i>Experimental Dermatology</i> , 2016, 25, 447-452.	1.4	18
5079	Critical Pitfalls in the use of BRAF Mutation as a Diagnostic Tool in Thyroid Nodules: a Case Report. <i>Endocrine Pathology</i> , 2016, 27, 220-223.	5.2	7
5080	Sequence selective naked-eye detection of DNA harnessing extension of oligonucleotide-modified nucleotides. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 841-844.	1.0	7
5081	Colorectal clinical trials: what is on the horizon?. <i>Future Oncology</i> , 2016, 12, 525-531.	1.1	1
5082	Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma. <i>Experimental and Molecular Pathology</i> , 2016, 100, 236-241.	0.9	21
5083	Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1048405.	0.3	11
5084	Treatment of Melanoma CNS Metastases. <i>Cancer Treatment and Research</i> , 2016, 167, 263-279.	0.2	6
5085	Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1250-1255.	3.3	74
5086	B-Raf Inhibition in the Clinic: Present and Future. <i>Annual Review of Medicine</i> , 2016, 67, 29-43.	5.0	65
5087	Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization. <i>American Journal of Pathology</i> , 2016, 186, 43-56.	1.9	20
5088	p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib. <i>European Journal of Cancer</i> , 2016, 55, 98-110.	1.3	48

#	ARTICLE	IF	CITATIONS
5089	Clinical implications of recent advances in proteogenomics. <i>Expert Review of Proteomics</i> , 2016, 13, 185-199.	1.3	12
5090	The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 1-10.	3.3	8
5091	The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 15-22.	1.9	20
5092	A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2368-2376.	3.2	17
5093	Regulation of Cell Proliferation by Receptor Tyrosine Protein Kinases. , 2016, , 589-654.		0
5094	Prognostic and predictive biomarkers in melanoma: an update. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 223-237.	1.5	23
5095	Adjuvant Therapy of Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 181-208.	0.2	17
5096	Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. <i>Nature Reviews Urology</i> , 2016, 13, 47-60.	1.9	65
5097	Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 807-817.	1.1	43
5098	Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. <i>Cancer Research</i> , 2016, 76, 3067-3077.	0.4	75
5099	Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. <i>Cancer Cell</i> , 2016, 29, 477-493.	7.7	171
5100	Update on Metastatic Uveal Melanoma: Progress and Challenges. <i>BioDrugs</i> , 2016, 30, 161-172.	2.2	14
5101	Initiation of a formalized precision medicine program in gynecologic oncology. <i>Gynecologic Oncology</i> , 2016, 141, 24-28.	0.6	15
5102	Equal access to innovative therapies and precision cancer care. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 385-393.	12.5	43
5103	Synthesis of α,β -Unsaturated Carbonyl-Based Compounds, Oxime and Oxime Ether Analogs as Potential Anticancer Agents for Overcoming Cancer Multidrug Resistance by Modulation of Efflux Pumps in Tumor Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 3549-3561.	2.9	74
5104	Adjusting for treatment switching in the <i>METRIC</i> study shows further improved overall survival with trametinib compared with chemotherapy. <i>Cancer Medicine</i> , 2016, 5, 806-815.	1.3	38
5105	Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell. <i>Molecular and Cellular Biochemistry</i> , 2016, 415, 119-131.	1.4	17
5106	Rare glial tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 399-415.	1.0	10

#	ARTICLE	IF	CITATIONS
5107	Scientific Advances in Lung Cancer 2015. Journal of Thoracic Oncology, 2016, 11, 613-638.	0.5	231
5108	Regulation of BRAF protein stability by a negative feedback loop involving the MEK-ERK pathway but not the FBXW7 tumour suppressor. Cellular Signalling, 2016, 28, 561-571.	1.7	33
5109	Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature. American Journal of Dermatopathology, 2016, 38, e93-e96.	0.3	22
5110	EBI-907, a novel BRAF ^{V600E} inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biology and Therapy, 2016, 17, 199-207.	1.5	10
5111	Dissecting Therapeutic Resistance to ERK Inhibition. Molecular Cancer Therapeutics, 2016, 15, 548-559.	1.9	50
5112	Combination Therapies for Melanoma: A New Standard of Care?. American Journal of Clinical Dermatology, 2016, 17, 99-105.	3.3	23
5113	The Changing Landscape of Pediatric Low-Grade Gliomas: Clinical Challenges and Emerging Therapies. Neuropediatrics, 2016, 47, 070-083.	0.3	17
5114	<i>NRAS</i> mutant melanoma: an overview for the clinician for melanoma management. Melanoma Management, 2016, 3, 47-59.	0.1	12
5115	The ERK cascade inhibitors: Towards overcoming resistance. Drug Resistance Updates, 2016, 25, 1-12.	6.5	67
5116	Antitumor Activity of BRAF Inhibitor and IFN γ Combination in BRAF-Mutant Melanoma. Journal of the National Cancer Institute, 2016, 108, djv435.	3.0	35
5117	Reactivation of telomerase in cancer. Cellular and Molecular Life Sciences, 2016, 73, 1659-1670.	2.4	154
5118	Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. Journal of Neuro-Oncology, 2016, 127, 607-615.	1.4	51
5119	Hereditary Skin Cancer. , 2016, , 369-375.		0
5120	Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report. Targeted Oncology, 2016, 11, 557-563.	1.7	16
5121	The gene BRAF is underexpressed in bipolar subject olfactory neuroepithelial progenitor cells undergoing apoptosis. Psychiatry Research, 2016, 236, 130-135.	1.7	11
5122	Phosphatidylserine enhances <i>IKBKAP</i> transcription by activating the MAPK/ERK signaling pathway. Human Molecular Genetics, 2016, 25, 1307-1317.	1.4	12
5123	Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagnostic Pathology, 2016, 11, 21.	0.9	52
5124	Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors. Targeted Oncology, 2016, 11, 263-275.	1.7	17

#	ARTICLE	IF	CITATIONS
5125	Interplay between Oncogenes and Tumor Suppressor Genes in Human Disease. , 2016, , 411-422.		0
5126	Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 770-784.	1.9	148
5127	Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1188-1192.	1.0	41
5128	Optimization of tetrahydronaphthalene inhibitors of Raf with selectivity over hERG. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1156-1160.	1.0	6
5129	Cross-Linking Antisense Oligodeoxyribonucleotides with a Photoresponsive $\hat{\pm}$ -Chloroaldehyde Moiety for RNA Point Mutations. <i>Journal of Organic Chemistry</i> , 2016, 81, 981-986.	1.7	12
5130	Merkel Cell Carcinoma: Current Issues Regarding Diagnosis, Management, and Emerging Treatment Strategies. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 49-62.	3.3	26
5131	Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 245-251.	1.4	64
5132	BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. <i>Human Pathology</i> , 2016, 52, 61-67.	1.1	70
5133	Association of <i>BRAF</i> ^{V600E} Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. <i>Thyroid</i> , 2016, 26, 532-542.	2.4	50
5134	Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization. <i>Cancer Research</i> , 2016, 76, 1476-1484.	0.4	44
5135	Braf V600E mutation in melanoma: translational current scenario. <i>Clinical and Translational Oncology</i> , 2016, 18, 863-871.	1.2	13
5136	Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-RafV600E and C-Raf kinase inhibitory activities. <i>European Journal of Medicinal Chemistry</i> , 2016, 115, 201-216.	2.6	54
5137	Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules. <i>Journal of Thoracic Oncology</i> , 2016, 11, 334-345.	0.5	45
5138	Oncogene status as a diagnostic tool in ocular and cutaneous melanoma. <i>European Journal of Cancer</i> , 2016, 57, 112-117.	1.3	14
5139	Anti-EGFR Therapy for Metastatic Colorectal Cancer in the Era of Extended RAS Gene Mutational Analysis. <i>BioDrugs</i> , 2016, 30, 95-104.	2.2	7
5140	Biologic and molecular markers for staging colon carcinoma. <i>Colorectal Cancer</i> , 2016, 5, 41-51.	0.8	1
5141	BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival. <i>British Journal of Cancer</i> , 2016, 114, 801-808.	2.9	56
5143	Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells. <i>Cell Death and Disease</i> , 2016, 7, e2135-e2135.	2.7	22

#	ARTICLE	IF	CITATIONS
5144	The current state of the art of quantitative phosphoproteomics and its applications to diabetes research. <i>Expert Review of Proteomics</i> , 2016, 13, 421-433.	1.3	26
5145	The Oct1 transcription factor and epithelial malignancies: Old protein learns new tricks. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 792-804.	0.9	63
5146	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016, 48, 194-202.	0.3	19
5147	Uveal melanoma. <i>Seminars in Diagnostic Pathology</i> , 2016, 33, 141-147.	1.0	23
5148	Selumetinib for the treatment of melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 223-231.	0.5	1
5149	Probe-free allele-specific copy number detection and analysis of tumors. <i>Analytical Biochemistry</i> , 2016, 497, 95-102.	1.1	3
5150	Dogs as a Model for Cancer. <i>Annual Review of Animal Biosciences</i> , 2016, 4, 199-222.	3.6	138
5151	Regulation of PD-L1: a novel role of pro-survival signalling in cancer. <i>Annals of Oncology</i> , 2016, 27, 409-416.	0.6	597
5152	Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastoma. <i>Brain Tumor Pathology</i> , 2016, 33, 137-146.	1.1	35
5153	Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. <i>Nature Genetics</i> , 2016, 48, 117-125.	9.4	80
5154	Hsp90 as a "Chaperone" of the Epigenome. <i>Advances in Cancer Research</i> , 2016, 129, 107-140.	1.9	22
5155	Beyond the exome: the role of non-coding somatic mutations in cancer. <i>Annals of Oncology</i> , 2016, 27, 240-248.	0.6	31
5156	Quantitative Detection and Resolution of BRAF V600 Status in Colorectal Cancer Using Droplet Digital PCR and a Novel Wild-Type Negative Assay. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 190-204.	1.2	33
5157	Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 1-23.	0.8	7
5158	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. <i>Current Opinion in Immunology</i> , 2016, 39, 30-38.	2.4	23
5159	The rapidly evolving therapies for advanced melanoma "Towards immunotherapy, molecular targeted therapy, and beyond. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 91-99.	2.0	87
5160	Cancer immunology and canine malignant melanoma: A comparative review. <i>Veterinary Immunology and Immunopathology</i> , 2016, 169, 15-26.	0.5	62
5161	Personalized Therapy of Non-small Cell Lung Cancer (NSCLC). <i>Advances in Experimental Medicine and Biology</i> , 2016, 890, 203-222.	0.8	28

#	ARTICLE	IF	CITATIONS
5162	Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 48-56.	1.4	240
5163	Discovery of EBI-907: A highly potent and orally active B-Raf V600E inhibitor for the treatment of melanoma and associated cancers. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 819-823.	1.0	10
5165	BMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance. <i>Genes and Development</i> , 2016, 30, 18-33.	2.7	53
5166	<i>BRAF</i> ^{V600E} Is Correlated with Recurrence of Papillary Thyroid Microcarcinoma: A Systematic Review, Multi-Institutional Primary Data Analysis, and Meta-Analysis. <i>Thyroid</i> , 2016, 26, 248-255.	2.4	88
5167	DriverDBv2: a database for human cancer driver gene research. <i>Nucleic Acids Research</i> , 2016, 44, D975-D979.	6.5	102
5168	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. <i>Trends in Immunology</i> , 2016, 37, 141-153.	2.9	24
5169	Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. <i>Cancer Discovery</i> , 2016, 6, 300-315.	7.7	134
5170	Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. <i>Lung Cancer</i> , 2016, 91, 23-28.	0.9	112
5171	Primary salivary duct carcinoma of the lung, mucin-rich variant. <i>Human Pathology</i> , 2016, 47, 150-156.	1.1	9
5172	Prognostic significance of β -adrenergic receptor expression in malignant melanoma. <i>Tumor Biology</i> , 2016, 37, 5971-5978.	0.8	16
5173	¹⁸ F-FDG PET/CT imaging of squamous cell carcinoma induced by Vemurafenib. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2016, 35, 64-66.	0.0	0
5174	Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 30-36.	2.9	56
5175	Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. <i>Endocrine Research</i> , 2016, 41, 64-69.	0.6	15
5176	Emerging targeted therapies in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 177-187.	1.1	9
5177	Metastatic melanoma treatment: Combining old and new therapies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 242-253.	2.0	64
5178	Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2016, 9, 91-105.	1.0	7
5179	Molecular Diagnosis of Thyroid Cancer. , 2016, , 153-162.		2
5180	Identification of <i>BRAF</i> Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy. <i>JAMA Oncology</i> , 2016, 2, 272.	3.4	18

#	ARTICLE	IF	CITATIONS
5181	Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. <i>Leukemia</i> , 2016, 30, 937-946.	3.3	52
5182	BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 7-14.	1.9	16
5183	Toward a Better Understanding of the Complexity of Cancer Drug Resistance. <i>Annual Review of Pharmacology and Toxicology</i> , 2016, 56, 85-102.	4.2	261
5184	Novel Treatments in Development for Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 371-416.	0.2	15
5185	Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 251-259.	1.3	18
5186	Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. <i>Molecular Oncology</i> , 2016, 10, 73-84.	2.1	129
5187	Mutant B-Raf(V600E) Promotes Melanoma Paracellular Transmigration by Inducing Thrombin-mediated Endothelial Junction Breakdown. <i>Journal of Biological Chemistry</i> , 2016, 291, 2087-2106.	1.6	10
5188	Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. <i>Pharmacological Research</i> , 2016, 103, 26-48.	3.1	570
5189	ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome. <i>European Journal of Endocrinology</i> , 2016, 174, R117-R126.	1.9	64
5190	Malignant transformation of diffuse astrocytoma to glioblastoma associated with newly developed BRAF V600E mutation. <i>Brain Tumor Pathology</i> , 2016, 33, 50-56.	1.1	14
5191	Correlation of <i>BRAF</i> Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 567-574.	3.2	185
5192	Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors. <i>Seminars in Cell and Developmental Biology</i> , 2016, 50, 164-176.	2.3	31
5193	Cytoprotective role of autophagy against BH3 mimetic gossypol in ATG5 knockout cells generated by CRISPR-Cas9 endonuclease. <i>Cancer Letters</i> , 2016, 370, 19-26.	3.2	13
5194	EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 230-242.	3.2	97
5195	BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma. <i>Journal of Investigative Dermatology</i> , 2016, 136, 481-486.	0.3	87
5196	BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review. <i>Brain Tumor Pathology</i> , 2016, 33, 40-49.	1.1	30
5197	Is UV an etiological factor of acral melanoma?. <i>Journal of Exposure Science and Environmental Epidemiology</i> , 2016, 26, 539-545.	1.8	24
5198	Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling. <i>Oncogene</i> , 2016, 35, 2166-2177.	2.6	49

#	ARTICLE	IF	CITATIONS
5199	First-in-Man Dose-Escalation Study of the Selective BRAF Inhibitor RG7256 in Patients with BRAF V600-Mutated Advanced Solid Tumors. <i>Targeted Oncology</i> , 2016, 11, 149-156.	1.7	1
5200	Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549â€“BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 89-100.	1.2	46
5201	Thyroid Fine-Needle Aspiration and Cytological Diagnosis. , 2016, , 1417-1422.e2.		2
5202	Tumor suppression function of FoxD3 in lung cancer. <i>Irish Journal of Medical Science</i> , 2016, 185, 547-553.	0.8	9
5203	Biology of Lung Cancer. , 2016, , 912-926.e6.		1
5204	pâ€“scp>MAPK</scp>1 expression associated with poor prognosis in angioimmunoblastic Tâ€“cell lymphoma patients. <i>British Journal of Haematology</i> , 2017, 176, 661-664.	1.2	2
5205	<i>BRAF</i>â€“V600 mutational status affects recurrence patterns of melanoma brain metastasis. <i>International Journal of Cancer</i> , 2017, 140, 2716-2727.	2.3	24
5206	Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib. <i>Oncogene</i> , 2017, 36, 423-428.	2.6	30
5207	BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. <i>Journal of Neurosurgery</i> , 2017, 126, 726-734.	0.9	41
5209	Concurrent <i>TERT</i> promoter and <i>BRAF</i> V600E mutation in epithelioid glioblastoma and concomitant lowâ€“grade astrocytoma. <i>Neuropathology</i> , 2017, 37, 58-63.	0.7	38
5210	Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e11-e20.	0.7	8
5211	<i>BRAF</i>â€“V600E</i> Mutant Colorectal Cancer Subtypes Based on Gene Expression. <i>Clinical Cancer Research</i> , 2017, 23, 104-115.	3.2	167
5212	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 432-440.	2.9	59
5213	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. <i>Neuro-Oncology</i> , 2017, 19, now294.	0.6	54
5214	Synthetic lethality: emerging targets and opportunities in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 183-193.	1.5	12
5215	Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma. <i>Pathology Research and Practice</i> , 2017, 213, 522-530.	1.0	4
5216	Point of care assessment of melanoma tumor signaling and metastatic burden from ¹ / ₄ NMR analysis of tumor fine needle aspirates and peripheral blood. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 821-828.	1.7	9
5217	A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs. <i>Journal of Oncology Practice</i> , 2017, 13, e108-e119.	2.5	80

#	ARTICLE	IF	CITATIONS
5218	Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. <i>Journal of Hematology and Oncology</i> , 2017, 10, 3.	6.9	47
5219	P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells. <i>Molecular Carcinogenesis</i> , 2017, 56, 1515-1525.	1.3	29
5220	Use of New Techniques in Addition to IHC Applied to the Diagnosis of Melanocytic Lesions, With Emphasis on CGH, FISH, and Mass Spectrometry. <i>Actas Dermo-sifilograficas</i> , 2017, 108, 17-30.	0.2	0
5221	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
5223	KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. <i>Medical Oncology</i> , 2017, 34, 26.	1.2	94
5224	KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth. <i>Oncogene</i> , 2017, 36, 3322-3333.	2.6	75
5225	Single Amino Acid Variant Profiles of Subpopulations in the MCF-7 Breast Cancer Cell Line. <i>Journal of Proteome Research</i> , 2017, 16, 842-851.	1.8	10
5226	Clinicopathologic characteristics and outcomes of Chinese patients with non-small cell lung cancer and BRAF mutation. <i>Cancer Medicine</i> , 2017, 6, 555-562.	1.3	46
5227	Noncoding RNAs and immune checkpoints' clinical implications as cancer therapeutics. <i>FEBS Journal</i> , 2017, 284, 1952-1966.	2.2	99
5228	Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2017, 484, 378-384.	1.0	21
5229	Serum and tissue markers in colorectal cancer: State of art. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 103-116.	2.0	20
5230	Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. <i>Human Pathology</i> , 2017, 62, 206-214.	1.1	50
5231	Molecular investigation of the direct anti-tumour effects of nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell lines. <i>Veterinary Journal</i> , 2017, 221, 38-47.	0.6	35
5232	Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. <i>Cancer Discovery</i> , 2017, 7, 302-321.	7.7	128
5233	A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. <i>British Journal of Cancer</i> , 2017, 116, 575-583.	2.9	73
5234	Synergistic Activity of N-hydroxy-7-(2-naphthylthio) Heptanamide and Sorafenib Against Cancer Stem Cells, Anaplastic Thyroid Cancer. <i>Neoplasia</i> , 2017, 19, 145-153.	2.3	17
5235	Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. <i>Modern Pathology</i> , 2017, 30, 734-744.	2.9	28
5236	Targeting protein kinase-b3 (akt3) signaling in melanoma. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 273-290.	1.5	16

#	ARTICLE	IF	CITATIONS
5237	Influence of node abundance on signaling network state and dynamics analyzed by mass cytometry. <i>Nature Biotechnology</i> , 2017, 35, 164-172.	9.4	39
5238	Comparative mutational landscape analysis of patient-derived tumour xenografts. <i>British Journal of Cancer</i> , 2017, 116, 515-523.	2.9	11
5239	BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management. <i>British Journal of Dermatology</i> , 2017, 177, 914-923.	1.4	29
5240	Endogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 611-629.	1.4	5
5241	Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 209-216.	1.6	8
5242	Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. <i>Cancer Letters</i> , 2017, 391, 125-140.	3.2	117
5243	Molecular analysis of BRAF V600E mutation in multiple nodules of pulmonary Langerhans cell histiocytosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 429-435.	1.4	7
5244	Cost-Effectiveness of Immune Checkpoint Inhibition in <i>BRAF</i> Wild-Type Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1194-1202.	0.8	89
5245	microRNA-216b inhibits cell proliferation and migration in human melanoma by targeting FOXM1 in vitro and in vivo. <i>Cell Biology International</i> , 2017, 41, 1272-1282.	1.4	26
5246	The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 53-75.	2.7	30
5247	Context-Dependent Effects of Amplified MAPK Signaling during Lung Adenocarcinoma Initiation and Progression. <i>Cell Reports</i> , 2017, 18, 1958-1969.	2.9	33
5248	Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. <i>Tumor Biology</i> , 2017, 39, 101042831769226.	0.8	29
5249	Towards therapeutic advances in melanoma management: An overview. <i>Life Sciences</i> , 2017, 174, 50-58.	2.0	47
5251	Next-Generation Sequencing to Guide Treatment of Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 303-310.	3.3	12
5252	Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition. <i>Scientific Reports</i> , 2017, 7, 42604.	1.6	41
5253	Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification. <i>Expert Review of Proteomics</i> , 2017, 14, 351-362.	1.3	10
5254	Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells. <i>Pharmacological Research</i> , 2017, 119, 242-250.	3.1	32
5255	Crosstalk signaling in targeted melanoma therapy. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 23-33.	2.7	15

#	ARTICLE	IF	CITATIONS
5256	Droplet-Based Digital PCR. <i>Advances in Clinical Chemistry</i> , 2017, 79, 43-91.	1.8	87
5257	Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer. <i>Oncology Letters</i> , 2017, 13, 1063-1070.	0.8	18
5258	Mechanisms of Drug Resistance in Melanoma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 91-108.	0.9	63
5259	Precision medicine driven by cancer systems biology. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 91-108.	2.7	38
5260	EGFR TKI combination with immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 465-469.	1.0	156
5261	The Role of Autophagy in Cancer. <i>Annual Review of Cancer Biology</i> , 2017, 1, 19-39.	2.3	158
5262	Beyond the <i>BRAF</i> ^{V600E} hotspot: biology and clinical implications of rare <i>BRAF</i> gene mutations in melanoma patients. <i>British Journal of Dermatology</i> , 2017, 177, 936-944.	1.4	39
5263	Glioma Subclassifications and Their Clinical Significance. <i>Neurotherapeutics</i> , 2017, 14, 284-297.	2.1	471
5264	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017, 15, 46.	1.8	85
5265	BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. <i>American Journal of Kidney Diseases</i> , 2017, 70, 145-150.	2.1	25
5266	<i>PIK3CA</i> -mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 353-367.	1.5	9
5267	Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Odontogenic and Maxillofacial Bone Tumors. <i>Head and Neck Pathology</i> , 2017, 11, 68-77.	1.3	456
5268	Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1255-1262.	1.2	19
5269	Energy metabolism in skin cancers: A therapeutic perspective. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2017, 1858, 712-722.	0.5	26
5270	A water-mediated allosteric network governs activation of Aurora kinase A. <i>Nature Chemical Biology</i> , 2017, 13, 402-408.	3.9	53
5271	Biological screening of cucurbitacin inspired estrone analogs targeting mitogen-activated protein kinase (MAPK) pathway. <i>Chemical Biology and Drug Design</i> , 2017, 90, 478-484.	1.5	17
5272	Metastatic disease from uveal melanoma: treatment options and future prospects. <i>British Journal of Ophthalmology</i> , 2017, 101, 38-44.	2.1	287
5273	The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. <i>Cancer Discovery</i> , 2017, 7, 424-441.	7.7	57

#	ARTICLE	IF	CITATIONS
5274	AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or RAS Mutations: Impact on Melanoma Prognosis and Therapy. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1297-1310.	0.3	40
5275	Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells. <i>Cell Death and Disease</i> , 2017, 8, e2594-e2594.	2.7	53
5276	Distribution bias analysis of germline and somatic single-nucleotide variations that impact protein functional site and neighboring amino acids. <i>Scientific Reports</i> , 2017, 7, 42169.	1.6	1
5277	Implementing Genome-Driven Oncology. <i>Cell</i> , 2017, 168, 584-599.	13.5	405
5278	Tissue-specific tumorigenesis: context matters. <i>Nature Reviews Cancer</i> , 2017, 17, 239-253.	12.8	234
5279	In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. <i>Oncology Reports</i> , 2017, 37, 1367-1378.	1.2	5
5280	Clinical Pharmacokinetics of Vemurafenib. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1033-1043.	1.6	41
5281	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. <i>Lancet Oncology</i> , 2017, 18, 464-472.	5.1	139
5282	Cancer genomics guide clinical practice in personalized medicine. <i>Therapie</i> , 2017, 72, 439-451.	0.6	12
5283	B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. <i>Oncolmmunology</i> , 2017, 6, e1294296.	2.1	51
5284	Toxicology of Herbal Products. , 2017, , .		9
5285	The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. <i>Laboratory Investigation</i> , 2017, 97, 649-656.	1.7	197
5286	Optic Pathway Gliomas. <i>Journal of Pediatric Neurology</i> , 2017, 15, 015-024.	0.0	1
5287	Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 43-50.	2.7	23
5288	Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 663-679.	2.5	26
5289	Advances in Circulating Tumor DNA Analysis. <i>Advances in Clinical Chemistry</i> , 2017, 80, 73-153.	1.8	23
5290	Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma. <i>Scientific Reports</i> , 2017, 7, 46244.	1.6	19
5291	Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?. <i>Melanoma Research</i> , 2017, 27, 231-237.	0.6	15

#	ARTICLE	IF	CITATIONS
5294	Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2980-2992.	1.1	25
5296	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. <i>Annals of Oncology</i> , 2017, 28, 958-968.	0.6	107
5297	New Challenges in Cancer Therapy: MAPK Inhibitors from Bench to Bedside. , 2017, , 67-91.		1
5298	Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance. <i>European Journal of Medicinal Chemistry</i> , 2017, 135, 34-48.	2.6	61
5299	Optic Pathway Gliomas Secondary to Neurofibromatosis Type 1. <i>Seminars in Pediatric Neurology</i> , 2017, 24, 92-99.	1.0	20
5300	Translating Molecules into Medicines. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2017, , .	0.2	2
5301	The role of molecular diagnostic testing in the management of thyroid nodules. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 567-576.	1.5	5
5302	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 597-611.	3.3	11
5303	Phosphotyrosine-based-phosphoproteomics scaled-down to biopsy level for analysis of individual tumor biology and treatment selection. <i>Journal of Proteomics</i> , 2017, 162, 99-107.	1.2	31
5304	Characterization of common and rare mutations in EGFR and associated clinicopathological features in a large population of Chinese patients with lung cancer. <i>Pathology Research and Practice</i> , 2017, 213, 749-758.	1.0	9
5305	Indicators of responsiveness to immune checkpoint inhibitors. <i>Scientific Reports</i> , 2017, 7, 807.	1.6	70
5306	An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients. <i>Clinica Chimica Acta</i> , 2017, 470, 8-13.	0.5	20
5307	An alternative model for (breast) cancer predisposition. <i>Npj Breast Cancer</i> , 2017, 3, 13.	2.3	4
5308	Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours. <i>Oncogene</i> , 2017, 36, 4778-4789.	2.6	33
5309	BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response. <i>Melanoma Research</i> , 2017, 27, 281-287.	0.6	25
5310	Cutaneous Reactions to Targeted Therapy. <i>American Journal of Dermatopathology</i> , 2017, 39, 67-82.	0.3	9
5311	Molecular Alterations in Pancreatic Cancer. , 2017, , 11-23.		0
5312	Antagonistic Interactions between Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase and Retinoic Acid Receptor Signaling in Colorectal Cancer Cells. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	9

#	ARTICLE	IF	CITATIONS
5313	RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma. <i>Nature Communications</i> , 2017, 8, 15262.	5.8	38
5314	Nuclear Survivin as a Prognostic Factor in Squamous-Cell Carcinoma of the Oral Cavity. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 566-570.	0.6	19
5315	Focus on cutaneous and uveal melanoma specificities. <i>Genes and Development</i> , 2017, 31, 724-743.	2.7	75
5317	Melanoma antigens and related immunological markers. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 36-49.	2.0	54
5318	Immunotherapy in advanced melanoma: a network meta-analysis. <i>Immunotherapy</i> , 2017, 9, 471-479.	1.0	9
5319	Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, 299-307.	0.6	9
5320	Developability Assessment of Clinical Candidates. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2017, , 231-266.	0.2	1
5321	MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2017, 407, 117-151.	0.7	25
5322	The use of immunotherapy in the treatment of melanoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 88.	6.9	89
5323	High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model. <i>Stem Cell Reviews and Reports</i> , 2017, 13, 335-346.	5.6	59
5324	An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. <i>Journal of Experimental Medicine</i> , 2017, 214, 1691-1710.	4.2	71
5325	BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. <i>Journal of Clinical Pathology</i> , 2017, 70, 935-940.	1.0	16
5326	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. <i>Cancer Discovery</i> , 2017, 7, 832-851.	7.7	49
5327	Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma. <i>CNS Oncology</i> , 2017, 6, 5-9.	1.2	35
5328	Integrating Heterogeneous Datasets for Cancer Module Identification. <i>Methods in Molecular Biology</i> , 2017, 1526, 119-137.	0.4	2
5329	New Targets in Non-“Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 113-129.	0.9	20
5330	Deciphering the Role of Oncogenic MITF ^{E318K} in Senescence Delay and Melanoma Progression. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	27
5331	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. <i>Current Oncology Reports</i> , 2017, 19, 45.	1.8	70

#	ARTICLE	IF	CITATIONS
5332	Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity. <i>ACS Synthetic Biology</i> , 2017, 6, 1484-1495.	1.9	22
5333	Targeting <i>BRAF</i> -Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. <i>Oncologist</i> , 2017, 22, 786-796.	1.9	95
5334	Targeted Disruption of V600E-Mutant <i>BRAF</i> Gene by CRISPR-Cpf1. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 8, 450-458.	2.3	27
5335	Somatic driver mutations in melanoma. <i>Cancer</i> , 2017, 123, 2104-2117.	2.0	96
5336	<i>BRAF</i> V600E mutation in pediatric intracranial and cranial juvenile xanthogranuloma. <i>Human Pathology</i> , 2017, 69, 118-122.	1.1	31
5337	Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced <i>BRAF</i> -Mutated Melanoma. <i>Targeted Oncology</i> , 2017, 12, 365-371.	1.7	15
5339	Viral-Like Proteins. , 2017, , 545-559.		0
5340	B-Raf. , 2017, , 673-681.		0
5342	Concurrent <i>BRAF</i> and <i>PTEN</i> mutations in melanoma of unknown origin presenting as a breast mass. <i>SAGE Open Medical Case Reports</i> , 2017, 5, 2050313X1771106.	0.2	5
5343	<i>MEK</i> inhibitors induce Akt activation and drug resistance by suppressing negative feedback <i>ERK</i> -mediated <i>HER2</i> phosphorylation at Thr701. <i>Molecular Oncology</i> , 2017, 11, 1273-1287.	2.1	46
5344	S3â€œLeitlinie Diagnostik, Therapie und Nachsorge des Melanoms â€œ Update 2015/2016, Kurzversion 2.0. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, e1-e41.	0.4	29
5345	Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with <i>MEK</i> Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2315-2323.	1.9	8
5346	Statistical contributions to bioinformatics: Design, modelling, structure learning and integration. <i>Statistical Modelling</i> , 2017, 17, 245-289.	0.5	15
5347	Clinical research in small genomically stratified patient populations. <i>European Journal of Cancer</i> , 2017, 80, 73-82.	1.3	2
5348	Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on <i>BRAF</i> V600E Melanoma Lines with Vemurafenib. <i>Cancer Immunology Research</i> , 2017, 5, 582-593.	1.6	17
5349	N-Ras. , 2017, , 795-803.		0
5350	<i>MEK</i> Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 745-754.	3.3	104
5351	ETV1-Positive Cells Give Rise to <i>BRAF</i> V600E-Mutant Gastrointestinal Stromal Tumors. <i>Cancer Research</i> , 2017, 77, 3758-3765.	0.4	12

#	ARTICLE	IF	CITATIONS
5352	Ubiquitination in melanoma pathogenesis and treatment. <i>Cancer Medicine</i> , 2017, 6, 1362-1377.	1.3	24
5353	Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. <i>Cancer</i> , 2017, 123, 2118-2129.	2.0	121
5354	Molecular insights into melanoma brain metastases. <i>Cancer</i> , 2017, 123, 2163-2175.	2.0	34
5355	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	2.0	24
5356	AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes. <i>Biochemical and Biophysical Research Communications</i> , 2017, 489, 14-20.	1.0	5
5357	Multifocal Supra and Infratentorial Medulloblastoma in an Adult: Histologic, Immunohistochemical, and Molecular Evaluation of a Rare Case and Review of the Literature. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2017, 25, e89-e94.	0.6	4
5358	BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5631-5638.	3.2	56
5359	Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 370-398.	2.3	707
5360	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients. <i>Medicine (United States)</i> , 2017, 96, e6931.	0.4	3
5361	A review of binimetinib for the treatment of mutant cutaneous melanoma. <i>Future Oncology</i> , 2017, 13, 1755-1766.	1.1	35
5363	ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells. <i>Molecular Cancer</i> , 2017, 16, 102.	7.9	108
5364	p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2187-2196.	0.3	22
5365	Melanocytic nevi and melanoma: unraveling a complex relationship. <i>Oncogene</i> , 2017, 36, 5771-5792.	2.6	166
5366	Osteogenic Melanoma With Desmin Expression. <i>American Journal of Dermatopathology</i> , 2017, 39, 528-533.	0.3	8
5367	Cytotoxic and genotoxic effects of ¹³¹ I and ⁶⁰ Co in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid-stimulating hormone treatment. <i>Environmental and Molecular Mutagenesis</i> , 2017, 58, 451-461.	0.9	4
5368	Metastatic melanoma moves on: translational science in the era of personalized medicine. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 7-21.	2.7	16
5369	Systemic therapy for previously untreated advanced BRAF-mutated melanoma: navigating a shifting landscape. <i>Immunotherapy</i> , 2017, 9, 375-378.	1.0	5
5370	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	12.5	945

#	ARTICLE	IF	CITATIONS
5371	Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. <i>American Journal of Dermatopathology</i> , 2017, 39, 1-13.	0.3	10
5372	Initiative for Molecular Profiling and Advanced Cancer Therapy and challenges in the implementation of precision medicine. <i>Current Problems in Cancer</i> , 2017, 41, 176-181.	1.0	16
5373	Do the Side Effects of BRAF Inhibitors Mimic RASopathies?. <i>Journal of Investigative Dermatology</i> , 2017, 137, 805-809.	0.3	8
5375	The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 511-530.	1.5	101
5376	Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites. <i>Drug Metabolism and Disposition</i> , 2017, 45, 646-656.	1.7	12
5377	Cancerous perturbations within the ERK, PI3K/Akt, and Wnt/ β^2 -catenin signaling network constitutively activate inter-pathway positive feedback loops. <i>Molecular BioSystems</i> , 2017, 13, 830-840.	2.9	28
5378	Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma. <i>Scientific Reports</i> , 2017, 7, 45704.	1.6	54
5379	Autophagy inhibitors chloroquine and LY294002 enhance temozolomide cytotoxicity on cutaneous melanoma cell lines in vitro. <i>Anti-Cancer Drugs</i> , 2017, 28, 307-315.	0.7	35
5380	Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination. <i>Melanoma Research</i> , 2017, 27, 164-167.	0.6	19
5381	From fish bowl to bedside: The power of zebrafish to unravel melanoma pathogenesis and discover new therapeutics. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 402-412.	1.5	52
5382	Biomarkers for Anti-angiogenic Therapy. , 2017, , 1-18.		0
5383	Individual Biomarkers Using Molecular Personalized Medicine Approaches. <i>Orl</i> , 2017, 79, 7-13.	0.6	6
5384	Relationships of BRAF mutation and HMGB1 to papillary thyroid carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2017, 486, 898-903.	1.0	4
5385	HUMAN KINASES DISPLAY MUTATIONAL HOTSPOTS AT COGNATE POSITIONS WITHIN CANCER. , 2017, 22, 414-425.		1
5386	Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months. <i>Experimental Hematology and Oncology</i> , 2017, 6, 6.	2.0	38
5387	Molecular genetic and immunotherapeutic targets in metastatic melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 281-293.	1.4	16
5388	Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. <i>Cell Death and Disease</i> , 2017, 8, e2716-e2716.	2.7	355
5389	Genotoxicity and Carcinogenicity of Herbal Products. , 2017, , 179-215.		4

#	ARTICLE	IF	CITATIONS
5390	Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKK β inhibition. <i>Redox Biology</i> , 2017, 11, 562-576.	3.9	32
5391	Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 431-447.	2.5	15
5392	Spatial regulation of ARAF controls the MST2-Hippo pathway. <i>Small GTPases</i> , 2017, 10, 1-6.	0.7	7
5394	Synthetic Glycopolymers for Highly Efficient Differentiation of Embryonic Stem Cells into Neurons: Lipo- or Not?. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 11518-11527.	4.0	29
5395	BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 35-42.	2.7	35
5396	Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine. <i>Haematologica</i> , 2017, 102, 411-418.	1.7	14
5397	Mechanisms of Resistance to Immune Checkpoint Antibodies. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 109-128.	0.9	26
5398	Identifying the clonal relationship model of multifocal papillary thyroid carcinoma by whole genome sequencing. <i>Cancer Letters</i> , 2017, 396, 110-116.	3.2	9
5399	Drug nanocarriers for cancer chemotherapy based on microemulsions: The case of Vemurafenib analog PLX4720. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 154, 350-356.	2.5	34
5400	Radiogenomic evaluation of lung cancer "Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?". <i>Clinical Imaging</i> , 2017, 42, 147-151.	0.8	14
5401	Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients. <i>Pathology and Oncology Research</i> , 2017, 23, 181-188.	0.9	4
5402	Clinicopathological Features and Predictive Factors for Colorectal Cancer Outcome in the Kingdom of Saudi Arabia. <i>Oncology</i> , 2017, 92, 75-86.	0.9	16
5403	Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma. <i>Neuro-Oncology</i> , 2017, 19, i1-i24.	0.6	171
5404	P16 overexpression in BRAF-mutated gastrointestinal stromal tumors. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 195-201.	1.5	4
5405	Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK. <i>Cancer Treatment Reviews</i> , 2017, 53, 61-69.	3.4	118
5406	Energetics and structural characterization of the "DFG-flip" conformational transition of B-RAF kinase: a SITS molecular dynamics study. <i>Physical Chemistry Chemical Physics</i> , 2017, 19, 1257-1267.	1.3	17
5407	Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes. <i>American Journal of Human Genetics</i> , 2017, 100, 5-20.	2.6	72
5408	BRAF V600E-dependent role of autophagy in uveal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 447-455.	1.2	21

#	ARTICLE	IF	CITATIONS
5409	Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 46-58.	1.4	27
5410	Post-nano strategies for drug delivery: multistage porous silicon microvectors. <i>Journal of Materials Chemistry B</i> , 2017, 5, 207-219.	2.9	47
5411	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 75-102.	9.6	30
5412	Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E317-E326.	3.3	63
5413	An Overview of the Changing Landscape of Treatment for Advanced Melanoma. <i>Pharmacotherapy</i> , 2017, 37, 319-333.	1.2	33
5414	Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation. <i>Laboratory Investigation</i> , 2017, 97, 166-175.	1.7	37
5415	A case of vemurafenib-induced polyarthritis in a patient with melanoma: how to manage it?. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 398-401.	0.9	8
5416	Computational investigation on inhibition mechanism of BRAFV600E by Vemurafenib (PLX4032) and its analogue PLX4720. <i>Medicinal Chemistry Research</i> , 2017, 26, 390-396.	1.1	1
5417	Lifetime alcohol intake is associated with an increased risk of KRAS+ and BRAF+KRAS but not BRAF+ colorectal cancer. <i>International Journal of Cancer</i> , 2017, 140, 1485-1493.	2.3	27
5418	K-Ras, H-Ras, N-Ras and B-Raf mutation and expression analysis in Wilms tumors: association with tumor growth. <i>Medical Oncology</i> , 2017, 34, 6.	1.2	13
5419	Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas. <i>Pharmacological Research</i> , 2017, 117, 20-31.	3.1	78
5420	BRAF -mutated cells activate GCN2-mediated integrated stress response as a cytoprotective mechanism in response to vemurafenib. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 1491-1497.	1.0	18
5421	Dabrafenib and trametinib in BRAFV600E mutated glioma. <i>CNS Oncology</i> , 2017, 6, 291-296.	1.2	58
5422	Understanding and targeting resistance mechanisms in NSCLC. <i>Nature Reviews Cancer</i> , 2017, 17, 637-658.	12.8	679
5423	The natural product mensacarcin induces mitochondrial toxicity and apoptosis in melanoma cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 21102-21116.	1.6	31
5424	Anthrax lethal toxin rapidly reduces c-Jun levels by inhibiting c-Jun gene transcription and promoting c-Jun protein degradation. <i>Journal of Biological Chemistry</i> , 2017, 292, 17919-17927.	1.6	5
5425	Herbacetin suppresses cutaneous squamous cell carcinoma and melanoma cell growth by targeting AKT and ODC. <i>Carcinogenesis</i> , 2017, 38, 1136-1146.	1.3	25
5426	Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFR β . <i>Neoplasia</i> , 2017, 19, 932-940.	2.3	50

#	ARTICLE	IF	CITATIONS
5427	BRAF V600E mutation is a significant prognosticator of the tumour regrowth rate in brainstem gangliogliomas. <i>Journal of Clinical Neuroscience</i> , 2017, 46, 50-57.	0.8	29
5428	Development of the first model of a phosphorylated, ATP/Mg ²⁺ -containing B-Raf monomer by molecular dynamics simulations: a tool for structure-based design. <i>Physical Chemistry Chemical Physics</i> , 2017, 19, 31177-31185.	1.3	2
5429	New perspectives for targeting RAF kinase in human cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 676-691.	12.8	285
5430	Integrator orchestrates RAS/ERK1/2 signaling transcriptional programs. <i>Genes and Development</i> , 2017, 31, 1809-1820.	2.7	36
5431	Challenges for Biometry in 21st Century Oncology. , 2017, , 1-9.		0
5432	Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib. <i>Scientific Reports</i> , 2017, 7, 12020.	1.6	6
5433	Natural (and Unnatural) Small Molecules as Pharmacological Chaperones and Inhibitors in Cancer. <i>Handbook of Experimental Pharmacology</i> , 2017, 245, 155-190.	0.9	10
5435	Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects. <i>Clinical Therapeutics</i> , 2017, 39, 2260-2275.e1.	1.1	9
5436	Demographic history, selection and functional diversity of the canine genome. <i>Nature Reviews Genetics</i> , 2017, 18, 705-720.	7.7	125
5437	Rescue of cell cycle progression in BRAFV600E inhibitor-resistant human melanoma by a chromatin modifier. <i>Tumor Biology</i> , 2017, 39, 101042831772162.	0.8	5
5438	BRAFV600E mutation is not associated with central lymph node metastasis in all patients with papillary thyroid cancer: Different histological subtypes and preoperative lymph node status should be taken into account. <i>Oncology Letters</i> , 2017, 14, 4122-4134.	0.8	19
5439	KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling. <i>Cancer Research</i> , 2017, 77, 5820-5830.	0.4	15
5440	Chimeric RAF Kinases in the Development of Cancer. , 2017, , 209-220.		0
5441	<i>BRAF</i> and <i>NRAS</i> mutations in circulating Langerhans-like CD1a ⁺ cells in a patient with pulmonary Langerhans cell histiocytosis. <i>European Respiratory Journal</i> , 2017, 50, 1700521.	3.1	6
5443	Delayed-onset vemurafenib-induced panniculitis. <i>JAAD Case Reports</i> , 2017, 3, 384-386.	0.4	6
5444	Acne guidelines: pearls, pitfalls and questions. <i>British Journal of Dermatology</i> , 2017, 177, 892-893.	1.4	2
5445	Imidazo[1,2- a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 5221-5224.	1.0	8
5446	A path through the reticulate pigmentation disorder jungle. <i>British Journal of Dermatology</i> , 2017, 177, 893-894.	1.4	3

#	ARTICLE	IF	CITATIONS
5447	The evolving universe of <i>BRAF</i> mutations in melanoma. <i>British Journal of Dermatology</i> , 2017, 177, 893-893.	1.4	6
5448	Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 6479-6485.	1.4	43
5449	Activated <i>Braf</i> induces esophageal dilation and gastric epithelial hyperplasia in mice. <i>Human Molecular Genetics</i> , 2017, 26, 4715-4727.	1.4	13
5450	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. <i>British Journal of Cancer</i> , 2017, 117, 938-946.	2.9	18
5451	The Power of Zebrafish in Personalised Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1007, 179-197.	0.8	36
5452	Somatic mutation analysis in melanoma using targeted next generation sequencing. <i>Experimental and Molecular Pathology</i> , 2017, 103, 172-177.	0.9	19
5453	Attitudes of patients and physicians on repeat biopsies for lung cancer. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 181-202.	0.6	0
5454	Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment. <i>Seminars in Cancer Biology</i> , 2017, 46, 158-181.	4.3	57
5455	Pathways from senescence to melanoma: focus on MITF sumoylation. <i>Oncogene</i> , 2017, 36, 6659-6667.	2.6	31
5456	Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	16
5457	Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6946-6957.	3.2	73
5458	BRAF V600E Mutations Occur in a Subset of Glomus Tumors, and Are Associated With Malignant Histologic Characteristics. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1532-1541.	2.1	49
5459	GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. <i>British Journal of Cancer</i> , 2017, 117, 884-887.	2.9	70
5460	<i>BRAF</i> mutation as a novel driver of eosinophilic cystitis. <i>Cancer Biology and Therapy</i> , 2017, 18, 655-659.	1.5	5
5461	Binimetinib for the treatment of NRAS-mutant melanoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 985-990.	1.1	21
5462	Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy. <i>Acta Neurochirurgica</i> , 2017, 159, 2217-2221.	0.9	59
5463	Fine particle matters induce DNA damage and G2/M cell cycle arrest in human bronchial epithelial BEAS-2B cells. <i>Environmental Science and Pollution Research</i> , 2017, 24, 25071-25081.	2.7	36
5464	MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor. <i>Cancer Letters</i> , 2017, 409, 116-124.	3.2	23

#	ARTICLE	IF	CITATIONS
5465	Generation of a Potential Prognostic Matrix for Papillary Thyroid Cancer that Assesses Age, Tumor Size, Transforming Growth Factor- β^2 , and <i>BRAF</i> ^{V600E} Mutation. <i>Oncology Research and Treatment</i> , 2017, 40, 586-592.	0.8	3
5466	Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. <i>Scientific Reports</i> , 2017, 7, 8215.	1.6	10
5467	Molecular genetics of syndromic and non-syndromic forms of parathyroid carcinoma. <i>Human Mutation</i> , 2017, 38, 1621-1648.	1.1	82
5468	How I manage pulmonary Langerhans cell histiocytosis. <i>European Respiratory Review</i> , 2017, 26, 170070.	3.0	44
5469	Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches. <i>Cancer Treatment Reviews</i> , 2017, 60, 109-119.	3.4	45
5470	A Novel Notch-YAP Circuit Drives Stemness and Tumorigenesis in Embryonal Rhabdomyosarcoma. <i>Molecular Cancer Research</i> , 2017, 15, 1777-1791.	1.5	49
5471	Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma. <i>Oncology Letters</i> , 2017, 14, 3601-3605.	0.8	25
5472	Cardiovascular Effects of the MEK Inhibitor, Trametinib: A Case Report, Literature Review, and Consideration of Mechanism. <i>Cardiovascular Toxicology</i> , 2017, 17, 487-493.	1.1	62
5473	Histiocitosis sistĂ©micas. <i>EMC - Tratado De Medicina</i> , 2017, 21, 1-4.	0.0	0
5474	Approaches to identify kinase dependencies in cancer signalling networks. <i>FEBS Letters</i> , 2017, 591, 2577-2592.	1.3	11
5475	BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives. <i>Annals of Oncology</i> , 2017, 28, 2648-2657.	0.6	227
5476	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR α 2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from <i>BRAF</i> mutation status. <i>Cancer Medicine</i> , 2017, 6, 1904-1914.	1.3	24
5477	Inhibitory effect and mechanism of mesenchymal stem cells on melanoma cells. <i>Clinical and Translational Oncology</i> , 2017, 19, 1358-1374.	1.2	11
5478	P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition. <i>European Journal of Cancer</i> , 2017, 83, 154-165.	1.3	42
5479	Synthetic essentiality: Targeting tumor suppressor deficiencies in cancer. <i>BioEssays</i> , 2017, 39, 1700076.	1.2	22
5480	An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer. <i>Nature Medicine</i> , 2017, 23, 929-937.	15.2	146
5481	Concordancia mutacional de BRAF entre melanoma primario cutĂ©neo y sus correspondientes metĂ©stasis. Revisi3n de la evidencia actual. <i>Actas Dermo-sifiliogrĂ©ficas</i> , 2017, 108, 894-901.	0.2	4
5482	Nuevos avances de tratamiento inmunobiolĂ©gico en el melanoma avanzado. <i>Actas Dermo-sifiliogrĂ©ficas</i> , 2017, 108, 721-728.	0.2	0

#	ARTICLE	IF	CITATIONS
5483	Liquid Biopsy in Cancer Patients. <i>Current Clinical Pathology</i> , 2017, , .	0.0	6
5484	Isothermal Point Mutation Detection: Toward a First-Pass Screening Strategy for Multidrug-Resistant Tuberculosis. <i>Analytical Chemistry</i> , 2017, 89, 9017-9022.	3.2	27
5485	Target and Agent Prioritization for the Children's Oncology Group's National Cancer Institute Pediatric MATCH Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	85
5486	Critical role of glioma-associated oncogene homolog 1 in maintaining invasive and mesenchymal-like properties of melanoma cells. <i>Cancer Science</i> , 2017, 108, 1602-1611.	1.7	16
5487	Liquid Biopsies in Malignant Melanoma: From Bench to Bedside. <i>Current Clinical Pathology</i> , 2017, , 161-193.	0.0	0
5488	Cancer Clonal Evolution and Intra-tumor Heterogeneity. <i>Current Clinical Pathology</i> , 2017, , 27-39.	0.0	1
5489	Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. <i>Cancer Letters</i> , 2017, 406, 1-11.	3.2	46
5490	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017, 28, 2581-2587.	0.6	201
5491	Novel Targeted Therapies for Metastatic Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 54-58.	1.0	19
5492	The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression. <i>Immunity</i> , 2017, 47, 284-297.e5.	6.6	115
5493	Editorial: Tissue Acquisition in Clinical Trials—Essential for Progress. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	0
5494	Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE. <i>Melanoma Research</i> , 2017, 27, 507-510.	0.6	9
5495	Advances in the Immunobiological Therapies for Advanced Melanoma. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 721-728.	0.2	0
5496	Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma. <i>Oncology Letters</i> , 2017, 14, 1439-1444.	0.8	8
5497	Apoptotic Effect of Astragaloside in Melanoma Skin Cancers via Activation of Caspases and Inhibition of Sry-related HMG-Box Gene 10. <i>Phytotherapy Research</i> , 2017, 31, 1614-1620.	2.8	26
5498	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. <i>Cell Death and Disease</i> , 2017, 8, e2982-e2982.	2.7	17
5499	Immunotherapy of cancers comes of age. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1001-1015.	1.3	84
5500	Î²-Raf activation of the myocardial Na ⁺ /H ⁺ exchanger. <i>Channels</i> , 2017, 11, 181-182.	1.5	1

#	ARTICLE	IF	CITATIONS
5502	The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases. <i>Medicine (United States)</i> , 2017, 96, e8404.	0.4	17
5503	MELK Promotes Melanoma Growth by Stimulating the NF- κ B Pathway. <i>Cell Reports</i> , 2017, 21, 2829-2841.	2.9	61
5504	BRAF Mutation Status Concordance Between Primary Cutaneous Melanomas and Corresponding Metastases: A Review of the Latest Evidence. <i>Actas Dermo-sifiliogrÁficas</i> , 2017, 108, 894-901.	0.2	3
5505	Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells. <i>Scientific Reports</i> , 2017, 7, 16345.	1.6	16
5506	A HRM assay for identification of low level BRAF V600E and V600K mutations using the CADMA principle in FFPE specimens. <i>Pathology</i> , 2017, 49, 776-783.	0.3	3
5507	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. <i>Cell Reports</i> , 2017, 21, 1936-1952.	2.9	72
5508	UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 996, 27-40.	0.8	94
5509	Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. <i>Melanoma Research</i> , 2017, 27, 585-590.	0.6	21
5510	Resistance mechanisms to genetic suppression of mutant NRAS in melanoma. <i>Melanoma Research</i> , 2017, 27, 545-557.	0.6	6
5511	Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst. <i>Oral Oncology</i> , 2017, 74, 62-67.	0.8	23
5512	Correlation between BRAF V600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma. <i>Science China Life Sciences</i> , 2017, 60, 729-738.	2.3	28
5513	Synthesis and biological evaluation of novel N-(5-phenyl-1H-pyrazol-3-yl)benzenesulfonamide derivatives as potential BRAFV600E inhibitors. <i>Medicinal Chemistry Research</i> , 2017, 26, 2583-2591.	1.1	3
5514	A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. <i>Biochemical Pharmacology</i> , 2017, 142, 39-45.	2.0	9
5515	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 621-630.	0.2	5
5516	Heat shock protein 90 and serine/threonine kinase B-Raf inhibitors have overlapping chemical space. <i>RSC Advances</i> , 2017, 7, 31069-31074.	1.7	17
5517	Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. <i>Oncologist</i> , 2017, 22, 823-833.	1.9	69
5518	Kinase activity ranking using phosphoproteomics data (KARP) quantifies the contribution of protein kinases to the regulation of cell viability. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1694-1704.	2.5	18
5519	Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. <i>Pharmacological Research</i> , 2017, 123, 95-102.	3.1	52

#	ARTICLE	IF	CITATIONS
5520	Phosphorylation of the C-Raf N Region Promotes Raf Dimerization. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	20
5521	<scp>VEGF</scp> blockade enhances the antitumor effect of <scp> BRAF ^V </scp> ^{600E} inhibition. <i>EMBO Molecular Medicine</i> , 2017, 9, 219-237.	3.3	36
5522	The new paradigm of systemic therapies for metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 356-368.	0.6	34
5523	MicroRNA-26a inhibits the growth and invasiveness of malignant melanoma and directly targets on MITF gene. <i>Cell Death Discovery</i> , 2017, 3, 17028.	2.0	36
5524	Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6157-E6165.	3.3	90
5525	Novel carbohydrate-substituted metallo -porphyrazine comparison for cancer tissue-type specificity during PDT. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017, 173, 412-422.	1.7	5
5526	BRAF ^{V600} inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E5930-E5939.	3.3	101
5527	Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 341-358.	3.3	42
5528	Blue Nevi and Related Tumors. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 401-415.	0.7	34
5529	A case report of ascending colon adenosquamous carcinoma with BRAF V600E mutation. <i>International Cancer Conference Journal</i> , 2017, 6, 93-97.	0.2	4
5530	Primary Vaginal Malignant Melanoma with Urethral Involvement Managed by Bladder Preservation. <i>Indian Journal of Gynecologic Oncology</i> , 2017, 15, 1.	0.1	0
5531	Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF V600E mutant cancer. <i>Life Sciences</i> , 2017, 183, 37-44.	2.0	10
5532	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 4684-4696.	0.4	80
5533	BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity. <i>Molecular Cancer Research</i> , 2017, 15, 1431-1444.	1.5	18
5534	The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients. <i>BMC Cancer</i> , 2017, 17, 403.	1.1	28
5535	Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. <i>Journal of Translational Medicine</i> , 2017, 15, 146.	1.8	36
5536	The undifferentiated carcinoma that became a melanoma: Re-biopsy of a cancer of an unknown primary site: a case report. <i>Journal of Medical Case Reports</i> , 2017, 11, 82.	0.4	13
5537	Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer. <i>Experimental Hematology and Oncology</i> , 2017, 6, 1.	2.0	14

#	ARTICLE	IF	CITATIONS
5538	<i>BRAF</i> Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. <i>Oncologist</i> , 2017, 22, 864-872.	1.9	56
5539	Differential <scp>UBE2C</scp> and <scp>HOXA1</scp> expression in melanocytic nevi and melanoma. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 843-850.	0.7	8
5540	Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials. <i>Current Medical Research and Opinion</i> , 2017, 33, 1663-1675.	0.9	9
5541	Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression inÂvivo. <i>Cancer Letters</i> , 2017, 385, 179-187.	3.2	24
5543	Oncogene-Induced Senescence. <i>Methods in Molecular Biology</i> , 2017, , .	0.4	4
5544	Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 1457-1474.	2.4	77
5545	Association between dermoscopic and reflectance confocal microscopy features of cutaneous melanoma with <scp>BRAF</scp> mutational status. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 643-649.	1.3	15
5546	Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice. <i>Virus Genes</i> , 2017, 53, 52-62.	0.7	11
5547	Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells. <i>Oncogene</i> , 2017, 36, 1849-1861.	2.6	75
5548	Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas. <i>Journal of Neuro-Oncology</i> , 2017, 131, 495-505.	1.4	29
5549	<i>Cancer Genomics</i> . , 2017, , 43-63.		0
5551	Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC). <i>Seminars in Cancer Biology</i> , 2017, 45, 36-49.	4.3	11
5552	Detection of mutations in the BRAF gene in patients with KIT and PDGFRA wild-type gastrointestinal stromal tumors. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 29-36.	1.4	23
5553	Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth. <i>Cancer Letters</i> , 2017, 385, 243-250.	3.2	32
5554	Approved and Experimental Smallâ€Molecule Oncology Kinase Inhibitor Drugs: A Midâ€2016 Overview. <i>Medicinal Research Reviews</i> , 2017, 37, 314-367.	5.0	65
5555	Adaptive mechanisms of resistance to anti-neoplastic agents. <i>MedChemComm</i> , 2017, 8, 53-66.	3.5	12
5556	Systemic Therapy for Previously Untreated Advanced <i>BRAF</i>-Mutated Melanoma. <i>JAMA Oncology</i> , 2017, 3, 366.	3.4	68
5557	A comprehensive analysis identifies <i>BRAF</i> hotspot mutations associated with gliomas with peculiar epithelial morphology. <i>Neuropathology</i> , 2017, 37, 191-199.	0.7	33

#	ARTICLE	IF	CITATIONS
5558	Senescence-Like Phenotypes in Human Nevi. <i>Methods in Molecular Biology</i> , 2017, 1534, 175-184.	0.4	14
5559	Inverse expression of caveolin-1 and EGFR in thyroid cancer patients. <i>Human Pathology</i> , 2017, 61, 164-172.	1.1	15
5560	Mps1/TTK: a novel target and biomarker for cancer. <i>Journal of Drug Targeting</i> , 2017, 25, 112-118.	2.1	59
5561	Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 580-590.	0.3	2
5562	<i>In vivo</i> and <i>in vitro</i> disease modeling with CRISPR/Cas9. <i>Briefings in Functional Genomics</i> , 2017, 16, 13-24.	1.3	16
5563	Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. <i>Medicinal Research Reviews</i> , 2017, 37, 98-148.	5.0	92
5564	Mortality Risk Stratification by Combining <i>BRAF</i> V600E and <i>TERT</i> Promoter Mutations in Papillary Thyroid Cancer. <i>JAMA Oncology</i> , 2017, 3, 202.	3.4	217
5565	Epidemiology of Melanoma. , 2017, , 591-611.		2
5566	Pathology and Molecular Pathology of Melanoma. , 2017, , 613-653.		1
5567	The Role of Interleukin-1 in Inflammatory and Malignant Human Skin Diseases and the Rationale for Targeting Interleukin-1 Alpha. <i>Medicinal Research Reviews</i> , 2017, 37, 180-216.	5.0	57
5568	Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the <i>BRAF</i> V600E mutation. <i>Hematological Oncology</i> , 2017, 35, 890-893.	0.8	40
5569	Prognostic value of <i>BRAF</i> V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 151-160.	1.2	30
5570	Use of New Techniques in Addition to IHC Applied to the Diagnosis of Melanocytic Lesions, With Emphasis on CGH, FISH, and Mass Spectrometry. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 17-30.	0.2	11
5571	How to unleash mitochondrial apoptotic blockades to kill cancers?. <i>Acta Pharmaceutica Sinica B</i> , 2017, 7, 18-26.	5.7	52
5572	Synthetic Lethality in Cancer Therapeutics. <i>Annual Review of Cancer Biology</i> , 2017, 1, 141-161.	2.3	36
5573	<i>BRAF</i> signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 173, 139-147.	1.2	5
5574	Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. <i>Cancer Letters</i> , 2017, 384, 86-93.	3.2	27
5575	Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2017, 58, 666-675.	0.6	18

#	ARTICLE	IF	CITATIONS
5576	Pre-examination factors affecting molecular diagnostic test results and interpretation: A case-based approach. <i>Clinica Chimica Acta</i> , 2017, 467, 59-69.	0.5	5
5577	Kinase gene fusions in defined subsets of melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 53-62.	1.5	41
5578	Lentigo Maligna Melanoma. , 2017, , .		0
5579	Spitz Nevi and Other Spitzoid Neoplasms in Children: Overview of Incidence Data and Diagnostic Criteria. <i>Pediatric Dermatology</i> , 2017, 34, 25-32.	0.5	47
5580	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. <i>Cancer Research</i> , 2017, 77, 557-565.	0.4	10
5581	Determination of A Novel Selective B-RafV600E Inhibitor (LXK4) in Dog Plasma by HPLC-MS/MS and its Application in a Pharmacokinetic Study. <i>Chromatographia</i> , 2017, 80, 71-76.	0.7	0
5582	Next-Generation Strategies to Target RAF. , 2017, , 175-191.		0
5583	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 2017, 137, 197-206.	0.3	78
5584	Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 54-59.	0.6	10
5585	Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. <i>Human Pathology</i> , 2017, 59, 48-54.	1.1	8
5586	Targeted therapy of brain metastases: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 781-796.	1.4	46
5587	Epigenetic control of pheromone MAPK signaling determines sexual fecundity in <i>Candida albicans</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 13780-13785.	3.3	16
5588	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. <i>British Journal of Cancer</i> , 2017, 117, 1450-1458.	2.9	52
5589	Dabrafenib plus trametinib for compassionate use in metastatic melanoma. <i>Medicine (United States)</i> , 2017, 96, e9523.	0.4	6
5590	MAPK Pathway-Targeted Therapies: Care and Management of Unique Toxicities in Patients With Advanced Melanoma. <i>Clinical Journal of Oncology Nursing</i> , 2017, 21, 699-709.	0.3	15
5592	Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations. <i>Oncology Letters</i> , 2018, 15, 635-641.	0.8	7
5593	Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. <i>BMC Cancer</i> , 2017, 17, 536.	1.1	113
5594	Carnosic acid, an inducer of NAD(P)H quinone oxidoreductase 1, enhances the cytotoxicity of lapachone in melanoma cell lines. <i>Oncology Letters</i> , 2017, 15, 2393-2400.	0.8	10

#	ARTICLE	IF	CITATIONS
5595	Polarity based characterization of biologically active extracts of <i>Ajuga bracteosa</i> Wall. ex Benth. and RP-HPLC analysis. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 443.	3.7	61
5596	Virtual Screening for Dual Hsp90/B-Raf Inhibitors. <i>Methods in Pharmacology and Toxicology</i> , 2017, , 355-365.	0.1	0
5597	Overcoming resistance to BRAF inhibitors. <i>Annals of Translational Medicine</i> , 2017, 5, 387-387.	0.7	109
5598	Photosensitizers Imprinting Intracellular Signaling Pathways in Dermato-Oncology Therapy. , 2017, , .		0
5599	Design and Development of Fluorescent Vemurafenib Analogs for <i>In Vivo</i> Imaging. <i>Theranostics</i> , 2017, 7, 1257-1265.	4.6	16
5600	Mutation Clusters from Cancer Exome. <i>Genes</i> , 2017, 8, 201.	1.0	1
5601	Evolutionary biologic changes of gut microbiota in an "adenoma-carcinoma sequence" mouse colorectal cancer model induced by 1, 2-Dimethylhydrazine. <i>Oncotarget</i> , 2017, 8, 444-457.	0.8	47
5602	Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase. <i>Oncotarget</i> , 2017, 8, 35761-35775.	0.8	23
5603	Cancer Biology and the Principles of Targeted Cancer Drug Discovery. , 2017, , 1-38.		1
5604	Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors. <i>Translational Andrology and Urology</i> , 2017, 6, 848-854.	0.6	12
5605	Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 752.	1.8	86
5606	Differential Expression Profile of lncRNAs from Primary Human Hepatocytes Following DEET and Fipronil Exposure. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2104.	1.8	14
5607	Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies. <i>Molecules</i> , 2017, 22, 542.	1.7	7
5608	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. <i>World Journal of Gastroenterology</i> , 2017, 23, 4675.	1.4	91
5611	Dabrafenib. , 2017, , 505-530.		0
5612	Trametinib. , 2017, , 531-559.		0
5613	Cancer as a Paradigm for Translational and Clinical Biomedical Research. , 2017, , 587-607.		0
5614	Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. <i>Cancers</i> , 2017, 9, 52.	1.7	1,153

#	ARTICLE	IF	CITATIONS
5615	New Frontiers in Melanoma Epigeneticsâ€”The More We Know, the More We Donâ€™t Know. <i>Epigenomes</i> , 2017, 1, 3.	0.8	6
5616	MYC Deregulation in Primary Human Cancers. <i>Genes</i> , 2017, 8, 151.	1.0	281
5617	Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations. <i>International Journal of Molecular Sciences</i> , 2017, 18, 585.	1.8	28
5618	Function and Clinical Implications of Long Non-Coding RNAs in Melanoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 715.	1.8	37
5619	Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1527.	1.8	62
5620	Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1550.	1.8	39
5621	Vemurafenib Limits Influenza A Virus Propagation by Targeting Multiple Signaling Pathways. <i>Frontiers in Microbiology</i> , 2017, 8, 2426.	1.5	23
5622	MicroRNAs in Oncogenesis and Tumor Suppression. <i>International Review of Cell and Molecular Biology</i> , 2017, 333, 229-268.	1.6	44
5623	Are PD-1 antibodies safe for use in metastatic uveal melanoma?. <i>Melanoma Management</i> , 2017, 4, 79-82.	0.1	0
5624	Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Cancer</i> , 2017, 8, 227-239.	1.2	18
5625	BRAF<sup>V600</sup> mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 965-971.	1.0	28
5626	Therapeutic and Prognostic Applications. , 0, , 287-295.		0
5627	Therapy of Melanoma. , 2017, , 91-142.		0
5628	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. <i>Cancer Management and Research</i> , 2017, Volume 9, 433-442.	0.9	15
5629	Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma. <i>Chonnam Medical Journal</i> , 2017, 53, 173.	0.5	15
5630	SOX10 Expression as Well as <i>BRAF</i> and <i>GNAQ/11</i> Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas. , 2017, 58, 5445.		13
5631	c-Myc is Required for BRAF^{V600E}-Induced Epigenetic Silencing by H3K27me3 in Tumorigenesis. <i>Theranostics</i> , 2017, 7, 2092-2107.	4.6	30
5632	MAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma. <i>Oncology Reports</i> , 2017, 38, 1199-1205.	1.2	23

#	ARTICLE	IF	CITATIONS
5633	Inhibition of prenylated KRAS in a lipid environment. PLoS ONE, 2017, 12, e0174706.	1.1	25
5634	Addressing the challenges of applying precision oncology. Npj Precision Oncology, 2017, 1, 28.	2.3	43
5635	Trop2 enhances invasion of thyroid cancer by inducing MMP2 through ERK and JNK pathways. BMC Cancer, 2017, 17, 486.	1.1	52
5636	Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. BMC Cancer, 2017, 17, 649.	1.1	12
5637	microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer. BMC Cancer, 2017, 17, 723.	1.1	28
5638	Ocular toxicity due to Trametinib and Dabrafenib. BMC Ophthalmology, 2017, 17, 146.	0.6	46
5639	A framework to find the logic backbone of a biological network. BMC Systems Biology, 2017, 11, 122.	3.0	32
5640	Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells. Cancer Cell International, 2017, 17, 86.	1.8	28
5641	JMJD6 promotes melanoma carcinogenesis through regulation of the alternative splicing of PAK1, a key MAPK signaling component. Molecular Cancer, 2017, 16, 175.	7.9	61
5642	False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma. World Journal of Surgical Oncology, 2017, 15, 202.	0.8	10
5644	Variation of mutant allele frequency in NRAS Q61 mutated melanomas. BMC Dermatology, 2017, 17, 9.	2.1	19
5645	A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. European Journal of Dermatology, 2017, 27, 482-486.	0.3	10
5646	A case of keratoacanthoma in a patient receiving sorafenib for the treatment of hepatocellular carcinoma, which showed spontaneous disappearance after discontinuing sorafenib. Acta Hepatologica Japonica, 2017, 58, 248-254.	0.0	1
5647	Recent advances in the management of non-small cell lung cancer. F1000Research, 2017, 6, 2110.	0.8	21
5648	Targeted next generation sequencing of mucosal melanomas identifies frequent <i>NF1</i> and <i>RAS</i> mutations. Oncotarget, 2017, 8, 40683-40692.	0.8	69
5649	BRAF mutation in colorectal carcinomas with signet ring cell component. Cancer Biology and Medicine, 2017, 14, 287.	1.4	18
5650	Metastatic Hepatic Angiosarcoma and BRAF Inhibitor Therapy. Journal of Clinical Epigenetics, 2017, 03, .	0.3	0
5651	Racial disparity in metabolic regulation of cancer. Frontiers in Bioscience - Landmark, 2017, 22, 1221-1246.	3.0	5

#	ARTICLE	IF	CITATIONS
5652	Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies. <i>Oncotarget</i> , 2017, 8, 57680-57692.	0.8	62
5653	Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. <i>Oncotarget</i> , 2017, 8, 86356-86368.	0.8	147
5654	Flavonoids: Promising Natural Products for Treatment of Skin Cancer (Melanoma). , 0, , .		5
5655	ERK expression and its correlation with STAT1 in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 45249-45258.	0.8	19
5656	Mutation Clusters from Cancer Exome. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
5657	Management of intracranial melanomas in the era of precision medicine. <i>Oncotarget</i> , 2017, 8, 89326-89347.	0.8	16
5658	Itraconazole exerts its anti-melanoma effect by suppressing Hedgehog, Wnt, and PI3K/mTOR signaling pathways. <i>Oncotarget</i> , 2017, 8, 28510-28525.	0.8	56
5660	^{<sup>} Non-V600</sup><i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2624-2630.	0.8	267
5661	Genomics of Hairy Cell Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 1002-1010.	0.8	64
5662	BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor- κ B. <i>Medical Science Monitor</i> , 2017, 23, 5321-5329.	0.5	11
5663	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
5664	Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	1.5	3
5665	Not All BRAF-Mutant Metastatic Colorectal Cancers Are Identical: Distinct Clinical Consequences of non-V600BRAF Mutations. <i>Journal of Clinical Oncology</i> , 2017, 35, 2598-2599.	0.8	4
5666	Patient-Derived Xenografting of Human Melanoma. , 2017, , 341-363.		0
5667	Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. <i>Oncotarget</i> , 2017, 8, 3980-4000.	0.8	218
5668	Utilizing Tumor and Plasma Liquid Biopsy in Treatment Decision Making for an Estrogen Receptor-Positive Advanced Breast Cancer Patient. <i>Cureus</i> , 2017, 9, e1408.	0.2	10
5669	Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis. <i>Oncotarget</i> , 2017, 8, 6085-6101.	0.8	60
5670	The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 429-445.	1.1	45

#	ARTICLE	IF	CITATIONS
5671	Chronic Kidney Disease as a Complication of Cancer. <i>Journal of Onco-Nephrology</i> , 2017, 1, 74-80.	0.3	2
5672	Primary and acquired resistance to biologic therapies in gastrointestinal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 499-512.	0.6	10
5673	Biology and clinical significance of circulating tumor cell subpopulations in lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 431-443.	1.3	25
5674	Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung. <i>Journal of Thoracic Disease</i> , 2017, 9, E1079-E1083.	0.6	6
5675	Promising therapeutics of gastrointestinal cancers in clinical trials. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 524-533.	0.6	1
5676	Molecular Tests for the Choice of Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2017, 23, 4794-4806.	0.9	10
5677	Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 293-301.	0.6	47
5679	ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway. , 2018, 187, 45-60.		123
5680	Current Insights of BRAF Inhibitors in Cancer. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5775-5793.	2.9	76
5682	Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 281-286.	1.2	8
5683	Novel BRAF mutation in melanoma: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 8, 460-462.	0.4	5
5684	Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002618.	0.5	7
5685	Prediction of Human Pharmacokinetics of Ulixertinib, a Novel ERK1/2 Inhibitor from Mice, Rats, and Dogs Pharmacokinetics. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 453-460.	0.6	6
5686	Identification of 4-arylamino-2,3-pyridine derivatives for the development of new BRAF inhibitors. <i>Chemical Biology and Drug Design</i> , 2018, 92, 1382-1386.	1.5	3
5687	Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy. <i>Melanoma Research</i> , 2018, 28, 195-203.	0.6	17
5688	Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2018, 43, 373-382.	0.6	8
5689	High-throughput sequencing of nodal marginal zone lymphomas identifies recurrent BRAF mutations. <i>Leukemia</i> , 2018, 32, 2412-2426.	3.3	53
5690	ERK5 is activated by oncogenic BRAF and promotes melanoma growth. <i>Oncogene</i> , 2018, 37, 2601-2614.	2.6	50

#	ARTICLE	IF	CITATIONS
5691	BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. <i>Drugs</i> , 2018, 78, 549-566.	4.9	95
5692	Mutations in the signal transducer and activator of transcription family of genes in cancer. <i>Cancer Science</i> , 2018, 109, 926-933.	1.7	69
5693	Ophthalmic Findings of Rosai-Dorfman Disease. <i>American Journal of Ophthalmology</i> , 2018, 188, 164-172.	1.7	21
5694	Tyrosine Kinase Receptor Signaling in Prostate Cancer. <i>Molecular Pathology Library</i> , 2018, , 419-437.	0.1	0
5695	Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 999-1005.	1.1	56
5696	Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours. <i>Clinical Nuclear Medicine</i> , 2018, 43, 333-334.	0.7	1
5697	Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining. <i>Cellular Oncology (Dordrecht)</i> , 2018, 41, 395-408.	2.1	7
5698	Targeted-gene silencing of BRAF to interrupt BRAF/MEK/ERK pathway synergized photothermal therapeutics for melanoma using a novel FA-CNR-siBRAF nanosystem. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1679-1693.	1.7	16
5699	Regulation of cellular senescence via the FOXO-p53 axis. <i>FEBS Letters</i> , 2018, 592, 2083-2097.	1.3	73
5700	Colon cancers carrying BRAF V600E and β -catenin T41A activating mutations are resistant to numerous common anticancer drugs. <i>Oncology Letters</i> , 2018, 15, 4471-4476.	0.8	2
5701	DNA mismatch repair in cancer. , 2018, 189, 45-62.		356
5702	Concurrent BRAF/MEK Inhibitors in BRAF V600E Mutant High-Grade Primary Brain Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 343-347.	2.3	46
5703	Melanoma: What do all the mutations mean?. <i>Cancer</i> , 2018, 124, 3490-3499.	2.0	131
5704	RAF, MEK and ERK Inhibitors as Anti-Cancer Drugs: Intrinsic and Acquired Resistance as a Major Therapeutic Challenge. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 89-116.	0.1	1
5705	The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma. <i>Targeted Oncology</i> , 2018, 13, 437-446.	1.7	27
5706	Mutation analysis of adenomas and carcinomas of the colon: Early and late drivers. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 366-376.	1.5	50
5707	Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-RafV600E and VEGFR-2. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2381-2391.	1.4	13
5708	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3059-3068.	3.2	366

#	ARTICLE	IF	CITATIONS
5709	Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1775-1781.	0.7	30
5710	Reconstructing the molecular life history of gliomas. <i>Acta Neuropathologica</i> , 2018, 135, 649-670.	3.9	61
5711	Design, synthesis, and biological evaluation of new B-RafV600E kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2372-2380.	1.4	11
5712	Obstacles to improving outcomes in the treatment of uveal melanoma. <i>Cancer</i> , 2018, 124, 2693-2703.	2.0	15
5713	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. <i>Cell Reports</i> , 2018, 23, 172-180.e3.	2.9	119
5714	EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines. <i>Oncology Letters</i> , 2018, 15, 6763-6769.	0.8	5
5715	<i>BRAF</i> Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1332-1340.	1.9	21
5716	Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. <i>Endocrine Reviews</i> , 2018, 39, 154-191.	8.9	45
5717	Heat shock protein 90 inhibitor enhances apoptosis by inhibiting the AKT pathway in thermal-stimulated SK-MEL-2 human melanoma cell line. <i>Journal of Dermatological Science</i> , 2018, 90, 357-360.	1.0	14
5718	An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib. <i>Journal of Thoracic Oncology</i> , 2018, 13, e131-e133.	0.5	30
5719	Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases. <i>Drug Metabolism and Disposition</i> , 2018, 46, 658-666.	1.7	24
5720	FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring <i>BRAF V600E</i> Mutations. <i>Oncologist</i> , 2018, 23, 740-745.	1.9	168
5721	Prognostic Role of BRAFV600E Cellular Localization in Melanoma. <i>Journal of the American College of Surgeons</i> , 2018, 226, 526-537.	0.2	17
5722	Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF V600E</i> -Mutant Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 428-443.	7.7	448
5723	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2020, 2020, CD011123.	1.5	136
5724	Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in <i>BRAF V600E</i> Colorectal Cancer. <i>Cancer Discovery</i> , 2018, 8, 417-427.	7.7	61
5725	Overview of metastatic disease of the central nervous system. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2018, 149, 3-23.	1.0	28
5726	Leptomeningeal metastasis. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2018, 149, 169-204.	1.0	55

#	ARTICLE	IF	CITATIONS
5727	Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 149-161.	2.0	50
5728	RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma. <i>Cancer Research</i> , 2018, 78, 2191-2204.	0.4	47
5729	Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma. <i>ACS Nano</i> , 2018, 12, 1250-1261.	7.3	76
5730	Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. <i>Cell Death and Disease</i> , 2018, 9, 112.	2.7	94
5731	Inducibly decreased MITF levels do not affect proliferation and phenotype switching but reduce differentiation of melanoma cells. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 2240-2251.	1.6	18
5732	Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAF ^{V600E} inhibitors. <i>Molecular Carcinogenesis</i> , 2018, 57, 678-683.	1.3	26
5733	Ultraviolet light and melanoma. <i>Journal of Pathology</i> , 2018, 244, 578-585.	2.1	47
5734	Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. <i>Oncogene</i> , 2018, 37, 2181-2196.	2.6	24
5735	T-type calcium channels drive migration/invasion in BRAF ^{V600E} melanoma cells through Snail1. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 484-495.	1.5	23
5736	Palladium-catalysed stereoselective synthesis of 4-(diarylmethylidene)-3,4-dihydroisoquinolin-1(2 <i>H</i>)-ones: expedient access to 4-substituted isoquinolin-1(2 <i>H</i>)-ones and isoquinolines. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 963-980.	1.5	16
5737	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47.	0.1	3
5738	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577.	2.1	15
5739	Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer. <i>Nature Communications</i> , 2018, 9, 579.	5.8	140
5740	Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment. <i>Molecular and Cellular Biochemistry</i> , 2018, 447, 77-92.	1.4	27
5741	Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations—Chances and Challenges. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 529-541.	3.3	11
5742	Marked functional recovery and imaging response of refractory optic pathway glioma to BRAFV600E inhibitor therapy: a report of two cases. <i>Child's Nervous System</i> , 2018, 34, 605-610.	0.6	12
5743	Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis. <i>Cell and Tissue Research</i> , 2018, 372, 379-392.	1.5	16
5745	Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. <i>Oncogene</i> , 2018, 37, 1775-1787.	2.6	28

#	ARTICLE	IF	CITATIONS
5746	Dual suppression of inner and outer mitochondrial membrane functions augments apoptotic responses to oncogenic MAPK inhibition. <i>Cell Death and Disease</i> , 2018, 9, 29.	2.7	21
5747	miFAST: A novel and rapid microRNA target capture method. <i>Molecular Carcinogenesis</i> , 2018, 57, 559-566.	1.3	6
5748	Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma. <i>Melanoma Research</i> , 2018, 28, 126-133.	0.6	31
5749	The ESCRT protein Chmp4c regulates mitotic spindle checkpoint signaling. <i>Journal of Cell Biology</i> , 2018, 217, 861-876.	2.3	23
5750	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018, 8, 184-195.	7.7	283
5751	The biology and therapeutic management of melanoma brain metastases. <i>Biochemical Pharmacology</i> , 2018, 153, 35-45.	2.0	12
5752	PanCancer insights from The Cancer Genome Atlas: the pathologist's perspective. <i>Journal of Pathology</i> , 2018, 244, 512-524.	2.1	144
5753	Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. <i>Melanoma Research</i> , 2018, 28, 96-104.	0.6	41
5754	Discovery of EBI-1051: A novel and orally efficacious MEK inhibitor with benzofuran scaffold. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 581-589.	1.4	15
5755	Are redheads at an increased risk of melanoma?. <i>Future Oncology</i> , 2018, 14, 413-416.	1.1	2
5756	RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells. <i>Scientific Reports</i> , 2018, 8, 653.	1.6	13
5757	Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 3-16.	1.9	81
5758	Comparison of <i>Xiphophorus</i> and human melanoma transcriptomes reveals conserved pathway interactions. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 496-508.	1.5	21
5759	DNA terminal structure-mediated enzymatic reaction for ultra-sensitive discrimination of single nucleotide variations in circulating cell-free DNA. <i>Nucleic Acids Research</i> , 2018, 46, e24-e24.	6.5	28
5760	Recent advances in intradural spinal tumors. <i>Neuro-Oncology</i> , 2018, 20, 729-742.	0.6	36
5761	Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 240-252.	1.2	32
5762	Overexpression of sprouty2 in human oral squamous cell carcinogenesis. <i>Archives of Oral Biology</i> , 2018, 87, 131-142.	0.8	6
5763	Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma. <i>BMC Systems Biology</i> , 2018, 12, 33.	3.0	25

#	ARTICLE	IF	CITATIONS
5764	Neoadjuvant treatment for malignant and metastatic cutaneous melanoma. The Cochrane Library, 0, , .	1.5	4
5766	Genetics of metastasis: melanoma and other cancers. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 379-391.	1.7	73
5767	<i>N</i>-((7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5034-5046.	2.9	7
5768	BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. <i>Cancer Treatment Reviews</i> , 2018, 66, 82-94.	3.4	112
5769	BRAF-mutant colorectal cancer, a different breed evolving. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 499-512.	1.5	19
5770	Modification, Biological Evaluation and <sc>SAR</sc> Studies of Novel 1<i>H</i>-Pyrazol Derivatives Containing <i>N</i>-Disubstituted Urea Moiety as Potential Anti-melanoma Agents. <i>Chemistry and Biodiversity</i> , 2018, 15, e1700504.	1.0	5
5772	Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. <i>Neoplasia</i> , 2018, 20, 467-477.	2.3	13
5773	Cutaneous melanoma: From pathogenesis to therapy (Review). <i>International Journal of Oncology</i> , 2018, 52, 1071-1080.	1.4	281
5774	Controlling the masterâ€™ upstream regulation of the tumor suppressor LKB1. <i>Oncogene</i> , 2018, 37, 3045-3057.	2.6	48
5775	Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. <i>Oncogene</i> , 2018, 37, 3183-3199.	2.6	317
5776	Aberrations and clinical significance of BRAF in malignant melanoma. <i>Medicine (United States)</i> , 2018, 97, e9509.	0.4	15
5777	Photoreceptors Take Charge: Emerging Principles for Light Sensing. <i>Annual Review of Biophysics</i> , 2018, 47, 291-313.	4.5	65
5778	The mechanism of the adsorption of dsDNA on citrate-stabilized gold nanoparticles and a colorimetric and visual method for detecting the V600E point mutation of the BRAF gene. <i>Mikrochimica Acta</i> , 2018, 185, 240.	2.5	7
5779	Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 84-88.	2.0	38
5780	Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation. <i>European Radiology</i> , 2018, 28, 3751-3759.	2.3	24
5781	NF1 mutations in conjunctival melanoma. <i>British Journal of Cancer</i> , 2018, 118, 1243-1247.	2.9	59
5782	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
5783	Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes. <i>Advances in Cancer Research</i> , 2018, 138, 99-142.	1.9	136

#	ARTICLE	IF	CITATIONS
5784	AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. <i>Oncogene</i> , 2018, 37, 3275-3289.	2.6	82
5785	BRAF and EGFR inhibitors synergize to increase cytotoxic effects and decrease stem cell capacities in BRAF(V600E)-mutant colorectal cancer cells. <i>Acta Biochimica Et Biophysica Sinica</i> , 2018, 50, 355-361.	0.9	14
5786	Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 212-219.	0.6	3
5787	Modified Nanoantibodies Increase Sensitivity in Avidin-Biotin Immunohistochemistry. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 682-688.	0.6	2
5788	Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 374-382.	0.6	8
5789	Detection of Loss of Heterozygosity (LOH) Using Circulating Cell-free DNA (cfDNA) by Fluorescence-based Multiplex PCR for Identification of Patients With Prostate Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 749-759.	0.6	2
5790	The Role of SATB2 as a Diagnostic Marker of Sinonasal Intestinal-type Adenocarcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 140-146.	0.6	24
5791	The therapeutic potential of targeting the BRAF mutation in patients with colorectal cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 2162-2169.	2.0	49
5792	An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 611-619.	0.6	22
5793	Ectopic Thyroid Tissue: Immunohistochemistry and Molecular Analysis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 734-739.	0.6	11
5794	Comparative Analysis of Multicolor Flow Cytometry and Immunohistochemistry for the Detection of Disseminated Tumor Cells. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 305-315.	0.6	12
5795	Immunoreactivity of a Monoclonal Antibody to SS18-SSX Fusion Gene Product in Formalin-fixed Paraffin-embedded Synovial Sarcoma Tissue Section. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 206-211.	0.6	2
5796	The Stem Cell-associated Transcription Factor SOX2 as a Diagnostic Marker of High-grade Squamous Intraepithelial Lesion of the Uterine Cervix in Comparison With p16 and Ki-67. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 403-410.	0.6	1
5797	CD44 Immunoexpression is Unfavorable Predictor in Ovarian Serous Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 398-402.	0.6	13
5798	Combination therapy of BRAF inhibitors for advanced melanoma with <i>BRAF</i> V600 mutation: a systematic review and meta-analysis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 314-321.	1.1	11
5799	Mitotic Index Determined by Phosphohistone H3 Immunohistochemistry for Precise Grading in Follicular Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 579-585.	0.6	8
5800	A Brief Report of Immunohistochemical Markers to Identify Aggressive Hepatoblastoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 654-657.	0.6	7
5801	Napsin-A, a Possible Diagnostic Marker for Differentiating Clear Cell Ovarian Carcinoma From Other High-grade Ovarian Carcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 605-610.	0.6	5

#	ARTICLE	IF	CITATIONS
5802	Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 246-253.	0.6	9
5803	Fading With Time of PD-L1 Immunoreactivity in Non-“Small Cells Lung Cancer Tissues: A Methodological Study. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 489-494.	0.6	38
5804	The Usefulness of Phospholipase A2 Receptor and IgG4 Detection in Differentiation Primary Membranous Nephropathy From Secondary Membranous Nephropathy in Renal Biopsy. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 591-598.	0.6	11
5805	Paired Box 5 (PAX5) Expression in Poorly Differentiated Neuroendocrine Carcinoma of the Gastrointestinal and Pancreatobiliary Tract: Diagnostic and Potentially Therapeutic Implications. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 545-551.	0.6	8
5806	Gastrointestinal Stromal Tumor: Genotype Frequency and Prognostic Relevance. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 153-160.	0.6	6
5807	A Diagnostic Algorithm Combining Immunohistochemistry and Molecular Cytogenetics to Diagnose Challenging Melanocytic Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 714-720.	0.6	17
5808	Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1-6.	1.6	29
5809	Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 408-419.	1.2	70
5810	Genetic study of the <i>BRAF</i> gene reveals new variants and high frequency of the V600E mutation among Iranian ameloblastoma patients. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 86-90.	1.4	23
5811	The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, 658-663.	0.6	6
5812	Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors. <i>Oncology</i> , 2018, 7, e1392426.	2.1	49
5813	Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2018, 17, e69-e76.	1.0	44
5814	The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 73-87.	1.0	32
5815	Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma. <i>Journal of the National Cancer Institute</i> , 2018, 110, 290-303.	3.0	32
5816	RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. <i>Oncogene</i> , 2018, 37, 821-832.	2.6	55
5817	Copper signaling in the brain and beyond. <i>Journal of Biological Chemistry</i> , 2018, 293, 4628-4635.	1.6	121
5818	Synthesis, anti-lung cancer activity and molecular docking study of 3-methylene-2-oxoindoline-5-carboxamide derivatives. <i>Medicinal Chemistry Research</i> , 2018, 27, 161-170.	1.1	7
5819	Genomic Hallmarks of Thyroid Neoplasia. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 141-162.	9.6	50

#	ARTICLE	IF	CITATIONS
5820	Dual or multi-targeting inhibitors: The next generation anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 1277-1300.	2.6	182
5821	No Tissue Expression of KRAS or BRAF Mutations in 61 Adult Patients Treated for Esophageal Atresia in Early Childhood. <i>European Journal of Pediatric Surgery</i> , 2018, 28, 413-419.	0.7	1
5822	Frequent PD-L1 Expression in Malignant Melanomas of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 477-481.	0.9	10
5823	miR-216b enhances the efficacy of vemurafenib by targeting Beclin-1, UVRAG and ATG5 in melanoma. <i>Cellular Signalling</i> , 2018, 42, 30-43.	1.7	25
5824	Frequent <i>BRAF</i> mutations suggest a novel oncogenic driver in colonic neuroendocrine carcinoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 284-289.	0.8	21
5825	NADPH Oxidases and Their Roles in Skin Homeostasis and Carcinogenesis. <i>Antioxidants and Redox Signaling</i> , 2018, 28, 1238-1261.	2.5	16
5826	Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 181-193.	3.3	18
5827	Impact of Metastasectomy in the Multimodality Approach for <i>BRAF</i> V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , 2018, 23, 128-134.	1.9	34
5828	Associations of alcohol intake, smoking, physical activity and obesity with survival following colorectal cancer diagnosis by stage, anatomic site and tumor molecular subtype. <i>International Journal of Cancer</i> , 2018, 142, 238-250.	2.3	83
5829	Targeted drug delivery to melanoma. <i>Advanced Drug Delivery Reviews</i> , 2018, 127, 208-221.	6.6	99
5830	Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study. <i>Investigational New Drugs</i> , 2018, 36, 259-268.	1.2	8
5831	Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma. <i>Pathology Research and Practice</i> , 2018, 214, 303-307.	1.0	16
5832	Efforts to Develop KRAS Inhibitors. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a031864.	2.9	27
5833	Neurological update: gliomas and other primary brain tumours in adults. <i>Journal of Neurology</i> , 2018, 265, 717-727.	1.8	24
5834	Imbalance in DNA repair machinery is associated with BRAF V600E mutation and tumor aggressiveness in papillary thyroid carcinoma. <i>Molecular and Cellular Endocrinology</i> , 2018, 472, 140-148.	1.6	10
5835	Medical bioinformatics in melanoma. <i>Current Opinion in Oncology</i> , 2018, 30, 113-117.	1.1	13
5836	BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report. <i>Melanoma Research</i> , 2018, 28, 143-146.	0.6	4
5837	Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. <i>British Journal of Cancer</i> , 2018, 118, 495-508.	2.9	47

#	ARTICLE	IF	CITATIONS
5838	Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 378-389.	1.5	99
5839	Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2018, 56, 122-126.	0.3	6
5840	Molecular Markers and Mutational Analysis. , 2018, , 295-312.		1
5841	HDAC inhibitors restore BRAF inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. <i>International Journal of Cancer</i> , 2018, 142, 1926-1937.	2.3	48
5842	Melanoma brain metastases harboring BRAF V600K or NRAS mutations are associated with an increased local failure rate following conventional therapy. <i>Journal of Neuro-Oncology</i> , 2018, 137, 67-75.	1.4	17
5843	BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 299-310.	2.0	48
5844	Why target the tumor stroma in melanoma?. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 113-118.	1.8	22
5845	Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. <i>Modern Pathology</i> , 2018, 31, 24-38.	2.9	324
5846	Biology and Genomics of LCH and Related Disorders. , 2018, , 53-71.		2
5847	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 303-317.	3.3	78
5848	Wnt/ β -Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 806-813.	1.9	79
5849	Animal Models of Melanoma. , 2018, , 1-31.		3
5850	Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases. <i>Histopathology</i> , 2018, 72, 814-825.	1.6	10
5851	Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas <i>In Vivo</i> and <i>Ex Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2018, 17, 84-95.	1.9	22
5852	Cytotoxicity mechanisms in melanoma cells and UPLC-QTOF/MS2 chemical characterization of two Brazilian stingless bee propolis: Uncommon presence of piperidinic alkaloids. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 149, 502-511.	1.4	37
5853	Association of single nucleotide polymorphism of melanocortin gene with feed intake in rabbit (<i>Oryctolagus cuniculus</i>). <i>Journal of Animal Physiology and Animal Nutrition</i> , 2018, 102, 564-567.	1.0	5
5854	Trajectories of premalignancy during the journey from melanocyte to melanoma. <i>Pathology</i> , 2018, 50, 16-23.	0.3	23
5855	Rae1-mediated nuclear export of Rnc1 is an important determinant in controlling MAPK signaling. <i>Current Genetics</i> , 2018, 64, 103-108.	0.8	10

#	ARTICLE	IF	CITATIONS
5856	Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma. <i>Melanoma Research</i> , 2018, 28, 390-397.	0.6	6
5857	<i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	1.5	24
5858	Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic <i>BRAF</i> . <i>JCO Precision Oncology</i> , 2018, 2018, 1-7.	1.5	7
5859	Contemporary Approaches to In-Transit Melanoma. <i>Journal of Oncology Practice</i> , 2018, 14, 292-300.	2.5	25
5860	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With <i>BRAF</i> -Mutated Malignancies. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	13
5861	Large-Cell Neuroendocrine Carcinoma of the Lung: A Focused Analysis of <i>BRAF</i> Alterations and Case Report of a <i>BRAF</i> Non-V600E Mutated Tumor Responding to Targeted Therapy. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	6
5862	Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma. <i>Journal of Global Oncology</i> , 2018, 4, 1-5.	0.5	2
5864	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	0.9	1
5866	Functional interaction-based nonlinear models with application to multiplatform genomics data. <i>Statistics in Medicine</i> , 2018, 37, 2715-2733.	0.8	0
5867	The Smallest Reported Malignant Struma Ovarii: A Case Report. <i>Case Reports in Oncology</i> , 2018, 11, 693-698.	0.3	4
5868	Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma. <i>Melanoma Management</i> , 2018, 5, MMT08.	0.1	2
5869	The growing role of precision and personalized medicine for cancer treatment. <i>Technology</i> , 2018, 06, 79-100.	1.4	237
5870	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. <i>Scientifica</i> , 2018, 2018, 1-7.	0.6	14
5871	Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 648-651.	0.6	23
5872	Exploring the efficacy and cellular uptake of sorafenib in colon cancer cells by Raman micro-spectroscopy. <i>Analyst</i> , The, 2018, 143, 6069-6078.	1.7	13
5873	JTC-801 Suppresses Melanoma Cells Growth through the PI3K/Akt/mTOR Signaling Pathways. <i>Medicine/Sciences</i> , 2018, 34, 8-14.	0.0	2
5874	BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor- κ B, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia. <i>Medical Science Monitor</i> , 2018, 24, 6795-6808.	0.5	12
5875	MicroRNA-143-3p suppresses cell growth and invasion in laryngeal squamous cell carcinoma via targeting the Ras/Raf/MEK/ERK signaling pathway. <i>International Journal of Oncology</i> , 2018, 54, 689-701.	1.4	12

#	ARTICLE	IF	CITATIONS
5876	Relation between RASSF1A Methylation and BRAF Mutation in Thyroid Tumor. <i>International Journal of Thyroidology</i> , 2018, 11, 123.	0.1	1
5878	Novel PDE10A-BRAF Fusion With Concomitant NF1 Mutation Identified in an Undifferentiated Sarcoma of Infancy With Sustained Response to Trametinib. <i>JCO Precision Oncology</i> , 2018, 2, 1-13.	1.5	3
5879	Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision Oncology. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	10
5880	Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies. <i>JCO Precision Oncology</i> , 2018, 2, 1-19.	1.5	2
5881	Risk factors for brain metastases in patients with non-small cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 6357-6364.	1.3	37
5882	Counteracting Resistance to BRAF V600E Mutation in Melanoma Using Dietary Polyphenols. , 2018, , 185-193.		0
5883	Microneedle-Assisted Topical Delivery of Photodynamically Active Mesoporous Formulation for Combination Therapy of Deep-Seated Melanoma. <i>ACS Nano</i> , 2018, 12, 11936-11948.	7.3	121
5884	Patients with Non-Small-Cell Lung Cancer Harboring a BRAF Mutation: A Multicentre Study Exploring Clinical Characteristics, Management, and Outcomes in a Real-Life Setting: EXPLORE GFPC 02-14. <i>Current Oncology</i> , 2018, 25, 398-402.	0.9	9
5885	Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study. <i>Neoplasia</i> , 2018, 20, 1219-1226.	2.3	21
5886	The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. <i>Oncotarget</i> , 2018, 9, 35226-35240.	0.8	59
5887	Single nucleotide polymorphisms alter kinase anchoring and the subcellular targeting of A-kinase anchoring proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11465-E11474.	3.3	41
5888	Aberrant RNA Splicing in Cancer and Drug Resistance. <i>Cancers</i> , 2018, 10, 458.	1.7	145
5889	Ultraviolet Radiation as a Carcinogen†. , 2018, , 168-182.		0
5890	A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor vixtalisib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 119, 1471-1476.	2.9	74
5891	Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses. <i>Oncolmmunology</i> , 2018, 7, e1500671.	2.1	31
5892	Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. <i>Nature Communications</i> , 2018, 9, 4775.	5.8	70
5893	Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population. <i>Turkish Journal of Medical Sciences</i> , 2018, 48, 973-979.	0.4	3
5894	Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network. <i>Cancer Investigation</i> , 2018, 36, 520-536.	0.6	17

#	ARTICLE	IF	CITATIONS
5895	Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. <i>PLoS ONE</i> , 2018, 13, e0206942.	1.1	35
5896	BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association. <i>Cell Reports</i> , 2018, 25, 1501-1510.e3.	2.9	34
5897	Real-time Simulation Realization of Modular Multilevel Converter Based on FPGA. , 2018, , .		1
5898	Targeting Colon Cancers with Mutated BRAF and Microsatellite Instability. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1110, 7-21.	0.8	6
5899	Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. <i>Clinics</i> , 2018, 73, e479s.	0.6	7
5900	Genomic Landscape of Spitzoid Neoplasms Impacting Patient Management. <i>Frontiers in Medicine</i> , 2018, 5, 344.	1.2	18
5901	Nile Tilapia Derived TP4 Shows Broad Cytotoxicity Toward to Non-Small-Cell Lung Cancer Cells. <i>Marine Drugs</i> , 2018, 16, 506.	2.2	17
5902	Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK. <i>Heliyon</i> , 2018, 4, e01065.	1.4	1
5903	How the <i>BRAF</i> V600E Mutation Defines a Distinct Subgroup of Colorectal Cancer: Molecular and Clinical Implications. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-14.	0.7	34
5904	Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9081-9089.	1.0	41
5905	Quaternized chitosan promotes the antiproliferative effect of vemurafenib in melanoma cells by increasing cell permeability. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8293-8299.	1.0	6
5906	The Power of Fish Models to Elucidate Skin Cancer Pathogenesis and Impact the Discovery of New Therapeutic Opportunities. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3929.	1.8	14
5907	Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report. <i>Head and Neck</i> , 2018, 41, E26-E29.	0.9	0
5908	The potential functions of FAM46C in oral squamous cell carcinoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 8915-8923.	1.0	7
5909	Oleuropein, the Main Polyphenol of <i>Olea europaea</i> Leaf Extract, Has an Anti-Cancer Effect on Human BRAF Melanoma Cells and Potentiates the Cytotoxicity of Current Chemotherapies. <i>Nutrients</i> , 2018, 10, 1950.	1.7	79
5910	CBNPC et autres cibles thérapeutiques (BRAF, HER2, MET, RET, NTRK...). <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, 446-453.	0.0	0
5911	The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma. <i>Melanoma Research</i> , 2018, 28, 521-526.	0.6	13
5912	Role of Photodynamic Therapy in Cancer Treatment. , 2018, , 159-177.		0

#	ARTICLE	IF	CITATIONS
5913	Runs of homozygosity associate with decreased risks of lung cancer in never-smoking East Asian females. <i>Journal of Cancer</i> , 2018, 9, 3858-3866.	1.2	1
5914	Characterization of PI3KCA and BRAF mutations in gastric adenocarcinoma: An approach to a personalized targeted therapy for Moroccan HER2 overexpressed patients. <i>Arab Journal of Gastroenterology</i> , 2018, 19, 155-158.	0.4	1
5915	Lower Urinary Tract Neoplasia. <i>Veterinary Sciences</i> , 2018, 5, 96.	0.6	22
5916	BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies (Review). <i>Oncology Reports</i> , 2018, 40, 3-15.	1.2	57
5917	Favorable Outcome With Pemetrexed Treatment for Advanced BRAF-V600E-Positive Lung Adenocarcinoma in a Patient Followed up Over 8 Years. <i>Journal of Thoracic Oncology</i> , 2018, 13, e199-e202.	0.5	7
5918	Braf v600 mutation profile of metastatic melanoma in the thrace region of turkey. <i>Turk Patoloji Dergisi</i> , 2018, , .	0.1	1
5919	Bayesian variable selection with graphical structure learning: Applications in integrative genomics. <i>PLoS ONE</i> , 2018, 13, e0195070.	1.1	7
5920	Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10058-10063.	3.3	17
5921	Suppression of CCT3 inhibits malignant proliferation of human papillary thyroid carcinoma cell. <i>Oncology Letters</i> , 2018, 15, 9202-9208.	0.8	21
5922	The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 234.	3.5	72
5923	The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. <i>Neoplasia</i> , 2018, 20, 1121-1134.	2.3	32
5924	A novel RFLP-ARMS TaqMan PCR-based method for detecting the BRAF V600E mutation in melanoma. <i>Oncology Letters</i> , 2018, 16, 1615-1621.	0.8	6
5925	EGFR and FGFR in Growth and Metastasis of Colorectal Cancer. , 2018, , 141-170.		1
5926	A Novel Naphthyridine Derivative, 3u, Induces Necroptosis at Low Concentrations and Apoptosis at High Concentrations in Human Melanoma A375 Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2975.	1.8	22
5927	A Small Molecule Targeting the Transmembrane Domain of Death Receptor p75NTR Induces Melanoma Cell Death and Reduces Tumor Growth. <i>Cell Chemical Biology</i> , 2018, 25, 1485-1494.e5.	2.5	20
5928	T-blocker: a simple and robust probe-free quantitative PCR assay to detect somatic mutations down to 0.1% frequency. <i>BioTechniques</i> , 2018, 65, 205-210.	0.8	3
5929	The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe. <i>Current Oncology Reports</i> , 2018, 20, 87.	1.8	119
5930	Machine Learning Classification and Structure-Functional Analysis of Cancer Mutations Reveal Unique Dynamic and Network Signatures of Driver Sites in Oncogenes and Tumor Suppressor Genes. <i>Journal of Chemical Information and Modeling</i> , 2018, 58, 2131-2150.	2.5	20

#	ARTICLE	IF	CITATIONS
5931	NCI 8628: A randomized phase 2 study of zivâ€œaffibercept and highâ€œdose interleukin 2 or highâ€œdose interleukin 2 alone for inoperable stage III or IV melanoma. <i>Cancer</i> , 2018, 124, 4332-4341.	2.0	15
5932	LOH12CR1 is a Novel Tumor Suppressor Inhibiting Tumor Growth Through Deregulation of G1/S Checkpoint in Human Colorectal Carcinoma. <i>Current Molecular Medicine</i> , 2018, 18, 25-35.	0.6	1
5933	Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. <i>Nature Communications</i> , 2018, 9, 4490.	5.8	135
5934	Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7095-7107.	1.0	187
5935	Comparative Gene Expression Analysis in WM164 Melanoma Cells Revealed That Î²-Î²-Dimethylacrylshikonin Leads to ROS Generation, Loss of Mitochondrial Membrane Potential, and Autophagy Induction. <i>Molecules</i> , 2018, 23, 2823.	1.7	17
5936	Targeted nextâ€œgeneration sequencing of cancerâ€œrelated genes in thyroid carcinoma: A single institution's experience. <i>Oncology Letters</i> , 2018, 16, 7278-7286.	0.8	17
5937	Development of ultra-short PCR assay to reveal BRAF V600 mutation status in Thai colorectal cancer tissues. <i>PLoS ONE</i> , 2018, 13, e0198795.	1.1	7
5938	Prognostic value of the combination of microsatellite instability and <i>BRAF</i> mutation in colorectal cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 3911-3929.	0.9	22
5939	Tumor Type-Agnostic Treatment and the Future of Cancer Therapy. <i>Targeted Oncology</i> , 2018, 13, 541-544.	1.7	7
5940	Sensitivity and Usefulness of VE1 Immunohistochemical Staining in Acral Melanomas with <i>BRAF</i> Mutation. <i>Annals of Dermatology</i> , 2018, 30, 556.	0.3	4
5941	Fast Dynamic in vivo Monitoring of Erk Activity at Single Cell Resolution in DREKA Zebrafish. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 111.	1.8	33
5942	From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1092, 113-138.	0.8	19
5943	Human tumor genomics and zebrafish modeling identify <i>SPRED1</i> loss as a driver of mucosal melanoma. <i>Science</i> , 2018, 362, 1055-1060.	6.0	123
5944	Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells. <i>Thyroid Research</i> , 2018, 11, 13.	0.7	21
5945	Targeted Therapy in Advanced Melanoma. , 2018, , 1-20.		0
5946	The association between rs16917496 T/C polymorphism of <i>SET8</i> gene and cancer risk in Asian populations: a meta-analysis. <i>Bioscience Reports</i> , 2018, 38, .	1.1	6
5947	Discovery of 2-(aminopyrimidin-5-yl)-4-(morpholin-4-yl)-6- substituted triazine as PI3K and BRAF dual inhibitor. <i>Future Medicinal Chemistry</i> , 2018, 10, 2445-2455.	1.1	7
5948	Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation. <i>BMC Cancer</i> , 2018, 18, 887.	1.1	48

#	ARTICLE	IF	CITATIONS
5949	Preclinical studies reveal that <scp>LSD</scp>1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations. <i>Molecular Oncology</i> , 2018, 12, 1965-1979.	2.1	26
5950	Cancer driver mutations in endometriosis: Variations on the major theme of fibrogenesis. <i>Reproductive Medicine and Biology</i> , 2018, 17, 369-397.	1.0	35
5951	A machine learning approach for somatic mutation discovery. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	80
5952	Structural insights and influence of V599 mutations on the overall dynamics of <i>BRAF</i> protein against its kinase domains. <i>Integrative Biology (United Kingdom)</i> , 2018, 10, 646-657.	0.6	10
5953	Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells. <i>Frontiers in Oncology</i> , 2018, 8, 328.	1.3	12
5954	Acquisition of resistance to vemurafenib leads to interleukinâ€10 production through an aberrant activation of Akt in a melanoma cell line. <i>Journal of Dermatology</i> , 2018, 45, 1434-1439.	0.6	3
5955	BRAFV600e mutation combined with thyroglobulin and fine-needle aspiration in diagnosis of lymph node metastasis of papillary thyroid carcinoma. <i>Pathology Research and Practice</i> , 2018, 214, 1892-1897.	1.0	8
5956	Dabrafenib and trametinib for the treatment of non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1063-1068.	1.1	17
5957	Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1315-1327.	5.1	469
5958	Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. <i>Scientific Reports</i> , 2018, 8, 13522.	1.6	11
5959	Molecular Diagnostics in Clinical Oncology. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 76.	1.6	93
5960	MC1R: Front and Center in the Bright Side of Dark Eumelanin and DNA Repair. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2667.	1.8	70
5961	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , 2018, 14, e1007589.	1.5	56
5962	Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents. <i>European Journal of Medicinal Chemistry</i> , 2018, 158, 144-166.	2.6	31
5963	Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A. <i>Cancer Genomics and Proteomics</i> , 2018, 15, 349-364.	1.0	22
5964	MEK inhibitors for the treatment of NRAS mutant melanoma. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2553-2565.	2.0	37
5965	Report from the 19th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29â€30 September 2017. <i>Current Oncology</i> , 2018, 25, 275-284.	0.9	3
5966	Polyamine metabolism and cancer: treatments, challenges andÂopportunities. <i>Nature Reviews Cancer</i> , 2018, 18, 681-695.	12.8	468

#	ARTICLE	IF	CITATIONS
5967	Langerhans-Cell Histiocytosis. <i>New England Journal of Medicine</i> , 2018, 379, 856-868.	13.9	336
5968	Cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy. <i>Cancer Cytopathology</i> , 2018, 126, 724-737.	1.4	2
5969	Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 144-153.	3.4	27
5970	Epigenetics in Melanoma Development and Drug Resistance. , 2018, , .		1
5971	Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. <i>Clinical and Translational Oncology</i> , 2018, 20, 1422-1429.	1.2	6
5972	Melanoma protective antitumor immunity activated by catalytic DNA. <i>Oncogene</i> , 2018, 37, 5115-5126.	2.6	15
5973	ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 4044-4055.	3.2	36
5974	Association of <i>BRAF</i> Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. <i>JAMA Surgery</i> , 2018, 153, e180996.	2.2	151
5975	Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. <i>Investigational New Drugs</i> , 2018, 36, 1037-1043.	1.2	23
5977	Advances in the systemic treatment of melanoma brain metastases. <i>Annals of Oncology</i> , 2018, 29, 1509-1520.	0.6	31
5978	Mutalisk: a web-based somatic MUTation AnaLYS toolKit for genomic, transcriptional and epigenomic signatures. <i>Nucleic Acids Research</i> , 2018, 46, W102-W108.	6.5	77
5980	An Update Regarding the Molecular Genetics of Melanocytic Neoplasms and the Current Applications of Molecular Genetic Technologies in Their Diagnosis and Treatment. <i>Clinics in Laboratory Medicine</i> , 2018, 38, 385-399.	0.7	1
5981	Procedures in the Diagnosis and Treatment of Skin Cancer. , 2018, , 249-267.		2
5982	Anthrax Bacterium: Its Etiology and Possible Therapeutics Against Cancer. , 2018, , 211-228.		0
5984	Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer. <i>Scientific Reports</i> , 2018, 8, 8256.	1.6	13
5985	Bronchiolar Adenoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1010-1026.	2.1	91
5986	Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAFV600E and VEGFR-2 dual inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 210-228.	2.6	32
5987	Highly efficient organic photosensitizer with aggregation-induced emission for imaging-guided photodynamic ablation of cancer cells. <i>Tetrahedron Letters</i> , 2018, 59, 2704-2707.	0.7	12

#	ARTICLE	IF	CITATIONS
5988	Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection. <i>Anti-Cancer Drugs</i> , 2018, 29, 802-805.	0.7	9
5990	K27/G34 versus K28/G35 in histone H3-mutant gliomas: A note of caution. <i>Acta Neuropathologica</i> , 2018, 136, 175-176.	3.9	12
5991	Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e315-e325.	0.2	7
5992	Stepwise nanoassembly of a single hairpin probe and its biosensing. <i>Talanta</i> , 2018, 187, 272-278.	2.9	6
5993	Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy. <i>Case Reports in Immunology</i> , 2018, 2018, 1-8.	0.2	5
5994	Zeaxanthin from <i>Porphyridium purpureum</i> induces apoptosis in human melanoma cells expressing the oncogenic BRAF V600E mutation and sensitizes them to the BRAF inhibitor vemurafenib. <i>Revista Brasileira De Farmacognosia</i> , 2018, 28, 457-467.	0.6	25
5995	Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting. <i>Medical Oncology</i> , 2018, 35, 110.	1.2	6
5996	IL6/STAT3 axis mediates resistance to BRAF inhibitors in thyroid carcinoma cells. <i>Cancer Letters</i> , 2018, 433, 147-155.	3.2	27
5997	Bioadhesives and Biosealants. , 2018, , 195-230.		2
5998	KIT, NRAS, BRAF and FMNL2 mutations in oral mucosal melanoma and a systematic review of the literature. <i>Oncology Letters</i> , 2018, 15, 9786-9792.	0.8	10
5999	Targeting the RAS-RAF-MEK-ERK Signaling Pathway in Gliomas. , 2018, , 323-332.		4
6000	Microorganisms in the Treatment of Cancer: Advantages and Limitations. <i>Journal of Immunology Research</i> , 2018, 2018, 1-8.	0.9	46
6001	Hierarchical closeness-based properties reveal cancer survivability and biomarker genes in molecular signaling networks. <i>PLoS ONE</i> , 2018, 13, e0199109.	1.1	5
6002	Principles of Targeted Therapy. , 2018, , 1-15.		0
6003	Locked Nucleic Acid Technology for Highly Sensitive Detection of Somatic Mutations in Cancer. <i>Advances in Clinical Chemistry</i> , 2018, 83, 53-72.	1.8	22
6004	Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors. , 2018, 192, 65-73.		35
6005	Skin commensal bacteria <i>Staphylococcus epidermidis</i> promote survival of melanocytes bearing UVB-induced DNA damage, while bacteria <i>Propionibacterium acnes</i> inhibit survival of melanocytes by increasing apoptosis. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2018, 34, 405-414.	0.7	10
6006	Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 664-676.	1.2	19

#	ARTICLE	IF	CITATIONS
6007	Photochemistry for Biomedical Applications. , 2018, , .		6
6008	Anticancer effects of combinational treatment with BRAFV600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAFV600E. <i>Oncology Letters</i> , 2018, 16, 632-642.	0.8	6
6009	Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAFV600E inhibition. <i>European Journal of Medicinal Chemistry</i> , 2018, 155, 725-735.	2.6	18
6010	When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. <i>Annals of Internal Medicine</i> , 2018, 169, 233.	2.0	20
6011	Allosteric activation of RAF in the MAPK signaling pathway. <i>Current Opinion in Structural Biology</i> , 2018, 53, 100-106.	2.6	23
6012	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2365-2376.	0.3	59
6013	Small Molecules in Oncology. <i>Recent Results in Cancer Research</i> , 2018, , .	1.8	5
6014	Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions. <i>Journal of Surgical Research</i> , 2018, 232, 72-81.	0.8	19
6015	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 3114.	5.8	122
6016	BRAF V600E mutation and BRAF VE1 immunoeexpression profiles in different types of glioblastoma. <i>Oncology Letters</i> , 2018, 16, 2402-2408.	0.8	13
6017	Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor. <i>Cancer Biomarkers</i> , 2018, 23, 67-77.	0.8	8
6018	Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor). <i>Cancers</i> , 2018, 10, 157.	1.7	39
6020	Molecular Applications in Cytology. , 2018, , .		1
6021	SUV39H1/DNMT3A-dependent methylation of the <i>RB1</i> promoter stimulates PIN1 expression and melanoma development. <i>FASEB Journal</i> , 2018, 32, 5647-5660.	0.2	22
6022	Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. <i>Molecular Cancer</i> , 2018, 17, 106.	7.9	46
6023	Emerging treatment options for <i>BRAF</i> -mutant colorectal cancer. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2018, Volume 8, 13-23.	5.5	55
6024	Pathways in melanoma development. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 68-76.	0.1	4
6025	Biomarkers for Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 270.	1.3	47

#	ARTICLE	IF	CITATIONS
6026	Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells. <i>International Journal of Oncology</i> , 2018, 53, 1149-1159.	1.4	12
6027	Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 639-646.	3.3	1
6028	Post-translational modifications at the ATP-positioning G-loop that regulate protein kinase activity. <i>Pharmacological Research</i> , 2018, 135, 181-187.	3.1	25
6029	Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations. <i>Cancer Biology and Therapy</i> , 2018, 19, 871-874.	1.5	18
6030	Melanoma treatment in review. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 35-49.	2.7	483
6031	Cobimetinib (GDC-0973, XL518). <i>Recent Results in Cancer Research</i> , 2018, 211, 177-186.	1.8	9
6032	Vemurafenib. <i>Recent Results in Cancer Research</i> , 2018, 211, 77-89.	1.8	52
6033	Trametinib (GSK1120212). <i>Recent Results in Cancer Research</i> , 2018, 211, 91-100.	1.8	26
6034	Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy. <i>Cancer Management and Research</i> , 2018, Volume 10, 647-652.	0.9	12
6035	Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. <i>Frontiers in Oncology</i> , 2018, 8, 202.	1.3	35
6036	Overcoming Resistance of Human Non-Hodgkinâ€™s Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors. <i>Cancers</i> , 2018, 10, 200.	1.7	36
6037	Multistage Carcinogenesis: Cell and Animal Models. , 2018, , 11-35.		2
6038	Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. <i>Journal of Virology</i> , 2018, 92, .	1.5	35
6039	Oil-In-Water Microemulsions as Hosts for Benzothioephene-Based Cytotoxic Compounds: An Effective Combination. <i>Biomimetics</i> , 2018, 3, 13.	1.5	6
6040	Kinases and Cancer. <i>Cancers</i> , 2018, 10, 63.	1.7	93
6041	Potential Use of Spin Traps to Control ROS in Antipollution Cosmeticsâ€™A Review. <i>Cosmetics</i> , 2018, 5, 8.	1.5	5
6042	Tetzâ€™s theory and law of longevity. <i>Theory in Biosciences</i> , 2018, 137, 145-154.	0.6	1
6043	A Fluorescent Probe for Early Detection of Melanoma and Its Metastasis by Specifically Imaging Tyrosinase Activity in a Mouse Model. <i>Analytical Chemistry</i> , 2018, 90, 8807-8815.	3.2	53

#	ARTICLE	IF	CITATIONS
6044	The Ashitaba (<i>Angelica keiskei</i>) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K. <i>Cancer Prevention Research</i> , 2018, 11, 607-620.	0.7	8
6045	The Emerging Therapeutic Landscape of Advanced Melanoma. <i>Current Pharmaceutical Design</i> , 2018, 24, 549-558.	0.9	16
6046	BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 289.	1.8	16
6047	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogsâ€™ Revolution for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 799.	1.8	33
6048	Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1259.	1.8	98
6049	NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 807-821.	2.3	394
6050	Current trends in Bioinformatics: An Insight. , 2018, , .		1
6051	Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib+trametinib versus nivolumab or pembrolizumab monotherapy. <i>Current Medical Research and Opinion</i> , 2018, 34, 2169-2176.	0.9	5
6052	BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2489-2491.	0.3	5
6053	Stochastic models of cell invasion with fluorescent cell cycle indicators. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2018, 510, 375-386.	1.2	17
6054	Nanocatalyst Complex Can Dephosphorylate Key Proteins in MAPK Pathway for Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2018, 7, e1800533.	3.9	3
6055	Reinventing the randomized controlled trial in medical oncology: The registry-based trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 365-373.	0.7	30
6056	Mechanism of BRAF Activation through Biochemical Characterization of the Recombinant Full-Length Protein. <i>ChemBioChem</i> , 2018, 19, 1988-1997.	1.3	32
6057	Emerging findings into molecular mechanism of brain metastasis. <i>Cancer Medicine</i> , 2018, 7, 3820-3833.	1.3	34
6058	In Silico Studies on Colon Cancer. , 2018, , 145-158.		0
6059	Myosin X is required for efficient melanoblast migration and melanoma initiation and metastasis. <i>Scientific Reports</i> , 2018, 8, 10449.	1.6	38
6060	Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine. <i>Pharmaceutical Research</i> , 2018, 35, 177.	1.7	53
6061	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520.	1.7	9

#	ARTICLE	IF	CITATIONS
6062	Small molecule inhibition of RAS/MAPK signaling ameliorates developmental pathologies of Kabuki Syndrome. <i>Scientific Reports</i> , 2018, 8, 10779.	1.6	50
6063	Identification of a novel BRAF Thr599dup mutation in lung adenocarcinoma. <i>Open Medicine (Poland)</i> , 2018, 13, 278-280.	0.6	2
6064	A Novel Polyamine-Targeted Therapy for BRAF Mutant Melanoma Tumors. <i>Medical Sciences (Basel)</i> , 2018, 7, 10779.	1.3	25
6065	The window of opportunities for targeted therapy in BRAFwt/NRASwt/KITwt melanoma: biology and clinical implications of fusion proteins and other mutations. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 349-360.	0.1	4
6067	MLH1 93A polymorphism is associated with MLH1 promoter methylation and protein loss in dysplastic sessile serrated adenomas with BRAFV600E mutation. <i>BMC Cancer</i> , 2018, 18, 35.	1.1	15
6068	Downregulation of BRAF-activated non-protein coding RNA in patients with hepatitis B virus-associated hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 7794-7798.	0.8	5
6069	Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. <i>BMC Cancer</i> , 2018, 18, 145.	1.1	16
6070	Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study. <i>BMC Cancer</i> , 2018, 18, 520.	1.1	10
6071	Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. <i>Clinical Proteomics</i> , 2018, 15, 13.	1.1	17
6072	Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. <i>Molecular Cancer</i> , 2018, 17, 55.	7.9	75
6073	Kinase-targeted cancer therapies: progress, challenges and future directions. <i>Molecular Cancer</i> , 2018, 17, 48.	7.9	796
6075	A case of epidural glioblastoma metastasis presenting with a cervical myelopathy, torticollis, and Lhermitte's phenomenon. <i>Brain Tumor Pathology</i> , 2018, 35, 181-185.	1.1	3
6076	Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. <i>BMC Cancer</i> , 2018, 18, 542.	1.1	16
6077	Concordance of somatic mutation profiles (BRAF, NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. <i>Human Pathology</i> , 2018, 82, 206-214.	1.1	14
6078	Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. <i>Pharmacological Research</i> , 2018, 135, 239-258.	3.1	154
6079	Melanoma Adjuvant Treatment: Current Insight and Clinical Features. <i>Current Cancer Drug Targets</i> , 2018, 18, 442-456.	0.8	5
6080	Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features. <i>Journal of Neurosurgery</i> , 2018, 129, 27-34.	0.9	35
6081	Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1090.	1.8	34

#	ARTICLE	IF	CITATIONS
6082	Eastern Canadian Colorectal Cancer Consensus Conference 2017. <i>Current Oncology</i> , 2018, 25, 262-274.	0.9	4
6083	Langerhansâ€™ Cell Histiocytosis Masquerading as Metastatic Papillary Thyroid Cancer on F-18 FDG PET/CT: Diagnostic Dilemma Solved by PET/CT-Guided Biopsy. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 394-397.	0.6	5
6084	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. <i>Drugs</i> , 2018, 78, 1197-1209.	4.9	34
6085	Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 545-551.	0.5	6
6086	Quality and practical aspects of pathological and molecular diagnostics in metastatic colorectal cancer (mCRC). <i>Wspolczesna Onkologia</i> , 2018, 22, 75-85.	0.7	3
6087	Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib. <i>PLoS ONE</i> , 2018, 13, e0195956.	1.1	4
6088	A Clamp-Based One-Step Droplet Digital Reverse Transcription PCR (ddRT-PCR) for Precise Quantitation of Messenger RNA Mutation in Single Cells. <i>ACS Sensors</i> , 2018, 3, 1795-1801.	4.0	18
6089	Comprehensive evaluation of coding region point mutations in microsatelliteâ€™unstable colorectal cancer. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	10
6090	Transplantable Melanomas in Hamsters and Gerbils as Models for Human Melanoma. Sensitization in Melanoma Radiotherapyâ€™From Animal Models to Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1048.	1.8	30
6091	Co-existence of BRAFV600E</sup> and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. <i>Cancer Management and Research</i> , 2018, Volume 10, 1005-1013.	0.9	50
6092	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2298.	1.8	4
6093	shRNAâ€™induced knockdown of the SPERT gene inhibits proliferation and promotes apoptosis of human colorectal cancer RKO cells. <i>Oncology Reports</i> , 2018, 40, 813-822.	1.2	6
6094	Key Signaling Pathways in Normal and Neoplastic Melanocytes. , 2018, , 1-19.		0
6095	Proteinâ€™Protein Interactions: Emerging Oncotargets in the RAS-ERK Pathway. <i>Trends in Cancer</i> , 2018, 4, 616-633.	3.8	44
6096	Identification of recurrent USP48 and BRAF mutations in Cushingâ€™s disease. <i>Nature Communications</i> , 2018, 9, 3171.	5.8	106
6097	Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. <i>BMC Cancer</i> , 2018, 18, 790.	1.1	7
6099	Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer. <i>Cancer Management and Research</i> , 2018, Volume 10, 2289-2301.	0.9	24
6100	Dermoscopy and confocal microscopy for metachronous multiple melanomas: morphological, clinical, and molecular correlations. <i>European Journal of Dermatology</i> , 2018, 28, 149-156.	0.3	5

#	ARTICLE	IF	CITATIONS
6101	Uveal Melanoma. , 2018, , 273-312.		3
6102	Surgery for Stage IV Metastatic Melanoma. , 2018, , 467-481.		1
6103	The Genetic Evolution of Melanoma. , 2018, , 105-114.		0
6104	Immunobiology of the Melanoma Microenvironment. , 2018, , 133-142.		0
6105	Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. Journal of Experimental Medicine, 2018, 215, 1913-1928.	4.2	41
6106	Characterization and Molecular Docking Study of New 4-Acetamidoalkyl Pyrazoles As B-Raf /Cox-2 Inhibitors. Journal of Structural Chemistry, 2018, 59, 335-343.	0.3	0
6107	Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas. Clinical Cancer Research, 2018, 24, 6483-6494.	3.2	55
6108	Heightened <i>BRAF</i> and <i>BRAF</i> pseudogene expression levels in 2 Japanese patients with Erdheim-Chester disease. Journal of Cutaneous Immunology and Allergy, 2018, 1, 16-22.	0.2	0
6109	A Secondary Mutation in <i>BRAF</i> Confers Resistance to RAF Inhibition in a <i>BRAF</i> V600E-Mutant Brain Tumor. Cancer Discovery, 2018, 8, 1130-1141.	7.7	56
6110	Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms. Journal of Sexual Medicine, 2018, 15, 982-989.	0.3	6
6111	The Endosomal Protein CEMIP Links WNT Signaling to MEK1/ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids. Cancer Research, 2018, 78, 4533-4548.	0.4	30
6112	Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. British Journal of Cancer, 2018, 118, 1580-1585.	2.9	16
6113	Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment. Precision Clinical Medicine, 2018, 1, 29-48.	1.3	79
6114	Codon-specific translation reprogramming promotes resistance to targeted therapy. Nature, 2018, 558, 605-609.	13.7	177
6115	PIK3CA mutations in colorectal and breast cancer: impact on oncogenesis and response to nonsteroidal anti-inflammatory drugs. , 2019, , 123-144.		2
6116	Cutaneous pH landscape as a facilitator of melanoma initiation and progression. Acta Physiologica, 2019, 225, e13105.	1.8	11
6117	The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathology, 2019, 29, 85-96.	2.1	88
6118	Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma. Acta Pharmacologica Sinica, 2019, 40, 268-278.	2.8	12

#	ARTICLE	IF	CITATIONS
6119	The Association Between Mutations in BRAF and Colorectal Cancer—Specific Survival Depends on Microsatellite Status and Tumor Stage. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 455-462.e6.	2.4	62
6120	Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities. <i>Seminars in Cancer Biology</i> , 2019, 55, 37-52.	4.3	125
6121	BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study. <i>Neurosurgery</i> , 2019, 84, 868-880.	0.6	32
6122	Evaluating the Combination of Microsatellite Instability and Mutation in BRAF as Prognostic Factors for Patients With Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 391-394.	2.4	10
6123	BRAF ^{V600E} mutation: A promising target in colorectal neuroendocrine carcinoma. <i>International Journal of Cancer</i> , 2019, 144, 1379-1390.	2.3	33
6124	A novel fusion gene PLEKHA6-NTRK3 in langerhans cell histiocytosis. <i>International Journal of Cancer</i> , 2019, 144, 117-124.	2.3	10
6125	Cycloartane triterpenoid (23R, 24E)-23-acetoxymangiferonic acid inhibited proliferation and migration in B16-F10 melanoma via MITF downregulation caused by inhibition of both β -catenin and c-Raf-MEK1-ERK signaling axis. <i>Journal of Natural Medicines</i> , 2019, 73, 47-58.	1.1	13
6126	Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib. <i>Clinical Pharmacokinetics</i> , 2019, 58, 451-467.	1.6	72
6127	Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities. , 2019, 193, 20-30.		49
6128	MITF and UV responses in skin: From pigmentation to addiction. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 224-236.	1.5	84
6129	Identification of Local Clusters of Mutation Hotspots in Cancer-Related Genes and Their Biological Relevance. <i>IEEE/ACM Transactions on Computational Biology and Bioinformatics</i> , 2019, 16, 1656-1662.	1.9	11
6130	BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS. <i>Science Advances</i> , 2019, 5, eaav8463.	4.7	25
6131	p21cip1/waf1 Coordinates Autophagy, Proliferation and Apoptosis in Response to Metabolic Stress. <i>Cancers</i> , 2019, 11, 1112.	1.7	31
6132	Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	4
6133	Langerhans Cell Histiocytosis, Non-Langerhans histiocytosis and concurrent Papillary Thyroid Carcinoma with BRAF V600E mutations: A case report and literature review. <i>Human Pathology: Case Reports</i> , 2019, 17, 200302.	0.2	3
6134	Targeted Therapy in Advanced Melanoma. , 2019, , 667-686.		0
6135	Key Signaling Pathways in Normal and Neoplastic Melanocytes. , 2019, , 63-81.		0
6136	Molecular Genetics of Melanocytic Neoplasia. , 2019, , 123-145.		1

#	ARTICLE	IF	CITATIONS
6137	Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. , 2019, , 181-224.		0
6138	Animal Models of Melanoma. , 2019, , 303-333.		0
6139	Principles of Targeted Therapy. , 2019, , 165-179.		0
6140	Epigenetic Regulation in Melanoma. , 2019, , 83-98.		1
6141	The Medical Therapy of Craniopharyngiomas: The Way Ahead. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5751-5764.	1.8	26
6142	Kinome-Wide Screening with Small Interfering RNA Identified Polo-like Kinase 1 as a Key Regulator of Proliferation in Oral Cancer Cells. Cancers, 2019, 11, 1117.	1.7	15
6143	Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors. JAMA Network Open, 2019, 2, e198890.	2.8	96
6144	MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells. Epigenetics and Chromatin, 2019, 12, 50.	1.8	12
6145	Upregulation of S100A9 contributes to the acquired resistance to BRAF inhibitors. Genes and Genomics, 2019, 41, 1273-1280.	0.5	5
6146	Personalised approach in combined treatment of cholangiocarcinoma: a case report of healing from cholangiocellular carcinoma at stage IV. Journal of Gastrointestinal Oncology, 2019, 10, 815-820.	0.6	14
6147	Clinicopathological and biological analysis of PIK3CA mutation and amplification in cervical carcinomas. Experimental and Therapeutic Medicine, 2019, 18, 2278-2284.	0.8	8
6148	Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. Cancers, 2019, 11, 1176.	1.7	20
6149	A patent review of RAF kinase inhibitors (2010â€“2018). Expert Opinion on Therapeutic Patents, 2019, 29, 675-688.	2.4	13
6150	Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. Expert Opinion on Investigational Drugs, 2019, 28, 695-708.	1.9	38
6151	The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma. Cancers, 2019, 11, 1093.	1.7	18
6152	Neoadjuvant therapy of locally/regionally advanced melanoma. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591986695.	1.4	21
6153	Src-Dependent DBL Family Members Drive Resistance to Vemurafenib in Human Melanoma. Cancer Research, 2019, 79, 5074-5087.	0.4	13
6154	An H-TERT Mutated Skin Metastasis as First Occurrence in a Case of Follicular Thyroid Carcinoma. Frontiers in Endocrinology, 2019, 10, 513.	1.5	3

#	ARTICLE	IF	CITATIONS
6155	Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. <i>European Journal of Cancer</i> , 2019, 119, 97-106.	1.3	75
6156	MAPK SIGNALLING PATHWAY: ROLE IN CANCER PATHOGENESIS. <i>Journal of Critical Reviews</i> , 2019, , 1-6.	0.7	2
6157	Pilocytic astrocytomas: BRAFV600E and BRAF fusion expression patterns in pediatric and adult age groups. <i>Child's Nervous System</i> , 2019, 35, 1525-1536.	0.6	17
6158	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
6159	Deciphering the genotype and phenotype of hairy cell leukemia: clues for diagnosis and treatment. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 857-867.	1.3	0
6160	Ocular Oncology. <i>Current Practices in Ophthalmology</i> , 2019, , .	0.1	0
6161	Pharmacogenetics of therapeutics. , 2019, , 41-74.		0
6162	Identification of anticancer drugs to radiosensitize BRAF-wild-type and mutant colorectal cancer. <i>Cancer Biology and Medicine</i> , 2019, 16, 234.	1.4	4
6163	Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners. , 2019, , .		0
6164	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 2978.	5.8	91
6165	Prognostic and predictive markers in liver limited stage IV colorectal cancer. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2251-2256.	0.5	23
6166	Progress towards molecular-based management of childhood Langerhans cell histiocytosis. <i>Archives De Pédiatrie</i> , 2019, 26, 301-307.	0.4	24
6167	Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms. <i>Theranostics</i> , 2019, 9, 4461-4473.	4.6	123
6168	BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. <i>Cancers</i> , 2019, 11, 998.	1.7	22
6169	Sphingolipid/Ceramide Pathways and Autophagy in the Onset and Progression of Melanoma: Novel Therapeutic Targets and Opportunities. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3436.	1.8	31
6170	Nickel oxide nanoparticles exert selective toxicity on skin mitochondria and lysosomes isolated from the mouse model of melanoma. <i>Journal of Biochemical and Molecular Toxicology</i> , 2019, 33, e22376.	1.4	6
6171	A Brief Overview of the Antitumoral Actions of Leelamine. <i>Biomedicines</i> , 2019, 7, 53.	1.4	14
6172	Understanding the impacts of missense mutations on structures and functions of human cancer-related genes: A preliminary computational analysis of the COSMIC Cancer Gene Census. <i>PLoS ONE</i> , 2019, 14, e0219935.	1.1	10

#	ARTICLE	IF	CITATIONS
6173	BRAF Mutation and Its Importance in Colorectal Cancer. , 0, , .		11
6174	Microarray Approach Combined with ddPCR: An Useful Pipeline for the Detection and Quantification of Circulating Tumour dna Mutations. <i>Cells</i> , 2019, 8, 769.	1.8	13
6175	Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAFE600 inhibition in melanoma cells. <i>Journal of Controlled Release</i> , 2019, 309, 158-172.	4.8	3
6176	Exploring the best treatment options for BRAF-mutant metastatic colon cancer. <i>British Journal of Cancer</i> , 2019, 121, 434-442.	2.9	54
6177	Global view of the RAF-MEK-ERK module and its immediate downstream effectors. <i>Scientific Reports</i> , 2019, 9, 10865.	1.6	12
6178	Immunotherapies for the Treatment of Uveal Melanomaâ€”History and Future. <i>Cancers</i> , 2019, 11, 1048.	1.7	56
6179	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2019, 21, 76.	1.8	18
6180	The long-term survival characteristics of a cohort of colorectal cancer patients and baseline variables associated with survival outcomes with or without time-varying effects. <i>BMC Medicine</i> , 2019, 17, 150.	2.3	32
6181	Paclitaxel-Loaded Nanosponges Inhibit Growth and Angiogenesis in Melanoma Cell Models. <i>Frontiers in Pharmacology</i> , 2019, 10, 776.	1.6	36
6182	Molecular targeted therapy of <i>BRAF</i>-mutant colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985649.	1.4	72
6183	Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report. <i>Clinical Drug Investigation</i> , 2019, 39, 1003-1007.	1.1	6
6184	Detection of the BRAF V600E Mutation in Colorectal Cancer by NIR Spectroscopy in Conjunction with Counter Propagation Artificial Neural Network. <i>Molecules</i> , 2019, 24, 2238.	1.7	20
6185	Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation. <i>PLoS ONE</i> , 2019, 14, e0219204.	1.1	19
6186	KSRP modulates melanoma growth and efficacy of vemurafenib. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2019, 1862, 759-770.	0.9	8
6187	Abrogation of B-RafV600E induced senescence by FoxM1 expression. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 866-871.	1.0	5
6188	Malignant melanoma with metaplastic cartilaginous transdifferentiation: A case report. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 935-941.	0.7	6
6189	Hexokinase2 controls angiogenesis in melanoma by promoting aerobic glycolysis and activating the p38â€”MAPK signaling. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 19721-19729.	1.2	13
6190	Application of immune repertoire sequencing in cancer immunotherapy. <i>International Immunopharmacology</i> , 2019, 74, 105688.	1.7	7

#	ARTICLE	IF	CITATIONS
6191	A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of <i>BRAF</i> -mutated Melanoma to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2019, 25, 6852-6867.	3.2	74
6192	Design, synthesis, and anticancer activity of imidazo[2,1-b]oxazole-based RAF kinase inhibitors. <i>Biorganic Chemistry</i> , 2019, 93, 103349.	2.0	21
6193	Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma. <i>Nanomaterials</i> , 2019, 9, 1455.	1.9	34
6194	Whole Genome Sequencing of Familial Non-Medullary Thyroid Cancer Identifies Germline Alterations in MAPK/ERK and PI3K/AKT Signaling Pathways. <i>Biomolecules</i> , 2019, 9, 605.	1.8	27
6195	Human Colorectal Cancer from the Perspective of Mouse Models. <i>Genes</i> , 2019, 10, 788.	1.0	26
6196	A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 727-738.	2.3	27
6197	Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA. <i>Diagnostics</i> , 2019, 9, 117.	1.3	6
6198	Precision medicine and companion diagnostics in drug development. , 2019, , 75-96.		0
6199	Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting. <i>BMC Cancer</i> , 2019, 19, 1025.	1.1	7
6200	Protein Allosterity in Drug Discovery. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	11
6201	Unique characteristics of CpG island methylator phenotype (CIMP) in a Chinese population with colorectal cancer. <i>BMC Gastroenterology</i> , 2019, 19, 173.	0.8	9
6202	The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors. , 2019, 7, 308.		51
6203	The Landscape of Atypical and Eukaryotic Protein Kinases. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 818-832.	4.0	87
6204	Altered 5-Hydroxymethylcytosine Landscape in Primary Gastric Adenocarcinoma. <i>DNA and Cell Biology</i> , 2019, 38, 1460-1469.	0.9	4
6205	Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers. <i>Nature Communications</i> , 2019, 10, 5143.	5.8	15
6206	Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine. <i>Frontiers in Medicine</i> , 2019, 6, 233.	1.2	8
6207	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16
6208	BRAF protein immunoprecipitation, elution, and digestion from cell extract using a microfluidic mixer for mutant BRAF protein quantification by mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 1085-1094.	1.9	3

#	ARTICLE	IF	CITATIONS
6209	Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. <i>Clinical Cancer Research</i> , 2019, 25, 7202-7217.	3.2	29
6210	Mucosal melanoma: current strategies and future directions. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 427-434.	0.5	2
6211	Advances in the therapy of BRAF ^{V600E} metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 823-829.	1.1	5
6212	Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care. <i>Cancers</i> , 2019, 11, 1203.	1.7	10
6213	<p>Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6045-6052.	1.0	6
6214	Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. <i>European Journal of Pharmacology</i> , 2019, 862, 172621.	1.7	65
6215	The adjuvant treatment revolution for high-risk melanoma patients. <i>Seminars in Cancer Biology</i> , 2019, 59, 283-289.	4.3	40
6216	BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors. <i>Cancers</i> , 2019, 11, 1262.	1.7	99
6217	Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4235.	1.8	32
6218	CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019, 121, 593-599.	2.9	24
6219	The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. <i>Journal of Translational Medicine</i> , 2019, 17, 298.	1.8	33
6220	The Kinetic Behaviors of H Impurities in the Li/Ta Bilayer: Application for the Accelerator-Based BNCT. <i>Nanomaterials</i> , 2019, 9, 1107.	1.9	3
6221	Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status. <i>Cell Death and Disease</i> , 2019, 10, 663.	2.7	16
6222	pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma. <i>Communications Biology</i> , 2019, 2, 334.	2.0	10
6223	Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases. <i>Science</i> , 2019, 366, 109-115.	6.0	127
6224	Analysis of Predictive Biomarkers in Patients With Lung Adenocarcinoma From Southern Brazil Reveals a Distinct Profile From Other Regions of the Country. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	13
6225	The Role of MET in Melanoma and Melanocytic Lesions. <i>American Journal of Pathology</i> , 2019, 189, 2138-2148.	1.9	21
6226	Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside. <i>Cancers</i> , 2019, 11, 1342.	1.7	22

#	ARTICLE	IF	CITATIONS
6227	Efficacy of Dabrafenib for three children with brainstem BRAFV600E positive ganglioglioma. <i>Journal of Neuro-Oncology</i> , 2019, 145, 135-141.	1.4	9
6228	Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1632-1643.	13.9	918
6229	BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis. <i>Pathology Research and Practice</i> , 2019, 215, 152671.	1.0	8
6230	Mutation profiling of cancer drivers in Brazilian colorectal cancer. <i>Scientific Reports</i> , 2019, 9, 13687.	1.6	31
6231	Estimating the Frequency of Single Point Driver Mutations across Common Solid Tumours. <i>Scientific Reports</i> , 2019, 9, 13452.	1.6	6
6232	Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway. <i>Scientific Reports</i> , 2019, 9, 14197.	1.6	22
6233	Epidermal growth factor receptor (EGFR) gene alteration and protein overexpression in Malaysian triple-negative breast cancer (TNBC) cohort. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7749-7756.	1.0	24
6234	Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency. <i>Cancers</i> , 2019, 11, 1480.	1.7	31
6235	BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas. <i>Journal of Clinical Medicine</i> , 2019, 8, 1577.	1.0	9
6236	Design, synthesis and biological evaluation of some new 1,3,4-thiadiazine-thiourea derivatives as potential antitumor agents against non-small cell lung cancer cells. <i>Bioorganic Chemistry</i> , 2019, 93, 103323.	2.0	13
6237	BRAF exon 11 mutant melanoma and sensitivity to BRAF/MEK inhibition: Two case reports. <i>European Journal of Cancer</i> , 2019, 121, 109-112.	1.3	2
6238	Discrimination of the V600E Mutation in <i>BRAF</i> by Rolling Circle Amplification and Förster Resonance Energy Transfer. <i>ACS Sensors</i> , 2019, 4, 2786-2793.	4.0	19
6239	BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives. <i>Cancers</i> , 2019, 11, 1388.	1.7	73
6240	The impact of CTLA-4 blockade and interferon- γ on clonality of T-cell repertoire in the tumor microenvironment and peripheral blood of metastatic melanoma patients. <i>Oncolimmunology</i> , 2019, 8, e1652538.	2.1	22
6241	An integrated multi-molecular sensor for simultaneous BRAFV600E protein and DNA single point mutation detection in circulating tumour cells. <i>Lab on A Chip</i> , 2019, 19, 738-748.	3.1	16
6242	Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexia. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 693-704.	1.1	21
6243	Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive. <i>Melanoma Research</i> , 2019, 29, 301-310.	0.6	7
6244	Spatio-Genetic and phenotypic modelling elucidates resistance and re-sensitisation to treatment in heterogeneous melanoma. <i>Journal of Theoretical Biology</i> , 2019, 466, 84-105.	0.8	12

#	ARTICLE	IF	CITATIONS
6245	Molecular evaluation of BRAF V600 mutation and its association with clinicopathological characteristics: First findings from Indian malignant melanoma patients. <i>Cancer Genetics</i> , 2019, 231-232, 46-53.	0.2	6
6246	Activated MEK/ERK Pathway Drives Widespread and Coordinated Overexpression of UHRF1 and DNMT1 in Cancer cells. <i>Scientific Reports</i> , 2019, 9, 907.	1.6	26
6247	Cyclical Treatment of Colorectal Tumor Spheroids Induces Resistance to MEK Inhibitors. <i>Translational Oncology</i> , 2019, 12, 404-416.	1.7	16
6248	Serrated Lesions of the Colon-Rectum: A Focus on New Diagnostic Tools and Current Management. <i>Gastroenterology Research and Practice</i> , 2019, 2019, 1-14.	0.7	9
6249	Detection of BRAFV600E Mutation in Melanoma Patients by Digital PCR of Circulating DNA. <i>Genetic Testing and Molecular Biomarkers</i> , 2019, 23, 241-245.	0.3	19
6250	Conjunctival melanoma copy number alterations and correlation with mutation status, tumor features, and clinical outcome. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 564-575.	1.5	42
6251	Genetic-guided Risk Assessment and Management of Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 109-124.	1.2	44
6252	Polymerase-amplified release of ATP (POLARA) for detecting single nucleotide variants in RNA and DNA. <i>Chemical Science</i> , 2019, 10, 3264-3270.	3.7	10
6253	Melatonin synergizes BRAF-targeting agent vemurafenib in melanoma treatment by inhibiting iNOS/hTERT signaling and cancer-stem cell traits. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 48.	3.5	38
6254	Extracellular-Signal Regulated Kinase: A Central Molecule Driving Epithelial-Mesenchymal Transition in Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2885.	1.8	100
6255	Targeted Therapies in Non-small-Cell Lung Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 3-43.	0.2	16
6256	Light-controlled inhibition of BRAFV600E kinase. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 133-146.	2.6	31
6257	Regulation of TEAD Transcription Factors in Cancer Biology. <i>Cells</i> , 2019, 8, 600.	1.8	159
6258	The molecular clock in the skin, its functionality, and how it is disrupted in cutaneous melanoma: a new pharmacological target?. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 3801-3826.	2.4	28
6259	Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal. <i>Diagnostic Pathology</i> , 2019, 14, 62.	0.9	4
6260	Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma. <i>IScience</i> , 2019, 16, 453-467.	1.9	14
6261	Integration of Random Forest Classifiers and Deep Convolutional Neural Networks for Classification and Biomolecular Modeling of Cancer Driver Mutations. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 44.	1.6	51
6262	Melanoma on chronically sun-damaged skin: Lentigo maligna and desmoplastic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 823-833.	0.6	44

#	ARTICLE	IF	CITATIONS
6263	Concomitant KRAS and BRAF mutations in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 577-581.	0.6	33
6265	Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019, 179, 707-722.	2.6	36
6266	Adjuvant Therapy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 63.	1.3	38
6267	Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. <i>Nature Medicine</i> , 2019, 25, 929-935.	15.2	188
6268	Role of melanoma inhibitory activity in melanocyte senescence. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 777-791.	1.5	20
6269	Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 817-827.	3.3	29
6270	The Role of Long Non-coding RNAs in Melanoma Genesis and Progression. , 2019, , 115-126.		0
6271	Emerging biomarkers in pulmonary metastasectomy. <i>Journal of Visualized Surgery</i> , 2019, 5, 44-44.	0.2	1
6272	Targeted Therapies in Veterinary Oncology. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2019, 49, 917-931.	0.5	12
6273	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 990.	2.2	86
6274	Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2530.	1.8	47
6275	NFE2L3 Inhibition Induces Cell Cycle Arrest at the G0/G1 Phase in Colorectal Cancer Cells through Downregulating CCND1 and pRb1-ser807/811. <i>Disease Markers</i> , 2019, 2019, 1-7.	0.6	11
6276	Biochemical Characterization of Full-length Oncogenic BRAF ^{V600E} together with Molecular Dynamics Simulations Provide Insight into the Activation and Inhibition Mechanisms of RAF Kinases. <i>ChemBioChem</i> , 2019, 20, 2850-2861.	1.3	7
6277	Increased expression of long noncoding RNA GAS6 ^{AS2} promotes proliferation and inhibits apoptosis of melanoma cells via upregulating GAS6 expression. <i>IUBMB Life</i> , 2019, 71, 1503-1514.	1.5	16
6278	Key candidate genes associated with BRAF ^{V600E} in papillary thyroid carcinoma on microarray analysis. <i>Journal of Cellular Physiology</i> , 2019, 234, 23369-23378.	2.0	17
6279	Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort. <i>Leukemia Research</i> , 2019, 83, 106165.	0.4	5
6280	Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF. <i>ACS Chemical Biology</i> , 2019, 14, 1471-1480.	1.6	34
6281	Migration through physical constraints is enabled by MAPK-induced cell softening via actin cytoskeleton re-organization. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	37

#	ARTICLE	IF	CITATIONS
6282	Structural simplification: an efficient strategy in lead optimization. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 880-901.	5.7	49
6283	Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 1074-1080.	1.3	10
6284	Thalamic Gliomas. , 2019, , 459-480.		1
6286	Oncogenic BRAF Alterations and Their Role in Brain Tumors. <i>Cancers</i> , 2019, 11, 794.	1.7	62
6287	Multiple cancer pathways regulate telomere protection. <i>EMBO Molecular Medicine</i> , 2019, 11, e10292.	3.3	36
6288	Discovery of carbazole derivatives as novel allosteric MEK inhibitors by pharmacophore modeling and virtual screening. <i>European Journal of Medicinal Chemistry</i> , 2019, 178, 802-817.	2.6	12
6289	Harmine suppresses hyper-activated Ras/MAPK pathway by selectively targeting oncogenic mutated Ras/Raf in <i>Caenorhabditis elegans</i> . <i>Cancer Cell International</i> , 2019, 19, 159.	1.8	5
6290	Expression Signatures of Cisplatin- and Trametinib-Treated Early-Stage Medaka Melanomas. <i>G3: Genes, Genomes, Genetics</i> , 2019, 9, 2267-2276.	0.8	6
6291	A Melanoma Patient-Derived Xenograft Model. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	11
6292	Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma. <i>Molecular Oncology</i> , 2019, 13, 1836-1854.	2.1	15
6293	Cancer Cells Tune the Signaling Pathways to Empower de Novo Synthesis of Nucleotides. <i>Cancers</i> , 2019, 11, 688.	1.7	167
6294	Systemic Histiocytosis (Langerhans Cell Histiocytosis, Erdheim-Chester Disease,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 307 Oncology Reports, 2019, 21, 62.	1.8	48
6295	Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e721-e723.	0.9	7
6296	The significance of gene mutations across eight major cancer types. <i>Mutation Research - Reviews in Mutation Research</i> , 2019, 781, 88-99.	2.4	15
6297	Translating Nanomedicine to Comparative Oncology—the Case for Combining Zinc Oxide Nanomaterials with Nucleic Acid Therapeutic and Protein Delivery for Treating Metastatic Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 671-681.	1.3	7
6298	Multiplexed single-cell RNA-seq via transient barcoding for simultaneous expression profiling of various drug perturbations. <i>Science Advances</i> , 2019, 5, eaav2249.	4.7	81
6299	Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. <i>Clinical Cancer Research</i> , 2019, 25, 4749-4760.	3.2	39
6300	SIRT2 Contributes to the Resistance of Melanoma Cells to the Multikinase Inhibitor Dasatinib. <i>Cancers</i> , 2019, 11, 673.	1.7	22

#	ARTICLE	IF	CITATIONS
6301	Systemic Therapy for Advanced and Metastatic Colon Cancer. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2019, 73, 202.	0.2	1
6302	Macroenvironment-gene-microenvironment interactions in ultraviolet radiation-induced melanomagenesis. Advances in Cancer Research, 2019, 144, 1-54.	1.9	14
6303	Negative feedback regulation of ErbB4 tyrosine kinase activity by ERK-mediated non-canonical phosphorylation. Biochemical and Biophysical Research Communications, 2019, 514, 456-461.	1.0	5
6304	Capsaicin-like analogue induced selective apoptosis in A2058 melanoma cells: Design, synthesis and molecular modeling. Bioorganic and Medicinal Chemistry, 2019, 27, 2893-2904.	1.4	16
6305	Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Letters, 2019, 457, 129-141.	3.2	16
6306	Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells. Cancers, 2019, 11, 659.	1.7	43
6307	Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma. Experimental and Molecular Pathology, 2019, 110, 104260.	0.9	8
6308	Countering TRAIL Resistance in Melanoma. Cancers, 2019, 11, 656.	1.7	36
6309	Systematic Profiling and Evaluation of Structure-based Kinase-Inhibitor Interactome in Cervical Cancer by Integrating In Silico Analyses and In Vitro Assays at Molecular and Cellular Levels. Computational Biology and Chemistry, 2019, 80, 324-332.	1.1	5
6310	Modelling bistable tumour population dynamics to design effective treatment strategies. Journal of Theoretical Biology, 2019, 474, 88-102.	0.8	19
6311	Uncommon mutational profiles of metastatic colorectal cancer detected during routine genotyping using next generation sequencing. Scientific Reports, 2019, 9, 7083.	1.6	5
6312	DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties. Translational Oncology, 2019, 12, 932-950.	1.7	13
6313	Immunohistochemical Analysis of BRAF (V600E) Mutation and P16 Expression in Malignant Melanoma in Lagos, Nigeria: A 10-Year Retrospective Study. Journal of Skin Cancer, 2019, 2019, 1-6.	0.5	3
6314	A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells. BMC Cancer, 2019, 19, 402.	1.1	41
6315	NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children. Experimental Hematology and Oncology, 2019, 8, 11.	2.0	16
6316	Comparative interactome analysis reveals distinct and overlapping properties of Raf family kinases. Biochemical and Biophysical Research Communications, 2019, 514, 1217-1223.	1.0	5
6317	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Molecular Cancer Therapeutics, 2019, 18, 1149-1157.	1.9	26
6318	Recent Advances on Electrochemical Biosensing Strategies toward Universal Point-of-Care Systems. Angewandte Chemie, 2019, 131, 12483-12496.	1.6	57

#	ARTICLE	IF	CITATIONS
6319	Determining cell type abundance and expression from bulk tissues with digital cytometry. <i>Nature Biotechnology</i> , 2019, 37, 773-782.	9.4	2,396
6320	Cancer Genetic Network Inference Using Gaussian Graphical Models. <i>Bioinformatics and Biology Insights</i> , 2019, 13, 117793221983940.	1.0	33
6321	<sc>INKA</sc> , an integrative data analysis pipeline for phosphoproteomic inference of active kinases. <i>Molecular Systems Biology</i> , 2019, 15, e8250.	3.2	53
6322	Recent Advances on Electrochemical Biosensing Strategies toward Universal Point-of-Care Systems. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 12355-12368.	7.2	155
6323	Cucurbitacins inspired organic synthesis: Potential dual inhibitors targeting EGFR and MAPK pathway. <i>European Journal of Medicinal Chemistry</i> , 2019, 173, 294-304.	2.6	18
6324	Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 5735-5742.	3.2	30
6325	Quantitative Interrogation of the Human Kinome Perturbed by Two BRAF Inhibitors. <i>Journal of Proteome Research</i> , 2019, 18, 2624-2631.	1.8	12
6326	Modelling of Protein Kinase Signaling Pathways in Melanoma and Other Cancers. <i>Cancers</i> , 2019, 11, 465.	1.7	14
6327	Utilization of palliative care consultations in pediatric oncology phase I clinical trials. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27771.	0.8	7
6328	A 3D Multiscale Model to Explore the Role of EGFR Overexpression in Tumorigenesis. <i>Bulletin of Mathematical Biology</i> , 2019, 81, 2323-2344.	0.9	2
6329	Ku80 promotes melanoma growth and regulates antitumor effect of melatonin by targeting HIF1- α dependent PDK-1 signaling pathway. <i>Redox Biology</i> , 2019, 25, 101197.	3.9	15
6330	Current and emerging systemic therapies for cutaneous metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1135-1152.	0.9	33
6331	The Clinical Trial Landscape for Melanoma Therapies. <i>Journal of Clinical Medicine</i> , 2019, 8, 368.	1.0	46
6332	Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. <i>Journal of Clinical Medicine</i> , 2019, 8, 373.	1.0	107
6333	The Combination of RET, BRAF and Demographic Data Identifies Subsets of Patients with Aggressive Papillary Thyroid Cancer. <i>Hormones and Cancer</i> , 2019, 10, 97-106.	4.9	7
6334	Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion. <i>Cancer Letters</i> , 2019, 452, 178-190.	3.2	32
6335	IVS2vec: A tool of Inverse Virtual Screening based on word2vec and deep learning techniques. <i>Methods</i> , 2019, 166, 57-65.	1.9	30
6336	Epigenetic Regulation in Melanoma. , 2019, , 1-16.		0

#	ARTICLE	IF	CITATIONS
6337	Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation. <i>Bioorganic Chemistry</i> , 2019, 87, 191-199.	2.0	35
6338	Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1096-1109.	2.5	25
6339	The immunocytochemical expression of VE α 1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology. <i>Cytopathology</i> , 2019, 30, 460-467.	0.4	12
6340	Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 61-69.	1.0	27
6341	Targeted Therapy in Non-Small-Cell Lung Cancer (Beyond Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1075-1085.	1.0	27
6342	A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib. <i>Clinical Lung Cancer</i> , 2019, 20, e224-e228.	1.1	11
6343	Anti-metastatic Properties of Naproxen-HBTA in a Murine Model of Cutaneous Melanoma. <i>Frontiers in Pharmacology</i> , 2019, 10, 66.	1.6	22
6344	Circulating 25-Hydroxyvitamin D Concentration and Risk of Breast, Prostate, and Colorectal Cancers: The Melbourne Collaborative Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 900-908.	1.1	22
6345	Recurrent Noncoding Mutations in Skin Cancers: UV Damage Susceptibility or Repair Inhibition as Primary Driver?. <i>BioEssays</i> , 2019, 41, e1800152.	1.2	10
6346	Concentration-Dependent Dual Effects of Ciprofloxacin on SB-590885-Resistant BRAF ^{V600E} A375 Melanoma Cells. <i>Chemical Research in Toxicology</i> , 2019, 32, 645-658.	1.7	5
6347	Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma. <i>Cancers</i> , 2019, 11, 356.	1.7	37
6348	Targeting FER Kinase Inhibits Melanoma Growth and Metastasis. <i>Cancers</i> , 2019, 11, 419.	1.7	15
6349	Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A α 1-C-Raf. <i>BMC Cancer</i> , 2019, 19, 266.	1.1	14
6350	BRAFV600E-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response. <i>Endocrine</i> , 2019, 64, 406-413.	1.1	28
6351	New strategy for the gene mutation identification using surface enhanced Raman spectroscopy (SERS). <i>Biosensors and Bioelectronics</i> , 2019, 132, 326-332.	5.3	40
6352	Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies. <i>Current Colorectal Cancer Reports</i> , 2019, 15, 53-60.	1.0	4
6353	The Role of the ER-Induced UPR Pathway and the Efficacy of Its Inhibitors and Inducers in the Inhibition of Tumor Progression. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-15.	1.9	50
6354	Mps1 is associated with the BRAFV600E mutation and predicts poor outcome in patients with colorectal cancer. <i>Oncology Letters</i> , 2019, 17, 2809-2817.	0.8	5

#	ARTICLE	IF	CITATIONS
6355	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1029-1043.	1.6	6
6356	Serum miRâ€22 may be a biomarker for papillary thyroid cancer. <i>Oncology Letters</i> , 2019, 17, 3355-3361.	0.8	13
6357	The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors. <i>Scientific Reports</i> , 2019, 9, 4390.	1.6	12
6358	<i>Clinical Ophthalmic Oncology.</i> , 2019, , .		5
6359	Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNÎ³ pathways. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 549-562.	12.5	72
6360	Natural products: An upcoming therapeutic approach to cancer. <i>Food and Chemical Toxicology</i> , 2019, 128, 240-255.	1.8	189
6361	Correlation of BRAF Variant V595E, Breed, Histological Grade and Cyclooxygenase-2 Expression in Canine Transitional Cell Carcinomas. <i>Veterinary Sciences</i> , 2019, 6, 31.	0.6	15
6362	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 381-392.	1.0	62
6363	Update on systemic therapy for colorectal cancer: biologics take sides. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 9-9.	1.5	22
6364	Divergent Dynamics and Functions of ERK MAP Kinase Signaling in Development, Homeostasis and Cancer: Lessons from Fluorescent Bioimaging. <i>Cancers</i> , 2019, 11, 513.	1.7	26
6365	Small Molecule Chemosensitizing Agents: Polo-Like Kinase 1 (Plk1), BRAF and Janus Kinase (JAK) Inhibitors. , 2019, , 169-185.		1
6366	Monoallelic expression in melanoma. <i>Journal of Translational Medicine</i> , 2019, 17, 112.	1.8	2
6367	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
6368	Medical Options for the Adjuvant Treatment and Management of Pediatric Melanoma. <i>Paediatric Drugs</i> , 2019, 21, 71-79.	1.3	4
6369	Ocular Complications of Targeted Therapy. , 2019, , 143-159.		0
6370	Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 2041-2051.	1.4	32
6371	Targeting the ERK Signaling Pathway in Melanoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1483.	1.8	116
6372	5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma. <i>Medicina (Lithuania)</i> , 2019, 55, 85.	0.8	18

#	ARTICLE	IF	CITATIONS
6373	Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With <i>BRAF</i> V600E Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1460-1469.	0.8	188
6374	Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients. <i>Cancer Medicine</i> , 2019, 8, 2157-2166.	1.3	27
6375	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. <i>Pharmacological Research</i> , 2019, 142, 151-168.	3.1	202
6376	Dissecting Intra-Tumor Heterogeneity by the Analysis of Copy Number Variations in Single Cells: The Neuroblastoma Case Study. <i>International Journal of Molecular Sciences</i> , 2019, 20, 893.	1.8	5
6377	Copper as the Target for Anticancer Nanomedicine. <i>Advanced Therapeutics</i> , 2019, 2, 1800147.	1.6	29
6378	Clonal analysis of early-stage bilateral papillary thyroid cancer identifies field cancerization. <i>Endocrine</i> , 2019, 64, 614-621.	1.1	5
6379	Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. <i>Cancer Treatment Reviews</i> , 2019, 74, 43-48.	3.4	38
6380	Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 111, 8-11.	1.3	6
6381	Sudden elevation of plasma D-dimer levels induced by the combination therapy of dabrafenib and trametinib: Report of two cases. <i>Journal of Dermatology</i> , 2019, 46, 358-360.	0.6	7
6382	Biomarker concordance between primary colorectal cancer and its metastases. <i>EBioMedicine</i> , 2019, 40, 363-374.	2.7	75
6383	Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation. <i>Cell Communication and Signaling</i> , 2019, 17, 12.	2.7	6
6384	Targeting Alterations in the RAF-MEK Pathway. <i>Cancer Discovery</i> , 2019, 9, 329-341.	7.7	282
6385	PIK3CA in cancer: The past 30 years. <i>Seminars in Cancer Biology</i> , 2019, 59, 36-49.	4.3	122
6386	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 765-772.	2.0	35
6387	Myelodysplastic Syndrome related alterations of MAPK signaling in the bone marrow of experimental mice including stem/progenitor compartment. <i>Acta Histochemica</i> , 2019, 121, 330-343.	0.9	6
6388	Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR. <i>Pathology Research and Practice</i> , 2019, 215, 761-765.	1.0	4
6389	Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management. <i>Seminars in Radiation Oncology</i> , 2019, 29, 166-170.	1.0	3
6390	Mutation status and surgical selection. <i>Journal of Surgical Oncology</i> , 2019, 119, 616-622.	0.8	5

#	ARTICLE	IF	CITATIONS
6391	An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer. , 2019, , 21-38.		1
6392	Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4583-4591.	3.3	33
6393	Update on emerging biomarkers in lung cancer. Journal of Thoracic Disease, 2019, 11, S81-S88.	0.6	23
6394	BRAF Mutation Status in Primary, Recurrent, and Metastatic Malignant Melanoma and Its Relation to Histopathological Parameters. Dermatology Practical and Conceptual, 2019, 9, 54-62.	0.5	21
6395	BRAF in the cross-hairs. Expert Review of Hematology, 2019, 12, 183-193.	1.0	0
6396	Lessons learned from exceptional responders. Expert Review of Precision Medicine and Drug Development, 2019, 4, 73-80.	0.4	0
6397	Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing. Oncologist, 2019, 24, 657-663.	1.9	5
6398	Primary malignant melanoma of esophagus: clinicopathologic characterization of 20 cases including molecular genetic profiling of 15 tumors. Modern Pathology, 2019, 32, 957-966.	2.9	19
6399	Microsatellite Instability Occurs in a Subset of Follicular Thyroid Cancers. Thyroid, 2019, 29, 523-529.	2.4	31
6400	Treatment in metastatic melanomaâ€”time to re-think. Annals of Oncology, 2019, 30, 501-503.	0.6	8
6401	Precision medicine: BRAF mutations in thyroid cancer. Precision Cancer Medicine, 2019, 2, 29-29.	1.8	2
6402	Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies. Cancer and Metastasis Reviews, 2019, 38, 625-642.	2.7	31
6403	Advances in the management of genitourinary melanomas. AME Medical Journal, 0, 4, 41-41.	0.4	3
6404	Adverse Event Management in Patients with <i>BRAF</i> V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. Oncologist, 2019, 24, 963-972.	1.9	16
6405	Mutation spectrum in GNAQ and GNA11 in Chinese uveal melanoma. Precision Clinical Medicine, 2019, 2, 213-220.	1.3	3
6406	Response to Anti-EGFR Therapy in Patients with BRAF non-V600â€”Mutant Metastatic Colorectal Cancer. Clinical Cancer Research, 2019, 25, 7089-7097.	3.2	79
6407	Characteristics of <i>BRAF</i> <i>V600E</i> Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. Oncologist, 2019, 24, e1331-e1340.	1.9	20
6408	Leveraging protein dynamics to identify cancer mutational hotspots using 3D structures. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 18962-18970.	3.3	26

#	ARTICLE	IF	CITATIONS
6409	Management of V600E and V600K BRAF-Mutant Melanoma. Current Treatment Options in Oncology, 2019, 20, 81.	1.3	28
6410	Immunohistochemical Study Using Monoclonal VE1 Antibody Can Substitute the Molecular Tests for Apprehension of BRAF V600E Mutation in Patients with Non-small-Cell Lung Carcinoma. Analytical Cellular Pathology, 2019, 2019, 1-6.	0.7	5
6411	Zebrafish Models of Cancer—New Insights on Modeling Human Cancer in a Non-Mammalian Vertebrate. Genes, 2019, 10, 935.	1.0	125
6412	Architecture of autoinhibited and active BRAF—MEK1—14-3-3 complexes. Nature, 2019, 575, 545-550.	13.7	197
6413	Severe Drug-Induced Liver Injury from Combination Encorafenib/Binimetinib. Case Reports in Oncological Medicine, 2019, 2019, 1-4.	0.2	2
6414	Immunization With the CSF-470 Vaccine Plus BCG and rhGM-CSF Induced in a Cutaneous Melanoma Patient a TCR ² Repertoire Found at Vaccination Site and Tumor Infiltrating Lymphocytes That Persisted in Blood. Frontiers in Immunology, 2019, 10, 2213.	2.2	9
6415	Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications, 2019, 10, 5157.	5.8	46
6416	Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. Nature Communications, 2019, 10, 5232.	5.8	17
6417	CPEM: Accurate cancer type classification based on somatic alterations using an ensemble of a Random forest and a deep neural network. Scientific Reports, 2019, 9, 16927.	1.6	21
6418	Somatic mutations in intracranial arteriovenous malformations. PLoS ONE, 2019, 14, e0226852.	1.1	51
6419	ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports, 2019, 9, 17471.	1.6	26
6420	Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells. Cancers, 2019, 11, 1866.	1.7	35
6421	MiRNA therapeutics based on logic circuits of biological pathways. BMC Bioinformatics, 2019, 20, 344.	1.2	11
6422	Mutational Profile of Driver Genes in Brazilian Melanomas. Journal of Global Oncology, 2019, 5, 1-14.	0.5	6
6423	Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?. Translational Gastroenterology and Hepatology, 2019, 4, 73-73.	1.5	4
6424	Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. Journal of Cancer, 2019, 10, 6114-6123.	1.2	3
6425	Molecular/Targeted Therapy of Cancer. , 2019, , 251-285.		0
6426	A Phage-Assisted Continuous Selection Approach for Deep Mutational Scanning of Protein—Protein Interactions. ACS Chemical Biology, 2019, 14, 2757-2767.	1.6	23

#	ARTICLE	IF	CITATIONS
6427	Protein kinase C- β is upregulated by IMP1 in melanoma and is linked to poor survival. <i>Melanoma Research</i> , 2019, 29, 539-543.	0.6	9
6428	Inflammatory side effects of BRAF and MEK inhibitors. <i>Melanoma Research</i> , 2019, 29, 522-526.	0.6	12
6429	Acral Lentiginous Melanomas Harbour Intratumor Heterogeneity in BRAF Exon 15, With Mutations Distinct From V600E/V600K. <i>American Journal of Dermatopathology</i> , 2019, 41, 733-740.	0.3	4
6430	The Impact of PI3-kinase/RAS Pathway Cooperating Mutations in the Evolution of <i>t(8;21) KMT2A</i> -rearranged Leukemia. <i>HemaSphere</i> , 2019, 3, e195.	1.2	9
6431	Immunohistochemistry as a Genetic Surrogate in Dermatopathology: Pearls and Pitfalls. <i>Advances in Anatomic Pathology</i> , 2019, 26, 390-420.	2.4	5
6432	The stabilization of equilibria in evolutionary game dynamics through mutation: mutation limits in evolutionary games. <i>Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences</i> , 2019, 475, 20190355.	1.0	6
6433	A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 2041.	1.7	17
6434	Evolving management of positive regional lymph nodes in melanoma: Past, present and future directions. <i>Oncology Reviews</i> , 2019, 13, 433.	0.8	9
6435	A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. <i>BMC Cancer</i> , 2019, 19, 1250.	1.1	93
6436	All-trans Retinoic Acid Overcomes Acquired Resistance to PLX4032 via Inhibition of PIN1 in Melanoma Cells. <i>Anticancer Research</i> , 2019, 39, 6537-6546.	0.5	5
6437	RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metalloproteinase 2. <i>Melanoma Research</i> , 2019, 29, 382-389.	0.6	65
6438	Effect of Sentinel Node Biopsy in Clinically N0, BRAF V600E-Mutated, Small Papillary Thyroid Carcinoma. <i>Clinical Nuclear Medicine</i> , 2019, 44, 359-364.	0.7	6
6439	Clinical Application of Next-Generation Sequencing-Based Panel to <i>BRAF</i> Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 937-944.	1.9	14
6440	Current treatment of optic nerve gliomas. <i>Current Opinion in Ophthalmology</i> , 2019, 30, 356-363.	1.3	56
6441	Novel small molecule decreases cell proliferation, migration, clone formation, and gene expression through ERK inhibition in MCF-7 and MDA-MB-231 breast cancer cell lines. <i>Anti-Cancer Drugs</i> , 2019, 30, 618-627.	0.7	5
6442	¹⁸ F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. <i>Melanoma Research</i> , 2019, 29, 178-186.	0.6	43
6443	Real-world treatment patterns and clinical outcomes among patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e16328.	0.4	30
6444	Filigree-like Rete Ridges, Lobulated Nests, Rosette-like Structures, and Exaggerated Maturation Characterize Spitz Tumors With NTRK1 Fusion. <i>American Journal of Surgical Pathology</i> , 2019, 43, 737-746.	2.1	55

#	ARTICLE	IF	CITATIONS
6445	An Integrated Model of Minor Intron Emergence and Conservation. <i>Frontiers in Genetics</i> , 2019, 10, 1113.	1.1	17
6446	Erdheim-Chester Disease: a Concise Review. <i>Current Rheumatology Reports</i> , 2019, 21, 66.	2.1	38
6447	Vemurafenib impairs the repair of ultraviolet radiation-induced DNA damage. <i>Melanoma Research</i> , 2019, 29, 134-144.	0.6	12
6448	Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1349-1363.	0.6	5
6449	Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets. <i>Cancers</i> , 2019, 11, 1972.	1.7	8
6450	Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond. <i>Current Oncology</i> , 2019, 26, 33-42.	0.9	7
6451	Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review. <i>Cancers</i> , 2019, 11, 1950.	1.7	24
6452	Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6191.	1.8	19
6453	Current and Emerging Biomarkers in Metastatic Colorectal Cancer. <i>Current Oncology</i> , 2019, 26, 7-15.	0.9	31
6454	Innovation in Oncology Drug Development. <i>Journal of Oncology</i> , 2019, 2019, 1-16.	0.6	10
6455	Resistance mechanism of the oncogenic G13C deletion mutation in BRAF kinase to dabrafenib and vemurafenib revealed by molecular dynamics simulations and binding free energy calculations. <i>Chemical Biology and Drug Design</i> , 2019, 93, 177-187.	1.5	6
6456	Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors. <i>European Biophysics Journal</i> , 2019, 48, 73-82.	1.2	11
6457	PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 1313-1325.	2.0	288
6458	Hyperactivation of MAPK Signaling Is Deleterious to RAS/RAF-mutant Melanoma. <i>Molecular Cancer Research</i> , 2019, 17, 199-211.	1.5	44
6459	DT-13 inhibited the proliferation of colorectal cancer via glycolytic metabolism and AMPK/mTOR signaling pathway. <i>Phytomedicine</i> , 2019, 54, 120-131.	2.3	38
6460	Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology. <i>Survey of Ophthalmology</i> , 2019, 64, 272-288.	1.7	25
6461	Genotoxic and cytotoxic effects of neolignans isolated from <i>Nectandra leucantha</i> (Lauraceae). <i>Toxicology in Vitro</i> , 2019, 55, 116-123.	1.1	6
6462	ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma. <i>Cancers</i> , 2019, 11, 3.	1.7	26

#	ARTICLE	IF	CITATIONS
6463	The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 568-577.	1.4	25
6464	Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 128, 74-90.	0.9	13
6465	BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 143-148.	1.9	16
6466	Indications for the surgical resection of stage IV disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 249-261.	0.8	14
6467	Rational combination of cancer immunotherapy in melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 433-447.	1.4	7
6468	ER stress promotes antitumor effects in BRAFi/MEKi resistant human melanoma induced by natural compound 4-nerolidylcatechol (4-NC). <i>Pharmacological Research</i> , 2019, 141, 63-72.	3.1	14
6469	High prevalence of KRAS/BRAF somatic mutations in brain and spinal cord arteriovenous malformations. <i>Brain</i> , 2019, 142, 23-34.	3.7	107
6470	KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 706-717.	1.9	45
6471	Oxidative stress generated by irradiation of a zinc(II) phthalocyanine induces a dual apoptotic and necrotic response in melanoma cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2019, 24, 119-134.	2.2	16
6472	RNA-DNA fibers and polygons with controlled immunorecognition activate RNAi, FRET and transcriptional regulation of NF- κ B in human cells. <i>Nucleic Acids Research</i> , 2019, 47, 1350-1361.	6.5	64
6473	Effects of Oncogenic G1 \pm q and G1 \pm 11 Inhibition by FR900359 in Uveal Melanoma. <i>Molecular Cancer Research</i> , 2019, 17, 963-973.	1.5	68
6474	The atypical MAPK ERK3 potently suppresses melanoma cell growth and invasiveness. <i>Journal of Cellular Physiology</i> , 2019, 234, 13220-13232.	2.0	14
6475	Advanced stage melanoma therapies: Detailing the present and exploring the future. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 99-111.	2.0	48
6476	Multicentric Squamous Cell Tumors in Panther Chameleons (<i>Furcifer pardalis</i>). <i>Journal of Exotic Pet Medicine</i> , 2019, 29, 166-172.	0.2	3
6477	Severe vemurafenib-induced photosensitivity in a 6-year-old boy. <i>Pediatric Dermatology</i> , 2019, 36, e62-e63.	0.5	5
6478	IMP1 3' UTR shortening enhances metastatic burden in colorectal cancer. <i>Carcinogenesis</i> , 2019, 40, 569-579.	1.3	16
6479	BRAF-Mutant Melanoma. , 2019, , 655-668.		0
6480	BRAF mutation testing in melanoma: results from a German observational multicenter study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 71-78.	1.4	1

#	ARTICLE	IF	CITATIONS
6481	Induction of MNK Kinase-dependent eIF4E Phosphorylation by Inhibitors Targeting BET Proteins Limits Efficacy of BET Inhibitors. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 235-244.	1.9	14
6482	High concordance of BRAF mutational status in matched primary and metastatic melanoma. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 117-122.	0.7	10
6483	Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma. <i>Cancer Letters</i> , 2019, 442, 453-463.	3.2	33
6484	Targeting tyrosine kinases for treatment of ocular tumors. <i>Archives of Pharmacal Research</i> , 2019, 42, 305-318.	2.7	5
6485	E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon- γ in Advanced Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 524-532.	3.2	8
6486	A comparative analysis of KMT2D missense variants in Kabuki syndrome, cancers and the general population. <i>Journal of Human Genetics</i> , 2019, 64, 161-170.	1.1	26
6487	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 190-194.	0.7	6
6488	Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 446-461.	1.3	15
6489	Thyroid Nodule: Current Evaluation and Management. , 2019, , 493-516.		4
6490	Coding Molecular Determinants of Thyroid Cancer Development and Progression. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 37-59.	1.2	21
6491	Nivolumab to pembrolizumab switch induced a durable melanoma response. <i>Medicine (United States)</i> , 2019, 98, e13804.	0.4	14
6492	A high-performance liquid chromatography-tandem mass spectrometry method for the determination of lifrafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine and its application in clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 166, 20-29.	1.4	1
6493	EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells. <i>EBioMedicine</i> , 2019, 39, 194-206.	2.7	31
6494	Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. <i>Scientific Reports</i> , 2019, 9, 30.	1.6	22
6495	Role of ultrasonographic features and quantified BRAFV600E mutation in lymph node metastasis in Chinese patients with papillary thyroid carcinoma. <i>Scientific Reports</i> , 2019, 9, 75.	1.6	33
6496	Autosomal dominant polycystic kidney disease: Disrupted pathways and potential therapeutic interventions. <i>Journal of Cellular Physiology</i> , 2019, 234, 12451-12470.	2.0	32
6497	Relationship between the upregulation of Notch1 signaling and the clinical characteristics of patients with papillary thyroid carcinoma in East Asia: a systematic review and meta-analysis. <i>Cancer Cell International</i> , 2019, 19, 5.	1.8	5
6498	Translation regulation in skin cancer from a tRNA point of view. <i>Epigenomics</i> , 2019, 11, 215-245.	1.0	25

#	ARTICLE	IF	CITATIONS
6499	Biophysical simulations and structure-based modeling of residue interaction networks in the tumor suppressor proteins reveal functional role of cancer mutation hotspots in molecular communication. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2019, 1863, 210-225.	1.1	24
6500	Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e208-e217.	1.1	9
6501	Melanoma: Where we are and where we go. <i>Journal of Cellular Physiology</i> , 2019, 234, 3307-3320.	2.0	53
6502	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019, 125, 463-472.	2.0	10
6503	Anticipation of food intake induces phosphorylation switch to regulate basolateral amino acid transporter LAT4 (SLC43A2) function. <i>Journal of Physiology</i> , 2019, 597, 521-542.	1.3	11
6504	Signal transducer and activator of transcription 3 inhibition enhances vemurafenib sensitivity in colon cancers harboring the BRAF ^{V600E} mutation. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 5315-5325.	1.2	8
6505	Inhibition of extracellular signal-regulated kinase potentiates the apoptotic and antimetastatic effects of cyclin-dependent kinase inhibitors on metastatic DU145 and PC3 prostate cancer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 5558-5569.	1.2	2
6507	Defining the Molecular Genetics of Dermoscopic Naevus Patterns. <i>Dermatology</i> , 2019, 235, 19-34.	0.9	10
6508	Detection of driver mutations in FFPE samples from patients with verified malignant melanoma. <i>Neoplasma</i> , 2019, 66, 33-38.	0.7	8
6509	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. <i>Annual Review of Cancer Biology</i> , 2019, 3, 385-408.	2.3	17
6510	Forkhead box O4 transcription factor in human neoplasms: Cannot afford to lose the novel suppressor. <i>Journal of Cellular Physiology</i> , 2019, 234, 8647-8658.	2.0	6
6512	Cancer3D 2.0: interactive analysis of 3D patterns of cancer mutations in cancer subsets. <i>Nucleic Acids Research</i> , 2019, 47, D895-D899.	6.5	12
6513	Mit/TFE Family of Transcription Factors, Lysosomes, and Cancer. <i>Annual Review of Cancer Biology</i> , 2019, 3, 203-222.	2.3	97
6514	Mutant p53 in colon cancer. <i>Journal of Molecular Cell Biology</i> , 2019, 11, 267-276.	1.5	170
6515	Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review. <i>Journal of Oral Pathology and Medicine</i> , 2019, 48, 201-205.	1.4	41
6516	Rapid discrimination of colon cancer cells with single base mutation in KRAS gene segment using laser tweezers Raman spectroscopy. <i>Journal of Biophotonics</i> , 2019, 12, e201800332.	1.1	8
6517	Spinal cord astrocytomas: progresses in experimental and clinical investigations for developing recovery neurobiology-based novel therapies. <i>Experimental Neurology</i> , 2019, 311, 135-147.	2.0	16
6518	Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 292-302.	1.5	17

#	ARTICLE	IF	CITATIONS
6519	Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 576-586.	1.7	40
6520	Homeopathy Seen as Personalised Nanomedicine. <i>Homeopathy</i> , 2019, 108, 066-070.	0.5	10
6521	Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis. <i>Journal of Cellular Physiology</i> , 2019, 234, 6731-6745.	2.0	18
6522	Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability. <i>Briefings in Bioinformatics</i> , 2019, 20, 254-266.	3.2	46
6523	Co-dependency between KRAS addiction and ARHGEF2 promotes an adaptive escape from MAPK pathway inhibition. <i>Small GTPases</i> , 2019, 10, 441-448.	0.7	5
6524	Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review. <i>Pathology and Oncology Research</i> , 2019, 25, 349-359.	0.9	24
6525	Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications. <i>Seminars in Cancer Biology</i> , 2019, 54, 14-28.	4.3	51
6526	New insights into RAS biology reinvigorate interest in mathematical modeling of RAS signaling. <i>Seminars in Cancer Biology</i> , 2019, 54, 162-173.	4.3	16
6527	Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. <i>Journal of Neurosurgery</i> , 2019, 130, 1299-1303.	0.9	49
6528	FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA. <i>Retina</i> , 2019, 39, 502-513.	1.0	27
6529	Evaluation of a DNA Extraction and Purification Protocol Using Archived Formalin-fixed Paraffin-embedded Tissues for BRAF Mutations Analysis in Papillary Thyroid Microcarcinomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 70-76.	0.6	3
6530	Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. <i>Wiener Medizinische Wochenschrift</i> , 2019, 169, 314-322.	0.5	5
6531	Primary Mediastinal Yolk Sac Tumors: An Immunohistochemical Analysis of 14 Cases. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 125-133.	0.6	12
6532	PAX8-positive Biphasic Synovial Sarcoma Expressing Hormonal Receptors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, e71-e74.	0.6	3
6533	Small change, big effect: Taking RAS by the tail through suppression of post-prenylation carboxymethylation. <i>Small GTPases</i> , 2020, 11, 271-279.	0.7	3
6534	Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Pathology and Oncology Research</i> , 2020, 26, 317-325.	0.9	20
6535	Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?. <i>Annals of Surgery</i> , 2020, 271, 147-154.	2.1	82
6536	Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status. <i>Journal of Surgical Research</i> , 2020, 246, 325-334.	0.8	15

#	ARTICLE	IF	CITATIONS
6537	Detection of cell-free circulating <i>BRAF</i> ^{V600E} by droplet digital polymerase chain reaction in patients with and without melanoma under dermatological surveillance. <i>British Journal of Dermatology</i> , 2020, 182, 382-389.	1.4	7
6538	Targeting metabolic reprogramming in metastatic melanoma: The key role of nicotinamide phosphoribosyltransferase (NAMPT). <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 192-201.	2.3	30
6539	Immunohistochemical assessment of growth factor signaling molecules: MAPK, Akt, and STAT3 pathways in oral epithelial precursor lesions and squamous cell carcinoma. <i>Odontology / the Society of the Nippon Dental University</i> , 2020, 108, 91-101.	0.9	14
6540	Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 419-432.	1.2	55
6541	<i>Cancer Immunology</i> , 2020, , 84-96.e5.		0
6542	The <i>BRAF</i> p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2020, 129, 229-235.	0.2	12
6543	Automated in vivo screen in zebrafish identifies Clotrimazole as targeting a metabolic vulnerability in a melanoma model. <i>Developmental Biology</i> , 2020, 457, 215-225.	0.9	12
6544	Pathway perturbations in signaling networks: Linking genotype to phenotype. <i>Seminars in Cell and Developmental Biology</i> , 2020, 99, 3-11.	2.3	13
6545	Genome-wide screening identifies novel genes implicated in cellular sensitivity to <i>BRAF</i> ^{V600E} expression. <i>Oncogene</i> , 2020, 39, 723-738.	2.6	11
6546	Recurrent <i>KRAS</i> mutations in papillary renal neoplasm with reverse polarity. <i>Modern Pathology</i> , 2020, 33, 1157-1164.	2.9	48
6548	Rapid fully-automated assay for routine molecular diagnosis of <i>BRAF</i> mutations for personalized therapy of low grade gliomas. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 29-40.	0.3	4
6549	Pathways of Colorectal Carcinogenesis. <i>Gastroenterology</i> , 2020, 158, 291-302.	0.6	241
6550	Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 1-11.	3.3	13
6551	<i>Pathology, Biomarkers, and Molecular Diagnostics</i> , 2020, , 225-253.e8.		4
6552	Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 11-26.	2.5	8
6553	Dabrafenib in <i>BRAF</i> ^{V600E} mutant pilocytic astrocytoma in a pediatric patient. <i>Child's Nervous System</i> , 2020, 36, 203-207.	0.6	8
6554	<i>DYNLRB1</i> regulation of MEK/ERK signaling and <i>Ras</i> in invasive human colorectal cancer cells. <i>Cell Biology International</i> , 2020, 44, 155-165.	1.4	6
6555	<i>HO</i> ¹ downregulation favors <i>BRAF</i> V600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition. <i>International Journal of Cancer</i> , 2020, 146, 1950-1962.	2.3	19

#	ARTICLE	IF	CITATIONS
6556	SHARPIN Promotes Melanoma Progression via RAp1 Signaling Pathway. <i>Journal of Investigative Dermatology</i> , 2020, 140, 395-403.e6.	0.3	36
6557	Molecular Genetics and the Role of Molecularly Targeted Agents in Metastatic Colorectal Carcinoma. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 387-400.	0.6	6
6558	Gene mutation and surgical technique: Suggestion or more?. <i>Surgical Oncology</i> , 2020, 33, 210-215.	0.8	10
6559	Dermoscopic features in BRAF and NRAS primary cutaneous melanoma: association with peppering and blue-white veil. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e57-e59.	1.3	5
6560	Aberrant epigenetic inactivation of RASSF1A and MGMT gene and genetic mutations of KRAS, cKIT and BRAF in Indian testicular germ cell tumours. <i>Cancer Genetics</i> , 2020, 241, 42-50.	0.2	7
6561	Surgical Considerations and Systemic Therapy of Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 141-159.	0.5	4
6562	Principles of Targeted Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 175-188.	0.5	40
6563	A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. <i>International Journal of Cancer</i> , 2020, 146, 1409-1420.	2.3	22
6564	From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 years. <i>Human Pathology</i> , 2020, 95, 149-160.	1.1	6
6565	Translational pathology, genomics and the development of systemic therapies for acral melanoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 149-157.	4.3	30
6566	Melanocytic aggregates with unique morphology associated with regression of basal cell carcinoma. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 219-225.	0.7	3
6567	Image Guided Dermatologic Treatments. , 2020, , .		4
6568	Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2020, 1864, 129448.	1.1	13
6569	Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 390-402.	1.5	19
6571	Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. , 2020, 206, 107438.		117
6572	Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2020, 36, 126-134.	0.7	6
6573	Prevalence of NRAS Mutation, PD-L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas. <i>Oncologist</i> , 2020, 25, e291-e301.	1.9	13
6574	T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAFV600E Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1253-1265.	0.3	17

#	ARTICLE	IF	CITATIONS
6575	Therapeutic potential of targeting mixed lineage kinases in cancer and inflammation. , 2020, 207, 107457.		12
6576	MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis. Pathology Research and Practice, 2020, 216, 152791.	1.0	24
6577	Intermittent Versus Continuous Dosing of MAPK Inhibitors in the Treatment of BRAF-Mutated Melanoma. Translational Oncology, 2020, 13, 275-286.	1.7	13
6578	Role of GPCRs in cancer. , 2020, , 463-474.		1
6579	Functionalization of Nanomaterials and Their Application in Melanoma Cancer Theranostics. ACS Biomaterials Science and Engineering, 2020, 6, 167-181.	2.6	28
6580	Neoadjuvant therapy with vemurafenib in Horner's syndrome as a very rare first diagnosis of a malignant melanoma of unknown primary. JDDG - Journal of the German Society of Dermatology, 2020, 18, 47-49.	0.4	0
6581	The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies" Theranostics, 2020, 10, 1777-1797.	4.6	44
6582	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 2020, 30, 261-267.	0.6	27
6584	Metabolic imaging using hyperpolarized ¹³ C-pyruvate to assess sensitivity to the BRAF inhibitor vemurafenib in melanoma cells and xenografts. Journal of Cellular and Molecular Medicine, 2020, 24, 1934-1944.	1.6	13
6585	SnapshotDx Quiz: January 2020. Journal of Investigative Dermatology, 2020, 140, e1-e6.	0.3	0
6586	The Significance of Molecular Biomarkers on Clinical Survival Outcome Differs Depending on Colon Cancer Sidedness. Anticancer Research, 2020, 40, 201-211.	0.5	2
6587	Targeting fusions for improved outcomes in oncology treatment. Cancer, 2020, 126, 1315-1321.	2.0	14
6588	Chemotherapy in chronic kidney disease and dialysis. , 2020, , 183-196.e7.		0
6589	Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours. British Journal of Cancer, 2020, 122, 564-568.	2.9	8
6590	SSIPE: accurately estimating protein-protein binding affinity change upon mutations using evolutionary profiles in combination with an optimized physical energy function. Bioinformatics, 2020, 36, 2429-2437.	1.8	42
6591	Heterotrimeric G Proteins as Therapeutic Targets in Drug Discovery. Journal of Medicinal Chemistry, 2020, 63, 5013-5030.	2.9	23
6592	Primary sellar melanocytoma: pathological, clinical and treatment review. Journal of Endocrinological Investigation, 2020, 43, 575-585.	1.8	4
6593	Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma. British Journal of Cancer, 2020, 122, 506-516.	2.9	16

#	ARTICLE	IF	CITATIONS
6594	The clinical characteristics of melanoma with BRAF V600R mutation: a case series study. <i>Melanoma Research</i> , 2020, 30, 107-112.	0.6	6
6595	Characterization of glycolysis-related gene expression in malignant melanoma. <i>Pathology Research and Practice</i> , 2020, 216, 152752.	1.0	22
6596	Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia. <i>Oncologist</i> , 2020, 25, e170-e177.	1.9	15
6597	<i>BRAF</i> molecular testing in cytopathology: Implications for diagnosis, prognosis, and targeted therapeutics. <i>Cancer Cytopathology</i> , 2020, 128, 9-11.	1.4	1
6598	Detection of BRAF V600E mutation by immunohistochemistry and PCR-RFLP in Moroccan patients with Pediatric Low-Grade Gliomas. <i>Gene Reports</i> , 2020, 18, 100572.	0.4	0
6599	Partial response in hairy cell leukemia with vemurafenib despite early discontinuation due to agranulocytosis. <i>Anti-Cancer Drugs</i> , 2020, 31, 196-198.	0.7	1
6600	Study of fatty acid profiles in fish wastes and in silico evaluation of unsaturated fatty acids for mutant <i>BRAF</i> kinase inhibition. <i>Journal of Food Process Engineering</i> , 2020, 43, e13272.	1.5	1
6601	Connecting Cancer Pathways to Tumor Engines: A Stratification Tool for Colorectal Cancer Combining Human In Vitro Tissue Models with Boolean In Silico Models. <i>Cancers</i> , 2020, 12, 28.	1.7	14
6602	Genomic Mutation as A Potential Driver of The Development of Bone-Related Cancers. , 2020, , 273-280.		0
6603	Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours. <i>Journal of Oncology</i> , 2020, 2020, 1-14.	0.6	14
6604	Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 1748.	1.3	9
6605	Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment. <i>Cancers</i> , 2020, 12, 2799.	1.7	8
6606	Drug-Induced Uveitis: Part 1. <i>Advances in Ophthalmology and Optometry</i> , 2020, 5, 265-306.	0.3	0
6607	Oncogenic mutation in RAS- <i>RAF</i> axis leads to increased expression of GREB1 , resulting in tumor proliferation in colorectal cancer. <i>Cancer Science</i> , 2020, 111, 3540-3549.	1.7	5
6608	SnapshotDx Quiz: November 2020. <i>Journal of Investigative Dermatology</i> , 2020, 140, e121-e126.	0.3	0
6609	Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1957.	3.4	46
6611	Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma. <i>Archives of Medical Research</i> , 2020, 51, 827-838.	1.5	17
6612	Isolation of extracellular vesicles improves the detection of mutant DNA from plasma of metastatic melanoma patients. <i>Scientific Reports</i> , 2020, 10, 15745.	1.6	41

#	ARTICLE	IF	CITATIONS
6613	iGMDR: Integrated Pharmacogenetic Resource Guide to Cancer Therapy and Research. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 150-160.	3.0	5
6614	New insights on the role of autophagy in the pathogenesis and treatment of melanoma. <i>Molecular Biology Reports</i> , 2020, 47, 9021-9032.	1.0	22
6615	Modeling and analysis of site-specific mutations in cancer identifies known plus putative novel hotspots and bias due to contextual sequences. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 1664-1675.	1.9	5
6616	Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103119.	2.0	97
6617	BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103118.	2.0	17
6618	Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. <i>Journal of Neuro-Oncology</i> , 2020, 149, 463-472.	1.4	10
6619	Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma. <i>International Immunopharmacology</i> , 2020, 88, 106971.	1.7	7
6620	Dimerization Induced by C-Terminal 14 ^{aa} Binding Is Sufficient for BRAF Kinase Activation. <i>Biochemistry</i> , 2020, 59, 3982-3992.	1.2	29
6621	Harnessing Omics Approaches on Advanced Preclinical Models to Discovery Novel Therapeutic Targets for the Treatment of Metastatic Colorectal Cancer. <i>Cancers</i> , 2020, 12, 1830.	1.7	2
6622	Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. <i>Gastroenterology Report</i> , 2020, 8, 179-191.	0.6	60
6623	Cationic Lipid-based Intracellular Delivery of Bacterial Effectors for Rewiring Malignant Cell Signaling. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 18087-18094.	7.2	27
6624	Does nutrition for cancer patients feed the tumour? A clinical perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103061.	2.0	17
6625	Elevated BANC expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1835-1842.	0.5	6
6626	Activation Loop Dynamics Are Coupled to Core Motions in Extracellular Signal-Regulated Kinase-2. <i>Biochemistry</i> , 2020, 59, 2698-2706.	1.2	15
6627	BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. <i>Gastroenterology Report</i> , 2020, 8, 192-205.	0.6	59
6628	Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256.	3.4	38
6629	Next Generation Kinase Inhibitors. , 2020, , .		8
6630	Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 100-108.	2.0	12

#	ARTICLE	IF	CITATIONS
6631	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> V600E/K-mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5102-5112.	3.2	23
6632	Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients. <i>Cancers</i> , 2020, 12, 1871.	1.7	14
6633	Rapid BRAF Mutation Testing in Pigmented Melanomas. <i>American Journal of Dermatopathology</i> , 2020, 42, 343-348.	0.3	7
6634	Targeted and immunotherapies in <i>BRAF</i> mutant melanoma: where we stand and what to expect. <i>British Journal of Dermatology</i> , 2021, 185, 253-262.	1.4	20
6635	<i>BRAF</i> and <i>KRAS</i> Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 595-600.	0.3	5
6636	Clinical significance of eukaryotic translation initiation factor 5A2 in papillary thyroid cancer. <i>Bioengineered</i> , 2020, 11, 1325-1333.	1.4	3
6637	<i>BRAF</i> ^{V595E} Mutation Associates CCL17 Expression and Regulatory T Cell Recruitment in Urothelial Carcinoma of Dogs. <i>Veterinary Pathology</i> , 2021, 58, 971-980.	0.8	7
6638	Prevention of Melanoma Extravasation as a New Treatment Option Exemplified by p38/MK2 Inhibition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8344.	1.8	3
6639	Outcomes of Treatment for Melanoma Brain Metastases. <i>Journal of Skin Cancer</i> , 2020, 2020, 1-10.	0.5	11
6640	Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks. <i>Genes</i> , 2020, 11, 1342.	1.0	58
6641	Cell Death Mechanisms Induced by CLytA-DAAO Chimeric Enzyme in Human Tumor Cell Lines. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8522.	1.8	8
6642	PTMsnP: A Web Server for the Identification of Driver Mutations That Affect Protein Post-translational Modification. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 593661.	1.8	7
6643	Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 31105-31113.	3.3	9
6644	Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. <i>Cancers</i> , 2020, 12, 3456.	1.7	12
6645	CDK4/6 and MAPK Crosstalk as Opportunity for Cancer Treatment. <i>Pharmaceuticals</i> , 2020, 13, 418.	1.7	28
6646	Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements towards Individualizing the Treatment. <i>Cancers</i> , 2020, 12, 3481.	1.7	9
6647	BRAF: A Two-Faced Janus. <i>Cells</i> , 2020, 9, 2549.	1.8	23
6648	Regulatory Single Nucleotide Polymorphism Increases <i>TERT</i> Promoter Activity in Thyroid Carcinoma Cells. <i>Pathobiology</i> , 2020, 87, 338-344.	1.9	1

#	ARTICLE	IF	CITATIONS
6649	Whole Exome Sequencing of <i>SMO</i> , <i>BRAF</i> , <i>PTCH1</i> and <i>GNAS</i> in Odontogenic Diseases. <i>In Vivo</i> , 2020, 34, 3233-3240.	0.6	6
6650	RAGE Signaling in Melanoma Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8989.	1.8	13
6651	The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9107.	1.8	28
6652	The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy. <i>Cancers</i> , 2020, 12, 3594.	1.7	126
6653	Identification and Characterization of a B-Raf Kinase α -Helix Critical for the Activity of MEK Kinase in MAPK Signaling. <i>Biochemistry</i> , 2020, 59, 4755-4765.	1.2	4
6654	The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?. <i>Molecular Cancer</i> , 2020, 19, 170.	7.9	32
6655	Prediction of driver variants in the cancer genome via machine learning methodologies. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	13
6656	SOX4 Mediates BRAF Inhibitor Resistance in Melanoma through Regulation of IGF-1R Signaling: In Vitro Study. <i>International Journal of Dermatology and Venereology</i> , 2020, 3, 156-165.	0.1	1
6657	Targeting NF- κ B-Inducing Kinase (NIK) in Immunity, Inflammation, and Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8470.	1.8	82
6658	3D in vitro cutaneous melanoma models. , 2020, , 287-303.		0
6659	MiR-9-5p Inhibits the Proliferation, Migration and Invasion of Choroidal Melanoma by Targeting BRAF. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382095698.	0.8	7
6660	Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127478.	1.0	11
6661	Small molecule inhibitors of RAS proteins with oncogenic mutations. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1107-1126.	2.7	15
6662	Identification and validation of an immune prognostic signature in colorectal cancer. <i>International Immunopharmacology</i> , 2020, 88, 106868.	1.7	21
6663	A compendium of mutational cancer driver genes. <i>Nature Reviews Cancer</i> , 2020, 20, 555-572.	12.8	605
6664	The non-linearity of RAF-MEK signaling in dendritic cells. <i>Cell Cycle</i> , 2020, 19, 2249-2259.	1.3	5
6665	Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> ^{V600E} Mutations: Results of the NCI-MATCH Trial Subprotocol H. <i>Journal of Clinical Oncology</i> , 2020, 38, 3895-3904.	0.8	145
6666	Cationic Lipid-based Intracellular Delivery of Bacterial Effectors for Rewiring Malignant Cell Signaling. <i>Angewandte Chemie</i> , 2020, 132, 18243-18250.	1.6	9

#	ARTICLE	IF	CITATIONS
6667	Ameloblastoma: A succinct review of the classification, genetic understanding and novel molecular targeted therapies. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2021, 19, 238-243.	0.8	30
6668	Genomic Alterations and Their Implications on Survival in Nonmetastatic Colorectal Cancer: Status Quo and Future Perspectives. <i>Cancers</i> , 2020, 12, 2001.	1.7	2
6669	Pediatric meningioma: a clinicopathologic and molecular study with potential grading implications. <i>Brain Pathology</i> , 2020, 30, 1134-1143.	2.1	17
6670	Design, synthesis and molecular modeling of phenyl dihydropyridazinone derivatives as B-Raf inhibitors with anticancer activity. <i>Bioorganic Chemistry</i> , 2020, 103, 104148.	2.0	11
6671	Preclinical discovery and clinical development of encorafenib for the treatment of melanoma. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 1373-1380.	2.5	7
6672	Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5025.	1.8	8
6673	Plasmacytoid Dendritic Cell Impairment in Metastatic Melanoma by Lactic Acidosis. <i>Cancers</i> , 2020, 12, 2085.	1.7	17
6674	Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer. <i>European Journal of Medicinal Chemistry</i> , 2020, 206, 112675.	2.6	16
6675	Comparison of BRAF Mutation Screening Strategies in a Large Real-Life Series of Advanced Melanoma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 2430.	1.0	10
6676	Clinical Development of BRAF plus MEK Inhibitor Combinations. <i>Trends in Cancer</i> , 2020, 6, 797-810.	3.8	169
6677	Investigation of essential cell cycle regulator genes as candidates for immortalized shrimp cell line establishment based on the effect of in vitro culturing on gene expression of shrimp primary cells. <i>Aquaculture</i> , 2020, 529, 735733.	1.7	4
6678	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 687-701.	1.1	6
6679	TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma. <i>Cancers</i> , 2020, 12, 2224.	1.7	8
6680	Tyrosinase-activated prodrug nanomedicine as oxidative stress amplifier for melanoma-specific treatment. <i>Biomaterials</i> , 2020, 259, 120329.	5.7	41
6681	<p>>Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 3137-3152.	0.9	12
6682	Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7649.	1.8	6
6683	KRAS or BRAF mutations cause hepatic vascular cavernomas treatable with MAP2KâMAPK1 inhibition. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	10
6684	Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient. <i>Scientific Reports</i> , 2020, 10, 17455.	1.6	1

#	ARTICLE	IF	CITATIONS
6685	CIC Is a Mediator of the ERK1/2-DUSP6 Negative Feedback Loop. <i>IScience</i> , 2020, 23, 101635.	1.9	22
6686	KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 227.	3.5	49
6687	BRAF G469A, BRAF L597V, FGFR1 N546K, FGFR1 K656E and P53 R273H mutations: How are they distributed in Moroccan patients with pediatric Low-Grade Gliomas?. <i>Gene Reports</i> , 2020, 21, 100885.	0.4	1
6688	PREVALENCE OF MISMATCH REPAIR GENE MUTATIONS IN UVEAL MELANOMA. <i>Retina</i> , 2020, 40, 2216-2220.	1.0	4
6689	Retrospective Cohort: Genomic Differences Between Pigmented Spindle Cell Nevi of Reed and Reed-Like Melanomas. <i>American Journal of Dermatopathology</i> , 2020, 42, 641-647.	0.3	0
6690	New Insights into the Role of Sphingolipid Metabolism in Melanoma. <i>Cells</i> , 2020, 9, 1967.	1.8	15
6691	Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated â€“ NIVACOR trial (GOIRC-03-2018). <i>BMC Cancer</i> , 2020, 20, 822.	1.1	13
6692	An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAFâ€“mutant advanced melanoma treated with firstâ€“line antiâ€“PDâ€“1 monotherapies or BRAF/MEK inhibitors in a communityâ€“based oncology setting. <i>Cancer Medicine</i> , 2020, 9, 7863-7878.	1.3	4
6693	Decoding the Role of CD271 in Melanoma. <i>Cancers</i> , 2020, 12, 2460.	1.7	15
6694	Tumors Responsive to Autophagy-Inhibition: Identification and Biomarkers. <i>Cancers</i> , 2020, 12, 2463.	1.7	4
6695	Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test. <i>Disease Markers</i> , 2020, 2020, 1-10.	0.6	4
6696	The transcription factor NRF2 enhances melanoma malignancy by blocking differentiation and inducing COX2 expression. <i>Oncogene</i> , 2020, 39, 6841-6855.	2.6	53
6697	Multiple signaling pathways converge on proapoptotic protein BAD to promote survival of melanocytes. <i>FASEB Journal</i> , 2020, 34, 14602-14614.	0.2	5
6698	Comparison of Hydrogels for the Development of Well-Defined 3D Cancer Models of Breast Cancer and Melanoma. <i>Cancers</i> , 2020, 12, 2320.	1.7	22
6699	Novel genetic alteration in congenital melanocytic nevus: MAP2K1 germline mutation with BRAF somatic mutation. <i>Hereditas</i> , 2020, 157, 35.	0.5	3
6700	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 172.	1.6	25
6701	The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. <i>Journal of Gastrointestinal Cancer</i> , 2021, 52, 932-939.	0.6	1
6702	Isolation and Characterization of Two Novel Colorectal Cancer Cell Lines, Containing a Subpopulation with Potential Stem-Like Properties: Treatment Options by MYC/NMYC Inhibition. <i>Cancers</i> , 2020, 12, 2582.	1.7	10

#	ARTICLE	IF	CITATIONS
6703	From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 511-525.	2.6	13
6704	Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2020, 15, 567-577.	1.7	14
6705	Inhibitors of BRAF dimers using an allosteric site. <i>Nature Communications</i> , 2020, 11, 4370.	5.8	48
6706	Making NSCLC Crystal Clear: How Kinase Structures Revolutionized Lung Cancer Treatment. <i>Crystals</i> , 2020, 10, 725.	1.0	4
6707	Mast Cells, microRNAs and Others: The Role of Translational Research on Colorectal Cancer in the Forthcoming Era of Precision Medicine. <i>Journal of Clinical Medicine</i> , 2020, 9, 2852.	1.0	39
6708	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	0.6	14
6709	Visualizing Subcellular Enrichment of Glycogen in Live Cancer Cells by Stimulated Raman Scattering. <i>Analytical Chemistry</i> , 2020, 92, 13182-13191.	3.2	28
6710	Function and evolution of B-Raf loop dynamics relevant to cancer recurrence under drug inhibition. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 468-483.	2.0	12
6713	B-Raf-Mutated Melanoma. , 2020, , .		0
6714	The Malignant Role of Exosomes as Nanocarriers of Rare RNA Species. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5866.	1.8	16
6715	ERK1/2 Signaling Induces Upregulation of ANGPT2 and CXCR4 to Mediate Liver Metastasis in Colon Cancer. <i>Cancer Research</i> , 2020, 80, 4668-4680.	0.4	35
6716	Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000â€”2016. <i>Cancers</i> , 2020, 12, 2354.	1.7	8
6717	Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives. <i>Cancers</i> , 2020, 12, 2362.	1.7	22
6718	Role of serine 365 in BRAF V600E sensitivity to RAF inhibition. <i>Pigment Cell and Melanoma Research</i> , 2020, 34, 696-702.	1.5	2
6719	Use of DNA methylation profiling in translational oncology. <i>Seminars in Cancer Biology</i> , 2022, 83, 523-535.	4.3	36
6720	NAMPT Over-Expression Recapitulates the BRAF Inhibitor Resistant Phenotype Plasticity in Melanoma. <i>Cancers</i> , 2020, 12, 3855.	1.7	17
6721	Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9730.	1.8	15
6722	Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. <i>Scientific Reports</i> , 2020, 10, 18878.	1.6	16

#	ARTICLE	IF	CITATIONS
6723	Polyamines and related signaling pathways in cancer. <i>Cancer Cell International</i> , 2020, 20, 539.	1.8	68
6724	BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation. <i>Cancers</i> , 2020, 12, 3236.	1.7	23
6726	Uveal melanoma: progress in molecular biology and therapeutics. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096585.	1.4	29
6727	Targeted Molecular Therapy in Palliative Cancer Management. , 2020, 5, .		1
6728	The Coexistence of Genetic Mutations in Thyroid Carcinoma Predicts Histopathological Factors Associated With a Poor Prognosis: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 540238.	1.3	20
6730	Evaluation of the expression levels of BRAFV600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay. <i>BMC Cancer</i> , 2020, 20, 368.	1.1	6
6731	Amplification of 3q26.2, 5q14.3, 8q24.3, 8q22.3, and 14q32.33 Are Possible Common Genetic Alterations in Oral Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 683.	1.3	12
6732	Plasma miR-323 as a Biomarker for Screening Papillary Thyroid Cancer From Healthy Controls. <i>Frontiers in Medicine</i> , 2020, 7, 122.	1.2	4
6733	Synthesis and biological evaluation of a new series of 1-aryl-3-[4-(pyridin-2-ylmethoxy)phenyl]urea derivatives as new anticancer agents. <i>Medicinal Chemistry Research</i> , 2020, 29, 1413-1423.	1.1	4
6734	HotSpotAnnotationsâ€”a database for hotspot mutations and annotations in cancer. <i>Database: the Journal of Biological Databases and Curation</i> , 2020, 2020, .	1.4	21
6735	Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1. <i>Respiratory Medicine Case Reports</i> , 2020, 30, 101071.	0.2	2
6736	Giant congenital melanocytic nevus of the scalp: from clinical-histological to molecular diagnosis. <i>Hereditas</i> , 2020, 157, 21.	0.5	3
6737	Current Molecular Markers of Melanoma and Treatment Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3535.	1.8	45
6738	Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation. <i>Anticancer Research</i> , 2020, 40, 2667-2673.	0.5	6
6739	Metabolic Plasticity of Melanoma Cells and Their Crosstalk With Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020, 10, 722.	1.3	66
6740	Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma. <i>Scientific Reports</i> , 2020, 10, 7826.	1.6	14
6741	Ultra-high throughput single-cell analysis of proteins and RNAs by split-pool synthesis. <i>Communications Biology</i> , 2020, 3, 213.	2.0	9
6742	Functional Genomic Screening Independently Identifies CUL3 as a Mediator of Vemurafenib Resistance via Src-Rac1 Signaling Axis. <i>Frontiers in Oncology</i> , 2020, 10, 442.	1.3	45

#	ARTICLE	IF	CITATIONS
6743	Biomimetic Coatings Obtained by Combinatorial Laser Technologies. <i>Coatings</i> , 2020, 10, 463.	1.2	7
6744	Rational Design of Polyglutamic Acid Delivering an Optimized Combination of Drugs Targeting Mutated BRAF and MEK in Melanoma. <i>Advanced Therapeutics</i> , 2020, 3, 2000028.	1.6	9
6745	Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated. <i>Journal of Translational Medicine</i> , 2020, 18, 192.	1.8	7
6746	BRAF mutation and its inhibitors in sarcoma treatment. <i>Cancer Medicine</i> , 2020, 9, 4881-4896.	1.3	26
6747	Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1209-1219.	1.0	2
6748	Review of gynaecological malignant melanomas. <i>The Obstetrician and Gynaecologist</i> , 2020, 22, 199-207.	0.2	0
6749	DNA damage and repair scenario in ameloblastoma. <i>Oral Oncology</i> , 2020, 108, 104804.	0.8	10
6750	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , 2020, 12, 1196.	1.7	65
6751	CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma. <i>Genomics, Proteomics and Bioinformatics</i> , 2020, 18, 26-40.	3.0	14
6752	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
6753	Oxidative Stress and Genotoxicity in Melanoma Induction: Impact on Repair Rather Than Formation of DNA Damage?. <i>Photochemistry and Photobiology</i> , 2020, 96, 962-972.	1.3	17
6754	Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 631.	1.6	15
6755	Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis. <i>Cancer Medicine</i> , 2020, 9, 7194-7204.	1.3	8
6756	Function, Structure and Topology of Protein Kinases. <i>Topics in Medicinal Chemistry</i> , 2020, , 1-24.	0.4	4
6757	A combinatorial strategy for overcoming primary and acquired resistance of MEK inhibition in colorectal cancer. <i>Experimental Cell Research</i> , 2020, 393, 112060.	1.2	5
6758	Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. <i>Translational Oncology</i> , 2020, 13, 100795.	1.7	26
6759	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e292-e308.	1.8	3
6760	Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening. <i>Bioorganic Chemistry</i> , 2020, 100, 103967.	2.0	12

#	ARTICLE	IF	CITATIONS
6761	Emerging functions and clinical prospects of connexins and pannexins in melanoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188380.	3.3	14
6762	AKT drives sustained motility following MEK inhibition via promoting SNAIL and AXL in MDA-MB-231 LM2. <i>Biochemical and Biophysical Research Communications</i> , 2020, 528, 92-98.	1.0	0
6763	A BRAF new world. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 103008.	2.0	39
6764	Identification of common and dissimilar biomarkers for different cancer types from gene expressions of RNA-sequencing data. <i>Gene Reports</i> , 2020, 19, 100654.	0.4	2
6765	HuRdling Senescence: HuR Breaks BRAF-Induced Senescence in Melanocytes and Supports Melanoma Growth. <i>Cancers</i> , 2020, 12, 1299.	1.7	14
6766	From Tank to Treatment: Modeling Melanoma in Zebrafish. <i>Cells</i> , 2020, 9, 1289.	1.8	17
6767	Induction of IRAK-M in melanoma induces caspase-3 dependent apoptosis by reducing TRAF6 and calpastatin levels. <i>Communications Biology</i> , 2020, 3, 306.	2.0	5
6768	Differences in Pathology and Mutation Status Among Colorectal Cancer Patients Younger Than, Older Than, and of Screening Age. <i>Clinical Colorectal Cancer</i> , 2020, 19, e264-e271.	1.0	8
6769	Rational Cancer Treatment Combinations: An Urgent Clinical Need. <i>Molecular Cell</i> , 2020, 78, 1002-1018.	4.5	95
6770	Advances in Noninvasive Neurodiagnostics. <i>World Neurosurgery</i> , 2020, 139, 1-3.	0.7	2
6771	Senescence as a therapeutically relevant response to CDK4/6 inhibitors. <i>Oncogene</i> , 2020, 39, 5165-5176.	2.6	73
6772	Targeting mitochondria in melanoma: Interplay between MAPK signaling pathway and mitochondrial dynamics. <i>Biochemical Pharmacology</i> , 2020, 178, 114104.	2.0	15
6773	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1611-1623.	0.5	43
6774	Inhibition of NRAS Signaling in Melanoma through Direct Depalmitoylation Using Amphiphilic Nucleophiles. <i>ACS Chemical Biology</i> , 2020, 15, 2079-2086.	1.6	5
6775	Preclinical anticancer studies on the ethyl acetate leaf extracts of <i>Datura stramonium</i> and <i>Datura innoxia</i> . <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 188.	1.2	20
6776	Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant BraFV600E Melanoma. <i>Cancers</i> , 2020, 12, 1500.	1.7	9
6777	Persistent STAG2 mutation despite multimodal therapy in recurrent pediatric glioblastoma. <i>Npj Genomic Medicine</i> , 2020, 5, 23.	1.7	3
6778	Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 223-235.	0.8	18

#	ARTICLE	IF	CITATIONS
6779	Targeted Therapy for Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 409-434.	0.8	11
6781	Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment. <i>Cancers</i> , 2020, 12, 1524.	1.7	24
6782	Combining the Sensitivity of LAMP and Simplicity of Primer Extension via a DNA-Modified Nucleotide. <i>Chemistry</i> , 2020, 2, 490-498.	0.9	0
6783	Cancer Development and Damped Electromagnetic Activity. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 1826.	1.3	2
6784	N-acetylglycoside of oleanolic acid (aridanin) displays promising cytotoxicity towards human and animal cancer cells, inducing apoptotic, ferroptotic and necroptotic cell death. <i>Phytomedicine</i> , 2020, 76, 153261.	2.3	45
6785	Treatment options in BRAF-mutant metastatic colorectal cancer. <i>Anti-Cancer Drugs</i> , 2020, 31, 545-557.	0.7	7
6786	Phosphorylation Sites in Protein Kinases and Phosphatases Regulated by Formyl Peptide Receptor 2 Signaling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3818.	1.8	18
6787	Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1741.	1.0	22
6788	BRAF and NRAS mutated melanoma: Different Ca ²⁺ responses, Na ⁺ /Ca ²⁺ exchanger expression, and sensitivity to inhibitors. <i>Cell Calcium</i> , 2020, 90, 102241.	1.1	10
6789	Targeting Kras ^{G12C} mutant cancer with a mutation-specific inhibitor. <i>Journal of Internal Medicine</i> , 2020, 288, 183-191.	2.7	56
6790	GLI1 Inhibitor SRI-38832 Attenuates Chemotherapeutic Resistance by Downregulating NBS1 Transcription in BRAFV600E Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 241.	1.3	11
6791	Swinhopeptolides A and B: Cyclic Depsipeptides from the Sponge <i>Theonella swinhoei</i> That Inhibit Ras/Raf Interaction. <i>Journal of Natural Products</i> , 2020, 83, 1288-1294.	1.5	10
6792	Clinical validation of qPCR Target Selector [®] assays using highly specific switch-blockers for rare mutation detection. <i>Journal of Clinical Pathology</i> , 2020, 73, 648-655.	1.0	4
6793	An unusual hematopoietic stem cell transplantation for donor acute lymphoblastic leukemia: a case report. <i>BMC Cancer</i> , 2020, 20, 195.	1.1	3
6794	Low-grade developmental and epilepsy associated brain tumors: a critical update 2020. <i>Acta Neuropathologica Communications</i> , 2020, 8, 27.	2.4	110
6795	VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAFV600E Mutation in Papillary Thyroid Cancer. <i>Cancers</i> , 2020, 12, 596.	1.7	22
6796	Challenging diagnosis of two neoplasms, Langerhans cell histiocytosis and papillary thyroid carcinoma, from fine needle aspiration of the thyroid by cell block immunocytochemistry and molecular testing for BRAF V 600E mutation. <i>Cytopathology</i> , 2020, 31, 598-601.	0.4	5
6797	An update on the implications of cyclin D1 in melanomas. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 788-805.	1.5	34

#	ARTICLE	IF	CITATIONS
6798	Molecular Targets Beyond the Big 3. <i>Thoracic Surgery Clinics</i> , 2020, 30, 157-164.	0.4	6
6799	Polyacrylamide/Phytic Acid/Polydopamine Hydrogel as an Efficient Substrate for Electrochemical Enrichment of Circulating Cell-Free DNA from Blood Plasma. <i>ACS Omega</i> , 2020, 5, 5365-5371.	1.6	6
6800	Heterotrimeric Gq proteins as therapeutic targets?. <i>Journal of Biological Chemistry</i> , 2020, 295, 5206-5215.	1.6	58
6801	Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy. <i>Current Oncology Reports</i> , 2020, 22, 38.	1.8	15
6802	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	7.1	853
6803	Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.2	8
6804	RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors. <i>BMC Cancer</i> , 2020, 20, 251.	1.1	16
6805	Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 232.	1.3	5
6806	Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells. <i>Experimental Cell Research</i> , 2020, 390, 111942.	1.2	10
6807	Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma. <i>Oncogene</i> , 2020, 39, 4061-4076.	2.6	12
6808	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. <i>Cancers</i> , 2020, 12, 767.	1.7	2
6809	Discovery of Selective Small Molecule Degraders of BRAF-V600E. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4069-4080.	2.9	43
6810	BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma. <i>Modern Pathology</i> , 2020, 33, 1660-1668.	2.9	9
6811	Difference contact maps: From what to why in the analysis of the conformational flexibility of proteins. <i>PLoS ONE</i> , 2020, 15, e0226702.	1.1	11
6813	Progressive Disease in Sentinel-negative Melanoma Patients: Biological Differences and Importance of Sentinel Lymph Node Biopsy. <i>Anticancer Research</i> , 2020, 40, 891-899.	0.5	0
6814	Nevo de Spitz y otros tumores spitzoides en la infancia. Parte 2: características citogenéticas y moleculares. Pronóstico y tratamiento. <i>Actas Dermo-sifilográficas</i> , 2020, 111, 20-25.	0.2	9
6815	Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma. <i>BMC Cancer</i> , 2020, 20, 177.	1.1	4
6816	Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 493-504.	3.3	30

#	ARTICLE	IF	CITATIONS
6817	How to make an undruggable enzyme druggable: lessons from ras proteins. <i>Advances in Protein Chemistry and Structural Biology</i> , 2020, 122, 181-202.	1.0	3
6818	Erdheim-Chester disease: a rapidly evolving disease model. <i>Leukemia</i> , 2020, 34, 2840-2857.	3.3	35
6819	Erdheim-Chester Disease: a Rare but Important Cause of Recurrent Pericarditis. <i>Current Cardiology Reports</i> , 2020, 22, 75.	1.3	7
6820	Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 951.	1.3	35
6821	Mucinous borderline ovarian tumors with BRAFV600E mutation may have low risk for progression to invasive carcinomas. <i>Archives of Gynecology and Obstetrics</i> , 2020, 302, 487-495.	0.8	9
6822	Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids. <i>Pathology and Oncology Research</i> , 2020, 26, 2557-2566.	0.9	5
6823	Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2896-2909.	0.6	5
6824	Targeted Therapy in Melanoma and Mechanisms of Resistance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4576.	1.8	107
6825	Adjuvant Therapy for Cutaneous Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 455-465.	0.6	1
6826	Oncogenic BRAF, endoplasmic reticulum stress, and autophagy: Crosstalk and therapeutic targets in cutaneous melanoma. <i>Mutation Research - Reviews in Mutation Research</i> , 2020, 785, 108321.	2.4	25
6827	Role of Melanin Chemiexcitation in Melanoma Progression and Drug Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 1305.	1.3	21
6828	Review of the Agnostic-Type Treatment Approach: Treating Cancer by Mutations, Not by Location. <i>Oncology and Therapy</i> , 2020, 8, 59-66.	1.0	4
6829	AEBP1 is a Novel Oncogene: Mechanisms of Action and Signaling Pathways. <i>Journal of Oncology</i> , 2020, 2020, 1-20.	0.6	31
6830	Melanoma Brain Metastases in the Era of Target Therapies: An Overview. <i>Cancers</i> , 2020, 12, 1640.	1.7	29
6831	Molecular therapeutic targets in non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 647-661.	1.1	46
6832	Pediatric <i>BRAF</i> (V600E)-Mutated Pancreatic Acinar Cell Carcinoma With Complete and Durable Response to Dabrafenib and Trametinib. <i>JCO Precision Oncology</i> , 2020, 4, 801-805.	1.5	6
6833	20/20 in 2020: seeking clarity on the management of stage III melanoma in a rapidly changing treatment environment. <i>Annals of Translational Medicine</i> , 2020, 8, 776-776.	0.7	0
6834	A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report. <i>Frontiers in Oncology</i> , 2020, 10, 1056.	1.3	5

#	ARTICLE	IF	CITATIONS
6835	BRAF Inhibitors: Molecular Targeting and Immunomodulatory Actions. <i>Cancers</i> , 2020, 12, 1823.	1.7	82
6836	Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm. <i>Targeted Oncology</i> , 2020, 15, 531-540.	1.7	12
6837	Bioinspired Biomaterials. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	5
6838	Predicting and affecting response to cancer therapy based on pathway-level biomarkers. <i>Nature Communications</i> , 2020, 11, 3296.	5.8	55
6839	Tacrolimus and ascomycin inhibit melanoma cell growth, migration and invasion via targeting nuclear factor of activated T-cell 3. <i>Melanoma Research</i> , 2020, 30, 325-335.	0.6	3
6840	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092521.	1.4	31
6841	Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications. <i>Cancer Treatment Reviews</i> , 2020, 88, 102060.	3.4	27
6842	Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFV600E-Driven Melanoma. <i>Cancer Research</i> , 2020, 80, 1387-1400.	0.4	29
6843	Cell-free DNA BRAF V600E measurements during BRAF inhibitor therapy of metastatic melanoma: long-term analysis. <i>Tumori</i> , 2020, 106, 241-248.	0.6	13
6844	Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance. <i>Cancers</i> , 2020, 12, 512.	1.7	15
6845	Procyanidin C1 Inhibits Melanoma Cell Growth by Activating 67kDa Laminin Receptor Signaling. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1900986.	1.5	14
6846	An overview of binimetinib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 747-754.	0.9	8
6847	Baseline neutrophil-to-lymphocyte ratio (NLR) is associated with outcome of patients treated with BRAF inhibitors. <i>Clinical and Translational Oncology</i> , 2020, 22, 1818-1824.	1.2	7
6848	RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events. <i>Neuro-Oncology Practice</i> , 2020, 7, 369-375.	1.0	2
6849	Mesencephalic astrocyte-derived neurotrophic factor is a novel radioresistance factor in mouse B16 melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 869-875.	1.0	3
6850	Loss of Both CDKN2A and CDKN2B Allows for Centrosome Overduplication in Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1837-1846.e1.	0.3	8
6851	The paradox of cancer genes in non-malignant conditions: implications for precision medicine. <i>Genome Medicine</i> , 2020, 12, 16.	3.6	33
6852	Pulsatile MAPK Signaling Modulates p53 Activity to Control Cell Fate Decisions at the G2 Checkpoint for DNA Damage. <i>Cell Reports</i> , 2020, 30, 2083-2093.e5.	2.9	43

#	ARTICLE	IF	CITATIONS
6853	Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth. <i>Biomolecules</i> , 2020, 10, 285.	1.8	18
6854	Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma. <i>Science Advances</i> , 2020, 6, eaax3223.	4.7	97
6855	Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation. <i>Modern Pathology</i> , 2020, 33, 1420-1432.	2.9	17
6856	Guanylyl Cyclase-cGMP Signaling Pathway in Melanocytes: Differential Effects of Altered Gravity in Non-Metastatic and Metastatic Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1139.	1.8	6
6857	A Germline <i>CHEK2</i> Mutation in a Family with Papillary Thyroid Cancer. <i>Thyroid</i> , 2020, 30, 924-930.	2.4	19
6858	Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma. <i>Pathology International</i> , 2020, 70, 280-286.	0.6	5
6859	Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 417.	1.8	32
6860	Erdheim-Chester disease: An in vivo human model of $M\ddot{u}$ activation at the crossroad between chronic inflammation and cancer. <i>Journal of Leukocyte Biology</i> , 2020, 108, 591-599.	1.5	9
6862	Protein kinase inhibitor-based cancer therapies: Considering the potential of nitric oxide (NO) to improve cancer treatment. <i>Biochemical Pharmacology</i> , 2020, 176, 113855.	2.0	11
6863	Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling. <i>Journal of Biological Chemistry</i> , 2020, 295, 2407-2420.	1.6	20
6864	Metastatic melanoma: Surgical treatment of brain metastases – Analysis of 110 patients. <i>Journal of Clinical Neuroscience</i> , 2020, 73, 144-149.	0.8	11
6865	Solid-Phase Microextraction Enables Isolation of BRAF V600E Circulating Tumor DNA from Human Plasma for Detection with a Molecular Beacon Loop-Mediated Isothermal Amplification Assay. <i>Analytical Chemistry</i> , 2020, 92, 3346-3353.	3.2	30
6866	Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. <i>Cells</i> , 2020, 9, 198.	1.8	314
6867	ADT-OH, a hydrogen sulfide-releasing donor, induces apoptosis and inhibits the development of melanoma in vivo by upregulating FADD. <i>Cell Death and Disease</i> , 2020, 11, 33.	2.7	19
6868	BRAFV600E dictates cell survival via c-Myc-dependent induction of Skp2 in human melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2020, 524, 28-35.	1.0	4
6869	Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1172-1174.	0.7	3
6870	Spinal cord anaplastic astrocytoma with BRAF V600E mutation: A case report and review of literature. <i>Neuropathology</i> , 2020, 40, 275-279.	0.7	4
6871	The miRNAs Role in Melanoma and in Its Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 878.	1.8	50

#	ARTICLE	IF	CITATIONS
6873	Spitz Nevus and Other Spitzoid Tumors in Children. Part 2: Cytogenetic and Molecular Features. Prognosis and Treatment. <i>Actas Dermo-sifiliográficas</i> , 2020, 111, 20-25.	0.2	1
6874	An ultrasensitive colorimetric test for the detection of somatic rare mutations in DNA. <i>Nanoscale</i> , 2020, 12, 2973-2979.	2.8	6
6875	Downregulating integrin subunit alpha 7 (ITGA7) promotes proliferation, invasion, and migration of papillary thyroid carcinoma cells through regulating epithelial-to-mesenchymal transition. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 52, 116-124.	0.9	10
6876	Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of <i>BRAF</i> V600E mutation in plasma from melanoma patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1799-1807.	1.4	10
6877	KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study. <i>Cells</i> , 2020, 9, 219.	1.8	46
6878	Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 601-611.	1.5	15
6879	Clinicopathological significance of the single nucleotide polymorphism, rs2853669 within the <i>TERT</i> promoter in papillary thyroid carcinoma. <i>Pathology International</i> , 2020, 70, 217-223.	0.6	7
6880	An immunohistochemical and genetic study of BRAF V600E mutation in Japanese patients with ameloblastoma. <i>Pathology International</i> , 2020, 70, 224-230.	0.6	20
6881	Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. <i>Cancer Cell</i> , 2020, 37, 85-103.e9.	7.7	91
6882	Identification of Novel Pathogenic Sequence Variants of the Mismatch Repair Genes During Screening for Lynch Syndrome in a Single Centre of Eastern Hungary. <i>Journal of Gastrointestinal Cancer</i> , 2020, 51, 1007-1015.	0.6	0
6883	PTPN11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein. <i>Biochemistry (Moscow)</i> , 2020, 85, 108-118.	0.7	6
6884	The heterogeneous clinical and pathological landscapes of metastatic <i>Braf</i> -mutated colorectal cancer. <i>Cancer Cell International</i> , 2020, 20, 30.	1.8	63
6885	Prolonged Complete Response With Combined Dabrafenib and Trametinib After BRAF Inhibitor Failure in BRAF-Mutant Glioblastoma. <i>JCO Precision Oncology</i> , 2020, 4, 44-50.	1.5	18
6886	Prognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges. <i>Cancers</i> , 2020, 12, 319.	1.7	141
6887	Trametinib and Dabrafenib in histiocytic sarcoma transdifferentiated from chronic lymphocytic leukemia with a K-RAS and a unique BRAF mutation. <i>Annals of Hematology</i> , 2020, 99, 649-651.	0.8	6
6888	CuO/Cu ₂ O nanowire array photoelectrochemical biosensor for ultrasensitive detection of tyrosinase. <i>Science China Chemistry</i> , 2020, 63, 1012-1018.	4.2	22
6889	Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis. <i>Molecular Oncology</i> , 2020, 14, 1760-1778.	2.1	27
6890	Functionalized Graphene Oxide Thin Films for Anti-tumor Drug Delivery to Melanoma Cells. <i>Frontiers in Chemistry</i> , 2020, 8, 184.	1.8	22

#	ARTICLE	IF	CITATIONS
6891	Adult Craniopharyngiomas. , 2020, , .		3
6892	Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1867-1876.	1.2	5
6893	Trends in socioeconomic inequalities in the incidence of cutaneous melanoma in Canada from 1992 to 2010. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2021, 29, 1215-1224.	0.8	2
6895	Design and synthesis of novel pyrrolo[2,3-b]pyridine derivatives targeting V600EBRAF. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115493.	1.4	12
6896	Identification of Small Molecule Enhancers of Immunotherapy for Melanoma. <i>Scientific Reports</i> , 2020, 10, 5688.	1.6	7
6897	The ectopic expression of meiCT genes promotes meiomitosis and may facilitate carcinogenesis. <i>Cell Cycle</i> , 2020, 19, 837-854.	1.3	17
6898	Acquired Secondary RAS Mutation in BRAF ^{V600E} -Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. <i>Thyroid</i> , 2020, 30, 1288-1296.	2.4	66
6899	Targeted chemotherapy overcomes drug resistance in melanoma. <i>Genes and Development</i> , 2020, 34, 637-649.	2.7	25
6900	CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers. <i>Frontiers in Immunology</i> , 2020, 11, 508.	2.2	58
6901	Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?. <i>Cancers</i> , 2020, 12, 774.	1.7	10
6902	Innate and Adaptive Immunity Linked to Recognition of Antigens Shared by Neural Crest-Derived Tumors. <i>Cancers</i> , 2020, 12, 840.	1.7	6
6903	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020, 12, 1009.	1.7	123
6904	RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in KRAS mutant tumors. <i>Molecular Oncology</i> , 2020, 14, 1833-1849.	2.1	24
6905	Molecular and immunohistochemical analysis of BRAF gene in primary cutaneous melanoma: Discovery of novel mutations. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 794-799.	0.7	1
6906	Identification of FOS as a Candidate Risk Gene for Liver Cancer by Integrated Bioinformatic Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-10.	0.9	12
6907	Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis. <i>Scientific Reports</i> , 2020, 10, 6623.	1.6	29
6908	Erdheim-Chester disease. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101510.	1.4	21
6909	Applications of personalised signalling network models in precision oncology. , 2020, 212, 107555.		14

#	ARTICLE	IF	CITATIONS
6910	BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004820.	0.5	4
6911	BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer. <i>ESMO Open</i> , 2020, 5, e000624.	2.0	15
6912	Prevalence of the BRAFp.v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations. <i>Journal of Investigative Medicine</i> , 2020, 68, 985-991.	0.7	8
6913	New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1). <i>Current Oncology Reports</i> , 2020, 22, 48.	1.8	39
6914	Disrupting ATF4 Expression Mechanisms Provides an Effective Strategy for BRAF-Targeted Melanoma Therapy. <i>IScience</i> , 2020, 23, 101028.	1.9	12
6915	BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis. <i>Acta Oncol</i> , 2020, 59, 833-844.	0.8	48
6916	BRAF and TERT promoter mutations: clinical application in thyroid cancer. <i>Endocrine Journal</i> , 2020, 67, 577-584.	0.7	26
6917	Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition. <i>Clinical Cancer Research</i> , 2020, 26, 3803-3818.	3.2	21
6918	Improvements in Clinical Outcomes for BRAFV600E-Mutant Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4435-4441.	3.2	17
6919	Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1754-1758.	0.5	2
6920	ROCK1 and ROCK2 Are Down-regulated in Aggressive and Advanced Skin Melanomas – A Clinicopathological Perspective. <i>Anticancer Research</i> , 2020, 40, 1931-1942.	0.5	8
6921	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. <i>Cancers</i> , 2020, 12, 927.	1.7	6
6922	Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses. <i>Cells</i> , 2020, 9, 830.	1.8	23
6923	Treatment of Advanced Melanoma in 2020 and Beyond. <i>Journal of Investigative Dermatology</i> , 2021, 141, 23-31.	0.3	193
6924	Emerging strategies to treat rare and intractable subtypes of melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 44-58.	1.5	22
6925	Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 1029-1038.	0.7	4
6926	Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 136-143.	1.5	9
6927	Landscape of drug-resistance mutations in kinase regulatory hotspots. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	15

#	ARTICLE	IF	CITATIONS
6928	Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study. <i>Clinical and Translational Oncology</i> , 2021, 23, 122-129.	1.2	2
6929	Resistance mechanisms to immune checkpoints—blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma. <i>Journal of Cellular Physiology</i> , 2021, 236, 791-805.	2.0	13
6930	Metastatic Pancreatic Cancer with BRAF and P53 Mutations: Case Report of Therapeutic Response to Doublet Targeted Therapy. <i>Case Reports in Oncology</i> , 2021, 13, 1239-1243.	0.3	10
6931	Melanoma Cell Intrinsic GABAA Receptor Enhancement Potentiates Radiation and Immune Checkpoint Inhibitor Response by Promoting Direct and T Cell-Mediated Antitumor Activity. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1040-1053.	0.4	18
6932	Analysis of CRISPR-Cas9 screens identifies genetic dependencies in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 122-131.	1.5	10
6933	Stimuli-responsive and cellular targeted nanoplateforms for multimodal therapy of skin cancer. <i>European Journal of Pharmacology</i> , 2021, 890, 173633.	1.7	6
6934	Targetable <i>BRAF</i> and <i>RAF1</i> Alterations in Advanced Pediatric Cancers. <i>Oncologist</i> , 2021, 26, e153-e163.	1.9	14
6935	The meiosis-specific cohesin component stromal antigen 3 promotes cell migration and chemotherapeutic resistance in colorectal cancer. <i>Cancer Letters</i> , 2021, 497, 112-122.	3.2	12
6936	Clinical and molecular spectra of BRAF-associated RASopathy. <i>Journal of Human Genetics</i> , 2021, 66, 389-399.	1.1	15
6937	<i>BRAF</i> ^{V600E} Overrides NOTCH Signaling in Thyroid Cancer. <i>Thyroid</i> , 2021, 31, 787-799.	2.4	6
6938	Prevalence of class III BRAF mutations among 114,662 cancer patients in a large genomic database. <i>Experimental Biology and Medicine</i> , 2021, 246, 31-39.	1.1	36
6939	Current Management of Melanoma. <i>Updates in Surgery Series</i> , 2021, , .	0.0	0
6940	The alkaloid, soyauxinium chloride, displays remarkable cytotoxic effects towards a panel of cancer cells, inducing apoptosis, ferroptosis and necroptosis. <i>Chemico-Biological Interactions</i> , 2021, 333, 109334.	1.7	30
6941	Surgery of metastatic melanoma after systemic therapy—the SUMMIST trial: study protocol for a randomized controlled trial. <i>Acta Oncologica</i> , 2021, 60, 52-55.	0.8	5
6942	Multifaceted activities of transcription factor EB in cancer onset and progression. <i>Molecular Oncology</i> , 2021, 15, 327-346.	2.1	29
6943	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. <i>Cancer Treatment Reviews</i> , 2021, 92, 102135.	3.4	2
6944	Familial cardiofacio-cutaneous syndrome: Vertical transmission of the <i>BRAF</i> p.G464R pathogenic variant and review of the literature. <i>American Journal of Medical Genetics, Part A</i> , 2021, 185, 469-475.	0.7	4
6945	Mitochondrial oxidative phosphorylation in cutaneous melanoma. <i>British Journal of Cancer</i> , 2021, 124, 115-123.	2.9	39

#	ARTICLE	IF	CITATIONS
6946	MageC2 protein is upregulated by oncogenic activation of MAPK pathway and causes impairment of the p53 transactivation function. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118918.	1.9	3
6947	Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer. <i>Trends in Cancer</i> , 2021, 7, 410-429.	3.8	13
6949	Making a melanoma: Molecular and cellular changes underlying melanoma initiation. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 280-287.	1.5	3
6950	State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1-27.	0.9	4
6951	Clinicopathological features of mismatch repair protein expression patterns in colorectal cancer. <i>Pathology Research and Practice</i> , 2021, 217, 153288.	1.0	10
6952	Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients. <i>Cancer Genetics</i> , 2021, 250-251, 25-35.	0.2	5
6953	PIN1 facilitates ubiquitin-mediated degradation of serine/threonine kinase 3 and promotes melanoma development via TAZ activation. <i>Cancer Letters</i> , 2021, 499, 164-174.	3.2	8
6954	Sirtuins' control of autophagy and mitophagy in cancer. , 2021, 221, 107748.		58
6955	BRAF inhibitor-induced panniculitis in patients treated for stage IV metastatic melanoma: a case series. <i>Skeletal Radiology</i> , 2021, 50, 1257-1262.	1.2	3
6956	Equivocal, explicit and emergent actions of PKC isoforms in cancer. <i>Nature Reviews Cancer</i> , 2021, 21, 51-63.	12.8	37
6957	Multi-sample measurement of hyperpolarized pyruvate-to-lactate flux in melanoma cells. <i>NMR in Biomedicine</i> , 2021, 34, e4447.	1.6	6
6958	Senescence in RASopathies, a possible novel contributor to a complex pathophenoype. <i>Mechanisms of Ageing and Development</i> , 2021, 194, 111411.	2.2	8
6959	VE1 immunohistochemistry is an adjunct tool for detection of <i>BRAF</i> ^{V600E} mutation: Validation in thyroid cancer patients. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23628.	0.9	9
6960	Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib + binimetinib or alpelisib. <i>British Journal of Cancer</i> , 2021, 124, 176-182.	2.9	17
6961	Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAFV600E inhibitors. <i>Bioorganic Chemistry</i> , 2021, 106, 104508.	2.0	20
6962	Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 1-10.	3.3	12
6963	Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation. <i>Thoracic Cancer</i> , 2021, 12, 272-276.	0.8	3
6964	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with <i>BRAF</i> mutated advanced cancers. <i>Cancer</i> , 2021, 127, 391-402.	2.0	6

#	ARTICLE	IF	CITATIONS
6965	Glioblastoma and malignant melanoma: Serendipitous or anticipated association?. <i>Neuropathology</i> , 2021, 41, 65-71.	0.7	4
6966	Biology of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 29-56.	0.9	40
6967	Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation. <i>Modern Pathology</i> , 2021, 34, 438-444.	2.9	19
6968	The insect-killing bacterium <i>Photobacterium luminescens</i> has the lowest mutation rate among bacteria. <i>Marine Life Science and Technology</i> , 2021, 3, 20-27.	1.8	10
6969	New advances in the clinical management of RAS and BRAF mutant colorectal cancer patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 65-79.	1.4	4
6970	Systematic review of BRAF/MEK inhibitorsâ€”induced Severe Cutaneous Adverse Reactions (SCARs). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 607-614.	1.3	26
6971	NRAS ^{Q61K} melanoma tumor formation is reduced by p38â€”MAPK14 activation in zebrafish models and NRASâ€”mutated human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 150-162.	1.5	6
6972	Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129736.	1.1	38
6973	Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 133-146.	0.6	3
6975	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
6976	The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis. <i>Genes and Diseases</i> , 2021, 8, 48-60.	1.5	33
6977	Markers of Sensitivity and Resistance to EGFR Inhibitors in Colorectal Cancer. , 2021, , 221-270.		0
6978	Metabolic Regulator IAPP (Amylin) Is Required for BRAF and RAS Oncogene-Induced Senescence. <i>Molecular Cancer Research</i> , 2021, 19, 874-885.	1.5	2
6980	Molecular Landscape Profile of Melanoma. , 2021, , 31-55.		0
6981	Regulation of NKG2D by RKIP: Implications on NK-mediated cytotoxicity and cytokine production. , 2021, , 233-265.		1
6982	Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer. <i>RSC Advances</i> , 2021, 11, 25228-25257.	1.7	10
6983	The mechanism of activation of monomeric B-Raf V600E. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3349-3363.	1.9	38
6984	NECTIN4: A Novel Therapeutic Target for Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 976.	1.8	22

#	ARTICLE	IF	CITATIONS
6985	Mechanisms of Cetuximab Resistance and How to Overcome It. , 2021, , 21-51.		1
6986	Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review. Hepatobiliary Surgery and Nutrition, 2022, 11, 253-266.	0.7	8
6987	<i>BRAF</i> V600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma. Tumori, 2021, 107, NP28-NP32.	0.6	0
6988	Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study. Scientific Reports, 2021, 11, 126.	1.6	2
6989	Cross-regulation between CDK and MAPK control cellular fate. Quantitative Biology, 2021, 9, 341-359.	0.3	3
6990	Genomic and epigenomic biomarkers in colorectal cancer: From diagnosis to therapy. Advances in Cancer Research, 2021, 151, 231-304.	1.9	8
6991	Novel genetic characteristics of multifocal micronodular pneumocyte hyperplasia (MMPH): a case report with frequent BRAF mutations analyzed by next-generation sequencing supporting benign behaviors of MMPH. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 637-641.	1.4	1
6992	Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 612.	1.8	79
6993	Advances in anti-BRAF therapies for lung cancer. Investigational New Drugs, 2021, 39, 879-890.	1.2	22
6994	The Evolutionary Landscape of Treatment for BRAFV600E Mutant Metastatic Colorectal Cancer. Cancers, 2021, 13, 137.	1.7	46
6995	Identification of novel biomarkers and candidate small-molecule drugs in cutaneous melanoma by comprehensive gene microarrays analysis. Journal of Cancer, 2021, 12, 1307-1317.	1.2	6
6996	Thyroid Cancer and SNPs. , 2021, , 235-280.		0
6998	Pathology of Melanoma and Skin Carcinomas. , 2021, , 3-30.		2
6999	Concomitant Langerhans cell histiocytosis of cervical lymph nodes in adult patients with papillary thyroid carcinoma: A report of two cases and review of the literature. Autopsy and Case Reports, 2021, 11, e2021253.	0.2	3
7000	Simultaneously monitoring endogenous MAPK members in single living cells by multi-channel fluorescence correlation spectroscopy. Analyst, The, 2021, 146, 2581-2590.	1.7	5
7001	Design and Discovery of Kinase Inhibitors Using Docking Studies. , 2021, , 337-365.		0
7002	Immunohistochemical Surrogates for Molecular Pathology. Molecular Pathology Library, 2021, , 175-195.	0.1	0
7003	The i-Motif as a Molecular Target: More Than a Complementary DNA Secondary Structure. Pharmaceuticals, 2021, 14, 96.	1.7	51

#	ARTICLE	IF	CITATIONS
7004	Melanoma Cell Resistance to Vemurafenib Modifies Inter-Cellular Communication Signals. <i>Biomedicines</i> , 2021, 9, 79.	1.4	10
7005	Skin Cancer: Molecular Biomarker for Diagnosis, Prognosis, Prevention, and Targeted Therapy. , 2021, , 101-130.		0
7006	BRAF p.V600E associated poly-neoplastic syndrome. <i>Rare Tumors</i> , 2021, 13, 203636132110129.	0.3	4
7007	Drug resistance in targeted cancer therapies with RAF inhibitors. , 2021, 4, 665-683.		9
7008	Cell Proliferation Is Strongly Associated with the Treatment Conditions of an ER Stress Inducer New Anti-Melanoma Drug in Melanoma Cell Lines. <i>Biomedicines</i> , 2021, 9, 96.	1.4	5
7009	Amelanotic Malignant Melanoma with a <i>BRAF V600E</i> Mutation Mimicking Primary Lung Cancer. <i>Internal Medicine</i> , 2021, , .	0.3	0
7010	New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking. <i>Cells</i> , 2021, 10, 367.	1.8	8
7012	Fetal-Derived Immune Cells at the Roots of Lifelong Pathophysiology. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 648313.	1.8	27
7013	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. <i>Cancer Discovery</i> , 2021, 11, 1716-1735.	7.7	30
7014	Immunohistochemistry features and molecular pathology of appendiceal neoplasms. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 369-384.	2.7	5
7015	A Real-Time Oocyte Polar Body Detection Method. <i>Journal of Physics: Conference Series</i> , 2021, 1754, 012219.	0.3	0
7016	Concomitant KIAA1549-BRAF fusion and IDH mutation in Pediatric spinal cord astrocytoma: a case report and literature review. <i>Brain Tumor Pathology</i> , 2021, 38, 132-137.	1.1	3
7017	Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma. <i>Neurosurgical Review</i> , 2021, 44, 3335-3348.	1.2	6
7018	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102.	4.3	21
7019	Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 273-284.	0.8	254
7020	Immunotherapy for the treatment of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 760-774.	0.8	18
7021	Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. <i>Nature Communications</i> , 2021, 12, 734.	5.8	26
7022	Harnessing the polyamine transport system to treat BRAF inhibitor-resistant melanoma. <i>Cancer Biology and Therapy</i> , 2021, 22, 225-237.	1.5	7

#	ARTICLE	IF	CITATIONS
7023	Personalized oncology and BRAFK601N melanoma: model development, drug discovery, and clinical correlation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1365-1378.	1.2	2
7024	Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with <i>BRAF</i> p.T599dup mutation. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006023.	0.5	7
7025	V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as a prognostic biomarker of poor outcomes in esophageal cancer patients. <i>BMC Gastroenterology</i> , 2021, 21, 86.	0.8	3
7026	Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK. <i>BMC Cancer</i> , 2021, 21, 136.	1.1	21
7027	The BH3 mimetic (±) gossypol induces ROS-independent apoptosis and mitochondrial dysfunction in human A375 melanoma cells in vitro. <i>Archives of Toxicology</i> , 2021, 95, 1349-1365.	1.9	13
7028	Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China. <i>Current Medical Science</i> , 2021, 41, 118-126.	0.7	11
7029	Defining and Targeting BRAF Mutations in Solid Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 30.	1.3	25
7030	ERK and mTORC1 Inhibitors Enhance the Anti-Cancer Capacity of the Octpep-1 Venom-Derived Peptide in Melanoma BRAF(V600E) Mutations. <i>Toxins</i> , 2021, 13, 146.	1.5	7
7031	Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells. <i>Biology</i> , 2021, 10, 153.	1.3	6
7032	Efficacy of BRAF Inhibitors in Combination With Stereotactic Radiosurgery for the Treatment of Melanoma Brain Metastases: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 586029.	1.3	4
7034	Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. <i>ESMO Open</i> , 2021, 6, 100002.	2.0	12
7035	BRAF Heterogeneity in Melanoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 20.	1.3	21
7036	Differential Sensitivity of Wild-Type and BRAF-Mutated Cells to Combined BRAF and Autophagy Inhibition. <i>Biomolecules and Therapeutics</i> , 2021, 29, 434-444.	1.1	5
7037	Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. <i>Cancers</i> , 2021, 13, 804.	1.7	76
7038	New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. <i>Frontiers in Oncology</i> , 2021, 11, 627229.	1.3	24
7039	Ocoxin Increases the Antitumor Effect of BRAF Inhibition and Reduces Cancer Associated Fibroblast-Mediated Chemoresistance and Protumoral Activity in Metastatic Melanoma. <i>Nutrients</i> , 2021, 13, 686.	1.7	7
7040	Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells. <i>Molecules</i> , 2021, 26, 1867.	1.7	9
7041	Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 661214.	2.0	7

#	ARTICLE	IF	CITATIONS
7042	Elucidating molecular mechanisms of acquired resistance to BRAF inhibitors in melanoma using a microfluidic device and deep sequencing. <i>Genomics and Informatics</i> , 2021, 19, e2.	0.4	3
7043	Response to Vemurafenib in Metastatic Triple-Negative Breast Cancer Harboring a BRAF V600E Mutation: A Case Report and Electronically Captured Patient-Reported Outcome. <i>Case Reports in Oncology</i> , 2021, 14, 616-621.	0.3	13
7044	Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation. <i>Frontiers in Immunology</i> , 2021, 12, 629519.	2.2	10
7045	Selective extraction of low-abundance BRAF V600E mutation from plasma, urine, and sputum using ion-tagged oligonucleotides and magnetic ionic liquids. <i>Analytical and Bioanalytical Chemistry</i> , 2022, 414, 277-286.	1.9	4
7046	Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome. <i>JAAD Case Reports</i> , 2021, 9, 42-44.	0.4	1
7047	MITF induces escape from innate immunity in melanoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 117.	3.5	16
7048	Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling. <i>Nature Communications</i> , 2021, 12, 1747.	5.8	39
7049	A MAPK/miR-29 Axis Suppresses Melanoma by Targeting MAFC and MYBL2. <i>Cancers</i> , 2021, 13, 1408.	1.7	16
7050	LncRNA SAMMSON Mediates Adaptive Resistance to RAF Inhibition in BRAF-Mutant Melanoma Cells. <i>Cancer Research</i> , 2021, 81, 2918-2929.	0.4	16
7051	FAM129B-dependent activation of NRF2 promotes an invasive phenotype in BRAF mutant melanoma cells. <i>Molecular Carcinogenesis</i> , 2021, 60, 331-341.	1.3	14
7053	Thinking Differently about Cancer Treatment Regimens. <i>Cancer Discovery</i> , 2021, 11, 1016-1023.	7.7	29
7054	CYP27A1-dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism. <i>Cell Chemical Biology</i> , 2021, 28, 1407-1419.e6.	2.5	11
7055	A study of pathological characteristics and BRAF V600E status in Langerhans cell histiocytosis of Vietnamese children. <i>Journal of Pathology and Translational Medicine</i> , 2021, 55, 112-117.	0.4	1
7056	Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis. <i>Journal of Immunotherapy</i> , 2021, 44, 224-233.	1.2	3
7057	Recent Advances in Understanding the Role of Autophagy in Paediatric Brain Tumours. <i>Diagnostics</i> , 2021, 11, 481.	1.3	5
7058	Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy. <i>Cancers</i> , 2021, 13, 1148.	1.7	19
7059	The conformation-specific Hsp90 inhibition interferes with the oncogenic RAF kinase adaptation and triggers premature cellular senescence, hence, acts as a tumor suppressor mechanism. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118943.	1.9	3
7060	PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK. <i>Cell Reports</i> , 2021, 34, 108928.	2.9	17

#	ARTICLE	IF	CITATIONS
7061	Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3228.	1.8	5
7062	RAF-Mutant Melanomas Differentially Depend on ERK2 Over ERK1 to Support Aberrant MAPK Pathway Activation and Cell Proliferation. <i>Molecular Cancer Research</i> , 2021, 19, 1063-1075.	1.5	3
7063	Emerging systemic antitarget treatment for differentiated thyroid carcinoma. <i>Current Opinion in Oncology</i> , 2021, 33, 184-195.	1.1	5
7065	BRAF Gene and Melanoma: Back to the Future. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3474.	1.8	40
7066	Clinical Characteristics of BRAF V600E Gene Mutation in Patients of Epilepsy-Associated Brain Tumor: a Meta-analysis. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 1815-1824.	1.1	9
7067	Systemic Therapy of Metastatic Melanoma: On the Road to Cure. <i>Cancers</i> , 2021, 13, 1430.	1.7	50
7068	Blood-Based Detection of BRAF V600E in Gliomas and Brain Tumor Metastasis. <i>Cancers</i> , 2021, 13, 1227.	1.7	9
7069	Playing the Whack-A-Mole Game: ERK5 Activation Emerges Among the Resistance Mechanisms to RAF-MEK1/2-ERK1/2- Targeted Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 647311.	1.8	13
7071	USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization. <i>Oncology Letters</i> , 2021, 21, 394.	0.8	9
7073	<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1072-1079.	1.9	6
7074	Comparative efficacy of dabrafenib+trametinib versus treatment options for metastatic melanoma in first-line settings. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 267-280.	0.6	4
7075	The Binary Classification of Protein Kinases. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 929-947.	1.6	4
7076	Adult pilocytic astrocytoma in the molecular era: a comprehensive review. <i>CNS Oncology</i> , 2021, 10, CNS68.	1.2	13
7077	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 301-314.	3.3	18
7078	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 329-359.	2.3	758
7080	Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 850-869.	0.5	9
7081	Cytoplasmic phosphorylated ERK1/2 expression in patients with melanoma is associated with tumor stage and metastasis. <i>Biotechnic and Histochemistry</i> , 2021, , 1-8.	0.7	1
7082	Coexisting BRAF-Mutated Langerhans Cell Histiocytosis and Primary Myelofibrosis with Shared JAK2 Mutation. <i>Case Reports in Hematology</i> , 2021, 2021, 1-5.	0.3	4

#	ARTICLE	IF	CITATIONS
7083	First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?. <i>JMIR Cancer</i> , 2021, 7, e29912.	0.9	4
7084	Spectroscopic (FT-IR, FT-Raman) investigations, quantum chemical calculations, ADMET and molecular docking studies of phloretin with B-RAF inhibitor. <i>Chemical Papers</i> , 2021, 75, 3771-3785.	1.0	10
7085	Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. <i>Circulation Research</i> , 2021, 128, 1040-1061.	2.0	59
7086	Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAFV600E/p38 β inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 215, 113277.	2.6	17
7087	The long non-coding RNA MIR31HG regulates the senescence associated secretory phenotype. <i>Nature Communications</i> , 2021, 12, 2459.	5.8	27
7088	Regulation of MAPK ERK1/2 Signaling by Phosphorylation: Implications in Physiological and Pathological Contexts. , 0, , .		1
7089	Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans. <i>Nature Communications</i> , 2021, 12, 2028.	5.8	12
7091	From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis. <i>Cancers</i> , 2021, 13, 2024.	1.7	5
7092	Personalized and targeted therapies. <i>ChemistrySelect</i> , 2023, 8, 2103-2126.	0.7	0
7093	The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 329-342.	0.5	1
7094	Context-Dependent Glioblastoma Macrophage/Microglia Symbiosis and Associated Mechanisms. <i>Trends in Immunology</i> , 2021, 42, 280-292.	2.9	42
7095	hTERT Transduction Extends the Lifespan of Primary Pediatric Low-Grade Glioma Cells While Preserving the Biological Response to NGF. <i>Pathology and Oncology Research</i> , 2021, 27, 612375.	0.9	4
7096	Personalized patient care with aggressive hematological malignancies in non-responders to first-line treatment. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 203-215.	0.4	2
7097	The Role of Notch, Hedgehog, and Wnt Signaling Pathways in the Resistance of Tumors to Anticancer Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 650772.	1.8	81
7098	Advances in Targeting Cutaneous Melanoma. <i>Cancers</i> , 2021, 13, 2090.	1.7	19
7099	Design and synthesis of 4-anilinoquinazolines as Raf kinase inhibitors. Part 1. Selective B-Raf/B-RafV600E and potent EGFR/VEGFR2 inhibitory 4-(3-hydroxyanilino)-6-(1H-1,2,3-triazol-4-yl)quinazolines. <i>Bioorganic Chemistry</i> , 2021, 109, 104715.	2.0	8
7100	Low expression of the PPAR β -regulated gene thioredoxin-interacting protein accompanies human melanoma progression and promotes experimental lung metastases. <i>Scientific Reports</i> , 2021, 11, 7847.	1.6	12
7103	ERK1/2: An Integrator of Signals That Alters Cardiac Homeostasis and Growth. <i>Biology</i> , 2021, 10, 346.	1.3	17

#	ARTICLE	IF	CITATIONS
7104	Systemic Therapy for Mutation-Driven NSCLC. <i>Seminars in Radiation Oncology</i> , 2021, 31, 140-148.	1.0	4
7105	Targeted transcriptome analysis using synthetic long read sequencing uncovers isoform reprogramming in the progression of colon cancer. <i>Communications Biology</i> , 2021, 4, 506.	2.0	10
7106	The BRAF P.V600E Mutation Status of Melanoma Lung Metastases Cannot Be Discriminated on Computed Tomography by LIDC Criteria nor Radiomics Using Machine Learning. <i>Journal of Personalized Medicine</i> , 2021, 11, 257.	1.1	4
7107	Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3837.	1.8	22
7108	Reconciling the Biological and Transcriptional Variability of Hepatoblastoma with Its Mutational Uniformity. <i>Cancers</i> , 2021, 13, 1996.	1.7	6
7109	Dermoscopic Features as Predictors of BRAF Mutational Status and Sentinel Lymph Node Positivity in Primary Cutaneous Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, e2021040.	0.5	0
7112	Improving the diagnosis of AUS/FLUS thyroid nodules using an algorithm with combination of BRAFV600E mutation analysis and ultrasound pattern-based risk stratification. <i>Clinical Hemorheology and Microcirculation</i> , 2021, 77, 273-285.	0.9	3
7113	Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade. <i>Journal of Controlled Release</i> , 2021, 332, 194-209.	4.8	25
7114	Integrated computational approaches on pyrazoline derivatives as B-Raf kinase inhibitors for the development of novel anticancer agents. <i>Journal of Molecular Structure</i> , 2021, 1230, 129861.	1.8	2
7115	Xeroderma Pigmentosum C: A Valuable Tool to Decipher the Signaling Pathways in Skin Cancers. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-14.	1.9	3
7117	IN11-negative colorectal undifferentiated carcinoma with rhabdoid features and postoperative rapidly growing liver metastases: a case report and review of the literature. <i>Surgical Case Reports</i> , 2021, 7, 104.	0.2	6
7118	Recent advances in development of hetero-bivalent kinase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021, 216, 113318.	2.6	15
7119	BRAF paradox breakers PLX8394, PLX7904 are more effective against BRAFV600E CRC cells compared with the BRAF inhibitor PLX4720 and shown by detailed pathway analysis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166061.	1.8	14
7120	Precision oncology in metastatic colorectal cancer "from biology to medicine". <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 506-525.	12.5	113
7122	Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?. <i>Frontiers in Oncology</i> , 2021, 11, 645008.	1.3	6
7123	Bioactivity of fractions and constituents of Piper capense fruits towards a broad panel of cancer cells. <i>Journal of Ethnopharmacology</i> , 2021, 271, 113884.	2.0	24
7124	PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma. <i>Scientific Reports</i> , 2021, 11, 11023.	1.6	6
7125	A Review of Epidemiology and Cancer Biology of Malignant Melanoma. <i>Cureus</i> , 2021, 13, e15087.	0.2	26

#	ARTICLE	IF	CITATIONS
7126	Multiple sclerosis is linked to MAPK/ERK overactivity in microglia. <i>Journal of Molecular Medicine</i> , 2021, 99, 1033-1042.	1.7	22
7127	Analysis of Genetic Alterations in Cutaneous Malignant Melanomas Unveils Unique Loco-Regional Variations and Novel Predictors of Metastatic Potential. <i>American Journal of Dermatopathology</i> , 2021, 43, e185-e189.	0.3	4
7128	Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA. <i>Clinical and Translational Oncology</i> , 2021, 23, 2020-2029.	1.2	0
7129	Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. <i>Oncologist</i> , 2021, 26, 731-e1498.	1.9	20
7130	Antitumor effect of Melaleuca alternifolia essential oil and its main component terpinen-4-ol in combination with target therapy in melanoma models. <i>Cell Death Discovery</i> , 2021, 7, 127.	2.0	24
7131	Daily Lifestyle and Cutaneous Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5227.	1.8	13
7132	LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance. <i>Oncogene</i> , 2021, 40, 3707-3718.	2.6	8
7133	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 661737.	2.2	29
7134	A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 3385-3405.	3.3	8
7135	Cutaneous Melanoma Classification: The Importance of High-Throughput Genomic Technologies. <i>Frontiers in Oncology</i> , 2021, 11, 635488.	1.3	36
7136	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. <i>Nature</i> , 2021, 594, 418-423.	13.7	64
7137	A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer. <i>Protein Science</i> , 2021, 30, 1535-1553.	3.1	17
7138	The Role of Senescent Cells in Acquired Drug Resistance and Secondary Cancer in BRAFi-Treated Melanoma. <i>Cancers</i> , 2021, 13, 2241.	1.7	8
7139	Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants. <i>Cancers</i> , 2021, 13, 2440.	1.7	6
7140	Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists. <i>Clinical Lung Cancer</i> , 2021, 22, e901-e910.	1.1	15
7141	Adenosquamous carcinoma of the hepatic flexure of colon: a case report: a case report. <i>Translational Cancer Research</i> , 2021, 10, 2496-2502.	0.4	0
7142	Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective. <i>Survey of Ophthalmology</i> , 2022, 67, 388-410.	1.7	8
7143	Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study. <i>Cancers</i> , 2021, 13, 2312.	1.7	11

#	ARTICLE	IF	CITATIONS
7144	Anorectal Melanoma. , 0, , .		0
7145	Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer. <i>Cancer Science</i> , 2021, 112, 2884-2894.	1.7	18
7146	Impact of BRAF mutations on clinical outcomes following liver surgery for colorectal liver metastases: An updated meta-analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2722-2733.	0.5	4
7147	Perifosine enhances the potential antitumor effect of 5-fluorouracil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation. <i>European Journal of Pharmacology</i> , 2021, 898, 173957.	1.7	11
7148	Heart Failure With Targeted Cancer Therapies. <i>Circulation Research</i> , 2021, 128, 1576-1593.	2.0	33
7149	Photosensitizing Medications and Skin Cancer: A Comprehensive Review. <i>Cancers</i> , 2021, 13, 2344.	1.7	10
7150	Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma. <i>Cell Cycle</i> , 2021, 20, 1041-1051.	1.3	29
7152	Phase II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism. <i>Clinical Cancer Research</i> , 2021, 27, 3876-3883.	3.2	8
7153	Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE). <i>Cancers</i> , 2021, 13, 2529.	1.7	15
7154	Melanoma pathology: new approaches and classification*. <i>British Journal of Dermatology</i> , 2021, 185, 282-293.	1.4	25
7155	Many Distinct Ways Lead to Drug Resistance in BRAF- and NRAS-Mutated Melanomas. <i>Life</i> , 2021, 11, 424.	1.1	3
7156	Systematic interrogation of mutation groupings reveals divergent downstream expression programs within key cancer genes. <i>BMC Bioinformatics</i> , 2021, 22, 233.	1.2	1
7158	Discovery of New Imidazo[2,1-b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising <i>In Vitro</i> and <i>In Vivo</i> Anti-melanoma Activity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6877-6901.	2.9	15
7159	The Role of the Meiotic Component in Reproduction of B-RAF-Mutated Melanoma: A Review and Brainstorming Session. , 0, , .		2
7160	Therapeutic Application of Melatonin in the Treatment of Melanoma: A Review. <i>Current Cancer Therapy Reviews</i> , 2021, 17, 283-291.	0.2	3
7161	Analysis of the Prognostic Value and Potential Molecular Mechanisms of TREM-1 Overexpression in Papillary Thyroid Cancer via Bioinformatics Methods. <i>Frontiers in Endocrinology</i> , 2021, 12, 646793.	1.5	3
7162	Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations. <i>Clinical Epigenetics</i> , 2021, 13, 117.	1.8	8
7163	40 Years of RAS: A Historic Overview. <i>Genes</i> , 2021, 12, 681.	1.0	24

#	ARTICLE	IF	CITATIONS
7164	Molecular pathology as a diagnostic aid in difficult-to-classify melanocytic tumours with spitzoid morphology. <i>European Journal of Cancer</i> , 2021, 148, 340-347.	1.3	5
7165	ExTraMapper: exon- and transcript-level mappings for orthologous gene pairs. <i>Bioinformatics</i> , 2021, 37, 3412-3420.	1.8	3
7166	Cancer Selective Target Degradation by Folate-Caged PROTACs. <i>Journal of the American Chemical Society</i> , 2021, 143, 7380-7387.	6.6	117
7167	Prognostic Value of ctDNA Mutation in Melanoma: A Meta-Analysis. <i>Journal of Oncology</i> , 2021, 2021, 1-13.	0.6	6
7168	HDAC8 Activates AKT through Upregulating PLCB1 and Suppressing DESC1 Expression in MEK1/2 Inhibition-Resistant Cells. <i>Cells</i> , 2021, 10, 1101.	1.8	10
7169	Stromal-Derived Extracellular Vesicles Suppress Proliferation of Bone Metastatic Cancer Cells Mediated by ERK2. <i>Molecular Cancer Research</i> , 2021, 19, 1763-1777.	1.5	5
7170	Retinal toxicities of systemic anticancer drugs. <i>Survey of Ophthalmology</i> , 2022, 67, 97-148.	1.7	16
7171	Systemic Therapy for Head and Neck Skin Cancers. <i>Face</i> , 2021, 2, 121-130.	0.1	0
7172	The landscape and driver potential of site-specific hotspots across cancer genomes. <i>Npj Genomic Medicine</i> , 2021, 6, 33.	1.7	8
7173	Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5158.	1.8	3
7174	Current management of melanoma patients with nodal metastases. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 181-199.	1.7	8
7176	BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage. <i>BMC Neurology</i> , 2021, 21, 195.	0.8	3
7177	Molecular Profiles of Brain Metastases: A Focus on Heterogeneity. <i>Cancers</i> , 2021, 13, 2645.	1.7	16
7178	An ultrasensitive biosensor for dual-specific DNA based on deposition of polyaniline on a self-assembled multi-functional DNA hexahedral-nanostructure. <i>Biosensors and Bioelectronics</i> , 2021, 179, 113066.	5.3	18
7179	Current Status and Prospects of Immunotherapy for Gynecologic Melanoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 403.	1.1	4
7180	Interference between copper transport systems and platinum drugs. <i>Seminars in Cancer Biology</i> , 2021, 76, 173-188.	4.3	38
7181	Identifying Novel Actionable Targets in Colon Cancer. <i>Biomedicines</i> , 2021, 9, 579.	1.4	13
7182	Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF Inhibition. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1317-1324.e1.	0.3	9

#	ARTICLE	IF	CITATIONS
7183	RAF-MEK-ERK pathway in cancer evolution and treatment. <i>Seminars in Cancer Biology</i> , 2022, 85, 123-154.	4.3	113
7184	Kinase drug discovery 20 years after imatinib: progress and future directions. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 551-569.	21.5	497
7185	Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study. <i>Cancers</i> , 2021, 13, 3302.	1.7	3
7186	The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of Î±C-Î²4 loop. <i>Science Advances</i> , 2021, 7, .	4.7	13
7187	The Functional Impact of Alternative Splicing and Single Nucleotide Polymorphisms in Rheumatoid Arthritis. <i>Current Pharmaceutical Biotechnology</i> , 2021, 22, 1014-1029.	0.9	2
7188	A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 189.	3.5	23
7189	Molecular Biomarkers for Lung Adenocarcinoma: A Short Review. <i>Current Cancer Therapy Reviews</i> , 2021, 17, 97-106.	0.2	3
7190	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	13.9	201
7191	Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract. <i>BMC Cancer</i> , 2021, 21, 677.	1.1	6
7192	Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer. <i>Scientific Reports</i> , 2021, 11, 13263.	1.6	1
7193	Landmark Series on Disparities in Surgical Oncology: Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6986-6993.	0.7	4
7194	Advancing targeted protein degradation for cancer therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 638-654.	12.8	251
7195	Natural Phytochemicals Derived from Gymnosperms in the Prevention and Treatment of Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6636.	1.8	10
7196	The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and BRAFV600E Mutation. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3959-3969.	1.0	6
7197	SNP-based detection of allelic imbalance: A novel approach for identifying KIAA1549-BRAF fusion in pilocytic astrocytoma using DNA sequencing. <i>Experimental and Molecular Pathology</i> , 2021, 120, 104621.	0.9	1
7198	Selection of Oral Therapeutics in China for the Treatment of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2021, 22, 55.	1.3	4
7199	A Rare BRAF Fusion in Advanced Rectal Cancer Treated with Anti-Epidermal Growth Factor Receptor Therapy. <i>Case Reports in Oncology</i> , 2021, 14, 938-943.	0.3	1
7200	BRN2 is a non-canonical melanoma tumor-suppressor. <i>Nature Communications</i> , 2021, 12, 3707.	5.8	10

#	ARTICLE	IF	CITATIONS
7201	A hajas sejtes leuk�mia korszer� diagnosztik�ja �s kezel�se. Transfusio, 2021, 54, 90-102.	0.0	0
7202	Current status of intralesional agents in treatment of malignant melanoma. Annals of Translational Medicine, 2021, 9, 1038-1038.	0.7	21
7203	Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4072-e4083.	1.8	10
7204	Somatic BRAF V600E Mutation in Familial Colorectal Cancer Type X: A New Study in Central Iran. Jentashapir Journal of Cellular and Molecular Biology, 2021, 12, .	0.1	1
7205	Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era. Diagnostics, 2021, 11, 1110.	1.3	4
7206	Pan-cancer network disorders revealed by overall and local signaling entropy. Journal of Molecular Cell Biology, 2021, 13, 622-635.	1.5	2
7207	Frequency detection of BRAF V600E mutation in a cohort of pediatric langerhans cell histiocytosis patients by next-generation sequencing. Orphanet Journal of Rare Diseases, 2021, 16, 272.	1.2	11
7208	Genetic and biological hallmarks of colorectal cancer. Genes and Development, 2021, 35, 787-820.	2.7	159
7209	Unveiling the pathogenesis of perineural invasion from the perspective of neuroactive molecules. Biochemical Pharmacology, 2021, 188, 114547.	2.0	8
7210	Implementation of clinical sequencing for molecular profiling in patients with advanced cancer. Cancer Biomarkers, 2021, 31, 119-126.	0.8	1
7211	Physio-pathological effects of m6A modification and its potential contribution to melanoma. Clinical and Translational Oncology, 2021, 23, 2269-2279.	1.2	12
7212	Inhibition of the Human Hsc70 System by Small Ligands as a Potential Anticancer Approach. Cancers, 2021, 13, 2936.	1.7	7
7213	Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 6813.	1.8	20
7214	Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer. European Journal of Medicinal Chemistry, 2021, 218, 113386.	2.6	29
7215	Hairy Cell Leukemia Masquerading as CD5+ Lymphoproliferative Disease: The Importance of BRAF V600E Testing in Diagnosis and Treatment. JCO Precision Oncology, 2021, 5, 1035-1039.	1.5	3
7216	High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients. ESMO Open, 2021, 6, 100133.	2.0	12
7217	Melanoma genomics: a state-of-the-art review of practical clinical applications*. British Journal of Dermatology, 2021, 185, 272-281.	1.4	12
7218	Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling. Cell Reports Methods, 2021, 1, 100015.	1.4	10

#	ARTICLE	IF	CITATIONS
7219	Autophagy Inhibition in BRAF-Driven Cancers. <i>Cancers</i> , 2021, 13, 3498.	1.7	13
7220	The human melanoma proteome atlasâ€”Defining the molecular pathology. <i>Clinical and Translational Medicine</i> , 2021, 11, e473.	1.7	14
7222	A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer. <i>Scientific Reports</i> , 2021, 11, 13683.	1.6	8
7223	Interpretable deep learning uncovers cellular properties in label-free live cell images that are predictive of highly metastatic melanoma. <i>Cell Systems</i> , 2021, 12, 733-747.e6.	2.9	48
7224	Fermitin family member 2 promotes melanoma progression by enhancing the binding of p115-Pix to Rac1 to activate the MAPK pathway. <i>Oncogene</i> , 2021, 40, 5626-5638.	2.6	8
7225	BRAF Mutation Analysis in Primary Acral Melanoma of 41 Cases from South of Iran. <i>Iranian Journal of Pathology</i> , 2021, 16, 370-375.	0.2	0
7226	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 334-341.	1.0	9
7227	Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer. <i>Cancer Science</i> , 2021, 112, 3856-3870.	1.7	9
7228	Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2021, 30, 200294.	3.0	7
7229	Cytologic diagnosis of metastatic melanoma by FNA: A practical review. <i>Cancer Cytopathology</i> , 2022, 130, 18-29.	1.4	15
7230	Colorectal Cancer: From Genetic Landscape to Targeted Therapy. <i>Journal of Oncology</i> , 2021, 2021, 1-17.	0.6	28
7231	Pre-existing Thyroiditis Ameliorates Papillary Thyroid Cancer: Insights From a New Mouse Model. <i>Endocrinology</i> , 2021, 162, .	1.4	10
7232	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3453.	1.7	6
7233	Evolution of the Clinical, Dermoscopic and Pathologic Diagnosis of Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021163S.	0.5	9
7234	Cancer Genomic Profiling in Colorectal Cancer: Current Challenges in Subtyping Colorectal Cancers Based on Somatic and Germline Variants. <i>Journal of the Anus, Rectum and Colon</i> , 2021, 5, 213-228.	0.4	2
7235	The prognostic and predictive impact of BRAF mutations in deficient mismatch repair/microsatellite instability-high colorectal cancer: systematic review/meta-analysis. <i>Future Oncology</i> , 2021, 17, 4221-4231.	1.1	4
7236	PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN. <i>Npj Precision Oncology</i> , 2021, 5, 68.	2.3	6
7237	Recognition, Staging, and Management of Melanoma. <i>Medical Clinics of North America</i> , 2021, 105, 643-661.	1.1	4

#	ARTICLE	IF	CITATIONS
7238	Histiocytosis. <i>Lancet, The</i> , 2021, 398, 157-170.	6.3	58
7239	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. <i>Oncogene</i> , 2021, 40, 5590-5599.	2.6	33
7240	Cisplatin-induced hydroxyl radicals mediate pro-survival autophagy in human lung cancer H460 cells. <i>Biological Research</i> , 2021, 54, 22.	1.5	8
7241	BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options. <i>Der Pathologe</i> , 2021, 42, 98-109.	0.7	5
7242	B-Raf autoinhibition in the presence and absence of 14-3-3. <i>Structure</i> , 2021, 29, 768-777.e2.	1.6	26
7243	Novel insights into the pathogenesis and treatment of NRAS mutant melanoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 281-294.	0.4	4
7244	Pulmonary metastatic melanoma: current state of diagnostic imaging and treatments. <i>Melanoma Management</i> , 2021, 8, MMT58.	0.1	7
7245	CDK7 and MITF repress a transcription program involved in survival and drug tolerance in melanoma. <i>EMBO Reports</i> , 2021, 22, e51683.	2.0	10
7246	BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 705060.	1.8	20
7247	Characterization and Clinical Utility of BRAFV600 Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma. <i>Cancers</i> , 2021, 13, 3591.	1.7	4
7248	Polymorphisms at site 469 of B-RAF protein associated with skin melanoma may be correlated with dabrafenib resistance: An <i>in silico</i> study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 10862-10877.	2.0	1
7249	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. <i>Current Problems in Surgery</i> , 2022, 59, 101030.	0.6	4
7250	BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells. <i>Anti-Cancer Drugs</i> , 2021, 32, 1076-1083.	0.7	2
7252	Skin Cancers and the Contribution of Rho GTPase Signaling Networks to Their Progression. <i>Cancers</i> , 2021, 13, 4362.	1.7	4
7253	Hyperactivation of MEK/ERK pathway by Ca ²⁺ /calmodulin-dependent protein kinase kinase 2 promotes cellular proliferation by activating cyclin-dependent kinases and minichromosome maintenance protein in gastric cancer cells. <i>Molecular Carcinogenesis</i> , 2021, 60, 769-783.	1.3	15
7254	MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). <i>BMC Cancer</i> , 2021, 21, 932.	1.1	3
7255	Detection of Circulating Tumor DNA in Patients with Thyroid Nodules. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-8.	0.6	5
7256	Establishment of Canine Transitional Cell Carcinoma Cell Lines Harboring BRAF V595E Mutation as a Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9151.	1.8	9

#	ARTICLE	IF	CITATIONS
7257	Gastrointestinal stromal tumors with <i>BRAF</i> gene fusions. A report of two cases showing low or absent <i>KIT</i> expression resulting in diagnostic pitfalls. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 789-795.	1.5	11
7258	Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA. <i>International Journal of Hematology</i> , 2021, 114, 725-734.	0.7	17
7259	Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics. <i>Biochemistry</i> , 2021, 60, 3470-3484.	1.2	5
7260	Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer. <i>Cancers</i> , 2021, 13, 4353.	1.7	6
7261	The Evolution of Acquired Resistance to BRAFV600E Kinase inhibitor Is Sustained by IGF1-Driven Tumor Vascular Remodeling. <i>Journal of Investigative Dermatology</i> , 2022, 142, 445-458.	0.3	11
7262	Glycoprotein non- <i>metastatic melanoma protein B</i> functions with growth factor signaling to induce tumorigenesis through its serine phosphorylation. <i>Cancer Science</i> , 2021, 112, 4187-4197.	1.7	7
7264	The Downregulation of eIF3a Contributes to Vemurafenib Resistance in Melanoma by Activating ERK via PPP2R1B. <i>Frontiers in Pharmacology</i> , 2021, 12, 720619.	1.6	4
7265	Occurrence, functionality and abundance of the <i>TERT</i> promoter mutations. <i>International Journal of Cancer</i> , 2021, 149, 1852-1862.	2.3	13
7266	Metabolism-associated genes in occurrence and development of gastrointestinal cancer: Latest progress and future prospect. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 758-771.	0.8	3
7267	Expression of oncogenic HRAS in human Rh28 and RMS-YM rhabdomyosarcoma cells leads to oncogene-induced senescence. <i>Scientific Reports</i> , 2021, 11, 16505.	1.6	1
7268	Melanoma medicine in the new millennium. <i>British Journal of Dermatology</i> , 2021, 185, 239-240.	1.4	0
7269	Plasma proteome alterations by MAPK inhibitors in BRAF-mutated metastatic cutaneous melanoma. <i>Neoplasia</i> , 2021, 23, 783-791.	2.3	1
7270	Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. <i>JCO Precision Oncology</i> , 2021, 5, 1325-1338.	1.5	14
7271	Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. <i>Annals of Oncology</i> , 2021, 32, 959-967.	0.6	102
7272	Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. <i>Clinical Cancer Research</i> , 2021, 27, 6197-6208.	3.2	20
7273	Biomarkers in metastatic melanoma of the skin: can we more accurately choose the tactics of treating our patients?. <i>Meditinskiy Sovet</i> , 2021, , 48-63.	0.1	2
7274	Integrated genotype-phenotype analysis of long-term epilepsy-associated ganglioglioma. <i>Brain Pathology</i> , 2022, 32, e13011.	2.1	15
7275	Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study. <i>European Journal of Cancer</i> , 2021, 153, 16-26.	1.3	5

#	ARTICLE	IF	CITATIONS
7276	Membrane Bound Peroxiredoxin-1 Serves as a Biomarker for <i>In Vivo</i> Detection of Sessile Serrated Adenomas. <i>Antioxidants and Redox Signaling</i> , 2022, 36, 39-56.	2.5	4
7277	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. <i>Cancer Treatment Reviews</i> , 2021, 99, 102253.	3.4	26
7278	Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models. <i>Viruses</i> , 2021, 13, 1758.	1.5	5
7279	BRAF mutation correlates with worse local/regional control following radiation therapy in patients with stage III melanoma. <i>Radiation Oncology</i> , 2021, 16, 181.	1.2	5
7280	Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition. <i>Kidney International</i> , 2021, 100, 1214-1226.	2.6	16
7281	The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. <i>Targeted Oncology</i> , 2021, 16, 537-552.	1.7	20
7282	Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 30, 95-99.	0.9	5
7283	Thyroid carcinoma associated with other primary neoplasms, a single center study. <i>Medicine and Pharmacy Reports</i> , 0, , .	0.2	0
7284	Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study. <i>European Journal of Cancer</i> , 2021, 154, 111-119.	1.3	16
7286	ERK: A Double-Edged Sword in Cancer. ERK-Dependent Apoptosis as a Potential Therapeutic Strategy for Cancer. <i>Cells</i> , 2021, 10, 2509.	1.8	85
7287	Pharmacologically induced uveitis. <i>Survey of Ophthalmology</i> , 2021, 66, 781-801.	1.7	6
7288	Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?. <i>Brain Sciences</i> , 2021, 11, 1260.	1.1	4
7289	The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven Tumors. <i>Frontiers in Oral Health</i> , 2021, 2, 740788.	1.2	26
7290	MicroRNA Isoforms Contribution to Melanoma Pathogenesis. <i>Non-coding RNA</i> , 2021, 7, 63.	1.3	6
7291	Molecular Markers and Targets in Melanoma. <i>Cells</i> , 2021, 10, 2320.	1.8	72
7292	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 145-155.	0.5	4
7293	<i>BRAF</i> V600E potentially determines "Oncological Resectability" for "Technically Resectable" colorectal liver metastases. <i>Cancer Medicine</i> , 2021, 10, 6998-7011.	1.3	7
7294	Remarkable response of <i>BRAF</i> V600E-mutated metastatic pancreatic cancer to BRAF/MEK inhibition: a case report. <i>Gastroenterology Report</i> , 2022, 10, goab031.	0.6	4

#	ARTICLE	IF	CITATIONS
7295	Design, Synthesis and Anticancer Profile of New 4-(1H-benzo[d]imidazol-1-yl)pyrimidin-2-amine-Linked Sulfonamide Derivatives with V600EBRAF Inhibitory Effect. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10491.	1.8	7
7296	Genetic and Genomic Pathways of Melanoma Development, Invasion and Metastasis. <i>Genes</i> , 2021, 12, 1543.	1.0	12
7297	RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient. <i>Cancers</i> , 2021, 13, 4950.	1.7	13
7298	The role of the ubiquitin-proteasome pathway in skin cancer development: 26S proteasome-activated NF- κ B signal transduction. <i>Cancer Biology and Therapy</i> , 2021, 22, 479-492.	1.5	9
7299	Enabling oncogenes. <i>Science</i> , 2021, 373, 1088-1089.	6.0	1
7300	TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. <i>Nature Cell Biology</i> , 2021, 23, 978-991.	4.6	29
7301	Combined targeted therapy and immunotherapy for cancer treatment. <i>World Journal of Clinical Cases</i> , 2021, 9, 7643-7652.	0.3	5
7302	Melanoma metastasis, BRAF mutation and GJB5 connexin expression: a new prognostic factor. <i>British Journal of Dermatology</i> , 2021, , .	1.4	0
7303	Dermatologic adverse events associated with targeted therapies for melanoma. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 385-395.	1.0	0
7304	Canonical Signaling Pathways in Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 551-560.	0.7	2
7305	Mutational spectrum of BRAF gene in colorectal cancer patients in Saudi Arabia. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 5906-5912.	1.8	8
7306	EVALUATION OF ORAL CANCER AWARENESS LEVEL OF FACULTY OF DENTISTRY STUDENTS AND ACADEMICIANS. <i>Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi</i> , 0, , 1-1.	0.0	0
7307	LC-MS/MS studies for identification and characterization of new forced degradation products of dabrafenib and establishment of their degradation pathway. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 206, 114351.	1.4	11
7308	TOP1 modulation during melanoma progression and in adaptive resistance to BRAF and MEK inhibitors. <i>Pharmacological Research</i> , 2021, 173, 105911.	3.1	5
7309	Cancer driver gene and non-coding RNA alterations as biomarkers of brain metastasis in lung cancer: A review of the literature. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112190.	2.5	24
7310	New insights into Raf regulation from structural analyses. <i>Current Opinion in Structural Biology</i> , 2021, 71, 223-231.	2.6	4
7311	Advances in Targeted Treatments for NSCLC (Excluding EGFR/ALK/ROS-1/K-Ras). , 2022, , 889-904.		0
7312	Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy. <i>International Journal of Medical Sciences</i> , 2021, 18, 1657-1669.	1.1	12

#	ARTICLE	IF	CITATIONS
7313	Mechanisms of Lung Cyst Formation. <i>Respiratory Medicine</i> , 2021, , 21-42.	0.1	0
7314	Extrapulmonary Manifestations of Diffuse Cystic Lung Diseases. <i>Respiratory Medicine</i> , 2021, , 283-308.	0.1	0
7315	Therapeutic Applications of Noble Metal (Au, Ag, Pt)-Based Nanomedicines for Melanoma. , 2021, , 161-202.		2
7316	Molecular Targeting of HuR Oncoprotein Suppresses MITF and Induces Apoptosis in Melanoma Cells. <i>Cancers</i> , 2021, 13, 166.	1.7	12
7317	Assessing the Educational and Supportive Care Needs of Canadian Metastatic Melanoma Patients and Survivors Attending an Outpatient Clinic. <i>Journal of Patient Experience</i> , 2021, 8, 237437352110331.	0.4	1
7318	MITF reprograms the extracellular matrix and focal adhesion in melanoma. <i>ELife</i> , 2021, 10, .	2.8	45
7319	Role of Epigenetics in Colorectal Cancer. , 2021, , 91-99.		0
7320	uPAR Controls Vasculogenic Mimicry Ability Expressed by Drug-Resistant Melanoma Cells. <i>Oncology Research</i> , 2021, 28, 873-884.	0.6	10
7321	Bromamine T (BAT) Exerts Stronger Anti-Cancer Properties than Taurine (Tau). <i>Cancers</i> , 2021, 13, 182.	1.7	7
7324	Novel Targeted Therapies in Clinical Use and on the Horizon for Cholangiocarcinoma. , 2021, , 449-468.		0
7325	Light-excited chemiresistive sensors integrated on LED microchips. <i>Journal of Materials Chemistry A</i> , 2021, 9, 16545-16553.	5.2	7
7326	BRAFAMP Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAFV600E. <i>Frontiers in Oncology</i> , 2020, 10, 531968.	1.3	8
7327	Tetrahedral Framework Nucleic Acids Loaded with Aptamer AS1411 for siRNA Delivery and Gene Silencing in Malignant Melanoma. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 6109-6118.	4.0	52
7328	The Era of Radiogenomics in Precision Medicine: An Emerging Approach to Support Diagnosis, Treatment Decisions, and Prognostication in Oncology. <i>Frontiers in Oncology</i> , 2020, 10, 570465.	1.3	60
7329	Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1 α to re-activate MAPK signaling. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 767-777.	1.2	11
7330	Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. <i>Annual Review of Medicine</i> , 2021, 72, 399-413.	5.0	12
7333	The Genetics of Melanoma. , 0, , 472-488.		3
7336	The roles of exosomes in cancer drug resistance and its therapeutic application. <i>Clinical and Translational Medicine</i> , 2020, 10, e257.	1.7	47

#	ARTICLE	IF	CITATIONS
7337	RAS and the RAF/MEK/ERK Cascade. , 2006, , 67-93.		1
7338	The Origin of Cancer. , 2004, 122, 1-22.		3
7339	Molecular Events in Follicular Thyroid Tumors. , 2004, 122, 85-106.		41
7340	Biology of Ras in Thyroid Cells. , 2004, 122, 131-148.		15
7341	The Role of Mammalian Coronins in Development and Disease. Sub-Cellular Biochemistry, 2008, 48, 124-135.	1.0	30
7342	New Promises in the Adjuvant, and Palliative Treatment of Melanoma. Cancer Treatment and Research, 2007, 135, 277-292.	0.2	3
7343	Molecular Biology of Malignant Melanoma. Advances in Experimental Medicine and Biology, 2008, 624, 252-264.	0.8	7
7344	Apoptosis and Pathogenesis of Melanoma and Nonmelanoma Skin Cancer. Advances in Experimental Medicine and Biology, 2008, 624, 283-295.	0.8	54
7345	Ras-Superfamily GTP-ases in Ovarian Cancer. Cancer Treatment and Research, 2009, 149, 229-240.	0.2	12
7346	Getting familiar with familial colon cancer. , 0, , 27-60.		1
7347	Signal Transduction Pathways as Therapeutic Targets in Cancer Therapy. , 2010, , 37-83.		2
7348	The Biology of Thyroid Oncogenesis. Cancer Treatment and Research, 2010, 153, 3-21.	0.2	6
7349	Well-Differentiated Papillary Thyroid Carcinoma. Molecular Pathology Library, 2010, , 57-71.	0.1	1
7350	Systems Biology of the MAPK1,2 Network. Systems Biology, 2010, , 455-489.	0.1	2
7351	Crosstalk Between Mitogen-Activated Protein Kinase and Phosphoinositide-3 Kinase Signaling Pathways in Development and Disease. Systems Biology, 2010, , 505-529.	0.1	1
7353	Mechanisms and Potential Therapies for Acquired Resistance to Inhibitors Targeting the Raf or MEK Kinases in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 47-67.	0.1	2
7354	Molecular Mechanisms of Colorectal Carcinogenesis. , 2013, , 25-65.		7
7355	Novel Next-Generation Sequencing Applications. SpringerBriefs in Systems Biology, 2014, , 61-70.	0.1	3

#	ARTICLE	IF	CITATIONS
7356	Circulating Cell-Free DNA in Cancer. <i>Methods in Molecular Biology</i> , 2014, 1160, 133-145.	0.4	13
7357	Targeted Therapies in Melanoma. <i>Current Clinical Pathology</i> , 2015, , 211-227.	0.0	4
7358	Melanoma Pathogenesis. <i>Cancer Drug Discovery and Development</i> , 2015, , 25-45.	0.2	3
7359	HTRF Kinase Assay Development and Methods in Inhibitor Characterization. <i>Methods in Molecular Biology</i> , 2016, 1360, 1-18.	0.4	9
7360	Inherited Gene Mutations in Melanoma. , 2016, , 117-149.		1
7361	The MAPK Pathway in Melanoma. , 2016, , 151-163.		1
7362	The PI3K-AKT Pathway in Melanoma. , 2016, , 165-180.		3
7363	Isolation and Characterization of Intrinsically Active (MEK-Independent) Mutants of Mpk1/Erk. <i>Methods in Molecular Biology</i> , 2017, 1487, 65-88.	0.4	3
7364	Emerging Molecular Therapies. , 2004, , 569-606.		3
7365	Genetic Markers in Sporadic Tumors. , 2004, , 73-150.		1
7366	Familial Melanoma Genes, Melanocyte Immortalization, and Melanoma Initiation. , 2006, , 183-196.		2
7367	The Biology of Melanoma Progression. , 2006, , 365-398.		1
7368	Molecular Basis of Lung Carcinogenesis. , 2017, , 447-496.		4
7369	Genetic Markers in Sporadic Tumors. , 2008, , 43-84.		2
7370	Cancer Genome Analysis Informatics. <i>Methods in Molecular Biology</i> , 2010, 628, 75-102.	0.4	7
7371	DNA Sequencing of Cancer-Related Genes for Biomarker Discovery. <i>Methods in Molecular Biology</i> , 2009, 520, 205-220.	0.4	2
7373	Evasion of G1 Checkpoints in Cancer. , 2010, , 3-26.		1
7374	MicroRNA Biomarkers in Melanoma. , 2012, , 113-126.		1

#	ARTICLE	IF	CITATIONS
7375	Targeted Inhibition of B-Raf. , 2012, , 63-76.		1
7376	Presymptomatic Genetic Testing: Shifting the Emphasis from Reaction to Prevention. , 2012, , 131-146.		1
7377	Integrating Molecular Biomarkers into Current Clinical Management in Melanoma. Methods in Molecular Biology, 2014, 1102, 27-42.	0.4	7
7378	Selecting Patients for KIT Inhibition in Melanoma. Methods in Molecular Biology, 2014, 1102, 137-162.	0.4	4
7379	Molecular Pathology and Genomics of Melanoma. , 2020, , 381-422.		1
7380	Biology of Melanocytes and Primary Melanoma. , 2020, , 3-40.		4
7381	Targeting Transient Receptor Potential Channels by MicroRNAs Drives Tumor Development and Progression. Advances in Experimental Medicine and Biology, 2020, 1131, 605-623.	0.8	16
7382	Breaking Bad: Uncoupling of Modularity in Centriole Biogenesis and the Generation of Excess Centrioles in Cancer. Results and Problems in Cell Differentiation, 2019, 67, 391-411.	0.2	3
7383	Melanoma Metabolism: Cell Survival and Resistance to Therapy. Advances in Experimental Medicine and Biology, 2020, 1219, 203-223.	0.8	15
7384	Avoiding or Co-Opting ATP Inhibition: Overview of Type III, IV, V, and VI Kinase Inhibitors. , 2020, , 29-59.		9
7385	Dysregulation of Sphingolipid Metabolism in Melanoma: Roles in Pigmentation, Cell Survival and Tumor Progression. , 2015, , 123-139.		2
7386	Molecular Pathology and Genomics of Melanoma. , 2019, , 1-42.		2
7387	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2019, , 1-27.		1
7388	Stratifying Cancer Therapies by Molecular Interactions and Imaging. , 2017, , 315-358.		1
7389	Bcl-2 Proteins and TRAIL Resistance in Melanoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 79-90.	0.1	1
7390	Implementation of Exome Sequencing Assay. , 2019, , 203-217.		2
7392	The Ras Signalling Pathway as a Target in Cancer Therapy. , 2007, 172, 125-153.		9
7393	The Mitogen-Activated Protein Kinase Pathway for Molecular-Targeted Cancer Treatment. , 2007, 172, 155-167.		13

#	ARTICLE	IF	CITATIONS
7394	Vascular Endothelial Growth Factor. , 2008, , 395-423.		5
7395	New Aspects on the Pathogenesis of Conjunctival Melanoma. , 2008, , 201-216.		1
7396	Oncogenic Signaling Pathways and Deregulated Target Genes. , 2007, 176, 7-24.		6
7397	Carcinogenesis: UV Radiation*. , 2010, , 567-578.		1
7398	Medikamentöse Tumorthherapie in der Dermato-Onkologie. , 2014, , .		2
7399	Nevogenesis: Changing Theories. , 2012, , 1-23.		2
7400	Etiology of Congenital Melanocytic Nevi and Related Conditions. , 2012, , 73-97.		3
7401	Dabrafenib. Recent Results in Cancer Research, 2014, 201, 227-240.	1.8	7
7402	Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics. , 2015, , 7-27.		2
7403	Carcinogenesis: UV Radiation. , 2017, , 887-902.		1
7404	Melanom. , 2018, , 1869-1885.		1
7405	Epithelial Cell Signalling in Colorectal Cancer Metastasis. Cancer Metastasis - Biology and Treatment, 2010, , 205-241.	0.1	5
7406	Roles of Signaling Pathways in Cancer Cells and Immune Cells in Generation of Immunosuppressive Tumor-Associated Microenvironments. , 2013, , 307-323.		2
7407	Contact Normalization or Escape from the Matrix. , 2015, , 297-342.		4
7408	Melanoma and Non-Melanoma Skin Cancers. , 2014, , 435-452.		1
7409	Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors. Advances in Experimental Medicine and Biology, 2019, 1163, 253-278.	0.8	18
7410	Dynamic Protein Allosteric Regulation and Disease. Advances in Experimental Medicine and Biology, 2019, 1163, 25-43.	0.8	13
7411	Overview of Cancer Genomics, Organization, and Variations in the Human Genome. , 2020, , 3-33.		2

#	ARTICLE	IF	CITATIONS
7412	KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 315-323.	3.3	64
7413	<i>Thyroid gland.</i> , 2011, , 487-564.		59
7414	<i>Progressing from Gene Mutations to Cancer.</i> , 2008, , 207-222.		3
7415	<i>Protein Kinase Inhibitors.</i> , 2003, , 451-461.		1
7416	<i>Ewing's Sarcoma.</i> , 2009, , 829-869.		1
7417	<i>Genetics of Skin Cancer.</i> , 2011, , 12-22.		2
7418	<i>Cancer Immunology.</i> , 2014, , 78-97.e5.		3
7420	Visualizing cellular heterogeneity by quantifying the dynamics of MAPK activity in live mammalian cells with synthetic fluorescent biosensors. <i>Heliyon</i> , 2020, 6, e05574.	1.4	7
7422	Genetics, prevention and screening for melanoma. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 707-728.	0.5	1
7423	Chemotherapy, cytokines, and biochemotherapy for melanoma. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, , 739-748.	0.5	3
7425	Discovery of Inactive Conformation-Selective Kinase Inhibitors by Utilizing Cascade Assays. <i>Biochemistry</i> , 2017, 56, 4449-4456.	1.2	8
7426	Ric-8A gene deletion or phorbol ester suppresses tumorigenesis in a mouse model of GNAQQ209L-driven melanoma. <i>Oncogenesis</i> , 2016, 5, e236-e236.	2.1	12
7427	Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. <i>Scientific Reports</i> , 2020, 10, 8537.	1.6	28
7428	Expression of transgenes enriched in rare codons is enhanced by the MAPK pathway. <i>Scientific Reports</i> , 2020, 10, 22166.	1.6	11
7429	Photosensitivity Diseases: Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 1999, 4, 73-78.	0.8	20
7430	Introduction: Biomarkers in Translational and Personalized Medicine. <i>RSC Drug Discovery Series</i> , 2013, , 3-39.	0.2	1
7431	Inhibition of RAF dimers: it takes two to tango. <i>Biochemical Society Transactions</i> , 2021, 49, 237-251.	1.6	35
7433	Molecular pathogenesis of sporadic melanoma and melanoma-initiating cells. <i>Archives of Pathology and Laboratory Medicine</i> , 2010, 134, 1740-9.	1.2	11

#	ARTICLE	IF	CITATIONS
7434	Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 1861804.	0.8	5
7435	Understanding molecular pathways and the identification of subgroups of patients with specific biomarker predictors of drug response related to orphan drugs. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 67-76.	0.5	1
7436	Cutaneous and Ocular Melanoma. , 2006, , 1196-1229.		29
7437	The Ras/Raf/MAPK Pathway. <i>Journal of Thoracic Oncology</i> , 2006, 1, 7-9.	0.5	95
7438	Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation. <i>Melanoma Research</i> , 2010, 20, 361-371.	0.6	31
7439	Multiple metastases from cutaneous malignant melanoma patients may display heterogeneous genomic and epigenomic patterns. <i>Melanoma Research</i> , 2010, 20, 381-391.	0.6	30
7440	An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. <i>Melanoma Research</i> , 2010, 20, 401-407.	0.6	22
7441	Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 179-187.	0.6	13
7442	Optic Pathway Gliomas in Neurofibromatosis Type 1: Imaging and Monitoring. <i>International Ophthalmology Clinics</i> , 2018, 58, 97-112.	0.3	4
7443	Encapsulated Papillary Oncocytic Neoplasms of the Thyroid: Morphologic, Immunohistochemical, and Molecular Analysis of 18 Cases. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1582-1590.	2.1	19
7459	DNA Sequence Variation of Homo sapiens. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2003, 68, 55-64.	2.0	2
7460	Clinical and Neuroimaging Manifestations of Erdheim-Chester Disease: A Review. <i>Journal of Neuroimaging</i> , 2021, 31, 35-44.	1.0	8
7461	Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. <i>Gut</i> , 2003, 52, 706-712.	6.1	309
7462	Designing Inorganic Light-Protective Skin Nanotechnology Products. <i>Journal of Biomedical Nanotechnology</i> , 2010, 6, 432-451.	0.5	48
7463	Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. <i>JCI Insight</i> , 2017, 2, .	2.3	48
7464	Inactivation of Icm1 inhibits transformation by oncogenic K-Ras and B-Raf. <i>Journal of Clinical Investigation</i> , 2004, 113, 539-550.	3.9	95
7465	Inactivation of Icm1 inhibits transformation by oncogenic K-Ras and B-Raf. <i>Journal of Clinical Investigation</i> , 2004, 113, 539-550.	3.9	147
7466	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. <i>Journal of Clinical Investigation</i> , 2005, 115, 1068-1081.	3.9	126

#	ARTICLE	IF	CITATIONS
7467	Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. <i>Journal of Clinical Investigation</i> , 2005, 115, 94-101.	3.9	371
7468	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. <i>Journal of Clinical Investigation</i> , 2008, 118, 1739-1749.	3.9	437
7469	Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. <i>Journal of Clinical Investigation</i> , 2008, 118, 3651-3659.	3.9	184
7470	Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 1216-1229.	3.9	215
7471	Conditional ablation of Ikkb inhibits melanoma tumor development in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 2563-2574.	3.9	81
7472	Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. <i>Journal of Clinical Investigation</i> , 2010, 120, 2829-2841.	3.9	61
7473	Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. <i>Journal of Clinical Investigation</i> , 2010, 120, 3940-3952.	3.9	120
7474	Wnt/ β -catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. <i>Journal of Clinical Investigation</i> , 2011, 121, 1935-1945.	3.9	142
7475	Hooked! Modeling human disease in zebrafish. <i>Journal of Clinical Investigation</i> , 2012, 122, 2337-2343.	3.9	408
7476	Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. <i>Journal of Clinical Investigation</i> , 2013, 123, 2155-2168.	3.9	215
7477	Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 5104-5118.	3.9	72
7478	WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. <i>Journal of Clinical Investigation</i> , 2014, 124, 2877-2890.	3.9	144
7479	Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma. <i>Journal of Clinical Investigation</i> , 2017, 127, 2310-2325.	3.9	26
7480	Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma. <i>Journal of Clinical Investigation</i> , 2017, 128, 294-308.	3.9	55
7481	Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. <i>Journal of Clinical Investigation</i> , 2019, 129, 1596-1611.	3.9	84
7482	Polymorphisms of the BRAF gene predispose males to malignant melanoma. <i>Journal of Carcinogenesis</i> , 2003, 2, 7.	2.5	34
7483	Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules. <i>CytoJournal</i> , 2006, 3, 10.	0.8	80
7485	Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 161-173.	1.8	7

#	ARTICLE	IF	CITATIONS
7486	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1081.	0.8	101
7487	A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma. <i>Medical Science Monitor</i> , 2020, 26, e920957.	0.5	43
7488	BRAF inhibitors in clinical oncology. <i>F1000prime Reports</i> , 2013, 5, 11.	5.9	32
7489	Current options and future directions in the systemic treatment of metastatic melanoma. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 20-26.	0.1	5
7490	Erdheim-Chester disease with asymmetric talus involvement: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 614-623.	0.3	1
7492	Kinase Inhibition Leads to Hormesis in a Dual Phosphorylation-Dephosphorylation Cycle. <i>PLoS Computational Biology</i> , 2016, 12, e1005216.	1.5	5
7493	Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression. <i>PLoS Computational Biology</i> , 2017, 13, e1005347.	1.5	14
7494	The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas. <i>PLoS Genetics</i> , 2017, 13, e1006913.	1.5	20
7495	Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF. <i>PLoS ONE</i> , 2008, 3, e2734.	1.1	226
7496	Genome Wide Identification of Recessive Cancer Genes by Combinatorial Mutation Analysis. <i>PLoS ONE</i> , 2008, 3, e3380.	1.1	12
7497	Regulator of G-Protein Signaling 14 (RGS14) Is a Selective H-Ras Effector. <i>PLoS ONE</i> , 2009, 4, e4884.	1.1	40
7498	Induction of Thyroid Gene Expression and Radioiodine Uptake in Melanoma Cells: Novel Therapeutic Implications. <i>PLoS ONE</i> , 2009, 4, e6200.	1.1	17
7499	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. <i>PLoS ONE</i> , 2009, 4, e7464.	1.1	205
7500	Analysis of the Association between CIMP and BRAFV600E in Colorectal Cancer by DNA Methylation Profiling. <i>PLoS ONE</i> , 2009, 4, e8357.	1.1	133
7501	DMSO and Betaine Greatly Improve Amplification of GC-Rich Constructs in De Novo Synthesis. <i>PLoS ONE</i> , 2010, 5, e11024.	1.1	108
7502	Changed Genome Heterochromatinization Upon Prolonged Activation of the Raf/ERK Signaling Pathway. <i>PLoS ONE</i> , 2010, 5, e13322.	1.1	7
7503	DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset. <i>PLoS ONE</i> , 2010, 5, e13978.	1.1	102
7504	Functional Characterization of Human Cancer-Derived TRKB Mutations. <i>PLoS ONE</i> , 2011, 6, e16871.	1.1	46

#	ARTICLE	IF	CITATIONS
7505	High-Content, High-Throughput Analysis of Cell Cycle Perturbations Induced by the HSP90 Inhibitor XL888. PLoS ONE, 2011, 6, e17692.	1.1	26
7506	Primary Cilium Depletion Typifies Cutaneous Melanoma In Situ and Malignant Melanoma. PLoS ONE, 2011, 6, e27410.	1.1	83
7507	LIV-1 Promotes Prostate Cancer Epithelial-to-Mesenchymal Transition and Metastasis through HB-EGF Shedding and EGFR-Mediated ERK Signaling. PLoS ONE, 2011, 6, e27720.	1.1	94
7508	Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials. PLoS ONE, 2012, 7, e35309.	1.1	173
7509	Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension. PLoS ONE, 2012, 7, e38364.	1.1	46
7510	BAY61-3606 Affects the Viability of Colon Cancer Cells in a Genotype-Directed Manner. PLoS ONE, 2012, 7, e41343.	1.1	16
7511	Evidence of Melanoma in Wild Marine Fish Populations. PLoS ONE, 2012, 7, e41989.	1.1	58
7512	A Functional Screen Identifies Specific MicroRNAs Capable of Inhibiting Human Melanoma Cell Viability. PLoS ONE, 2012, 7, e43569.	1.1	52
7513	Oxidized LDL Triggers Pro-Oncogenic Signaling in Human Breast Mammary Epithelial Cells Partly via Stimulation of MiR-21. PLoS ONE, 2012, 7, e46973.	1.1	38
7514	Multiparametric Analysis of Cell-Free DNA in Melanoma Patients. PLoS ONE, 2012, 7, e49843.	1.1	60
7515	Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma. PLoS ONE, 2013, 8, e56134.	1.1	35
7516	Automated Universal BRAF State Detection within the Activation Segment in Skin Metastases by Pyrosequencing-Based Assay U-BRAFV600. PLoS ONE, 2013, 8, e59221.	1.1	13
7517	The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling. PLoS ONE, 2013, 8, e59588.	1.1	58
7518	Comprehensive Genomic Characterization of Cutaneous Malignant Melanoma Cell Lines Derived from Metastatic Lesions by Whole-Exome Sequencing and SNP Array Profiling. PLoS ONE, 2013, 8, e63597.	1.1	32
7519	Dabrafenib; Preclinical Characterization, Increased Efficacy when Combined with Trametinib, while BRAF/MEK Tool Combination Reduced Skin Lesions. PLoS ONE, 2013, 8, e67583.	1.1	168
7520	Development and Validation of a Clinical Trial Patient Stratification Assay That Interrogates 27 Mutation Sites in MAPK Pathway Genes. PLoS ONE, 2013, 8, e72239.	1.1	3
7521	CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features. PLoS ONE, 2013, 8, e77945.	1.1	104
7522	C-Terminal Tensin-Like Protein Is a Novel Prognostic Marker for Primary Melanoma Patients. PLoS ONE, 2013, 8, e80492.	1.1	21

#	ARTICLE	IF	CITATIONS
7523	Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/ β -Catenin Signaling. PLoS ONE, 2014, 9, e94748.	1.1	35
7524	Modification, Biological Evaluation and 3D QSAR Studies of Novel 2-(1,3-Diaryl)-Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 702 To	1.1	6
7525	Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells. PLoS ONE, 2014, 9, e102983.	1.1	41
7526	The Ginsenoside 20-O- β -D-Glucopyranosyl-20(S)-Protopanaxadiol Induces Autophagy and Apoptosis in Human Melanoma via AMPK/JNK Phosphorylation. PLoS ONE, 2014, 9, e104305.	1.1	31
7527	Heat Shock Protein-90 Inhibitors Enhance Antigen Expression on Melanomas and Increase T Cell Recognition of Tumor Cells. PLoS ONE, 2014, 9, e114506.	1.1	23
7528	Detection of BRAF V600 Mutations in Melanoma: Evaluation of Concordance between the Cobas [®] 4800 BRAF V600 Mutation Test and the Methods Used in French National Cancer Institute (INCa) Platforms in a Real-Life Setting. PLoS ONE, 2015, 10, e0120232.	1.1	24
7529	BRAF Mutations in Canine Cancers. PLoS ONE, 2015, 10, e0129534.	1.1	95
7530	Novel Reporter for Faithful Monitoring of ERK2 Dynamics in Living Cells and Model Organisms. PLoS ONE, 2015, 10, e0140924.	1.1	5
7531	Impact of Pre-Analytical Variables on Cancer Targeted Gene Sequencing Efficiency. PLoS ONE, 2015, 10, e0143092.	1.1	13
7532	BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma. PLoS ONE, 2015, 10, e0143688.	1.1	49
7533	Pigmentary Markers in Danes " Associations with Quantitative Skin Colour, Nevi Count, Familial Atypical Multiple-Mole, and Melanoma Syndrome. PLoS ONE, 2016, 11, e0150381.	1.1	5
7534	Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data. PLoS ONE, 2016, 11, e0159235.	1.1	12
7535	Novel and Practical Scoring Systems for the Diagnosis of Thyroid Nodules. PLoS ONE, 2016, 11, e0163039.	1.1	3
7536	Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets. PLoS ONE, 2017, 12, e0171512.	1.1	21
7537	A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma. PLoS ONE, 2017, 12, e0175638.	1.1	27
7538	Reflectance confocal microscopy features of BRAF V600E mutated thin melanomas detected by immunohistochemistry. PLoS ONE, 2017, 12, e0179745.	1.1	5
7539	KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia. PLoS ONE, 2017, 12, e0184937.	1.1	26
7540	Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer. PLoS ONE, 2017, 12, e0185436.	1.1	12

#	ARTICLE	IF	CITATIONS
7541	Variables that influence BRAF mutation probability: A next-generation sequencing, non-interventional investigation of BRAFV600 mutation status in melanoma. PLoS ONE, 2017, 12, e0188602.	1.1	5
7542	Characteristics of percutaneous core biopsies adequate for next generation genomic sequencing. PLoS ONE, 2017, 12, e0189651.	1.1	27
7543	17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model. PLoS ONE, 2018, 13, e0191264.	1.1	12
7544	Active BRAF-V600E is the key player in generation of a sessile serrated polyp-specific DNA methylation profile. PLoS ONE, 2018, 13, e0192499.	1.1	18
7545	Comparison of characteristics in patients with both thyroid and breast cancer: Based on order of incidence. Korean Journal of Clinical Oncology, 2017, 13, 1-9.	0.1	5
7546	The Notch pathway: hair graying and pigment cell homeostasis. Histology and Histopathology, 2008, 23, 609-19.	0.5	44
7547	c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histology and Histopathology, 2009, 24, 643-50.	0.5	64
7548	Mechanisms of Resistance to Mitogen-Activated Protein Kinase Pathway Inhibition in BRAF-Mutant Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 680-684.	1.8	7
7549	New Options and New Questions: How to Select and Sequence Therapies for Patients with Metastatic Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 524-530.	1.8	3
7550	A Systematic Literature Review and Meta-Analysis Describing the Prevalence of KRAS, NRAS, and BRAF Gene Mutations in Metastatic Colorectal Cancer. Gastroenterology Research, 2020, 13, 184-198.	0.4	23
7551	Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. Journal of Clinical Medicine Research, 2016, 8, 63-75.	0.6	49
7552	Genome-wide profiling of copy number alterations in cancer: focus on melanoma. Biomedical Reviews, 2014, 24, 11.	0.6	1
7553	BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry. Endocrine Connections, 2019, 8, 1310-1317.	0.8	12
7554	Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancer. Endocrine-Related Cancer, 2019, 26, R319-R344.	1.6	24
7555	Radiation Therapy for Melanoma. , 0, , 101-120.		5
7556	Genetics of Uveal Melanoma. , 0, , 19-35.		3
7557	Clinical prognosis in BRAF-mutated PTC. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 736-747.	1.3	21
7558	BRAF mutations in cutaneous melanoma: no correlation with histological prognostic factors or overall survival. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2010, 46, 487-493.	0.3	6

#	ARTICLE	IF	CITATIONS
7559	Liquid Biopsies for Assessing Metastatic Melanoma Progression. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 141-154.	0.2	15
7560	BRAF mutations in melanocytic tumors (nevi and melanomas) from organ transplant recipients. <i>European Journal of Dermatology</i> , 2010, 20, 167-171.	0.3	14
7561	Targeted Therapy for Cutaneous Melanoma: Beyond BRAF.... <i>Journal of Patient-centered Research and Reviews</i> , 2014, 1, 12-20.	0.6	3
7562	Multi-omics approach to infer cancer therapeutic targets on chromosome 20q across tumor types. <i>Advances in Modern Oncology Research</i> , 2016, 2, 215.	0.1	6
7563	ARMS-PCR for detection of BRAF V600E hotspot mutation in comparison with Real-Time PCR-based techniques.. <i>Acta Biochimica Polonica</i> , 2013, 60, .	0.3	16
7564	The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence. <i>Aging</i> , 2009, 1, 542-556.	1.4	70
7565	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011, 3, 192-222.	1.4	520
7566	Transcriptomic analysis functionally maps the intrinsically disordered domain of EWS/FLI and reveals novel transcriptional dependencies for oncogenesis. <i>Genes and Cancer</i> , 2019, 10, 21-38.	0.6	19
7567	ALK-rearrangements and testing methods in non-small cell lung cancer: a review. <i>Genes and Cancer</i> , 2014, 5, 1-14.	0.6	54
7568	BCL-2 proteins: melanoma lives on the edge. <i>Oncoscience</i> , 2015, 2, 729-730.	0.9	11
7569	Targeted proteomic approach in prostatic tissue: a panel of potential biomarkers for cancer detection. <i>Oncoscience</i> , 2016, 3, 220-241.	0.9	34
7570	Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling. <i>Oncotarget</i> , 2016, 7, 48517-48532.	0.8	11
7571	Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922. <i>Oncotarget</i> , 2016, 7, 49597-49610.	0.8	14
7572	Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib. <i>Oncotarget</i> , 2018, 9, 12408-12417.	0.8	11
7573	Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway. <i>Oncotarget</i> , 2016, 7, 56889-56903.	0.8	37
7574	Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation. <i>Oncotarget</i> , 2017, 8, 54096-54105.	0.8	22
7575	Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function. <i>Oncotarget</i> , 2016, 7, 60858-60871.	0.8	14
7576	Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas. <i>Oncotarget</i> , 2017, 8, 583-595.	0.8	24

#	ARTICLE	IF	CITATIONS
7577	Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial. <i>Oncotarget</i> , 2017, 8, 1760-1773.	0.8	10
7578	Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. <i>Oncotarget</i> , 2016, 7, 71211-71222.	0.8	20
7579	Phosphatidylcholine Metabolic Transformation and Progression Signature as a Pharmacodynamic Biomarker. <i>Oncotarget</i> , 2010, 1, 163-166.	0.8	7
7580	Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples. <i>Oncotarget</i> , 2017, 8, 3746-3760.	0.8	8
7581	CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins. <i>Oncotarget</i> , 2016, 7, 78242-78254.	0.8	27
7582	Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. <i>Oncotarget</i> , 2016, 7, 81995-82012.	0.8	18
7583	Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. <i>Oncotarget</i> , 2017, 8, 900-914.	0.8	12
7584	Molecular mechanism of hepatitis B virus (HBV) on suppression of raf kinase inhibitor protein (RKIP) expression. <i>Oncotarget</i> , 2017, 8, 1132-1140.	0.8	6
7585	Investigating the utility of human melanoma cell lines as tumour models. <i>Oncotarget</i> , 2017, 8, 10498-10509.	0.8	53
7586	MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. <i>Oncotarget</i> , 2017, 8, 17795-17809.	0.8	35
7587	Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway. <i>Oncotarget</i> , 2017, 8, 23436-23447.	0.8	61
7588	Efficacy and safety of BRAF inhibition alone versus combined BRAF and MEK inhibition in melanoma: a meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 32258-32269.	0.8	37
7589	Long non-coding RNAs in cutaneous melanoma: clinical perspectives. <i>Oncotarget</i> , 2017, 8, 43470-43480.	0.8	35
7590	Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing. <i>Oncotarget</i> , 2017, 8, 36319-36330.	0.8	13
7591	Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 107492-107499.	0.8	9
7592	The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells. <i>Oncotarget</i> , 2017, 8, 80393-80404.	0.8	16
7593	Pathologic subtype-defined prognosis is dependent on both tumor stage and status of oncogenic driver mutations in lung adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 82244-82255.	0.8	7
7594	Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. <i>Oncotarget</i> , 2014, 5, 3770-3784.	0.8	57

#	ARTICLE	IF	CITATIONS
7595	A highly recurrent RPS27 5'UTR mutation in melanoma. <i>Oncotarget</i> , 2014, 5, 2912-2917.	0.8	60
7596	Combined targeting of Raf and Mek synergistically inhibits tumorigenesis in triple negative breast cancer model systems. <i>Oncotarget</i> , 2017, 8, 80804-80819.	0.8	24
7597	Overcoming resistance to single-agent therapy for oncogenic <i>BRAF</i> gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. <i>Oncotarget</i> , 2017, 8, 84697-84713.	0.8	38
7598	The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?. <i>Oncotarget</i> , 2010, 1, 751-756.	0.8	42
7599	Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 83280-83291.	0.8	36
7600	PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. <i>Oncotarget</i> , 2017, 8, 103207-103222.	0.8	18
7601	Prognostic factors for histiocytic and dendritic cell neoplasms. <i>Oncotarget</i> , 2017, 8, 98723-98732.	0.8	20
7602	WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of <i>IDH2</i> gene expression. <i>Oncotarget</i> , 2017, 8, 106352-106368.	0.8	4
7603	Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells. <i>Oncotarget</i> , 2017, 8, 110257-110272.	0.8	60
7604	Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas. <i>Oncotarget</i> , 2017, 8, 109457-109467.	0.8	32
7605	New role of ID3 in melanoma adaptive drug-resistance. <i>Oncotarget</i> , 2017, 8, 110166-110175.	0.8	20
7606	Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas. <i>Oncotarget</i> , 2018, 9, 1852-1867.	0.8	39
7607	Activation of Grm1 expression by mutated BRaf (V600E) <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2018, 9, 5861-5875.	0.8	5
7608	CKS1 expression in melanocytic nevi and melanoma. <i>Oncotarget</i> , 2018, 9, 4173-4187.	0.8	1
7609	Genetic alterations in main candidate genes during melanoma progression. <i>Oncotarget</i> , 2018, 9, 8531-8541.	0.8	50
7610	Methotrexate sensitizes drug-resistant metastatic melanoma cells to <i>BRAF</i> V600E inhibitors dabrafenib and encorafenib. <i>Oncotarget</i> , 2018, 9, 13324-13336.	0.8	6
7611	miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. <i>Oncotarget</i> , 2014, 5, 9444-9459.	0.8	62
7612	Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas. <i>Oncotarget</i> , 2018, 9, 16832-16846.	0.8	5

#	ARTICLE	IF	CITATIONS
7613	Analysis of KIT gene mutations in patients with melanoma of the head and neck mucosa: a retrospective clinical report. <i>Oncotarget</i> , 2018, 9, 22886-22894.	0.8	14
7614	Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. <i>Oncotarget</i> , 2018, 9, 22243-22253.	0.8	15
7615	BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications. <i>Oncotarget</i> , 2014, 5, 11752-11777.	0.8	83
7616	Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma. <i>Oncotarget</i> , 2018, 9, 31888-31903.	0.8	18
7617	Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors. <i>Oncotarget</i> , 2018, 9, 32570-32579.	0.8	15
7618	Accelerated BRAF mutation analysis using a fully automated PCR platform improves the management of patients with metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 32232-32237.	0.8	5
7619	Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. <i>Oncotarget</i> , 2014, 5, 10206-10221.	0.8	104
7620	B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells. <i>Oncotarget</i> , 2014, 5, 12607-12620.	0.8	16
7621	Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. <i>Oncotarget</i> , 2014, 5, 11237-11251.	0.8	34
7622	Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers. <i>Oncotarget</i> , 2011, 2, 336-346.	0.8	114
7623	Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma. <i>Oncotarget</i> , 2011, 2, 329-335.	0.8	19
7624	Establishment of a novel cell line from a rare human duodenal poorly differentiated neuroendocrine carcinoma. <i>Oncotarget</i> , 2018, 9, 36503-36514.	0.8	8
7625	Bioenergetic modulation with the mitochondria uncouplers SR4 and niclosamide prevents proliferation and growth of treatment-naïve and vemurafenib-resistant melanomas. <i>Oncotarget</i> , 2018, 9, 36945-36965.	0.8	20
7626	Targeted therapies for advanced non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 37589-37607.	0.8	52
7627	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. <i>Oncotarget</i> , 2019, 10, 930-941.	0.8	31
7628	Melanoma patients with additional primary cancers: a single-center retrospective analysis. <i>Oncotarget</i> , 2019, 10, 3373-3384.	0.8	4
7629	The multifaceted anti-cancer effects of BRAF-inhibitors. <i>Oncotarget</i> , 2019, 10, 6623-6640.	0.8	48
7630	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. <i>Oncotarget</i> , 2019, 10, 6739-6753.	0.8	13

#	ARTICLE	IF	CITATIONS
7631	Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). <i>Oncotarget</i> , 2020, 11, 1942-1952.	0.8	45
7632	Stage-specific prognostic biomarkers in melanoma. <i>Oncotarget</i> , 2015, 6, 4180-4189.	0.8	26
7633	A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. <i>Oncotarget</i> , 2015, 6, 5118-5133.	0.8	37
7634	Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. <i>Oncotarget</i> , 2015, 6, 7195-7208.	0.8	79
7635	Cisplatin fails to induce puma mediated apoptosis in mucosal melanomas. <i>Oncotarget</i> , 2015, 6, 9887-9896.	0.8	4
7636	NUAK2: an emerging acral melanoma oncogene. <i>Oncotarget</i> , 2011, 2, 695-704.	0.8	17
7637	Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway. <i>Oncotarget</i> , 2015, 6, 14290-14299.	0.8	46
7638	Short-term expansion of breast circulating cancer cells predicts response to anti-cancer therapy. <i>Oncotarget</i> , 2015, 6, 15578-15593.	0.8	134
7639	EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. <i>Oncotarget</i> , 2015, 6, 21993-22005.	0.8	27
7640	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015, 6, 22348-22360.	0.8	12
7641	Molecular spectrum of <i>BRAF</i> , <i>NRAS</i> and <i>KRAS</i> gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. <i>Oncotarget</i> , 2015, 6, 24205-24217.	0.8	65
7642	LINE-1 hypomethylation in normal colon mucosa is associated with poor survival in Chinese patients with sporadic colon cancer. <i>Oncotarget</i> , 2015, 6, 23820-23836.	0.8	7
7643	Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. <i>Oncotarget</i> , 2015, 6, 19868-19879.	0.8	8
7644	Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. <i>Oncotarget</i> , 2015, 6, 20863-20874.	0.8	41
7645	ErbB-3 activation by NRG-1 ^{Δ2} sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). <i>Oncotarget</i> , 2015, 6, 16902-16911.	0.8	29
7646	New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?. <i>Oncotarget</i> , 2015, 6, 24780-24796.	0.8	77
7647	INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. <i>Oncotarget</i> , 2015, 6, 39891-39907.	0.8	40
7648	Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 37895-37905.	0.8	26

#	ARTICLE	IF	CITATIONS
7649	MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. <i>Oncotarget</i> , 2015, 6, 38854-38865.	0.8	54
7650	Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. <i>Oncotarget</i> , 2015, 6, 40535-40556.	0.8	59
7651	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. <i>Oncotarget</i> , 2012, 3, 1011-1025.	0.8	126
7652	Transcription factor LSF (TFCP2) inhibits melanoma growth. <i>Oncotarget</i> , 2016, 7, 2379-2390.	0.8	21
7653	Mutation specific antibodies: tool or dinosaur?. <i>Oncotarget</i> , 2012, 3, 907-908.	0.8	6
7654	SUV420H1 enhances the phosphorylation and transcription of ERK1 in cancer cells. <i>Oncotarget</i> , 2015, 6, 43162-43171.	0.8	28
7655	Genomic landscape of liposarcoma. <i>Oncotarget</i> , 2015, 6, 42429-42444.	0.8	94
7656	Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells. <i>Oncotarget</i> , 2016, 7, 7297-7306.	0.8	29
7657	miR-30e controls DNA damage-induced stress responses by modulating expression of the CDK inhibitor p21WAF1/CIP1 and caspase-3. <i>Oncotarget</i> , 2016, 7, 15915-15929.	0.8	14
7658	Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response. <i>Oncotarget</i> , 2016, 7, 28356-28368.	0.8	16
7659	Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors. <i>Oncotarget</i> , 2016, 7, 30109-30118.	0.8	25
7660	Which melanoma patient carries a BRAF-mutation? A comparison of predictive models. <i>Oncotarget</i> , 2016, 7, 36130-36137.	0.8	12
7661	Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene. <i>Oncotarget</i> , 2013, 4, 584-599.	0.8	166
7663	Adaptive response of resistant cancer cells to chemotherapy. <i>Cancer Biology and Medicine</i> , 2020, 17, 842-863.	1.4	30
7664	Radiotherapy: killing with complement. <i>Annals of Translational Medicine</i> , 2016, 4, 94-94.	0.7	4
7665	Colorectal cancer genomics and designing rational trials. <i>Annals of Translational Medicine</i> , 2018, 6, 159-159.	0.7	19
7666	Resistance patterns to anti-PD-1 therapy in metastatic melanoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 75-75.	0.4	3
7667	Impact and clinical usefulness of genetic data in the surgical management of colorectal cancer liver metastasis: a narrative review. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 705-716.	0.7	9

#	ARTICLE	IF	CITATIONS
7668	GENETIC POLYMORPHISM OF RETROPERITONEAL MYXOID LIPOSARCOMA. <i>Siberian Journal of Oncology</i> , 2020, 19, 89-96.	0.1	3
7669	Preliminary Study on the Identification of BRAFV600E Mutation in Colorectal Cancer by Near-Infrared Spectroscopy. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13077-13085.	1.0	1
7670	Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy. <i>Molecular Diagnosis and Therapy</i> , 2009, 13, 283-96.	1.6	16
7671	Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors. <i>Current Medicinal Chemistry</i> , 2014, 21, 1938-1955.	1.2	6
7672	Exploring Dysregulated Signaling Pathways in Cancer. <i>Current Pharmaceutical Design</i> , 2020, 26, 429-445.	0.9	18
7673	Evolution of Molecular Targets in Melanoma Treatment. <i>Current Pharmaceutical Design</i> , 2020, 26, 396-414.	0.9	10
7674	Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas. <i>Current Genomics</i> , 2011, 12, 609-617.	0.7	71
7675	Application of Molecular Diagnostics to the Evaluation of the Surgical Approach to Thyroid Cancer. <i>Current Genomics</i> , 2014, 15, 184-189.	0.7	7
7676	Phytochemicals for the Management of Melanoma. <i>Mini-Reviews in Medicinal Chemistry</i> , 2016, 16, 953-979.	1.1	62
7677	Synthesis and Biological Evaluations of 3-Benzothiazol-2-yl Coumarin Derivatives as MEK1 Inhibitors. <i>Letters in Drug Design and Discovery</i> , 2013, 10, 727-732.	0.4	9
7678	Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. <i>Current Cancer Therapy Reviews</i> , 2014, 10, 70-79.	0.2	34
7679	Insight into the Binding of DFG-out Allosteric Inhibitors to B-Raf Kinase Using Molecular Dynamics and Free Energy Calculations. <i>Current Computer-Aided Drug Design</i> , 2015, 11, 124-136.	0.8	2
7680	Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 697-706.	0.9	14
7681	Metalloproteinases Suppression Driven by the Curcumin Analog DM-1 Modulates Invasion in BRAF-Resistant Melanomas. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1038-1050.	0.9	4
7682	Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1415-1430.	0.9	3
7683	Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma. <i>The Open Cancer Journal</i> , 2011, 4, 1-6.	0.2	5
7684	Fluorescent Cascade and Direct Assays for Characterization of RAF Signaling Pathway Inhibitors. <i>Current Chemical Genomics</i> , 2008, 1, 43-53.	2.0	10
7685	The Therapeutic Promise of Anti-Cancer Drugs Against the Ras/Raf/MEK/ERK Pathway. , 2013, , 63-94.		2

#	ARTICLE	IF	CITATIONS
7686	Prognostic Role of BRAF Mutations in Colorectal Cancer Liver Metastases. <i>Anticancer Research</i> , 2016, 36, 4805-4812.	0.5	22
7687	Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma. <i>Anticancer Research</i> , 2016, 36, 4997-5008.	0.5	6
7688	New Drug Combination Strategies in Melanoma: Current Status and Future Directions. <i>Anticancer Research</i> , 2017, 37, 5941-5953.	0.5	27
7689	BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma. <i>Anticancer Research</i> , 2018, 38, 1335-1341.	0.5	9
7690	Molecular Sequence of Events and Signaling Pathways in Cerebral Metastases. <i>Anticancer Research</i> , 2018, 38, 1859-1877.	0.5	6
7691	Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series. <i>Anticancer Research</i> , 2018, 38, 2891-2895.	0.5	17
7692	Coexistence of and Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity. <i>Cell Journal</i> , 2017, 19, 113-117.	0.2	34
7693	Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00142.	0.6	3
7694	Prolonged survival of a patient with brain melanoma metastasis treated with BRAF and MEK inhibitors combination therapy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 245-247.	0.8	2
7695	Integrating radiomics into clinical trial design. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 339-346.	0.4	9
7696	Telomerase reverse transcriptase promoter mutation and its clinical implication in thyroid cancer. <i>Precision and Future Medicine</i> , 2018, 2, 8-17.	0.5	5
7697	KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician. <i>Radiology and Oncology</i> , 2019, 53, 265-274.	0.6	88
7698	Advances in the management of craniopharyngioma in children and adults. <i>Radiology and Oncology</i> , 2019, 53, 388-396.	0.6	42
7699	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. <i>Frontiers in Bioscience - Landmark</i> , 2005, 10, 2986.	3.0	227
7700	Dual BRAF/MEK therapy in BRAF V600E-mutated primary brain tumors: a case series showing dramatic clinical and radiographic responses and a reduction in cutaneous toxicity. <i>Journal of Neurosurgery</i> , 2020, 133, 1704-1709.	0.9	15
7701	A knowledge network for a dynamic taxonomy of psychiatric disease. <i>Dialogues in Clinical Neuroscience</i> , 2015, 17, 79-87.	1.8	3
7702	Animal Models of Cancer in the Head and Neck Region. <i>Clinical and Experimental Otorhinolaryngology</i> , 2009, 2, 55.	1.1	38
7703	A Novel Probe for Spliceosomal Proteins that Induces Autophagy and Death of Melanoma Cells Reveals New Targets for Melanoma Drug Discovery. <i>Cellular Physiology and Biochemistry</i> , 2019, 53, 656-686.	1.1	12

#	ARTICLE	IF	CITATIONS
7704	Apparent Lack of BRAFV600E Derived HLA Class I Presented Neoantigens Hampers Neoplastic Cell Targeting by CD8+ T Cells in Langerhans Cell Histiocytosis. <i>Frontiers in Immunology</i> , 2019, 10, 3045.	2.2	4
7705	Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2019, 9, 263.	1.3	62
7706	Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?. <i>Cancers</i> , 2015, 7, 1900-1924.	1.7	18
7707	Grapefruit-Derived Micro and Nanovesicles Show Distinct Metabolome Profiles and Anticancer Activities in the A375 Human Melanoma Cell Line. <i>Cells</i> , 2020, 9, 2722.	1.8	61
7708	Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. <i>International Journal of Molecular Sciences</i> , 2021, 22, 130.	1.8	160
7709	Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing. <i>International Journal of Molecular Sciences</i> , 2021, 22, 336.	1.8	21
7710	Clinicopathologic Significance of BRAF Mutation and Extracellular Signal Regulated Kinase 1/2 Expression in Patients With a Colorectal Adenocarcinoma. <i>Annals of Coloproctology</i> , 2015, 31, 9.	0.5	4
7711	Next generation therapies change the landscape in melanoma. <i>F1000 Medicine Reports</i> , 2011, 3, 8.	2.9	7
7712	Complete therapeutic response to anti-PD1 therapy in patient with advanced melanoma and resistance to targeted therapy of BRAF inhibitors. <i>Onkologie (Czech Republic)</i> , 2018, 12, 21-24.	0.0	1
7713	Colorectal cancer genomic biomarkers in the clinical management of patients with metastatic colorectal carcinoma. , 2020, 1, 53-70.		5
7714	Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients. , 2020, 1, 101-108.		4
7715	Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. <i>World Journal of Gastroenterology</i> , 2008, 14, 2461.	1.4	30
7716	Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. <i>World Journal of Gastroenterology</i> , 2008, 14, 7021.	1.4	11
7717	Serrated neoplasia of the colorectum. <i>World Journal of Gastroenterology</i> , 2007, 13, 3792.	1.4	37
7718	Involvement of KrÄ½ppel-like factor 6 (<i>KLF6</i>) mutation in the development of nonpolypoid colorectal carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 3932.	1.4	24
7719	Growth inhibitory effect of wild-type Kras2 gene on a colonic adenocarcinoma cell line. <i>World Journal of Gastroenterology</i> , 2007, 13, 934.	1.4	11
7720	Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2010, 16, 1177.	1.4	24
7721	Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2011, 17, 809.	1.4	48

#	ARTICLE	IF	CITATIONS
7722	Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia. <i>World Journal of Gastroenterology</i> , 2013, 19, 5286.	1.4	10
7723	Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 4230.	1.4	79
7724	Alternative splicing of DNA damage response genes and gastrointestinal cancers. <i>World Journal of Gastroenterology</i> , 2014, 20, 17305.	1.4	16
7725	Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 926.	1.4	28
7726	Non-coding landscapes of colorectal cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 11709.	1.4	73
7727	Genomic diversity of colorectal cancer: Changing landscape and emerging targets. <i>World Journal of Gastroenterology</i> , 2016, 22, 5668.	1.4	14
7728	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6345.	1.4	94
7730	Overview of MDM2 and B-RAF Expression in Gastric Lesions. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2018, 6, 1795-1802.	0.1	4
7731	ERK/MAPK signalling pathway and tumorigenesis (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 1997-2007.	0.8	670
7732	Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition. <i>International Journal of Oncology</i> , 2020, 56, 1429-1441.	1.4	10
7733	Synergistic effects of vemurafenib and fingolimod (FTY720) in vemurafenib-resistant melanoma cell lines. <i>Molecular Medicine Reports</i> , 2018, 18, 5151-5158.	1.1	3
7734	The evolution in melanoma treatment as a reflection of precision-oriented medicine. <i>Oncology Letters</i> , 2013, 5, 424-426.	0.8	7
7735	Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer (Review). <i>Oncology Letters</i> , 2020, 19, 3617-3626.	0.8	7
7736	Mutations of the TERT promoter are associated with aggressiveness and recurrence/distant metastasis of papillary thyroid carcinoma. <i>Oncology Letters</i> , 2020, 20, 50.	0.8	9
7737	Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. <i>Oncology Reports</i> , 2017, 38, 3291-3296.	1.2	46
7738	Paclitaxel-Induced G2/M Arrest via Different Mechanism of Actions in Glioma Cell Lines with Differing p53 Mutational Status. <i>International Journal of Pharmacology</i> , 2015, 12, 19-27.	0.1	3
7739	Prevalence of BRAFV600E Mutation in Iranian Patients with Papillary Thyroid Carcinoma: A Single-Center Study. <i>Journal of Applied Sciences</i> , 2009, 9, 3593-3597.	0.1	6
7740	Synthesis and Evaluation of a Novel Small-molecule Compound as an Anticancer Inhibitor of CD147. <i>Biomedical and Environmental Sciences</i> , 2019, 32, 673-686.	0.2	5

#	ARTICLE	IF	CITATIONS
7741	Molecular biology of lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S479-90.	0.6	173
7742	Colorectal carcinoma: Pathologic aspects. <i>Journal of Gastrointestinal Oncology</i> , 2012, 3, 153-73.	0.6	385
7743	The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 72-81.	0.6	11
7744	Signature of microsatellite instability, KRAS and BRAF gene mutations in German patients with locally advanced rectal adenocarcinoma before and after neoadjuvant 5-FU radiochemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 182-92.	0.6	12
7745	Clinicopathological features and survival outcomes of primary signet ring cell and mucinous adenocarcinoma of colon: retrospective analysis of VACCR database. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 18-24.	0.6	35
7746	New therapeutic strategies for BRAF mutant colorectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 650-9.	0.6	21
7747	BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 660-7.	0.6	128
7748	BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors. <i>Translational Lung Cancer Research</i> , 2013, 2, 244-50.	1.3	45
7749	BRAF mutations in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 142-8.	1.3	41
7750	Lung cancer biomarkers, targeted therapies and clinical assays. <i>Translational Lung Cancer Research</i> , 2015, 4, 503-14.	1.3	23
7751	An improved understanding of cancer genomics through massively parallel sequencing. <i>Translational Cancer Research</i> , 2014, 3, 243-259.	0.4	10
7752	Somatic DNA mutation analysis in targeted therapy of solid tumours. <i>Translational Pediatrics</i> , 2015, 4, 125-38.	0.5	19
7753	Genotyping of cutaneous melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 27.	0.4	17
7754	Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research. <i>Annals of Translational Medicine</i> , 2015, 3, 24.	0.7	31
7755	Melanoma: oncogenic drivers and the immune system. <i>Annals of Translational Medicine</i> , 2015, 3, 265.	0.7	19
7756	Other targeted drugs in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 266.	0.7	9
7757	cfDNA analysis from blood in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 309.	0.7	14
7758	Current Omics Technologies in Biomarker Discovery. , 2011, , 79-111.		1

#	ARTICLE	IF	CITATIONS
7759	Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells. <i>Biomolecules and Therapeutics</i> , 2015, 23, 320-326.	1.1	14
7760	Diphloretohydroxycarmalol Suppresses Ultraviolet B-Induced Matrix Metalloproteinases via Inhibition of JNK and ERK Signaling in Human Keratinocytes. <i>Biomolecules and Therapeutics</i> , 2015, 23, 557-563.	1.1	12
7761	Differential Gene Expression Common to Acquired and Intrinsic Resistance to BRAF Inhibitor Revealed by RNA-Seq Analysis. <i>Biomolecules and Therapeutics</i> , 2019, 27, 302-310.	1.1	19
7762	Apoptosis and genes involved in oral cancer - a comprehensive review. <i>Oncology Reviews</i> , 2020, 14, 472.	0.8	19
7763	Vemurafenib-related sterile scrotal abscess in a patient with BRAFV600K-mutant advanced melanoma mimicking distant metastasis. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 647.	0.3	4
7764	A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors. <i>Research in Pharmaceutical Sciences</i> , 2016, 11, 445.	0.6	12
7765	Detection of BRAF mutation in the cytocentrifugation supernatant fluid from fine-needle aspiration of thyroid lesions may enhance the diagnostic yield. <i>CytoJournal</i> , 2017, 14, 4.	0.8	14
7766	Amplification of cellular oncogenes in solid tumors. <i>North American Journal of Medical Sciences</i> , 2015, 7, 341.	1.7	24
7767	Clinical Aspects of Microsatellite Instability Testing in Colorectal Cancer. <i>Advanced Biomedical Research</i> , 2018, 7, 28.	0.2	33
7768	Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature. <i>Indian Journal of Cancer</i> , 2017, 54, 372.	0.2	7
7769	Lack of association of B-type raf kinase V600E mutation with high-risk tumor features and adverse outcome in conventional and follicular variants of papillary thyroid carcinoma. <i>Indian Journal of Endocrinology and Metabolism</i> , 2017, 21, 329.	0.2	15
7770	The hallmarks of cancer and their therapeutic targeting in current use and clinical trials. <i>Iraqi Journal of Hematology</i> , 2020, 9, 1.	0.0	6
7771	Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study. <i>Journal of Oral and Maxillofacial Pathology</i> , 2018, 22, 353.	0.3	15
7772	Targeted next-generation sequencing for locally advanced prostate cancer in the Korean population. <i>Investigative and Clinical Urology</i> , 2020, 61, 127.	1.0	8
7773	Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 1-9.	0.4	21
7774	Evaluation of the VE1 Antibody in Thyroid Cytology Using <i>Ex Vivo</i> Papillary Thyroid Carcinoma Specimens. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 58-66.	0.4	9
7775	The Significance of TROP2 Expression in Predicting BRAF Mutations in Papillary Thyroid Carcinoma. <i>Journal of Pathology and Translational Medicine</i> , 2018, 52, 14-20.	0.4	10
7776	The Frequency of BRAF Mutation in Very Small Papillary Thyroid Carcinomas. <i>Korean Journal of Pathology</i> , 2010, 44, 308.	1.2	3

#	ARTICLE	IF	CITATIONS
7777	An Update on BRAF Inhibitors and Other New Molecular Targets for the Treatment of Malignant Melanoma of the Skin. <i>Clinical Medicine Insights Dermatology</i> , 0, , 1.	0.0	2
7778	Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF. <i>Cancer Research and Treatment</i> , 2017, 49, 947-959.	1.3	41
7779	Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions. <i>Cancer Research and Treatment</i> , 2018, 50, 1378-1387.	1.3	12
7780	Pharmacogenomics- Personalized Treatment of Cancer, Diabetes and Cardiovascular Diseases. <i>Journal of Pharmacogenomics & Pharmacoproteomics</i> , 2012, 03, .	0.2	3
7781	Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Non-“Small Cell Lung Cancer. , 2012, 02, .		1
7782	Quest for Cancer Biomarkers: Assaying Mutant Proteins and RNA that Provides the Much Needed Specificity. <i>Journal of Proteomics and Bioinformatics</i> , 2012, 05, .	0.4	4
7783	Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma. <i>Genetics and Molecular Research</i> , 2015, 14, 7377-7385.	0.3	9
7784	Molecular predictive markers in tumors of the gastrointestinal tract. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 772.	0.8	6
7785	An extremely rare case of concurrent BRAF V600E mutation driven hairy cell leukemia and melanoma: Case report and review of literature. <i>Autopsy and Case Reports</i> , 2017, 7, 13-19.	0.2	10
7786	Hyperplastic Polyposis Syndrome Identified with a BRAF Mutation. <i>Gut and Liver</i> , 2012, 6, 280-283.	1.4	4
7787	Docking and Quantum Mechanics-Guided CoMFA Analysis of b-RAF Inhibitors. <i>Bulletin of the Korean Chemical Society</i> , 2008, 29, 1499-1504.	1.0	3
7788	Design and Synthesis of an Anticancer Diarylurea Derivative with Multiple-Kinase Inhibitory Effect. <i>Bulletin of the Korean Chemical Society</i> , 2012, 33, 1571-1576.	1.0	15
7789	Design, synthesis, anticancer evaluation and molecular docking of new V600EBRAF inhibitors derived from pyridopyrazinone. <i>European Journal of Chemistry</i> , 2016, 7, 19-29.	0.3	9
7790	Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. <i>International Journal of Biological Markers</i> , 2007, 22, 12-18.	0.7	18
7791	Mutational analysis of the BRAF gene in transitional cell carcinoma of the bladder. <i>International Journal of Biological Markers</i> , 2009, 24, 17-21.	0.7	22
7792	Colorectal liver metastases: Current management and future perspectives. <i>World Journal of Clinical Oncology</i> , 2020, 11, 761-808.	0.9	98
7793	Inhibition of N-Myc down regulated gene 1 in vitro cultured human glioblastoma cells. <i>World Journal of Clinical Oncology</i> , 2012, 3, 104.	0.9	2
7794	Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma. <i>World Journal of Clinical Oncology</i> , 2013, 4, 29.	0.9	11

#	ARTICLE	IF	CITATIONS
7795	<i>BRAF</i> V600Q-mutated lung adenocarcinoma with duodenal metastasis and extreme leukocytosis. World Journal of Clinical Oncology, 2017, 8, 360.	0.9	7
7796	Increased Phospho-Keratin 8 Isoforms in Colorectal Tumors Associated with EGFR Pathway Activation and Reduced Apoptosis. , 2012, 2012, 1-8.		4
7797	Clinical neuropathology practice news 2-2012: BRAF V600E testing. , 2012, 31, 64-66.		12
7798	Somatic mutation patterns and compound response in cancers. BMB Reports, 2013, 46, 97-102.	1.1	2
7799	Genetic interactions in translational research on cancer. World Journal of Medical Genetics, 2011, 1, 14.	1.0	3
7800	Animal models of melanoma: a somatic cell gene delivery mouse model allows rapid evaluation of genes implicated in human melanoma. Chinese Journal of Cancer, 2011, 30, 153-162.	4.9	26
7801	Recent Progress of Genome Study for Anaplastic Thyroid Cancer. Genomics and Informatics, 2013, 11, 68.	0.4	25
7802	Simultaneous Presentation of Cerebellopontine Angle Pleomorphic Xanthoastrocytoma and Malignant Melanoma in a Known Case of Neurofibromatosis 1; Probable Role of BRAF Gene: A Case Report and Review of Literature. International Journal of Cancer Management, 2017, 10, .	0.2	1
7803	The T1799A BRAF Mutation Is Absent in Cribriform-Morular Variant of Papillary Carcinoma. Archives of Pathology and Laboratory Medicine, 2009, 133, 803-805.	1.2	20
7804	Mixed Adenocarcinomas of the Lung: Place in New Proposals in Classification, Mandatory for Target Therapy. Archives of Pathology and Laboratory Medicine, 2010, 134, 55-65.	1.2	28
7805	<i>BRAF</i> Mutation Testing in Colorectal Cancer. Archives of Pathology and Laboratory Medicine, 2010, 134, 1225-1228.	1.2	22
7806	Molecular Pathogenesis of Sporadic Melanoma and Melanoma-Initiating Cells. Archives of Pathology and Laboratory Medicine, 2010, 134, 1740-1749.	1.2	30
7807	Molecular Diagnostics in Melanoma: Current Status and Perspectives. Archives of Pathology and Laboratory Medicine, 2011, 135, 860-869.	1.2	29
7808	Prognostication in Thin Cutaneous Melanomas. Archives of Pathology and Laboratory Medicine, 2010, 134, 1758-1763.	1.2	33
7809	Lentigo Maligna: Melanoma In Situ on Chronically Sun-Damaged Skin. Archives of Pathology and Laboratory Medicine, 2011, 135, 838-841.	1.2	43
7810	Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma. Journal of the Advanced Practitioner in Oncology, 2014, 5, .	0.2	9
7811	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 367-402.	2.3	326
7812	Molecular designing and in silico evaluation of darunavir derivatives as anticancer agents. Bioinformation, 2014, 10, 221-226.	0.2	15

#	ARTICLE	IF	CITATIONS
7813	Gastrointestinal Stromal Tumors: Clinicopathology and Advances in Molecular Pathogenesis. North American Journal of Medicine & Science, 2012, 5, 94.	3.8	1
7814	Mutational Analysis of Key EGFR Pathway Genes in Chinese Breast Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2012, 13, 5599-5603.	0.5	18
7815	BRAF Mutations in Iranian Patients with Papillary Thyroid Carcinoma. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2521-2523.	0.5	16
7816	Efficacy and Safety of Selumetinib Compared with Current Therapies for Advanced Cancer: a Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2369-2374.	0.5	3
7817	Treatment of Vemurafenib-Resistant SKMEL-28 Melanoma Cells with Paclitaxel. Asian Pacific Journal of Cancer Prevention, 2015, 16, 699-705.	0.5	11
7818	Perturbation biology nominates upstreamâ€“downstream drug combinations in RAF inhibitor resistant melanoma cells. ELife, 2015, 4, .	2.8	95
7819	Erk regulation of actin capping and bundling by Eps8 promotes cortex tension and leader bleb-based migration. ELife, 2015, 4, e08314.	2.8	96
7820	Registered report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. ELife, 2016, 5, .	2.8	12
7821	Systematic morphological profiling of human gene and allele function via Cell Painting. ELife, 2017, 6, .	2.8	129
7822	Dynamics of nevus development implicate cell cooperation in the growth arrest of transformed melanocytes. ELife, 2020, 9, .	2.8	22
7823	Metastatic melanoma â€“ a review of current and future drugs. Drugs in Context, 2012, 2012, 1-17.	1.0	25
7824	Loss of CITED1, an MITF regulator, drives a phenotype switch <i>in vitro</i> and can predict clinical outcome in primary melanoma tumours. PeerJ, 2015, 3, e788.	0.9	20
7825	BRAF V600E Mutation in Multiple Primary Malignancies: A Hairy Affair. Cureus, 2018, 10, e3600.	0.2	4
7826	A Novel Combination of Metachronous Primary Malignancies of the Thyroid and Breast in a Patient with Neurofibromatosis Type 1. Cureus, 2020, 12, e7590.	0.2	1
7827	Oncogenes as Therapeutic Targets in Cancer: A Review. IOSR Journal of Dental and Medical Sciences, 2013, 5, 46-56.	0.0	2
7828	<sc>RAF1</sc>â€“<sc>MEK</sc>/<sc>ERK</sc> pathwayâ€“dependent <sc>ARL4C</sc> expression promotes ameloblastoma cell proliferation and osteoclast formation. Journal of Pathology, 2022, 256, 119-133.	2.1	32
7829	Cervical Lymphadenopathies as Unusual Presentations of Erdheimâ€“Chester Disease: The Need for Knowledge for Diagnosis and Treatment. Life, 2021, 11, 1116.	1.1	0
7830	Synthesis, In Silico Study, and Anti-Cancer Activity of Thiosemicarbazone Derivatives. Biomedicines, 2021, 9, 1375.	1.4	11

#	ARTICLE	IF	CITATIONS
7831	Targeted Therapy for BRAF Mutant Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 105.	1.3	4
7832	BRAFV600E Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics. <i>Cancers</i> , 2021, 13, 5073.	1.7	2
7833	The Genomic Landscape of Serrated Lesion of the Colorectum: Similarities and Differences With Tubular and Tubulovillous Adenomas. <i>Frontiers in Oncology</i> , 2021, 11, 668466.	1.3	4
7834	The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation. <i>Journal of Biological Chemistry</i> , 2021, 297, 101314.	1.6	21
7835	Development of a Molecular Assay for Detection and Quantification of the <i>BRAF</i> Variation in Residual Tissue From Thyroid Nodule Fine-Needle Aspiration Biopsy Specimens. <i>JAMA Network Open</i> , 2021, 4, e2127243.	2.8	8
7836	Increase in the sensitivity to PLX4720 through inhibition of transcription factor EB-dependent autophagy in BRAF inhibitor-resistant cells. <i>Toxicological Research</i> , 2022, 38, 35-44.	1.1	3
7837	Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100163.	2.5	7
7838	Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 328.	3.5	62
7839	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. <i>ELife</i> , 2021, 10, .	2.8	22
7841	Addressing Frequently Asked Questions and Dispelling Myths About Melanocytic Nevi in Children. <i>Dermatologic Clinics</i> , 2022, 40, 51-59.	1.0	1
7842	A novel xenonucleic acid-mediated molecular clamping technology for early colorectal cancer screening. <i>PLoS ONE</i> , 2021, 16, e0244332.	1.1	6
7843	Treatment of BRAF V600E mutated ganglioglioma of the third ventricle with dabrafenib. , 2021, 12, 529.		2
7844	Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors. <i>Cancer Research</i> , 2021, 81, 5833-5848.	0.4	7
7845	Impact of alternative splicing on mechanisms of resistance to anticancer drugs. <i>Biochemical Pharmacology</i> , 2021, 193, 114810.	2.0	14
7846	The Role of Kinase Inhibitors in Cancer Therapies. <i>Biochemistry</i> , 0, .	0.8	0
7848	Regulation of signal transduction pathways in colorectal cancer: implications for therapeutic resistance. <i>PeerJ</i> , 2021, 9, e12338.	0.9	7
7849	Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans. <i>Biomedicines</i> , 2021, 9, 1472.	1.4	7
7850	Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN- β signaling and tumor-infiltrating lymphocytes. <i>Journal of Hematology and Oncology</i> , 2021, 14, 160.	6.9	37

#	ARTICLE	IF	CITATIONS
7851	Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling. <i>British Journal of Cancer</i> , 2021, 125, 1552-1560.	2.9	6
7852	Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers. <i>Cancers</i> , 2021, 13, 5059.	1.7	39
7853	Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape. <i>Pharmaceutics</i> , 2021, 13, 1617.	2.0	11
7854	In-depth proteomic profiling captures subtype-specific features of craniopharyngiomas. <i>Scientific Reports</i> , 2021, 11, 21206.	1.6	4
7855	BRAF V600 Mutation Detection in Plasma Cell-Free DNA: NCCTG N0879 (Alliance). <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 1012-1020.	1.2	4
7857	Activation of Oncogenic Protein Kinases. , 2003, , 441-449.		0
7858	Die Bedeutung intrazellulärer Signalwege in gynäkologischen Tumoren " Von der Grundlagenforschung zur Therapie. , 2003, , 203-205.		0
7859	A biologia molecular no prognóstico do carcinoma da tireóide. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2003, 30, 470-482.	0.3	0
7860	Pharmacological Intervention With Multistep Oncogenesis. , 2004, , 325-337.		0
7861	Development of an Inhibitor of raf Kinase. , 2004, , 379-382.		0
7862	Identifying Agents to Test in Phase III Trials. , 2004, , 539-578.		0
7863	Skin cancer induction by UV radiation: molecular UV targets and quantitative risk models. <i>Cancer Prevention, Cancer Causes</i> , 2004, , 195-209.	0.3	0
7864	What is known from molecular genetic analyses of melanomas and how is it introduced in daily clinical practice?. <i>Skin Cancer</i> , 2004, 19, 287-292.	0.1	0
7865	Molecular Responses to Stress Induced in Normal Human Caucasian Melanocytes in Culture by Exposure to Simulated Solar UV. <i>Photochemistry and Photobiology</i> , 2004, 81, 367-75.	1.3	17
7866	Signal Transduction and Apoptosis Pathways as Therapeutic Targets. <i>Progress in Molecular and Subcellular Biology</i> , 2004, 36, 307-323.	0.9	0
7867	Hauterkrankungen. , 2004, , 465-490.		0
7868	Molecular Targets. , 2004, , 1-27.		1
7872	Systemic therapy for renal cell carcinoma. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2005, 22, 263-272.	0.5	1

#	ARTICLE	IF	CITATIONS
7875	Therapeutic Approaches to Modulation of Cell Death (non-HIV). , 2005, , 475-504.		0
7877	Ras Stories: The State of the Art. , 2006, , 1-14.		0
7878	Melanocyte stem cells and their potential implications for melanoma progression. Skin Cancer, 2006, 21, 10-17.	0.1	0
7879	Effectors of Ras-Mediated Oncogenesis. , 2006, , 121-142.		0
7880	Bases genéticas del cáncer de piel. , 2006, , 15-27.		0
7881	Molecular Pathogenesis of Thyroid Cancer. , 2006, , 15-32.		3
7882	Comparison of the Effects of Ras Effector Mutants and Ras Effectors on Transformed and Tumorigenic Growth of Human and Rodent Cells. , 2006, , 257-272.		0
7883	Pharmacoproteomics. , 2006, , 35-50.		0
7884	Photobiology of Photocarcinogenesis. , 2006, , 1-20.		0
7885	LRRK2-Associated Parkinsonism. , 2007, , 45-59.		0
7886	BRAF in Papillary Thyroid Carcinoma. Analytical Cellular Pathology, 2007, 29, 269-277.	0.7	4
7887	<i>BRAF</i> Mutations in Melanocytic Lesions and Papillary Thyroid Carcinoma Samples Identified Using Melting Curve Analysis of Polymerase Chain Reaction Products. Archives of Pathology and Laboratory Medicine, 2007, 131, 1361-1367.	1.2	18
7888	What is cancer?. , 2007, , 1-16.		3
7889	Cancer-Specific Vaccines. , 2008, , 649-669.		1
7893	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.		2
7894	Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. , 2008, , 317-365.		0
7897	Cancer Immunology. , 2008, , 77-93.		1
7899	Therapeutic Targeting of the Melanoma Stem Cell Population. Translational Medicine Series, 2008, , 83-98.	0.0	0

#	ARTICLE	IF	CITATIONS
7900	Challenging Melanocytic Neoplasms: Spitzoid Melanoma Vs. Spitz Nevus. Translational Medicine Series, 2008, , 27-36.	0.0	0
7901	Targeting BRAF Activity as a Novel Paradigm for Melanoma Therapy. , 2008, , 67-82.		0
7902	Melanoma Genomicsâ€™Techniques and Implications for Therapy. Translational Medicine Series, 2008, , 37-54.	0.0	0
7903	Overview of Molecular Pathways inMelanoma. Translational Medicine Series, 2008, , 9-26.	0.0	0
7904	RAS Signaling in Melanoma Development and Prevention. Translational Medicine Series, 2008, , 55-66.	0.0	0
7905	Targeting BRAF Activity as a NovelParadigm for Melanoma Therapy. Translational Medicine Series, 2008, , 67-82.	0.0	0
7906	The Future of Molecular Neuro-Oncology. , 2009, , 3201-3228.		0
7907	Molecular Biology of Thyroid Cancer. , 2009, , 97-110.		0
7908	Molecular Signatures in Melanoma Progression. , 2009, , 497-509.		0
7909	Targeted Approaches to Drug Development. , 2009, , 57-98.		3
7910	Cancer Genes, Genomes, and the Environment. , 2009, , 808-817.		0
7911	mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside. , 2009, , 99-111.		0
7912	Molecular Therapeutics of Melanoma. , 2009, , 967-976.		0
7913	Genomic Identification of Significant Targets in Brain Cancer. , 2009, , 395-413.		0
7914	Molecular Basis of Human Malignancy. , 2009, , 41-55.		1
7916	Melanoma: Mutations in Multiple Pathways at the Tumor-Stroma Interface. , 2010, , 455-469.		0
7917	Neurofibromatosis Type 1-Associated Malignant Melanoma: Molecular Evidence of Inactivation of the NF1 Gene. , 2010, , 300-309.		0
7918	Hereditary Mutations and Cancer Management. , 2009, , 981-1004.		0

#	ARTICLE	IF	CITATIONS
7920	Biology of Non-“Small Cell Lung Cancer. , 2010, , 1080-1097.		2
7921	Molecular Pathology of Lung Cancer. , 2010, , 1-25.		1
7922	Genetic Epidemiology of Mismatch Repair Deficiency in Ovarian Cancer. , 2010, , 367-398.		0
7924	Pathogenesis of Malignant Melanoma. , 2010, , 55-64.		0
7926	Biology and Pathology of Ovarian Cancer. , 2010, , 17-32.		1
7927	Pathogenesis of Merkel Cell Carcinoma. , 2010, , 81-86.		0
7928	The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis. Cancer Metastasis - Biology and Treatment, 2010, , 25-40.	0.1	0
7929	Insulin and Growth Factor Signaling Pathways. , 2010, , 38-82.		1
7931	Basic Pathobiology of Merkel Cell Carcinoma. Molecular Medicine and Medicinal, 2010, , 35-54.	0.4	0
7932	Targeted Therapeutics in Cancer Treatment. , 2011, , 403-461.		0
7933	Transcriptional Modulation Using Histone Deacetylase Inhibitors for Cancer Immunotherapy. , 2011, , 307-322.		0
7934	Melanoma Genetics and Genomics. , 2011, , 57-77.		0
7935	Targeted Therapy for Melanoma. , 2011, , 613-622.		0
7936	BRAF Mutations and their Implications in Molecular Targeting Therapies for Gastrointestinal Cancers. Journal of Pharmacogenomics & Pharmacoproteomics, 2011, 02, .	0.2	4
7937	To Test or Not To Test: Colon Cancer Pharmacogenetics and Predisposition Genetics. Journal of Pharmacogenomics & Pharmacoproteomics, 2011, 02, .	0.2	2
7938	Altered Signal Transduction Pathways in Melanoma. , 2011, , 137-163.		0
7941	The Dynamics of the Cell Signaling Network; Implications for Targeted Therapies. , 2011, , 33-53.		0
7942	Cytologic Features and BRAF Mutation of Hyalinizing Trabecular Adenoma of the Thyroid - A Case Report with Review of the Literature -. Korean Journal of Pathology, 2011, 45, 428.	1.2	2

#	ARTICLE	IF	CITATIONS
7943	Treatment of Disseminated Melanoma. , 2011, , 629-633.		0
7944	Regulation of Apoptosis in Melanoma Cells: Targets for Therapeutic Strategies. , 2011, , 217-233.		0
7945	New Therapeutic Approaches in Signaling. , 2011, , 337-357.		0
7946	ERK Suppression in DU145 Cells Selected for AG2034 Resistance is Associated with Decreased ATP, GARFT Inactivation and Increased ERK Signaling. The Open Drug Resistance Journal, 2011, 1, 1-11.	0.0	0
7947	Principles of Translational Medicine and Applications to Thyroid Cancer Investigation. , 2011, , 1-10.		0
7948	Genetic and Epigenetic Alterations in the MAP Kinase and PI3K/Akt Pathways in Thyroid Cancer. , 2011, , 27-38.		0
7949	Understanding Melanocyte Transformation â€œ A Work in Progress. , 0, , .		0
7950	Reactive Oxygen Species in the Biology of Melanoma. , 0, , .		2
7951	Recombinant protein vaccination for antigen-specific cancer immunotherapy. , 2011, , 87-102.		0
7953	Melanoma Epidemiology, Risk Factors, and Clinical Phenotypes. , 0, , .		0
7954	Thyroid Carcinoma: Molecular Signature by Histotype-Specific Mutations and Gene Expression Patterns. , 2012, , 165-178.		0
7955	Update on Clinical Trials for Malignant Melanoma. , 0, , .		0
7956	Targeting Apoptotic Pathways in Melanoma. , 2012, , 125-153.		0
7957	Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview. , 2012, , 305-317.		1
7958	Molecular-Targeted Therapy for Melanoma. , 2012, , 265-279.		0
7959	KIT as a Therapeutic Target for Melanoma. , 2012, , 43-61.		0
7960	Molecular Targets and Subtypes in Melanoma. , 2012, , 3-15.		0
7961	Predictive Biomarkers as a Guide to Future Therapy Selection in Melanoma. , 2012, , 27-40.		0

#	ARTICLE	IF	CITATIONS
7962	Melanoma Genomics. , 2012, , 17-25.		0
7963	Anti-Angiogenesis Therapy for Melanoma. , 2012, , 281-294.		0
7964	Analysis of BRAF and KRAS gene mutations in human pancreatic carcinomas. Academic Journal of Second Military Medical University, 2011, 31, 1158-1160.	0.0	0
7965	Benign neck disease. , 2011, , 241-262.		0
7966	The Different Expression of BRAFV600E Mutation in Patients with Papillary Thyroid Carcinomas Coexisting with or without Benign Thyroid Nodules. The Korean Journal of Endocrine Surgery, 2012, 12, 11.	0.1	1
7967	Melanom. , 2012, , 1710-1726.		0
7968	Understanding the Molecular and Functional Mechanisms that Underlie Pharamcogenomics-Based Therapy. Journal of Pharmacogenomics & Pharmacoproteomics, 2012, 03, .	0.2	1
7971	Malignant Transformation of Melanocytic Nevi. , 2012, , 137-144.		0
7972	Genes and Nevogenesis. , 2012, , 127-135.		0
7973	Molecular Classification of Patients with Cutaneous Melanoma: A Reality. Journal of Molecular Biomarkers & Diagnosis, 2012, 01, .	0.4	0
7974	Current Trends and Future Directions in Clinical Trials for Malignant Melanoma Treatment Using Anti-Angiogenic Strategies. Journal of Cancer Therapy, 2012, 03, 312-320.	0.1	0
7975	The Development of Cancer Genome Research and its Clinical Opportunity brought by Next Generation Sequencing. Journal of Health & Medical Informatics, 0, s1, .	0.2	0
7977	Melanoma and Other Skin Cancers. , 2012, , 439-468.		0
7978	Mutations and Tumorigenesis Pathways Driving Personalized Treatment in Non-Small Cell Lung Cancer. , 2012, 02, .		0
7979	Molecular Nevogenesis: An Update. , 2012, , 99-110.		2
7980	Genetic and epigenetic alterations in colorectal tumors and its clinical implications. Seibutsu Butsuri Kagaku, 2012, 56, 15-18.	0.1	1
7981	The Genetics of Pancreatic Cancer. , 0, , .		0
7983	Glioma-Parvovirus Interactions: Molecular Insights and Therapeutic Potential. , 0, , .		0

#	ARTICLE	IF	CITATIONS
7984	Genotipo complejo en un paciente con GIST.. Revista Colombiana De Hematología Y Oncología, 2012, 1, 70-77.	0.0	0
7985	Oncogenic driver mutations. , 2012, , 45-58.		0
7986	Missense Mutation in Cancer in Correlation to Its Phenotype “ VHL as a Model. , 0, , .		1
7988	B-Raf. , 2013, , 1-9.		0
7989	Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 125-141.	0.1	0
7990	Prerequisite Genetic Traits for Metastasis. , 2013, , 403-444.		0
7991	Futurs biomarqueurs et cibles thérapeutiques : c-MET, MEK et ALK. , 2013, , 363-372.		0
7992	Detection of BRAF V600E Mutation in Langerhans Cell Histiocytosis Using High-resolution Melting Analysis in Decalcified, Paraffin-embedded Tissue. Journal of Leukemia (Los Angeles, Calif), 2013, 01, .	0.1	0
7993	Primary Melanoma of the Vagina Treated by Imatinib: Case Report. Journal of Cancer Therapy, 2013, 04, 1158-1161.	0.1	0
7994	The Role of TGF- β^2 in Cutaneous Melanoma Biology. , 2013, , 235-254.		0
7995	Treatment of Distant and Irresectable Metastatic Disease. , 2013, , 79-104.		0
7996	Mutational Activation of KRAS and BRAF in Colorectal Cancer. , 2013, , 121-156.		1
7997	N-Ras. , 2013, , 1-9.		0
7998	Personalized Medicine in Oncology and Companion Diagnostics:Development and Challenges. Translational Medicine (Sunnyvale, Calif), 2013, 03, .	0.4	0
7999	Mechanisms of Resistance to Targeted B-Raf Therapies. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 69-88.	0.1	0
8000	TYPES OF DNA DAMAGE. , 2013, , 115-118.		0
8001	The Biology of K-Ras Signaling Pathways in Pancreatic Cancer. , 2013, , 83-115.		0
8002	A case of metastatic cecal cancer with mutation in the BRAF oncogene and poor survival. Okayama Igakkai Zasshi, 2013, 125, 47-50.	0.0	0

#	ARTICLE	IF	CITATIONS
8003	An Overview of Important Genetic Aspects in Melanoma. , 0, , .		0
8006	Melanoma: Molecular Classification and Therapy. , 2014, , 461-471.		0
8007	BRAF-Targeted Therapy in Metastatic Melanoma. , 2013, , 473-490.		0
8008	Gastrointestinal Stromal Tumors. , 2013, , 267-311.		0
8009	Molecular Pathology of Melanocytic Skin Cancer. , 2014, , 59-74.		0
8010	Cutaneous Squamous Cell Carcinoma: Focus on Biochemical and Molecular Characteristics. , 2014, , 29-57.		0
8014	Genotipificaci3n del melanoma.. Revista Colombiana De Hematologíe Y Oncologíe, 2013, 2, 10-11.	0.0	0
8017	The Role of Phase III Trials in Modern Drug Development. Cancer Drug Discovery and Development, 2014, , 763-783.	0.2	0
8018	Melanom. , 2014, , 31-97.		0
8019	Primary Anorectal Melanomas Interest of Targeting C-KIT in Two Cases from a Series of 11 Patients. Journal of Cancer Therapy, 2014, 05, 225-230.	0.1	0
8020	Benign Neck Disease. , 2014, , .		2
8021	Pathology, Biomarkers, and Molecular Diagnostics. , 2014, , 226-252.e6.		1
8022	Molecular Testing in Thyroid Cancer. , 2014, , 319-329.		0
8024	Biopsies, Tissue Processing, Immunohistochemistry, and Ancillary Techniques. , 2014, , 13-32.		0
8025	The Importance of Targeted Drug Delivery Systems on Pancreatic Cancer. British Journal of Applied Science & Technology, 2014, 4, 2400-2416.	0.2	0
8026	Melanoma. Part II. Personalized Medicine: Using Molecular Tools to Guide Targeted Therapy. , 2014, , 97-131.		1
8027	B-Raf Somatic Alterations. , 2014, , 1-5.		0
8028	Cutaneous Melanoma. , 2014, , 331-487.		0

#	ARTICLE	IF	CITATIONS
8029	Predictive Biomarkers to Anti-EGFR Inhibitors Treatment in the Management of Metastatic Colorectal Cancer. <i>Journal of Carcinogenesis & Mutagenesis</i> , 2014, S10, .	0.3	0
8030	Targeting the Raf-MEK-ERK Mitogen-Activated Protein Kinase Cascade for the Treatment of RAS Mutant Cancers. , 2014, , 135-156.		5
8031	Molecular testing in Cutaneous Melanoma. , 2014, , 363-374.		1
8032	The Molecular Biology and Treatment of Malignant Melanoma with BRAFV600 Mutations. <i>Journal of Patient-centered Research and Reviews</i> , 2014, 1, 21-26.	0.6	0
8033	METASTAZAVUSIOS MELANOMOS GYDYMAS BRAF INHIBITORIAIS KLAIPĀ–DOS UNIVERSITETINĀ–JE LIGONINĀ–JE. NEPAGEIDAUJAMI REIĀKINIAI. <i>Health Sciences</i> , 2014, 24, 39-42.	0.0	0
8036	Combined BRAF and MEK inhibition of BRAF mutated metastatic melanoma: incremental progress?. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 232-233.	0.1	0
8040	Strategies in Patients with Other Molecular Alterations. , 2015, , 187-202.		0
8041	Implementation of Exome Sequencing Assay. , 2015, , 225-240.		0
8042	Melanomagenic Gene Alterations Viewed from a Redox Perspective: Molecular Mechanisms and Therapeutic Opportunities. , 2015, , 285-309.		2
8044	Molecular Diagnostics and Tumor Mutational Analysis. <i>Cancer Drug Discovery and Development</i> , 2015, , 47-65.	0.2	2
8045	Clinical Utility of BRAF-Targeted Therapy in Melanoma. <i>Cancer Drug Discovery and Development</i> , 2015, , 67-84.	0.2	0
8046	Melanoma: Historical Context. <i>Cancer Drug Discovery and Development</i> , 2015, , 1-23.	0.2	0
8047	Carcinogenesis: UV Radiation. , 2015, , 1-17.		0
8048	Basis for Molecular Genetics in Cancer. , 2015, , 15-30.		0
8049	Next-Generation Sequencing Applications in Head and Neck Oncology. , 2015, , 401-422.		0
8051	Pharmacogenetics and Antineoplastic Therapies. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 275-305.	0.6	0
8052	Genetic markers and evolution of targeted therapy in cancer. <i>Biomedical Research Journal</i> , 2015, 2, 179.	0.4	0
8053	Molekulare Diagnostik und Techniken. , 2015, , 1-12.		0

#	ARTICLE	IF	CITATIONS
8054	Nodular Melanoma-Like Superficial Spreading Melanoma Arising from Intradermal Unna Nevus-Can Incomplete Oncogenic-senescence be Responsible for Non-hierarchical Melanomagenesis?. Journal of Pigmentary Disorders, 2015, 2, .	0.2	0
8055	The Role of Pharmacogenomics in Individualized Medicine. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 93-112.	0.6	3
8056	Skin toxicity of targeted therapy: Vemurafenib, first experiences from Montenegro. Sanamed, 2015, 10, 109-114.	0.1	0
8057	Application of Molecular Pathology to Cutaneous Melanocytic Lesions. Molecular Pathology Library, 2015, , 103-124.	0.1	0
8058	Universal BRAF State Detection by the Pyrosequencing [®] -Based U-BRAFV600 Assay. Methods in Molecular Biology, 2015, 1315, 63-82.	0.4	0
8059	Therapy for Late Stage Melanoma. Journal of Carcinogenesis & Mutagenesis, 2015, 06, .	0.3	0
8060	çşè†šè...«ç~â...ç-«ã@ãf~ãf”ãffã,ã,1. Skin Cancer, 2015, 30, 58-61.	0.1	0
8061	Papillary Thyroid Cancer. , 2015, , 139-149.		0
8062	Evaluation of Pyrosequencing Method for a BRAFV600E Mutation Test. Korean Journal of Clinical Laboratory Science, 2015, 47, 17-23.	0.1	1
8063	Features of Colon Cancer with Liver Metastasis: A Case Report and Literature Review. Clinical Medical Reviews and Case Reports, 2015, 2, .	0.1	0
8068	Therapie des malignen Melanoms. , 2016, , 169-178.		0
8069	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2016, , 1-39.		0
8070	Melanom. , 2016, , 1-17.		0
8071	Molecular Targeted Anticancer Drugs. , 2016, , 175-238.		0
8072	Incorporating Clinical Biomarkers into Clinical Trials. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 57-67.	0.2	0
8073	High-throughput analysis of kinase inhibitor drugs on cardiac function using engineered heart tissue constructs. Frontiers in Bioengineering and Biotechnology, 0, 4, .	2.0	0
8074	Targeted Cancer Therapy. Nishinohon Journal of Dermatology, 2016, 78, 221-228.	0.0	0
8075	Molecular Testing. , 2016, , 89-107.		0

#	ARTICLE	IF	CITATIONS
8076	Etiology. , 2016, , 49-77.		0
8077	New Treatments for Advanced Melanoma. Nishinon Journal of Dermatology, 2016, 78, 5-12.	0.0	0
8078	Biomarker Analysis of Gene-Mutated Protein Products by Immunohistochemistry in Melanoma. , 2016, , 181-191.		0
8079	Viral-Like Proteins. , 2016, , 1-15.		0
8080	Targeted Therapy in Melanoma. , 2016, , 237-265.		0
8081	Meta-Analyses of Epidemiologic Associations between Cutaneous Melanoma and Thyroid Cancer. Journal of Clinical & Experimental Dermatology Research, 2016, 07, .	0.1	1
8082	Melanomaâ€”Introduction, History and Epidemiology. , 2016, , 3-20.		0
8083	Small-Molecule Inhibitors in Glioblastoma: Key Pathways and Resistance Mechanisms. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 145-174.	0.1	0
8084	BRAF Mutations. , 2016, , 4-16-4-17.		0
8085	Primary Urethral Melanoma. , 2016, , 173-189.		1
8086	Gastrointestinal Malignancy: Genetic Implications to Clinical Applications. Cancer Treatment and Research, 2016, 168, 393-479.	0.2	0
8087	Immunohistology of Melanocytic Lesions. , 2016, , 311-334.		0
8088	Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 27-107.	0.1	0
8090	Identification of Potential Off-Targets of Chemotherapeutic Agent Sorafenib: A Molecular Docking Approach. International Letters of Natural Sciences, 0, 51, 51-57.	1.0	1
8091	Sequencing methods in dermatology. Russian Journal of Skin and Venereal Diseases, 2016, 19, 7-12.	0.0	0
8092	Erdheim-Chester Disease: A Case of Cardiac and Hypophyseal Involvement Showing Positive Response with High Dose Pegylated Interferon-Î±. Journal of Rheumatic Diseases and Treatment, 2016, 2, .	0.1	0
8094	Pathology and Molecular Pathology of Colorectal Cancer. , 2017, , 409-446.		2
8098	Regulation of Apoptosis in Melanoma Cells: Critical Targets for Therapeutic Strategies. , 2017, , 271-287.		0

#	ARTICLE	IF	CITATIONS
8099	The role of autophagy inhibition in the enhanced cytotoxicity of temozolomide on melanoma cell lines. <i>Uspehi Molekularnoj Onkologii</i> , 2017, 4, 75-82.	0.1	0
8100	Targeting BRAF-mutant tumours with TGFBR1 inhibitors. <i>Aging</i> , 2017, 9, 5-6.	1.4	0
8101	Melanoma Genetics and Genomics. , 2017, , 63-93.		0
8102	Current Topics on Cancer Stem Cell Associated Melanoma Treatment Researches. <i>Journal of Brain Tumors & Neurooncology</i> , 2017, 02, .	0.1	1
8103	BRAF Somatic Alterations. , 2017, , 604-608.		0
8104	Altered Signal Transduction Pathways in Melanoma. , 2017, , 177-207.		0
8105	Revisiting Epidermal Melanocytes: Regulation of Their Survival, Proliferation, and Function in Human Skin. , 2017, , 7-38.		1
8106	Molecular Carcinogenesis of Uveal Melanoma. , 2017, , 151-174.		0
8107	New Approaches to Signaling. , 2017, , 399-425.		0
8108	Minor-Driver Mutant. , 2017, , 199-212.		0
8110	A Case of Pilocytic Astrocytoma with BRAF V600E Mutation and Anaplastic Features occurred in Adult Temporal Lobe. <i>Japanese Journal of Neurosurgery</i> , 2017, 26, 452-458.	0.0	0
8111	High-Risk and Poorly Differentiated Thyroid Cancer. , 2017, , 115-123.		0
8112	Myometrium and Sigmoid Colon Metastatic Melanoma Simulating a Ewing Tumor: A Case Report. <i>Open Journal of Obstetrics and Gynecology</i> , 2017, 07, 897-906.	0.1	0
8113	Molecular Genetics of Thyroid Cancer. , 2017, , 15-27.		0
8115	Erdheim-Chester Disease and Other Histiocytoses. <i>Rare Diseases of the Immune System</i> , 2017, , 155-172.	0.1	0
8116	Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2017, 6, 35.	0.0	0
8117	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2017, , 1065-1102.		0
8118	æ—¥æœ-ã•ã,%ã,-ç•CEã«ç™ãä;ã™ã,çš®è†šæ,æ€šè...«ç~ãf^ãf©ãf³ã,1ãf-ãf¼ã,ãfšãfšãf«ãfªã,µãf¼ãf• Skin Cancer, 2017, 32, 14		0

#	ARTICLE	IF	CITATIONS
8120	QSAR modeling useful in anti-cancer drug discovery: Prediction of V600EBRAF-dependent p-ERK using Monte Carlo Method. <i>Journal of Medicinal Chemistry and Toxicology</i> , 2017, 2, 34-39.	0.2	1
8121	MUTATIONAL STATUS AND SOME CLINICO-MORPHOLOGICAL FEATURES OF CUTANEOUS MELANOMA. <i>Russian Journal of Oncology</i> , 2017, 22, 60-65.	0.1	0
8122	BRAF MUTATION ANALYSIS IN THYROID DISEASES- A STUDY FROM A TERTIARY CARE HOSPITAL/CENTRE IN KERALA. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2017, 6, 3359-3361.	0.1	0
8123	Multiple primary cancer: prostate cancer and melanoma in patient with end-stage of chronic kidney disease on peritoneal dialysis. <i>Health of Man</i> , 2017, .	0.1	0
8126	Next-Generation Sequencing. <i>Molecular Pathology Library</i> , 2018, , 169-192.	0.1	0
8127	Molecular Genetics of Melanocytic Neoplasia. , 2018, , 1-23.		1
8129	Immunotherapy of advanced melanoma. <i>Up to date</i> . <i>Skin Cancer</i> , 2018, 33, 107-111.	0.1	0
8130	Melanom der Vulva. , 2018, , 155-173.		0
8131	CILJANA TERAPIJA I METASTATSKI MELANOM. , 2018, , .		0
8132	The Dynamics of ERK Signaling in Melanoma, and the Response to BRAF or MEK Inhibition, Are Cell Cycle Dependent. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
8133	Melanomics: Comprehensive Molecular Analysis of Normal and Neoplastic Melanocytes. , 2018, , 1-44.		0
8134	Molecular Pathology of Pediatric Renal Tumors. <i>Molecular Pathology Library</i> , 2018, , 331-349.	0.1	0
8135	Molecular Cytology Applications in Metastases. , 2018, , 247-259.		0
8136	Principles of Molecular Biology and Oncogenesis. <i>Molecular Pathology Library</i> , 2018, , 3-8.	0.1	0
8137	Diagnostic value of BRAFV600E mutation analysis in fine needle aspiration for evaluation of thyroid nodules. <i>Kosin Medical Journal</i> , 2018, 33, 1.	0.1	0
8140	Malignes Melanom: Optionen für Patienten im fortgeschrittenen Stadium. <i>Deutsches A&#x0308;rztblatt International</i> , 0, , .	0.6	0
8141	THE ROLE OF THE EPITHELIALLY-MESENCHYMAL TRANSITION IN THE DEVELOPMENT OF COLORECTAL CANCER (review). <i>Koloproktologia</i> , 2018, , 111-117.	0.1	2
8144	Biology of Melanocytes and Primary Melanoma. , 2019, , 1-38.		0

#	ARTICLE	IF	CITATIONS
8145	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2019, , 1-19.		0
8147	Genomic Applications in Melanoma. , 2019, , 509-540.		0
8148	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2019, , 1-34.		0
8149	Non small cell lung cancer with targetable driver alterations: Imaging perspective. Integrative Cancer Science and Therapeutics, 2019, 6, .	0.1	0
8150	Physical Impairments Associated with Diseases: A Pathophysiological Approach. , 2019, , 597-617.		0
8151	The effects of aranose, cisplatin or paclitaxel in monotherapy and in combination on the expression of Pdâ€“I1 and Pdâ€“I2 in melanoma cells. , 2019, 17, 71-80.	0.3	1
8153	Genetic Implications of Ocular Melanoma. Current Practices in Ophthalmology, 2019, , 37-46.	0.1	0
8154	Novel Immunotherapies and Novel Combinations of Immunotherapy. , 2019, , 1-22.		0
8155	Melanom. , 2019, , 45-134.		0
8156	BRAF: Novel Therapies for an Emerging Target. Current Cancer Research, 2019, , 79-100.	0.2	0
8157	Cell lines of human melanoma and their xenograft with braf or nras mutations a targets for targeted therapy. Reviews. , 2019, 17, 27-35.	0.3	0
8158	KRAS as Potential Target in Colorectal Cancer Therapy. , 2019, , 389-424.		1
8159	Biology of Pancreas and Possible Diseases. , 2019, , 1-25.		0
8160	Association between BRAFV600E Mutations and Clinicopathological Features of Papillary Thyroid Microcarcinoma (PTMC). Journal of Endocrine Surgery, 2019, 19, 76.	0.0	3
8161	Biomarkers for Anti-angiogenic Therapy. , 2019, , 293-310.		0
8163	Role of Heat Shock Protein 90 in Mammary Tumorigenesis. Heat Shock Proteins, 2019, , 103-124.	0.2	0
8166	Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. Journal of Immunotherapy and Precision Oncology, 2019, 2, 23-35.	0.6	1
8167	Mutation alleleâ€“specific multiplex PCR for the detection of BRAFV600E mutations in breast carcinomas. World Academy of Sciences Journal, 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
8168	Vasculitis secundaria al uso de vemurafenib en una paciente con melanoma metastásico. Una complicación infrecuente de un inhibidor BRAF. <i>Piel</i> , 2019, 34, 445-447.	0.0	0
8169	Lymphomas. , 2020, , 253-315.		0
8171	Lung Carcinoma. , 2020, , 83-101.		0
8173	Neurological Complications of Targeted Therapies. , 2020, , 341-363.		0
8174	Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy. , 2020, , 55-65.		3
8175	Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.		0
8176	Pathology of Brain Metastasis. , 2020, , 15-29.		1
8177	Genomic Characterization of Brain Metastases: Implications for Precision Medicine. , 2020, , 43-58.		0
8179	BRAF expression in keratoacanthoma. <i>Middle Black Sea Journal of Health Science</i> , 0, , .	0.2	0
8180	Vemurafenib resistant melanoma cells acquire mesenchymal stem cell-like properties. <i>Uspehi Molekularnoj Onkologii</i> , 2019, 6, 47-57.	0.1	0
8182	BRAF mutations as a therapeutic target in metastatic colorectal cancer patients: a long due success. <i>Colorectal Cancer</i> , 2019, 8, .	0.8	1
8183	Mapping the Radiogenome of Human Cancers. <i>Cancer Drug Discovery and Development</i> , 2020, , 35-61.	0.2	0
8184	Tumors: Melanoma. , 2020, , 1-11.		0
8186	Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents. <i>Drugs in Context</i> , 2020, 9, 1-13.	1.0	6
8188	Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy. <i>Cell Death and Disease</i> , 2020, 11, 392.	2.7	14
8189	Histology and its prognostic effect on KRAS mutated colorectal carcinomas in Korea. <i>Oncology Letters</i> , 2020, 20, 655-666.	0.8	4
8195	The Recent Advances of Anti-PD-1/PD-L1 Immunotherapy. , 2020, , .		0
8198	Spirocyclic thienopyrimidines: synthesis, new rearrangements under Vilsmeier conditions and in silico prediction of anticancer activity. <i>Biopolymers and Cell</i> , 2020, 36, 279-293.	0.1	8

#	ARTICLE	IF	CITATIONS
8200	Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11726.	1.8	3
8201	Bioinformatic and Machine Learning Applications in Melanoma Risk Assessment and Prognosis: A Literature Review. <i>Genes</i> , 2021, 12, 1751.	1.0	7
8202	Disruption of Tumor Suppressors HNF4 \pm /HNF1 \pm Causes Tumorigenesis in Liver. <i>Cancers</i> , 2021, 13, 5357.	1.7	4
8203	Synergistic effect of metformin and vemurafenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study. <i>Molecular Biology Reports</i> , 2021, 48, 7443-7456.	1.0	6
8204	Prevalence of <i>BRAF</i> V600 in glioma and use of <i>BRAF</i> Inhibitors in patients with <i>BRAF</i> V600 mutation-positive glioma: systematic review. <i>Neuro-Oncology</i> , 2022, 24, 528-540.	0.6	26
8205	Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy. <i>Cancers</i> , 2021, 13, 5411.	1.7	1
8206	High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma. <i>Journal of Computer-Aided Molecular Design</i> , 2021, 35, 1165-1176.	1.3	5
8207	Orbital Histiocytic Disease. , 2020, , 1-32.		0
8208	The Relationship between BRAF V600E Mutation and the Clinicopathological Features of the Papillary Thyroid Carcinoma. <i>International Journal of Clinical Medicine</i> , 2020, 11, 216-227.	0.1	0
8210	Molecular and Biological Basis of Lung Cancer-Part I. , 2020, 01, .		0
8211	Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. <i>Topics in Medicinal Chemistry</i> , 2020, , 125-153.	0.4	0
8212	Modern combined targeted and immunotherapy of metastatic skin melanoma. <i>Meditinskiy Sovet</i> , 2020, , 54-61.	0.1	1
8213	KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature. <i>Aging Male</i> , 2020, 23, 1627-1641.	0.9	4
8214	Liquid Biopsy: A New, Non-Invasive Early Diagnostic and Prognostic Tool in Oncology. <i>Journal of Cancer Research Updates</i> , 0, 9, 37-68.	0.3	0
8215	Multidimensional indicators of scholarly impact in the skin oncology literature: is there a correlation between bibliometric and altmetric profiles?. <i>Journal of Plastic Surgery and Hand Surgery</i> , 2021, 55, 232-241.	0.4	3
8216	Exploring the Anti-Cancer Mechanism of Novel 3,4-Substituted Diaryl Guanidinium Derivatives. <i>Pharmaceuticals</i> , 2020, 13, 485.	1.7	3
8217	RNA Splicing: Basic Aspects Underlie Antitumor Targeting. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2020, 15, 293-305.	0.8	1
8219	Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis. <i>Current Opinion in Oncology</i> , 2021, 33, 101-109.	1.1	10

#	ARTICLE	IF	CITATIONS
8220	Molecularly targeted therapy in metastatic CRC. , 2022, , 357-364.		0
8221	Pediatric ganglioglioma of the brainstem and cervicomedullary junction: a retrospective cohort study. <i>Journal of Neurosurgery: Pediatrics</i> , 2020, 25, 30-36.	0.8	4
8222	Mechanisms of Toxicities Associated With Targeted Therapy. , 2020, , 113-118.		0
8223	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2020, , 1215-1241.		0
8224	Recent Advances in Systemic Therapy for Malignant Melanoma. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020, 4, 4-14.	0.1	0
8225	Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma. , 2020, , 1165-1186.		0
8226	Glimmers of Hopeâ€”New Strategies for Overcoming Treatment Resistance in Patients with <i>BRAF</i> V600E-mutated Metastatic Colorectal Cancer. <i>Oncology & Hematology Review</i> , 2020, 16, 31.	0.2	1
8227	Regorafenib â€” Five Years in Review. <i>European Oncology and Haematology</i> , 2020, 16, 24.	0.0	0
8228	Dermatological Toxicities of Targeted Therapy. , 2020, , 147-164.		1
8229	Precision Medicine in Metastatic Colorectal Cancerâ€”Finding and Hitting the Right Targets. <i>Oncology & Hematology Review</i> , 2020, 16, 36.	0.2	0
8230	Application of Ultrasonography in the Diagnosis and Management of Papillary Thyroid Microcarcinoma. <i>Advanced Ultrasound in Diagnosis and Therapy</i> , 2020, 4, 284.	0.1	4
8231	Molecular Targets in Craniopharyngioma. , 2020, , 209-221.		1
8232	Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target. <i>International Journal of Oncology</i> , 2020, 56, 761-771.	1.4	1
8233	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. , 2020, , 1421-1454.		0
8235	Targeted Therapies for BRAF-Mutant Metastatic Melanoma. , 2020, , 1067-1085.		0
8236	Visible Light-Curable Hydrogel Systems for Tissue Engineering and Drug Delivery. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1249, 85-93.	0.8	8
8237	Chemical Probes for Kinases. <i>Chemical Biology</i> , 2020, , 182-213.	0.1	0
8238	Biomarkers in colon cancer and its clinical implications. <i>Journal of Current Oncology</i> , 2020, 3, 66.	0.2	1

#	ARTICLE	IF	CITATIONS
8239	Adverse Cutaneous Reactions to Chemotherapeutic Agents. , 2020, , 757-795.		0
8240	A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer. <i>Medicine (United States)</i> , 2020, 99, e18917.	0.4	2
8241	Non-melanoma Skin Cancer and Cutaneous Melanoma from Dermatological Point of View. , 2020, , 3-40.		1
8242	Candidate genes for predicting the survival of patients with gastric cancer: a study based on The Cancer Genome Atlas (TCGA) database. <i>Translational Cancer Research</i> , 2020, 9, 2599-2608.	0.4	2
8243	A Case of <i>BRAF</i> -V600E Mutation-positive Metachronous Secondary Lung Cancer Detected by Bone Metastatic Lesion. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 125-128.	0.0	0
8244	Unusual Site of Langerhans Cell Histiocytosis Involving Nasopharynx. <i>Global Journal of Otolaryngology</i> , 2021, 24, .	0.0	0
8245	Regulation of Mitogen-Activated Protein Kinase Signaling Pathways by the Ubiquitin-Proteasome System and Its Pharmacological Potential. <i>Pharmacological Reviews</i> , 2021, 73, 1434-1467.	7.1	12
8246	The Therapeutic Potential of MAPK/ERK Inhibitors in the Treatment of Colorectal Cancer. <i>Current Cancer Drug Targets</i> , 2021, 21, 932-943.	0.8	21
8247	<i>BRAF</i> and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11951.	1.8	8
8248	Thyroid cancer under the scope of emerging technologies. <i>Molecular and Cellular Endocrinology</i> , 2022, 541, 111491.	1.6	9
8249	<i>BRAF</i> <i>V600E</i> mutation is associated with aggressive features in papillary thyroid carcinomasâ€”1.5Åcm. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2021, 50, 63.	0.9	16
8250	<i>BRAF</i> Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. <i>Frontiers in Oncology</i> , 2021, 11, 772052.	1.3	18
8254	Current Omics Technologies in Biomarker Discovery. , 0, , 465-497.		0
8259	Small-molecule Hsp90 Inhibitors: Applications in Cancer and Neurodegenerative diseases. , 2007, , 275-294.		0
8260	Targeting Signaling Pathways â€” In the Search of Melanomaâ€™s Achillesâ€™ Heel. , 2008, , 27-42.		0
8261	Molecular pathology. , 0, , 95-118.		2
8262	Melanoma and Nevi. , 2006, , 1004-1010.		1
8263	Cutaneous Melanoma. , 2006, , 757-759.		0

#	ARTICLE	IF	CITATIONS
8264	Genetic Progression From Melanocyte to Malignant Melanoma. , 2006, , 197-209.		0
8265	Melanoma Development and Pigment Cell Transformation. , 2006, , 247-263.		0
8266	The Biology and Genetics of Melanoma. , 2006, , 265-290.		0
8267	Divergent Pathways to Cutaneous Melanoma. , 2006, , 311-327.		0
8268	The Clinical Use of Molecular Markers as Predictors of Disease Outcome and Response to Therapy in Malignant Melanoma. , 2006, , 551-576.		0
8269	Apoptosis in Melanoma. , 2006, , 605-617.		0
8270	Altered Signal Transduction in Melanoma. , 2006, , 119-147.		0
8271	Tyrosine Kinase Inhibitors. , 2007, , 477-508.		0
8275	Signal Transduction by the Ras- \rightarrow MAP Kinase Pathway in Prostate Cancer Progression. , 2008, , 223-256.		1
8277	Clinical Development of Sorafenib (BAY 43-9006) VEGFR and RAF Inhibitor. , 2008, , 655-671.		1
8279	Melanozyt-Äre LÄsionen. , 2009, , 869-925.		0
8280	LCH of the Scapula in a 2-Year-Old Masquerading as an ABC: A Case Report and Literature Review. The Open Orthopaedics Journal, 2020, 14, 130-134.	0.1	0
8281	Introduction to Multiparametric Flow Cytometry and Analysis of High-Dimensional Data. Methods in Molecular Biology, 2021, 2194, 239-253.	0.4	6
8282	<i>KRAS</i> , <i>NRAS</i> , and <i>BRAF</i> mutations in plasma cell myeloma at a single Korean institute. Blood Research, 2020, 55, 159-168.	0.5	0
8284	Systemic Treatment in Advanced Melanoma. Updates in Surgery Series, 2021, , 167-174.	0.0	0
8286	Immunotherapy Benefit in a Patient With Non-Small Cell Lung Cancer and a Rare BRAF Mutation. Cureus, 2020, 12, e11224.	0.2	4
8287	Cancer Epigenomics and Beyond: Advancing the Precision Oncology Paradigm. Journal of Immunotherapy and Precision Oncology, 2020, 3, 147-156.	0.6	0
8288	BRAF mutations in KIT/PDGFR α positive gastrointestinal stromal tumours (GISTs): Is their frequency underestimated?. Pathology Research and Practice, 2020, 216, 153171.	1.0	6

#	ARTICLE	IF	CITATIONS
8289	The Molecular Genetics of Lung Cancer. , 0, , 61-83.		24
8293	Genetics of papillary thyroid cancer initiation: implications for therapy. Transactions of the American Clinical and Climatological Association, 2005, 116, 259-69; discussion 269-71.	0.9	37
8294	Renal cell carcinoma and the use of sorafenib. Therapeutics and Clinical Risk Management, 2006, 2, 87-98.	0.9	12
8295	The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics. Biologics: Targets and Therapy, 2007, 1, 407-14.	3.0	6
8297	Evolving role of cetuximab in the treatment of colorectal cancer. Cancer Management and Research, 2009, 1, 79-88.	0.9	5
8298	Six genes associated with the clinical phenotypes of individuals with deficient and proficient DNA repair. Translational Oncogenomics, 2008, 3, 1-13.	1.7	1
8299	The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?. Oncotarget, 2010, 1, 751-6.	0.8	24
8300	Novel targeted therapies for the treatment of metastatic melanoma. Ochsner Journal, 2010, 10, 117-24.	0.5	4
8301	New horizons in melanoma treatment: targeting molecular pathways. Ochsner Journal, 2010, 10, 93-8.	0.5	1
8303	Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker. Oncotarget, 2010, 1, 163-6.	0.8	3
8304	Mechanisms of aneuploidy induction by RAS and RAF oncogenes. American Journal of Cancer Research, 2011, 1, 955-71.	1.4	14
8305	Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. American Journal of Cancer Research, 2012, 2, 178-91.	1.4	23
8306	Primary mucosal melanomas: a comprehensive review. International Journal of Clinical and Experimental Pathology, 2012, 5, 739-53.	0.5	189
8307	The histogenic origin of melanoma arising in respiratory epithelium of a teratomatous germ cell tumor of the mediastinum: an enigma unraveled from an unlikely source. International Journal of Clinical and Experimental Pathology, 2012, 5, 982-90.	0.5	5
8308	Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. American Journal of Cancer Research, 2012, 2, 726-35.	1.4	10
8309	Cancer-linked targets modulated by curcumin. International Journal of Biochemistry and Molecular Biology, 2012, 3, 328-51.	0.1	46
8311	The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P and T, 2013, 38, 96-108.	1.0	69
8312	Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. American Journal of Blood Research, 2013, 3, 181-5.	0.6	1

#	ARTICLE	IF	CITATIONS
8313	Ocular melanoma: an overview of the current status. <i>International Journal of Clinical and Experimental Pathology</i> , 2013, 6, 1230-44.	0.5	126
8314	Aberrant apoptotic machinery confers melanoma dual resistance to BRAF(V600E) inhibitor and immune effector cells: immunosensitization by a histone deacetylase inhibitor. <i>American Journal of Clinical and Experimental Immunology</i> , 2014, 3, 43-56.	0.2	19
8316	Molecular profile of colorectal cancer in Indonesia: is there another pathway?. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2012, 5, 71-8.	0.6	12
8317	Clinical implications of BRAF mutation test in colorectal cancer. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2013, 6, 6-13.	0.6	28
8318	Diagnostic and prognostic biomarkers in melanoma. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2014, 7, 13-24.	0.1	65
8319	BRAF, K-ras and BAT26 mutations in colorectal polyps and stool. <i>World Journal of Gastroenterology</i> , 2006, 12, 5148-52.	1.4	6
8320	Langerhans cell histiocytosis in Chinese adults: absence of BRAF mutations and increased FOXP3(+) regulatory T cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 3166-73.	0.5	16
8321	Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia. <i>International Journal of Clinical and Experimental Pathology</i> , 2014, 7, 4323-8.	0.5	11
8323	Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 72-86.	1.4	10
8324	Melanoma: Molecular Pathogenesis and Therapeutic Management. <i>Molecular and Cellular Pharmacology</i> , 2014, 6, 228.	1.7	72
8325	MET inhibition in lung cancer. <i>Translational Lung Cancer Research</i> , 2013, 2, 23-39.	1.3	11
8326	BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3294-8.	0.5	3
8327	Hairy cell leukemia: A retrospective study on 11 patients in the Western of Iran. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2015, 9, 133-7.	0.3	1
8328	Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2014, 5, 400-10.	0.2	13
8329	Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 8487-93.	0.5	9
8331	Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. <i>Yale Journal of Biology and Medicine</i> , 2015, 88, 389-95.	0.2	3
8332	Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 15072-8.	0.5	13
8333	Lack of BRAFV600E mutation in stage I and II of colorectal cancer. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2016, 9, 94-9.	0.6	5

#	ARTICLE	IF	CITATIONS
8335	A Sensitive Peptide Nucleic Acid Probe Assay for Detection of BRAF V600 Mutations in Melanoma. <i>Cancer Genomics and Proteomics</i> , 2016, 13, 381-6.	1.0	2
8336	PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab. <i>American Journal of Cancer Research</i> , 2016, 6, 2117-2128.	1.4	19
8338	Biologically distinct subsets of nevi. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2016, 151, 365-84.	0.8	11
8341	BANCR: a cancer-related long non-coding RNA. <i>American Journal of Cancer Research</i> , 2017, 7, 1779-1787.	1.4	16
8342	Leptomeningeal Disease and the Evolving Role of Molecular Targeted Therapy and Immunotherapy. <i>Ochsner Journal</i> , 2017, 17, 362-378.	0.5	15
8343	Extracted metabolite from ABR11N111 altered the gene expression in colon cancer. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2018, 11, 34-41.	0.6	3
8349	Advances in the systemic treatment of metastatic melanoma. <i>Oncology</i> , 2013, 27, 374-81.	0.4	3
8350	Proteomics and melanoma: a current perspective. <i>Global Dermatology</i> , 2016, 3, 366-370.	0.1	1
8351	Droplet digital PCR for detection of mutation in formalin-fixed, paraffin-embedded melanoma tissues: a comparison with Cobas 4800, Sanger sequencing, and allele-specific PCR. <i>American Journal of Translational Research (discontinued)</i> , 2018, 10, 3773-3781.	0.0	12
8352	Molecular Profiles Guide Colorectal Cancer Treatment. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2016, 33, 50S-53S.	0.6	1
8353	Inhibition of peptidyl-prolyl isomerase (PIN1) and BRAF signaling to target melanoma. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4425-4437.	0.0	0
8354	Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis. <i>American Journal of Cancer Research</i> , 2019, 9, 1786-1795.	1.4	6
8355	Relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of papillary thyroid microcarcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 3492-3499.	0.5	4
8356	Targeting STAT3 restores BRAF inhibitor sensitivity through miR-759-3p in human cutaneous melanoma cells. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 2550-2560.	0.5	1
8358	Downregulated CDH3 decreases proliferation, migration, and invasion in thyroid cancer. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3057-3067.	0.0	2
8360	The inhibition of BRAF activity sensitizes chemoresistant human ovarian cancer cells to paclitaxel-induced cytotoxicity and tumor growth inhibition. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 8084-8098.	0.0	5
8361	KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis. <i>Caspian Journal of Internal Medicine</i> , 2020, 11, 355-369.	0.1	0
8362	The Sensitivity and Specificity of Novel Primers for Detection of BRAFV600E Mutation. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3191-3198.	0.5	0

#	ARTICLE	IF	CITATIONS
8363	BRAF Mutation Analysis in Primary Acral Melanoma of 41 Cases from South of Iran. Iranian Journal of Pathology, 2021, 16, 370-375.	0.2	0
8364	Tumors: Melanoma. , 2021, , 5260-5270.		0
8365	Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis. Pathology Research and Practice, 2022, 229, 153689.	1.0	1
8366	High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Translational Oncology, 2022, 15, 101290.	1.7	4
8367	Treatment Failure in Acute Myeloid Leukemia: Focus on the Role of Extracellular Vesicles. Leukemia Research, 2022, 112, 106751.	0.4	8
8368	BRAF-Inhibitor-Induced Metabolic Alterations in A375 Melanoma Cells. Metabolites, 2021, 11, 777.	1.3	3
8369	RGS2 Suppresses Melanoma Growth via Inhibiting MAPK and AKT Signaling Pathways. Anticancer Research, 2021, 41, 6135-6145.	0.5	3
8371	Contribution of endoplasmic reticulum stress, MAPK and PI3K/Akt pathways to the apoptotic death induced by a penicillin derivative in melanoma cells. Apoptosis: an International Journal on Programmed Cell Death, 2022, 27, 34-48.	2.2	4
8372	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. Cancers, 2021, 13, 5847.	1.7	16
8373	Cutaneous and uveal melanoma: two different cancers in therapeutic needs. Comptes Rendus - Biologies, 2021, 344, 219-231.	0.1	1
8374	Tools used to assay genomic instability in cancers and cancer meiomitosis. Journal of Cell Communication and Signaling, 2022, 16, 159-177.	1.8	6
8376	MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells. Cancers, 2021, 13, 5861.	1.7	2
8377	BRAFV600E induces reversible mitotic arrest in human melanocytes via microRNA-mediated suppression of AURKB. ELife, 2021, 10, .	2.8	16
8378	MMP-9 drives the melanomagenic transcription program through histone H3 tail proteolysis. Oncogene, 2022, 41, 560-570.	2.6	12
8379	In Silico Epitope Prediction Analyses Highlight the Potential for Distracting Antigen Immunodominance with Allogeneic Cancer Vaccines. Cancer Research Communications, 2021, 1, 115-126.	0.7	1
8380	Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers. International Journal of Molecular Sciences, 2021, 22, 12142.	1.8	13
8381	The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval. Cells, 2021, 10, 3088.	1.8	22
8382	Anal Cancer. , 2022, , 357-373.		0

#	ARTICLE	IF	CITATIONS
8383	Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. <i>ESMO Open</i> , 2021, 6, 100303.	2.0	7
8384	The positive feedback loop of NHE1-ERK phosphorylation mediated by BRAFV600E mutation contributes to tumorigenesis and development of glioblastoma. <i>Biochemical and Biophysical Research Communications</i> , 2022, 588, 1-7.	1.0	5
8385	The mechanism of Raf activation through dimerization. <i>Chemical Science</i> , 2021, 12, 15609-15619.	3.7	15
8387	Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1350, 123-143.	0.8	0
8388	Nevi, dysplastic nevi, and melanoma: Molecular and immune mechanisms involving the progression. <i>Tzu Chi Medical Journal</i> , 2022, 34, 1.	0.4	8
8389	Nuclear PD-L1 promotes cell cycle progression of BRAF-mutated colorectal cancer by inhibiting THRAP3. <i>Cancer Letters</i> , 2022, 527, 127-139.	3.2	18
8390	Design and synthesis of new triarylimidazole derivatives as dual inhibitors of BRAFV600E/p38 β with potential antiproliferative activity. <i>Journal of Molecular Structure</i> , 2022, 1253, 132218.	1.8	31
8392	Fortgeschrittenes malignes Melanom: Kernpunkte der aktualisierten Leitlinie. , 0, , .		0
8394	Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations. <i>Healthbook TIMES Oncology Hematology</i> , 2020, , .	0.1	3
8395	The Sensitivity and Specificity of Novel Primers for Detection of BRAFV600E Mutation. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 3191-3198.	0.5	0
8396	Manifestation of Langerhans cell histiocytosis in the oral cavity: The authorsâ€™ experience. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2021, 75, 933-938.	0.1	0
8398	EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature. , 2021, 4, 1019-1027.		1
8399	ĐœĐžĐ”Đ~ĐĐ†ĐšĐžĐ”ĐĐĐ”Đ™ ĐœĐ•ĐčĐžĐ” ĐŸĐ†ĐĐ£ĐĐ“Đ†ĐšĐĐžĐ”Đž Đ•Đ†ĐšĐ£Đ”ĐĐĐĐ” ĐŸĐčĐ•ĐĐ”Đ†ĐĐœĐ• Archive of L		
8400	B-RAF PROTEIN IMMUNOEXPRESSION IN HEPATOCELLULAR CARCINOMA DUE TO HEPATITIS C VIRUS RELATED CIRRHOSIS. <i>Arquivos De Gastroenterologia</i> , 2021, 58, 419-423.	0.3	0
8401	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115
8402	MOB3A Bypasses BRAF and RAS Oncogene-Induced Senescence by Engaging the Hippo Pathway. <i>Molecular Cancer Research</i> , 2022, 20, 770-781.	1.5	9
8403	Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1119.	1.8	10
8405	Targeting PGC1 β to wrestle cancer: a compelling therapeutic opportunity. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 767-774.	1.2	2

#	ARTICLE	IF	CITATIONS
8406	TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic Apoptosis. <i>Biology</i> , 2022, 11, 141.	1.3	3
8408	Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors. <i>Health Economics Review</i> , 2022, 12, 8.	0.8	1
8410	Comparison of the clinicopathological features and oncologic outcomes of the classic papillary thyroid carcinoma with tall cell features and tall cell variant. <i>Gland Surgery</i> , 2022, 11, 56-66.	0.5	0
8411	A Need for More Molecular Profiling in Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 785064.	1.3	1
8412	Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 801320.	1.3	5
8413	Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences. <i>Journal of Cancer Research and Therapeutics</i> , 2023, .	0.3	2
8414	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. <i>Cancers</i> , 2022, 14, 664.	1.7	7
8415	Feline Uveal Melanoma Review: Our Current Understanding and Recent Research Advances. <i>Veterinary Sciences</i> , 2022, 9, 46.	0.6	4
8416	Nuclear Localization of BRAFV600E Is Associated with HMOX-1 Upregulation and Aggressive Behavior of Melanoma Cells. <i>Cancers</i> , 2022, 14, 311.	1.7	4
8417	Genomic landscape of colorectal carcinogenesis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 533-545.	1.2	13
8419	Plant-Derived Terpenoids: A Promising Tool in the Fight against Melanoma. <i>Cancers</i> , 2022, 14, 502.	1.7	8
8420	Genes Involved in Immune Reinduction May Constitute Biomarkers of Response for Metastatic Melanoma Patients Treated with Targeted Therapy. <i>Biomedicines</i> , 2022, 10, 284.	1.4	2
8421	Genetic Study of <i>BRAF</i> V600E and <i>SMO</i> L412F Mutations in Japanese Patients with Ameloblastoma. <i>International Journal of Surgical Pathology</i> , 2022, 30, 378-384.	0.4	5
8422	B-Raf inhibitor vemurafenib counteracts sulfur mustard-induced epidermal impairment through MAPK/ERK signaling. <i>Drug and Chemical Toxicology</i> , 2022, , 1-10.	1.2	0
8423	BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences. <i>Cancer Research</i> , 2022, 82, 12-14.	0.4	3
8424	Canine models of human cancer: Bridging the gap to improve precision medicine. <i>Progress in Molecular Biology and Translational Science</i> , 2022, , 67-99.	0.9	8
8425	Precision medicine for metastatic colorectal cancer in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110727.	1.4	23
8426	Distribution of copy number variations and rearrangement endpoints in human cancers with a review of literature. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2022, 824, 111773.	0.4	6

#	ARTICLE	IF	CITATIONS
8427	DEPDC1B Promotes Melanoma Angiogenesis and Metastasis through Sequestration of Ubiquitin Ligase CDC16 to Stabilize Secreted SCUBE3. <i>Advanced Science</i> , 2022, 9, e2105226.	5.6	9
8428	Second Primary Malignancies following a Diagnosis of Conjunctival Melanoma. <i>Current Eye Research</i> , 2021, , 1-8.	0.7	0
8429	Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1735-1748.	2.9	16
8430	The Effects of Hedgehog Signaling Pathway on the Proliferation and Apoptosis of Melanoma Cells. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	0.6	3
8431	Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review. <i>Frontiers in Medicine</i> , 2021, 8, 652005.	1.2	3
8432	MITF activity is regulated by a direct interaction with RAF proteins in melanoma cells. <i>Communications Biology</i> , 2022, 5, 101.	2.0	6
8433	A Transient Metabolic State in Melanoma Persister Cells Mediated by Chemotherapeutic Treatments. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 780192.	1.6	8
8434	Acetylation-dependent regulation of BRAF oncogenic function. <i>Cell Reports</i> , 2022, 38, 110250.	2.9	13
8436	Molecular Genetic Investigation of Digital Melanoma in Dogs. <i>Veterinary Sciences</i> , 2022, 9, 56.	0.6	6
8437	New Approaches with Precision Medicine in Adult Brain Tumors. <i>Cancers</i> , 2022, 14, 712.	1.7	2
8438	Evaluation of Colorectal Cancer Inhibition Ability of <i>Rosmarinus officinalis</i> L. via Molecular Docking and Pharmacophore Analysis. <i>International Journal of Pharmacology</i> , 2022, 18, 262-278.	0.1	0
8439	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	3.4	21
8440	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 26-30.	0.6	1
8441	Cytoskeletal Remodelling as an Achilles's™ Heel for Therapy Resistance in Melanoma. <i>Cells</i> , 2022, 11, 518.	1.8	1
8442	The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma. <i>Cancers</i> , 2022, 14, 777.	1.7	3
8443	How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC). <i>Cancer Treatment Reviews</i> , 2022, 103, 102335.	3.4	19
8444	Optimization and SAR investigation of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as EGFR and BRAFV600E dual inhibitors with potent antiproliferative and antioxidant activities. <i>Bioorganic Chemistry</i> , 2022, 120, 105616.	2.0	38
8445	Recent advances in B-RAF inhibitors as anticancer agents. <i>Bioorganic Chemistry</i> , 2022, 120, 105597.	2.0	10

#	ARTICLE	IF	CITATIONS
8446	Cetuximab and vemurafenib plus FOLFIRI(5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial. <i>European Journal of Cancer</i> , 2022, 163, 152-162.	1.3	7
8448	Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas. , 0, 79, .		11
8449	Treatment of Advanced BRAF-Mutated Colorectal Cancer: Where We Are and Where We Are Going. <i>Clinical Colorectal Cancer</i> , 2022, 21, 71-79.	1.0	4
8451	Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer. , 2022, 10, e003731.		18
8452	Qa-1b functions as an oncogenic factor in mouse melanoma cells. <i>Journal of Dermatological Science</i> , 2022, 105, 159-169.	1.0	2
8453	Glioma targeted therapy: insight into future of molecular approaches. <i>Molecular Cancer</i> , 2022, 21, 39.	7.9	274
8454	Diagnostic Challenge in Rapidly Growing Langerhans Cell Histiocytosis with Aneurysmal Bone Cyst in the Maxilla: A Case Report. <i>Diagnostics</i> , 2022, 12, 400.	1.3	2
8455	Prediction of Drug-Drug Interaction Between Dabrafenib and Irinotecan via UGT1A1-Mediated Glucuronidation. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2022, 47, 353-361.	0.6	3
8456	Managing Metastatic Melanoma in 2022: A Clinical Review. <i>JCO Oncology Practice</i> , 2022, 18, 335-351.	1.4	91
8457	The dosimetric enhancement of GRID profiles using an external collimator in pencil beam scanning proton therapy. <i>Medical Physics</i> , 2022, , .	1.6	1
8458	Regulation of LncRNAs in Melanoma and Their Functional Roles in the Metastatic Process. <i>Cells</i> , 2022, 11, 577.	1.8	13
8459	Tomatoes: An Extensive Review of the Associated Health Impacts of Tomatoes and Factors That Can Affect Their Cultivation. <i>Biology</i> , 2022, 11, 239.	1.3	48
8460	Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 413-418.	0.4	7
8461	Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma. <i>Annals of Diagnostic Pathology</i> , 2022, 58, 151909.	0.6	1
8462	Cholangiocarcinogenesis and targeted therapy for cholangiocarcinoma. <i>Meditinskiy Sovet</i> , 2021, , 101-109.	0.1	0
8463	Prophylactic vaccines against cancers of non-infectious origin: a dream or a real possibility?. <i>Central European Journal of Public Health</i> , 2021, 29, 247-258.	0.4	0
8466	Excellent Response to MEK Inhibition in an <i>AGK-BRAF</i> Gene Fusion Driven Carcinoma: Case Report and Literature Review. <i>Anticancer Research</i> , 2022, 42, 373-379.	0.5	4
8467	Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies. <i>Antioxidants</i> , 2021, 10, 1942.	2.2	33

#	ARTICLE	IF	CITATIONS
8468	Genetic Mutations of Pancreatic Cancer and Genetically Engineered Mouse Models. <i>Cancers</i> , 2022, 14, 71.	1.7	13
8470	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	0.6	2
8471	Herbal medicines and skin disorders. , 2022, , 307-328.		0
8472	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. <i>Experientia Supplementum (2012)</i> , 2022, 113, 295-350.	0.5	3
8473	From engineered heart tissue to cardiac organoid. <i>Theranostics</i> , 2022, 12, 2758-2772.	4.6	21
8474	First experiences with the use of targeted and immunotherapy in the treatment of cutaneous melanoma: A single centre experience. <i>Scripta Medica</i> , 2022, 53, 29-35.	0.0	0
8475	Biology and pathophysiology of central nervous system metastases. , 2022, , 55-78.		0
8476	Pathophysiology roles and translational opportunities of miRNAs in cutaneous melanoma. , 2022, , 339-384.		0
8477	Skin cancer, including related pathways and therapy and the role of luteolin derivatives as potential therapeutics. <i>Medicinal Research Reviews</i> , 2022, 42, 1423-1462.	5.0	19
8478	CBX3 is associated with metastasis and glutathione/glycosphingolipid metabolism in colon adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 246-255.	0.6	2
8480	Role of the Skin Microenvironment in Melanomagenesis: Epidermal Keratinocytes and Dermal Fibroblasts Promote BRAF Oncogene-Induced Senescence Escape in Melanocytes. <i>Cancers</i> , 2022, 14, 1233.	1.7	6
8481	RAS pathway regulation in melanoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	11
8482	TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 833-840.	1.2	6
8484	The RAF Kinase Inhibitor Protein (RKIP): Good as Tumour Suppressor, Bad for the Heart. <i>Cells</i> , 2022, 11, 654.	1.8	2
8485	Integration of Palladium Nanoparticles with Surface Engineered Metal-Organic Frameworks for Cell-Selective Bioorthogonal Catalysis and Protein Activity Regulation. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 10117-10124.	4.0	12
8486	Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation. <i>Oncogene</i> , 2022, 41, 2571-2586.	2.6	6
8487	C1QTNF6 is a Prognostic Biomarker and Related to Immune Infiltration and Drug Sensitivity: A Pan-Cancer Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 855485.	1.6	3
8488	STARBOARD: encorafenib+binimetinib+ pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. <i>Future Oncology</i> , 2022, 18, 2041-2051.	1.1	9

#	ARTICLE	IF	CITATIONS
8490	Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway. <i>Frontiers in Pharmacology</i> , 2022, 13, 847905.	1.6	2
8491	BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective. <i>Frontiers in Oncology</i> , 2022, 12, 863043.	1.3	16
8492	Current Advances in the Management of Adult Craniopharyngiomas. <i>Current Oncology</i> , 2022, 29, 1645-1671.	0.9	15
8493	Comparison of Two Rapid Assays for the Detection of BRAF V600 Mutations in Metastatic Melanoma including Positive Sentinel Lymph Nodes. <i>Diagnostics</i> , 2022, 12, 751.	1.3	3
8494	Tumors carrying BRAF-mutations over-express NAMPT that is genetically amplified and possesses oncogenic properties. <i>Journal of Translational Medicine</i> , 2022, 20, 118.	1.8	3
8495	Cancer progression as a learning process. <i>IScience</i> , 2022, 25, 103924.	1.9	8
8498	Brain Metastases among Cancer Patients Diagnosed from 2010â€“2017 in Canada: Incidence Proportion at Diagnosis and Estimated Lifetime Incidence. <i>Current Oncology</i> , 2022, 29, 2091-2105.	0.9	4
8499	Combined HP 13C Pyruvate and 13C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts. <i>Biomedicines</i> , 2022, 10, 717.	1.4	3
8500	Response of metastatic melanoma with a rare BRAF V600K mutation to dabrafenib and trametinib. <i>Melanoma Research</i> , 2022, 32, 124-127.	0.6	1
8502	Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies. <i>Frontiers in Oncology</i> , 2022, 12, 854402.	1.3	12
8503	TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types. <i>Aging</i> , 2022, 14, 2868-2879.	1.4	0
8504	Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016). <i>Frontiers in Oncology</i> , 2022, 12, 853076.	1.3	2
8505	Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors. <i>JACC: CardioOncology</i> , 2022, 4, 1-18.	1.7	18
8506	Pediatric High Grade Glioma Classification Criteria and Molecular Features of a Case Series. <i>Genes</i> , 2022, 13, 624.	1.0	11
8507	Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3660.	1.8	18
8508	Intermittent treatment of BRAF ^{V600E} melanoma cells delays resistance by adaptive resensitization to drug rechallenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2113535119.	3.3	20
8509	Novel chloroquine derivative suppresses melanoma cell growth by DNA damage through increasing ROS levels. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2579-2593.	1.6	2
8510	SWI/SNF Chromatin Remodeling Enzymes in Melanoma. <i>Epigenomes</i> , 2022, 6, 10.	0.8	6

#	ARTICLE	IF	CITATIONS
8511	Primary vitreoretinal involvement and immunopositivity for <sc> <i>BRAFV600E</i> </sc> help distinguish metastatic from primary intraocular melanoma: a detailed histopathologic study of metastatic cutaneous melanoma to the eye. <i>Histopathology</i> , 2022, , .	1.6	0
8512	Targeted therapies in the medical management of craniopharyngioma. <i>Pituitary</i> , 2022, 25, 383-392.	1.6	9
8513	BRAF-mutated colorectal adenocarcinomas: Pathological heterogeneity and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103647.	2.0	10
8514	Tyrosinase suppresses vasculogenic mimicry in human melanoma cells. <i>Oncology Letters</i> , 2022, 23, 169.	0.8	6
8515	Malignant peripheral nerve sheath tumor: models, biology, and translation. <i>Oncogene</i> , 2022, 41, 2405-2421.	2.6	27
8517	The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1353-1369.	0.9	3
8518	Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer. <i>Journal of Controlled Release</i> , 2022, 346, 43-70.	4.8	17
8519	Cause, Epidemiology, and Histology of Polyps and Pathways to Colorectal Cancer. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2022, 32, 177-194.	0.6	29
8520	Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2235-2245.	0.8	21
8521	Tebentafusp for the treatment of metastatic uveal melanoma. <i>Future Oncology</i> , 2022, 18, 1303-1311.	1.1	1
8522	Characterization of the treatment-naive immune microenvironment in melanoma with <i>BRAF</i> mutation. , 2022, 10, e004095.		7
8523	Therapeutic Efficacy of Pharmacological Ascorbate on Braf Inhibitor Resistant Melanoma Cells In Vitro and In Vivo. <i>Cells</i> , 2022, 11, 1229.	1.8	2
8524	Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103657.	2.0	6
8525	C-phycocyanin decreases proliferation and migration of melanoma cells: In silico and in vitro evidences. <i>Bioorganic Chemistry</i> , 2022, 122, 105757.	2.0	3
8526	A novel photocaged B-RafV600E inhibitor toward precise melanoma treatment. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 64, 128683.	1.0	3
8527	Mechanisms underlying melanoma invasion as a consequence of MLK3 loss. <i>Experimental Cell Research</i> , 2022, 415, 113106.	1.2	0
8528	The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer. <i>Molecular and Cellular Probes</i> , 2022, 63, 101807.	0.9	3
8529	O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia. <i>Phytomedicine</i> , 2022, 100, 154061.	2.3	5

#	ARTICLE	IF	CITATIONS
8530	Adjuvant therapy of malignant melanoma: general and practical experience. <i>Onkologie (Czech)</i> 2021, 26, 100-105.	0.0	0
8531	A case of sialadenoma papilliferum-like intraductal papillary tumor in the tongue. <i>Nihon Koku Geka Gakkai Zasshi</i> , 2021, 67, 646-648.	0.0	0
8532	Predicting patient response with models trained on cell lines and patient-derived xenografts by nonlinear transfer learning. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	19
8533	Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers. <i>Cancers</i> , 2021, 13, 6180.	1.7	8
8534	Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis. <i>Cancers</i> , 2022, 14, 123.	1.7	11
8535	Fast reaction and long duration application of dabrafenib plus trametinib in treatment of metastatic melanoma with B-Raf V600E mutation: A case report. <i>Chinese Journal of Plastic and Reconstructive Surgery</i> , 2021, 3, 193-196.	0.1	0
8536	The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles. <i>Journal of Cellular Physiology</i> , 2022, 237, 1720-1752.	2.0	27
8537	Primary Malignant Melanoma of the Bladder: A Rare Case Report in Asia and Review of the Literature. <i>Research and Reports in Urology</i> , 2021, Volume 13, 833-839.	0.6	0
8538	Rechallenge With BRAF and anti-EGFR Inhibitors in Patients With Metastatic Colorectal Cancer Harboring BRAF Mutation Who Progressed on Cetuximab and Encorafenib With or Without Binimetinib: A Case Series. <i>Clinical Colorectal Cancer</i> , 2022, 21, 267-271.	1.0	5
8539	YK-4-279 Attenuates Progression of Pre-Existing Pigmented Lesions to Nodular Melanoma in a Mouse Model. <i>Cancers</i> , 2022, 14, 143.	1.7	0
8540	BRAF ^{V600E} mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2129-2148.	0.8	15
8542	Activating BRAF G469A Missense Mutation in a Pediatric Patient With High-Grade Glioma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 1141-1142.	0.9	2
8543	Targeting Oncogenic G11 in Uveal Melanoma. <i>Cancers</i> , 2021, 13, 6195.	1.7	10
8544	The ionophore thiomaltol induces rapid lysosomal accumulation of copper and apoptosis in melanoma. <i>Metallomics</i> , 2022, 14, .	1.0	2
8545	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	2.9	8
8546	Variations in MAP kinase gliadators and risk of differentiated thyroid carcinoma. <i>Molecular and Clinical Oncology</i> , 2021, 16, 45.	0.4	3
8547	FOLFOXIRI/Bevacizumab Plus Nivolumab as First-Line Treatment in Metastatic Colorectal Cancer RAS/BRAF Mutated: Safety Run-In of Phase II NIVACOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 766500.	1.3	12
8548	Role of Biomarkers in the Integrated Management of Melanoma. <i>Disease Markers</i> , 2021, 2021, 1-13.	0.6	10

#	ARTICLE	IF	CITATIONS
8549	Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study. <i>ESMO Open</i> , 2021, 6, 100328.	2.0	15
8550	The Curious Case of the HepG2 Cell Line: 40 Years of Expertise. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13135.	1.8	86
8551	Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2779-2788.	3.2	11
8552	Rapidly Changing Serous Detachment During BRAF and MEK Inhibitor Therapy. <i>Cureus</i> , 2021, 13, e20491.	0.2	0
8553	Development of Potential Prognostic Biomarkers Based on DNA Methylation-Driven Genes for Patients with Endometrial Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10541-10555.	0.8	5
8554	Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts. <i>Cell Communication and Signaling</i> , 2021, 19, 123.	2.7	3
8555	Dabrafenib: A narrative drug review. <i>Cancer Research Statistics and Treatment</i> , 2020, 3, 537.	0.1	4
8557	A dual identification strategy based on padlock ligation and CRISPR/Cas14a for highly specific detection of BRAF V600E mutation in clinical samples. <i>Analytical Methods</i> , 2022, 14, 1913-1921.	1.3	3
8558	Revisiting the melanomagenic pathways and current therapeutic approaches. <i>Molecular Biology Reports</i> , 2022, 49, 9651-9671.	1.0	2
8559	Review: Neurological Complications From Therapies for Pediatric Brain Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 853034.	1.3	5
8560	Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, 1964-1975.	0.6	15
8561	Genetic Basis and Molecular Mechanisms of Uveal Melanoma Metastasis: A Focus on Prognosis. <i>Frontiers in Oncology</i> , 2022, 12, 828112.	1.3	15
8562	Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 865656.	1.3	0
8563	Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups. <i>Cancers</i> , 2022, 14, 2019.	1.7	4
8564	Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600E-Mutant Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 871-878.	1.9	23
8566	Novel potential NOX2 inhibitors, <i>Dudleya brittonii</i> water extract and polygalatenoside A inhibit intracellular ROS generation and growth of melanoma. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 112967.	2.5	3
8567	RAS signaling networks. , 0, , 183-192.		0
8680	The Transformed Phenotype of Melanocytes. , 0, , 489-494.		0

#	ARTICLE	IF	CITATIONS
8681	Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. <i>Expert Review of Proteomics</i> , 2022, 19, 115-129.	1.3	3
8682	RAF suppresses ERBB3 expression and metastasis in a subset of lung cancers. <i>Science Advances</i> , 2022, 8, eabk1538.	4.7	4
8684	Metastatic melanoma: a regional review and future directions. <i>Tumori</i> , 2012, 98, 575-80.	0.6	12
8698	Treatment of BRAF-mutated advanced cutaneous melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 28.	0.4	5
8700	Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.. <i>Journal of Clinical and Translational Research</i> , 2021, 7, 771-785.	0.3	1
8701	Neoadjuvant therapy for melanoma: new and evolving concepts.. <i>Clinical Advances in Hematology and Oncology</i> , 2022, 20, 47-55.	0.3	0
8702	Clinicopathological aspects of V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutated non-small cell lung carcinoma in an Indian cohort: is there a difference?. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2021, 12, 112-119.	0.4	0
8703	Gene expression based profiling of pleomorphic xanthoastrocytoma highlights two prognostic subgroups.. <i>American Journal of Translational Research (discontinued)</i> , 2022, 14, 1010-1023.	0.0	0
8705	Orbital Histiocytic Disease. , 2022, , 5327-5357.		0
8706	Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210903.	1.4	4
8707	Pro-Prion is a Membrane Adaptor Protein for E3 Ligase C-Cbl to Ubiquitinate IGF-IR Promoting Melanoma Metastasis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
8708	BRAF Modulates Lipid Use and Accumulation. <i>Cancers</i> , 2022, 14, 2110.	1.7	3
8709	Preclinical Development of Seriniquinones as Selective Dermcidin Modulators for the Treatment of Melanoma. <i>Marine Drugs</i> , 2022, 20, 301.	2.2	2
8710	Morphological Analyses of Colorectal Adenocarcinomas in Japanese Familial Adenomatous Polyposis Patients. <i>Journal of the Anus, Rectum and Colon</i> , 2022, 6, 121-128.	0.4	0
8711	Overcoming Cancer Drug Resistance Utilizing PROTAC Technology. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 872729.	1.8	32
8712	Performance of Idyllaâ„¢ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1180-1187.	1.0	5
8713	The MAPK Pathway in Pulmonary Langerhans Cell Histiocytosis. <i>Archivos De Bronconeumologia</i> , 2022, , .	0.4	2
8714	The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 864302.	1.6	6

#	ARTICLE	IF	CITATIONS
8715	The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanomaâ€”A Retrospective, Real-World Cohort Study. <i>Cancers</i> , 2022, 14, 2082.	1.7	9
8716	The Evolving Treatment Landscape in <i>BRAF-V600E</i> Mutated Metastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 254-263.	1.8	13
8717	The Use and Technique of Sentinel Node Biopsy for Skin Cancer. <i>Plastic and Reconstructive Surgery</i> , 2022, 149, 995e-1008e.	0.7	0
8719	Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAFV600E Mutant Metastatic Colorectal Cancer: German Health Technology Assessment-Driven Analyses From the BEACON CRC Study. <i>Clinical Colorectal Cancer</i> , 2022, 21, 244-251.	1.0	3
8720	Molecular Pathways and Mechanisms of BRAF in Cancer Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 4618-4628.	3.2	37
8721	The multifaceted role of autophagy in cancer. <i>EMBO Journal</i> , 2022, 41, e110031.	3.5	63
8722	Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5158.	1.8	16
8723	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 315-324.	0.4	2
8724	Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor-targeted peptide for targeting BRAF V600E and MERTK receptors. <i>Molecular Diversity</i> , 2022, , 1.	2.1	1
8726	Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapyâ€”Present State and Perspectives. <i>Cancers</i> , 2022, 14, 2315.	1.7	7
8727	MITF deficiency accelerates GNAQ-driven uveal melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2107006119.	3.3	12
8728	CB-RAF600E-1 exerts efficacy in vemurafenib-resistant and non-resistant-melanoma cells via dual inhibition of RAS/RAF/MEK/ERK and PI3K/Akt signaling pathways. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 103285.	1.8	2
8729	BRAF mutation in colorectal cancer: An update. <i>Archive of Oncology</i> , 2023, 29, 16-19.	0.2	0
8730	Dysplastic nevi and melanoma: microRNAs tell a divergent story. <i>Pathology Research and Practice</i> , 2022, , 153942.	1.0	0
8731	Recent Molecular and Genetic Findings in Intramedullary Spinal Cord Tumors. <i>Neurospine</i> , 2022, 19, 262-271.	1.1	6
8732	Raf and RhoA Cooperate to Transform Intestinal Epithelial Cells and Induce Growth Resistance to Transforming Growth Factor β . <i>Molecular Cancer Research</i> , 2004, 2, 233-241.	1.5	16
8734	Development of a potent small-molecule degrader against oncogenic <i>BRAF^{V600E}</i> protein that evades paradoxical <i>MAPK</i> activation. <i>Cancer Science</i> , 2022, 113, 2828-2838.	1.7	5
8735	Nitric-oxide enriched plasma-activated water inactivates 229E coronavirus and alters antiviral response genes in human lung host cells. <i>Bioactive Materials</i> , 2023, 19, 569-580.	8.6	17

#	ARTICLE	IF	CITATIONS
8737	Human Melanoma-Associated Mast Cells Display a Distinct Transcriptional Signature Characterized by an Upregulation of the Complement Component 3 That Correlates With Poor Prognosis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	8
8738	Targeting RASâ€“RAFâ€“MEKâ€“ERK signaling pathway in human cancer: Current status in clinical trials. <i>Genes and Diseases</i> , 2023, 10, 76-88.	1.5	34
8739	RAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. <i>Molecular Cell</i> , 2022, 82, 2443-2457.e7.	4.5	9
8740	Quantum chemical calculations, spectroscopic studies and molecular docking investigations of the anti-cancer drug quercitrin with B-RAF inhibitor. <i>Heliyon</i> , 2022, 8, e09539.	1.4	10
8741	Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use. <i>Cancers</i> , 2022, 14, 2640.	1.7	12
8744	Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial. <i>Acta OncolÃ³gica</i> , 2022, 61, 869-873.	0.8	1
8745	Potent Imidazothiazole-based Inhibitor of BRAF V600E Overcomes Acquired Resistance <i>via</i> Inhibition of RAF Dimerization in PLX4032-resistant Melanoma. <i>Anticancer Research</i> , 2022, 42, 2911-2921.	0.5	1
8746	Distinct mutational features across preinvasive and invasive subtypes identified through comprehensive profiling of surgically resected lung adenocarcinoma. <i>Modern Pathology</i> , 2022, 35, 1181-1192.	2.9	11
8747	The Genetics of Early-Stage Melanoma in a Veteran Population. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
8748	Targeting BRAF-mutant non-small cell lung cancer: Current status and future directions. <i>Lung Cancer</i> , 2022, 169, 102-114.	0.9	8
8749	Application of nanomedicine in the treatment of melanoma. <i>International Journal of Health Sciences</i> , 0, , .	0.0	0
8750	Overcoming chemoresistance to b-raf inhibitor in melanoma via targeted inhibition of phosphoenolpyruvate carboxykinase1 using 3-mercaptopropionic acid. <i>Bioengineered</i> , 2022, 13, 13571-13586.	1.4	0
8751	Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 1-14.	2.0	11
8752	Genitourinary melanoma: An overview for the clinician. <i>Asian Journal of Urology</i> , 2022, 9, 407-422.	0.5	4
8753	Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?. <i>British Journal of Cancer</i> , 2022, 127, 957-967.	2.9	6
8754	BRAFâ€“V600E utilizes posttranscriptional mechanisms to amplify LPSâ€“induced TNFÎ± production in dendritic cells in a mouse model of Langerhans cell histiocytosis. <i>Journal of Leukocyte Biology</i> , 0, , .	1.5	0
8755	Application of precision medicine in clinical routine in haematologyâ€“Challenges and opportunities. <i>Journal of Internal Medicine</i> , 2022, 292, 243-261.	2.7	12
8756	Clinical Updates for Colon Cancer Care in 2022. <i>Clinical Colorectal Cancer</i> , 2022, 21, 198-203.	1.0	32

#	ARTICLE	IF	CITATIONS
8757	The fluorescence amplification strategy based on 3D DNA walker and CRISPR/Cas12a for the rapid detection of BRAF V600E. <i>Analytical Sciences</i> , 2022, 38, 1057-1066.	0.8	2
8758	Cutaneous melanoma. , 2023, , 370-375.		0
8762	Serum from morbidly obese patients affects melanoma cell behavior in vitro. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 0, 58, .	1.2	1
8763	The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population. <i>International Journal of Endocrinology</i> , 2022, 2022, 1-7.	0.6	6
8764	Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
8765	Application of histology-agnostic treatments in metastatic colorectal cancer. <i>Digestive and Liver Disease</i> , 2022, 54, 1291-1303.	0.4	5
8766	Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
8767	<scp>BRAF V600E</scp> protect from cell death via inhibition of the mitochondrial permeability transition in papillary and anaplastic thyroid cancers. <i>Journal of Cellular and Molecular Medicine</i> , 0, , .	1.6	2
8768	Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
8769	The current state of molecular profiling in gastrointestinal malignancies. <i>Biology Direct</i> , 2022, 17, .	1.9	5
8770	HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia. <i>Antioxidants</i> , 2022, 11, 1171.	2.2	1
8771	m6A in the Signal Transduction Network. <i>Molecules and Cells</i> , 2022, 45, 435-443.	1.0	20
8772	Can artificial intelligence accelerate preclinical drug discovery and precision medicine?. <i>Expert Opinion on Drug Discovery</i> , 0, , 1-5.	2.5	2
8773	Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
8774	The Spectrum of Spitz Melanocytic Lesions: From Morphologic Diagnosis to Molecular Classification. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
8775	Novel GLCC11-BRAF fusion drives kinase signaling in a case of pheochromocytomatosis. <i>European Journal of Endocrinology</i> , 2022, 187, 185-196.	1.9	1
8776	Two smoking-related lesions in the same pulmonary lobe of squamous cell carcinoma and pulmonary Langerhans cell histiocytosis: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 6722-6727.	0.3	1
8777	Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma. <i>Cancer Letters</i> , 2022, 543, 215799.	3.2	3

#	ARTICLE	IF	CITATIONS
8778	Emerging trends in immunotoxin targeting cancer stem cells. <i>Toxicology in Vitro</i> , 2022, 83, 105417.	1.1	8
8779	Encorafenib plus cetuximab for the treatment of <i>BRAF-V600E</i> -mutated metastatic colorectal cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482211106.	1.4	4
8780	Knockdown of 15-bp Deletion-Type v-raf Murine Sarcoma Viral Oncogene Homolog B1 mRNA in Pancreatic Ductal Adenocarcinoma Cells Repressed Cell Growth In Vitro and Tumor Volume In Vivo. <i>Cancers</i> , 2022, 14, 3162.	1.7	1
8782	New Ameloblastoma Cell Lines Enable Preclinical Study of Targeted Therapies. <i>Journal of Dental Research</i> , 0, , 002203452211007.	2.5	4
8783	Targeting Ferroptosis Pathway to Combat Therapy Resistance and Metastasis of Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13
8784	Expression of active B-Raf proto-oncogene in kidney collecting ducts induces cyst formation in normal mice and accelerates cyst growth in mice with polycystic kidney disease. <i>Kidney International</i> , 2022, 102, 1103-1114.	2.6	2
8785	Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL). <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	1
8786	Clinical and morphological features of thyroid tumors with mutations in the <i>NTRK</i> , <i>RAS</i> , <i>BRAF</i> , and <i>RET</i> genes. <i>Journal of Anatomy and Histopathology</i> , 2022, 11, 70-77.	0.1	1
8787	La résistance aux inhibiteurs de BRAF. <i>Medecine/Sciences</i> , 2022, 38, 570-578.	0.0	0
8788	The structural conformation of the tachykinin domain drives the anti-tumoral activity of an octopus peptide in melanoma BRAF ^{V600E} . <i>British Journal of Pharmacology</i> , 0, , .	2.7	1
8789	Mislocalization of protein kinase A drives pathology in Cushing's syndrome. <i>Cell Reports</i> , 2022, 40, 111073.	2.9	18
8790	Extrapolating evidence for molecularly targeted therapies from common to rare cancers: a scoping review of methodological guidance. <i>BMJ Open</i> , 2022, 12, e058350.	0.8	1
8791	The Value of Histopathological Characteristics and BRAF and NRAS Mutations for the Diagnosis, Risk Stratification, and Prognosis of Malignant Invasive Melanoma. , 0, , .		0
8792	The emerging era of personalized medicine in advanced colorectal cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1411-1425.	1.4	6
8793	Lung Organoids—The Ultimate Tool to Dissect Pulmonary Diseases?. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	12
8794	The <i>MITF</i> regulatory network in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 517-533.	1.5	11
8795	The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
8796	Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. <i>Journal of Biological Chemistry</i> , 2022, 298, 102247.	1.6	31

#	ARTICLE	IF	CITATIONS
8797	Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. <i>Journal of Biological Chemistry</i> , 2022, 298, 102226.	1.6	8
8798	Analysis on the desert adaptability of indigenous sheep in the southern edge of Taklimakan Desert. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
8800	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
8801	Pilocytic astrocytoma of the optic nerve with intracystic hemorrhage in an adult: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 4, .	0.1	0
8802	Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells. <i>Biomolecules</i> , 2022, 12, 993.	1.8	2
8803	Targeting EGFR in melanoma – The sea of possibilities to overcome drug resistance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188754.	3.3	21
8804	Pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione derivatives as RAF-MEK-ERK pathway signaling pathway blockers: Synthesis, cytotoxic activity, mechanistic investigation and structure-activity relationships. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114579.	2.6	3
8805	Cancer Biology and Implications for the Perioperative Period. , 2023, , 24-45.		1
8806	Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. <i>Molecular Cancer Therapeutics</i> , 2004, 3, 755-762.	1.9	8
8807	COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600 Mutant Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 4178-4188.	0.8	57
8808	Unusual Clinical Experience in BRAF Exon 15 p.K601E-Mutated Lung Cancer: A Case Report and Brief Review of the Literature. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 7552.	1.3	0
8811	Prevalence and Detection of Actionable BRAF V600 and NRAS Q61 Mutations in Malignant Peripheral Nerve Sheath Tumor by Droplet Digital PCR. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
8812	Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes. <i>Cancers</i> , 2022, 14, 3674.	1.7	3
8813	Discovery of BRAF/HDAC Dual Inhibitors Suppressing Proliferation of Human Colorectal Cancer Cells. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	3
8814	A distinct four-value blood signature of pyrexia under combination therapy of malignant melanoma with dabrafenib and trametinib evidenced by an algorithm-defined pyrexia score. <i>PLoS ONE</i> , 2022, 17, e0273478.	1.1	1
8815	Molecular mechanisms of resistance to kinase inhibitors in thyroid cancers. <i>Endocrine-Related Cancer</i> , 2022, , .	1.6	4
8816	The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8535.	1.8	9
8817	Adrenomedullin2 stimulates progression of thyroid cancer in mice and humans under nutrient excess conditions. <i>Journal of Pathology</i> , 2022, 258, 264-277.	2.1	5

#	ARTICLE	IF	CITATIONS
8819	Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions. <i>Cancers</i> , 2022, 14, 4066.	1.7	1
8820	Pleiotropic Roles of Atrial Natriuretic Peptide in Anti-Inflammation and Anti-Cancer Activity. <i>Cancers</i> , 2022, 14, 3981.	1.7	3
8821	Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	1
8822	Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
8823	Pollution free UV-C radiation to mitigate COVID-19 transmission. <i>Gondwana Research</i> , 2023, 114, 78-86.	3.0	5
8824	WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-institutional Registry-based Study (BRACELET Study). <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	0
8825	Predominance of the Rare EGFR Mutation p.L861Q in Tunisian Patients with Non-Small Cell Lung Carcinoma. <i>Genes</i> , 2022, 13, 1499.	1.0	1
8826	Differential roles and regulation of the protein kinases PAK4, PAK5 and PAK6 in melanoma cells. <i>Biochemical Journal</i> , 0, , .	1.7	0
8827	Olive leaf extract inhibits metastatic melanoma spread through suppression of epithelial to mesenchymal transition. <i>Phytotherapy Research</i> , 2022, 36, 4002-4013.	2.8	8
8829	Prediction of BRAF mutation status in glioblastoma multiforme by preoperative ring enhancement appearances on MRI. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
8830	Cytoglobin Silencing Promotes Melanoma Malignancy but Sensitizes for Ferroptosis and Pyroptosis Therapy Response. <i>Antioxidants</i> , 2022, 11, 1548.	2.2	8
8831	Treatment of Metastatic Melanoma at First Diagnosis: Review of the Literature. <i>Life</i> , 2022, 12, 1302.	1.1	5
8832	Case report: Spindle cell neoplasm presenting as a spontaneous intestinal perforation in a term infant. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	0
8833	Divergent kinase WNG1 is regulated by phosphorylation of an atypical activation sub-domain. <i>Biochemical Journal</i> , 2022, 479, 1877-1889.	1.7	1
8834	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 554-572.	1.5	3
8836	Papillary renal neoplasm with reverse polarity may be a novel renal cell tumor entity with low malignant potential. <i>Diagnostic Pathology</i> , 2022, 17, .	0.9	4
8837	Alterations in key signaling pathways in sinonasal tract melanoma. A molecular genetics and immunohistochemical study of 90 cases and comprehensive review of the literature. <i>Modern Pathology</i> , 2022, 35, 1609-1617.	2.9	9
8838	Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) – A case series. <i>European Journal of Cancer</i> , 2022, 174, 37-39.	1.3	1

#	ARTICLE	IF	CITATIONS
8839	Chemistries of bifunctional PROTAC degraders. <i>Chemical Society Reviews</i> , 2022, 51, 7066-7114.	18.7	73
8840	Melanoma-targeted photodynamic therapy based on hypericin-loaded multifunctional P123-spermine/folate micelles. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 40, 103103.	1.3	3
8841	Mechanism and inhibition of BRAF kinase. <i>Current Opinion in Chemical Biology</i> , 2022, 71, 102205.	2.8	7
8842	Molecular pathways in periampullary cancer: An overview. <i>Cellular Signalling</i> , 2022, 100, 110461.	1.7	2
8843	Understanding the Molecular Kinetics in NSCLC Through Computational Method. , 2022, , 129-163.		0
8844	Polyglutamate-based nanoconjugates for image-guided surgery and post-operative melanoma metastases prevention. <i>Theranostics</i> , 2022, 12, 6339-6362.	4.6	0
8845	Novel thiazole derivatives incorporating phenyl sulphonyl moiety as potent BRAFV600E kinase inhibitors targeting melanoma. <i>RSC Advances</i> , 2022, 12, 27355-27369.	1.7	9
8846	Nonsurgical Management of Cholangiocarcinoma. , 2022, , 307-323.		0
8847	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2022, , 1235-1269.		0
8848	Computational analysis of natural product B-Raf inhibitors. <i>Journal of Molecular Graphics and Modelling</i> , 2023, 118, 108340.	1.3	2
8849	Optimal Surgical Indications for Resectable Metastatic Colorectal Cancer with BRAF V600E Mutation. <i>Japanese Journal of Gastroenterological Surgery</i> , 2022, 55, 473-482.	0.0	0
8850	BRAF and MEK Targeted Therapies in Pediatric Central Nervous System Tumors. <i>Cancers</i> , 2022, 14, 4264.	1.7	9
8851	The Chaperone System in Salivary Glands: Hsp90 Prospects for Differential Diagnosis and Treatment of Malignant Tumors. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9317.	1.8	3
8852	UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma. <i>Life</i> , 2022, 12, 1339.	1.1	7
8853	Senescence and cancer "role and therapeutic opportunities. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 619-636.	12.5	141
8854	<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced Melanoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	5
8855	Endogenous DOPA inhibits melanoma through suppression of CHRM1 signaling. <i>Science Advances</i> , 2022, 8, .	4.7	8
8856	<i>BRAF</i> mutation in neuroblastoma: A rare finding. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	0.8	0

#	ARTICLE	IF	CITATIONS
8857	Multifunctionality of Calebin A in inflammation, chronic diseases and cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
8858	A Perspective Study on the RTK, PI3K, Bâ€Raf, CDK and the Multiâ€Protein Targeting in Medicinal Chemistry. <i>Chemistry and Biodiversity</i> , 2022, 19, .	1.0	2
8860	Phylogenetic and Expression Analysis of Fos Transcription Factors in Zebrafish. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10098.	1.8	4
8861	Current and promising treatment strategies in glioma. <i>Reviews in the Neurosciences</i> , 2022, .	1.4	3
8862	Incidence of BRAF V600E Gene Mutation Among Lebanese Population in Melanoma and Colorectal Cancer: A Retrospective Study Between 2010 and 2019. <i>Cureus</i> , 2022, , .	0.2	0
8863	Treatment related toxicities with combination BRAF and MEK inhibitor therapy in resected stage III melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
8864	A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	3
8865	First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600â€ mutant advanced melanoma. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 989-996.	0.6	3
8866	RNA-seq and ChIP-seq Identification of Unique and Overlapping Targets of GLI Transcription Factors in Melanoma Cell Lines. <i>Cancers</i> , 2022, 14, 4540.	1.7	3
8867	Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancersâ€”An Overview. <i>Gels</i> , 2022, 8, 560.	2.1	2
8868	CCT196969 effectively inhibits growth and survival of melanoma brain metastasis cells. <i>PLoS ONE</i> , 2022, 17, e0273711.	1.1	1
8869	Chronic rhinosinusitis with nasal polyps does not harbor <i>KRAS</i>, <i>BRAF</i>, and <i>EGFR</i> mutations. <i>Journal of Oral Pathology and Medicine</i> , 2023, 52, 426-430.	1.4	0
8870	From simplicity to complexity in current melanoma models. <i>Experimental Dermatology</i> , 2022, 31, 1818-1836.	1.4	3
8871	Prevalence and detection of actionable BRAF V600 and NRAS Q61 mutations in malignant peripheral nerve sheath tumor by droplet digital PCR. <i>Human Pathology</i> , 2022, 129, 90-97.	1.1	3
8872	Endoplasmic reticulum stress in melanoma pathogenesis and resistance. <i>Biomedicine and Pharmacotherapy</i> , 2022, 155, 113741.	2.5	9
8873	Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA. <i>Drug Resistance Updates</i> , 2022, 65, 100883.	6.5	10
8875	Prediction of BRAF V600E variant from cancer gene expression data. <i>Translational Cancer Research</i> , 2022, 11, 4051-4056.	0.4	2
8876	Phosphorylation-mediated interaction between human E26 transcription factor 1 and specific protein 1 is required for tumor cell migration. <i>Acta Biochimica Et Biophysica Sinica</i> , 2022, , .	0.9	0

#	ARTICLE	IF	CITATIONS
8877	Escape from G1 arrest during acute MEK inhibition drives the acquisition of drug resistance. <i>NAR Cancer</i> , 2022, 4, .	1.6	1
8878	Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase. <i>Current Computer-Aided Drug Design</i> , 2022, 18, 506-518.	0.8	1
8881	Three-target treatment combined with surgery for BRAF V600E-mutant colon cancer with peritoneal metastasis: a case report. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 2647-2653.	0.6	1
8882	Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing. <i>Journal of Personalized Medicine</i> , 2022, 12, 1684.	1.1	6
8883	Comparison between antineoplastic treatments with selective inhibitors (BRAF/MEK) and the new potentials combinatorial therapies for metastatic melanoma. <i>Research, Society and Development</i> , 2022, 11, e326111436275.	0.0	0
8884	The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
8885	Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma. <i>Cancers</i> , 2022, 14, 4930.	1.7	7
8887	The <sc>AhR–SRC</sc> axis as a therapeutic vulnerability in <sc>BRAFi</sc>-resistant melanoma. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	8
8888	Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management. <i>Cancers</i> , 2022, 14, 5370.	1.7	1
8891	Tackling the translational challenges of multi-omics research in the realm of European personalised medicine: A workshop report. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	6
8892	Clinical associations and genetic interactions of oncogenic BRAF alleles. <i>PeerJ</i> , 0, 10, e14126.	0.9	0
8893	Resistor: An algorithm for predicting resistance mutations via Pareto optimization over multistate protein design and mutational signatures. <i>Cell Systems</i> , 2022, 13, 830-843.e3.	2.9	5
8894	Melanoma classification and management in the era of molecular medicine. <i>Dermatologic Clinics</i> , 2023, 41, 49-63.	1.0	15
8898	Computed cancer interactome explains the effects of somatic mutations in cancers. <i>Protein Science</i> , 2022, 31, .	3.1	8
8899	Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
8900	Fusion gene recurrence in non-small cell lung cancers and its association with cigarette smoke exposure. <i>Translational Lung Cancer Research</i> , 2022, 11, 2022-2039.	1.3	1
8901	The clinical and pathological features of low-grade epilepsy-associated glioneuronal tumors. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
8903	Potential role of Marine Bioactive Compounds in cancer signaling pathways: A review. <i>European Journal of Pharmacology</i> , 2022, 936, 175330.	1.7	8

#	ARTICLE	IF	CITATIONS
8904	Hypoxia-Activatable Nanovesicles as In Situ Bombers for Combined Hydrogen-Sulfide-Mediated Respiration Inhibition and Photothermal Therapy. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 50637-50648.	4.0	13
8905	Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	1
8906	Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 14324.	1.2	2
8907	Spindle cell sarcoma with <i>KIAA1549</i> â€BRAF</i> resembling infantile fibrosarcoma morphologically: A case report and literature review. <i>Oncology Letters</i> , 2022, 24, .	0.8	2
8908	Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation. <i>Biochemical Pharmacology</i> , 2022, 206, 115336.	2.0	3
8909	Flavonoids from <i>Ericameria nauseosa</i> inhibiting PI3K/AKT pathway in human melanoma cells. <i>Biomedicine and Pharmacotherapy</i> , 2022, 156, 113754.	2.5	3
8910	Identification of Potential Off-Targets of Chemotherapeutic Agent Sorafenib: A Molecular Docking Approach. <i>International Letters of Natural Sciences</i> , 0, 51, 51-57.	1.0	0
8911	Systematic Review and Meta-analysis of TP53, HER2/ERBB2, KRAS, APC, and PIK3CA Genes Expression Pattern in Gastric Cancer. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 335-345.	0.2	7
8912	Establishment and Characterisation of Human Clear Cell Sarcoma and Malignant Melanoma Cell Lines. <i>Anticancer Research</i> , 2022, 42, 5315-5322.	0.5	0
8913	Identification of Dihydropyridone Dehydrogenase as Potential Target of Vemurafenib-Resistant Melanoma Cells. <i>Molecules</i> , 2022, 27, 7800.	1.7	3
8914	Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
8915	Allyl ether of mansonone G as a potential anticancer agent for colorectal cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
8916	CRISPR/Cas9 Edited RAS & MEK Mutant Cells Acquire BRAF and MEK Inhibitor Resistance with MEK1 Q56P Restoring Sensitivity to MEK/BRAF Inhibitor Combo and KRAS G13D Gaining Sensitivity to Immunotherapy. <i>Cancers</i> , 2022, 14, 5449.	1.7	4
8917	BRAF V600E Mutation in Ameloblastoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 5593.	1.7	6
8918	<sc>BRAF V600E</sc> immunohistochemistry as a useful tool in the diagnosis of melanomas with ambiguous morphologies and immunophenotypes. <i>Journal of Cutaneous Pathology</i> , 2023, 50, 223-229.	0.7	1
8919	Capitalizing on paradoxical activation of the mitogenâ€activated protein kinase pathway for treatment of Imatinibâ€resistant mast cell leukemia. <i>Hematological Oncology</i> , 2023, 41, 520-534.	0.8	1
8920	Non-small-cell lung cancer-associated gene mutations and inhibitors. <i>Advances in Cancer Biology Metastasis</i> , 2022, 6, 100076.	1.1	2
8921	Non-canonical Small GTPase RBJ Promotes NSCLC Progression Through the Canonical MEK/ERK Signaling Pathway. <i>Current Pharmaceutical Design</i> , 2022, 29, .	0.9	0

#	ARTICLE	IF	CITATIONS
8922	RASopathy mutations open new insights into the mechanism of BRAF activation. <i>Molecular Cell</i> , 2022, 82, 4192-4193.	4.5	2
8926	Understanding of "Networks"™ In Vitro and/or In Vivo. , 2016, , 344-355.		0
8927	Analysis of top-cited articles on melanoma. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2022, 31, .	0.1	0
8929	Insights into the aberrant CDK4/6 signaling pathway as a therapeutic target in tumorigenesis. <i>Advances in Protein Chemistry and Structural Biology</i> , 2023, , 179-201.	1.0	4
8930	High-Throughput Functional Evaluation of <i>MAP2K1</i> Variants in Cancer. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 227-239.	1.9	3
8932	Decoding molecular programs in melanoma brain metastases. <i>Nature Communications</i> , 2022, 13, .	5.8	7
8933	ERK MAP Kinase Signaling Regulates RAR Signaling to Confer Retinoid Resistance on Breast Cancer Cells. <i>Cancers</i> , 2022, 14, 5890.	1.7	0
8934	Pure somatic pathogenic variation profiles for patients with serrated polyposis syndrome: a case series. <i>BMC Research Notes</i> , 2022, 15, .	0.6	0
8935	Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. <i>Oncology Letters</i> , 2022, 25, .	0.8	9
8936	HSP90-CDC37-PP5 forms a structural platform for kinase dephosphorylation. <i>Nature Communications</i> , 2022, 13, .	5.8	15
8937	Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. <i>Med</i> , 2023, 4, 15-30.e8.	2.2	4
8938	Analysis of <i>KRAS</i> , <i>BRAF</i> , and <i>EGFR</i> mutational status in respiratory epithelial adenomatoid hamartoma (<sc>REAH</sc>). <i>Journal of Oral Pathology and Medicine</i> , 2023, 52, 548-553.	1.4	1
8939	Discovery of new cyanopyridine/chalcone hybrids as dual inhibitors of EGFR/BRAF ^{V600E} with promising antiproliferative properties. <i>Archiv Der Pharmazie</i> , 2023, 356, .	2.1	7
8940	Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis. <i>Cell Reports</i> , 2022, 41, 111834.	2.9	3
8941	New prospectives on treatment opportunities in <sc>RASopathies</sc>. <i>American Journal of Medical Genetics, Part C: Seminars in Medical Genetics</i> , 2022, 190, 541-560.	0.7	4
8942	Role of miRNA in Melanoma Development and Progression. <i>International Journal of Molecular Sciences</i> , 2023, 24, 201.	1.8	21
8943	Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein. <i>Molecules</i> , 2022, 27, 8513.	1.7	4
8945	Highly recurrent <sc><i>BRAF</i></sc> p.<sc>V595E</sc> mutation in canine papillary oral squamous cell carcinoma. <i>Veterinary and Comparative Oncology</i> , 2023, 21, 138-144.	0.8	4

#	ARTICLE	IF	CITATIONS
8946	A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
8947	Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. <i>Clinical Cancer Research</i> , 2023, 29, 521-531.	3.2	5
8948	Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
8949	Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 7523.	1.0	1
8950	Diagnostic and Prognostic Deep Learning Applications for Histological Assessment of Cutaneous Melanoma. <i>Cancers</i> , 2022, 14, 6231.	1.7	2
8951	The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
8952	Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
8953	CERN Large Hadron Collider (LHC) Radiation Source for Magnetic Resonance Biospectroscopy in Metabolic and Molecular Imaging and Diagnosis of Cancer. <i>Journal of New Developments in Chemistry</i> , 2021, 3, 29-30.	0.5	0
8954	DNMT3B overexpression downregulates genes with CpG islands, common motifs, and transcription factor binding sites that interact with DNMT3B. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
8955	Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. <i>Molecular Biomedicine</i> , 2022, 3, .	1.7	8
8956	MEK inhibition enhances presentation of targetable MHC-I tumor antigens in mutant melanomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
8957	p53 Family in Resistance to Targeted Therapy of Melanoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 65.	1.8	8
8958	Establishment and characterization of urothelial carcinoma cell lines with and without BRAF mutation (V595E) in dogs. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2022, 58, 898-911.	0.7	0
8960	Melanogenesis and the Targeted Therapy of Melanoma. <i>Biomolecules</i> , 2022, 12, 1874.	1.8	9
8961	Primary Malignant Melanoma of the Oral Cavity: A Retrospective Study From a Tertiary Care Centre of North India. <i>Cureus</i> , 2022, , .	0.2	0
8963	Intracellular Ellagic Acid Derived from Goat Urine DMSO Fraction (GUDF) Predicted as an Inhibitor of c-Raf Kinase. <i>Current Molecular Medicine</i> , 2024, 24, 264-279.	0.6	0
8965	Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	12
8967	Neoadjuvant treatment for stage III and IV cutaneous melanoma. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	1

#	ARTICLE	IF	CITATIONS
8968	Signaling pathways in brain tumors and therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	13
8969	MAPK inhibitors dynamically affect melanoma release of immune NKG2D-ligands, as soluble protein and extracellular vesicle-associated. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2
8970	Melanoma and Glioblastomaâ€”Not a Serendipitous Association. <i>Advances in Anatomic Pathology</i> , 0, Publish Ahead of Print, .	2.4	0
8971	A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study. <i>Clinical Cancer Research</i> , 2023, 29, 1017-1030.	3.2	13
8972	Progress of small molecules for targeted protein degradation: PROTACs and other technologies. <i>Drug Development Research</i> , 2023, 84, 337-394.	1.4	6
8973	Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies. <i>Frontiers in Veterinary Science</i> , 0, 9, .	0.9	4
8974	BRAF L485â€”P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
8975	Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
8976	Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1294.	1.8	6
8978	Advances in Molecular Pathophysiology and Targeted Therapy for Cushingâ€™s Disease. <i>Cancers</i> , 2023, 15, 496.	1.7	2
8979	Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-14.	2.4	0
8980	Effect of Food (Low and High Fat) on Pharmacokinetics of FCN-159, a Selective MEK Inhibitor, in Healthy Chinese Males. <i>Advances in Therapy</i> , 2023, 40, 1074-1086.	1.3	1
8981	Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
8982	Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2023, 57, 792-799.	1.9	3
8983	Genomics and Epigenomics in the Molecular Biology of Melanomaâ€”A Prerequisite for Biomarkers Studies. <i>International Journal of Molecular Sciences</i> , 2023, 24, 716.	1.8	3
8984	Seeking therapeutic synergy in BRAF mutant colorectal cancer. <i>Nature Medicine</i> , 0, , .	15.2	4
8985	Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. <i>Nature Medicine</i> , 2023, 29, 458-466.	15.2	28
8986	Characterization of proteome-size scaling by integrative omics reveals mechanisms of proliferation control in cancer. <i>Science Advances</i> , 2023, 9, .	4.7	6

#	ARTICLE	IF	CITATIONS
8987	Melanoma with Brain Metastasis. , 2023, , 1-30.		0
8988	Mechanistic model of <scp>MAPK</scp> signaling reveals how allosterity and rewiring contribute to drug resistance. Molecular Systems Biology, 2023, 19, .	3.2	14
8989	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. , 2023, , 13-27.		0
8990	Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-b]indol-3-one Derivatives as Potent Inhibitors of EGFR T790M/BRAF V600E Pathways. Molecules, 2023, 28, 1269.	1.7	7
8992	Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group. Acta Medica Academica, 2023, 51, 217-231.	0.3	2
8993	Detection of BRAF mutations in malignant melanoma and colorectal cancer by SensiScreen® FFPE BRAF qPCR assay. PLoS ONE, 2023, 18, e0281558.	1.1	0
8994	Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study. BMC Cancer, 2023, 23, .	1.1	3
8995	The Complex Interplay between Nevi and Melanoma: Risk Factors and Precursors. International Journal of Molecular Sciences, 2023, 24, 3541.	1.8	7
8996	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World Journal of Gastroenterology, 0, 29, 926-948.	1.4	4
8997	Pigment cell progenitor heterogeneity and reiteration of developmental signaling underlie melanocyte regeneration in zebrafish. ELife, 0, 12, .	2.8	0
8998	BRAF Landscape and Its Implications among Patients with Pediatric Low-Grade Gliomas: A Comprehensive Review of the Literature. Journal of Pediatric Neurology, 0, , .	0.0	0
8999	Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy. Drug Resistance Updates, 2023, 68, 100939.	6.5	10
9000	Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. European Journal of Cancer, 2023, 184, 137-150.	1.3	6
9001	Optically activated MEK1/2 inhibitors (Opti-MEKi) as potential antimelanoma agents. European Journal of Medicinal Chemistry, 2023, 251, 115236.	2.6	1
9002	Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open, 2023, 8, 100788.	2.0	22
9003	Recent Developments in the Management of Orbital and Periocular Neoplasms. , 2022, , 311-325.		0
9004	Autophagy Paradox: Strategizing Treatment Modality in Melanoma. Current Treatment Options in Oncology, 2023, 24, 130-145.	1.3	4
9005	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0

#	ARTICLE	IF	CITATIONS
9006	Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines. <i>Translational Medicine Communications</i> , 2023, 8, .	0.5	2
9007	Helper Innate Lymphoid Cellsâ€”Unappreciated Players in Melanoma Therapy. <i>Cancers</i> , 2023, 15, 933.	1.7	1
9008	Universal Approach to De Novo Drug Design for Target Proteins Using Deep Reinforcement Learning. <i>ACS Omega</i> , 2023, 8, 5464-5474.	1.6	6
9009	Establishment of a <sc>BRAF V595E</sc>â€”mutant canine prostate cancer cell line and the antitumor effects of <sc>MEK</sc> inhibitors against canine prostate cancer. <i>Veterinary and Comparative Oncology</i> , 2023, 21, 221-230.	0.8	1
9010	Discovery of New Quinoline-Based Diarylamides as Potent B-RAFV600E/C-RAF Kinase Inhibitors Endowed with Promising In Vitro Anticancer Activity. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3216.	1.8	2
9011	Identifying a wide range of mutations in the <i>BRAF</i> gene for prescribing targeted drugs for melanoma treatment. <i>Vestnik Medicinskogo Instituta REAVIZ ReabilitaciÄ, VraÄl ZdrovË¹e</i> , 2023, 13, 71-76.	0.1	0
9012	Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertensionâ€”Mechanisms and Mitigation. <i>Hypertension</i> , 2023, 80, 685-710.	1.3	7
9013	Co-dependent regulation of p-BRAF and potassium channel KCNMA1 levels drives glioma progression. <i>Cellular and Molecular Life Sciences</i> , 2023, 80, .	2.4	2
9014	Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	5
9015	Increasing the Editing Efficiency of the MS2-ADAR System for Site-Directed RNA Editing. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 2383.	1.3	0
9016	Survival improvement for patients with metastatic colorectal cancer over twenty years. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	22
9017	Glycolysis regulator PFKP induces human melanoma cell proliferation and tumor growth. <i>Clinical and Translational Oncology</i> , 2023, 25, 2183-2191.	1.2	4
9018	Real Check RIO: A Real-World Analysis of Nivolumab in First Line Metastatic Melanoma Assessing Efficacy, Safety and Predictive Factors. <i>Cancers</i> , 2023, 15, 1265.	1.7	0
9019	Understanding disruption of the gut barrier during inflammation: Should we abandon traditional epithelial cell lines and switch to intestinal organoids?. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
9020	Expanding the Spectrum of BRAF Non-V600E Mutations in Thyroid Nodules: Evidence-Based Data from a Tertiary Referral Centre. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4057.	1.8	3
9021	BRAF v600Eâ€”mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	4
9023	A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF<i>V600E</i>-Mutant<i>KRAS</i>Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2023, 28, 230-238.	1.9	9
9024	Metastatic colorectal cancer: mechanisms and emerging therapeutics. <i>Trends in Pharmacological Sciences</i> , 2023, 44, 222-236.	4.0	30

#	ARTICLE	IF	CITATIONS
9025	The clinicopathological features of ganglioglioma with CD34 expression and BRAF mutation in patients with epilepsy. <i>Frontiers in Molecular Neuroscience</i> , 0, 16, .	1.4	0
9026	Characterization of network hierarchy reflects cell state specificity in genome organization. <i>Genome Research</i> , 2023, 33, 247-260.	2.4	2
9027	Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor. <i>European Journal of Medicinal Chemistry</i> , 2023, 250, 115231.	2.6	1
9028	Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations. <i>Translational Lung Cancer Research</i> , 2023, 12, 219-229.	1.3	1
9029	Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4520.	1.8	2
9030	Integrated molecular and clinical analysis of BRAF-mutant glioma in adults. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	4
9031	3D Spheroid Configurations Are Possible Indictors for Evaluating the Pathophysiology of Melanoma Cell Lines. <i>Cells</i> , 2023, 12, 759.	1.8	8
9032	Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant. <i>International Journal of Clinical Oncology</i> , 2023, 28, 654-663.	1.0	1
9033	Melanoma: A Historical Walk-through from Palliative Treatment to Modern-day Practice. , 2023, 126, 266-274.		0
9034	Recent updates on thienopyrimidine derivatives as anticancer agents. <i>Medicinal Chemistry Research</i> , 2023, 32, 659-681.	1.1	6
9035	Acscs2/HIF-2 signaling facilitates colon cancer growth and metastasis. <i>PLoS ONE</i> , 2023, 18, e0282223.	1.1	5
9036	Association of <i>BRAF</i> Variants With Disease Characteristics, Prognosis, and Targeted Therapy Response in Intrahepatic Cholangiocarcinoma. <i>JAMA Network Open</i> , 2023, 6, e231476.	2.8	5
9037	Evolution of cancer genomics and its clinical implications. <i>Journal of Pediatrics & Neonatal Care</i> , 2019, 9, 173-178.	0.0	0
9038	Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 184, 103954.	2.0	3
9039	Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4961.	1.8	2
9040	Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	9
9041	Intracellular delivery of bacterial effectors for cancer therapy using biodegradable lipid nanoparticles. <i>Biomaterials Science</i> , 2023, 11, 3172-3179.	2.6	1
9042	Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. <i>Cancers</i> , 2023, 15, 1679.	1.7	6

#	ARTICLE	IF	CITATIONS
9043	First passage time analysis of spatial mutation patterns reveals sub-clonal evolutionary dynamics in colorectal cancer. <i>PLoS Computational Biology</i> , 2023, 19, e1010952.	1.5	1
9044	Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
9045	Multi-range ERK responses shape the proliferative trajectory of single cells following oncogene induction. <i>Cell Reports</i> , 2023, 42, 112252.	2.9	5
9046	Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. <i>Annals of Oncology</i> , 2023, 34, 543-552.	0.6	15
9047	Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer. <i>Translational Cancer Research</i> , 2023, 12, 456-460.	0.4	1
9048	Current Advances in Papillary Craniopharyngioma: State-Of-The-Art Therapies and Overview of the Literature. <i>Brain Sciences</i> , 2023, 13, 515.	1.1	5
9050	The <i>CLIP1</i> – <i>LTK</i> fusion: a new oncogenic driver in non-small-cell lung cancer?. <i>Future Oncology</i> , 2023, 19, 273-275.	1.1	1
9051	Exposure–response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 0, , .	1.1	2
9052	Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib. <i>Journal of Biological Chemistry</i> , 2023, 299, 104634.	1.6	8
9054	Emerging Targeted Therapeutic Strategies to Overcome Imatinib Resistance of Gastrointestinal Stromal Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6026.	1.8	1
9055	Molecular Pathology of Lung Cancer. , 0, , .		0
9056	The therapeutic potential of targeting minimal residual disease in melanoma. <i>Clinical and Translational Medicine</i> , 2023, 13, .	1.7	1
9057	The inhibitory role of microRNA-141-3p in human cutaneous melanoma growth and metastasis through the fibroblast growth factor 13-mediated mitogen-activated protein kinase axis. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	0
9058	Precision Oncology Targets in Biliary Tract Cancer. <i>Cancers</i> , 2023, 15, 2105.	1.7	5
9060	Molecular pharmacology of multitarget cyclin-dependent kinase inhibitors in human colorectal carcinoma cells. <i>Expert Opinion on Therapeutic Targets</i> , 0, , 1-11.	1.5	0
9061	Epidemiology of Melanoma. , 0, , .		0
9062	Target Hyperactive ERK Signaling for Cancer Therapy. , 2023, , 1-39.		0
9063	Langerhans Cell Granulomatosis and Smoking-Related Interstitial Lung Diseases. , 2023, , 311-334.		0

#	ARTICLE	IF	CITATIONS
9064	A Comprehensive Pan-Cancer Analysis of the Regulation and Prognostic Effect of Coat Complex Subunit Zeta 1. <i>Genes</i> , 2023, 14, 889.	1.0	1
9065	Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with <i>BRAF</i> mutant solid tumors. <i>Cancer</i> , 0, , .	2.0	0
9066	<i>BRAF</i> -mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
9067	Dabrafenib plus trametinib in <i>BRAF</i> V600E-mutated rare cancers: the phase 2 ROAR trial. <i>Nature Medicine</i> , 2023, 29, 1103-1112.	15.2	47
9068	MDM2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy by Increasing IL15 and MHC Class II Production. <i>Molecular Cancer Research</i> , 2023, 21, 849-864.	1.5	2
9070	Cell Signaling Pathways in Cancer. , 2023, , 242-272.		0
9075	Genetic and Epigenetic Dysregulation in Environmental Disease. , 2024, , 465-492.		0
9076	Treatment of Langerhans Cell Histiocytosis and Histiocytic Disorders: A Focus on MAPK Pathway Inhibitors. <i>Paediatric Drugs</i> , 2023, 25, 399-409.	1.3	3
9078	Precision medicine-based cancer care. , 2024, , 272-283.		0
9089	Histological transformation to gliosarcoma with combined <i>BRAF</i> /MEK inhibition in <i>BRAF</i> V600E mutated glioblastoma. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	1
9101	<i>BRAF</i> V600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist. <i>Advances in Therapy</i> , 0, , .	1.3	0
9123	Integrated pharmacokinetic/pharmacodynamic/efficacy analysis in oncology: importance of pharmacodynamic/efficacy relationships. , 2023, , 305-315.		0
9126	Oncogenic Genomic Changes in Cancer. , 2023, , 25-38.		1
9135	Pathogenesis of cancers derived from thyroid follicular cells. <i>Nature Reviews Cancer</i> , 2023, 23, 631-650.	12.8	6
9140	The Value of Cell-Free Circulating DNA Profiling in Patients with Skin Diseases. <i>Methods in Molecular Biology</i> , 2023, , 247-262.	0.4	0
9141	Other Less Prevalent Tumors of the Central Nervous System. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 607-643.	0.8	0
9148	Pathology of Digestive System Malignancies. , 2023, , 259-273.		0
9156	Immunotherapy for Ocular Tumors. , 2023, , 1-61.		0

#	ARTICLE	IF	CITATIONS
9172	Engineering yeast for the production of plant terpenoids using synthetic biology approaches. <i>Natural Product Reports</i> , 2023, 40, 1822-1848.	5.2	5
9177	An updated literature on BRAF inhibitors (2018–2023). <i>Molecular Diversity</i> , 0, , .	2.1	1
9181	NGS Analysis of Plasma cfDNA and cfmiRNA Signatures in Melanoma Brain Metastasis Patients. <i>Current Cancer Research</i> , 2023, , 491-510.	0.2	0
9190	The mechanism and consequences of BRAF inhibitor resistance in melanoma. <i>Genome Instability & Disease</i> , 2023, 4, 266-274.	0.5	3
9198	Signal Transduction Inhibitors. , 2023, , 89-110.		2
9199	Cancer Immunotherapy. , 2023, , 121-154.		0
9215	Future Directions in Pathology. , 2023, , 235-243.		0
9223	Targeted Treatments for Cutaneous Melanoma. , 2023, , 1787-1800.		0
9224	Other molecular cohorts including ROS1, BRAF, HER2, MET, NTRK, RET, KRAS. , 2024, , 269-282.		0
9260	Case Report: Balancing immune responses – multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
9287	The role of CRAF in cancer progression: from molecular mechanisms to precision therapies. <i>Nature Reviews Cancer</i> , 2024, 24, 105-122.	12.8	3
9289	Chromosome 7. , 2023, , 223-242.		0
9315	Fighting melanoma and resistant phenotypes African medicinal plants and their phytoconstituents. <i>Advances in Botanical Research</i> , 2024, , .	0.5	0
9322	BRAF – a tumour-agnostic drug target with lineage-specific dependencies. <i>Nature Reviews Clinical Oncology</i> , 2024, 21, 224-247.	12.5	1
9329	Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	0
9334	Incidental finding of leukaemia in circulating tumour DNA – the importance of a molecular tumour board. , 2024, 2, .		0
9341	Experience in Molecular Testing Using FNA Cytology in EU Countries. , 2023, , 661-674.		0
9342	Molecular Classification of Thyroid Tumors and Key Molecular Features to Identify High-Grade Thyroid Carcinomas. , 2023, , 139-146.		0

#	ARTICLE	IF	CITATIONS
9357	Lung Cancer Therapy: Synergistic Potential of PD-1/PD-L1 and CTLA-4 Inhibitors. , 2024, , 297-316.		0